assay_description	canonical_smiles	document_journal	document_year	molecule_chembl_id	relation	standard_relation	standard_type	standard_units	standard_value	type	units	value
Inhibition of cytochrome P450 3A4 of isolated guinea pig heart	Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4cccc(-c5ccccc5)c4)CC3)ccc2s1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL152968	=	=	IC50	nM	37000.0	IC50	uM	37.0
Inhibition of human cytochrome P450 3A4 as total cyclosporin oxidation (1 uM)	COc1ccc(NS(=O)(=O)c2ccc(Br)cc2)cc1N1CCN(C)CC1	J. Med. Chem.	1999.0	CHEMBL292759	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of cytochrome P450 3A4 of isolated guinea pig heart	Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4ccc(-c5ccccc5)cc4)CC3)ccc2s1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL153741	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of cytochrome P450 3A4 of isolated guinea pig heart	CCn1c2ccccc2c2cc(NC(=O)CN3CCN(C[C@@H](O)COc4ccc5sc(C)nc5c4)CC3)ccc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL150614	=	=	IC50	nM	39000.0	IC50	uM	39.0
Inhibition of human cytochrome P450 3A4 as total cyclosporin oxidation (1 uM)	COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1.Cl	J. Med. Chem.	1999.0	CHEMBL542139	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of cytochrome P450 3A4 of isolated guinea pig heart	Cc1nc2cc(OC[C@H](O)CN3CCN(CC(=O)Nc4c(C)cccc4C)CC3)ccc2s1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL154751	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of Cytochrome P450 3A4 as BFC substrate	CC(C)C[C@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C	J. Med. Chem.	2003.0	CHEMBL168471	=	=	IC50	nM	81000.0	IC50	uM	81.0
Inhibition of Cytochrome P450 3A4 as BQ substrate	CC(C)C[C@H](C=O)NC(=O)[C@@H](NS(=O)(=O)c1ccc(F)cc1)C(C)C	J. Med. Chem.	2003.0	CHEMBL168471	=	=	IC50	nM	531000.0	IC50	uM	531.0
In vitro inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3cccnc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706623	=	=	IC50	nM	440.0	IC50	uM	0.44
In vitro inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL115	=	=	IC50	nM	150.0	IC50	uM	0.15
In vitro inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccn3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706619	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of cytochrome P450 3A4 enzyme	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2c[nH]c3ncnc-3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL352806	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2cccc3cnccc23)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL170159	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of cytochrome P450 3A4 enzyme	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]c(C)nc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL349638	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of cytochrome P450 3A4 enzyme	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]nnc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL168563	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of cytochrome P450 3A4 enzyme	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]cnc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL168538	=	=	IC50	nM	100.0	IC50	nM	100.0
In vitro inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(c1ccc(-c2ccncc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706620	=	=	IC50	nM	10.0	IC50	uM	0.01
Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3ncoc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL263004	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of cytochrome P450 3A4 enzyme	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3[nH]c(C(F)(F)F)nc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL168726	>	>	IC50	nM	10000.0	IC50	uM	10.0
In vitro inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccncc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL114756	=	=	IC50	nM	320.0	IC50	uM	0.32
Inhibition of cytochrome P450 3A4 enzyme; Range 1-2 uM	Cc1cc(C)cc(-c2[nH]c3ccc(C(C)(C)C(=O)N4CC5CCC4CC5)cc3c2[C@H](C)CNCCc2ccc3nsnc3c2)c1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL169620	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCCC2	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10501	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(C)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10532	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibitory activity against CYP450 3A4 isozyme	CCCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL274551	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Br)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10271	=	=	IC50	nM	39000.0	IC50	uM	39.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cl)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10769	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c(C)c1C	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10759	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(C)cc(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL268764	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL204021	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10921	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibitory activity against CYP450 3A4 isozyme	CCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(Cl)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL273503	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibitory activity against CYP450 3A4 isozyme	CCc1cn(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)c(SCc2ccc(F)cc2)nc1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10604	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(SC)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10600	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(C)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10440	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCC2	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10663	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibitory activity against CYP450 3A4 isozyme	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1c(SCc2ccc(F)cc2)nc(=O)c2c1CCCC2	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL10441	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of heterologously expressed human Cytochrome P450 3A at 100 uM	CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2	J. Med. Chem.	1997.0	CHEMBL276140	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of heterologously expressed human Cytochrome P450 3A at 1 uM	Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1	J. Med. Chem.	1997.0	CHEMBL297784	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of heterologously expressed human Cytochrome P450 3A at 1 uM	Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2	J. Med. Chem.	1997.0	CHEMBL14563	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibitory activity against cytochrome P450 3A4	COC(=O)c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1	J. Med. Chem.	2004.0	CHEMBL27257	=	=	IC50	nM	2530.0	IC50	uM	2.53
Inhibition of cytochrome P450 3A4 of human liver microsomes	Cn1c2cc(Cl)ncc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL26686			IC50	nM		IC50	uM	
Inhibitory activity against cytochrome P450 3A4	Cn1c2cccnc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL282365	=	=	IC50	nM	19300.0	IC50	uM	19.3
Inhibition of cytochrome P450 3A4 of human liver microsomes	COc1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1	J. Med. Chem.	2004.0	CHEMBL431503			IC50	nM		IC50	uM	
Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1ccncc1	J. Med. Chem.	2004.0	CHEMBL29743	=	=	IC50	nM	5780.0	IC50	uM	5.78
Inhibitory activity against cytochrome P450 3A4	CN(C)c1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL26150	=	=	IC50	nM	26410.0	IC50	uM	26.41
Inhibition of cytochrome P450 3A4 of human liver microsomes	CC(=O)Nc1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1	J. Med. Chem.	2004.0	CHEMBL287181			IC50	nM		IC50	uM	
Inhibition of cytochrome P450 3A4 of human liver microsomes	Fc1ccc(CCN2CCN(c3[nH]cnc4c5c(Cl)cccc5nc3-4)CC2)cc1F	J. Med. Chem.	2004.0	CHEMBL28584			IC50	nM		IC50	uM	
Inhibitory activity against cytochrome P450 3A4	CC(C)Oc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL283253	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of Cytochrome P450 3A4 with testosterone	CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL332643	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of Cytochrome P450 3A4 with midazolam (4-OH)	CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL332643	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of Cytochrome P450 3A4 with midazolam (1'-OH)	CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL332643	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of Cytochrome P450 3A4 with nifedipine	CCOC(=O)CCCn1c(=O)nc2n(CCCCOC(=O)C[C@@H]3CC4C5CC[C@H](O)C5CCC4[C@@]4(C)CCC(=O)C=C34)c3ccccc3cc-2c1=O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL332643	=	=	IC50	nM	4100.0	IC50	uM	4.1
Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)nc(CN4CCOCC4)nc3c2c1	J. Med. Chem.	2004.0	CHEMBL283693	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of cytochrome P450 3A4 of human liver microsomes	Cc1nc2c(c(C(N)=O)c1[N+](=O)[O-])c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL26779			IC50	nM		IC50	uM	
Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM	OC1N=C(c2ccccc2F)c2cc(Cl)ccc2-n2cncc21	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL121550	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibitory activity against cytochrome P450 3A4	NC(=O)c1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12	J. Med. Chem.	2004.0	CHEMBL283438	=	=	IC50	nM	1360.0	IC50	uM	1.36
Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL386630	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibitory activity against cytochrome P450 3A4	Cn1c2cccc([N+](=O)[O-])c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL30052	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibitory activity against cytochrome P450 3A4	COc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL284676	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibitory activity against cytochrome P450 3A4	Cn1c2ccnc(Cl)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL27415	=	=	IC50	nM	9440.0	IC50	uM	9.44
Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1cc([N+](=O)[O-])c2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)nc(CN4CCOCC4)nc3c2c1	J. Med. Chem.	2004.0	CHEMBL284024	=	=	IC50	nM	42260.0	IC50	uM	42.26
Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1	J. Med. Chem.	2004.0	CHEMBL25867	=	=	IC50	nM	12580.0	IC50	uM	12.58
Inhibitory activity against cytochrome P450 3A4	Cn1c2cccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL26678	=	=	IC50	nM	260.0	IC50	uM	0.26
Inhibitory activity against cytochrome P450 3A4	CCOC(=O)Cn1c2ccc([N+](=O)[O-])cc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL26039	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibitory activity against cytochrome P450 3A4	Cn1c2ccnc(Cl)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL418382	=	=	IC50	nM	20030.0	IC50	uM	20.03
Inhibitory activity against cytochrome P450 3A4	Cn1c2ccnc(N3CCOCC3)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL28629	=	=	IC50	nM	20800.0	IC50	uM	20.8
Inhibitory activity against cytochrome P450 3A4	Cn1c2nccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL25903	=	=	IC50	nM	1230.0	IC50	uM	1.23
Inhibitory activity against cytochrome P450 3A4	Cn1c2cccc(C(N)=O)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL439727	=	=	IC50	nM	31310.0	IC50	uM	31.31
Inhibitory activity against cytochrome P450 3A4	Cn1c2ccnc(NCc3ccccn3)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL281326	=	=	IC50	nM	18480.0	IC50	uM	18.48
Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM	OCc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL1188	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibitory activity against cytochrome P450 3A4	CNc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL25731	=	=	IC50	nM	53810.0	IC50	uM	53.81
Inhibition of cytochrome P450 3A4 of human liver microsomes	CCOC(=O)n1c2cccc(C(N)=O)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL27536			IC50	nM		IC50	uM	
Inhibitory activity against cytochrome P450 3A4	Cc1nccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2C	J. Med. Chem.	2004.0	CHEMBL27007	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibitory activity against cytochrome P450 3A4	NC(=O)c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1ccncc1	J. Med. Chem.	2004.0	CHEMBL283255	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibitory activity against cytochrome P450 3A4	Cc1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12	J. Med. Chem.	2004.0	CHEMBL26369	=	=	IC50	nM	9250.0	IC50	uM	9.25
Inhibitory activity against cytochrome P450 3A4	Cc1cc(C#N)c2c3ncnc(N4CCN(CCc5ccc(F)c(F)c5)CC4)c3n(C)c2n1	J. Med. Chem.	2004.0	CHEMBL28168	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibitory activity against cytochrome P450 3A4	COCc1nc(N2CCN(CCc3ccc(F)c(F)c3)CC2)c2c(n1)c1c(Cl)nccc1n2C	J. Med. Chem.	2004.0	CHEMBL25905	=	=	IC50	nM	36820.0	IC50	uM	36.82
Inhibitory activity against cytochrome P450 3A4	COc1ccc2c(c1)[nH]c1c(N3CCN(CCc4ccc(F)c(F)c4)CC3)ncnc12	J. Med. Chem.	2004.0	CHEMBL281284	=	=	IC50	nM	1530.0	IC50	uM	1.53
Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2Cc1cccnc1	J. Med. Chem.	2004.0	CHEMBL29631	=	=	IC50	nM	8100.0	IC50	uM	8.1
Inhibition of cytochrome P450 3A4 of human liver microsomes	Fc1ccc(CCN2CCN(c3ncnc4c5cnccc5n(Cc5ccccc5)c34)CC2)cc1F	J. Med. Chem.	2004.0	CHEMBL26081			IC50	nM		IC50	uM	
Binding affinity for Cytochrome P450 3A4; Range = 1-10 uM	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL193	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of cytochrome P450 3A4 of human liver microsomes	N#Cc1cccc2nc3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)[nH]cnc-3c12	J. Med. Chem.	2004.0	CHEMBL430925			IC50	nM		IC50	uM	
Inhibition of cytochrome P450 3A4 of human liver microsomes	O=S(=O)(c1ccc2nc3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)[nH]cnc-3c2c1)N1CCCC1	J. Med. Chem.	2004.0	CHEMBL27128			IC50	nM		IC50	uM	
Inhibition of cytochrome P450 3A4 of human liver microsomes	Cn1c2nccc(C#N)c2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL286948			IC50	nM		IC50	uM	
Inhibitory activity against cytochrome P450 3A4	Cn1c2nccc(C(N)=O)c2c2nc(CN3CCOCC3)nc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL281496	=	=	IC50	nM	33690.0	IC50	uM	33.69
Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12	J. Med. Chem.	2004.0	CHEMBL282156	=	=	IC50	nM	6620.0	IC50	uM	6.62
Inhibitory activity against cytochrome P450 3A4	COc1ccc2c3nc[nH]c(N4CCN(CCc5ccc(F)c(F)c5)CC4)c-3nc2c1[N+](=O)[O-]	J. Med. Chem.	2004.0	CHEMBL281743	=	=	IC50	nM	1790.0	IC50	uM	1.79
Inhibition of cytochrome P450 3A4 of human liver microsomes	COc1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1[N+](=O)[O-]	J. Med. Chem.	2004.0	CHEMBL27191			IC50	nM		IC50	uM	
Inhibitory activity against cytochrome P450 3A4	Cc1cc(C(N)=O)c2c3ncnc(N4CCN(CCc5ccc(F)c(F)c5)CC4)c3n(C)c2n1	J. Med. Chem.	2004.0	CHEMBL287400	=	=	IC50	nM	210.0	IC50	uM	0.21
Inhibition of cytochrome P450 3A4 of human liver microsomes	NC(=O)c1ccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c2c1	J. Med. Chem.	2004.0	CHEMBL286963			IC50	nM		IC50	uM	
Inhibition of cytochrome P450 3A4 of human liver microsomes	O=C(Nc1ccncc1)c1cccc2nc3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)[nH]cnc-3c12	J. Med. Chem.	2004.0	CHEMBL281235			IC50	nM		IC50	uM	
Inhibitory activity against cytochrome P450 3A4	Cn1c2ccncc2c2ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c21	J. Med. Chem.	2004.0	CHEMBL430724	=	=	IC50	nM	17850.0	IC50	uM	17.85
Inhibition of cytochrome P450 3A4 of human liver microsomes	Nc1cccc2[nH]c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc3c12	J. Med. Chem.	2004.0	CHEMBL25972			IC50	nM		IC50	uM	
Inhibitory activity against cytochrome P450 3A4	O=[N+]([O-])c1cccc2c1c1ncnc(N3CCN(CCc4ccc(F)c(F)c4)CC3)c1n2CCc1ccccc1	J. Med. Chem.	2004.0	CHEMBL285343	=	=	IC50	nM	11790.0	IC50	uM	11.79
Binding affinity for progesterone 6-beta-hydroxylase of hepatic microsomes	Nc1ccc(SC[C@H]2CO[C@@](CCc3ccc(Cl)cc3)(Cn3ccnc3)O2)cc1	J. Med. Chem.	1993.0	CHEMBL305220	=	=	Ki	nM	33.0	Ki	nM	33.0
Binding affinity for progesterone 6-beta-hydroxylase of hepatic microsomes	Nc1ccc(SC[C@@H]2CO[C@](CCc3ccc(Cl)cc3)(Cn3ccnc3)O2)cc1	J. Med. Chem.	1993.0	CHEMBL70611	=	=	Ki	nM	28.0	Ki	nM	28.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-n2ccnc2)cc1	J. Med. Chem.	2003.0	CHEMBL112532	=	=	IC50	nM	348.0	IC50	nM	348.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cccnc2)cc1	J. Med. Chem.	2003.0	CHEMBL151646	=	=	IC50	nM	29300.0	IC50	nM	29300.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cc(C)no2)cc1	J. Med. Chem.	2003.0	CHEMBL422858	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2[nH]ncc2C)cc1	J. Med. Chem.	2003.0	CHEMBL434317	=	=	IC50	nM	26800.0	IC50	nM	26800.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccno2)cc1	J. Med. Chem.	2003.0	CHEMBL150681	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1cccc(-c2ccno2)c1	J. Med. Chem.	2003.0	CHEMBL151449	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-n2cncn2)cc1	J. Med. Chem.	2003.0	CHEMBL345544	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cc[nH]c2)cc1	J. Med. Chem.	2003.0	CHEMBL359116	=	=	IC50	nM	7520.0	IC50	nM	7520.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cc[n+](C)[nH]2)cc1	J. Med. Chem.	2003.0	CHEMBL347303	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccncc2)cc1	J. Med. Chem.	2003.0	CHEMBL151280	=	=	IC50	nM	51100.0	IC50	nM	51100.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccccc1-c1ccno1	J. Med. Chem.	2003.0	CHEMBL150799	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-n2ccnc2C)cc1	J. Med. Chem.	2003.0	CHEMBL358214	=	=	IC50	nM	50900.0	IC50	nM	50900.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccnn2C)cc1	J. Med. Chem.	2003.0	CHEMBL151037	=	=	IC50	nM	93800.0	IC50	nM	93800.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(N/C=N\O)cc1	J. Med. Chem.	2003.0	CHEMBL348263	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cnccn2)cc1	J. Med. Chem.	2003.0	CHEMBL150146	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccns2)cc1	J. Med. Chem.	2003.0	CHEMBL151354	=	=	IC50	nM	22900.0	IC50	nM	22900.0
In vitro inhibition of Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3ccccc3)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL341089	=	=	IC50	nM	400.0	IC50	uM	0.4
In vitro inhibition of Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3cccc(Cl)c3)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL276081	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of Cytochrome P450 3A4; not tested	COc1ccc(-c2ccno2)cc1	J. Med. Chem.	2003.0	CHEMBL347302			IC50	nM		IC50	nM	
In vitro inhibition of Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3ccc(F)c(F)c3F)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL334379	=	=	IC50	nM	50.0	IC50	uM	0.05
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cnco2)cc1	J. Med. Chem.	2003.0	CHEMBL358216	=	=	IC50	nM	58100.0	IC50	nM	58100.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccon2)cc1	J. Med. Chem.	2003.0	CHEMBL433737	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Inhibition of Cytochrome P450 3A4; not tested	CCCCOc1ccc(-c2cocn2)cc1	J. Med. Chem.	2003.0	CHEMBL151096			IC50	nM		IC50	nM	
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2nn[nH]n2)cc1	J. Med. Chem.	2003.0	CHEMBL150278	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccncn2)cc1	J. Med. Chem.	2003.0	CHEMBL151974	>	>	IC50	nM	100000.0	IC50	nM	100000.0
In vitro inhibition of Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccn(-c3ccc(Cl)cc3)c2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL127589	=	=	IC50	nM	50.0	IC50	uM	0.05
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cc[nH]n2)cc1	J. Med. Chem.	2003.0	CHEMBL149750	=	=	IC50	nM	70600.0	IC50	nM	70600.0
Inhibition of Cytochrome P450 3A4; not tested	c1ccc(-c2ccno2)cc1	J. Med. Chem.	2003.0	CHEMBL81948			IC50	nM		IC50	nM	
In vitro inhibition of Cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL115	=	=	IC50	nM	150.0	IC50	uM	0.15
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-n2cncc2C)cc1	J. Med. Chem.	2003.0	CHEMBL358880	=	=	IC50	nM	116.0	IC50	nM	116.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCc1ccc(/N=C/NO)c(C)c1	J. Med. Chem.	2003.0	CHEMBL267865	=	=	IC50	nM	65400.0	IC50	nM	65400.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2cc(C)[nH]n2)cc1	J. Med. Chem.	2003.0	CHEMBL356594	>	>	IC50	nM	100000.0	IC50	nM	100000.0
In vitro inhibition of Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL444533	=	=	IC50	nM	430.0	IC50	uM	0.43
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ccccn2)cc1	J. Med. Chem.	2003.0	CHEMBL150653	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2c[nH]cn2)cc1	J. Med. Chem.	2003.0	CHEMBL151170	=	=	IC50	nM	883.0	IC50	nM	883.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2ncc[nH]2)cc1	J. Med. Chem.	2003.0	CHEMBL150999	=	=	IC50	nM	44300.0	IC50	nM	44300.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-c2oncc2C)cc1	J. Med. Chem.	2003.0	CHEMBL151038	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Concentration required to inhibit cytochrome P450 3A4.	CCCCOc1ccc(-n2cnc(C)c2)cc1	J. Med. Chem.	2003.0	CHEMBL151207	=	=	IC50	nM	9170.0	IC50	nM	9170.0
Inhibition of human Cytochrome P450 3A4	O=C1c2ccccc2CCCN1CCN1CCC(n2c(O)nc3cc(F)ccc32)CC1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL273921	>	>	IC50	nM	100000.0	IC50	uM	100.0
Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL163	=	=	IC50	nM	250.0	IC50	uM	0.25
Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	COc1ccc(CN2CCN(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)OCc3csc(C)n3)C(C)C)[C@H](C(=O)NC(C)(C)C)C2)cc1OC	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL442398	=	=	IC50	nM	120000.0	IC50	uM	120.0
Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CCc1ncc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3ccc(OC)c(OC)c3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)s1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL331186	=	=	IC50	nM	35000.0	IC50	uM	35.0
Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cccnc3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL324033	=	=	IC50	nM	2300.0	IC50	uM	2.3
Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3ccc4c(c3)OCO4)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL116772	=	=	IC50	nM	9600.0	IC50	uM	9.6
Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cncs3)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL263179	=	=	IC50	nM	15000.0	IC50	uM	15.0
Antiviral activity as inhibition of human liver microsomal Cytochrome P450 3A4	CC(C)c1nc(COC(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CN2CCN(Cc3cccc4c3COC4)C[C@H]2C(=O)NC(C)(C)C)C(C)C)cs1	Bioorg. Med. Chem. Lett.	1998.0	CHEMBL3706711	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of cytochrome P450 3A4	CC(C)(c1cc2cnccc2o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL79236			IC50	nM	30.0	IC50	uM	0.03
Inhibition of cytochrome P450 3A4	CN(C)CCCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL87355	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of cytochrome P450 3A4	CCN(CC)CCCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL315766	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of cytochrome P450 3A4	CN(C)C(=O)CN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL85080	>	>	IC50	nM	500.0	IC50	uM	0.5
Inhibition of cytochrome P450 3A4	Cn1cc(Cc2cn(CC(=O)N(CC(=O)O)Cc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL89750	=	=	IC50	nM	31000.0	IC50	uM	31.0
Inhibition of cytochrome P450 3A4	CCN(CC)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL10921	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of cytochrome P450 3A4	COc1ncc(Cc2cn(CC(=O)N(CC(=O)N(C)C)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL84894	<	<	IC50	nM	500.0	IC50	uM	0.5
Inhibition of cytochrome P450 3A4	Cn1cc(Cc2cn(CC(=O)N(CCN)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL87071	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of cytochrome P450 3A4	Cn1cc(Cc2cn(CC(=O)N(CCO)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL276856	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of cytochrome P450 3A4	CN(C)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL415274	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of cytochrome P450 3A4	CN1CCN(CCCN(Cc2ccc(-c3ccc(Cl)cc3)cc2)C(=O)Cn2cc(Cc3cnn(C)c3)c(=O)nc2SCc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL327705	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of cytochrome P450 3A4	CCN(CC)CCN(Cc1ccc(-c2ccc(Cl)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL86932	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1CN(C(C)(C)c2cc3cnccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL312238	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of cytochrome P450 3A4	Cn1cc(Cc2cn(CC(=O)N(CCN3CCCCC3)Cc3ccc(-c4ccc(C(F)(F)F)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL314768	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of cytochrome P450 3A4	Cn1cc(Cc2cn(CC(=O)N(CCN3CCCC3)Cc3ccc(-c4ccc(Cl)cc4)cc3)c(SCc3ccc(F)cc3)nc2=O)cn1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL405981	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL115	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of cytochrome P450 3A4	CN(C)CCN(Cc1ccc(-c2ccc(C(F)(F)F)cc2)cc1)C(=O)Cn1cc(Cc2cnn(C)c2)c(=O)nc1SCc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2002.0	CHEMBL87792	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(c1ncc(-c2cnccc2Cl)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706622	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of human liver microsome Cytochrome P450 3A4	COc1cncc(-c2cnc(C(C)(C)N3CCN(C[C@@H](O)C[C@@H](Cc4ccccc4)C(=O)N[C@H]4c5ccccc5OC[C@H]4O)[C@H](C(=O)NCC(F)(F)F)C3)o2)c1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706615	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL115	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(c1ncc(-c2ccccn2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706621	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human liver microsome Cytochrome P450 3A4	CC(C)(c1ncc(-c2cccnc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL3706613	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of recombinant human Cytochrome P450 3A4	CCCCc1ccc(C)c(N/C=N/O)c1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL319862	=	=	IC50	nM	94000.0	IC50	uM	94.0
Inhibition of human cytochrome P450 3A4	Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(C)c3ccccc32)n1	J. Med. Chem.	2004.0	CHEMBL330425	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human Cytochrome P450 3A4	CC(C)c1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL101180	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human Cytochrome P450 3A4	Cc1ccccc1/N=C/NO	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL103651	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human cytochrome P450 3A4	Cc1cc(C)cc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1	J. Med. Chem.	2004.0	CHEMBL96347	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of recombinant human Cytochrome P450 3A4	CCCCCCc1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL321051	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human Cytochrome P450 3A4	Cc1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL103320	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human Cytochrome P450 3A4	Nn1nnc2ccccc21	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL101168	=	=	IC50	nM	450.0	IC50	uM	0.45
Inhibition of human cytochrome P450 3A4	CCCCc1cccc([C@]2([C@H](Oc3nc(C)cc(C)n3)C(=O)O)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)c1	J. Med. Chem.	2004.0	CHEMBL330354	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of recombinant human Cytochrome P450 3A4	CCC(C)c1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL100899	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human Cytochrome P450 3A4	CC(C)(C)c1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL103163	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human Cytochrome P450 3A4	CCc1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL101296	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human Cytochrome P450 3A4	CCCCc1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL103313	=	=	IC50	nM	65000.0	IC50	uM	65.0
Inhibition of recombinant human Cytochrome P450 3A4	ON/C=N/c1ccc(Cc2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL445120	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human Cytochrome P450 3A4	CCCCc1ccc(/N=C/NO)c(C)c1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL267865	=	=	IC50	nM	71000.0	IC50	uM	71.0
Inhibition of recombinant human Cytochrome P450 3A4	CCCCc1ccccc1/N=C/NO	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL100917	=	=	IC50	nM	51000.0	IC50	uM	51.0
Inhibition of human cytochrome P450 3A4	Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3ccccc3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1	J. Med. Chem.	2004.0	CHEMBL329477	=	=	IC50	nM	41000.0	IC50	uM	41.0
Inhibition of recombinant human Cytochrome P450 3A4	CCCOc1ccc(N/C=N/O)cc1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL317798	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human cytochrome P450 3A4	Cc1cc(C)nc(O[C@H](C(=O)O)[C@@]2(c3cccc(-c4ccccc4)c3)NCC(=O)N(Cc3c(F)cc(F)cc3F)c3ccccc32)n1	J. Med. Chem.	2004.0	CHEMBL319754	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of cytochrome P450 3A4	c1cncc(CCCOc2ccc(-n3ccnc3)cc2)c1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL262968	=	=	IC50	nM	417.0	IC50	nM	417.0
Inhibition of cytochrome P450 3A4	CCOC(=O)N1CCN(CCOc2ccc(-n3ccnc3)cc2)CC1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL114555	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Inhibition of cytochrome P450 3A4	c1cn(-c2ccc(OCCN3CCOCC3)cc2)cn1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL113018	=	=	IC50	nM	5670.0	IC50	nM	5670.0
Inhibition of cytochrome P450 3A4	CN(C)CCOc1ccc(-n2ccnc2)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL325429	>	>	IC50	nM	100000.0	IC50	nM	100000.0
Inhibition of cytochrome P450 3A4	c1cc(CCCOc2ccc(-n3ccnc3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL113227	=	=	IC50	nM	344.0	IC50	nM	344.0
Inhibition of cytochrome P450 3A4	CN(C)CCCOc1ccc(-n2ccnc2)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL114297	=	=	IC50	nM	39000.0	IC50	nM	39000.0
Inhibition of cytochrome P450 3A4	c1ccc(CCCOc2ccc(-n3ccnc3)cc2)nc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL115876	=	=	IC50	nM	252.0	IC50	nM	252.0
Inhibition of cytochrome P450 3A4	CCCCOc1ccc(-n2ccnc2)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL112532	=	=	IC50	nM	348.0	IC50	nM	348.0
Inhibition of cytochrome P450 3A4	CN(C)CCCCCCOc1ccc(-n2ccnc2)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL113275	=	=	IC50	nM	4460.0	IC50	nM	4460.0
Inhibition of cytochrome P450 3A4	c1ccc(COc2ccc(-n3ccnc3)cc2)nc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL112592	=	=	IC50	nM	630.0	IC50	nM	630.0
Inhibition of cytochrome P450 3A4	CCCCCCOc1ccc(-n2ccnc2)cn1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL320105	=	=	IC50	nM	76900.0	IC50	nM	76900.0
Inhibition of heterologously expressed human cytochrome P450 3A4	CSc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cccnc1)CC2	J. Med. Chem.	2000.0	CHEMBL276140	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of heterologously expressed human cytochrome P450 3A4	Cc1cc2c(cc1Cl)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2	J. Med. Chem.	2000.0	CHEMBL14563	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of heterologously expressed human cytochrome P450 3A4	Cc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1ccc(Oc3cccnc3C)nc1)CC2	J. Med. Chem.	2000.0	CHEMBL14460	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of heterologously expressed human cytochrome P450 3A4	COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(F)cc(-c3cccnc3)c1)CC2	J. Med. Chem.	2000.0	CHEMBL14276	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of human liver microsome cytochrome P450 3A4	COCCN(C)c1nc(N)c(CN)c(-c2ccc(Cl)cc2Cl)n1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL324777	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human liver microsome Cytochrome P3A4	NCc1c(N)nc(-c2ccccc2)nc1-c1ccc(Cl)cc1Cl	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL36020	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL444533	=	=	IC50	nM	430.0	IC50	uM	0.43
Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccccc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccncc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL326796	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2ccc(-c3ccncc3)o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL114756	=	=	IC50	nM	320.0	IC50	uM	0.32
Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(CC2=CC3C=CSC3S2)CCN1C[C@@H](O)C[C@@H](Cc1ccncc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL326849	=	=	IC50	nM	470.0	IC50	uM	0.47
Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3ccccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1ccncc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL325829	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(CC2=CC3C=CSC3S2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL419396	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3ccccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL324461	=	=	IC50	nM	480.0	IC50	uM	0.48
Inhibition of human liver microsome Cytochrome P450 3A4	O=C(NCC(F)(F)F)[C@@H]1CN(Cc2cc3cccc(Cl)c3o2)CCN1C[C@@H](O)C[C@@H](Cc1cccnc1)C(=O)N[C@H]1c2ccccc2OC[C@H]1O	Bioorg. Med. Chem. Lett.	2003.0	CHEMBL321814	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc(Cn2cncc2CN[C@H]2CCN(Cc3cccc(Cl)c3)C2=O)cc1	J. Med. Chem.	2002.0	CHEMBL312137	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1cccc(c1)CN1CC[C@@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL502560	=	=	IC50	nM	8900.0	IC50	uM	8.9
Inhibition of human Cytochrome P450 3A4 by macrocycles	CN1Cc2cncn2Cc2ccc(C#N)c(c2)Oc2ccc3cccc(c3c2)N2CCC1C2=O	J. Med. Chem.	2002.0	CHEMBL312121	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL526466	=	=	IC50	nM	6600.0	IC50	uM	6.6
Inhibition of dog Cytochrome P450 3A by macrocycles	N#Cc1ccc2cc1Oc1ccc3c(c1)[C@@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL526466	=	=	IC50	nM	10400.0	IC50	uM	10.4
Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1ccc3c(c1)[C@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL526656	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of dog Cytochrome P450 3A by macrocycles	N#Cc1ccc2cc1Oc1ccc3c(c1)[C@H](CC3)N1CC[C@@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL526656	=	=	IC50	nM	14800.0	IC50	uM	14.8
Inhibition of recombinant human Cytochrome P450 3A4 with BFC	CSc1nc2ccccn2c(=N)c1S(=O)(=O)c1ccccc1	J. Med. Chem.	2003.0	CHEMBL355905	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human Cytochrome P450 3A4 with BzRes	CSc1nc2ccccn2c(=N)c1S(=O)(=O)c1ccccc1	J. Med. Chem.	2003.0	CHEMBL355905	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL80702	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of dog Cytochrome P450 3A by macrocycles	N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCC(NCCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL80702	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CC[C@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL53821	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of dog Cytochrome P450 3A by macrocycles	N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CC[C@H](NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL53821	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of dog Cytochrome P450 3A by macrocycles	CC1c2ccc(C#N)c(c2)Oc2cccc(c2)CN2CCC(NCc3cncn31)C2=O	J. Med. Chem.	2002.0	CHEMBL78742	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1ccc(Br)c(c1)CN1CCC(NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL311561	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of human Cytochrome P450 3A4 by macrocycles	N#Cc1ccc2cc1Oc1cccc(c1)-c1ccccc1N1CCC(NCc3cncn3C2)C1=O	J. Med. Chem.	2002.0	CHEMBL310586	<	<	IC50	nM	50.0	IC50	uM	0.05
Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL421841	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)ccnc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL421841	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay	O=C(NCc1ccccn1)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2	J. Med. Chem.	2004.0	CHEMBL26485	=	=	IC50	nM	30150.0	IC50	uM	30.15
Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL164261	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(Cl)nc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL164261	=	=	IC50	nM	8100.0	IC50	uM	8.1
Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BFC	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL162383	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP450 (Cytochrome P450) 3A4 with fluorogenic substrate BQ	CCN1c2ncc(CSc3cc(C)nc(C)c3)cc2C(=O)Nc2c(C)cc(F)nc21	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL162383	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay	COc1cccc(CNC(=O)c2c3n(c4c(N5CCN(CCc6ccc(F)c(F)c6)CC5)ncnc24)CCCC3)c1OC	J. Med. Chem.	2004.0	CHEMBL27102	=	=	IC50	nM	2440.0	IC50	uM	2.44
Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay	NC(=O)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2	J. Med. Chem.	2004.0	CHEMBL26599	=	=	IC50	nM	45800.0	IC50	uM	45.8
Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay	O=C(Nc1cccnc1)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2	J. Med. Chem.	2004.0	CHEMBL280981	=	=	IC50	nM	9730.0	IC50	uM	9.73
Inhibitory concentration to inhibit MRP1 in CYP 3A4 assay	CCNC(=O)c1c2n(c3c(N4CCN(CCc5ccc(F)c(F)c5)CC4)ncnc13)CCCC2	J. Med. Chem.	2004.0	CHEMBL286272	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human cytochrome P450 3A4	COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1	J. Med. Chem.	2003.0	CHEMBL296419	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of human cytochrome P450 3A4	COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2	J. Med. Chem.	2003.0	CHEMBL107	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human cytochrome P450 3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL157101	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of human cytochrome P450 3A4	COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O	J. Med. Chem.	2003.0	CHEMBL44657	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL157101	=	=	IC50	nM	16.0	IC50	uM	0.016
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL157101	=	=	IC50	nM	13.0	IC50	uM	0.013
Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL157101	=	=	IC50	nM	17.0	IC50	uM	0.017
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL157101	=	=	IC50	nM	22.0	IC50	uM	0.022
Inhibition of human cytochrome P450 3A4	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	J. Med. Chem.	2003.0	CHEMBL6966	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of human cytochrome P450 3A4	COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1	J. Med. Chem.	2003.0	CHEMBL1484	=	=	IC50	nM	420.0	IC50	uM	0.42
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin]	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of recombinant human Cytochrome P450 3A4 with Benzoylresorufin	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	76000.0	IC50	uM	76.0
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	96000.0	IC50	uM	96.0
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	62000.0	IC50	uM	62.0
Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes	C[C@H](NC(=O)/C=C/c1ccccc1)c1cccc(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL317935	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of human cytochrome P450 3A4	CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H]1C(=O)O	J. Med. Chem.	2003.0	CHEMBL294616	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human cytochrome P450 3A4	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	J. Med. Chem.	2003.0	CHEMBL584	=	=	IC50	nM	550.0	IC50	uM	0.55
Inhibition of human cytochrome P450 3A4	CN/C(=N/CCSCc1nc[nH]c1C)NC#N	J. Med. Chem.	2003.0	CHEMBL30	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes	C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL100379	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes	C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL100379	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes	C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL100379	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes	C[C@H](NC(=O)/C=C/c1ccc(F)cc1)c1ccc(F)c(N2CCOCC2)c1	J. Med. Chem.	2003.0	CHEMBL100379	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of human cytochrome P450 3A4	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO	J. Med. Chem.	2003.0	CHEMBL389621	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 5 minutes	CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	J. Med. Chem.	2003.0	CHEMBL564085	=	=	IC50	nM	61000.0	IC50	uM	61.0
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 15 minutes	CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	J. Med. Chem.	2003.0	CHEMBL564085	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of recombinant human Cytochrome P450 3A4 using BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 30 minutes	CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	J. Med. Chem.	2003.0	CHEMBL564085	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human Cytochrome P450 3A4 with BFC [7-benzyloxy-4-trifluoromethylcoumarin] after 45 minutes	CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	J. Med. Chem.	2003.0	CHEMBL564085	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of human cytochrome P450 3A4	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	J. Med. Chem.	2003.0	CHEMBL45816	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of human cytochrome P450 3A4	Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2	J. Med. Chem.	2003.0	CHEMBL655	=	=	IC50	nM	8100.0	IC50	uM	8.1
Inhibition of human cytochrome P450 3A4	CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1	J. Med. Chem.	2003.0	CHEMBL17157	=	=	IC50	nM	320.0	IC50	uM	0.32
Inhibition of human cytochrome P450 3A4	CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5	J. Med. Chem.	2003.0	CHEMBL70	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human cytochrome P450 3A4	C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O	J. Med. Chem.	2003.0	CHEMBL1751	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human cytochrome P450 3A4	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	J. Med. Chem.	2003.0	CHEMBL114	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of human cytochrome P450 3A4	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	J. Med. Chem.	2003.0	CHEMBL104	=	=	IC50	nM	20.0	IC50	uM	0.02
Inhibition of human cytochrome P450 3A4	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	J. Med. Chem.	2003.0	CHEMBL163	=	=	IC50	nM	30.0	IC50	uM	0.03
Inhibition of human cytochrome P450 3A4	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	J. Med. Chem.	2003.0	CHEMBL64391	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of human cytochrome P450 3A4	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O	J. Med. Chem.	2003.0	CHEMBL1200633	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human cytochrome P450 3A4	O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	J. Med. Chem.	2003.0	CHEMBL1423	=	=	IC50	nM	9700.0	IC50	uM	9.7
Inhibition of human cytochrome P450 3A4	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO	J. Med. Chem.	2003.0	CHEMBL384467	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human cytochrome P450 3A4	C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	J. Med. Chem.	2003.0	CHEMBL1294	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human cytochrome P450 3A4	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	J. Med. Chem.	2003.0	CHEMBL91	=	=	IC50	nM	180.0	IC50	uM	0.18
Inhibition of human cytochrome P450 3A4	CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1	J. Med. Chem.	2003.0	CHEMBL1790041	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human cytochrome P450 3A4	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	J. Med. Chem.	2003.0	CHEMBL160	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of human cytochrome P450 3A4	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2003.0	CHEMBL532	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of human cytochrome P450 3A4	CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1	J. Med. Chem.	2003.0	CHEMBL159	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of human cytochrome P450 3A4	C[C@H](Nc1cc(-c2sc(C3CCN(C)CC3)nc2-c2ccc(F)cc2)ccn1)c1ccccc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL2111784	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human cytochrome P450 3A4	COc1ccc(C#CC(C)(C)N)cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL419409	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human cytochrome P450 3A4	CN1CCN(c2ccc3c(n2)nc(-c2ccc(F)cc2)n3-c2ccnc(NC3CCCC3)n2)CC1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL120185	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human cytochrome P450 3A4	OC1(c2nc(-c3ccc(F)cc3)c(-c3ccnc(NC4CCCCC4)c3)o2)CCNCC1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL121405	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human cytochrome P450 3A4	COc1cc2[nH]c(C)nc2cc1C(=O)c1ccc(Nc2ccc(F)cc2F)cc1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL120067	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of cytochrome P450 CYP3A4 in human liver microsomes	Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1	Bioorg. Med. Chem. Lett.	2001.0	CHEMBL416146	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human cytochrome P450 3A4	CN1CCC(O)(c2cn(-c3ccnc(NC4CCCC4)n3)c(-c3cccc(C(F)(F)F)c3)n2)CC1	Bioorg. Med. Chem. Lett.	2004.0	CHEMBL118258	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	1992.0	CHEMBL157101	=	=	IC50	nM	786.0	IC50	uM	0.786
Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes	CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	1992.0	CHEMBL328863	=	=	IC50	nM	897.0	IC50	uM	0.897
Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	1992.0	CHEMBL319160	=	=	IC50	nM	570.0	IC50	uM	0.57
Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	1992.0	CHEMBL157101	=	=	IC50	nM	1260.0	IC50	uM	1.26
Inhibitory concentration value against human cytochrome P-450 3A4	CNc1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL179529	=	=	IC50	nM	6300.0	IC50	uM	6.3
Inhibitory concentration value against human cytochrome P-450 3A4	Cn1cnc(-c2cccnc2)c1	J. Med. Chem.	2005.0	CHEMBL360999	=	=	IC50	nM	262000.0	IC50	uM	262.0
Inhibitory concentration value against human cytochrome P-450 3A4	CCn1cnc(-c2cccnc2)c1	J. Med. Chem.	2005.0	CHEMBL361364	=	=	IC50	nM	79200.0	IC50	uM	79.2
Inhibitory concentration value against human cytochrome P-450 3A4	c1ccc(Cn2cnc(-c3cccnc3)c2)cc1	J. Med. Chem.	2005.0	CHEMBL178780	=	=	IC50	nM	75100.0	IC50	uM	75.1
Inhibitory concentration value against human cytochrome P-450 3A4	Cc1cn(-c2cccnc2)cn1	J. Med. Chem.	2005.0	CHEMBL178781	=	=	IC50	nM	109000.0	IC50	uM	109.0
Inhibitory concentration value against human cytochrome P-450 3A4	c1cncc(-c2cccs2)c1	J. Med. Chem.	2005.0	CHEMBL179618	=	=	IC50	nM	57000.0	IC50	uM	57.0
Inhibitory concentration value against human cytochrome P-450 3A4	Cc1ccsc1-c1cccnc1	J. Med. Chem.	2005.0	CHEMBL179669	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibitory concentration value against human cytochrome P-450 3A4	O=Cc1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL179398	=	=	IC50	nM	23900.0	IC50	uM	23.9
Inhibitory concentration value against human cytochrome P-450 3A4	CC(=O)c1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL362702	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibitory concentration value against human cytochrome P-450 3A4	c1cncc(-c2ccsc2)c1	J. Med. Chem.	2005.0	CHEMBL361153	=	=	IC50	nM	56900.0	IC50	uM	56.9
Inhibitory concentration value against human cytochrome P-450 3A4	Fc1ccc(-c2ccsc2)cn1	J. Med. Chem.	2005.0	CHEMBL179005	=	=	IC50	nM	114000.0	IC50	uM	114.0
Inhibitory concentration value against human cytochrome P-450 3A4	Cc1cscc1-c1cccnc1	J. Med. Chem.	2005.0	CHEMBL179704	=	=	IC50	nM	80900.0	IC50	uM	80.9
Inhibitory concentration value against human cytochrome P-450 3A4	Cc1cscc1-c1ccc(F)nc1	J. Med. Chem.	2005.0	CHEMBL425519	=	=	IC50	nM	39100.0	IC50	uM	39.1
Inhibitory concentration value against human cytochrome P-450 3A4	c1cncc(-c2cccnc2)c1	J. Med. Chem.	2005.0	CHEMBL179763	=	=	IC50	nM	64700.0	IC50	uM	64.7
Inhibitory concentration value against human cytochrome P-450 3A4	c1cncc(-c2c[nH]cn2)c1	J. Med. Chem.	2005.0	CHEMBL178516	=	=	IC50	nM	139900.0	IC50	uM	139.9
Inhibitory concentration value against human cytochrome P-450 3A4	O/N=C/c1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL178534	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibitory concentration value against human cytochrome P-450 3A4	O/N=C/c1ccc(-c2cccnc2)o1	J. Med. Chem.	2005.0	CHEMBL178547	>	>	IC50	nM	400000.0	IC50	uM	400.0
Inhibitory concentration value against human cytochrome P-450 3A4	O/N=C\c1ccc(-c2cccnc2)o1	J. Med. Chem.	2005.0	CHEMBL178330	>	>	IC50	nM	400000.0	IC50	uM	400.0
Inhibitory concentration value against human cytochrome P-450 3A4	NCc1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL359657	=	=	IC50	nM	58700.0	IC50	uM	58.7
Inhibitory concentration value against human cytochrome P-450 3A4	c1cncc(-c2ccc(CNCc3ccc(-c4cccnc4)s3)s2)c1	J. Med. Chem.	2005.0	CHEMBL178711	>	>	IC50	nM	400000.0	IC50	uM	400.0
Inhibitory concentration value against human cytochrome P-450 3A4	NCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2005.0	CHEMBL178090	=	=	IC50	nM	47100.0	IC50	uM	47.1
Inhibitory concentration value against human cytochrome P-450 3A4	C[n+]1c[nH]cc1-c1cccnc1	J. Med. Chem.	2005.0	CHEMBL179399	=	=	IC50	nM	262000.0	IC50	uM	262.0
Inhibitory concentration value against human cytochrome P-450 3A4	O/N=C/c1ccc(-c2cccnc2)o1.O/N=C\c1ccc(-c2cccnc2)o1	J. Med. Chem.	2005.0	CHEMBL1795039	=	=	IC50	nM	51900.0	IC50	uM	51.9
Inhibitory concentration value against human cytochrome P-450 3A4	N=Cc1ccc(-c2cccnc2)s1.N=Cc1ccc(-c2cccnc2)s1.NCc1ccc(-c2cccnc2)s1	J. Med. Chem.	2005.0	CHEMBL178681	=	=	IC50	nM	77500.0	IC50	uM	77.5
Inhibitory concentration value against human cytochrome P-450 3A4	Cc1nccn1-c1cccnc1	J. Med. Chem.	2005.0	CHEMBL368883	=	=	IC50	nM	152000.0	IC50	uM	152.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(OC(C)(C)C)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL181385	=	=	IC50	nM	580.0	IC50	nM	580.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(OC(C)(C)C)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL181385	=	=	IC50	nM	40.0	IC50	nM	40.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccccc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180856	=	=	IC50	nM	200.0	IC50	nM	200.0
Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)Cc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL179825	=	=	IC50	nM	4.0	IC50	nM	4.0
Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)COc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL362412	=	=	IC50	nM	220.0	IC50	nM	220.0
Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)COc1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL362412	=	=	IC50	nM	140.0	IC50	nM	140.0
Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL181309	=	=	IC50	nM	210.0	IC50	nM	210.0
Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL181309	=	=	IC50	nM	160.0	IC50	nM	160.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180805	=	=	IC50	nM	700.0	IC50	nM	700.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180805	=	=	IC50	nM	220.0	IC50	nM	220.0
Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)c1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL178474	=	=	IC50	nM	40.0	IC50	nM	40.0
Selectivity towards cytochrome P450 3A4 enzyme activity	COC(=O)c1ccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)cc1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL178474	=	=	IC50	nM	10.0	IC50	nM	10.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(C#N)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL359627	=	=	IC50	nM	320.0	IC50	nM	320.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(C#N)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL359627	=	=	IC50	nM	260.0	IC50	nM	260.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc([N+](=O)[O-])cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180592	=	=	IC50	nM	344.0	IC50	nM	344.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(=O)O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL178873	=	=	IC50	nM	2200.0	IC50	nM	2200.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(CC(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180348	=	=	IC50	nM	4.0	IC50	nM	4.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(OCC(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL179550	=	=	IC50	nM	750.0	IC50	nM	750.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3cccc(C(=O)O)c3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL426789	=	=	IC50	nM	3790.0	IC50	nM	3790.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3cccc(C(=O)O)c3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL426789	=	=	IC50	nM	1590.0	IC50	nM	1590.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(C(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL368448	=	=	IC50	nM	640.0	IC50	nM	640.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3ccc(C(=O)O)cc3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL368448	=	=	IC50	nM	1180.0	IC50	nM	1180.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL360771	=	=	IC50	nM	6300.0	IC50	nM	6300.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL360771	=	=	IC50	nM	1488.0	IC50	nM	1488.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3cccc(C(N)=O)c3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL360148	=	=	IC50	nM	481.0	IC50	nM	481.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CNC(=O)c1cccc(COc2ccc3cc(C(C(C)N(C)C)n4ccnc4)ccc3c2)c1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL182438	=	=	IC50	nM	397.0	IC50	nM	397.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCc3cccc(C(=O)N(C)C)c3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL360072	=	=	IC50	nM	357.0	IC50	nM	357.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C(N)=O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL362489	=	=	IC50	nM	1835.0	IC50	nM	1835.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CNC(=O)C(C)(C)COc1ccc2cc(C(C(C)N(C)C)n3ccnc3)ccc2c1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL180829	=	=	IC50	nM	2010.0	IC50	nM	2010.0
Selectivity towards cytochrome P450 3A4 enzyme activity	CC(C(c1ccc2cc(OCC(C)(C)C(=O)N(C)C)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL367357	=	=	IC50	nM	2032.0	IC50	nM	2032.0
Inhibitory concentration against Cytochrome P450 3A4	O=C(O)c1cnc(N(C(=O)c2ccc(OCc3cccc(C(F)(F)F)c3)cc2)C2CCCCC2)s1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL360033	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibitory concentration against Cytochrome 450 3A4	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(C3)C1)C2	J. Med. Chem.	2005.0	CHEMBL3350935	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibitory concentration against Cytochrome P450 3A4	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2	J. Med. Chem.	2005.0	CHEMBL385517	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-4-(trifluoromethyl)coumarin (BFC) as fluorogenic substrate	CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2cccnc21	J. Med. Chem.	2005.0	CHEMBL192530	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-quinoline (BQ) as fluorogenic substrate	CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2cccnc21	J. Med. Chem.	2005.0	CHEMBL192530	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-4-(trifluoromethyl)coumarin (BFC) as fluorogenic substrate	CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2ccc(F)nc21	J. Med. Chem.	2005.0	CHEMBL189942	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibitory concentration (1.5 mM) against human CYP450 3A4 dissolved in acetonitrile/methanol using 7-Benzyloxy-quinoline (BQ) as fluorogenic substrate	CCN1c2ncc(CCOc3ccc(C(=O)O)cc3C)cc2C(=O)N(C)c2ccc(F)nc21	J. Med. Chem.	2005.0	CHEMBL189942	>	>	IC50	nM	30000.0	IC50	uM	30.0
In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)ncn3C)cc21	J. Med. Chem.	2005.0	CHEMBL193305			IC50	nM		IC50	uM	
In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)cc21	J. Med. Chem.	2005.0	CHEMBL434957			IC50	nM		IC50	uM	
In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(-c4c(F)cccc4F)nc3-c3ccccc3)cc21	J. Med. Chem.	2005.0	CHEMBL364572	=	=	IC50	nM	6.3	IC50	nM	6.3
In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]cnc3-c3ccccc3)cc21	J. Med. Chem.	2005.0	CHEMBL192848	=	=	IC50	nM	1600.0	IC50	uM	1.6
In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]cnc3-c3ccc(F)cc3)cc21.CS(=O)(=O)O.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL192850	=	=	IC50	nM	800.0	IC50	uM	0.8
In vitro inhibitory concentration against Cytochrome P450 3A4	CCc1nc(-c2ccc(F)cc2)c(-c2ccc3nc(N)n(S(=O)(=O)C(C)C)c3c2)[nH]1.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL191053	=	=	IC50	nM	4400.0	IC50	uM	4.4
In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)c1nc(-c2ccc(F)cc2)c(-c2ccc3nc(N)n(S(=O)(=O)C(C)C)c3c2)[nH]1.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL364925	=	=	IC50	nM	6100.0	IC50	uM	6.1
In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)cc21.CS(=O)(=O)O.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL193055	=	=	IC50	nM	31800.0	IC50	uM	31.8
In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3F)cc21.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL363831			IC50	nM		IC50	uM	
In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)(C)c1nc(-c2ccc(F)cc2F)c(-c2ccc3nc(N)n(S(=O)(=O)C(C)(C)C)c3c2)[nH]1.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL190514			IC50	nM		IC50	uM	
In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(-c4c(Cl)cccc4Cl)nc3-c3ccccc3)cc21.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL192889			IC50	nM		IC50	uM	
In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(C4CCNCC4)nc3-c3ccccc3)cc21	J. Med. Chem.	2005.0	CHEMBL191113			IC50	nM		IC50	uM	
In vitro inhibitory concentration against Cytochrome P450 3A4	CC(C)CN1CCC(c2nc(-c3ccc4nc(N)n(S(=O)(=O)C(C)C)c4c3)c(-c3ccccc3)[nH]2)CC1	J. Med. Chem.	2005.0	CHEMBL371145	=	=	IC50	nM	5300.0	IC50	uM	5.3
In vitro inhibitory concentration against Cytochrome P450 3A4	CS(=O)(=O)O.CS(=O)(=O)O.Nc1nc2ccc(-c3[nH]c(-c4c(F)cccc4F)nc3-c3ccccc3)cc2n1S(=O)(=O)C1CCCC1	J. Med. Chem.	2005.0	CHEMBL193247	=	=	IC50	nM	13000.0	IC50	uM	13.0
In vitro inhibitory concentration against Cytochrome P450 3A4; NT means not tested	CN(C)S(=O)(=O)n1c(N)nc2ccc(-c3[nH]c(-c4c(F)cccc4F)nc3-c3ccccc3)cc21.CS(=O)(=O)O.CS(=O)(=O)O	J. Med. Chem.	2005.0	CHEMBL363852			IC50	nM		IC50	uM	
Inhibitory concentration against human cytochrome P450 3A4	CONC(=O)c1cc(Nc2ncnn3cc(-c4ncc(C)o4)c(C(C)C)c23)c(F)cc1F	J. Med. Chem.	2005.0	CHEMBL193306	=	=	IC50	nM	5100.0	IC50	uM	5.1
In vitro inhibitory concentration against human Cytochrome P450 3A4	O=C(O)Cc1ccc2oc(-c3ccc(NC(=O)/C=C/c4ccc(Br)cc4)c(F)c3)nc2c1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL196875	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibitory concentration against human hepatic cytochrome P450 3A4 enzyme	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2005.0	CHEMBL157101	=	=	IC50	nM	50.0	IC50	nM	50.0
Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy-4-trifluoromethylcoumarin	O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL222460	=	=	IC50	nM	8100.0	IC50	uM	8.1
Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzylether	O=c1[nH]c2ccc(C(F)(F)F)cc2c(-c2cc(Cl)ccc2O)c1CCO	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL222460	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin	N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL195561	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether	N#CCn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL195561	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin	NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL371409	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether	NC(=O)Cn1c(=O)c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL371409	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using 7-benzyloxy- 4-trifluoromethylcoumarin	O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL193647	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition against Cytochrome P450 3A4 prepared from baculovirus-infected insect cells using resorufin benzyl ether	O=c1c(CCO)c(-c2cc(Cl)ccc2O)c2cc(C(F)(F)F)ccc2n1Cc1nn[nH]n1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL193647	=	=	IC50	nM	13000.0	IC50	uM	13.0
Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BFC in vitro by 50%	Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2005.0	CHEMBL231306	<	<	IC50	nM	18.0	IC50	uM	0.018
Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BzRes in vitro by 50%	Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2005.0	CHEMBL231306	<	<	IC50	nM	18.0	IC50	uM	0.018
Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BFC in vitro by 50%	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2005.0	CHEMBL401930	=	=	IC50	nM	500.0	IC50	uM	0.5
Concentration required to inhibit cytochrome P450 isozyme CYP3A4-BzRes in vitro by 50%	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2005.0	CHEMBL401930	=	=	IC50	nM	5300.0	IC50	uM	5.3
Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	CC(C(=O)O)c1ccc(-c2ccc(-c3ccc(O)cc3)cc2)c(F)c1	J. Med. Chem.	2005.0	CHEMBL197202	=	=	IC50	nM	74000.0	IC50	uM	74.0
Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	O=C(O)C1(c2ccc(-c3ccc(Cl)c(Cl)c3)c(F)c2)CC1	J. Med. Chem.	2005.0	CHEMBL196945	=	=	IC50	nM	48000.0	IC50	uM	48.0
Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	CC1(C)CCC(c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC1	J. Med. Chem.	2005.0	CHEMBL372751	=	=	IC50	nM	84000.0	IC50	uM	84.0
Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	CC(C)(C(=O)O)c1ccc(-c2ccc(C3CCCCC3)cc2)c(F)c1	J. Med. Chem.	2005.0	CHEMBL364738	=	=	IC50	nM	59000.0	IC50	uM	59.0
Inhibition of cytochrome P450 3A4 at 100 uM; activation observed	O=C(O)C1(c2ccc(-c3ccc(C4CCCCC4)cc3)c(F)c2)CC1	J. Med. Chem.	2005.0	CHEMBL194838	=	=	IC50	nM	59000.0	IC50	uM	59.0
Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	O=C(O)C1(c2ccc(-c3ccc(-c4ccc(O)cc4)c(F)c3)c(F)c2)CC1	J. Med. Chem.	2005.0	CHEMBL372846	=	=	IC50	nM	58000.0	IC50	uM	58.0
Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	O=C(O)C1(c2ccc(-c3ccc(-c4ccc(F)cc4)c(F)c3)c(F)c2)CC1	J. Med. Chem.	2005.0	CHEMBL427548	=	=	IC50	nM	38000.0	IC50	uM	38.0
Interaction with human cytochrome P450 isoform 3A4 expressed in baculovirus-insect cells	CC1(C)CC(Oc2ccc(-c3ccc(C4(C(=O)O)CC4)cc3F)cc2)CC(C)(C)C1	J. Med. Chem.	2005.0	CHEMBL197140	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibitory activity against cytochrome P450 3A4 isoform	O=C(CN(c1ccc(Cl)cc1)S(=O)(=O)c1ccc(NCCN2CCOCC2)cc1)N/N=C1\C(=O)Nc2ccccc21	J. Med. Chem.	2005.0	CHEMBL2113177	=	=	IC50	nM	310.0	IC50	nM	310.0
Inhibitory activity against CYP3A4	CC(C)(c1ncc(-c2ccc(Cl)cc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2cc3cnccc3s2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL373039	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibitory activity against CYP3A4	CC(C)(c1ncc(-c2ccc(Cl)cc2)o1)N1CCN(C[C@@H](O)C[C@@H](Cc2cc3ccncc3o2)C(=O)N[C@H]2c3ccccc3OC[C@H]2O)[C@H](C(=O)NCC(F)(F)F)C1	Bioorg. Med. Chem. Lett.	2005.0	CHEMBL381630	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibitory activity against CYP3A4	c1ccc(OCCCN2CCC(Cc3c[nH]cn3)CC2)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL200267	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibitory activity against CYP3A4	CN(C)CCCOc1ccc(CN2CCCCC2)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL381717	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of cytochrome P450 3A4	Nc1c(C(=O)c2cccc(OC[C@@H](O)CO)c2)cnn1-c1ccc(F)cc1	J. Med. Chem.	2006.0	CHEMBL203567	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2006.0	CHEMBL157101	=	=	IC50	nM	50.0	IC50	nM	50.0
Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCCN5CCCCC5)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL205142	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCCNS(C)(=O)=O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL206545	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCCS(C)(=O)=O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL383077	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibitory activity against CYP3A4	COC[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C	J. Med. Chem.	2006.0	CHEMBL205710	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@H](C)O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL427202	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL377300	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCN5CC[C@H](O)C5)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL380957	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCCN5CCCC5)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL206146	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibitory activity against CYP3A4	Cc1cc2c(F)c(Oc3ncnn4cc(OCCC5CCN(C)CC5)c(C)c34)ccc2[nH]1	J. Med. Chem.	2006.0	CHEMBL206145	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccccc34)sc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205742	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4	Cc1nc(Cl)c(Cl)n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205245	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL204772	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CC[C@@H](O)C1)c(=O)n(C)c(=O)n2CC(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL426851	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3c[nH]c4ncccc34)sc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205092	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3c[nH]c4ccccc34)sc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205807	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3cncc4ccccc34)sc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207100	<	<	IC50	nM	70.0	IC50	uM	0.07
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3cccc4ncccc34)sc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL204476	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCNC(C)=O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL411885	=	=	IC50	nM	82.0	IC50	nM	82.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2CSc2ccc3c(c2)N(CC(=O)O)C(=O)CO3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL380360	=	=	IC50	nM	15000.0	IC50	nM	15000.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CC(=O)O)C(=O)CO3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL381076	=	=	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COCCCN1C(=O)COc2ccc(SC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205345	=	=	IC50	nM	14.0	IC50	nM	14.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COCCCN1C(=O)CCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL193816	=	=	IC50	nM	35.0	IC50	nM	35.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCC(=O)O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL382144	=	=	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCCO)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL372416	=	=	IC50	nM	455.0	IC50	nM	455.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COCCCN1CCCc2ccc(OC[C@H]3CNCC(=O)N3c3ccc(OCCCOCc4ccccc4OC)cc3)cc21	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL377531	=	=	IC50	nM	12.0	IC50	nM	12.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCOC(=O)C(C)C)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208112	=	=	IC50	nM	54.0	IC50	nM	54.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN2CCOC2=O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL381568	=	=	IC50	nM	3790.0	IC50	nM	3790.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN2CCCC2=O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL380866	=	=	IC50	nM	42.0	IC50	nM	42.0
Inhibition of CYP3A4 using BFC fluorogenic substrate	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCN(C)C(C)=O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL377512	=	=	IC50	nM	18.0	IC50	nM	18.0
Inhibition of CYP3A4	CCOC(=O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1	J. Med. Chem.	2006.0	CHEMBL205808	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)(C(=O)O)N1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)C1	J. Med. Chem.	2006.0	CHEMBL205993	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CCN(Cc2cccc(Oc3ccccc3Cl)c2)CC1)C1(c2ccccc2)CCNC1	J. Med. Chem.	2006.0	CHEMBL381619	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)(C(=O)O)N1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1	J. Med. Chem.	2006.0	CHEMBL380492	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCN1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1	J. Med. Chem.	2006.0	CHEMBL204419	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCN1CCC(C(=O)NC2CCN(Cc3cccc(Oc4ccccc4OC)c3)CC2)(c2ccccc2)CC1	J. Med. Chem.	2006.0	CHEMBL209350	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccccc4)CCNCC3)CC2)c1	J. Med. Chem.	2006.0	CHEMBL205447	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccc(Cl)cc4)CCCCC3)CC2)c1	J. Med. Chem.	2006.0	CHEMBL205457	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1ccccc1Oc1cccc(CN2CCC(NC(=O)Cc3ccccc3)CC2)c1	J. Med. Chem.	2006.0	CHEMBL210322	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(Cc1ccccc1)NC1CCN(Cc2cccc(Oc3ccccc3)c2)CC1	J. Med. Chem.	2006.0	CHEMBL205692	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCC(=O)NC1CCN(Cc2cccc(Oc3ccccc3)c2)CC1	J. Med. Chem.	2006.0	CHEMBL381354	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCNC(=O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1	J. Med. Chem.	2006.0	CHEMBL205304	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)C1CCN(Cc2cccc(Oc3ccccc3)c2)CC1	J. Med. Chem.	2006.0	CHEMBL377931	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1ccccc1Oc1cccc(CN2CCC(NC(=O)C3(c4ccccc4)CCNCC3)(C(=O)O)CC2)c1	J. Med. Chem.	2006.0	CHEMBL379834	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCN1CCC(C(=O)NC2(C(=O)O)CCN(Cc3cccc(Oc4ccccc4Cl)c3)CC2)(c2ccccc2)CC1	J. Med. Chem.	2006.0	CHEMBL436753	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	NC(=O)c1sc(-c2ccc(F)cc2)cc1N	J. Med. Chem.	2006.0	CHEMBL207071	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	Cc1cc(C)c2c(N)c(C(N)=O)sc2n1	J. Med. Chem.	2006.0	CHEMBL377085	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	NC(=O)c1sc2ncccc2c1N	J. Med. Chem.	2006.0	CHEMBL207012	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	NC(=O)c1nc(-c2ccc(C(F)(F)F)cc2)oc1N	J. Med. Chem.	2006.0	CHEMBL377928	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	NC(=O)c1nc(-c2ccccc2)oc1N	J. Med. Chem.	2006.0	CHEMBL207987	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	NC(=O)c1sc(-c2ccccc2)cc1N	J. Med. Chem.	2006.0	CHEMBL207028	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP450 3A4	O=C(O)c1cccc(-n2cncc2-c2cc(Cl)ccc2OCc2ccccc2)c1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207293	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP450 3A4	O=C(O)c1cccc(-c2ncccc2-c2cc(Cl)ccc2OCc2ccccc2)c1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL206096	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP450 3A4	O=C(O)c1cccc(-c2ccncc2-c2cc(Cl)ccc2OCc2ccccc2)c1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL209244	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208154	=	=	IC50	nM	6300.0	IC50	nM	6300.0
Inhibition of CYP3A4	CC[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208443	=	=	IC50	nM	3300.0	IC50	nM	3300.0
Inhibition of CYP3A4	CN(C)C(C)(C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL382574	=	=	IC50	nM	2100.0	IC50	nM	2100.0
Inhibition of CYP3A4	CN(C)C[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL204684	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of CYP3A4	CCN(CC)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205862	=	=	IC50	nM	1010.0	IC50	nM	1010.0
Inhibition of CYP3A4	CC(C)N(C)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207304	=	=	IC50	nM	800.0	IC50	nM	800.0
Inhibition of CYP3A4	CCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207942	=	=	IC50	nM	2300.0	IC50	nM	2300.0
Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N1CCOCC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208158	=	=	IC50	nM	2150.0	IC50	nM	2150.0
Inhibition of CYP3A4	CCCCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL205280	=	=	IC50	nM	2270.0	IC50	nM	2270.0
Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1)N(C)C1CCCCC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207411	=	=	IC50	nM	448.0	IC50	nM	448.0
Inhibition of CYP3A4	CC(C)N(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207486	=	=	IC50	nM	400.0	IC50	nM	400.0
Inhibition of CYP3A4	CCN(CC)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208155	=	=	IC50	nM	580.0	IC50	nM	580.0
Inhibition of CYP3A4	CCN(C)[C@H](C)[C@@H](c1ccc2cc(OCC(C)(C)C(=O)O)ccc2c1)n1ccnc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL210780	=	=	IC50	nM	1700.0	IC50	nM	1700.0
Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCOCC3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL378132	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCCCC3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207638	=	=	IC50	nM	8000.0	IC50	nM	8000.0
Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCCC3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL377177	=	=	IC50	nM	8200.0	IC50	nM	8200.0
Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CCC3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207345	=	=	IC50	nM	7000.0	IC50	nM	7000.0
Inhibition of CYP3A4	C[C@H]([C@@H](c1ccc2cc(OCC3(C(=O)O)CC3)ccc2c1)n1ccnc1)N(C)C	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL206884	=	=	IC50	nM	7500.0	IC50	nM	7500.0
Inhibition of CYP3A4	CCC(CC)(COc1ccc2cc([C@H]([C@@H](C)N(C)C)n3ccnc3)ccc2c1)C(=O)O	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL377286	=	=	IC50	nM	5300.0	IC50	nM	5300.0
Inhibition of human recombinant CYP3A4	CCCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL208528	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of human recombinant CYP3A4	C=CCc1ccc(C(=O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL207831	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of CYP3A4	COc1nc(NCCCN2CCOCC2)nc(OC)c1NC(=O)c1ccc(Oc2cc3c(cc2C)CCC3(C)C)o1	J. Med. Chem.	2006.0	CHEMBL210514	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc2occc2c1	J. Med. Chem.	2006.0	CHEMBL208787	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc2occc2c1	J. Med. Chem.	2006.0	CHEMBL208787	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F	J. Med. Chem.	2006.0	CHEMBL377414	=	=	IC50	nM	89000.0	IC50	uM	89.0
Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F	J. Med. Chem.	2006.0	CHEMBL377414	=	=	IC50	nM	62000.0	IC50	uM	62.0
Inhibition of P450 3A4	CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@H](c2ccc(S(C)(=O)=O)cc2)c2cc(F)cc(F)c2)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL212689	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC[C@H](N)C(=O)N[C@H](C#N)Cc1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL212521	=	=	IC50	nM	3604.0	IC50	nM	3604.0
Inhibition of CYP3A4	Cl.Clc1ccccc1CC(c1ccccc1)N1CCNCC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL534942	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCOc1ccccc1C[C@@H](c1ccccc1)N1CCNCC1.Cl	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL540107	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1.Cl	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL534723	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cl.Clc1ccccc1CC(c1ccccc1)N1CCNCC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL534942	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsome	CN1CCN(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL213743	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsome	c1cn(Cc2ccc3c(c2)-c2[nH]nc(-c4ccsc4)c2C3)cn1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL212084	=	=	IC50	nM	254.0	IC50	nM	254.0
Inhibition of cytochrome P450 3A4	O=C(Nc1ccc2cccnc2c1)c1ccc(-c2ccccc2)nc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL213390	>	>	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP450 3A4	Cc1cc(C(=O)O)nn1Cc1cc(Br)ccc1OCc1ccccc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL213221	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	C#C[C@H]1CC[C@@H](C#N)N1C(=O)CNC1(C)CCN(c2cc(C(=O)O)ccn2)CC1	J. Med. Chem.	2006.0	CHEMBL386369	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	N[C@H]1CC(C(=O)N2CCn3c(nnc3C(F)(F)F)C2)=CC[C@@H]1c1cc(F)c(F)c(F)c1.O=C(O)C(F)(F)F	J. Med. Chem.	2006.0	CHEMBL437341	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	NCc1ccc(-c2cccnc2)s1	J. Med. Chem.	2006.0	CHEMBL359657	=	=	Ki	nM	29400.0	Ki	uM	29.4
Inhibition of human CYP3A4	NCc1cc(-c2cccnc2)n[nH]1	J. Med. Chem.	2006.0	CHEMBL385008	>	>	Ki	nM	400000.0	Ki	uM	400.0
Inhibition of human CYP3A4	NCCCc1cccnc1	J. Med. Chem.	2006.0	CHEMBL385023	>	>	Ki	nM	400000.0	Ki	uM	400.0
Inhibition of human CYP3A4	c1cncc(-c2cc[nH]n2)c1	J. Med. Chem.	2006.0	CHEMBL218397	>	>	Ki	nM	400000.0	Ki	uM	400.0
Inhibition of human CYP3A4	Cc1csc(-c2cccnc2)n1	J. Med. Chem.	2006.0	CHEMBL410355	=	=	Ki	nM	22900.0	Ki	uM	22.9
Inhibition of human CYP3A4	c1ccc(-c2ccsc2)cc1	J. Med. Chem.	2006.0	CHEMBL386250	>	>	Ki	nM	400000.0	Ki	uM	400.0
Inhibition of human CYP3A4	Cc1cscc1-c1ccccc1	J. Med. Chem.	2006.0	CHEMBL215183	>	>	Ki	nM	400000.0	Ki	uM	400.0
Inhibition of human CYP3A4	NCc1ccc(-c2ccccc2)s1	J. Med. Chem.	2006.0	CHEMBL215134	=	=	Ki	nM	95500.0	Ki	uM	95.5
Inhibition of human CYP3A4	NCc1ccc(-c2ccccc2)o1	J. Med. Chem.	2006.0	CHEMBL214859	=	=	Ki	nM	63000.0	Ki	uM	63.0
Inhibition of human CYP3A4	c1cncc(-c2ccc(C3SCCS3)o2)c1	J. Med. Chem.	2006.0	CHEMBL215174	=	=	Ki	nM	1100.0	Ki	uM	1.1
Inhibition of human CYP3A4	CSCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL214990	=	=	Ki	nM	7400.0	Ki	uM	7.4
Inhibition of human CYP3A4	SCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL214784	=	=	Ki	nM	3100.0	Ki	uM	3.1
Inhibition of human CYP3A4	CC(=O)SCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL386124	=	=	Ki	nM	1500.0	Ki	uM	1.5
Inhibition of human CYP3A4	Cc1cscc1-c1cccnc1	J. Med. Chem.	2006.0	CHEMBL179704	<	<	Ki	nM	25000.0	Ki	uM	25.0
Inhibition of human CYP3A4	c1cncc(-c2c[nH]cn2)c1	J. Med. Chem.	2006.0	CHEMBL178516	=	=	Ki	nM	70000.0	Ki	uM	70.0
Inhibition of human CYP3A4	Cc1nccn1-c1cccnc1	J. Med. Chem.	2006.0	CHEMBL368883	=	=	Ki	nM	76000.0	Ki	uM	76.0
Inhibition of human CYP3A4	c1cncc(-c2ccsc2)c1	J. Med. Chem.	2006.0	CHEMBL361153	=	=	Ki	nM	28000.0	Ki	uM	28.0
Inhibition of human CYP3A4	Cc1ccsc1-c1ccc(F)nc1	J. Med. Chem.	2006.0	CHEMBL179621	=	=	Ki	nM	19600.0	Ki	uM	19.6
Inhibition of human CYP3A4	Cn1cnc(-c2cccnc2)c1	J. Med. Chem.	2006.0	CHEMBL360999	=	=	Ki	nM	131000.0	Ki	uM	131.0
Inhibition of human CYP3A4	Cc1ccsc1-c1cccnc1	J. Med. Chem.	2006.0	CHEMBL179669	=	=	Ki	nM	3000.0	Ki	uM	3.0
Inhibition of human CYP3A4	CN(C)CC#Cc1cccnc1	J. Med. Chem.	2006.0	CHEMBL180270	>	>	Ki	nM	400000.0	Ki	uM	400.0
Inhibition of human CYP3A4	CNCC#Cc1cccnc1	J. Med. Chem.	2006.0	CHEMBL149808	=	=	Ki	nM	251000.0	Ki	uM	251.0
Inhibition of human CYP3A4	NCC#Cc1cccnc1	J. Med. Chem.	2006.0	CHEMBL360541	=	=	Ki	nM	15200.0	Ki	uM	15.2
Inhibition of human CYP3A4	CN(C)Cc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL360998	=	=	Ki	nM	147000.0	Ki	uM	147.0
Inhibition of human CYP3A4	CNCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL178938	>	>	Ki	nM	400000.0	Ki	uM	400.0
Inhibition of human CYP3A4	NCc1ccc(-c2cccnc2)o1	J. Med. Chem.	2006.0	CHEMBL178090	=	=	Ki	nM	23600.0	Ki	uM	23.6
Inhibition of human CYP3A4	CN(C)Cc1ccc(-c2cccnc2)s1	J. Med. Chem.	2006.0	CHEMBL361969	=	=	Ki	nM	110000.0	Ki	uM	110.0
Inhibition of human CYP3A4	CNCc1ccc(-c2cccnc2)s1	J. Med. Chem.	2006.0	CHEMBL369285	>	>	Ki	nM	400000.0	Ki	uM	400.0
Inhibition of human CYP3A4	NCc1cc(-c2cccnc2)no1	J. Med. Chem.	2006.0	CHEMBL217125	>	>	Ki	nM	400000.0	Ki	uM	400.0
Inhibition of CYP3A4	O=C(NC1CCN(Cc2ccc3c(c2)OCO3)CC1)c1cc(=O)c2ccc(F)cc2o1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL214021	=	=	IC50	nM	23500.0	IC50	uM	23.5
Inhibition of CYP450 3A4	O=C(NO)c1ccc(-c2ccc(CNCc3ccccc3)cn2)s1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL216884	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP450 3A4	O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL217716	=	=	IC50	nM	53000.0	IC50	uM	53.0
Inhibition of CYP450 3A4	O=C(CCCCCCC(=O)Nc1ccccc1)NO	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL98	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)N1CCN(C(=O)N2CCC(NC(=O)C3CCCC3)CC2)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL220407	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)N1CCN(C(=O)N2CCC(C(C)(C)C)CC2)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL219128	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)N1CCN(C(=O)N2CCC(C(=O)OC(C)(C)C)CC2)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL218410	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)N1CCN(C(=O)N2CCC(C(=O)N3CC4CCC(CC4)C3)CC2)CC1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL218834	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4	O=C(O)c1c(O)c(-c2ccc(Cl)cc2)nc2c(-c3ccccc3)cccc12	J. Med. Chem.	2007.0	CHEMBL218583	=	=	IC50	nM	55000.0	IC50	uM	55.0
Inhibition of human CYP3A4	Cc1ccc2c(C(=O)O)c(O)c(-c3ccc(Cl)cc3)nc2c1C	J. Med. Chem.	2007.0	CHEMBL267210	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccccc34)sc21	J. Med. Chem.	2007.0	CHEMBL205742	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4	Cc1n[nH]c(C)c1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C	J. Med. Chem.	2007.0	CHEMBL375166	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1C[C@H](O)CO1)c(=O)n(C)c(=O)n2CC(C)C	J. Med. Chem.	2007.0	CHEMBL218628	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3c[nH]c4ncccc34)sc21	J. Med. Chem.	2007.0	CHEMBL384536	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3ccccc3C(F)(F)F)sc21	J. Med. Chem.	2007.0	CHEMBL218573	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3C[C@H](O)CO3)c(Cc3ccnc4ccccc34)sc21	J. Med. Chem.	2007.0	CHEMBL219861	=	=	IC50	nM	46000.0	IC50	uM	46.0
Inhibition of CYP3A4	CON(C)C(=O)c1c(Cn2c(C)nc(Cl)c2Cl)sc2c1c(=O)n(C)c(=O)n2CC(C)C	J. Med. Chem.	2007.0	CHEMBL387125	=	=	IC50	nM	44000.0	IC50	uM	44.0
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Oc3cccc4ccccc34)sc21	J. Med. Chem.	2007.0	CHEMBL219098	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4	CNc1nc2ccccc2n1Cc1sc2c(c1C(=O)N1CCC1)c(=O)n(C)c(=O)n2CC(C)C	J. Med. Chem.	2007.0	CHEMBL219483	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	CC(C)Cn1c(=O)n(C)c(=O)c2c(C(=O)N3CC[C@@H](O)C3)c(Cc3ccnc4ccc(F)cc34)sc21	J. Med. Chem.	2007.0	CHEMBL218468	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes	COC(=O)N(NC(=O)c1c(CN2CCN(C(C)(C)C)CC2)c(-c2ccccc2)nc2c(F)cccc12)c1ccccc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL221445	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	COC(=O)N(NC(=O)c1c(OC)c(-c2ccccc2)nc2ccccc12)c1ccccc1	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL219162	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL373751	<	<	IC50	nM	50118.72	Log IC50		-4.3
Inhibition of CYP3A4	CN1C(=O)NC(=O)[C@]12Cc1ccc(NC(=O)Cn3c(=O)n(-c4ccccn4)c4ccccc43)cc1C2	Bioorg. Med. Chem. Lett.	2006.0	CHEMBL223156	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2ccncc2)CC1	J. Med. Chem.	2007.0	CHEMBL219060	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2ccncn2)CC1	J. Med. Chem.	2007.0	CHEMBL218068	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2nncs2)CC1	J. Med. Chem.	2007.0	CHEMBL219113	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2nccs2)CC1	J. Med. Chem.	2007.0	CHEMBL218547	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2ncccn2)CC1	J. Med. Chem.	2007.0	CHEMBL435316	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2cnccn2)CC1	J. Med. Chem.	2007.0	CHEMBL220660	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2cccnc2)CC1	J. Med. Chem.	2007.0	CHEMBL218067	=	=	IC50	nM	9100.0	IC50	uM	9.1
Inhibition of CYP3A4 in human liver microsomes	O=C(OCc1ccccc1)N1CCC(CNc2ccccn2)CC1	J. Med. Chem.	2007.0	CHEMBL218017	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CCOC(=O)N1CCC(NS(=O)(=O)c2ccc(NC(=O)c3ccccc3C)c3ccccc23)CC1	J. Med. Chem.	2007.0	CHEMBL218375	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)C[C@@H]1CCc2cc(OCCCOc3ccc(-c4nc5c(s4)CCCC5)cc3)ccc21	J. Med. Chem.	2007.0	CHEMBL375812	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCCc1cc(C2=NC3OCCCC3S2)ccc1OCCCOc1ccc2c(c1)CC[C@H]2CC(=O)O	J. Med. Chem.	2007.0	CHEMBL221044	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCCc1cc(-c2nc3c(s2)CCCC3)ccc1OCCCOc1ccc2c(c1)CC[C@H]2CC(=O)O	J. Med. Chem.	2007.0	CHEMBL2113263	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of cytochrome P450 3A4	CCc1cc2c(c(C(F)(F)F)c1)C(=O)N1CCNC[C@@H]21	J. Med. Chem.	2007.0	CHEMBL221113	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of human CYP3A4 expressed in insect cells	O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2ccccc2)CC1	J. Med. Chem.	2007.0	CHEMBL222424	=	=	IC50	nM	91900.0	IC50	uM	91.9
Inhibition of human CYP3A4 expressed in insect cells	O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2cccc(Cl)c2)CC1	J. Med. Chem.	2007.0	CHEMBL223079	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 expressed in insect cells	O=C1NC(c2ccc(F)cc2)(c2ccc(F)cc2)CN1C1CCN(Cc2cccc(F)c2)CC1	J. Med. Chem.	2007.0	CHEMBL221401	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	CNC(=O)N1CCN(Cc2ccnc(Nc3ncc(C#N)s3)c2)CC1	J. Med. Chem.	2004.0	CHEMBL375248	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	CNC(=O)N1CCN(Cc2ccnc(Nc3ncc(C#N)s3)c2C)CC1	J. Med. Chem.	2004.0	CHEMBL376722	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	Clc1ccc(C2(c3ccc(-c4ncnc5[nH]cnc45)cc3)CCNCC2)cc1	J. Med. Chem.	2007.0	CHEMBL228133	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(C)C(C)(C)c1nc(O)c(O)c(C(=O)NCc2ccc(F)cc2)n1	J. Med. Chem.	2007.0	CHEMBL386515	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccccc2c1=O	J. Med. Chem.	2007.0	CHEMBL227954	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cc(N3CCOCC3)c(F)cc2c1=O	J. Med. Chem.	2007.0	CHEMBL227356	=	=	IC50	nM	790.0	IC50	uM	0.79
Inhibition of human CYP3A4	COc1cccc2c(=O)n(Cc3ccccc3C#N)c(N3CCCC(N)C3)nc12	J. Med. Chem.	2007.0	CHEMBL390776	=	=	IC50	nM	630.0	IC50	uM	0.63
Inhibition of human CYP3A4	COc1cc2nc(N3CCC[C@@H](N)C3)n(Cc3ccccc3C#N)c(=O)c2cc1OC	J. Med. Chem.	2007.0	CHEMBL227089	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human CYP3A4	COc1cc2c(=O)n(Cc3ccccc3C#N)c(N3CCC[C@@H](N)C3)nc2cc1F	J. Med. Chem.	2007.0	CHEMBL375508	=	=	IC50	nM	250.0	IC50	uM	0.25
Inhibition of human CYP3A4	COc1ccc2nc(N3CCC[C@@H](N)C3)n(Cc3ccccc3C#N)c(=O)c2c1	J. Med. Chem.	2007.0	CHEMBL227670	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(Br)cc2c1=O	J. Med. Chem.	2007.0	CHEMBL227676	=	=	IC50	nM	250.0	IC50	uM	0.25
Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2c(Cl)cc(Cl)cc2c1=O	J. Med. Chem.	2007.0	CHEMBL390529	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCCC(N)C2)nc2c(Cl)cccc2c1=O	J. Med. Chem.	2007.0	CHEMBL387552	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cc(Cl)ccc2c1=O	J. Med. Chem.	2007.0	CHEMBL228004	=	=	IC50	nM	250.0	IC50	uM	0.25
Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(Cl)cc2c1=O	J. Med. Chem.	2007.0	CHEMBL389074	=	=	IC50	nM	250.0	IC50	uM	0.25
Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(F)cc2c1=O	J. Med. Chem.	2007.0	CHEMBL425483	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of human CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2cccc(F)c2c1=O	J. Med. Chem.	2007.0	CHEMBL227464	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human CYP3A4	O=C(NCc1ccc(F)cc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL389908	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	O=C(NCC1CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL226067	=	=	IC50	nM	82000.0	IC50	uM	82.0
Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cc(F)cc(F)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL390526	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2F)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL225465	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2F)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL225464	=	=	IC50	nM	68000.0	IC50	uM	68.0
Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2F)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL225413	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)cc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL225412	=	=	IC50	nM	38000.0	IC50	uM	38.0
Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)c(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL389408	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL225411	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	O=C(NCC1(O)CCCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL387620	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	O=C(NCC1CCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL227899	=	=	IC50	nM	75000.0	IC50	uM	75.0
Inhibition of human CYP3A4	O=C(NCC1CCCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL226386	=	=	IC50	nM	65000.0	IC50	uM	65.0
Inhibition of human CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL226385	=	=	IC50	nM	51000.0	IC50	uM	51.0
Inhibition of human CYP3A4	O=C(NCc1ccncc1)c1cnc(Nc2cccc(Cl)c2)nc1C(F)(F)F	J. Med. Chem.	2007.0	CHEMBL375955	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human CYP3A4	CCC(C)COc1ccc(C(CC(=O)O)c2ccccc2)cc1	J. Med. Chem.	2007.0	CHEMBL229176	>	>	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4	CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(C)CC3)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231334	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	CN1CCc2ccc(NS(=O)(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231430	=	=	IC50	nM	58000.0	IC50	uM	58.0
Inhibition of CYP3A4	CC(C)Nc1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231350	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4	Cc1cccc(C)c1-c1cc(C)c2nc(Nc3ccc(OCCN4CCCC4)cc3)nnc2c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL436137	=	=	IC50	nM	42000.0	IC50	uM	42.0
Inhibition of CYP3A4	Cc1cc(-c2c(Cl)cccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230686	=	=	IC50	nM	62000.0	IC50	uM	62.0
Inhibition of CYP3A4	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cccnc5)cnc(N)c34)cc2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL427267	=	=	IC50	nM	250.0	IC50	nM	250.0
Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-n5ccnc5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230080	=	=	IC50	nM	35.0	IC50	nM	35.0
Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-n5cccc5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231147	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5ccncc5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL266738	=	=	IC50	nM	300.0	IC50	nM	300.0
Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cccnc5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL389608	=	=	IC50	nM	1100.0	IC50	nM	1100.0
Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cccc(C#N)c5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL389810	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	N#Cc1cccc(-c2ccc(CN3CCC4(CC3)C(=O)NC(=O)N4c3ccccc3)cc2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230626	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	COc1cncc(-c2ccc(CN3CCC4(CC3)C(=O)N(c3cccc(OC)c3)C(=O)N4Cc3ccccc3F)cc2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL267690	=	=	IC50	nM	2000.0	IC50	nM	2000.0
Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cncc(C#N)c5)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL389809	=	=	IC50	nM	6200.0	IC50	nM	6200.0
Inhibition of CYP3A4	COc1cccc(N2C(=O)N(Cc3ccccc3F)C3(CCN(Cc4ccc(-c5cnccc5OC)cc4)CC3)C2=O)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL266513	=	=	IC50	nM	1700.0	IC50	nM	1700.0
Inhibition of CYP3A4 in microsomes	CNC(=N)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL425819	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in microsomes	Cc1cnc(-c2cc(C)c3nc(-c4c(NCC(O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)[nH]1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231620	=	=	IC50	nM	360.0	IC50	uM	0.36
Inhibition of CYP3A4 in microsomes	Cc1cc(-n2ccnc2)cc2nc(-c3c(NCc4ccccn4)cc[nH]c3=O)[nH]c12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397666	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of CYP3A4 in microsomes	Cc1cc(C2=NCCCN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230043	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in microsomes	Cc1cc(C2=NC(C)(C)CN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230042	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in microsomes	Cc1cc(C2=NC(C)CN2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL390002	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP3A4 in microsomes	Cc1cc(C2=NCCN2C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL387611	=	=	IC50	nM	35000.0	IC50	uM	35.0
Inhibition of CYP3A4 in microsomes	Cc1cc(C(=O)NC2CCCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231610	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in microsomes	Cc1cc(C(=O)NC2CCCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231609	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 in microsomes	Cc1cc(C(=O)NC2CC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231510	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in microsomes	Cc1cc(C(=O)N(C)C)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231509	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 in microsomes	CNC(=O)c1cc(C)c2nc(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)[nH]c2c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231409	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of CYP3A4 in microsomes	Cc1cccc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230309	=	=	IC50	nM	710.0	IC50	uM	0.71
Inhibition of CYP3A4 in microsomes	COc1ccc(-c2cc(C)c3nc(-c4c(N[C@H](CO)Cc5ccccc5)cc[nH]c4=O)[nH]c3c2)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL440964	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of CYP3A4 in microsomes	Cc1cc(-c2ccc(F)cc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230308	=	=	IC50	nM	6300.0	IC50	uM	6.3
Inhibition of CYP3A4 in microsomes	Cc1cc(-c2ccccc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230205	=	=	IC50	nM	3600.0	IC50	uM	3.6
Inhibition of CYP3A4 in microsomes	Cc1cc(Br)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397667	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 in microsomes	Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231306	<	<	IC50	nM	46.0	IC50	uM	0.046
Inhibition of CYP3A4 in microsomes	Cc1cc(-n2ccnc2)cc2[nH]c(-c3c(N[C@H](CO)Cc4ccccc4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230204	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)CCC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230367	=	=	IC50	nM	8000.0	IC50	nM	8000.0
Inhibition of CYP3A4	COc1ccccc1COCCCOc1ccc(N2C(=O)CNC[C@@H]2COc2ccc3c(c2)N(CCNC(C)=O)CCC3)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL411885	=	=	IC50	nM	82.0	IC50	nM	82.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCC(=O)OC)CCC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230262	=	=	IC50	nM	12000.0	IC50	nM	12000.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)OC)CCC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL390642	=	=	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)CCC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL230260	=	=	IC50	nM	2800.0	IC50	nM	2800.0
Inhibition of CYP3A4	CC[C@H]1[C@@H]2[C@@H](O)CCN2C(=O)N1c1ccc(C#N)c(Cl)c1C	J. Med. Chem.	2007.0	CHEMBL229861	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	CCN1CCN(c2ccc(C(C)(C)NC(=O)c3cc4[nH]c5ccccc5c(=O)c4cc3F)cn2)CC1	J. Med. Chem.	2007.0	CHEMBL229008	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes	CCCCCOc1ccc(C(=O)c2cccc3ccccc23)c2ccccc12	J. Med. Chem.	2007.0	CHEMBL244403	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of human recombinant CYP3A4	O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2cccnc2)c(F)c1	J. Med. Chem.	2007.0	CHEMBL394864	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of human recombinant CYP3A4	Cc1cnc(C)n1CC(=O)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1	J. Med. Chem.	2007.0	CHEMBL231383	=	=	IC50	nM	10700.0	IC50	uM	10.7
Inhibition of human recombinant CYP3A4	Cc1nccn1CC(=O)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1	J. Med. Chem.	2007.0	CHEMBL388012	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4	Cc1cn(CC(=O)c2ccc(-c3ccc(N4C[C@H](Cn5ccnn5)OC4=O)cc3F)cn2)cn1	J. Med. Chem.	2007.0	CHEMBL387785	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4	O=C(Cn1ccnc1)c1ccc(-c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)cn1	J. Med. Chem.	2007.0	CHEMBL230964	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of human recombinant CYP3A4	O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccc(CO)nc2)c(F)c1	J. Med. Chem.	2007.0	CHEMBL398160	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	O=C(O)COc1c(C(=O)O)sc(-c2cccc(NC3CCN(S(=O)(=O)Cc4ccccc4)CC3)c2)c1Br	J. Med. Chem.	2007.0	CHEMBL541214	>	>	IC50	nM	500000.0	IC50	uM	500.0
Inhibition of CYP3A4	CCCc1[nH]cnc1CNc1cc(Cl)c2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2c1	J. Med. Chem.	2007.0	CHEMBL230654	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4	N#Cc1cnc2c(Cl)cc(NCc3cnc[nH]3)cc2c1Nc1ccc(F)c(Cl)c1	J. Med. Chem.	2007.0	CHEMBL436817	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4	N#Cc1cnc2c(Cl)cc(NCc3cccc[n+]3[O-])cc2c1Nc1ccc(F)c(Cl)c1	J. Med. Chem.	2007.0	CHEMBL395573	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4	Cn1cnc(CNc2cc(Br)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)c1	J. Med. Chem.	2007.0	CHEMBL230761	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins	COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2	Bioorg. Med. Chem.	2007.0	CHEMBL348475	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins	COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL242983	=	=	IC50	nM	195.0	IC50	uM	0.195
Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins	COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL266212	=	=	IC50	nM	20200.0	IC50	uM	20.2
Inhibition of human CYP3A4 expressed in insect microsome using 7-benzyloxy-4-trifluoromethylcoumarin substrate after 30 mins	COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL244239	=	=	IC50	nM	1620.0	IC50	uM	1.62
Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins	COc1cc2c(cc1OC)CN(CCc1ccc(NC(=O)c3cc(OC)c(OC)cc3NC(=O)c3cnc4ccccc4c3)cc1)CC2	Bioorg. Med. Chem.	2007.0	CHEMBL348475	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins	COc1ccc(CN2CCN(c3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL242983	=	=	IC50	nM	2480.0	IC50	uM	2.48
Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins	COc1ccc(CN2CCN(c3ccc(NC(=O)c4ccccc4NC(=O)c4cnc5ccccc5c4)cc3)CC2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL266212	=	=	IC50	nM	3580.0	IC50	uM	3.58
Inhibition of human CYP2E1 expressed in insect microsome using 7-benzyloxyquinoline substrate after 30 mins	COc1ccc(CCN(C)CCNC(=O)c2ccccc2NC(=O)c2cnc3ccccc3c2)cc1OC	Bioorg. Med. Chem.	2007.0	CHEMBL244239	=	=	IC50	nM	7750.0	IC50	uM	7.75
Inhibition of human recombinant CYP3A4	O=c1ccc2c(O)c3ccoc3cc2o1	Bioorg. Med. Chem.	2007.0	CHEMBL242711	=	=	IC50	nM	24920.0	IC50	uM	24.92
Inhibition of human recombinant CYP3A4	C/C(=C\COc1ccc2ccc(=O)oc2c1)C/C=C/C(C)C	Bioorg. Med. Chem.	2007.0	CHEMBL241896	=	=	IC50	nM	42930.0	IC50	uM	42.93
Inhibition of CYP3A4	CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL536743	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of CYP3A4	CC(=O)Nc1cc(C(=O)O)cc(-n2c(C)ccc2-c2cc(Br)ccc2OCc2ccc(F)cc2F)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL427844	>=	>=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4	O=C(O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL207881	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4	CCCC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1N	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL234412	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc2c(cc1OC)[C@@H]1C[C@H](N)[C@@H](c3cccc(C)c3)CN1CC2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391070	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(=O)Nc1cccc(-c2ccc(Cc3ocnc3C(=O)N[C@@H](Cc3ccccc3)C(=O)O)cc2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL400404	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CN(Cc1ccccc1)C(=O)[C@@H](NC(=O)c1cc2cc(NC(=O)c3ccccc3-c3ccc(C(F)(F)F)cc3)ccc2n1C)c1ccccc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL410414	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Cl)N2	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL231924	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(C)O2	Bioorg. Med. Chem.	2007.0	CHEMBL400431	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCC(F)(F)F)C(=O)[C@](C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL241663	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4	CCOCCCN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21	Bioorg. Med. Chem.	2007.0	CHEMBL393109	=	=	IC50	nM	1060.0	IC50	uM	1.06
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC(F)(F)F)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL241241	=	=	IC50	nM	270.0	IC50	uM	0.27
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCC#N)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL429642	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)OC)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL241032	=	=	IC50	nM	670.0	IC50	uM	0.67
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNS(C)(=O)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL240813	=	=	IC50	nM	2180.0	IC50	uM	2.18
Inhibition of CYP3A4	CCNC(=O)CN1C(=O)C(C)(c2cc(F)cc(F)c2)Oc2ccc(-c3c(N)nc(N)nc3CC)cc21	Bioorg. Med. Chem.	2007.0	CHEMBL398811	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCC(=O)NC)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL240598	=	=	IC50	nM	160.0	IC50	uM	0.16
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(=O)CO)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL240391	=	=	IC50	nM	1670.0	IC50	uM	1.67
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL429459	=	=	IC50	nM	4790.0	IC50	uM	4.79
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCO)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL393218	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL398584	=	=	IC50	nM	860.0	IC50	uM	0.86
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239496	=	=	IC50	nM	1140.0	IC50	uM	1.14
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@@](C)(c1ccccc1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239085	=	=	IC50	nM	530.0	IC50	uM	0.53
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@](C)(c1ccccc1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL391463	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)ccc1F)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239078	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1ccc(Cl)cc1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239074	=	=	IC50	nM	590.0	IC50	uM	0.59
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cccc(C(F)(F)F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL393363	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1ccc(F)c(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL238866	=	=	IC50	nM	920.0	IC50	uM	0.92
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239497	=	=	IC50	nM	460.0	IC50	uM	0.46
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL398584	=	=	IC50	nM	860.0	IC50	uM	0.86
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(c1cc(F)cc(F)c1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239496	=	=	IC50	nM	1140.0	IC50	uM	1.14
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C1(CC1)O2	Bioorg. Med. Chem.	2007.0	CHEMBL398387	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(CC)(CC)O2	Bioorg. Med. Chem.	2007.0	CHEMBL239495	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCCOC)C(=O)C(C)(CC)O2	Bioorg. Med. Chem.	2007.0	CHEMBL240566	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(C(F)(F)F)O2	Bioorg. Med. Chem.	2007.0	CHEMBL394016	>	>	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(C)O2	Bioorg. Med. Chem.	2007.0	CHEMBL240355	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@H](c3ccccc3)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391963	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](c3noc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392465	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@@H](c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)[C@H](c3ccc(F)cc3C)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392464	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](c3nc(C(C)(C)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)no3)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392463	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of human CYP3A4	Cc1cnc(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)cn1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL235882	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)C(C)(C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391615	=	=	IC50	nM	49000.0	IC50	uM	49.0
Inhibition of human CYP3A4	CC(=O)N1CCC(C(=O)N2C[C@H](c3ccc(F)cc3C)[C@@H](C(=O)N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391964	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human CYP3A4	C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL1471	=	=	IC50	nM	46.0	IC50	nM	46.0
Inhibition of CYP3A4	C[C@H]1CN(c2ccc(C(=O)Nc3ccccc3N)cn2)CCN1C(=O)OCc1ccccc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236902	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](N)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391914	=	=	IC50	nM	120.0	IC50	nM	120.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396186	=	=	IC50	nM	15000.0	IC50	nM	15000.0
Inhibition of microsomal CYP3A4	Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@H](CC(C)C)NC(=O)CCN(C)C)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236521	=	=	IC50	nM	6000.0	IC50	nM	6000.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCN(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397584	=	=	IC50	nM	6900.0	IC50	nM	6900.0
Inhibition of microsomal CYP3A4	CNCCC(=O)N[C@@H](CC(C)C)c1cc(C)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397583	=	=	IC50	nM	3400.0	IC50	nM	3400.0
Inhibition of microsomal CYP3A4	CNCCC(=O)N[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397582	=	=	IC50	nM	1300.0	IC50	nM	1300.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397581	=	=	IC50	nM	5400.0	IC50	nM	5400.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236520	=	=	IC50	nM	6400.0	IC50	nM	6400.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397580	=	=	IC50	nM	6700.0	IC50	nM	6700.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CCN)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391028	=	=	IC50	nM	2900.0	IC50	nM	2900.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)C(C)(C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397368	=	=	IC50	nM	28000.0	IC50	nM	28000.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)[C@H](C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397367	=	=	IC50	nM	8600.0	IC50	nM	8600.0
Inhibition of microsomal CYP3A4	Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@H](CC(C)C)NC(=O)[C@@H](C)N)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL262321	=	=	IC50	nM	2900.0	IC50	nM	2900.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)[C@@H](C)N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396434	=	=	IC50	nM	5300.0	IC50	nM	5300.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CN(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL412024	=	=	IC50	nM	15000.0	IC50	nM	15000.0
Inhibition of microsomal CYP3A4	CNCC(=O)N[C@@H](CC(C)C)c1cc(C)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL412023	=	=	IC50	nM	3600.0	IC50	nM	3600.0
Inhibition of microsomal CYP3A4	CNCC(=O)N[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL441136	=	=	IC50	nM	6500.0	IC50	nM	6500.0
Inhibition of microsomal CYP3A4	CNCC(=O)N[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL235640	=	=	IC50	nM	2300.0	IC50	nM	2300.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NC(=O)CN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL235421	=	=	IC50	nM	3600.0	IC50	nM	3600.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCCC(=O)O)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL262320	=	=	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCCC(=O)O)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL235955	=	=	IC50	nM	21000.0	IC50	nM	21000.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCC(=O)O)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396433	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCC(N)=O)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL393789	=	=	IC50	nM	720.0	IC50	nM	720.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL438683	=	=	IC50	nM	15000.0	IC50	nM	15000.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL393788	=	=	IC50	nM	16000.0	IC50	nM	16000.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCCN)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237578	=	=	IC50	nM	3400.0	IC50	nM	3400.0
Inhibition of microsomal CYP3A4	CCN(CC)CCN[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396432	=	=	IC50	nM	37000.0	IC50	nM	37000.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCN(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396431	=	=	IC50	nM	32000.0	IC50	nM	32000.0
Inhibition of microsomal CYP3A4	CNCCN[C@@H](CC(C)C)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237577	=	=	IC50	nM	11000.0	IC50	nM	11000.0
Inhibition of microsomal CYP3A4	CNCCN[C@@H](CC(C)C)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL393204	=	=	IC50	nM	4800.0	IC50	nM	4800.0
Inhibition of microsomal CYP3A4	CC(C)C[C@@H](c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1)N(C)CCN	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237365	=	=	IC50	nM	650.0	IC50	nM	650.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCN)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236519	=	=	IC50	nM	6300.0	IC50	nM	6300.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCN)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237364	=	=	IC50	nM	8900.0	IC50	nM	8900.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCN)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL393576	=	=	IC50	nM	4900.0	IC50	nM	4900.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCO)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL396884	=	=	IC50	nM	35000.0	IC50	nM	35000.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](NCCO)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237147	=	=	IC50	nM	480.0	IC50	nM	480.0
Inhibition of microsomal CYP3A4	CCN(CC)[C@@H](CC(C)C)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL237146	=	=	IC50	nM	2700.0	IC50	nM	2700.0
Inhibition of microsomal CYP3A4	CCN[C@@H](CC(C)C)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391915	=	=	IC50	nM	640.0	IC50	nM	640.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](N)c1cc(C(F)(F)F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236940	=	=	IC50	nM	49000.0	IC50	nM	49000.0
Inhibition of microsomal CYP3A4	Cc1ccc(N2CCN(C(=O)[C@@H](Cc3ccc(Cl)cc3Cl)N3CCCC3=O)CC2)c([C@@H](N)CC(C)C)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236939	=	=	IC50	nM	1900.0	IC50	nM	1900.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](N)c1cc(F)ccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236732	=	=	IC50	nM	220.0	IC50	nM	220.0
Inhibition of microsomal CYP3A4	CC(C)C[C@H](N)c1cccc(F)c1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2Cl)N2CCCC2=O)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236731	=	=	IC50	nM	170.0	IC50	nM	170.0
Inhibition of CYP3A4	Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](N)C(C)C)c1	J. Med. Chem.	2007.0	CHEMBL401250	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of CYP3A4	Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](NC(=O)CCN)C(C)C)c1	J. Med. Chem.	2007.0	CHEMBL240364	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CNCCC(=O)N[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1)C(C)C	J. Med. Chem.	2007.0	CHEMBL240780	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4	Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1	J. Med. Chem.	2007.0	CHEMBL427860	=	=	IC50	nM	9200.0	IC50	uM	9.2
Inhibition of CYP3A4	Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3C)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1	J. Med. Chem.	2007.0	CHEMBL240572	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of CYP3A4	Cc1ccc(N2CCN(C(=O)[C@H](C)Cc3ccc(Cl)cc3F)CC2)c([C@@H](NC(=O)CCN(C)C)C(C)C)c1	J. Med. Chem.	2007.0	CHEMBL391056	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of CYP3A4	CNCC(=O)N[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2F)CC1)C(C)C	J. Med. Chem.	2007.0	CHEMBL240571	=	=	IC50	nM	6900.0	IC50	uM	6.9
Inhibition of CYP3A4	CNCCN[C@H](c1cc(C)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2F)CC1)C(C)C	J. Med. Chem.	2007.0	CHEMBL240568	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of human CYP3A4 after 10 mins	CN(C)c1ccc(-c2nc3c(N4CCN(CC(=O)Nc5nccs5)CC4)c(Cl)cnc3[nH]2)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392525	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	NCCc1cn(S(=O)(=O)c2c(Cl)nc3sccn23)c2ccccc12	J. Med. Chem.	2007.0	CHEMBL392760	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1CCOC(=O)NCCCCO	J. Med. Chem.	2007.0	CHEMBL398372	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human liver microsome CYP3A4	NC(=O)[C@H]1CN(c2ccc([C@H]3CC[S@+]([O-])CC3)c(F)c2)C(=O)O1	J. Med. Chem.	2007.0	CHEMBL2062151	>	>	IC50	nM	900000.0	IC50	uM	900.0
Inhibition of CYP3A4	CC(C)C[C@H](NC(=O)CCN(C)C)c1cc(Cl)ccc1N1CCN(C(=O)[C@H](C)Cc2ccc(Cl)cc2)CC1	J. Med. Chem.	2007.0	CHEMBL266647	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 using diethoxyfluorescein substrate	O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1.O=CO	J. Med. Chem.	2007.0	CHEMBL240185	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate	O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1.O=CO	J. Med. Chem.	2007.0	CHEMBL240185	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using diethoxyfluorescein substrate	N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1.O=CO	J. Med. Chem.	2007.0	CHEMBL239099	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using diethoxyfluorescein substrate	C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1.O=CO	J. Med. Chem.	2007.0	CHEMBL239299	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate	N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1.O=CO	J. Med. Chem.	2007.0	CHEMBL239099	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using 7-benzloxyquinolone substrate	C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1.O=CO	J. Med. Chem.	2007.0	CHEMBL239299	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin substrate	C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1.O=CO	J. Med. Chem.	2007.0	CHEMBL239299	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin substrate	Cl.N#Cc1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCC4)cc3)C(=O)C2)cc1	J. Med. Chem.	2007.0	CHEMBL534958	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in presence of BFC substrate	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246970	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 in presence of BQ substrate	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246970	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 in presence of BFC substrate	O=[N+]([O-])c1cnc(NCc2ccccc2Cl)nc1NCC1CCNCC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246161	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of CYP3A4 in presence of BFC substrate	CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246160	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 in presence of BFC substrate	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392642	=	=	IC50	nM	6900.0	IC50	uM	6.9
Inhibition of CYP3A4 in presence of BQ substrate	O=[N+]([O-])c1cnc(NCc2ccccc2Cl)nc1NCC1CCNCC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246161	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in presence of BQ substrate	CN(C)CC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246160	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in presence of BQ substrate	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392642	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCc1ccccc1N(CC(=O)NCc1ccc(Cl)cc1)S(=O)(=O)c1ccc(C)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240436	=	=	IC50	nM	251.19	Log IC50		-6.6
Inhibition of CYP3A4	NC1CN(c2cc(-c3ccsc3)ncn2)CC1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL395426	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CS(=O)(=O)c1cccc(-c2ncnc(N3CC(N)C(c4cc(F)c(F)cc4F)C3)n2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246530	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	NC1CN(c2cc(-c3cccc(S(=O)(=O)N4CCOCC4)c3)ncn2)CC1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL246322	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	NC1CN(c2cc(-c3cccc(C(=O)O)c3)ncn2)CC1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL245585	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cl.NC1CN(c2cc(-c3ccsc3)ncn2)CC1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL536086	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C([C@H](O)c1ccccc1Cl)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL239772	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4	NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL239816	=	=	IC50	nM	490.0	IC50	uM	0.49
Inhibition of CYP3A4	NC(C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392609	=	=	IC50	nM	170.0	IC50	uM	0.17
Inhibition of CYP3A4	N[C@@H](Cc1ccccc1)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240889	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	N[C@H](C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1)c1ccccc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL238763	=	=	IC50	nM	450.0	IC50	uM	0.45
Inhibition of CYP3A4	C[C@H](N)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL238762	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(C(O)c1ccc(Br)cc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL241271	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4	O=C([C@@H](O)c1cccc(Cl)c1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL241270	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	O=C([C@@H](O)c1ccccc1Cl)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL392064	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4	O=C([C@H](O)c1ccccc1)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL241064	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	C[C@H](O)C(=O)N1CCC(Nc2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL395942	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Br)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240867	=	=	IC50	nM	410.0	IC50	uM	0.41
Inhibition of CYP3A4	C[C@@H](N)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL397114	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	N[C@H](Cc1ccccc1)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240646	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4	NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1cccc(Cl)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240645	=	=	IC50	nM	250.0	IC50	uM	0.25
Inhibition of CYP3A4	NC(C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL394438	=	=	IC50	nM	530.0	IC50	uM	0.53
Inhibition of CYP3A4	N[C@@H](C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1)c1ccccc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL391189	=	=	IC50	nM	470.0	IC50	uM	0.47
Inhibition of CYP3A4	O=C([C@@H]1Cc2ccccc2CN1)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL442086	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(C(O)c1ccc(Br)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL239150	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4	O=C([C@H](O)c1ccccc1)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL239149	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)[C@@H](O)C(=O)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL238945	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(C(O)c1ccc(Cl)cc1)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL394993	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	O=C([C@H](O)c1cccc(Cl)c1)N1CCN(c2ccc3[nH]ncc3c2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL238744	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4	O=C(O)COc1ccc(Cl)cc1C1CCCCCC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL398126	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(C)C(=O)CO5)CC3)cccc2n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL399719	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(CCc4ccccc4)C(=O)CO5)CC3)cccc2n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248407	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4	Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4)N(Cc4ccccc4)C(=O)CO5)CC3)cccc2n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248231	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	Cc1ccc2c(OCCN3CCN(Cc4cc(F)c5c(c4)N(C)C(=O)CO5)CC3)cccc2n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL247428	>	>	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4	Cc1ccc2c(OCCN3CCN(Cc4ccc5c(c4F)N(C)C(=O)CO5)CC3)cccc2n1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL247609	>	>	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4	CCN1C(=O)COc2ccc(CN3CCN(CCOc4cccc5nc(C)ccc45)CC3)c(F)c21	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL443060	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4	O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3ccc(Cl)s3)s2)C1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248849	=	=	IC50	nM	2330.0	IC50	uM	2.33
Inhibition of CYP3A4	O=C(C1CCN(c2ccncc2)CC1)N1CC[C@@H](CNS(=O)(=O)/C=C/c2ccc(-c3ccc(Cl)s3)s2)C1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248849	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4	O=C(/C=C/c1ccc(Cl)c(Cl)c1)N1CCC(CN2CCC(c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL399045	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 after 30 mins	O=C(OC[C@H]1CCC[C@@H](C2CC2)N1S(=O)(=O)c1ccc(Cl)cc1)N1CCC(N2CCCCC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL398430	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)CC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249494	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249493	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL399507	=	=	IC50	nM	19500.0	IC50	uM	19.5
Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL393941	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249293	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 after 30 mins	CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL236184	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 after 30 mins	C[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249292	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](c4cc(F)cc(F)c4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249087	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@@H](O)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL401323	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@H](O)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249086	=	=	IC50	nM	15600.0	IC50	uM	15.6
Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@@H](OC)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL249085	=	=	IC50	nM	10100.0	IC50	uM	10.1
Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@H](OC)C[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL438525	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1CCC[C@H](COC(=O)N2CCN(CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248880	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 after 30 mins	O=C(OC[C@H]1CCC[C@@H](C2CC2)N1S(=O)(=O)c1ccc(Cl)cc1)N1CCN(CCO)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL401122	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@H](O)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248879	=	=	IC50	nM	24300.0	IC50	uM	24.3
Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@@H](OC)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248867	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4 after 30 mins	CC[C@@H]1C[C@H](OC)C[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248866	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1CCC[C@H](COC(=O)N2CCC(N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL248677	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2CCC[C@@H](c3cc(F)cc(F)c3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL239629	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of CYP3A4 after 30 mins	CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(CCO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240070	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL240069	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of human CYP3A4	CC(=O)N1CCN(CC(O)CN2CCN(CCc3c(-c4cc(C)cc(C)c4)[nH]c4sc(C(C)(C)C(=O)N5C6CCC5CC6)cc34)CC2)CC1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL401352	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human CYP3A4	Cc1cc(C)cc(-c2[nH]c3sc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2CCN2CCN(CC(O)CN3CCNCC3)CC2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL401418	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	Cc1cc(C)cc(-c2[nH]c3sc(C(C)(C)C(=O)N4C5CCC4CC5)cc3c2CCN2CCN(CC(=O)N3CCOCC3)CC2)c1	Bioorg. Med. Chem. Lett.	2007.0	CHEMBL399772	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Nat. Prod.	2007.0	CHEMBL157101	=	=	IC50	nM	210.0	IC50	uM	0.21
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	COc1cc2c(cc1O)-c1cc3ccc(O)c(OC)c3c[n+]1CC2	J. Nat. Prod.	2007.0	CHEMBL251229	>	>	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12C[C@H](c3ccoc3)OC(=O)[C@@H]1[C@@H](O)C[C@]1(C)[C@H]2[C@@H]2OC(=O)[C@@]1(O)[C@H]1O[C@@H]21	J. Nat. Prod.	2007.0	CHEMBL398472	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	COc1cc2c(cc1OC)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2.[Cl-]	J. Nat. Prod.	2007.0	CHEMBL274189	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@H](C[C@@H](O)[C@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C)C(C)(C)O	J. Nat. Prod.	2007.0	CHEMBL255034	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12C[C@H](c3ccoc3)OC(=O)C1=CC[C@]1(C)[C@H]2[C@H]2C=C[C@]1(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O2	J. Nat. Prod.	2007.0	CHEMBL399973	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12C[C@H](c3ccoc3)OC(=O)C1=CC[C@]1(C)[C@H]2[C@@H]2OC(=O)[C@@]1(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1O[C@@H]21	J. Nat. Prod.	2007.0	CHEMBL399731	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@H](C[C@@H](O)[C@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C)C(C)(C)O	J. Nat. Prod.	2007.0	CHEMBL254592	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12C[C@H](c3ccoc3)OC(=O)[C@@H]1CC[C@@]1(CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(=O)C=CC[C@@H]21	J. Nat. Prod.	2007.0	CHEMBL251672	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12[C@H]3CC=C[C@@]1(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(=O)O[C@@H]2C[C@]1(O)C(=O)O[C@H](c2ccoc2)C[C@@]31C	J. Nat. Prod.	2007.0	CHEMBL249243	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	C[C@@]12C[C@@H](c3ccoc3)OC(=O)[C@@]1(O)C[C@H]1OC(=O)[C@@]3(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C=CC[C@@H]2[C@@]13C	J. Nat. Prod.	2007.0	CHEMBL400494	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	COc1cc2c(cc1O)-c1cc3ccc(OC)c(OC)c3c[n+]1CC2	J. Nat. Prod.	2007.0	CHEMBL400345	=	=	IC50	nM	30600.0	IC50	uM	30.6
Inhibition of human CYP3A4 expressed in Escherichia coli assessed as inhibition of nifedipine oxidation	COc1cc2c(cc1O)CC[n+]1cc3c(OC)c(OC)ccc3cc1-2	J. Nat. Prod.	2007.0	CHEMBL251055	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(N)=O)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252615	=	=	IC50	nM	11500.0	IC50	uM	11.5
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3nc(CN4CCCC4)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252200	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 pre-incubated before 30 mins	O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2nc(CN3CC[C@@H](O)C3)no2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL399283	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4 pre-incubated before 30 mins	O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2nc(CN3CCCC3)no2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254080	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 pre-incubated before 30 mins	CN(Cc1noc(CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)n1)C(C)(C)CO	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252404	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3nc(CN(C)C(C)(C)CO)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252001	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 pre-incubated before 30 mins	O=S(=O)(c1ccc(Cl)cc1)N1[C@H](C2CC2)CCC[C@@H]1C1(Cc2noc(CN3CCCC3)n2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL251800	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 pre-incubated before 30 mins	CN(Cc1nc(CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)no1)C(C)(C)CO	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL443065	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3noc(CN4CCOCC4)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253655	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3nc(C)no3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252616	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3noc(CN(C)C(C)(C)CO)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253023	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3noc(C)n3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252817	=	=	IC50	nM	16900.0	IC50	uM	16.9
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(Cc3ncco3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403999	<	<	IC50	nM	30.0	IC50	uM	0.03
Inhibition of CYP3A4 pre-incubated before 30 mins	O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252614	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 pre-incubated before 30 mins	O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC2(CCN2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252414	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 pre-incubated before 30 mins	O=C(CC1([C@H]2CCC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN2CCCC[C@H]2C1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL428586	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 pre-incubated before 30 mins	CC(C)(CO)N1CCN(C(=O)CC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL249493	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC4CCC(C3)N4CCO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403998	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC4CCC(C3)N4C)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL438699	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCNCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252211	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC4(CCN4)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252210	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCN4CCCC[C@H]4C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252209	=	=	IC50	nM	4200.0	IC50	uM	4.2
Inhibition of CYP3A4 pre-incubated before 30 mins	CCCC1(O)CCN(C(=O)CC2([C@H]3CCC[C@@H](CC)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL398773	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC[C@H]3CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429836	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL398772	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCC(N4CCCCC4)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254912	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CC[C@@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254705	=	=	IC50	nM	11900.0	IC50	uM	11.9
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(CC(=O)N3CCCCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL399590	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 pre-incubated before 30 mins	CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL236184	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 pre-incubated before 30 mins	O=C(OC1([C@H]2CCC[C@@H](c3cc(F)cc(F)c3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCN(CCO)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL239629	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of CYP3A4	COc1cccc(CNC[C@@H](O)[C@H](Cc2ccccc2)NC(=O)c2cc(C(=O)N[C@H](C)c3ccccc3)cc(N(C)S(C)(=O)=O)c2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403268	=	=	IC50	nM	696.0	IC50	nM	696.0
Inhibition of CYP3A4	O=C(N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1)c1ccccc1OC(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL400262	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1Cc1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254497	=	=	IC50	nM	980.0	IC50	uM	0.98
Inhibition of CYP3A4	O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1c(F)ccc(F)c1F)NC(=O)C1(C(F)(F)F)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403809	=	=	IC50	nM	980.0	IC50	uM	0.98
Inhibition of CYP3A4	O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1c(F)cccc1F)NC(=O)C1(C(F)(F)F)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404229	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1ccccc1Cl)NC(=O)C1(C(F)(F)F)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252838	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL400846	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1cccc(F)c1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252240	=	=	IC50	nM	810.0	IC50	uM	0.81
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1cc(F)ccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252837	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL400845	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1c(F)ccc(F)c1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252836	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1c(F)cccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL400642	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1cccc(F)c1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252636	=	=	IC50	nM	4600.0	IC50	uM	4.6
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1cc(F)ccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404622	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1cccc(Cl)c1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252438	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1OC(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253660	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1Cl)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404621	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252437	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252239	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4	O=C(NCc1nc2cccnc2n1C1(c2ccccc2)CC1)[C@@H](Cc1ccccc1C(F)(F)F)NC(=O)C1(C(F)(F)F)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL400261	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1C1(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254918	=	=	IC50	nM	820.0	IC50	uM	0.82
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1CC1CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL399568	=	=	IC50	nM	2430.0	IC50	uM	2.43
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@H](Cc1ccccc1C(F)(F)F)C(=O)NCc1nc2cccnc2n1CC(F)(F)C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL252632	=	=	IC50	nM	980.0	IC50	uM	0.98
Inhibition of CYP3A4	CC(C1CC1)n1c(CNC(=O)[C@@H](Cc2ccccc2C(F)(F)F)NC(=O)OC(C)(C)C)nc2cccnc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253883	=	=	IC50	nM	860.0	IC50	uM	0.86
Inhibition of CYP3A4	Cc1cc[n+]([O-])c(C)c1C(=O)N1CCC(C)(N2CCC(N(c3ccccc3)c3cccnc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255858	=	=	IC50	nM	5300.0	IC50	nM	5300.0
Inhibition of human CYP3A4	O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCC[C@@H]4CO)ccc23)cn1)Nc1cccc(F)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253968	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	O=C(Cn1cc(Nc2nncc3cc(OCCCN4CCC[C@@H]4COP(=O)(O)O)ccc23)cn1)Nc1cccc(F)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL250766	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of CYP3A4	CN(C)S(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403313	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	COc1ccc(OCC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)c(CN(C)C)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429850	=	=	IC50	nM	1600.0	IC50	nM	1600.0
Inhibition of CYP3A4	Cc1cc(OCC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)cc(C)n1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL253528	=	=	IC50	nM	1100.0	IC50	nM	1100.0
Inhibition of CYP3A4	Cc1cc(C)n(-c2cc(NC(=O)COc3cccc(CN(C)C)c3)nc(-c3ccc(C)o3)n2)n1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL401895	>	>	IC50	nM	6000.0	IC50	nM	6000.0
Inhibition of CYP3A4	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL196478	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(C(F)(F)F)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL401960	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	Cc1nc([C@H](C(=O)NC(C)C)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL401910	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)NC(C)C)c1ccc(Br)s1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL410420	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	Cc1ccc([C@H](C(=O)NC(C)C)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL209864	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4	Cc1nc([C@H](C(=O)N(C)CCO)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256391	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1coc(C)n1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429736	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CC[C@@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1coc(C)n1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL401858	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	Cc1nc([C@H](C(=O)N2CCOCC2)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271039	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	Cc1nc([C@H](C(=O)N2CCC2)N2C(=O)[C@@H](C3Cc4ccccc4C3)NC(=O)[C@H]2CC(C)C)co1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403149	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	C[C@@H](NC(=O)[C@@](C)(O)C(F)(F)F)c1ncc(-c2cc(Cl)cc(F)c2-c2nnn(C)n2)cc1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258324	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(C)S(=O)(=O)N(C)[C@@H]1CCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O	J. Med. Chem.	2008.0	CHEMBL408479	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CN(C)C(=O)C(=O)N(C)[C@H]1CCCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O	J. Med. Chem.	2008.0	CHEMBL408962	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	CNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404401	=	=	IC50	nM	2100.0	IC50	nM	2100.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258046	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(OCC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270368	=	=	IC50	nM	7600.0	IC50	nM	7600.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(O[C@H]3CCNC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402279	=	=	IC50	nM	4800.0	IC50	nM	4800.0
Inhibition of human CYP3A4	CC(N)COc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256195	>	>	IC50	nM	40000.0	IC50	nM	40000.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(N3CCN(C)CC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429845	=	=	IC50	nM	200.0	IC50	nM	200.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(N3CCC(N)CC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271864	=	=	IC50	nM	300.0	IC50	nM	300.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270193	=	=	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271310	=	=	IC50	nM	29000.0	IC50	nM	29000.0
Inhibition of human CYP3A4	CNCCCNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271512	>	>	IC50	nM	40000.0	IC50	nM	40000.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402319	>	>	IC50	nM	40000.0	IC50	nM	40000.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCC(C)(C)CN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270869	=	=	IC50	nM	1400.0	IC50	nM	1400.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCC(C)(C)N)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271087	>	>	IC50	nM	40000.0	IC50	nM	40000.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(NCCO)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271941	=	=	IC50	nM	5200.0	IC50	nM	5200.0
Inhibition of human CYP3A4	CC(C)Nc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL407708	=	=	IC50	nM	400.0	IC50	nM	400.0
Inhibition of human CYP3A4	CCCNc1nnc(-c2cn3ncnc(Nc4cc(C(=O)NC5CC5)c(F)cc4F)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL407944	=	=	IC50	nM	400.0	IC50	nM	400.0
Inhibition of human CYP3A4	CC(C)c1c(-c2nnc(N(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255394	=	=	IC50	nM	800.0	IC50	nM	800.0
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate	CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271310	=	=	IC50	nM	37000.0	IC50	uM	37.0
Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate	CC(C)c1c(-c2nnc(NCCCN(C)C)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271310	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate	CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258046	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin substrate	CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270193	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate	CC(C)c1c(-c2nnc(OC3CCNCC3)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258046	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4 using 7-benzyloxyresorufin substrate	CC(C)c1c(-c2nnc(NCCCCN)o2)cn2ncnc(Nc3cc(C(=O)NC4CC4)c(F)cc3F)c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270193	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(-c2ccccc2)n1)[C@@H](C)O)B(O)O	J. Med. Chem.	2008.0	CHEMBL270515	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4	O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1	J. Med. Chem.	2008.0	CHEMBL217716	=	=	IC50	nM	510.0	IC50	uM	0.51
Inhibition of CYP3A4	COc1cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc(OC)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403525	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4	Cc1cc(C)n(-c2cc(NC(=O)Cc3ccc(S(C)(=O)=O)cc3)nc(-c3ccccn3)n2)n1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270654	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1cc(C)cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429420	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCOc1ccc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc1OC	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270655	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4	COc1ccc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccccn3)n2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402071	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4	COc1cc(CC(=O)Nc2cc(-n3nc(C)cc3C)nc(-c3ccc(C)o3)n2)cc(OC)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257670	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	NCc1ccc2c(c1)C1(CCN(C(=O)c3ccc(C#Cc4ccccc4)o3)CC1)CO2	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255590	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271876	=	=	IC50	nM	59000.0	IC50	uM	59.0
Inhibition of CYP3A4 using 7-benzyloxyresorufin as a substrate	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271876	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as a substrate	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccc1O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270666	=	=	IC50	nM	9800.0	IC50	uM	9.8
Inhibition of CYP3A4 using 7-benzyloxyresorufin as a substrate	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)c1nnnn1[C@H](CC#N)COc1ccccc1O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL270666	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL377300	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human CYP3A4 using 7-benzyloxyresorufin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL377300	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)CN)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL270996	=	=	IC50	nM	160.0	IC50	uM	0.16
Inhibition of human CYP3A4 using 7-benzyloxyresorufin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)CN)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL270996	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@@H](C)N)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL408444	=	=	IC50	nM	510.0	IC50	uM	0.51
Inhibition of human CYP3A4 using 7-benzyloxyresorufin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@@H](C)N)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL408444	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of human CYP3A4 using 7-benzyl-trifluoromethyl coumarin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](N)CC(C)C)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL408443	=	=	IC50	nM	95.0	IC50	uM	0.095
Inhibition of human CYP3A4 using 7-benzyloxyresorufin	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](N)CC(C)C)c(C)c34)ccc2[nH]1	J. Med. Chem.	2008.0	CHEMBL408443	=	=	IC50	nM	370.0	IC50	uM	0.37
Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	COc1ccc(N2C(=O)[C@@H](Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271240	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	COc1ccc(N2C(=O)[C@@H](Cc3cccc(OCCc4nc(-c5ccccc5)oc4C)c3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL271240	=	=	IC50	nM	830.0	IC50	uM	0.83
Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	Cc1oc(-c2ccc(Cl)cc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL272336	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404451	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256468	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL272963	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255389	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 in presence of 7-benzyloxy-4-trifluoromethyl coumarin substrate	COc1ccc(N2C(=O)[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL411118	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	COc1ccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257517	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	Cc1oc(-c2cccc(Cl)c2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL429734	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	COc1cccc(-c2nc(CCOc3cccc(C[C@@H]4C(=O)N(c5ccc(C(C)(C)C)cc5)[C@@H]4C(=O)O)c3)c(C)o2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404646	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404451	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	Cc1oc(-c2ccccc2)nc1CCOc1ccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256468	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	Cc1oc(-c2ccccc2)nc1CCOc1cccc(C[C@@H]2C(=O)N(c3ccc(C(C)(C)C)cc3)[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255389	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 in presence of 7-benzyloxyresorufin substrate	COc1ccc(N2C(=O)[C@@H](Cc3ccc(OCCc4nc(-c5ccccc5)oc4C)cc3)[C@H]2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL411118	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4	Cc1cc(C)n(-c2cc(NC(=O)CN3CCN(C)CC3)nc(-c3nccs3)n2)n1	J. Med. Chem.	2008.0	CHEMBL271202	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Brc1ccc(-n2c(SCc3ccccc3)nnc2-c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL406917	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Clc1ccc(OC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	J. Med. Chem.	2008.0	CHEMBL270902	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	O[C@](Cn1cccn1)(c1ccc(F)cc1F)n1cncn1	J. Med. Chem.	2008.0	CHEMBL3085388	=	=	IC50	nM	44000.0	IC50	uM	44.0
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	COC(=O)[C@H](Cc1c[nH]cn1)NCc1ccccc1	J. Med. Chem.	2008.0	CHEMBL270272	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CS(=O)(=O)OCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1	J. Med. Chem.	2008.0	CHEMBL410503	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1	J. Med. Chem.	2008.0	CHEMBL270271	=	=	IC50	nM	210.0	IC50	uM	0.21
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Clc1ccc(C2(Cn3cncn3)CC(Br)CO2)c(Cl)c1	J. Med. Chem.	2008.0	CHEMBL271579	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	COc1ccc(CCCOC(Cn2ccnc2)c2ccc(OC)cc2)cc1	J. Med. Chem.	2008.0	CHEMBL258502	=	=	IC50	nM	45.0	IC50	uM	0.045
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Cc1cc(C(C)(C)NC(=O)C(Br)C(C)(C)C)cc(C)n1	J. Med. Chem.	2008.0	CHEMBL271581	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Clc1ccc(Cn2cc(-c3ccncc3)cn2)c(Cl)c1	J. Med. Chem.	2008.0	CHEMBL271580	=	=	IC50	nM	230.0	IC50	uM	0.23
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CS(=O)(=O)c1ccc(Cn2cc(-c3ccncc3)cn2)cc1	J. Med. Chem.	2008.0	CHEMBL270903	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccncc3)n2)nc1	J. Med. Chem.	2008.0	CHEMBL271121	=	=	IC50	nM	71.0	IC50	uM	0.071
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3cccnc3)n2)nc1	J. Med. Chem.	2008.0	CHEMBL271120	=	=	IC50	nM	9600.0	IC50	uM	9.6
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccncc2)n1	J. Med. Chem.	2008.0	CHEMBL405565	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	O=C(Nc1ccccc1)OCc1cn(-c2ccc(Cl)cc2)nn1	J. Med. Chem.	2008.0	CHEMBL407246	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	COc1ccc(-c2cc(CNS(=O)(=O)c3ccccc3)on2)cc1	J. Med. Chem.	2008.0	CHEMBL271622	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CCOC(=O)C(Cc1ccc(Cl)cc1Cl)c1ccno1	J. Med. Chem.	2008.0	CHEMBL271621	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CCOc1ccc(NC(=O)c2ccc(-n3cnnn3)cc2)cc1	J. Med. Chem.	2008.0	CHEMBL271326	=	=	IC50	nM	34000.0	IC50	uM	34.0
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CCn1c(SCc2ccc(OC)cc2)nnc1-c1ccncc1	J. Med. Chem.	2008.0	CHEMBL271624	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	Cc1cnc(CNc2cc(-c3ccccc3)nc(-c3ccccn3)n2)nc1	J. Med. Chem.	2008.0	CHEMBL406832	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4 expressed in Saccharomyces cerevisiae by fluorescence assay	CS(=O)(=O)Cc1cc(N2CCCC2)nc(-c2ccccc2)n1	J. Med. Chem.	2008.0	CHEMBL271620	>	>	IC50	nM	40000.0	IC50	uM	40.0
Binding affinity to purified human recombinant CYP3A4 expressed in Escherichia coli assessed as spectral dissociation constant	Clc1ccc(Cn2cc(-c3ccncc3)cn2)c(Cl)c1	J. Med. Chem.	2008.0	CHEMBL271580	=	=	Kd	nM	380.0	Kd	uM	0.38
Binding affinity to purified human recombinant CYP3A4 expressed in Escherichia coli assessed as spectral dissociation constant	CS(=O)(=O)OCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1	J. Med. Chem.	2008.0	CHEMBL410503	=	=	Kd	nM	3500.0	Kd	uM	3.5
Binding affinity to purified human recombinant CYP3A4 expressed in Escherichia coli assessed as spectral dissociation constant	CCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1	J. Med. Chem.	2008.0	CHEMBL270271	=	=	Kd	nM	210.0	Kd	uM	0.21
Inhibition of CYP3A4	CNCc1cnc(C)cc1Oc1ccccc1Oc1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL273208	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccc(Cl)cc5)cccc4c3)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL429743	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccc(Cl)cc5)cccc4c3F)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL429585	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cc(C)no5)cccc4c3)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL270978	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccncc5)cccc4c3)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL272693	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5cccnc5)cccc4c3)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL406388	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	COc1cc2nccc(Oc3ccc4c(C(=O)Nc5ccccn5)cccc4c3)c2cc1OC	J. Med. Chem.	2008.0	CHEMBL269915	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4	Nc1nccn2c(C3CCC3)nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c12	Bioorg. Med. Chem.	2008.0	CHEMBL261805	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCOCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL258648	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCSCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL258951	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCCCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL408712	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL261146	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](N2CCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL411082	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CN(C)[C@H]1C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1	Bioorg. Med. Chem.	2008.0	CHEMBL430051	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@H](CN2CCOCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL261253	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](CN2CCOCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL411074	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@H](CN2CCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL260298	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](CN2CCC2)C1	Bioorg. Med. Chem.	2008.0	CHEMBL410659	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CN(C)C[C@H]1C[C@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1	Bioorg. Med. Chem.	2008.0	CHEMBL411062	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4	CN(C)C[C@H]1C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1	Bioorg. Med. Chem.	2008.0	CHEMBL413828	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human recombinant CYP3A4	O=C(O)CN1C(=O)C2(CC(=O)N(Cc3ccccc3)C2=O)c2cc(Cl)ccc21	J. Med. Chem.	2008.0	CHEMBL410333	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	Oc1cccc(-c2ccc3cc(O)ccc3c2)c1	J. Med. Chem.	2008.0	CHEMBL195217	=	=	IC50	nM	1580.0	IC50	uM	1.58
Inhibition of human CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2008.0	CHEMBL157101	=	=	IC50	nM	54.0	IC50	uM	0.054
Inhibition of CYP3A4	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1	J. Med. Chem.	2008.0	CHEMBL263664	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL259922	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2ccc(-c3ccccc3F)cc2N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL260636	=	=	IC50	nM	1.0	IC50	nM	1.0
Inhibition of CYP3A4	O=C1CC(c2cccc(-n3ccnn3)c2)=Nc2ccc(-c3ccccc3F)cc2N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL261288	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP3A4	O=C1CC(c2cccc(-n3ccnc3)c2)=Nc2cc(O)c(-c3ccccc3F)cc2N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL405895	=	=	IC50	nM	1.0	IC50	nM	1.0
Inhibition of CYP3A4	Nc1ccccc1NC(=O)c1ccc(C2CCN(CCC(=O)Nc3ccccc3F)CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL409494	=	=	IC50	nM	10000.0	Log IC50		-5.0
Inhibition of CYP3A4	CN(C)C(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL260200	<	<	IC50	nM	10000.0	Log IC50		-5.0
Inhibition of CYP3A4	CNC(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL264961	<	<	IC50	nM	10000.0	Log IC50		-5.0
Inhibition of CYP3A4	CCNC(=O)c1ccc(CN2CCC(c3ccc(C(=O)Nc4ccccc4N)cc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL412083	<	<	IC50	nM	10000.0	Log IC50		-5.0
Inhibition of CYP3A4	Nc1ccccc1NC(=O)c1ccc(C2CCN(Cc3ccc(C(=O)NC4CC4)cc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL409493	<	<	IC50	nM	10000.0	Log IC50		-5.0
Inhibition of CYP3A4	COc1cc(Cl)ccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL260259	>	>	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4	Cc1nnc(-c2cn3ncnc(Nc4cnc5[nH]ccc5c4)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258694	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	CNc1nnc(-c2cn3ncnc(Nc4cnc5[nH]c(C)cc5c4)c3c2C(C)C)o1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL409442	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of CYP3A4	Cc1cc2cc(Nc3ncnn4cc(-c5nnc(C)o5)c(C(C)C)c34)cnc2[nH]1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL261592	=	=	IC50	nM	11500.0	IC50	uM	11.5
Inhibition of CYP3A4	COc1cc(Cl)ccc1Oc1cc(C)ncc1CN(C)C	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL403080	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1cc(Oc2ccc(Cl)cc2C)c(CN(C)C)cn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256970	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(CC(=O)N1CCC[C@H](c2ccccc2)[C@@H]1CN1CCCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402303	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4	Cc1cc(NC(=O)OC(C)(C)C)nn1Cc1cc(Cl)ccc1OCc1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258199	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	Cc1cc(NC(=O)OC(C)C)nn1Cc1cc(Cl)ccc1OCc1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256092	>=	>=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254356	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4	O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255460	=	=	IC50	nM	680.0	IC50	uM	0.68
Inhibition of CYP3A4	O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255462	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	O=C(Cn1c(=O)oc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL404289	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4	O=C(Cn1c(=O)oc2ccc(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257150	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4	Cc1cc2ncc(=O)n(CC(=O)N3CCCC(c4ccccc4)C3CN3CCOCC3)c2cc1C	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256721	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4	Cc1cc2ncc(=O)n(CC(=O)N3CCCC(c4ccccc4)C3CN3CCCC3)c2cc1C	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257415	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of CYP3A4	O=C(Cn1c(=O)cnc2cc(Cl)c(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCOCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256988	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	O=C(Cn1c(=O)cnc2cc(Cl)c(Cl)cc21)N1CCCC(c2ccccc2)C1CN1CCCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256989	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4	Cc1cc2c(cc1C)N(CC(=O)N1CCCC(c3ccccc3)C1CN1CCCC1)C(=O)CO2	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257171	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of CYP3A4	O=C1COc2cc(Cl)c(Cl)cc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402520	=	=	IC50	nM	730.0	IC50	uM	0.73
Inhibition of CYP3A4	O=C1COc2cc(Cl)c(Cl)cc2N1CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL255509	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4	COCCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402813	=	=	IC50	nM	480.0	IC50	uM	0.48
Inhibition of CYP3A4	COCCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL256937	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4	N#CCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL258251	=	=	IC50	nM	490.0	IC50	uM	0.49
Inhibition of CYP3A4	N#CCN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL257767	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4	CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCOCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL402805	=	=	IC50	nM	770.0	IC50	uM	0.77
Inhibition of human recombinant CYP3A4 expressed in insect microsomes	COc1ccc2cc(-c3cnccc3N)ccc2c1	J. Med. Chem.	2008.0	CHEMBL453169	=	=	IC50	nM	21070.0	IC50	nM	21070.0
Inhibition of human recombinant CYP3A4 expressed in insect microsomes	COc1ccc2cc(-c3cncc4ccccc34)ccc2c1	J. Med. Chem.	2008.0	CHEMBL500394	=	=	IC50	nM	3540.0	IC50	nM	3540.0
Inhibition of human recombinant CYP3A4 expressed in insect microsomes	COc1ccc2cc(-c3cncc(C(C)=O)c3)ccc2c1	J. Med. Chem.	2008.0	CHEMBL502824	=	=	IC50	nM	9070.0	IC50	nM	9070.0
Inhibition of human recombinant CYP3A4 expressed in insect microsomes	COc1cncc(-c2ccc3cc(OC)ccc3c2)c1	J. Med. Chem.	2008.0	CHEMBL447591	=	=	IC50	nM	1913.0	IC50	nM	1913.0
Inhibition of human recombinant CYP3A4 expressed in insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2008.0	CHEMBL157101	=	=	IC50	nM	57.0	IC50	nM	57.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	OC1(c2cccnc2)CCc2cc(-c3ccc(F)cc3)ccc21	J. Med. Chem.	2008.0	CHEMBL498471	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2008.0	CHEMBL157101	=	=	IC50	nM	72.0	IC50	nM	72.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	J. Med. Chem.	2008.0	CHEMBL254328	=	=	IC50	nM	2704.0	IC50	nM	2704.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Br.Oc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL496469	=	=	IC50	nM	3386.0	IC50	nM	3386.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Br.Oc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1O	J. Med. Chem.	2008.0	CHEMBL522228	=	=	IC50	nM	632.0	IC50	nM	632.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL496456	=	=	IC50	nM	2300.0	IC50	nM	2300.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCCC3c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL496289	=	=	IC50	nM	2173.0	IC50	nM	2173.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCC3c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL496288	=	=	IC50	nM	1093.0	IC50	nM	1093.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCC3c2cccnc2)cc1	J. Med. Chem.	2008.0	CHEMBL496287	=	=	IC50	nM	1697.0	IC50	nM	1697.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Br.Oc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL496286	=	=	IC50	nM	2114.0	IC50	nM	2114.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Br.Oc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1O	J. Med. Chem.	2008.0	CHEMBL526081	=	=	IC50	nM	357.0	IC50	nM	357.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL497481	=	=	IC50	nM	3643.0	IC50	nM	3643.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CCC=C3c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL497480	=	=	IC50	nM	4199.0	IC50	nM	4199.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COc1ccc(-c2ccc3c(c2)CC=C3c2ccncc2)cc1.Cl	J. Med. Chem.	2008.0	CHEMBL497309	=	=	IC50	nM	2394.0	IC50	nM	2394.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CC=C3c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL498662	=	=	IC50	nM	159.0	IC50	nM	159.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	Cl.Fc1ccc(-c2ccc3c(c2)CC=C3c2cccnc2)cc1	J. Med. Chem.	2008.0	CHEMBL522730	>	>	IC50	nM	6947.0	IC50	nM	6947.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COc1ccc(-c2ccc3c(c2)CCCC3(O)c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL496263	=	=	IC50	nM	15190.0	IC50	nM	15190.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	OC1(c2ccncc2)CCCc2cc(-c3ccc(F)c(F)c3)ccc21	J. Med. Chem.	2008.0	CHEMBL496262	=	=	IC50	nM	13841.0	IC50	nM	13841.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	OC1(c2ccncc2)CCCc2cc(-c3ccc(F)cc3)ccc21	J. Med. Chem.	2008.0	CHEMBL498652	=	=	IC50	nM	8757.0	IC50	nM	8757.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COc1ccc(-c2ccc3c(c2)CCC3(O)c2ccncc2)cc1F	J. Med. Chem.	2008.0	CHEMBL539168	=	=	IC50	nM	3364.0	IC50	nM	3364.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COc1ccc(-c2ccc3c(c2)CCC3(O)c2ccncc2)cc1	J. Med. Chem.	2008.0	CHEMBL498643	=	=	IC50	nM	3291.0	IC50	nM	3291.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	OC1(c2ccncc2)CCc2cc(-c3ccc(F)cc3)ccc21	J. Med. Chem.	2008.0	CHEMBL498472	=	=	IC50	nM	3231.0	IC50	nM	3231.0
Inhibition of CYP3A4	CC(C)OC(=O)c1ccc(NC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H]2CCC[N+](C)(Cc3cccc(O)c3)C2)cc1.[I-]	J. Med. Chem.	2008.0	CHEMBL540359	=	=	IC50	nM	10000.0	pIC50		5.0
Inhibition of recombinant CYP3A4	O=C(Nc1ccc2c(c1)NC(=O)C(CCO)O2)C1CCN(c2cc(F)c(F)c(F)c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL446545	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	N[C@@H](Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL448656	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(C[C@@H](c2ccccc2)N(C)C)c(=O)n1Cc1c(F)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL509267	=	=	IC50	nM	42000.0	IC50	uM	42.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL451916	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	Cc1c(-c2cccc(OCCCCC(=O)O)c2F)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL454774	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	Cc1c(-c2cccc(OCCCCCC(=O)O)c2F)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL505033	=	=	IC50	nM	8200.0	IC50	uM	8.2
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	Cc1c(-c2cccc(OCCCC(=O)O)c2)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL448253	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	Cc1c(-c2cccc(OCCCCC(=O)O)c2)c(=O)n(C[C@H](N)c2ccccc2)c(=O)n1Cc1c(F)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL449468	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	N[C@@H](Cn1c(=O)c(-c2cccc(OCCCCCC(=O)O)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL444989	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CN[C@@H](Cn1c(=O)c(-c2cccc(OCCC(C)(C)CC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL447424	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCOCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL509347	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CN[C@@H](Cn1c(=O)c(-c2cccc(OCCOCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL506338	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CN[C@@H](Cn1c(=O)c(-c2cccc(OCCCNCC(=O)O)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499442	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL509075	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455769	=	=	IC50	nM	510.0	IC50	uM	0.51
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	N[C@@H](Cn1c(=O)c(-c2ccc(CNCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499849	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	CCOC(=O)CNCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL503624	=	=	IC50	nM	350.0	IC50	uM	0.35
Inhibition of recombinant CYP3A4 by microtiter plate-based fluorimetric assay	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL434936	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate	O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	J. Med. Chem.	2008.0	CHEMBL466555	=	=	IC50	nM	870.0	IC50	uM	0.87
Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate	O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	J. Med. Chem.	2008.0	CHEMBL466555	=	=	IC50	nM	84.0	IC50	uM	0.084
Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	J. Med. Chem.	2008.0	CHEMBL450668	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	J. Med. Chem.	2008.0	CHEMBL454791	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of recombinant CYP3A4 expressed in insect microsomes after 45 mins in presence of BZR substrate	O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	J. Med. Chem.	2008.0	CHEMBL454751	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	J. Med. Chem.	2008.0	CHEMBL454791	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate	O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	J. Med. Chem.	2008.0	CHEMBL454751	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of recombinant CYP3A4 expressed in insect microsomes after 20 mins in presence of BFC substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	J. Med. Chem.	2008.0	CHEMBL450668	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of human recombinant CYP3A4 expressed in insect microsomes assessed as metabolism of testosterone	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	J. Med. Chem.	2008.0	CHEMBL450668	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1	J. Med. Chem.	2009.0	CHEMBL495727	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4	O=C1/C(=C/c2ccc(O)cc2)CC/C1=C\c1ccc(O)cc1	Eur. J. Med. Chem.	2008.0	CHEMBL452101	=	=	IC50	nM	5100.0	IC50	mM	0.0051
Inhibition of human recombinant CYP3A4	COc1cc(/C=C2\CC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O	Eur. J. Med. Chem.	2008.0	CHEMBL270361	=	=	IC50	nM	64900.0	IC50	mM	0.0649
Inhibition of human recombinant CYP3A4	CCc1cc(/C=C2\CC/C(=C\c3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL497137	=	=	IC50	nM	73500.0	IC50	mM	0.0735
Inhibition of human recombinant CYP3A4	CC(C)c1cc(/C=C2\CC/C(=C\c3cc(C(C)C)c(O)c(C(C)C)c3)C2=O)cc(C(C)C)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL498371	=	=	IC50	nM	77600.0	IC50	mM	0.0776
Inhibition of human recombinant CYP3A4	COc1cc(/C=C2\CC/C(=C\c3cc(OC)c(O)c(OC)c3)C2=O)cc(OC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL498373	=	=	IC50	nM	38300.0	IC50	mM	0.0383
Inhibition of human recombinant CYP3A4	Cc1cc(/C=C/C(=O)/C=C/c2cc(C)c(O)c(C)c2)cc(C)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL407034	=	=	IC50	nM	40300.0	IC50	mM	0.0403
Inhibition of human recombinant CYP3A4	COc1cc(/C=C/C(=O)/C=C/c2cc(OC)c(O)c(OC)c2)cc(OC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL493001	=	=	IC50	nM	13200.0	IC50	mM	0.0132
Inhibition of human recombinant CYP3A4	O=C1/C(=C/c2ccc(O)cc2)CC/C1=C\c1ccc(O)cc1	Eur. J. Med. Chem.	2008.0	CHEMBL452101	=	=	IC50	nM	5105050.0	log(1/IC50)		2.292
Inhibition of human recombinant CYP3A4	COc1cc(/C=C2\CC/C(=C\c3ccc(O)c(OC)c3)C2=O)ccc1O	Eur. J. Med. Chem.	2008.0	CHEMBL270361	=	=	IC50	nM	64863443.35	log(1/IC50)		1.188
Inhibition of human recombinant CYP3A4	CCc1cc(/C=C2\CC/C(=C\c3cc(CC)c(O)c(CC)c3)C2=O)cc(CC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL497137	=	=	IC50	nM	73451386.82	log(1/IC50)		1.134
Inhibition of human recombinant CYP3A4	CC(C)c1cc(/C=C2\CC/C(=C\c3cc(C(C)C)c(O)c(C(C)C)c3)C2=O)cc(C(C)C)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL498371	=	=	IC50	nM	77624711.66	log(1/IC50)		1.11
Inhibition of human recombinant CYP3A4	COc1cc(/C=C2\CC/C(=C\c3cc(OC)c(O)c(OC)c3)C2=O)cc(OC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL498373	=	=	IC50	nM	38282474.33	log(1/IC50)		1.417
Inhibition of human recombinant CYP3A4	Cc1cc(/C=C/C(=O)/C=C/c2cc(C)c(O)c(C)c2)cc(C)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL407034	=	=	IC50	nM	40271703.43	log(1/IC50)		1.395
Inhibition of human recombinant CYP3A4	COc1cc(/C=C/C(=O)/C=C/c2cc(OC)c(O)c(OC)c2)cc(OC)c1O	Eur. J. Med. Chem.	2008.0	CHEMBL493001	=	=	IC50	nM	76032627.69	log(1/IC50)		1.119
Inhibition of human recombinant CYP3A4	COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O	Eur. J. Med. Chem.	2008.0	CHEMBL116438	=	=	IC50	nM	16300.0	IC50	uM	16.3
Inhibition of CYP3A4	CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2CCN(c3ccc(C#N)cc3F)CC2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL497999	>	>	IC50	nM	29100.0	IC50	uM	29.1
Inhibition of CYP3A4	CCCCNc1nccc2[nH]c3ccccc3c12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL497171	=	=	IC50	nM	100.0	pIC50		7.0
Inhibition of CYP3A4	COCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(CN(C)C3CCCCC3)ccc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL486757	>	>	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 green	C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](C[C@@H]2O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL464234	=	=	IC50	nM	13600.0	IC50	uM	13.6
Inhibition of CYP3A4 red	C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](C[C@@H]2O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL464234	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 red	C[C@H]1CN(S(=O)(=O)C[C@]23CC[C@H](CC2=O)C3(C)C)CCN1c1ncc(C(F)(F)F)cc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL480016	=	=	IC50	nM	320.0	IC50	uM	0.32
Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL517440	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL517440	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ccccc1S(C)(=O)=O	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL512127	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(Cl)cccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL461012	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL467633	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	CCN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1ncccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL520276	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4	CN(CC(O)(CNC(=O)c1cnn(-c2ccc(F)cc2)c1N)C(F)(F)F)C(=O)c1c(F)cccc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL464907	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	Nc1c(C(=O)NCC(O)(CN(CCF)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL464245	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4	Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(F)cccc2F)C(F)(F)F)cnn1-c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL517933	=	=	IC50	nM	76000.0	IC50	uM	76.0
Inhibition of CYP3A4	Nc1c(C(=O)NCC(O)(CN(CCO)C(=O)c2c(Cl)cccc2Cl)C(F)(F)F)cnn1-c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465451	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc([C@@](C)(O)C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL489500	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc([C@](C)(O)C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL460962	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	C[C@@H]1CN(CC2(C(N)=O)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465955	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 by microplate-based direct fluorometric assay	CN(CCC(=O)N1CCN(c2ccc(F)c(F)c2)CC1)CCC1c2ccccc2Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL460542	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 by microplate-based direct fluorometric assay	CN(CCC(=O)N1CCN(c2ccc(F)c(F)c2)CC1)CCC1c2ccccc2-c2ccccc21.Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL473763	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	COCCCN1CCN([C@H]2CC[C@H](n3nc(-c4ccc5nc(Cc6ccccc6OC)[nH]c5c4)c4c(N)ncnc43)CC2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL443098	>	>	IC50	nM	20000.0	IC50	uM	20.0
Activation of human CYP3A4 using DEF substrate	CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1F	J. Med. Chem.	2009.0	CHEMBL453384	>	>	IC50	nM	100000.0	IC50	uM	100.0
Activation of human CYP3A4 using DEF substrate	CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	J. Med. Chem.	2009.0	CHEMBL147587	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using DEF substrate	CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	J. Med. Chem.	2009.0	CHEMBL1235	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of human CYP3A4 using PPR substrate	CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	J. Med. Chem.	2009.0	CHEMBL1235	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using DEF substrate	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl	J. Med. Chem.	2009.0	CHEMBL1630	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of human CYP3A4 using PPR substrate	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl	J. Med. Chem.	2009.0	CHEMBL1630	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes	Clc1cccc(COc2cncc(N3CCNCC3)n2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494947	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes	C[C@H](Cc1cccc(F)c1)Oc1nc(N2CCNC[C@H]2C)ncc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494948	=	=	IC50	nM	4900.0	IC50	uM	4.9
Inhibition of human recombinant CYP3A4 after 45 mins using 7-benzyloxyquinoline as substrate	CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1	J. Med. Chem.	2009.0	CHEMBL493937	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human recombinant CYP3A4 after 45 mins using 7-benzyloxy 4-trifluoromethylcoumarin as substrate	CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1	J. Med. Chem.	2009.0	CHEMBL493937	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@H]1CN(CC2(C(N)=O)CCC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465956	=	=	IC50	nM	65000.0	IC50	uM	65.0
Inhibition of CYP3A4	C[C@@H]1CN(CC2(c3ccncc3)CC2)CCN1S(=O)(=O)c1ccc(C(C)(O)C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL522964	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL253641	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCCS2(=O)=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL253641	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL445734	=	=	IC50	nM	6300.0	IC50	uM	6.3
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)c(F)c(N2CCCC2=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL445734	=	=	IC50	nM	75000.0	IC50	uM	75.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cnn(CC)c2)cc(N2CCCCS2(=O)=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL399656	>	>	IC50	nM	89000.0	IC50	uM	89.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCNc1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cnn(CC)c2)cc(N2CCCCS2(=O)=O)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL399656	>	>	IC50	nM	89000.0	IC50	uM	89.0
Inhibition of human CYP3A4 by radiometric assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Nat. Prod.	2004.0	CHEMBL157101	=	=	IC50	nM	245.0	IC50	uM	0.245
Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O	J. Nat. Prod.	2004.0	CHEMBL519761	=	=	IC50	nM	14400.0	IC50	uM	14.4
Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1OC(C)=O	J. Nat. Prod.	2004.0	CHEMBL240954	=	=	IC50	nM	20600.0	IC50	uM	20.6
Inhibition of human CYP3A4 by radiometric assay	C/C1=C\CC(C)(C)/C=C/C(=O)/C(C)=C/CC1	J. Nat. Prod.	2004.0	CHEMBL245412	=	=	IC50	nM	21800.0	IC50	uM	21.8
Inhibition of human CYP3A4 by radiometric assay	COc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2OC)cc1	J. Nat. Prod.	2004.0	CHEMBL309061	=	=	IC50	nM	21800.0	IC50	uM	21.8
Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](OC(C)=O)[C@@H]1O	J. Nat. Prod.	2004.0	CHEMBL471074	=	=	IC50	nM	31600.0	IC50	uM	31.6
Inhibition of human CYP3A4 by radiometric assay	C/C1=C\CC(C)(C)/C=C/C(=O)/C(C)=C/[C@H](O)C1	J. Nat. Prod.	2004.0	CHEMBL469850	=	=	IC50	nM	35500.0	IC50	uM	35.5
Inhibition of human CYP3A4 by radiometric assay	COc1c(-c2ccc(O)cc2)oc2cc(O)cc(O)c2c1=O	J. Nat. Prod.	2004.0	CHEMBL165064	=	=	IC50	nM	36200.0	IC50	uM	36.2
Inhibition of human CYP3A4 by radiometric assay	CCCCC[C@H](O)CC(=O)CCc1ccc(OC)c(O)c1	J. Nat. Prod.	2004.0	CHEMBL471072	=	=	IC50	nM	36400.0	IC50	uM	36.4
Inhibition of human CYP3A4 by radiometric assay	C/C1=C\[C@H](O)C[C@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O	J. Nat. Prod.	2004.0	CHEMBL513372	=	=	IC50	nM	42600.0	IC50	uM	42.6
Inhibition of human CYP3A4 by radiometric assay	C/C1=C\CC[C@@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O	J. Nat. Prod.	2004.0	CHEMBL512339	=	=	IC50	nM	48400.0	IC50	uM	48.4
Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)O[C@@H](C)[C@H](O)[C@H]1OC(C)=O	J. Nat. Prod.	2004.0	CHEMBL469851	=	=	IC50	nM	55800.0	IC50	uM	55.8
Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)O[C@@H](C)[C@H](O)[C@H]1O	J. Nat. Prod.	2004.0	CHEMBL469431	=	=	IC50	nM	59000.0	IC50	uM	59.0
Inhibition of human CYP3A4 by radiometric assay	C/C1=C\[C@H](O)C[C@@]2(C)O[C@@H]2CC(C)(C)/C=C/C1=O	J. Nat. Prod.	2004.0	CHEMBL503727	=	=	IC50	nM	62500.0	IC50	uM	62.5
Inhibition of human CYP3A4 by radiometric assay	CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1	J. Nat. Prod.	2004.0	CHEMBL25948	=	=	IC50	nM	77700.0	IC50	uM	77.7
Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@H]1[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H]1O	J. Nat. Prod.	2004.0	CHEMBL470049	=	=	IC50	nM	90000.0	IC50	uM	90.0
Inhibition of human CYP3A4 by radiometric assay	CC(=O)O[C@@H]1[C@@H](O)[C@H](C)O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@@H]1O	J. Nat. Prod.	2004.0	CHEMBL470048	=	=	IC50	nM	98300.0	IC50	uM	98.3
Inhibition of human CYP3A4 by radiometric assay	C[C@@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@H](O)[C@H]1O	J. Nat. Prod.	2004.0	CHEMBL240528	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 by radiometric assay	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C)C(C)C	J. Nat. Prod.	2004.0	CHEMBL221542	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	O=C(O)c1cc2occc2[nH]1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL492591	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)c1cc2sccc2[nH]1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL507614	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	Nc1nccc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)c1C#CCO	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL500157	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of human CYP3A4	NCC#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL526929	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of human CYP3A4	C#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL502531	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of human CYP3A4	Nc1nccc(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)c1C#Cc1ccccn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL500422	=	=	IC50	nM	37000.0	IC50	uM	37.0
Inhibition of human CYP3A4	CN(C)CC#Cc1c(Oc2ccc(NC(=O)NC(=O)Cc3ccc(F)cc3)cc2F)ccnc1N	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL525049	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL434936	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4	CS(=O)(=O)c1cccc(F)c1Cn1cc(-c2ccccc2Cl)c(=O)n(C[C@H](NCCCC(=O)O)c2ccccc2)c1=O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL508020	=	=	IC50	nM	48000.0	IC50	uM	48.0
Inhibition of CYP3A4	O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL526887	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL450471	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3S(C)(=O)=O)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453167	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL526327	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL509075	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of CYP3A4	COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL445691	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of CYP3A4	COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455769	=	=	IC50	nM	510.0	IC50	uM	0.51
Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(CNCCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL456279	=	=	IC50	nM	31000.0	IC50	uM	31.0
Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(CNCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499849	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(CSCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499589	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(COCC(=O)O)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499588	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CCOC(=O)CNCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL503624	=	=	IC50	nM	350.0	IC50	uM	0.35
Inhibition of CYP3A4	NCC(=O)OCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499307	=	=	IC50	nM	670.0	IC50	uM	0.67
Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(COC(=O)CO)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499026	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(COC(=O)C3CC3)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL508435	=	=	IC50	nM	48.0	IC50	uM	0.048
Inhibition of CYP3A4	NCc1ccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL497747	=	=	IC50	nM	9100.0	IC50	uM	9.1
Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccc(CO)cc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL495882	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccccc2)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL365985	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4	CS(=O)(=O)c1cccc(F)c1Cn1cc(-c2ccccc2Cl)c(=O)n(C[C@H](N)c2ccccc2)c1=O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL371613	=	=	IC50	nM	180.0	IC50	uM	0.18
Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL192172	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of CYP3A4	N[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL189164	=	=	IC50	nM	160.0	IC50	uM	0.16
Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3S(C)(=O)=O)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL364914	=	=	IC50	nM	380.0	IC50	uM	0.38
Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL191817	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL509075	=	=	IC50	nM	39810.72	pIC50		4.4
Inhibition of CYP3A4	O=C(O)CCCN[C@@H](Cn1c(=O)c(-c2ccccc2Cl)cn(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL450471	=	=	IC50	nM	15848.93	pIC50		4.8
Inhibition of CYP3A4	Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1	J. Med. Chem.	2008.0	CHEMBL254316	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CN(C)C(=O)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C	J. Med. Chem.	2008.0	CHEMBL495331	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2008.0	CHEMBL157101	=	=	IC50	nM	57.0	IC50	nM	57.0
Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL401930	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL459729	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	COCCN1CCC(c2cc(C)c3nc(-c4c(NCCn5cc(Cl)cn5)cc[nH]c4=O)[nH]c3c2)CC1	J. Med. Chem.	2008.0	CHEMBL460997	=	=	IC50	nM	19500.0	IC50	uM	19.5
Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(C2CCN(CCO)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL460996	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(C2CCN(C)CC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL461422	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	COc1ccc([C@H](O)CNc2cc[nH]c(=O)c2-c2nc3c(C)cc(C4CCN(CCCF)CC4)cc3[nH]2)cc1Cl	J. Med. Chem.	2008.0	CHEMBL469292	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	COCCN1CCC(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5ccc(OC)c(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	J. Med. Chem.	2008.0	CHEMBL512126	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(C2CCN(CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL468672	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	COCCN1CCC(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	J. Med. Chem.	2008.0	CHEMBL468671	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human recombinant CYP3A4 in human liver microsomes using BFC as a substrate	Cc1cc(C2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL461198	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of human recombinant CYP3A4 in human liver microsomes using BzRes as a substrate	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	J. Med. Chem.	2008.0	CHEMBL401930	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of CYP3A4	C[C@H]1CN(Cc2cccc(-c3cc(CNC(=O)c4cccc(CC5CCNCC5)c4)ccc3F)c2)CCN1	J. Med. Chem.	2008.0	CHEMBL521523	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 in human liver microsomes	Cc1ccccc1-c1nncc2cc(-c3c(C)ccc4c(NC5CC5)noc34)ccc12	J. Med. Chem.	2008.0	CHEMBL495084	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 in human liver microsomes	Cc1ccc2c(N)nsc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1	J. Med. Chem.	2008.0	CHEMBL524054	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(C(C)C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL492661	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(OC(C)C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL494917	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	CC[C@H](C)Nc1nncc2cc(-c3c(C)ccc4c(NC)noc34)ccc12	J. Med. Chem.	2008.0	CHEMBL522689	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(NC(C)C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL494305	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(N5CCOC[C@H]5C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL493496	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)Nc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(Cl)ccc12	J. Med. Chem.	2008.0	CHEMBL523516	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(Cl)ccc12	J. Med. Chem.	2008.0	CHEMBL495118	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 in human liver microsomes	CC(=O)Nc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL521860	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	Cc1ccc2c(N)noc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1	J. Med. Chem.	2008.0	CHEMBL494916	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in human liver microsomes	CNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL523374	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	CCNc1noc2c(-c3ccc4c(N5CCOC[C@@H]5C)nncc4c3)c(C)ccc12	J. Med. Chem.	2008.0	CHEMBL495493	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1ccc2c(NC3CC3)noc2c1-c1ccc2c(NC(C)C)nncc2c1	J. Med. Chem.	2008.0	CHEMBL495492	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 in human liver microsomes	CC(=O)N1CCN(c2nncc3cc(-c4c(C)ccc5c(NC6CC6)noc45)ccc23)[C@@H](C)C1	J. Med. Chem.	2008.0	CHEMBL495290	=	=	IC50	nM	4200.0	IC50	uM	4.2
Inhibition of CYP3A4 in human liver microsomes	Cc1ccc2c(NC3CC3)noc2c1-c1ccc2c(N3CCOC[C@@H]3C)nncc2c1	J. Med. Chem.	2008.0	CHEMBL522877	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4	COc1ccc(C(=O)c2c(C)n(Cc3cccc(O[C@@H](C)C(=O)O)c3)c3ncccc23)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455126	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL434936	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4	COc1cccc(-c2cn(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL509075	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL179691	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@@H](c3ccccc3)N(C)CCCC(=O)O)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL503705	=	=	IC50	nM	69000.0	IC50	uM	69.0
Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL510538	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3Cl)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL502341	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)[O-])c3ccccc3)c2=O)c1F.[Na+]	J. Med. Chem.	2008.0	CHEMBL502182	=	=	IC50	nM	56000.0	IC50	uM	56.0
Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL506877	=	=	IC50	nM	135000.0	IC50	uM	135.0
Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL501329	=	=	IC50	nM	69000.0	IC50	uM	69.0
Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCC(=O)O)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL509440	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of CYP3A4	COC(=O)CCCN[C@@H](Cn1c(=O)c(-c2cccc(OC)c2F)c(C)n(Cc2c(F)cccc2C(F)(F)F)c1=O)c1ccccc1	J. Med. Chem.	2008.0	CHEMBL510285	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of CYP3A4	COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](N)c3ccccc3)c2=O)c1F	J. Med. Chem.	2008.0	CHEMBL468551	=	=	IC50	nM	230.0	IC50	uM	0.23
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	J. Med. Chem.	2009.0	CHEMBL473921	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2009.0	CHEMBL532	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	J. Med. Chem.	2009.0	CHEMBL473921	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2009.0	CHEMBL532	=	=	IC50	nM	190.0	IC50	uM	0.19
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CCC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL474130	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	J. Med. Chem.	2009.0	CHEMBL474934	=	=	IC50	nM	41000.0	IC50	uM	41.0
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489094	=	=	IC50	nM	4900.0	IC50	uM	4.9
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489095	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL523933	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	CC(C(=O)N1CCC(Nc2ccc(F)cc2)CC1)c1ccc(CN2C[C@H](C)N[C@H](C)C2)cc1	J. Med. Chem.	2009.0	CHEMBL489297	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(C(C)(C)C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	J. Med. Chem.	2009.0	CHEMBL489479	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(C#N)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489480	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CCC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL474130	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	J. Med. Chem.	2009.0	CHEMBL474934	=	=	IC50	nM	59000.0	IC50	uM	59.0
Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489094	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489095	=	=	IC50	nM	69000.0	IC50	uM	69.0
Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL523933	=	=	IC50	nM	69000.0	IC50	uM	69.0
Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(C#N)c4)CC3)cc2)CCN1	J. Med. Chem.	2009.0	CHEMBL489480	=	=	IC50	nM	58000.0	IC50	uM	58.0
Inhibition of CYP3A4	CCc1cc(CC[C@]2(C3CCCC3)CC(O)=C(Cc3nc4nc(C)cc(C)n4n3)C(=O)O2)cc(CC)n1	J. Med. Chem.	2009.0	CHEMBL490672	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C#Cc1c(Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)ccnc1N	J. Med. Chem.	2009.0	CHEMBL462622	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	Nc1nccc(Oc2ccc(NC(=O)c3cccn(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	J. Med. Chem.	2009.0	CHEMBL462624	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl	J. Med. Chem.	2009.0	CHEMBL1630	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate	CCNCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	J. Med. Chem.	2009.0	CHEMBL146826	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human recombinant CYP3A4 using N-N,diethyl-formamide as substrate	CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	J. Med. Chem.	2009.0	CHEMBL1235	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O.Cl	J. Med. Chem.	2009.0	CHEMBL1630	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate	CCN(CC)Cc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	J. Med. Chem.	2009.0	CHEMBL147587	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate	CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	J. Med. Chem.	2009.0	CHEMBL147806	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate	CCNCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	J. Med. Chem.	2009.0	CHEMBL146826	>=	>=	IC50	nM	55000.0	IC50	uM	55.0
Inhibition of human recombinant CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin as substrate	CCNCc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	J. Med. Chem.	2009.0	CHEMBL1235	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	O=C(CCN1C(=O)c2ccccc2C1=O)N1CCCCC1	J. Med. Chem.	2009.0	CHEMBL491273	<	<	Ki	nM	50000000.0	Ki	mM	50.0
Inhibition of CYP3A4	CCc1ccc(N2CC(C(=O)OC)CC2=O)cc1	J. Med. Chem.	2009.0	CHEMBL491274	<	<	Ki	nM	50000000.0	Ki	mM	50.0
Inhibition of CYP3A4	CC(C)c1ccc(OCC(=O)Nc2nc3ccccc3s2)cc1	J. Med. Chem.	2009.0	CHEMBL491275	<	<	Ki	nM	50000000.0	Ki	mM	50.0
Inhibition of CYP3A4	CCc1ccc(OCC(=O)Nc2ccc(C)cc2Br)cc1	J. Med. Chem.	2009.0	CHEMBL489096	<	<	Ki	nM	50000000.0	Ki	mM	50.0
Inhibition of CYP3A4	Cc1ccc(C)c(OCN2Cc3ccccc3C2C=O)c1	J. Med. Chem.	2009.0	CHEMBL504747	<	<	Ki	nM	50000000.0	Ki	mM	50.0
Inhibition of CYP3A4	CCc1ccc(OCC(=O)NCc2cccc3ccccc23)cc1	J. Med. Chem.	2009.0	CHEMBL452613	<	<	Ki	nM	50000000.0	Ki	mM	50.0
Inhibition of CYP3A4	CCc1ccc(OCC(=O)NCCc2ccccc2)cc1	J. Med. Chem.	2009.0	CHEMBL446965	<	<	Ki	nM	50000000.0	Ki	mM	50.0
Inhibition of CYP3A4	CCc1ccc(CCNS(=O)(=O)c2ccc(SC)cc2)cc1	J. Med. Chem.	2009.0	CHEMBL490678	<	<	Ki	nM	50000000.0	Ki	mM	50.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1cc(OC)cc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1	J. Med. Chem.	2008.0	CHEMBL487569	=	=	IC50	nM	380.0	IC50	uM	0.38
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1	J. Med. Chem.	2008.0	CHEMBL486950	=	=	IC50	nM	740.0	IC50	uM	0.74
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COCCN(C)c1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)n1	J. Med. Chem.	2008.0	CHEMBL485972	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2ccncc2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL520238	=	=	IC50	nM	8500.0	IC50	uM	8.5
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COC1CN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)C1	J. Med. Chem.	2008.0	CHEMBL487554	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COCCOc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1	J. Med. Chem.	2008.0	CHEMBL519383	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL519549	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL486140	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1cncc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1	J. Med. Chem.	2008.0	CHEMBL458242	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cncc(O)c2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL486130	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCOC(=O)Nc1cc(-c2cncc(OC)c2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL485752	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N(C)C)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL487572	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2ccccc2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL487765	=	=	IC50	nM	43000.0	IC50	uM	43.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccnc2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL487766	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1cccc(-c2cc(NC(C)=O)nc(-n3nc(C)cc3C)n2)c1F	J. Med. Chem.	2008.0	CHEMBL486745	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1cncc(-c2cc(NC(=O)CN3CCOCC3)nc(-n3nc(C)cc3C)n2)c1	J. Med. Chem.	2008.0	CHEMBL486131	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cncc(N3CCOCC3)c2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL521029	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N3CCOCC3)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL520229	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL487372	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N3CCCC3)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL485765	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N3CCCOCC3)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL520036	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N3CCN(C)CC3)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL486162	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COC1CCN(c2cccc(-c3cc(NC(C)=O)nc(-n4nc(C)cc4C)n3)n2)CC1	J. Med. Chem.	2008.0	CHEMBL487553	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)Nc1cc(-c2cccc(N3CCC(O)CC3)n2)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2008.0	CHEMBL521223	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	Br.CC(=O)SCC(=O)c1ccc(NS(=O)(=O)c2ccc(OCCCN(C)C)cc2)nc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL520237	>	>	EC50	nM	50000.0	EC50	uM	50.0
Inhibition of CYP3A4	CC(=O)SCC(=O)c1ccc(NS(=O)(=O)c2ccc3c(c2)COOC3)nc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL487965	>	>	EC50	nM	50000.0	EC50	uM	50.0
Inhibition of CYP3A4	O=C([C@@H]1C[C@H]1c1ccc(C(F)(F)F)cc1)N1CCN(S(=O)(=O)c2cc(-c3nnc[nH]3)cc(C(F)(F)F)c2)CC1	J. Med. Chem.	2009.0	CHEMBL529213	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay	Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCc4ccccn4)c4ccccc43)c(Cl)c2)n1	Bioorg. Med. Chem.	2009.0	CHEMBL528996	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay	Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCc4cccnn4)c4ccccc43)c(Cl)c2)n1	Bioorg. Med. Chem.	2009.0	CHEMBL475684	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay	Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)O)c4ccccc43)c(Cl)c2)n1	Bioorg. Med. Chem.	2009.0	CHEMBL478902	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsome assessed as 1'-hydroxymidazolam formation by competitive inhibition assay	Cc1ccn(-c2ccc(C(=O)N3CCC(F)(F)/C(=C\C(=O)NCCO)c4ccccc43)c(Cl)c2)n1	Bioorg. Med. Chem.	2009.0	CHEMBL478283	=	=	IC50	nM	47000.0	IC50	uM	47.0
Inhibition of CYP3A4 assessed as midazolam 1'- hydroxylation	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(-c2ccccn2)cc1)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N1CCN(Cc2ccccc2)C1=O)C(C)(C)C)C(C)(C)C	J. Med. Chem.	2009.0	CHEMBL507731	=	=	Ki	nM	18.0	Ki	nM	18.0
Inhibition of CYP3A4 assessed as midazolam 1'- hydroxylation	COC(=O)N[C@H](C(=O)N[C@H](Cc1ccc(-c2ccccn2)cc1)C[C@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N1CCN(Cc2cccc(C(C)(C)O)n2)C1=O)C(C)(C)C)C(C)(C)C	J. Med. Chem.	2009.0	CHEMBL470508	=	=	Ki	nM	66.0	Ki	nM	66.0
Inhibition of human CYP3A4	O=C(/C=C/c1ccc(O)cc1)OC[C@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H](O)[C@@H]1O	J. Nat. Prod.	2004.0	CHEMBL266564	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of human CYP3A4	CC(C)CC(=O)c1c(O)cc(O)cc1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	J. Nat. Prod.	2004.0	CHEMBL484029	=	=	IC50	nM	120000.0	IC50	uM	120.0
Inhibition of human CYP3A4	O=C(/C=C\c1ccc(O)cc1)OC[C@H]1O[C@@H](Oc2c(-c3ccc(O)cc3)oc3cc(O)cc(O)c3c2=O)[C@H](O)[C@@H](O)[C@@H]1O	J. Nat. Prod.	2004.0	CHEMBL499705	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 in human liver microsome	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL157101	=	=	IC50	nM	20.0	IC50	uM	0.02
Inhibition of CYP3A4 in human liver microsome	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@@](C)(c4ccc(F)cc4F)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479575	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL401930	=	=	IC50	nM	0.5	IC50	nM	0.5
Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCN(C(=O)N4CCN(C)CC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL454515	=	=	IC50	nM	40.0	IC50	nM	40.0
Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCN(C(=O)N4CCOCC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL459118	=	=	IC50	nM	19.0	IC50	nM	19.0
Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCN(C(=O)OCCO)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL505652	=	=	IC50	nM	1.8	IC50	nM	1.8
Inhibition of CYP3A4	COCCOC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL450610	=	=	IC50	nM	2.4	IC50	nM	2.4
Inhibition of CYP3A4	COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL505919	=	=	IC50	nM	3.5	IC50	nM	3.5
Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCN(C(=O)C4CC4)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL510298	=	=	IC50	nM	1.7	IC50	nM	1.7
Inhibition of CYP3A4	COCCOCC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL502778	=	=	IC50	nM	3.0	IC50	nM	3.0
Inhibition of CYP3A4	COCC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499584	=	=	IC50	nM	5.6	IC50	nM	5.6
Inhibition of CYP3A4	CC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL506169	=	=	IC50	nM	0.8	IC50	nM	0.8
Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCN(C)CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL451331	=	=	IC50	nM	2.4	IC50	nM	2.4
Inhibition of CYP3A4	Cc1cc(N2CCC(N3C[C@@H]4C[C@@H]3CO4)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL474469	=	=	IC50	nM	0.5	IC50	nM	0.5
Inhibition of CYP3A4	Cc1cc(N2CCC(N3C[C@H](C)O[C@H](C)C3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL502092	=	=	IC50	nM	3.1	IC50	nM	3.1
Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCOCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL482126	=	=	IC50	nM	4.1	IC50	nM	4.1
Inhibition of CYP3A4	COCCN(CCOC)C1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL454467	=	=	IC50	nM	1.0	IC50	nM	1.0
Inhibition of CYP3A4	COC(=O)NC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL521271	=	=	IC50	nM	0.5	IC50	nM	0.5
Inhibition of CYP3A4	Cc1cc(N2CCC(NC(=O)C3CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480966	=	=	IC50	nM	0.7	IC50	nM	0.7
Inhibition of CYP3A4	Cc1cc(N2CCC(N3CCCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480965	=	=	IC50	nM	4.5	IC50	nM	4.5
Inhibition of CYP3A4	Cc1cc(N2CCC(N(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL519300	=	=	IC50	nM	3.9	IC50	nM	3.9
Inhibition of CYP3A4	CNC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL482102	=	=	IC50	nM	2.6	IC50	nM	2.6
Inhibition of CYP3A4	Cc1cc(N2CCC3(CC2)OCCO3)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL482101	=	=	IC50	nM	0.7	IC50	nM	0.7
Inhibition of CYP3A4	Cc1cc(N2CCC(OCCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL482089	=	=	IC50	nM	1.3	IC50	nM	1.3
Inhibition of CYP3A4	COCCOC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL482088	=	=	IC50	nM	0.9	IC50	nM	0.9
Inhibition of CYP3A4	COC1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL519132	=	=	IC50	nM	1.0	IC50	nM	1.0
Inhibition of CYP3A4	Cc1cc(N2CCC(O)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL520419	=	=	IC50	nM	0.4	IC50	nM	0.4
Inhibition of CYP3A4	CCCCC[C@H]1OC(=O)c2ccc(OC)cc2[C@H]1OC(C)=O	J. Nat. Prod.	2008.0	CHEMBL529220	>	>	IC50	nM	65000.0	IC50	uM	65.0
Inhibition of CYP3A4	Cn1c(N(Cc2ccc(C(=O)Nc3nnn[nH]3)cc2)[C@H]2CC[C@H](C(C)(C)C)CC2)nc2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480501	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	CN(CC(=O)N1CCCC(c2ccccc2)C1CN1CCCC1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL254356	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4	COc1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)CN3C(=O)COc4cc(Cl)c(Cl)cc43)cc2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453329	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	CC(=O)Nc1ccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)CN3C(=O)COc4cc(C)c(C)cc43)cc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL449192	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of CYP3A4	CNC(=O)c1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)Cn3c(=O)cnc4cc(Cl)c(Cl)cc43)cc2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL507691	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN(C(=O)CN(CC#N)c1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1ccc(-c2cccc(C(N)=O)c2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453587	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4	COCCN(CC(=O)N(C)C(CN1CCCC1)c1ccc(-c2ccc(C(N)=O)cc2)cc1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453067	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4	CNC(=O)c1cccc(-c2ccc(C(CN3CCOCC3)N(C)C(=O)Cn3c(=O)cnc4cc(C)c(C)cc43)cc2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL499582	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4	CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)[C@H](CN1CCOCC1)c1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL452808	=	=	IC50	nM	4200.0	IC50	uM	4.2
Inhibition of CYP3A4	CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)[C@@H](CN1CCOCC1)c1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453075	=	=	IC50	nM	9100.0	IC50	uM	9.1
Inhibition of CYP3A4	CN(C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc21)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL453074	=	=	IC50	nM	4600.0	IC50	uM	4.6
Inhibition of CYP3A4	CN(CC(=O)N(C)C(CN1CCOCC1)c1ccc(-c2ccccc2)cc1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL452298	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4	CN(CC(=O)N(C)C(CN1CCCC1)c1ccc(-c2ccccc2)cc1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL488642	=	=	IC50	nM	4900.0	IC50	uM	4.9
Inhibition of CYP3A4	CN(CC(=O)N(C)C(CN1CCCC1)c1ccccc1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL527199	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4	O=C(O)[C@H](Cc1ccc(-n2c(-c3cccnc3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL481659	=	=	IC50	nM	62000.0	IC50	uM	62.0
Inhibition of CYP3A4	O=C(O)[C@H](Cc1ccc(-n2c(C3(C(F)(F)F)CC3)nc3cccnc32)cc1)NC1=C(Br)C(=O)C12CCCCC2	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL487438	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)c1nc2cccnc2n1-c1ccc(C[C@H](NC2=C(Br)C(=O)C23CCCCC3)C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL486444	=	=	IC50	nM	79000.0	IC50	uM	79.0
Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL517503	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL517828	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1ccccc1Cl)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478223	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1cccc(Cl)c1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL446054	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477387	=	=	IC50	nM	39000.0	IC50	uM	39.0
Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1ccsc1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL517503	=	=	IC50	nM	9700.0	IC50	uM	9.7
Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL515624	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	O=S(=O)(c1cccc(Cl)c1)n1cc(Cl)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478870	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	CN1CCc2cc3ccn(S(=O)(=O)c4cccc(Cl)c4)c3cc2CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL518591	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	Cn1cc(S(=O)(=O)c2ccccc2)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478871	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1ccccc1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL517828	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1cccc(Cl)c1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL446054	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	COc1cccc(S(=O)(=O)n2ccc3cc4c(cc32)CCNCC4)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477386	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1ccccn1)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477387	=	=	IC50	nM	77000.0	IC50	uM	77.0
Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1ccccc1)n1cc(Cl)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL515624	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1cccc(Cl)c1)n1cc(Cl)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478870	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	CN1CCc2cc3ccn(S(=O)(=O)c4cccc(Cl)c4)c3cc2CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL518591	=	=	IC50	nM	71000.0	IC50	uM	71.0
Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	Cn1cc(S(=O)(=O)c2ccccc2)c2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478871	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of human CYP3A4 by microtiter plate assays using PPR substrate	O=S(=O)(c1ccccc1Cl)n1ccc2cc3c(cc21)CCNCC3	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478223	=	=	IC50	nM	3200.0	IC50	uM	3.2
Inhibition of human CYP3A4 by microtiter plate assays using N-N,diethyl-formamide as substrate	COc1cccc(S(=O)(=O)n2ccc3cc4c(cc32)CCNCC4)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477386	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4	COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cc1	J. Med. Chem.	2008.0	CHEMBL520828	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1	J. Med. Chem.	2008.0	CHEMBL483401	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of CYP3A4	COc1ccc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)cn1	J. Med. Chem.	2008.0	CHEMBL483574	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4	COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3ccc4[nH]ncc4c3)=C(C)N2)ccn1	J. Med. Chem.	2008.0	CHEMBL483402	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP3A4	CC1=C(C(=O)Nc2cc3cn[nH]c3cc2F)C(c2ccc(Cl)cc2F)N=C(c2ccnc(Cl)c2)N1	J. Med. Chem.	2008.0	CHEMBL521347	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4	COc1cc(C2=NC(c3ccc(Cl)cc3F)C(C(=O)Nc3cc4cn[nH]c4cc3F)=C(C)N2)ccn1	J. Med. Chem.	2008.0	CHEMBL485612	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of CYP3A4	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccccc2)N1	J. Med. Chem.	2008.0	CHEMBL519680	=	=	IC50	nM	350.0	IC50	uM	0.35
Inhibition of human hepatic CYP3A4	Oc1cccc(-c2cnc(-c3cccc(O)c3)s2)c1	J. Med. Chem.	2008.0	CHEMBL456379	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of human hepatic CYP3A4	Oc1cccc(-c2ccc(-c3cccc(O)c3)cc2)c1	J. Med. Chem.	2008.0	CHEMBL502908	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of human hepatic CYP3A4	Oc1ccc(-c2cc(-c3cccc(O)c3)cs2)cc1	J. Med. Chem.	2008.0	CHEMBL462513	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of human CYP3A4	O=C(N[C@H]1C[C@@H]2CC[C@H](C1)N2Cc1ccc2cc(F)ccc2c1)c1cc[n+]([O-])cc1C(=O)N1CCCCC1	Bioorg. Med. Chem.	2008.0	CHEMBL3084581	>	>	IC50	nM	40000.0	IC50	nM	40000.0
Inhibition of human CYP3A4	O=C(NC1CC2CCC(C1)N2Cc1ccc2cc(F)ccc2c1)c1ccccc1-c1ccccc1	Bioorg. Med. Chem.	2008.0	CHEMBL522295	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of CYP3A4	O=C(CCc1ccccc1)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL514681	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(Cc1ccccc1)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476762	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccccc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476763	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475928	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475926	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	N#Cc1ccc(C(=O)NCC(=O)NC(c2ccccc2)c2ccc(Cl)cc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475927	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccncc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL452423	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccsc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476360	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)C1CCCC1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL514209	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(=O)NCC(=O)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476567	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476568	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1ccccc1C(NC(=O)CNC(=O)c1ccc(F)cc1)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476775	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479084	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479085	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccc(Cl)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL518287	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475926	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1cccc(F)c1)c1cccc(F)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476557	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479071	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479072	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1ccc(C(NC(=O)CNC(=O)c2ccc(F)cc2)c2ccc(OC)cc2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL514198	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CCC(NC(=O)CNC(=O)c1ccc(F)cc1)c1ccccc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478229	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ccncc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478230	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1cccnn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL516125	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1ncccn1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL514241	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NC(c1ccccc1)c1nccs1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478037	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2Sc2ccc(Cl)cc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478035	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2CCc2ccccc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478036	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(F)cc1)NCC1c2ccccc2COc2ccc(F)cc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL515644	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CN1C(=O)c2ccccc2C(CNC(=O)CNC(=O)c2ccc(F)cc2)c2ccccc21	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL490609	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475928	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(CNC(=O)c1ccc(Cl)cc1)NC(c1ccccc1)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL475928	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1nc(-c2ccc(F)cc2)ccc1C(=O)Nc1ccc2cccnc2c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477204	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)N1CCC(COc2ncc(C(=O)c3ccc(Cl)cc3)n2C)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL481745	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COC[C@H]1CCCN1c1cc(NC(C)=O)nc(-n2nc(C)cc2C)n1	J. Med. Chem.	2009.0	CHEMBL458224	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CCC(=O)c1cc(-c2ccc(Cl)cc2)n(-c2ccc(S(N)(=O)=O)cc2)c1C	J. Med. Chem.	2009.0	CHEMBL490153	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)CNc1nc(C#N)nc(N2CCOCC2)c1N	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL450061	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)(C)CNc1nc(C#N)nc(N2CCOCC2)c1N	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL471757	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)CNc1nc(C#N)nc(N2CCNCC2)c1N	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL474484	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C([C@@H]1C[C@H](N2CCN(c3ncccn3)CC2)CN1)N1CCC(F)(F)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL515387	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	NC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL512414	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using DEF substrate	O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(F)cc2Cl)n1.[Na+]	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL513491	=	=	IC50	nM	35000.0	IC50	uM	35.0
Inhibition of human CYP3A4 using PPR substrate	O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(F)cc2Cl)n1.[Na+]	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL513491	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	O=C([O-])c1cccc(Cc2cc(Cl)ccc2OCc2ccc(Cl)cc2F)n1.[Na+]	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL467114	>=	>=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human recombinant CYP3A4	NCc1noc(-c2nn(Cc3ccccc3)c3ccccc23)n1	J. Med. Chem.	2009.0	CHEMBL512079	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of human CYP3A4	C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	J. Med. Chem.	2009.0	CHEMBL447955	=	=	IC50	nM	39000.0	IC50	uM	39.0
Inhibition of CYP3A4	Cc1ncsc1C(=O)N(Cc1cc(=O)[nH]c2c(F)cccc12)c1cccc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL522771	=	=	EC50	nM	7000.0	EC50	uM	7.0
Inhibition of CYP3A4	Cc1ncsc1C(=O)N(Cc1c[n+]([O-])cc2c(F)c(F)ccc12)c1cccc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL524109	=	=	EC50	nM	1800.0	EC50	uM	1.8
Inhibition of CYP3A4	Cn1cncc1C(=O)N(Cc1cc(=O)[nH]c2c(F)c(F)ccc12)c1cccc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL491923	=	=	EC50	nM	1400.0	EC50	uM	1.4
Inhibition of CYP3A4	CC1=C(C(=O)N(Cc2cc(=O)[nH]c3c(F)c(F)ccc23)c2cccc(Cl)c2)CNCC1	J. Med. Chem.	2009.0	CHEMBL491922	=	=	EC50	nM	3400.0	EC50	uM	3.4
Inhibition of CYP3A4	Cc1ncsc1C(=O)N(Cc1cc(=O)[nH]c2c(F)c(F)ccc12)c1cccc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL489724	=	=	EC50	nM	4900.0	EC50	uM	4.9
Inhibition of CYP3A4	CC(C)C(=O)N(Cc1cc(=O)[nH]c2c(F)cccc12)c1cccc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL470908	=	=	EC50	nM	7600.0	EC50	uM	7.6
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2COC(=O)[C@@H]2Cc2cc(OC)c3c(c2)OCO3)cc(OC)c1O	J. Nat. Prod.	2005.0	CHEMBL482034	=	=	IC50	nM	7400.0	IC50	uM	7.4
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2[C@@H](O)OC[C@@H]2Cc2cc(OC)c3c(c2)OCO3)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL482233	=	=	IC50	nM	830.0	IC50	uM	0.83
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	CC1=CC(=O)C2=C(C)C[C@@H]3OC(=O)C(C)=C3C[C@@H]12	J. Nat. Prod.	2005.0	CHEMBL501260	=	=	IC50	nM	8800.0	IC50	uM	8.8
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	CC1=C[C@@H](O)[C@@]23O[C@]2(C)C[C@@H]2OC(=O)C(C)=C2C[C@@H]13	J. Nat. Prod.	2005.0	CHEMBL501119	=	=	IC50	nM	98200.0	IC50	uM	98.2
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	C/C=C/c1cc(OC)c(OC)cc1OC	J. Nat. Prod.	2005.0	CHEMBL333306	=	=	IC50	nM	92300.0	IC50	uM	92.3
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	CO[C@@H]1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2	J. Nat. Prod.	2005.0	CHEMBL520915	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(OC)c([C@@H]2[C@H](C)[C@@H](C)[C@H]2c2cc(OC)c(OC)cc2OC)cc1OC	J. Nat. Prod.	2005.0	CHEMBL156339	=	=	IC50	nM	85400.0	IC50	uM	85.4
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2	J. Nat. Prod.	2005.0	CHEMBL242011	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	O[C@H]1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2	J. Nat. Prod.	2005.0	CHEMBL399831	=	=	IC50	nM	9100.0	IC50	uM	9.1
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2C(O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL479701	=	=	IC50	nM	830.0	IC50	uM	0.83
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2COC(=O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL479314	=	=	IC50	nM	14900.0	IC50	uM	14.9
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	OC[C@H](Cc1ccc2c(c1)OCO2)[C@H](CO)Cc1ccc2c(c1)OCO2	J. Nat. Prod.	2005.0	CHEMBL486597	=	=	IC50	nM	9500.0	IC50	uM	9.5
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL471067	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(OC)c(OC)cc1CC(C)=O	J. Nat. Prod.	2005.0	CHEMBL481233	=	=	IC50	nM	28700.0	IC50	uM	28.7
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	CCOc1cc(C[C@H]2COC(O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc2c1OCO2	J. Nat. Prod.	2005.0	CHEMBL480295	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@H]2COC(O)[C@@H]2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL480296	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc3c(c2)OCO3)cc(OC)c1OC	J. Nat. Prod.	2005.0	CHEMBL469916	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(OC)c(C(=O)C(C)=O)cc1OC	J. Nat. Prod.	2005.0	CHEMBL450829	=	=	IC50	nM	74000.0	IC50	uM	74.0
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc(C[C@@H]2COC(=O)[C@H]2Cc2cc(OC)c(O)c(OC)c2)ccc1O	J. Nat. Prod.	2005.0	CHEMBL469917	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	COc1cc([C@H]2OC[C@@H]3C(c4cc(OC)c(O)c(OC)c4)OC[C@H]23)ccc1O	J. Nat. Prod.	2005.0	CHEMBL513023	=	=	IC50	nM	13700.0	IC50	uM	13.7
Inhibition of human liver microsome CYP3A4 in assessed as [14C]formaldehyde formation	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Nat. Prod.	2005.0	CHEMBL157101	=	=	IC50	nM	720.0	IC50	uM	0.72
Inhibition of CYP3A4	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	J. Nat. Prod.	2006.0	CHEMBL226335	>	>	IC50	nM	80000.0	IC50	uM	80.0
Inhibition of CYP3A4	CN1[C@H]2Cc3cc4c(cc3[C@@H]1Cc1cc3c(cc12)OCO3)OCO4	J. Nat. Prod.	2006.0	CHEMBL481839	=	=	IC50	nM	13400.0	IC50	uM	13.4
Inhibition of CYP3A4	C[N+]1(C)[C@H]2Cc3cc4c(cc3[C@@H]1Cc1cc3c(cc12)COC3)OCO4.[Cl-]	J. Nat. Prod.	2006.0	CHEMBL538357	>	>	IC50	nM	80000.0	IC50	uM	80.0
Inhibition of CYP3A4	CN1CCc2cc3c(cc2C(=O)Cc2cc4c(cc2C1)OCO4)OCO3	J. Nat. Prod.	2006.0	CHEMBL486179	>	>	IC50	nM	80000.0	IC50	uM	80.0
Inhibition of CYP3A4	COc1cc(-c2oc3cc(O)cc(O)c3c(=O)c2O[C@@H]2O[C@H](CO[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)ccc1O	J. Nat. Prod.	2006.0	CHEMBL258394	>	>	IC50	nM	80000.0	IC50	uM	80.0
Inhibition of CYP3A4	Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1	J. Med. Chem.	2008.0	CHEMBL476323	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of human recombinant CYP3A4 transfected in Escherichia coli co-expressed with human NADPH reductase	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478649	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1n[nH]c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12	J. Med. Chem.	2008.0	CHEMBL477611	=	=	IC50	nM	7600.0	IC50	uM	7.6
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C	J. Med. Chem.	2008.0	CHEMBL477563	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C	J. Med. Chem.	2008.0	CHEMBL478612	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1	J. Med. Chem.	2008.0	CHEMBL478402	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1	J. Med. Chem.	2008.0	CHEMBL476572	=	=	IC50	nM	74000.0	IC50	uM	74.0
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl.Cl	J. Med. Chem.	2008.0	CHEMBL1794074	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein substrate	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl	J. Med. Chem.	2008.0	CHEMBL1794073	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1n[nH]c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12	J. Med. Chem.	2008.0	CHEMBL477611	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1nc2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc2n1C	J. Med. Chem.	2008.0	CHEMBL477563	=	=	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1nc2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2n1C	J. Med. Chem.	2008.0	CHEMBL478612	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	CN(c1ccc2cn(C)nc2c1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1	J. Med. Chem.	2008.0	CHEMBL478402	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1Cc1ccccc1	J. Med. Chem.	2008.0	CHEMBL476572	=	=	IC50	nM	79000.0	IC50	uM	79.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl.Cl	J. Med. Chem.	2008.0	CHEMBL1794074	=	=	IC50	nM	31000.0	IC50	uM	31.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline substrate	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl	J. Med. Chem.	2008.0	CHEMBL1794073	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 in pooled human liver microsome using midazolam substrate	CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476302	=	=	IC50	nM	7200.0	IC50	nM	7200.0
Inhibition of CYP3A4 in pooled human liver microsome using atrovastatin substrate	CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476302	=	=	IC50	nM	4600.0	IC50	nM	4600.0
Inhibition of CYP3A4 in pooled human liver microsome using nifedipine substrate	CC(C)c1onc(-c2c(Cl)cccc2Cl)c1COc1ccc(-c2ccc3c(C(=O)O)cccc3c2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476302	=	=	IC50	nM	8800.0	IC50	nM	8800.0
Inhibition of CYP3A4	CS(=O)(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476312	>	>	IC50	nM	3000.0	IC50	nM	3000.0
Inhibition of CYP3A4	CC(C)C(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476116	>	>	IC50	nM	3000.0	IC50	nM	3000.0
Inhibition of CYP3A4	CCOC(=O)N(Cc1ccccc1-c1ccccc1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL478834	>	>	IC50	nM	3000.0	IC50	nM	3000.0
Inhibition of CYP3A4	CC1OC(Cc2ccc(Cl)c(Oc3cc(Cl)cc(C#N)c3)c2F)=NNC1=O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL467187	=	=	IC50	nM	270.0	IC50	uM	0.27
Inhibition of CYP3A4	Cc1ccc(Cc2n[nH]c(=O)n2C)c(F)c1Oc1cc(Cl)cc(C#N)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL513510	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL476954	=	=	IC50	nM	17900.0	IC50	uM	17.9
Inhibition of recombinant CYP3A4	O=C(c1cccc(Cl)c1)c1cc(Cc2ccc(=O)[nH]n2)cc2ccoc12	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL446793	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of recombinant CYP3A4	O=c1ccc(Cc2cc(Oc3cccc(Cl)c3)c3occc3c2)n[nH]1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL513868	=	=	IC50	nM	410.0	IC50	uM	0.41
Inhibition of recombinant CYP3A4	O=c1ccc(Cc2cc(Cc3cccc(Cl)c3)c3occc3c2)n[nH]1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL504522	=	=	IC50	nM	180.0	IC50	uM	0.18
Inhibition of recombinant CYP3A4	Cc1cc(Cc2ccc(Cl)c(Oc3cc(F)cc(C#N)c3)c2F)n[nH]c1=O	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL477145	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4	C1=C(CS/C(=N\C2CCCCC2)NC2CCCCC2)N2CCN=C2S1	J. Med. Chem.	2008.0	CHEMBL452864	=	=	IC50	nM	3860.0	IC50	nM	3860.0
Inhibition of CYP3A4	CC1(C)CN2C(CS/C(=N\C3CCCCC3)NC3CCCCC3)=CSC2=N1	J. Med. Chem.	2008.0	CHEMBL460491	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455683	=	=	IC50	nM	25200.0	IC50	uM	25.2
Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate	O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455683	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4 using dibenzylfluorescein as substrate	O=C(/C=C/c1cc(F)cc(F)c1)N1CCC([C@@H](CO)N2CCC(c3c[nH]c4ncccc34)CC2)CC1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL455683	=	=	IC50	nM	20600.0	IC50	uM	20.6
Inhibition of CYP3A4 using diethoxyfluorescein substrate	COc1cccc(CCN(Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)C(=O)NC2CCCCC2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL501315	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccccc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465244	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccc(F)cc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL464909	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)Cc3cccc(Cl)c3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465941	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)CS(=O)(=O)c3ccccc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465948	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cc(CC(=O)N(C)Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)on1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL516551	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccc(CN2C[C@H](C)N[C@H](C)C2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465289	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479418	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Oc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL518142	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccccc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479419	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccc(Cl)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL481575	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(C(=O)c4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480210	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL473921	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480219	=	=	IC50	nM	58000.0	IC50	uM	58.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465925	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	COc1cccc(CCN(Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)C(=O)NC2CCCCC2)c1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL501315	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccccc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465244	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)COc3ccc(F)cc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL464909	=	=	IC50	nM	7300.0	IC50	uM	7.3
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)Cc3cccc(Cl)c3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465941	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3CN(C)C(=O)CS(=O)(=O)c3ccccc3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465948	=	=	IC50	nM	8900.0	IC50	uM	8.9
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	Cc1cc(CC(=O)N(C)Cc2ccccc2-c2ccc(CN3C[C@H](C)N[C@H](C)C3)cc2)on1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL516551	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	CCN(CCc1ccccc1)C(=O)c1ccccc1-c1ccc(CN2C[C@H](C)N[C@H](C)C2)cc1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465289	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479418	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Oc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL518142	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccccc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL479419	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(Nc4ccc(Cl)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL481575	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3ccccc3C(=O)N3CCC(C(=O)c4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480210	=	=	IC50	nM	3600.0	IC50	uM	3.6
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Nc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL473921	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-n3ccnc3C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL480219	=	=	IC50	nM	46000.0	IC50	uM	46.0
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	C[C@H]1CN(Cc2ccc(-c3cccnc3C(=O)N3CCC(Cc4ccc(F)cc4)CC3)cc2)C[C@@H](C)N1	Bioorg. Med. Chem. Lett.	2008.0	CHEMBL465925	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cccc(OC(F)(F)F)c2)cc1C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL520413	=	=	IC50	nM	57000.0	IC50	uM	57.0
Inhibition of CYP3A4	CC(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL466191	=	=	IC50	nM	58000.0	IC50	uM	58.0
Inhibition of CYP3A4	CC(C)(C)c1cc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465470	=	=	IC50	nM	64000.0	IC50	uM	64.0
Inhibition of CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)cc1C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL517646	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cccc(Br)c2)cc1C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL480398	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	O=C(NCC1CCOCC1)c1cnc(Nc2cc(Cl)ccc2Cl)cc1C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL479628	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COC1CCc2cc(-c3cccnc3)ccc2C1	J. Med. Chem.	2008.0	CHEMBL460178	=	=	IC50	nM	12200.0	IC50	uM	12.2
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	O=C1CCc2cc(-c3cccnc3)ccc2C1	J. Med. Chem.	2008.0	CHEMBL462093	=	=	IC50	nM	6210.0	IC50	uM	6.21
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	O=C1CCc2cc(-c3cccnc3)ccc21	J. Med. Chem.	2008.0	CHEMBL448743	<	<	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	COc1cncc(-c2ccc3c(c2)CCC(=O)C3)c1	J. Med. Chem.	2008.0	CHEMBL499007	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	O=C1CCc2cc(-c3cccnc3)ccc2N1	J. Med. Chem.	2008.0	CHEMBL62811	=	=	IC50	nM	127000.0	IC50	uM	127.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	CN1C(=O)CCc2cc(-c3cccnc3)ccc21	J. Med. Chem.	2008.0	CHEMBL446083	<	<	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	O=C1CCc2cc(-c3cncc4ccccc34)ccc2N1	J. Med. Chem.	2008.0	CHEMBL456390	<	<	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2008.0	CHEMBL157101	=	=	IC50	nM	57000.0	IC50	uM	57.0
Inhibition of CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccc(F)cc2c1=O	Bioorg. Med. Chem.	2009.0	CHEMBL425483	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4	CCOc1cc([C@@H](CS(C)(=O)=O)N2C(=O)c3cccc(NC(C)=O)c3C2=O)ccc1OC	J. Med. Chem.	2009.0	CHEMBL514800	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C	J. Med. Chem.	2009.0	CHEMBL289228	=	=	IC50	nM	1700.0	IC50	nM	1700.0
Inhibition of human recombinant CYP3A4	Cc1c(Cl)cccc1-c1cc(=O)n(C)c2ccc([C@](N)(c3ccc(Cl)cc3)c3cncn3C)cc12	J. Med. Chem.	2009.0	CHEMBL456001	=	=	IC50	nM	1300.0	IC50	nM	1300.0
Inhibition of human recombinant CYP3A4	Cc1ccccc1-c1cc(=O)n(C)c2ccc([C@](N)(c3ccc(Cl)cc3)c3cncn3C)cc12	J. Med. Chem.	2009.0	CHEMBL456002	=	=	IC50	nM	1350.0	IC50	nM	1350.0
Inhibition of human recombinant CYP3A4	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc3ccccc13)cc(=O)n2C	J. Med. Chem.	2009.0	CHEMBL470996	=	=	IC50	nM	550.0	IC50	nM	550.0
Inhibition of human recombinant CYP3A4	CO[C@](c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1cccc(Cl)c1C)cc(=O)n2C)c1cncn1C	J. Med. Chem.	2009.0	CHEMBL471195	=	=	IC50	nM	870.0	IC50	nM	870.0
Inhibition of human recombinant CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2009.0	CHEMBL157101	=	=	IC50	nM	40.0	IC50	nM	40.0
Inhibition of human recombinant CYP3A4	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	J. Med. Chem.	2009.0	CHEMBL1397	=	=	IC50	nM	350.0	IC50	nM	350.0
Inhibition of CYP3A4	O=C(O)c1cccc(C2=C(c3cc(Cl)ccc3OCc3ccc(F)cc3F)CCC2)n1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL234940	=	=	IC50	nM	89000.0	IC50	uM	89.0
Inhibition of human CYP3A4	CCOC(=O)[C@H](Cc1ccc(NC(=O)c2c(Cl)cncc2Cl)cc1)NC(=O)[C@@H]1C[C@@H](NC2CCC2)CN1S(=O)(=O)c1cccc(C#N)c1	J. Med. Chem.	2009.0	CHEMBL443928	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of human CYP3A4	CCOC(=O)[C@H](Cc1ccc(NC(=O)c2c(Cl)cncc2Cl)cc1)NC(=O)[C@@H]1C[C@@H](NC2CCC2)CN1S(=O)(=O)c1cc(Cl)cc(Cl)c1	J. Med. Chem.	2009.0	CHEMBL502381	<	<	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4	CO/C(C)=C1/NC(=O)[C@H]([C@@H](C)O)NC(=O)c2csc(n2)-c2cc(OC)c(-c3nc(C(=O)NCCCN4CCOCC4)cs3)nc2-c2csc(n2)[C@@H]2COC(=O)c3c4c5c(cccc5n3O)COC(=O)[C@@H](O[C@H]3C[C@](C)(O)[C@H](N(C)C)[C@H](C)O3)[C@@H](OC4)[C@H](NC(=O)c3csc1n3)c1nc(cs1)C(=O)N2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL504492	>=	>=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccc(-c3ccncc3)cc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495992	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)NC3CCc4ccccc4CC3)CC2)Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL519149	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496189	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496189	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cn1nccc1-c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495792	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cn1nccc1Nc1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495793	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495794	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3ccccc3O2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495995	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3cc(F)ccc3O2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL483876	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL519336	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)CCC1(CCCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL482637	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)N[C@H]3C[C@@H]3c3ccccc3)CC2)Oc2cccnc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495993	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CC1)CC(O)c1ncccc1O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL523565	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(N[C@H]1C[C@@H]1c1ccccc1)N1CCC2(CCc3ncccc3O2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL522211	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(c1ccc(C(F)(F)F)cc1)N1CCC2(CCc3ccccc3O2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL524992	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)c3ccc(C(F)(F)F)cc3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497828	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)CCC1(CCN(C(=O)Cc3ccc(Cl)cc3Cl)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497829	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(CCc1ccccc1)N1CCC2(CCc3cc(F)ccc3O2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL447085	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)NC3CCc4ccccc4C3)CC2)Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495601	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C1CC2(CCN(C(=O)NC3CCc4ccccc43)CC2)Oc2ccccc21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL482845	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CS(=O)(=O)c1ccc2c(c1)C(=O)CC1(CCN(C(=O)N[C@@H]3CC[C@@H](c4ccccc4)C3)CC1)O2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495586	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498114	=	=	IC50	nM	31000.0	IC50	uM	31.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498434	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c3c(c(-n4cncn4)cn2c1C)CC[C@@H](c1ccccc1)N3	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498252	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498251	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498840	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(N[C@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL521724	=	=	IC50	nM	86000.0	IC50	uM	86.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL510171	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496402	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497419	=	=	IC50	nM	4200.0	IC50	uM	4.2
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497418	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL526841	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498220	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498026	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495787	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495786	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL523563	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496387	=	=	IC50	nM	8500.0	IC50	uM	8.5
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496386	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496227	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496035	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496624	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL521889	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496426	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496606	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL447822	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496605	=	=	IC50	nM	48000.0	IC50	uM	48.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL453246	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496400	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496806	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL523752	=	=	IC50	nM	6300.0	IC50	uM	6.3
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497011	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL238146	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CCc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498114	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1COc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498434	=	=	IC50	nM	9200.0	IC50	uM	9.2
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c3c(c(-n4cncn4)cn2c1C)CC[C@@H](c1ccccc1)N3	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498252	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c3c(c(-n4ccccc4=O)cn2c1C)CC[C@@H](c1ccccc1)N3	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL525001	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498251	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(N[C@H]3c4ccccc4C[C@@H]3O)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498840	=	=	IC50	nM	62000.0	IC50	uM	62.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(N[C@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL521724	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL510171	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(N[C@@H]3CCc4ccccc43)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496402	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	COc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497419	=	=	IC50	nM	4600.0	IC50	uM	4.6
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(NCc3ccccc3)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497418	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3cncn3)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL526841	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1nc2c(NCc3ccc(F)cc3Cl)cc(-n3ccccc3=O)cn2c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498220	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ccccc1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL498026	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ccccc1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495787	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2ccc(=O)cc2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL495786	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2cnccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL523563	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2ncccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496387	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2cc(C(N)=O)ccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496386	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2cnc(CO)n2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496227	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2ncnc2CO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496035	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCc1cccc(C)c1CNc1cc(-c2ncnn2C)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496624	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(N2CCNC2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL521889	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-c2ccco2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496426	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2cncn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496606	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-c2ccccn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL447822	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2ccccc2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496605	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-n2cccn2)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL453246	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(N2CCCCC2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496400	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(-c2c[nH]c(=O)[nH]c2=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496806	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCc1cccc(C)c1CNc1cccn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL523752	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497011	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL238146	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4	C[C@@H](Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1	Bioorg. Med. Chem.	2009.0	CHEMBL466496	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4	NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1	Bioorg. Med. Chem.	2009.0	CHEMBL467079	=	=	IC50	nM	8600.0	IC50	uM	8.6
Inhibition of CYP3A4	NC(=O)C(Nc1c(Nc2ccncc2)c(=O)c1=O)c1cccc(O)c1	Bioorg. Med. Chem.	2009.0	CHEMBL511410	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	C[C@@H](Nc1c(Nc2ccn[nH]2)c(=O)c1=O)c1ccccc1	Bioorg. Med. Chem.	2009.0	CHEMBL524472	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 expressed in human hepatocytes	C[C@H](N)C(=O)NCc1cccc(-n2nc(C(F)(F)F)cc2-c2nnc(-c3cccc4ncsc34)o2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL468927	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 coincubated with compound	CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565195	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 coincubated with compound	COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557885	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 coincubated with compound	CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL561696	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 preincubated with compound	CS(=O)(=O)c1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565195	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 preincubated with compound	COc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557885	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 preincubated with compound	CSc1ccc(Nc2nc3cc(C(N)=O)ccc3n2Cc2ccccc2C(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL561696	<	<	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of testosterone 6-beta-hydroxylation	Cl.O=c1n(C[C@@H](O)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1	J. Med. Chem.	2009.0	CHEMBL564840	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 by microtiter plate assay	Cc1cc(-c2ncsc2Cl)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1	J. Med. Chem.	2009.0	CHEMBL549534	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of human CYP3A4 by microtiter plate assay	Cc1cc(-c2[nH]ncc2C)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1	J. Med. Chem.	2009.0	CHEMBL563956	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of human CYP3A4 by microtiter plate assay	Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3Cn3cccc(C(F)(F)F)c3=O)c2n1	J. Med. Chem.	2009.0	CHEMBL559825	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4 by microtiter plate assay	Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3CNC(=O)C3CCCCC3)c2n1	J. Med. Chem.	2009.0	CHEMBL559565	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of human CYP3A4 by microtiter plate assay	Cc1cc(-c2ccnn2C)c2cccc(OCc3c(C)ccnc3CNC(=O)C(C)C)c2n1	J. Med. Chem.	2009.0	CHEMBL559506	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(C)(C)[Si](C)(C)O[C@H]1C=C2CCN3Cc4cc5c(cc4[C@H]([C@@H]1O)[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558873	=	=	Ki	nM	260.0	Ki	uM	0.26
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C=C2CCN3Cc4cc5c(cc4[C@H]1[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL564408	=	=	Ki	nM	210.0	Ki	uM	0.21
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@@H]1[C@@H](O)C=C2CCN3Cc4cc5c(cc4[C@H]1[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL251077	=	=	Ki	nM	7600.0	Ki	uM	7.6
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@H]1C=C2CCN3Cc4cc5c(cc4[C@H]([C@@H]1OC(C)=O)[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465295	=	=	Ki	nM	11000.0	Ki	uM	11.0
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	O=C1N[C@@H]2C(=C[C@H](O)[C@@H](O)[C@H]2O)c2cc3c(c(O)c21)OCO3	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL98745	=	=	Ki	nM	630.0	Ki	uM	0.63
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL157101	=	=	Ki	nM	24.0	Ki	uM	0.024
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(C)(C)[Si](C)(C)O[C@H]1C=C2CCN3Cc4cc5c(cc4[C@H]([C@@H]1O)[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558873	=	=	Ki	nM	251.19	pKi		6.6
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@@H]1[C@@H](O[Si](C)(C)C(C)(C)C)C=C2CCN3Cc4cc5c(cc4[C@H]1[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL564408	=	=	Ki	nM	158.49	pKi		6.8
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@@H]1[C@@H](O)C=C2CCN3Cc4cc5c(cc4[C@H]1[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL251077	=	=	Ki	nM	7943.28	pKi		5.1
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)O[C@H]1C=C2CCN3Cc4cc5c(cc4[C@H]([C@@H]1OC(C)=O)[C@@H]23)OCO5	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL465295	=	=	Ki	nM	10000.0	pKi		5.0
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	O=C1N[C@@H]2C(=C[C@H](O)[C@@H](O)[C@H]2O)c2cc3c(c(O)c21)OCO3	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL98745	=	=	Ki	nM	630.96	pKi		6.2
Inhibition of human CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL157101	=	=	Ki	nM	25.12	pKi		7.6
Inhibition of CYP3A4	CCNC(=O)c1cc2c(-c3cc(OCCN(CC)CC)c(Cl)cc3Cl)nc(N)nc2s1	J. Med. Chem.	2009.0	CHEMBL549749	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1ccc2c3c(ccc2n1)OC[C@H](CN1CCN(c2ccc4cc(C#N)ccc4n2)CC1)O3	J. Med. Chem.	2009.0	CHEMBL551964	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(n2ccnn2)CC1	J. Med. Chem.	2009.0	CHEMBL564975	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cn1cc(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)nn1	J. Med. Chem.	2009.0	CHEMBL562869	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cn1cnnc1C1CCN(C(=O)NC2CC2c2ccccc2)CC1	J. Med. Chem.	2009.0	CHEMBL550652	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(n2cncn2)CC1	J. Med. Chem.	2009.0	CHEMBL563732	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(n2cccn2)CC1	J. Med. Chem.	2009.0	CHEMBL559101	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1c(O)noc1C1CCN(C(=O)NC2CC2c2ccccc2)CC1	J. Med. Chem.	2009.0	CHEMBL552196	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nnco2)CC1	J. Med. Chem.	2009.0	CHEMBL561379	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2ncon2)CC1	J. Med. Chem.	2009.0	CHEMBL561259	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1noc(C2CCN(C(=O)NC3CC3c3ccccc3)CC2)n1	J. Med. Chem.	2009.0	CHEMBL564547	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc3ccccc3o2)CC1	J. Med. Chem.	2009.0	CHEMBL552402	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccc3C(F)(F)F)no2)CC1	J. Med. Chem.	2009.0	CHEMBL561788	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CS(=O)(=O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1	J. Med. Chem.	2009.0	CHEMBL551058	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)c1ccc(-c2noc(C3CCN(C(=O)NC4CC4c4ccccc4)CC3)n2)cc1	J. Med. Chem.	2009.0	CHEMBL559531	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL552382	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cccnc3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL564757	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccncc3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL556487	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3cnccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL557032	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ncccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL551517	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3nccc4ccccc34)no2)CC1	J. Med. Chem.	2009.0	CHEMBL552061	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL551921	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(Nc1ccc(C(F)(F)F)cc1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL555347	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CCc2ccccc2CC1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL562926	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CCc2ccccc2C1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL550242	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(N[C@@H]1C[C@H]1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL562822	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CC1c1ccccc1)N1CCC(c2nc(-c3ccccn3)no2)CC1	J. Med. Chem.	2009.0	CHEMBL552382	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome at 1 uM	CCC(c1ccc(-c2ccc(O)c(Cl)c2)cc1)n1ccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL541941	=	=	IC50	nM	91.0	IC50	nM	91.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2009.0	CHEMBL157101	=	=	IC50	nM	72.0	IC50	nM	72.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL254328	=	=	IC50	nM	2704.0	IC50	nM	2704.0
Inhibition of CYP3A4	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Eur. J. Med. Chem.	2009.0	CHEMBL532	=	=	IC50	nM	132129.56	-Log IC50(M)		3.879
Inhibition of CYP3A4	CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12	Eur. J. Med. Chem.	2009.0	CHEMBL76	=	=	IC50	nM	349945.17	-Log IC50(M)		3.456
Inhibition of CYP3A4	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Eur. J. Med. Chem.	2009.0	CHEMBL23	=	=	IC50	nM	217270.12	-Log IC50(M)		3.663
Inhibition of CYP3A4	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12	Eur. J. Med. Chem.	2009.0	CHEMBL493	=	=	IC50	nM	2999.16	-Log IC50(M)		5.523
Inhibition of CYP3A4	CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21	Eur. J. Med. Chem.	2009.0	CHEMBL1732	=	=	IC50	nM	2999.16	-Log IC50(M)		5.523
Inhibition of CYP3A4	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	Eur. J. Med. Chem.	2009.0	CHEMBL1191	=	=	IC50	nM	835603.02	-Log IC50(M)		3.078
Inhibition of CYP3A4	[O-][S+](Cc1ccccn1)c1nc2ccccc2[nH]1	Eur. J. Med. Chem.	2009.0	CHEMBL9861	=	=	IC50	nM	309029.54	-Log IC50(M)		3.51
Inhibition of CYP3A4	CCCCOC(=O)C(=O)Nc1cccc(-c2nnn[nH]2)c1	Eur. J. Med. Chem.	2009.0	CHEMBL564109	=	=	IC50	nM	289734.36	-Log IC50(M)		3.538
Inhibition of CYP3A4	CN/C(=N/CCSCc1nc[nH]c1C)NC#N	Eur. J. Med. Chem.	2009.0	CHEMBL30	=	=	IC50	nM	1000000.0	-Log IC50(M)		3.0
Inhibition of CYP3A4	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]	Eur. J. Med. Chem.	2009.0	CHEMBL193	=	=	IC50	nM	46989.41	-Log IC50(M)		4.328
Inhibition of CYP3A4	COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1	Eur. J. Med. Chem.	2009.0	CHEMBL1503	=	=	IC50	nM	77983.01	-Log IC50(M)		4.108
Inhibition of CYP3A4	Cc1ncc[nH]1	Eur. J. Med. Chem.	2009.0	CHEMBL293391	=	=	IC50	nM	1253141.17	-Log IC50(M)		2.902
Inhibition of CYP3A4	Oc1cccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL237847	=	=	IC50	nM	767361.49	-Log IC50(M)		3.115
Inhibition of CYP3A4	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1cncn1	Eur. J. Med. Chem.	2009.0	CHEMBL520897	=	=	IC50	nM	9289.66	-Log IC50(M)		5.032
Inhibition of CYP3A4	CCCC1COC(Cn2cncn2)(c2ccc(Cl)cc2Cl)O1	Eur. J. Med. Chem.	2009.0	CHEMBL560579	=	=	IC50	nM	1039.92	-Log IC50(M)		5.983
Inhibition of CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2009.0	CHEMBL157101	=	=	IC50	nM	199.99	-Log IC50(M)		6.699
Inhibition of CYP3A4	CC(C)(C(=O)c1cccnc1)c1cccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL934	=	=	IC50	nM	4931.74	-Log IC50(M)		5.307
Inhibition of CYP3A4	Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1	Eur. J. Med. Chem.	2009.0	CHEMBL1073	=	=	IC50	nM	7447.32	-Log IC50(M)		5.128
Inhibition of CYP3A4	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Eur. J. Med. Chem.	2009.0	CHEMBL91	=	=	IC50	nM	851.14	-Log IC50(M)		6.07
Inhibition of CYP3A4	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Eur. J. Med. Chem.	2009.0	CHEMBL106	=	=	IC50	nM	25003.45	-Log IC50(M)		4.602
Inhibition of CYP3A4	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1	Eur. J. Med. Chem.	2009.0	CHEMBL808	=	=	IC50	nM	430.53	-Log IC50(M)		6.366
Inhibition of CYP3A4	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Eur. J. Med. Chem.	2009.0	CHEMBL6966	=	=	IC50	nM	76032.63	-Log IC50(M)		4.119
Inhibition of CYP3A4	CO[C@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@]3(CO3)C[C@H](C)[C@H](O[C@@H]3O[C@H](C)C[C@H](N(C)C)[C@H]3OC(C)=O)[C@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	Eur. J. Med. Chem.	2009.0	CHEMBL564085	=	=	IC50	nM	7998.34	-Log IC50(M)		5.097
Inhibition of CYP3A4	CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O	Eur. J. Med. Chem.	2009.0	CHEMBL527	=	=	IC50	nM	1000000.0	-Log IC50(M)		3.0
Inhibition of CYP3A4	Cn1ccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL543	=	=	IC50	nM	2697739.43	-Log IC50(M)		2.569
Inhibition of CYP3A4	c1ccc(Nc2ccccn2)cc1	Eur. J. Med. Chem.	2009.0	CHEMBL555260	=	=	IC50	nM	430526.61	-Log IC50(M)		3.366
Inhibition of CYP3A4	S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1	Eur. J. Med. Chem.	2009.0	CHEMBL260374	=	=	IC50	nM	6095.37	-Log IC50(M)		5.215
Inhibition of CYP3A4	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Eur. J. Med. Chem.	2009.0	CHEMBL104	=	=	IC50	nM	50.0	-Log IC50(M)		7.301
Inhibition of CYP3A4	c1ccc2nc(COc3ccc(-c4n[nH]cc4Cc4ccncc4)cc3)ccc2c1	J. Med. Chem.	2009.0	CHEMBL562317	=	=	IC50	nM	450000.0	IC50	uM	450.0
Inhibition of CYP3A4	c1ccc2nc(COc3ccc(-c4n[nH]cc4-c4ccncc4)cc3)ccc2c1	J. Med. Chem.	2009.0	CHEMBL560377	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1cccc2c1O[C@@H](c1ccc(OCCCN3CCCC3)cc1)[C@H](C)S2(=O)=O	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL560386	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using BFC as substrate	Cc1cc2cc(/N=C(/NC#N)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL551991	=	=	IC50	nM	18500.0	IC50	uM	18.5
Inhibition of CYP3A4 using BZR as substrate	Cc1cc2cc(/N=C(/NC#N)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL551991	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human TC5 cells	Cc1cc2cc(/N=C(/NC#N)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL551991	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3nccs3)cc2)c2ccc(OCc3ccccn3)cc12	J. Med. Chem.	2009.0	CHEMBL539650	=	=	IC50	nM	1.4	IC50	nM	1.4
Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3cccnc3)cc2)c2ccc(OCc3ccccn3)cc12	J. Med. Chem.	2009.0	CHEMBL538632	=	=	IC50	nM	4.7	IC50	nM	4.7
Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	J. Med. Chem.	2009.0	CHEMBL16596	=	=	IC50	nM	5.8	IC50	nM	5.8
Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccccn3)cc12	J. Med. Chem.	2009.0	CHEMBL38958	=	=	IC50	nM	11.5	IC50	nM	11.5
Inhibition of CYP3A4	COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)nn1	J. Med. Chem.	2009.0	CHEMBL552567	=	=	IC50	nM	15.1	IC50	nM	15.1
Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(-c3ncccn3)cc2)c2ccc(OCc3ccccn3)cc12	J. Med. Chem.	2009.0	CHEMBL557052	>	>	IC50	nM	10.0	IC50	nM	10.0
Inhibition of CYP3A4	COc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccccn5)ccc43)cc2)cn1	J. Med. Chem.	2009.0	CHEMBL557527	>	>	IC50	nM	50.0	IC50	nM	50.0
Inhibition of human CYP3A4	Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL560993	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CN(C)c1nc(Cc2ccc(NC(=O)c3ccc(C(F)(F)F)cc3)cc2)nc(N(C)C)c1CC(=O)O	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL551813	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL361812	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CN([C@@H]1CCC2=C(C1)C1C=CC=CC1N2CC(=O)O)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL563664	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL561132	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of human CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccccn3c2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL564920	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CN([C@@H]1CCc2c(c3ccccn3c2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL564845	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human CYP3A4	CN([C@@H]1CCc2c(c3ncccc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550465	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CN([C@@H]1CCc2c(c3ccncc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550868	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CN([C@@H]1CCc2c(c3cccnc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL552211	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CN([C@@H]1CCc2c(c3nccnc3n2CC(=O)O)C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL556849	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ncccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557117	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 using felodipine as substrate	O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL552338	=	=	IC50	nM	22000.0	IC50	nM	22000.0
Inhibition of CYP3A4 using midazolam as substrate	O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL552338	=	=	IC50	nM	12200.0	IC50	nM	12200.0
Inhibition of CYP3A4 using testosterone as substrate	O=C(c1ccccc1C(F)(F)F)N(CC1CCC1)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL552338	=	=	IC50	nM	31200.0	IC50	nM	31200.0
Inhibition of CYP3A4	Cn1c(=O)cc(Nc2cc(C(=O)NC3CC3)ccc2Cl)c2cnn(-c3ccc(F)cc3)c21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL561932	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cc1c(CC(=O)O)c2cccnc2n1S(=O)(=O)c1ccc(F)c(F)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL563949	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1ccnc1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557263	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of human recombinant CYP3A4 after 45 mins	CC(Cn1ccnc1)NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL549930	=	=	IC50	nM	320.0	IC50	uM	0.32
Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cncn1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557262	=	=	IC50	nM	570.0	IC50	uM	0.57
Inhibition of human recombinant CYP3A4 after 45 mins	Cc1cc(C)n(CC(NC(=O)NC2CCN(Cc3ccn(-c4ccc(C(F)(F)F)cc4)c3)CC2)c2ccccc2)n1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL539475	=	=	IC50	nM	790.0	IC50	uM	0.79
Inhibition of human recombinant CYP3A4 after 45 mins	Cc1nccn1CC(NC(=O)NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL549595	=	=	IC50	nM	2020.0	IC50	uM	2.02
Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N1CCn2cccc2C1c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550068	=	=	IC50	nM	2490.0	IC50	uM	2.49
Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cc1cnccn1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL562285	=	=	IC50	nM	3220.0	IC50	uM	3.22
Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(Cn1cccn1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL556927	=	=	IC50	nM	4400.0	IC50	uM	4.4
Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(c1ccccc1)c1ncc[nH]1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL563791	=	=	IC50	nM	13400.0	IC50	uM	13.4
Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)NC(CN1CCOCC1)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550816	=	=	IC50	nM	16500.0	IC50	uM	16.5
Inhibition of human recombinant CYP3A4 after 45 mins	O=C(NC1CCN(Cc2ccn(-c3ccc(C(F)(F)F)cc3)c2)CC1)N[C@H](CO)c1ccccc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557329	=	=	IC50	nM	20600.0	IC50	uM	20.6
Inhibition of CYP3A4	CC1CCN(C(=O)c2ccc3cc(OCCCN4CCCCC4)ccc3c2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557461	>	>	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3cc(C(=O)N4CCOCC4)ccc3c2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL541483	>	>	IC50	nM	41000.0	IC50	uM	41.0
Inhibition of CYP3A4	CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL94454	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	COc1ccc(Cn2c(N3CCC(n4cc(C)cn4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL562894	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL556450	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Fc1ccc(Cn2c(N3CCC(n4cccn4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL551347	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Fc1ccc(Cn2c(N3CCC(n4ccnc4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL556449	=	=	IC50	nM	72000.0	IC50	uM	72.0
Inhibition of CYP3A4	Fc1ccc(Cn2c(N3CCC(n4cccc4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558339	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	O=C1CCCCN1C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL552026	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN(C)CCN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL559061	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	COc1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL563055	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Fc1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL559060	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN(CCO)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL557210	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	COCCN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550337	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	COc1ccc(Cn2c(N3CCC(N(C)CC4CCOCC4)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558663	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL550818	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	COc1ccc(Cn2c(N3CCC(N(C)C)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558468	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Cc1ccc(Cn2c(N3CCC(N(C)C)CC3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL563451	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL558467	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	CC1(C)O[C@@H](CO[Si](C)(C)C(C)(C)C)[C@H]([C@H](O)[C@@H](CNC(=O)c2ccccc2)c2ccc3c(c2)OCO3)O1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL574914	=	=	Ki	nM	170.0	Ki	uM	0.17
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573430	=	=	Ki	nM	30.0	Ki	uM	0.03
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577811	=	=	Ki	nM	1550.0	Ki	uM	1.55
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C)[C@@H](CNC(=O)OC(C)(C)C)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL583953	=	=	Ki	nM	320.0	Ki	uM	0.32
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL583954	=	=	Ki	nM	580.0	Ki	uM	0.58
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1COS(=O)(=O)c1ccc(C)cc1)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573665	=	=	Ki	nM	70.0	Ki	uM	0.07
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1COC(C)=O)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573149	=	=	Ki	nM	1010.0	Ki	uM	1.01
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL157101	=	=	Ki	nM	30.0	Ki	uM	0.03
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	CC1(C)O[C@@H](CO[Si](C)(C)C(C)(C)C)[C@H]([C@H](O)[C@@H](CNC(=O)c2ccccc2)c2ccc3c(c2)OCO3)O1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL574914	=	=	Ki	nM	165.96	pKi		6.78
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573430	=	=	Ki	nM	31.62	pKi		7.5
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577811	=	=	Ki	nM	1548.82	pKi		5.81
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C)[C@@H](CNC(=O)OC(C)(C)C)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL583953	=	=	Ki	nM	316.23	pKi		6.5
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1CO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL583954	=	=	Ki	nM	575.44	pKi		6.24
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1COS(=O)(=O)c1ccc(C)cc1)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573665	=	=	Ki	nM	70.79	pKi		7.15
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	COCO[C@@H]([C@@H]1OC(C)(C)O[C@H]1COC(C)=O)[C@@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL573149	=	=	Ki	nM	1023.29	pKi		5.99
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-benzyloxyquinoline to 7-hydroxyquinoline measured every 15 mins by fluorescence intensity analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL157101	=	=	Ki	nM	33.11	pKi		7.48
Inhibition of CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1	J. Med. Chem.	2009.0	CHEMBL575448	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 using 7-benzyloxy-resorufin as substrate	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1	J. Med. Chem.	2009.0	CHEMBL575448	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4	CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL584554	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12	J. Med. Chem.	2009.0	CHEMBL1645462	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 in pooled human liver microsome	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12	J. Med. Chem.	2009.0	CHEMBL1645462	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of human hepatic CYP3A4	Cc1cc(-c2csc(-c3cccc(O)c3)c2)ccc1O	J. Med. Chem.	2009.0	CHEMBL569862	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of human hepatic CYP3A4	Oc1cccc(-c2ccc(-c3ccc(O)c(F)c3)s2)c1	J. Med. Chem.	2009.0	CHEMBL577338	=	=	IC50	nM	820.0	IC50	uM	0.82
Inhibition of human hepatic CYP3A4	Cc1cc(-c2ccc(-c3cccc(O)c3)s2)ccc1O	J. Med. Chem.	2009.0	CHEMBL570596	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 in human liver microsomes	COc1ccc(CCN2C(=O)N(NS(C)(=O)=O)C[C@H]2c2ccc(OC)cc2)cc1	J. Med. Chem.	2009.0	CHEMBL569185	=	=	IC50	nM	37000.0	IC50	microM	37.0
Inhibition of CYP3A4	CN(C)Cc1nc2c(sc3ccc(-c4ccc(O)cc4)cc32)c(=O)[nH]1	J. Med. Chem.	2009.0	CHEMBL585182	>	>	IC50	nM	20000.0	IC50	microM	20.0
Inhibition of CYP3A4	Cc1onc(-c2ccccc2Cl)c1C(=O)N(C)c1ccc(Cl)cc1	J. Med. Chem.	2009.0	CHEMBL575966	=	=	IC50	nM	1258.93	pIC50		5.9
Inhibition of CYP3A4	Cc1ccc(N(C)C(=O)c2c(-c3ccccc3Cl)noc2C)cc1Cl	J. Med. Chem.	2009.0	CHEMBL576138	=	=	IC50	nM	1258.93	pIC50		5.9
Inhibition of human recombinant CYP3A4	CNCc1cc(=O)oc2cc(OCc3cccc(Cl)c3)ccc12.CS(=O)(=O)O	J. Med. Chem.	2009.0	CHEMBL593763	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	N#Cc1cc(Cl)cc(Oc2cc(OCc3n[nH]c4nc(N)ccc34)cc(F)c2Cl)c1	J. Med. Chem.	2009.0	CHEMBL572324	=	=	IC50	nM	4400.0	IC50	uM	4.4
Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(/N=C(/NC(=O)c3cccnc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567904	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc[n+]([O-])c3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565383	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3cncc(C(N)=O)c3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577965	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 using BFC as a substrate	Cc1ccc(C(=O)/N=C(\Nc2ccc3oc(C)cc3c2)N[C@H]2CCCCN(CC(=O)N3CCCC3)C2=O)cn1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565390	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc(Cl)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567487	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)O)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570639	=	=	IC50	nM	87000.0	IC50	uM	87.0
Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(N)=O)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL576093	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 using BFC as a substrate	CNC(=O)c1ccc(C(=O)/N=C(\Nc2ccc3oc(C)cc3c2)N[C@H]2CCCCN(CC(=O)N3CCCC3)C2=O)cn1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL576094	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 using BFC as a substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)N(C)C)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570867	=	=	IC50	nM	39000.0	IC50	uM	39.0
Inhibition of CYP3A4 using BZR as substrate	Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)N(C)C)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570867	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 by HHA assay	Cc1cc2cc(N/C(=N\C(=O)c3ccc(C(=O)N(C)C)nc3)N[C@H]3CCCCN(CC(=O)N4CCCC4)C3=O)ccc2o1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570867	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(/C=C/C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12	J. Med. Chem.	2010.0	CHEMBL565591	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of human CYP3A4 using dibenzylfluorescein as substrate	Cc1cn(Cc2ccc(Cl)cc2Cl)c2c(/C=C/C(=O)NS(=O)(=O)c3cc(Cl)c(Cl)s3)cc(F)cc12	J. Med. Chem.	2010.0	CHEMBL565591	=	=	IC50	nM	7600.0	IC50	uM	7.6
Inhibition of CYP3A4	Cc1c(C#N)c(N)nc2c3c(sc12)NC(=O)CC3c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578413	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	C[C@H](NC(=O)C(C)(C)Nc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL582806	=	=	IC50	nM	2030.0	IC50	uM	2.03
Inhibition of CYP3A4	C[C@H](NC(C)(C)C(=O)Nc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL571204	>	>	IC50	nM	35000.0	IC50	uM	35.0
Inhibition of human CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL157101	=	=	IC50	nM	4.0	IC50	uM	0.004
Inhibition of human CYP3A4	COc1cc2c(cc1OC)CN(C(=O)C13CC4CC(C1)CC(c1ccc(OCC(=O)Nc5cccc6cccnc56)cc1)(C4)C3)CC2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577316	=	=	IC50	nM	2840.0	IC50	uM	2.84
Inhibition of human CYP3A4	COc1cc2c(cc1OC)CN(C(=O)C13CC4CC(C1)CC(c1ccc(OCC(=O)Nc5cccc(C#N)c5)cc1)(C4)C3)CC2	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570403	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	COC(=O)c1ccccc1NC(=O)COc1ccc(C23CC4CC(CC(C(=O)N5CCc6cc(OC)c(OC)cc6C5)(C4)C2)C3)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577103	=	=	IC50	nM	3790.0	IC50	uM	3.79
Inhibition of human CYP3A4	COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7cccc(OC)c7)CC6)(C5)C3)C4)cc2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567798	=	=	IC50	nM	820.0	IC50	uM	0.82
Inhibition of human CYP3A4	COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7ccc(OC)cc7)CC6)(C5)C3)C4)cc2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL570402	=	=	IC50	nM	890.0	IC50	uM	0.89
Inhibition of human CYP3A4	COC(=O)c1cccc(NC(=O)COc2ccc(C34CC5CC(CC(C(=O)N6CCN(Cc7ccc(C(F)(F)F)cc7)CC6)(C5)C3)C4)cc2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568012	=	=	IC50	nM	2030.0	IC50	uM	2.03
Inhibition of CYP3A4	Cc1c(-c2cn(C(C)C)cn2)nn(-c2ccccc2Cl)c1-c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL584261	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1c[nH]c2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c12	J. Med. Chem.	2009.0	CHEMBL567911	=	=	IC50	nM	48000.0	IC50	uM	48.0
Inhibition of CYP3A4	Cn1ccc2c(Nc3cccc(Cl)c3)ncc(C(=O)N3CCOCC3)c21	J. Med. Chem.	2009.0	CHEMBL567292	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of human CYP3A4	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496102	=	=	IC50	nM	32000.0	IC50	uM	32.0
Inhibition of human CYP3A4	COc1ccc2c(OCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL522196	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494979	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of human CYP3A4	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494630	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1ccc2c(OCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567908	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human CYP3A4	COc1ccc2c(O[C@@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL585293	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of human CYP3A4	COc1ccc2c(O[C@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566253	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human CYP3A4	COc1ccc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566683	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1ccc2c(SCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567089	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of human CYP3A4	COc1cnc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566875	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1cnc2c(NCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566242	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1cnc2c(NCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565843	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1cnc2c(NCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568138	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566685	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL496102	=	=	IC50	nM	4100.0	IC50	uM	4.1
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(OCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL522196	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494979	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL494630	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(OCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567908	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(O[C@@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL585293	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(O[C@H](C)c3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566253	=	=	IC50	nM	8900.0	IC50	uM	8.9
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566683	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1ccc2c(SCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567089	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1cnc2c(NCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566875	=	=	IC50	nM	41000.0	IC50	uM	41.0
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1cnc2c(NCc3nnc4ccc(-c5ccc(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566242	=	=	IC50	nM	9100.0	IC50	uM	9.1
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1cnc2c(NCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565843	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1cnc2c(NCc3nnc4ccc(-c5cc(F)cc(F)c5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568138	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH	COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL566685	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(C(C)(C)C)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL576457	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	COc1cccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565361	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of human CYP3A4	CCOc1ccccc1CNC(=O)CC1(C)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578968	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL579199	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of human CYP3A4	COc1cc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc(OC)c1OC	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL579200	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of human CYP3A4	CC1(CC(=O)NCc2cccc(C(F)(F)F)c2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567169	=	=	IC50	nM	3200.0	IC50	uM	3.2
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(OC(F)F)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL583442	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccccc2OC(F)(F)F)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568242	=	=	IC50	nM	4200.0	IC50	uM	4.2
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(OC(F)(F)F)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565983	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of human CYP3A4	CC1(CC(=O)NCc2cccc(Cl)c2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577694	=	=	IC50	nM	4900.0	IC50	uM	4.9
Inhibition of human CYP3A4	CC1(CC(=O)NCc2cccc(Br)c2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL572184	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(Br)cc2F)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565362	=	=	IC50	nM	4400.0	IC50	uM	4.4
Inhibition of human CYP3A4	CC(C)(C)OC(=O)Nc1cccc(CCNC(=O)CC2(C)CC3(CCCCC3)OO2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567374	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(C(=O)O)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL577470	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	COC(=O)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578547	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccccc2N)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567376	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of human CYP3A4	CN(C)c1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578588	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc([N+](=O)[O-])cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568444	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	CSc1ccc(CNC(=O)CC2(C)CC3(CCCCC3)OO2)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578594	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(S(N)(=O)=O)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568456	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccccc2N2CCCCC2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578578	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc(N3CCOCC3)cc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL578579	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccccc2Sc2ccccc2CO)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL565360	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc3c(c2)OCC3)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL584886	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc3c(c2)OCCO3)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL585191	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccc3c(c2)OCC=CO3)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL567582	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccccn2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL568438	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	CC1(CC(=O)NCc2ccncc2)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL579016	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccccc12	J. Med. Chem.	2009.0	CHEMBL567570	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccccc12	J. Med. Chem.	2009.0	CHEMBL567570	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccnc12	J. Med. Chem.	2009.0	CHEMBL585487	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cccnc12	J. Med. Chem.	2009.0	CHEMBL585487	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12	J. Med. Chem.	2009.0	CHEMBL585498	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ccncc12	J. Med. Chem.	2009.0	CHEMBL585498	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cnccc12	J. Med. Chem.	2009.0	CHEMBL583867	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2cnccc12	J. Med. Chem.	2009.0	CHEMBL583867	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ncccc12	J. Med. Chem.	2009.0	CHEMBL442078	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	C[C@@H]1CN(C(=O)c2ccccc2)CCN1C(=O)C(=O)c1c[nH]c2ncccc12	J. Med. Chem.	2009.0	CHEMBL442078	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c12	J. Med. Chem.	2009.0	CHEMBL337301	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)C[C@H]3C)c12	J. Med. Chem.	2009.0	CHEMBL337301	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using benzyloxy-4-(trifluoromethyl)coumarin as substrate	COc1ncc(OC)c2c(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c[nH]c12	J. Med. Chem.	2009.0	CHEMBL238103	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 using 7-benzyloxyresorufin as substrate	COc1ncc(OC)c2c(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c[nH]c12	J. Med. Chem.	2009.0	CHEMBL238103	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4	CC1(CC(=O)NCCNc2ccnc3cc(Cl)ccc23)CC2(CCCCC2)OO1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL462360	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	Cc1c(Nc2c(C#N)cncc2-c2cc3cc(CN4CCN(C)CC4)ccc3o2)ccc2[nH]ccc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL571581	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1OCCc1ccc2ccccc2c1	Bioorg. Med. Chem.	2009.0	CHEMBL596515	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	O=C(O)/C=C/c1ccc(Cn2cccn2)cc1OCCc1ccc2ccccc2c1	Bioorg. Med. Chem.	2009.0	CHEMBL595632	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	O=C(O)CCc1ccc(Cn2cccn2)cc1OCCc1ccc2ccccc2c1	Bioorg. Med. Chem.	2009.0	CHEMBL605833	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cc1occc1-c1ncc(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596583	=	=	IC50	nM	630.0	IC50	uM	0.63
Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1ccc2[nH]nc(C)c2c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL593374	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL593375	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL595944	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c[nH]c3ccccc23)cc1-c1cc2c(C)n[nH]c2cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL595459	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c(C#N)nc3-c3ccoc3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL606467	=	=	IC50	nM	790.0	IC50	uM	0.79
Inhibition of CYP3A4	Cc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1c[nH]c2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL594523	=	=	IC50	nM	630.0	IC50	uM	0.63
Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2ccccc2)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL594755	=	=	IC50	nM	3200.0	IC50	uM	3.2
Inhibition of CYP3A4	CCNc1nc(-c2ccoc2)c(-c2cnc3[nH]nc(C)c3n2)cc1OC[C@@H](N)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL593573	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(Cl)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL593813	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C#N)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL605410	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4	Cc1occc1-c1nc(N)c(OC[C@@H](N)Cc2c(C(N)=O)[nH]c3ccccc23)cc1-c1cnc2[nH]nc(C)c2n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL594072	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4	NC[C@H]1CC[C@]2(CC1)OOC1(O2)C2CC3CC(C2)CC1C3	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL536636	=	=	IC50	nM	9700.0	IC50	uM	9.7
Inhibition of human CYP3A4	Cc1cc(NC2CCCCC2)nc(NCc2ccccc2)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL578928	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CC(C)(C)Sc1c(CC(C)(C)C(=O)O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL16596	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4	COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OC[C@@H]5Cc6ccccc6N5C(C)=O)ccc43)cc2)nc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL595092	=	=	IC50	nM	16700.0	IC50	uM	16.7
Inhibition of CYP3A4	FC(F)(F)c1ccccc1OC1CCN(c2ccc(-n3ccnc3)nn2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL595154	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4	Cc1[nH]nc2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL593490	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of CYP3A4	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596072	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4	Cc1n[nH]c2ccc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596073	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4	Cc1n[nH]c2ncc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596290	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4	Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL603197	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4	Cc1n[nH]c2cnc(-c3cc(OC[C@@H](N)Cc4c[nH]c5ccccc45)cnc3-c3ccoc3)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL594933	=	=	IC50	nM	16.0	IC50	uM	0.016
Inhibition of human liver CYP3A4	O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL376487	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of human liver CYP3A4	C[C@@H](NC(=O)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1)C(=O)Nc1ccc(/C=C/C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL590850	=	=	IC50	nM	12300.0	IC50	uM	12.3
Inhibition of CYP3A4	Cc1onc(-c2ccccc2Cl)c1C(=O)N(C)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL575966	=	=	IC50	nM	1258.93	pIC50		5.9
Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596699	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL596700	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	Cl.Cl.Cl.Cn1cnc(C(=O)N(Cc2cccc(Cl)c2)[C@H]2CC[C@@H](N)CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL3217125	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2ccc(F)c(OC3CCCC3)c2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL599060	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	CC(C)Oc1cccc(CN(C(=O)c2cn(C)cn2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL599264	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2cccc(OC3CCCC3)c2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL603691	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	COc1ccc(CN(C(=O)c2cn(C)cn2)[C@@H]2C[C@@H]3CNC[C@@H]3C2)cc1OC1CCCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL603893	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	CN1C[C@H]2C[C@@H](N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL598659	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	CCN1C[C@H]2C[C@@H](N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL599480	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition of CYP3A4	CN1C[C@H]2C[C@@H](N(Cc3ccc(F)c(C(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL603695	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	CN1C[C@H]2C[C@@H](N(Cc3ccc(F)c(OC4CCCC4)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL599482	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	CCN1C[C@H]2C[C@@H](N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL604805	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	CC(F)CN1C[C@H]2C[C@@H](N(Cc3cccc(OC(F)(F)F)c3)C(=O)c3cn(C)cn3)C[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL605540	=	=	IC50	nM	7900.0	IC50	nM	7900.0
Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CN(CCC(F)(F)F)C[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL597032	=	=	IC50	nM	8700.0	IC50	nM	8700.0
Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CN(CC(O)c4ccccc4)C[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL597033	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2cccc(OC(F)(F)F)c2)[C@@H]2C[C@@H]3CN(CC(C)(C)O)C[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL605744	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	Cn1cnc(C(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)[C@H]2C[C@@H]3CNC[C@@H]3C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL607982	=	=	IC50	nM	8200.0	IC50	nM	8200.0
Inhibition of CYP3A4	O=C(O)CC1CC2(CCN(C(=O)NC3C4CC5CC(C4)CC3C5)CC2)c2c(Br)cccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL605162	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4	Cc1cccc2c1C(=O)NC1CNCCN21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL590078	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	CCCc1nc(-c2ccccc2)oc1C(=O)NC(C)CN1CCN(c2ncccn2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL605325	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCN1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL601030	>=	>=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4	CC(C)N1CCN(C(=O)Cn2c(-c3ccoc3)c(C3CCCCC3)c3ccc(C(=O)O)cc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL601031	>=	>=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 muscle isoform in human liver microsomes	O[C@@H](CN1c2cccc(-c3cccc(OC(F)(F)F)c3)c2OC[C@@H]1c1cccc(OC(F)(F)C(F)F)c1)C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL602483	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 tissue isoform in human liver microsomes	O[C@@H](CN1c2cccc(-c3cccc(OC(F)(F)F)c3)c2OC[C@@H]1c1cccc(OC(F)(F)C(F)F)c1)C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL602483	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC	COc1c(C(C)(C)C)cc(C(=O)Cn2c(NCCCO)nc3cc(C)c(C)cc32)cc1C(C)(C)C	Bioorg. Med. Chem.	2010.0	CHEMBL590750	=	=	IC50	nM	67000.0	IC50	uM	67.0
Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC	Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C	Bioorg. Med. Chem.	2010.0	CHEMBL374350	=	=	IC50	nM	85000.0	IC50	uM	85.0
Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC	COCCCNc1nc2cc(C)c(C)cc2n1CC(=O)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1	Bioorg. Med. Chem.	2010.0	CHEMBL600058	=	=	IC50	nM	97000.0	IC50	uM	97.0
Inhibition of human CYP3A4 by fluorescence assay	Clc1ccc([C@]2(COC3CCC3)[C@H]3CNC[C@H]32)cc1Cl	J. Med. Chem.	2010.0	CHEMBL590472	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4 by fluorescence assay	Clc1ccc([C@]2(COCC3CC3)[C@H]3CNC[C@H]32)cc1Cl	J. Med. Chem.	2010.0	CHEMBL598644	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of human CYP3A4 by fluorescence assay	CCOC[C@@]1(c2ccc(Cl)c(Cl)c2)[C@H]2CCC[C@H]21	J. Med. Chem.	2010.0	CHEMBL2021582	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4 by fluorescence assay	COC[C@@H]1[C@H]2CNC[C@]21c1ccc2ccccc2c1	J. Med. Chem.	2010.0	CHEMBL598215	>	>	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of human CYP3A4 by fluorescence assay	CC(C)OC[C@@H]1[C@H]2CNC[C@]21c1ccc(Cl)c(Cl)c1	J. Med. Chem.	2010.0	CHEMBL605209	>	>	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human CYP3A4 by fluorescence assay	CCOC[C@H]1[C@@H]2CNC[C@@]21C	J. Med. Chem.	2010.0	CHEMBL2021577	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of human CYP3A4 by fluorescence assay	CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1	J. Med. Chem.	2010.0	CHEMBL608151	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of human CYP3A4 by fluorescence assay	CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1	J. Med. Chem.	2010.0	CHEMBL608151	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of human CYP3A4 by fluorescence assay	COC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1	J. Med. Chem.	2010.0	CHEMBL596809	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human CYP3A4 by fluorescence assay	Clc1ccc([C@@]23CNC[C@@H]2[C@H]3COCC2CC2)cc1Cl	J. Med. Chem.	2010.0	CHEMBL610795	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human microsomal preparation	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1	J. Med. Chem.	2010.0	CHEMBL263664	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human microsomal preparation	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1	J. Med. Chem.	2010.0	CHEMBL598194	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human microsomal preparation	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1	J. Med. Chem.	2010.0	CHEMBL597211	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 by LCMS/MS assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CO)cc3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL605360	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 by LCMS/MS assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1Cl	J. Med. Chem.	2010.0	CHEMBL592709	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 by LCMS/MS assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1C	J. Med. Chem.	2010.0	CHEMBL604249	=	=	IC50	nM	13500.0	IC50	uM	13.5
Inhibition of human CYP3A4 by LCMS/MS assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL604087	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1	J. Med. Chem.	2010.0	CHEMBL590810	=	=	IC50	nM	5900.0	IC50	uM	5.9
Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL597127	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL599792	=	=	IC50	nM	8100.0	IC50	uM	8.1
Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL599791	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL604085	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using BFC substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL598336	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCNCC3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL604085	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc(CN(C)C)cc3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL599792	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CN(C)CC4)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL599791	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCC3CCCNC3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL597127	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	N#Cc1ccc(NC(=O)NCc2cccc(C(=O)Nc3ccc4c(c3)CNCC4)c2)cc1	J. Med. Chem.	2010.0	CHEMBL590810	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using BQ substrate by fluorescence assay	COc1ccc(C(=O)NCc2cccc(C(=O)NCCc3ccncc3)c2)cc1OC	J. Med. Chem.	2010.0	CHEMBL598336	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL401930	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCNCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097357	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097358	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCN(CCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1078891	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CC[C@@H](N)C2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1078892	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CC[C@H](N)C2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1078991	>	>	IC50	nM	4400.0	IC50	uM	4.4
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCC(NC(=O)OC(C)(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077324	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CC[C@H](NC(=O)OC(C)(C)C)C2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077325	>	>	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCC(NC(=O)C3CC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL480966	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCC(N3CCOCC3)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL482126	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCC(N3C[C@@H]4C[C@H]3CO4)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077339	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NC[C@@H](O)c6cccc(Cl)c6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL505919	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCC3(CC2)OCCO3)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL482101	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCn4cc(Cl)cn4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL401766	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCCc4ncn(C)c4Cl)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL256072	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCCn6cc(Cl)cn6)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077340	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 after 20 mins by BFC fluorescence assay	COC(=O)N1CCN(C2CCN(c3cc(C)c4nc(-c5c(NCCc6ncn(C)c6Cl)cc[nH]c5=O)[nH]c4c3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077343	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4	CC(C)(Cc1nc(-c2ccc(O)cn2)no1)C(=O)NC1=C(C(=O)O)CCCC1	J. Med. Chem.	2010.0	CHEMBL1086657	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)c1cscn1)c1ccc2c(c1)nc(-c1ccoc1)n2C1CCCCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL376487	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of CYP3A4	O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccoc3)n4C3CCCCC3)CCCC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077334	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	O=C(O)/C=C/c1ccc(NC(=O)C2(NC(=O)c3ccc4c(c3)nc(-c3ccccn3)n4C3CCCCC3)CCCC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1077335	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1086754	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	Cc1ncccc1-c1nnc(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)n1C	J. Med. Chem.	2010.0	CHEMBL1081687	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	Cn1c(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccnnc1	J. Med. Chem.	2010.0	CHEMBL1081867	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	Cc1ccc2c(-c3nnc(SCCCN4CC5CC5(c5ccc(C(F)(F)F)cc5)C4)n3C)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1080293	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	c1ccc(COc2ccc3cccnc3c2)cc1	J. Med. Chem.	2010.0	CHEMBL1081779	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	O=C(NC1CC1)c1ccc(Cl)c(Nc2nncc3c2cnn3-c2c(F)cccc2F)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1082158	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080982	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(N2CCNC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079957	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079437	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079436	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076245	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080473	=	=	IC50	nM	6600.0	IC50	uM	6.6
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080472	=	=	IC50	nM	90000.0	IC50	uM	90.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	C=CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080088	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)n(CCO)c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080982	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)n(CCO)c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080803	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 using diethoxyfluorescein substrate	CCn1c(C)c(C)c2cc(-n3ccccc3=O)nc(NCc3c(C)cccc3C)c21	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079958	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(N2CCNC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079957	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(-c2cccc(=O)[nH]2)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079437	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(N2CCOCC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079436	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(N2CCCC2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076245	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(-c2ccccc2)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080473	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nc(-n2ccccc2=O)cc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080472	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076210	=	=	IC50	nM	9600.0	IC50	uM	9.6
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076192	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081870	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081505	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1ncnc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081504	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080717	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076536	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nccc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076210	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nccc2c1cc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076192	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nccc2c1nc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081870	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1cccc2c1nc(C)n2C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081505	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1ncnc2c(C)c(C)[nH]c12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081504	=	=	IC50	nM	8800.0	IC50	uM	8.8
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1nccn2c(C)c(C)cc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080717	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1COc1cccn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076536	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of CYP3A4 assessed as ratio of IC50 at 0 mins to IC50 at 10 mins using 7-benzyloxyquinoline substrate	Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1087758	=	=	IC50	nM	56.23	pIC50		7.25
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL47529	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497011	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL238146	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of CYP3A4 using 7-benzyloxyquinoline substrate	Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1087758	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL47529	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1cccc(C)c1CNc1cc(C(=O)NCCO)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL497011	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	CCc1cccc(C)c1CNc1cc(C(N)=O)cn2c(C)c(C)nc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL238146	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 using diethoxyfluorescein substrate	Cc1c(C)n(C[C@H]2C[C@@H]2C)c2c(OCc3ccc(F)cc3)nncc12	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1087758	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate	O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078207	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate	CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2cc[nH]n2)CC3)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080046	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate	O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccc(N2CCOCC2)nc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078595	>	>	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate	O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccc(-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078207	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate	CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(Cc2cc[nH]n2)CC3)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080046	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate	O=S(=O)(Nc1ccc2c(c1)CCN(Cc1cc[nH]n1)CC2)c1ccc(N2CCOCC2)nc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078595	>	>	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4	O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)CCNC1)N(Cc1cccc(Cl)c1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1088290	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4	O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)C[C@H]2CC[C@H]1N2)N(Cc1cccc(Cl)c1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076449	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4	COc1cccc(CN(C(=O)C2=C(c3ccc(CCCOc4c(F)ccc(F)c4Cl)cc3)C[C@H]3COC[C@H]2N3)C2CC2)c1C	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1076461	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 using felodipine as a substrate	CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080787	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 using midazolam as a substrate	CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080787	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 using testosterone as a substrate	CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080787	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL163	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@H](CNC[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079722	=	=	IC50	nM	148.0	IC50	uM	0.148
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079896	=	=	IC50	nM	90.0	IC50	uM	0.09
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](CNC[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)Cc1ccccc1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079897	=	=	IC50	nM	99.0	IC50	uM	0.099
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(NC(Cc1ccccc1)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079228	=	=	IC50	nM	65.0	IC50	uM	0.065
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)(C)CN(CC(Cc1ccccc1)NC(=O)OCc1cncs1)CC(Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079229	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)(C)CN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079230	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080964	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081147	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081874	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)CN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077929	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)CN(C[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077930	=	=	IC50	nM	90.0	IC50	uM	0.09
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)CN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077931	=	=	IC50	nM	67.0	IC50	uM	0.067
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(CC1CC1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077932	=	=	IC50	nM	52.0	IC50	uM	0.052
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CC(C)CCN(C[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077933	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077934	=	=	IC50	nM	135.0	IC50	uM	0.135
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077935	=	=	IC50	nM	87.0	IC50	uM	0.087
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@H](Cc1ccccc1)CN(Cc1ccccc1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077936	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	COc1cccc(CN(C[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C[C@@H](Cc2ccccc2)NC(=O)OCc2nccs2)c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077937	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1cccnc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077938	=	=	IC50	nM	66.0	IC50	uM	0.066
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1ccncc1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077939	=	=	IC50	nM	49.0	IC50	uM	0.049
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1c[nH]cn1)C[C@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077940	=	=	IC50	nM	66.0	IC50	uM	0.066
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	O=C(N[C@@H](Cc1ccccc1)CN(Cc1cnc2ccccc2c1)C[C@@H](Cc1ccccc1)NC(=O)OCc1nccs1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077941	=	=	IC50	nM	70.0	IC50	uM	0.07
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CCNC(=O)OCc1cncs1)CCNC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1082053	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](C)NC(=O)OCc1cncs1)C[C@H](C)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080244	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](C)NC(=O)OCc1cncs1)C[C@@H](C)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080417	=	=	IC50	nM	1790.0	IC50	uM	1.79
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@@H](C)NC(=O)OCc1cncs1)C[C@@H](C)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080418	=	=	IC50	nM	1330.0	IC50	uM	1.33
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](CC(C)C)NC(=O)OCc1cncs1)C[C@H](CC(C)C)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080419	=	=	IC50	nM	136.0	IC50	uM	0.136
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CC(CC(=O)OC)NC(=O)OCc1cncs1)CC(CC(=O)OC)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081514	=	=	IC50	nM	88.0	IC50	uM	0.088
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CC(CC1CCCCC1)NC(=O)OCc1cncs1)CC(CC1CCCCC1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081515	=	=	IC50	nM	66.0	IC50	uM	0.066
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CC(COCc1ccccc1)NC(=O)OCc1cncs1)CC(COCc1ccccc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078121	=	=	IC50	nM	135.0	IC50	uM	0.135
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CC(Cc1ccc(O)cc1)NC(=O)OCc1cncs1)CC(Cc1ccc(O)cc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078122	=	=	IC50	nM	91.0	IC50	uM	0.091
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(CC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1cncs1)CC(Cc1ccc(OCc2ccccc2)cc1)NC(=O)OCc1nccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078123	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cnco1)C[C@H](Cc1ccccc1)NC(=O)OCc1ncco1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081693	=	=	IC50	nM	274.0	IC50	uM	0.274
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cnc[nH]1)C[C@H](Cc1ccccc1)NC(=O)OCc1ncc[nH]1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079712	=	=	IC50	nM	348.0	IC50	uM	0.348
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cccs1)C[C@H](Cc1ccccc1)NC(=O)OCc1cccs1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080603	=	=	IC50	nM	741.0	IC50	uM	0.741
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cccnc1)C[C@H](Cc1ccccc1)NC(=O)OCc1cccnc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078218	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human recombinant CYP3A4-mediated oxidation of 7-benzyloxyquinoline	CCN(C[C@H](Cc1ccccc1)NC(=O)OCc1cn[nH]c1)C[C@H](Cc1ccccc1)NC(=O)OCc1cn[nH]c1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080604	>	>	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079360	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)Nc2noc3ccccc23)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079361	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)Nc2ccncc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079362	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(-c3ccccc3)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080076	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(Cl)cc2Cl)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080973	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccccc3C(F)(F)F)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080974	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3cccc(Cl)c3)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1080975	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccccn3)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1081703	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCc2ccc(-c3ccc4[nH]ccc4c3)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078264	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078265	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCCCc2cccnc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078353	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc3nc[nH]c3c2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078354	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)NCCc2ccc3nccnc3c2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078452	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC1(c2ccccc2)CCCN(C(=O)N[C@H]2C[C@@H]2c2ccccc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077780	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077781	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079256	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078565	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078657	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	N#CCCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078755	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(Nc1ccc(Cl)cc1)N1CCCC(CCO)(c2ccccc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079290	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(Nc1ccc(Cl)cc1)N1CCCC(CCCO)(c2ccccc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079291	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	NC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079292	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(C)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079140	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(Nc1ccc(Cl)cc1)N1CCCC(CCC2=NNNN2)(c2ccccc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079244	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1)NC1=NNNN1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079245	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CNC(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079246	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCN(CC)C(=O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078628	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1)N1CCOCC1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078232	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCC1(c2ccccc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079256	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	O=C(O)CCC1(c2ccccc2C(F)(F)F)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079257	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCC1(c2cccc(C(F)(F)F)c2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079258	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCC1(c2ccc(C(F)(F)F)cc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078715	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCC1(c2ccncc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078336	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCC1(c2cccnc2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1078337	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCC1(c2ccccn2)CCCN(C(=O)Nc2ccc(Cl)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1077963	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCC1(c2ccc(-c3ccccc3)cc2)CCCN(C(=O)Nc2ccc(OC(F)(F)F)cc2)C1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1079061	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay	CC(C)=CCC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12	J. Nat. Prod.	2009.0	CHEMBL1078442	=	=	IC50	nM	2420.0	IC50	uM	2.42
Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay	C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CC[C@@H](O)C(C)(C)O	J. Nat. Prod.	2009.0	CHEMBL1079119	=	=	IC50	nM	1580.0	IC50	uM	1.58
Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay	CCCCCCCCCC1O[C@H](CC/C(C)=C/COc2c3ccoc3cc3oc(=O)ccc23)C(C)(C)O1	J. Nat. Prod.	2009.0	CHEMBL1078190	=	=	IC50	nM	270.0	IC50	uM	0.27
Inhibition of CYP3A4 after 30 mins by fluorescence microplate reader assay	CCCCCCCC1O[C@H](CC/C(C)=C/COc2c3ccoc3cc3oc(=O)ccc23)C(C)(C)O1	J. Nat. Prod.	2009.0	CHEMBL1078189	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of CYP3A4	CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091356	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CC(C)(O)C(=O)c1oc2nc(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)cc2c1NC(=O)CO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092169	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	Cc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092600	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092258	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cnccn2)c2ccc(Cl)cc2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092259	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cnccn2)c2ccc(F)cc2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092649	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1nccnc1CC1=C(CCN(C)C)Cc2cc(Cl)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092650	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1nccnc1CC1=C(CCN(C)C)Cc2cc(F)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092651	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cccnn2)c2ccc(Cl)cc2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092652	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092662	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1cnccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092663	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1cnccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090175	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(C)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090176	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccnc1OC	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090186	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(F)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090526	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)C)Cc2cc(F)ccc21)c1nccs1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090527	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccs1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090528	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccs1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093623	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091777	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1ccncc1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091790	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	Cc1ccnc(C(C)c2c(CCN(C)C)sc3ccccc23)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091791	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	COc1cccc(C(C)c2c(CCN(C)C)sc3ccccc23)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091792	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1cccc(F)n1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091793	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	Cc1cccnc1[C@H](C)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092126	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	COc1cccnc1[C@H](C)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091069	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ncccc1F)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092377	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ncccc1Cl)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092494	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ccc(F)cn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092495	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	Cc1ccc(C(C)c2c(CCN(C)C)sc3ccccc23)cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092496	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	COc1ccc(C(C)c2c(CCN(C)C)sc3ccccc23)cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092812	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	Cc1ncccc1[C@@H](C)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092813	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	COc1ncccc1[C@@H](C)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093294	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@H](c1cccnc1F)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092765	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@H](c1cccnc1Cl)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092766	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1ccccn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090432	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL564144	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090433	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CNCCc1sc2ccccc2c1[C@@H](C)c1ccccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093044	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ccccn1)c1c(CCN2CCCC2)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091774	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1ccccn1)c1c(CCN2CCC2)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091775	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1cccnc1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091776	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091778	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1nccs1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092767	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1cscn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091782	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@@H](c1cncs1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092118	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CC(c1c(CCN(C)C)sc2ccccc12)n1ccnc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093607	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	C[C@H](c1c(CCN(C)C)sc2ccccc12)n1cccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093058	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 preincubated for 30 mins	O=C1CCC2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OCC2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089202	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 preincubated for 30 mins	O=S(=O)(c1ccc(Cl)cc1)C12CCC(O)CC1COc1c(F)ccc(F)c12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089525	=	=	IC50	nM	9100.0	IC50	uM	9.1
Inhibition of CYP3A4 preincubated for 30 mins	O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090209	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 preincubated for 30 mins	O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C1CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090210	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCn1c(=O)c(-c2cc(C(=O)NC3CC3)ccc2C)cc2cnn(-c3ccc(F)cc3F)c21	J. Med. Chem.	2010.0	CHEMBL1089866	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 in human liver microsomes	Cc1ccc(C(=O)NC2CC2)cc1-c1cc2cnn(-c3c(F)cccc3F)c2n(C)c1=O	J. Med. Chem.	2010.0	CHEMBL1089865	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	C[C@@H](O[C@H]1CN2C(=O)C=C(C3=CCN(C(C)(C)C)CC3)CC2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089270	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089299	=	=	Ki	nM	30.0	Ki	uM	0.03
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089299	=	=	Ki	nM	28.84	pKi		7.54
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)OC(C)(C)C)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089300	=	=	Ki	nM	240.0	Ki	uM	0.24
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)OC(C)(C)C)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO[Si](C)(C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089300	=	=	Ki	nM	239.88	pKi		6.62
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091763	=	=	Ki	nM	1780.0	Ki	uM	1.78
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1CO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1091763	=	=	Ki	nM	1778.28	pKi		5.75
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1COS(=O)(=O)c1ccc(C)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089957	=	=	Ki	nM	70.0	Ki	uM	0.07
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	COCO[C@@H]([C@H](CNC(=O)c1ccccc1)c1ccc2c(c1)OCO2)[C@@H]1OC(C)(C)O[C@H]1COS(=O)(=O)c1ccc(C)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089957	=	=	Ki	nM	69.18	pKi		7.16
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL157101	=	=	Ki	nM	30.0	Ki	uM	0.03
Inhibition of human recombinant CYP3A4 assessed as biotransformation of 7-hydroxyquinoline to 7-benzyloxyquinoline measured every minute for 15 mins by fluorescence intensity assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL157101	=	=	Ki	nM	33.11	pKi		7.48
Inhibition of human recombinant CYP3A4	CCCC(=O)Nc1n[nH]c2cc(Cl)c(-c3ccccc3)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095040	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4	CCCC(=O)Nc1n[nH]c2cc(-c3ccc(O)cc3)c(Br)cc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093747	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	COC(=O)N(CC(=O)O)Cc1cccc(OCc2nc(-c3ccc(Cl)cc3)oc2C)c1	J. Med. Chem.	2010.0	CHEMBL1089501	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	CC[C@@H]1CCC[C@H](C2(OC(=O)N3CCN(C(C)(C)CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	J. Med. Chem.	2009.0	CHEMBL236184	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 after 30 mins	COCCCc1ccc(Cl)c(CN(C(=O)[C@H](CN)Cc2ccc(CCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093286	=	=	IC50	nM	130.0	IC50	nM	130.0
Inhibition of CYP3A4 after 30 mins	COCCCc1cc(CN(C(=O)[C@@H](CN)Cc2ccc(CCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093937	=	=	IC50	nM	1300.0	IC50	nM	1300.0
Inhibition of human recombinant CYP3A4 by P450-Glo method	O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCC2CCN(C(=O)c3ccccc3)CC2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092929	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 by P450-Glo method	O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3)CC2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093469	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 by P450-Glo method	O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3Cl)CC2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092238	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 by P450-Glo method	O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3ccccc3F)CC2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1093802	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 by P450-Glo method	O=C(CNC(=O)c1cccc(C(F)(F)F)c1)N[C@@H]1CCN(CCN2CCN(C(=O)c3cc(F)ccc3F)CC2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1089793	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCOC(=O)[C@H](C)NP(=O)(COc1cc(C)c(C)c2c1-c1ncsc1C2)N[C@@H](C)C(=O)OCC	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096789	=	=	IC50	nM	580.0	IC50	uM	0.58
Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094552	=	=	IC50	nM	420.0	IC50	uM	0.42
Inhibition of CYP3A4	Cc1cc(OC[P@]2(=O)OCC[C@@H](c3cccc(Cl)c3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096871	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccc(Cl)cc3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097165	=	=	IC50	nM	650.0	IC50	uM	0.65
Inhibition of CYP3A4	Cc1cc(OC[P@]2(=O)OCC[C@@H](c3ccc(Cl)cc3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097180	=	=	IC50	nM	730.0	IC50	uM	0.73
Inhibition of CYP3A4	COc1cccc([C@@H]2CCO[P@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097507	=	=	IC50	nM	270.0	IC50	uM	0.27
Inhibition of CYP3A4	COc1cccc([C@@H]2CCO[P@@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098147	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccccn3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098148	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccnc3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097192	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3ccncc3)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095681	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4	Cc1cc(OC[P@]2(=O)OCC[C@H](c3cccnc3C)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096103	=	=	IC50	nM	5800.0	IC50	uM	5.8
Inhibition of CYP3A4	Cc1ccc([C@@H]2CCO[P@](=O)(COc3cc(C)c(C)c4c3-c3ncsc3C4)O2)cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096104	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4	Cc1cc(OC[P@@]2(=O)OCC[C@@H](c3cccnc3C)O2)c2c(c1C)Cc1scnc1-2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096105	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4	Cc1csc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095511	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CCOCCn1c(C2CCCN(C3CCOCC3)C2)nc2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095510	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CCOCCn1c(C2CCCN(C3CCCCC3)C2)nc2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095678	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	COc1ccc(Cn2c(C3CCCN(C4CCOCC4)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094852	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	COc1ccc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094851	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4	COc1ccc(Cn2c(C3CCCN(C(C)C)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095364	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Fc1ccc(Cn2c(C3CCCN(C4CCCCC4)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094525	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CC(C)N1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098766	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN1CCCC(c2nc3ccccc3n2CC2CCCO2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098125	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Cc1csc(Cn2c(C3CCCN(C)C3)nc3ccccc32)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094512	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN1CCCC(c2nc3ccccc3n2Cc2ccccn2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094511	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CCOCCn1c(C2CCCN(C)C2)nc2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095031	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN1CCCC(c2nc3ccccc3n2CCOc2ccccc2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094510	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	COc1ccc(Cn2c(C3CCCN(C)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094509	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1087089	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CCOCCn1c(N2CC[C@H](N(C)C)C2)nc2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1087493	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	COc1ccc(Cn2c(N3CC[C@@H](N(C)C)C3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1087367	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL556450	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL550818	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Cc1csc(Cn2c(C3CCCN(C4CCOCC4)C3)nc3ccccc32)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095818	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CN1C(=O)N(c2cc(Cl)cc(Cl)c2)C(=O)[C@]12CN(c1ccc(C(=O)O)cn1)C[C@H]2c1ccc(C#N)cc1	J. Med. Chem.	2010.0	CHEMBL1098726	>	>	IC50	nM	35000.0	IC50	uM	35.0
Inhibition of CYP3A4	O=c1c(-c2c(O)cc(O)c3c(=O)cc(-c4ccc(O)cc4)oc23)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12	J. Nat. Prod.	2010.0	CHEMBL515252	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of CYP3A4	Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(C)c8c1c2c(c34)c(c78)c65	J. Nat. Prod.	2010.0	CHEMBL286494	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of CYP3A4	CC(C)=CCC[C@]1(C)[C@@H](CC=C(C)C)C[C@@]2(CC=C(C)C)C(=O)[C@]1(C(=O)C(C)C)C(=O)C(CC=C(C)C)=C2O	J. Nat. Prod.	2010.0	CHEMBL501711	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)n2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1099330	>	>	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccc4c(c3)OCO4)cc(-c3ccccc3F)c2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1094349	>	>	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3cccc(F)c3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1094348	>	>	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccsc3)cc(-c3ccc4c(c3)OCO4)c2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1098560	>	>	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccncc3)cc(-c3ccncc3)c2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1099326	>	>	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 fluorescence method	O=C(O)CCCOc1cccc(CCCCCCOc2cc(-c3ccccc3)cc(-c3ccccc3)c2)c1CCC(=O)O	J. Med. Chem.	2010.0	CHEMBL1099323	>	>	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL401930	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCNCC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097357	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097358	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	CCN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098395	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	CC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098711	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	COCC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1098712	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(C(=O)CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096717	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(C(=O)OC(C)(C)C)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1099314	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	COC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097032	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	CCOC(=O)N1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095404	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(S(C)(=O)=O)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097425	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097426	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CCCO)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1095439	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	CNC(=O)CN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094457	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CC(=O)NCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1097982	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CCCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094458	=	=	IC50	nM	450.0	IC50	uM	0.45
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CCF)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1078891	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CC#N)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1096089	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	Cc1cc(N2CCN(CCC#N)CC2)cc2[nH]c(-c3c(NC[C@@H](O)c4cccc(Cl)c4)cc[nH]c3=O)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094164	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 assessed as dealkylation of 7-benzyloxy-4-trifluoromethylcoumarin	COCCN1CCN(c2cc(C)c3nc(-c4c(NC[C@@H](O)c5cccc(Cl)c5)cc[nH]c4=O)[nH]c3c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1094165	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1	J. Med. Chem.	2010.0	CHEMBL1090479	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4	Cc1cc(C(=O)N[C@@H]2CC(C)(C)Oc3nc(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)cc32)n[nH]1	J. Med. Chem.	2010.0	CHEMBL1096182	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of human CYP3A4 expressed in insect cell microsome after 30 mins by fluorescence assay	CC(C)(C)c1ccc(SCCc2c[nH]cn2)cc1	J. Med. Chem.	2010.0	CHEMBL1098230	=	=	IC50	nM	470.0	IC50	nM	470.0
Inhibition of human recombinant CYP3A4	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C	J. Med. Chem.	2010.0	CHEMBL289228	=	=	IC50	nM	4060.0	IC50	nM	4060.0
Inhibition of human recombinant CYP3A4	COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccccc1)cc(=O)n2C)c1cncn1C	J. Med. Chem.	2010.0	CHEMBL1097772	=	=	IC50	nM	2345.0	IC50	nM	2345.0
Inhibition of human recombinant CYP3A4	COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccc(Cl)cc1)cc(=O)n2C)c1cncn1C	J. Med. Chem.	2010.0	CHEMBL1097078	=	=	IC50	nM	923.0	IC50	nM	923.0
Inhibition of human recombinant CYP3A4	COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1ccc(F)cc1)cc(=O)n2C)c1cncn1C	J. Med. Chem.	2010.0	CHEMBL1097079	=	=	IC50	nM	1628.0	IC50	nM	1628.0
Inhibition of human recombinant CYP3A4	COC(c1ccc(Cl)cc1)(c1ccc2c(c1)c(-c1c(F)cccc1F)cc(=O)n2C)c1cncn1C	J. Med. Chem.	2010.0	CHEMBL1097187	=	=	IC50	nM	275.0	IC50	nM	275.0
Inhibition of human recombinant CYP3A4	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	J. Med. Chem.	2010.0	CHEMBL1397	=	=	IC50	nM	82.0	IC50	nM	82.0
Inhibition of human recombinant CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2010.0	CHEMBL157101	=	=	IC50	nM	11.0	IC50	nM	11.0
Inhibition of CYP3A4 from human liver microsome by LC-MS/MS analysis	Cc1cc(CN2CCN(c3c(Br)cnc4[nH]c(N5CCN(C)CC5)nc34)CC2)no1	J. Med. Chem.	2010.0	CHEMBL1086579	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)[C@]1(C)SC(N[C@H]2C[C@@H]3CC[C@H]2C3)=NC1=O	J. Med. Chem.	2010.0	CHEMBL1085107	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4	CCOc1ccccc1C[C@H](c1ccccc1)N1CCNCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL403441	=	=	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4	COc1ccccc1CC(c1ccccc1)N1CCNCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL214335	=	=	IC50	nM	194000.0	IC50	nM	194000.0
Inhibition of CYP3A4	O=C(O)c1ccccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1171008	=	=	IC50	nM	100000.0	pIC50		4.0
Inhibition of CYP3A4	O=C(NCCO)c1ccccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1169660	=	=	IC50	nM	20417.38	pIC50		4.69
Inhibition of CYP3A4	O=C(O)c1ccccc1Oc1ccc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1171786	=	=	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	O=S(=O)(Nc1cc(Cl)cnc1Oc1cncc(Cl)c1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1169994	=	=	IC50	nM	436.52	pIC50		6.36
Inhibition of CYP3A4	Cc1ncccc1Oc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1170725	=	=	IC50	nM	19498.45	pIC50		4.71
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(-c3ccncc3)cc2C2=CCCCC2)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1172346	=	=	IC50	nM	87.0	IC50	nM	87.0
Inhibition of human CYP3A4 after 10 mins	C=CCC(OC)[C@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2	J. Med. Chem.	2010.0	CHEMBL1173087	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4 after 10 mins	COC[C@@]12CNCC[C@]1(c1ccc3ccccc3c1)C2	J. Med. Chem.	2010.0	CHEMBL1172744	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human CYP3A4 after 10 mins	COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2	J. Med. Chem.	2010.0	CHEMBL1173532	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2	J. Med. Chem.	2010.0	CHEMBL1173532	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	COC[C@@]12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2	J. Med. Chem.	2010.0	CHEMBL1173532	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	Oc1cccc(-c2ccc(Cc3ccncc3)cc2)c1	J. Med. Chem.	2010.0	CHEMBL1172882	=	=	IC50	nM	538.0	IC50	nM	538.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(C)=C(c1ccncc1)c1ccc(-c2cccc(O)c2)cc1	J. Med. Chem.	2010.0	CHEMBL1173259	=	=	IC50	nM	730.0	IC50	nM	730.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1F	J. Med. Chem.	2010.0	CHEMBL1173260	=	=	IC50	nM	896.0	IC50	nM	896.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(C)=C(c1ccncc1)c1ccc(-c2ccc(O)c(F)c2)cc1	J. Med. Chem.	2010.0	CHEMBL1173335	=	=	IC50	nM	17650.0	IC50	nM	17650.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1O	J. Med. Chem.	2010.0	CHEMBL1172779	=	=	IC50	nM	7580.0	IC50	nM	7580.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(C)=C(c1ccncc1)c1ccc(-c2ccc(O)c(O)c2)cc1	J. Med. Chem.	2010.0	CHEMBL1172847	=	=	IC50	nM	464.0	IC50	nM	464.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	Nc1cccc(-c2ccc(Cc3ccncc3)cc2)c1	J. Med. Chem.	2010.0	CHEMBL1171987	=	=	IC50	nM	1520.0	IC50	nM	1520.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(C)=C(c1ccncc1)c1ccc(-c2cccc(N)c2)cc1	J. Med. Chem.	2010.0	CHEMBL1173326	=	=	IC50	nM	1330.0	IC50	nM	1330.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(C)=C(c1ccncc1)c1ccc(-c2ccc(N)c(N)c2)cc1	J. Med. Chem.	2010.0	CHEMBL1171991	=	=	IC50	nM	1770.0	IC50	nM	1770.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2010.0	CHEMBL157101	=	=	IC50	nM	57.0	IC50	nM	57.0
Inhibition of CYP3A4 expressed in baculovirus infected insect microsomes	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	J. Med. Chem.	2010.0	CHEMBL254328	=	=	IC50	nM	2700.0	IC50	nM	2700.0
Inhibition of CYP3A4	Cc1cc2nc(NCCCO)n(CC(=O)c3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)c2cc1C	J. Med. Chem.	2010.0	CHEMBL374350	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(C)(C)C	J. Med. Chem.	2010.0	CHEMBL2021600	>	>	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4	COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)[O-])c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1.[Na+]	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210423	=	=	IC50	nM	8800.0	IC50	uM	8.8
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(C(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1081957	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(C(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1079481	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3ccc(S(F)(F)(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210552	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(C(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1081957	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ncoc1-c1nnc(SCCCN2CC3CC3(c3cccc(S(F)(F)(F)(F)F)c3)C2)n1C	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210614	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using diethoxyfluorescein substrate	CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210434	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 using phenyl-piperazinyl-methyl-benzyl-resofurin substrate	CS(=O)(=O)N(c1ccccc1)c1cc(C(=O)N[C@@H](Cc2ccccc2)[C@H](O)CNCc2cccc(C(F)(F)F)c2)cc(C2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210434	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCNCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208894	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208958	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208959	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208960	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208961	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208964	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208965	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)n4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208966	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209016	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209017	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209018	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCNCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208894	=	=	IC50	nM	5900.0	IC50	uM	5.9
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208958	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208959	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208960	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208961	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCS(C)(=O)=O)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208962	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NCCO)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208963	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208964	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccc(NC5CCN(C)CC5)nc4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208965	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(NC5CCN(C)CC5)n4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208966	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCOCC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209015	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCN5CCN(C)CC5)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209016	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(CCCN(C)C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209017	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	CCN1CCN(CCCn2cc(-c3ccc4c(c3)ncn4-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)cn2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209018	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209842	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccncc4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209674	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human recombinant CYP3A4 using 7-{3-(4-phenylpiperazin-1-ylmethyl)benzyl}resorufin as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)c4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208835	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of human recombinant CYP3A4 using diethoxyfluorescein as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208892	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4cnn(C)c4)ccc32)sc1C(N)=O)c1ccccc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209842	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of human recombinant CYP3A4 using 7-benzyloxyquinoline as substrate by fluorescence plate reader	C[C@@H](Oc1cc(-n2cnc3cc(-c4ccnc(N)n4)ccc32)sc1C(N)=O)c1ccccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208892	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CC(C)C(=O)N1C[C@H]2[C@@H](CNc3nc(-c4ccccn4)cs3)[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209049	>=	>=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4	O=C(C1CCOC1)N1C[C@H]2[C@@H](CNc3nc(-c4ccccn4)cs3)[C@H]2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209217	>	>	IC50	nM	10000.0	IC50	uM	10.0
inhibition of CYP3A4	Cc1nc2cc(-c3ccccc3)nn2c(-c2ccc(Cl)cc2Cl)c1CN	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209538	=	=	IC50	nM	1000.0	IC50	uM	1.0
inhibition of CYP3A4	Cc1nc2nc(-c3ccccc3)cn2c(-c2ccc(Cl)cc2Cl)c1CN	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209853	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP1A2	CCCCCCCc1nc(-c2ccc(CNC(=O)[C@H]3NCC[C@@H]3O)cc2)no1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209322	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP1A2	C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCC3)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209617	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP1A2	C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209685	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP1A2	CC[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209686	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CCCCCCCc1nc(-c2ccc(CNC(=O)[C@H]3NCC[C@@H]3O)cc2)no1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209322	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCC3)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209617	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	C[C@H](NC(=O)[C@H]1NCC[C@@H]1O)c1ccc(-c2noc(CCC3CCCCC3)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209685	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209553	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209553	=	=	IC50	nM	87.0	IC50	nM	87.0
Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN(Cc2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209554	=	=	IC50	nM	1400.0	IC50	nM	1400.0
Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(OC(F)(F)F)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209555	=	=	IC50	nM	490.0	IC50	nM	490.0
Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(C(F)(F)F)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209556	=	=	IC50	nM	280.0	IC50	nM	280.0
Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN(Cc2cccs2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209623	=	=	IC50	nM	1160.0	IC50	nM	1160.0
Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209625	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated testosterone oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC(C)(C)O)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209627	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated testosterone oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2(C)COC2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209628	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated testosterone oxidation	COC(C)(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209693	=	=	IC50	nM	530.0	IC50	nM	530.0
Inhibition of human CYP3A4-mediated testosterone oxidation	CC(C)OCC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209694	=	=	IC50	nM	120.0	IC50	nM	120.0
Inhibition of human CYP3A4-mediated testosterone oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2CC2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208801	=	=	IC50	nM	180.0	IC50	nM	180.0
Inhibition of human CYP3A4-mediated testosterone oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@@H](O)c2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209695	=	=	IC50	nM	900.0	IC50	nM	900.0
Inhibition of human CYP3A4-mediated testosterone oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@H](O)c2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209696	=	=	IC50	nM	1920.0	IC50	nM	1920.0
Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN(Cc2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209554	=	=	IC50	nM	100.0	IC50	nM	100.0
Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(OC(F)(F)F)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209555	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN(Cc2ccc(C(F)(F)F)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209556	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN(Cc2cccs2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209623	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209625	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)CC1n2cncc2CN([C@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209626	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC(C)(C)O)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209627	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2(C)COC2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209628	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	COC(C)(C)CC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209693	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	CC(C)OCC1n2cncc2CN([C@@H](C)c2ccc(Cl)cc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209694	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(CC2CC2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1208801	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@H](O)c2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209696	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of human CYP3A4-mediated midazolam oxidation	C[C@@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@@H](O)c2ccccc2)S1(=O)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1209695	=	=	IC50	nM	100.0	IC50	nM	100.0
Inhibition of human CY3A4	CCc1ccc(S(=O)(=O)Nc2ccccc2Br)cc1NC1CCN(C)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210646	=	=	IC50	nM	9620.0	IC50	uM	9.62
Inhibition of human CY3A4	COc1ccc(S(=O)(=O)Nc2cc(Cl)cc(Cl)c2OC)cc1NC1CCN(C)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210648	=	=	IC50	nM	8440.0	IC50	uM	8.44
Inhibition of human recombinant CYP3A4 after 30 mins	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](SCCN(C)C)C(=O)N(C)[C@@H](CC(C)(C)O)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Antimicrob. Agents Chemother.	2010.0	CHEMBL1269597	=	=	IC50	nM	58500.0	IC50	uM	58.5
Inhibition of human recombinant CYP3A4 after 30 mins	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Antimicrob. Agents Chemother.	2010.0	CHEMBL160	=	=	IC50	nM	6600.0	IC50	uM	6.6
Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)cn3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214452	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(Cl)cn3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214451	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	Cc1cccnc1-c1ccc2c(c1)CC(NS(=O)(=O)C(C)C)C2	J. Med. Chem.	2010.0	CHEMBL1214450	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)nc1	J. Med. Chem.	2010.0	CHEMBL1214449	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)cn3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214448	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	Cc1ccc(-c2ccc3c(c2)C[C@@H](NS(=O)(=O)C(C)C)C3)cn1	J. Med. Chem.	2010.0	CHEMBL1214447	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)N[C@H]1Cc2ccc(-c3ccc(F)nc3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214399	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)cn1	J. Med. Chem.	2010.0	CHEMBL1214397	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	Cc1ccncc1-c1ccc2c(c1)CC(NS(=O)(=O)C(C)C)C2	J. Med. Chem.	2010.0	CHEMBL1214396	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3cncc(C#N)c3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214395	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	Cc1ccc(-c2ccc3c(c2)CC(NS(=O)(=O)C(C)C)C3)c(C)n1	J. Med. Chem.	2010.0	CHEMBL1214394	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3ccc(F)nc3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214338	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccnc3F)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214337	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 10 mins	CC(C)S(=O)(=O)NC1Cc2ccc(-c3cccnc3)cc2C1	J. Med. Chem.	2010.0	CHEMBL1214336	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COC(=O)C1=C(Cn2ccnc2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl	J. Med. Chem.	2010.0	CHEMBL1215552	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4	COC(=O)C1=C(Cn2cccn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl	J. Med. Chem.	2010.0	CHEMBL1215620	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4	COC(=O)C1=C(Cn2cncn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl	J. Med. Chem.	2010.0	CHEMBL1215621	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4	COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl	J. Med. Chem.	2010.0	CHEMBL1215622	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4	COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)[C@H]1c1ccc(F)cc1Cl	J. Med. Chem.	2010.0	CHEMBL1215623	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Oc1ccc(-c2ccc(C(O)c3ccncc3)cc2)cc1	J. Med. Chem.	2010.0	CHEMBL1215664	=	=	IC50	nM	3210.0	IC50	nM	3210.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Nc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1	J. Med. Chem.	2010.0	CHEMBL1215665	=	=	IC50	nM	2450.0	IC50	nM	2450.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Nc1cccc(-c2ccc(Cc3ccncc3)cc2)c1	J. Med. Chem.	2010.0	CHEMBL1171987	=	=	IC50	nM	1520.0	IC50	nM	1520.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Oc1cccc(-c2ccc(Cc3ccncc3)cc2)c1	J. Med. Chem.	2010.0	CHEMBL1172882	=	=	IC50	nM	538.0	IC50	nM	538.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1O	J. Med. Chem.	2010.0	CHEMBL1172779	=	=	IC50	nM	7580.0	IC50	nM	7580.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Oc1ccc(-c2ccc(Cc3ccncc3)cc2)cc1F	J. Med. Chem.	2010.0	CHEMBL1173260	=	=	IC50	nM	896.0	IC50	nM	896.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Fc1cccc(-c2ccc(Cc3ccncc3)cc2)c1	J. Med. Chem.	2010.0	CHEMBL1215732	=	=	IC50	nM	668.0	IC50	nM	668.0
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect microsome	Oc1ccc2cc(-c3ccc(Cc4ccncc4)cc3)ccc2c1	J. Med. Chem.	2010.0	CHEMBL1214739	=	=	IC50	nM	1140.0	IC50	nM	1140.0
Inhibition of CYP3A4 in human liver microsomes	COc1ccc(Cn2c(=O)n(C3CCN(C(=O)C4CCN(Cc5ccncc5)CC4)CC3)c3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223003	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 in human liver microsomes	COc1cccc(Cn2c(=O)n(C3CCN(C(=O)C4CCN(Cc5ccncc5)CC4)CC3)c3ccccc32)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223002	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccc(Cl)cc3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223001	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3cccc(Cl)c3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222940	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3Cl)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222939	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(Cc3ccccc3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222938	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 in human liver microsomes	CN(C)CCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222865	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCOCC3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222864	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCN3CCCCC3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222863	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	CN(C)CCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222800	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	CCOCCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222799	=	=	IC50	nM	10600.0	IC50	uM	10.6
Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCOc3ccccc3)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222798	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)OCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222719	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 in human liver microsomes	CCOCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222718	=	=	IC50	nM	13500.0	IC50	uM	13.5
Inhibition of CYP3A4 in human liver microsomes	COCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222717	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)n(CCO)c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222651	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222650	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 in human liver microsomes	Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccncc4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222649	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 in human liver microsomes	O=C(C1CCN(Cc2ccncc2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222485	=	=	IC50	nM	9500.0	IC50	uM	9.5
Inhibition of CYP3A4	CNCC[C@@H](c1ccc(Cl)c(Cl)c1)n1nnc(C)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224382	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1cc(C(N)=O)nn1-c1cccc(-c2ccc(C(F)(F)F)cc2C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224194	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	Cc1cc(C(N)=O)nn1-c1cccc(-c2cc(C(F)(F)F)ccc2C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224195	=	=	IC50	nM	51000.0	IC50	uM	51.0
Inhibition of CYP3A4	FC(F)(F)c1ccccc1-c1cccc(-c2c[nH]cn2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224524	<	<	IC50	nM	50.0	IC50	uM	0.05
Inhibition of CYP3A4	NC(=O)c1nc(-c2cccc(-c3ccccc3C(F)(F)F)c2)c[nH]1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224590	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	NC(=O)c1csc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224655	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	NC(=O)c1nc(-c2cccc(-c3ccccc3OC(F)(F)F)c2)cs1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1224197	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4	CNC(=O)c1ccc(C(c2nnnn2Cc2ccccc2)N2CCCN(C3CCC3)CC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1221429	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CS(=O)(=O)c1ccc(C(c2nnnn2Cc2ccccc2)N2CCCN(C3CCC3)CC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223157	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CN1CCN(Cc2ccc(C(c3nnnn3Cc3ccccc3)N3CCCN(C4CCC4)CC3)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223158	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	c1ccc(Cn2nnnc2C(c2ccc(-n3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223235	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4	c1ccc(Cn2nnnc2C(c2ccc(Cn3cncn3)cc2)N2CCCN(C3CCC3)CC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223236	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	c1ccc(Cn2nnnc2C(c2ccc3occc3c2)N2CCCN(C3CCC3)CC2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1223237	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4	Cc1n[nH]c(C)c1CC(=O)NCc1ccc(Cl)cc1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1210558	>	>	IC50	nM	100.0	pIC50		100.0
Inhibition of CYP3A4	CN1C(=O)CC[C@H]1C(=O)NCc1cccc(C(F)(F)F)c1Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222883	>	>	IC50	nM	100.0	pIC50		100.0
Inhibition of CYP3A4 in human liver microsome	COCCCc1ccc(Cl)c(CN(C(=O)[C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222884	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 in human liver microsome	COCCCc1ccc(Cl)c(CN(C(=O)[C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222884	=	=	Ki	nM	3200.0	Ki	uM	3.2
Inhibition of CYP3A4 in human liver microsome preincubated for 30 mins	COCCCc1ccc(Cl)c(CN(C(=O)[C@@H](CN)Cc2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1222884	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of CYP3A4 in human liver microsomes after 30 mins	Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1	Bioorg. Med. Chem.	2010.0	CHEMBL111	>	>	IC50	nM	20.0	IC50	nM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 mins	FC(F)(F)C1(c2nnc(-c3nn(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)c3Cn3cncn3)s2)CCC1	Bioorg. Med. Chem.	2010.0	CHEMBL1222969	>	>	IC50	nM	20.0	IC50	nM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 mins	C[C@H](NC(=O)C(C)(C)Oc1ccc(C(F)(F)F)cn1)[C@@H](Cc1ccc(Cl)cc1)c1cccc(C#N)c1	Bioorg. Med. Chem.	2010.0	CHEMBL220360	>	>	IC50	nM	20.0	IC50	nM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 mins	CC(C)(C)c1nnc(-c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1	Bioorg. Med. Chem.	2010.0	CHEMBL1223034	>	>	IC50	nM	20.0	IC50	nM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 mins	CC(C)(C)c1nnc(-c2nn(-c3ccccc3Cl)c(-c3ccc(Br)cc3)c2Cn2cncn2)s1	Bioorg. Med. Chem.	2010.0	CHEMBL1223259	>	>	IC50	nM	20.0	IC50	nM	20.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nnc(C)n4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241738	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nnc(C)n4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241738	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C)nnn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241546	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C)nnn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241546	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	CC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241736	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	CC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241736	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N(C)C)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241824	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N(C)C)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241824	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC(C)C)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241998	>	>	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC(C)C)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241998	>	>	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC6CC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242081	>	>	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NC6CC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242081	>	>	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NCC6CC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242345	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)NCC6CC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242345	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242533	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242533	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242623	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCCCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242623	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCOCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242717	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(=O)N6CCOCC6)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1242717	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes measured immediately	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes measured immediately	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes measured immediately	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	88000.0	IC50	uM	88.0
Inhibition of CYP3A4 in human liver microsomes measured after incubation	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	61000.0	IC50	uM	61.0
Inhibition of CYP3A4 in human liver microsomes measured after incubation	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes measured after incubation	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C(N)=O)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241913	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes measured immediately	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 in human liver microsomes measured immediately	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 in human liver microsomes measured immediately	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes measured after incubation	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes measured after incubation	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 in human liver microsomes measured after incubation	CNC(=O)c1ncn2c1COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241912	=	=	IC50	nM	82000.0	IC50	uM	82.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1cn2c(n1)COc1c(CCN3CCN(c4cccc5nc(C)ccc45)CC3)cccc1-2	J. Med. Chem.	2010.0	CHEMBL1241547	<	<	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nc(C)c(C)n4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241548	<	<	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4nc(C(F)(F)F)cn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241641	<	<	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4cncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241642	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 in human liver microsomes using diethoxyfluorescein/7-benzyloxyquinoline as substrate	Cc1ccc2c(N3CCN(CCc4cccc5c4OCc4c(C#N)ncn4-5)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1241825	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4	FC(F)(F)c1ccc(SCC(c2c[nH]cn2)C2CCNCC2)cc1	J. Med. Chem.	2010.0	CHEMBL1243305	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4	CC(C)(C)c1ccc(SCC(c2c[nH]cn2)C2CCNCC2)cc1	J. Med. Chem.	2010.0	CHEMBL1243333	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of CYP3A4	CC(C)(C)c1ccc(SCC(c2ccccn2)c2c[nH]cn2)cc1	J. Med. Chem.	2010.0	CHEMBL1243335	=	=	IC50	nM	270.0	IC50	uM	0.27
Inhibition of CYP3A4	FC(F)(F)c1ccc(SCC(c2ccncc2)c2c[nH]cn2)cc1	J. Med. Chem.	2010.0	CHEMBL1243367	=	=	IC50	nM	350.0	IC50	uM	0.35
Inhibition of CYP3A4	CC(C)(C)c1ccc(SCCc2c[nH]cn2)cc1	J. Med. Chem.	2010.0	CHEMBL1098230	=	=	IC50	nM	470.0	IC50	uM	0.47
Inhibition of CYP3A4	CCCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NC4CC4)ccc3C)c2c1C	J. Med. Chem.	2010.0	CHEMBL1230065	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human CYP3A4	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Antimicrob. Agents Chemother.	2008.0	CHEMBL163	<	<	Ki	nM	100.0	Ki	uM	0.1
Inhibition of CYP3A4	C[C@@H](O[C@H]1CN2C(=O)[C@H]3C[C@@](C)(O)C[C@H]3[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257706	=	=	IC50	nM	22680.0	IC50	uM	22.68
Inhibition of CYP3A4	O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258517	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccncc3)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257487	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3[C@@H](C)CNC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257964	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc(C(=O)N2CCC(F)(F)CC2)n3C(C)C)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL497031	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCNC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258754	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCCNC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258755	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(C)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258873	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(CC3CC3)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257138	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(Cc3ccc(F)cc3)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257376	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3CCN(CCO)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257607	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@@H](C)NC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257729	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@H](C)NC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257850	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3[C@H](C)CNC2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257851	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2ccc3c(c2)cc2n3C[C@@H](C)N(CC3CC3)C2=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1257965	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2cc3cc4n(c3cc2Br)[C@@H](C)CNC4=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258078	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(C)N1CCC(Oc2cc3cc4n(c3cc2Br)[C@@H](C)CN(CC2CC2)C4=O)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258079	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc2c(c1)cc1n2CCNC1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1258308	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	O=c1cc(-c2ccccc2)oc2cc(O)cc(O)c12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL117	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of human CYP3A4	Cc1ncoc1-c1nnc(SCCCN2[C@H]3CC[C@@H]2C[C@H](c2ccc(C(C)(C)C)cc2)C3)n1C	J. Med. Chem.	2010.0	CHEMBL1257215	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	Cc1ncoc1-c1nnc(SCCCN2[C@H]3CC[C@@H]2C[C@H](c2ccc(C(F)(F)F)cc2)C3)n1C	J. Med. Chem.	2010.0	CHEMBL1257336	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	Cn1c(SCCCN2CCC3CC3(c3ccc(C(F)(F)F)cc3)CC2)nnc1-c1ccnnc1	J. Med. Chem.	2010.0	CHEMBL1258034	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human CYP3A4	Cc1ncoc1-c1nnc(SCCCN[C@@H]2CC[C@]3(c4ccc(C(F)(F)F)cc4)CC23)n1C	J. Med. Chem.	2010.0	CHEMBL1258035	>	>	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of human CYP3A4	CCOc1ccc2c(c1)Oc1cc(OCC)ccc1C21OC(=O)c2ccccc21	J. Med. Chem.	2010.0	CHEMBL1257567	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4	c1ccc(COc2ccc3cccnc3c2)cc1	J. Med. Chem.	2010.0	CHEMBL1081779	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 by competitive inhibition assay	CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270362	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of CYP3A4 in presence of NADPH	CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270362	=	=	IC50	nM	4.0	IC50	uM	0.004
Inhibition of CYP3A4	CC(=O)N[C@@H](Cc1cc(F)cc(F)c1)[C@H](O)CNC1(c2cccc(C(C)(C)C(F)F)c2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270362	=	=	IC50	nM	46.0	IC50	uM	0.046
Inhibition of CYP3A4 using midazolam as substrate	COCCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269671	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of CYP3A4 using midazolam as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270661	=	=	IC50	nM	7400.0	IC50	uM	7.4
Inhibition of CYP3A4 using midazolam as substrate	COCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269672	=	=	IC50	nM	3200.0	IC50	uM	3.2
Inhibition of CYP3A4 using midazolam as substrate	CNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269673	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 using midazolam as substrate	CNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269674	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 using midazolam as substrate	CCNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269675	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 using midazolam as substrate	CCNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269676	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 using midazolam as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCCF)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269680	=	=	IC50	nM	7300.0	IC50	uM	7.3
Inhibition of CYP3A4 using midazolam as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCC(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269681	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 using midazolam as substrate	CC(=O)NCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269682	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4 using midazolam as substrate	CNC(=O)CCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269683	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 using midazolam as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CCNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269684	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of CYP3A4 using midazolam as substrate	CCNC(=O)Cc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269686	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 using midazolam as substrate	CC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269687	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of CYP3A4 using midazolam as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269692	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 using midazolam as substrate	COC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269696	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 using midazolam as substrate	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c(Cl)cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269697	=	=	IC50	nM	5900.0	IC50	uM	5.9
Inhibition of CYP3A4 using testosterone as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270661	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 using testosterone as substrate	COCCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269671	=	=	IC50	nM	8100.0	IC50	uM	8.1
Inhibition of CYP3A4 using testosterone as substrate	CNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269673	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 using testosterone as substrate	CNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269674	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 using testosterone as substrate	CCNCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269675	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 using testosterone as substrate	CCNCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269676	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 using testosterone as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCCF)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269680	=	=	IC50	nM	9900.0	IC50	uM	9.9
Inhibition of CYP3A4 using testosterone as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNCC(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269681	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of CYP3A4 using testosterone as substrate	CC(=O)NCCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269682	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 using testosterone as substrate	CNC(=O)CCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269683	=	=	IC50	nM	8900.0	IC50	uM	8.9
Inhibition of CYP3A4 using testosterone as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CCNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269684	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4 using testosterone as substrate	CCNC(=O)Cc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269686	=	=	IC50	nM	7100.0	IC50	uM	7.1
Inhibition of CYP3A4 using testosterone as substrate	CC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269687	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of CYP3A4 using testosterone as substrate	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cc(CNC(=O)CC(F)(F)F)ccc3Cl)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269692	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of CYP3A4 using testosterone as substrate	COC(=O)NCc1ccc(Cl)c(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269696	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of CYP3A4	Cc1cc(Cl)c(OCCOc2ccc([C@H]3CCNC[C@@H]3C(=O)N(Cc3cccc(C)c3C)C3CC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270661	>	>	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4	Cc1cc(Cl)c(OCCOc2ccc(C3=C(C(=O)N(Cc4cccc(Cl)c4Cl)C4CC4)CNCC3)cc2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1087637	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4	CC(C)(NCCCc1cc(-c2cccc(C(F)(F)F)c2)nc(C#N)n1)C(N)=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270269	=	=	IC50	nM	35000.0	IC50	uM	35.0
Inhibition of CYP3A4 in human liver microsomes by fluorometric assay	CS(=O)(=O)c1cccc(Nc2nccc(Nc3c(Cl)ccc4c3OCO4)n2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL445162	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 in human liver microsomes by fluorometric assay	Clc1ccc2c(c1Nc1ccnc(Nc3cc(N4CCOCC4)cc(N4CCOCC4)c3)n1)OCO2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL468970	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 in human liver microsomes by fluorometric assay	CN(c1ccnc(Nc2cc(N3CCOCC3)cc(N3CCOCC3)c2)n1)c1cccc2[nH]ncc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269858	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2ccccn2)cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270738	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	O=C(Nc1ccc(-n2nc(-c3cccnc3)cc2C(F)(F)F)cn1)c1ccccc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271608	>	>	IC50	nM	30.0	IC50	nM	30.0
Inhibition of human recombinant CYP3A4	CSc1nn(-c2ccccc2)c2cc(NC(=O)C3CCNCC3)ccc12	J. Med. Chem.	2010.0	CHEMBL1236391	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	CN1[C@H]2CCC[C@@H]1C[C@@H](NC(=O)c1cccc3oc(N4CCOCC4)nc13)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL3084761	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(N3CCOCC3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271520	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	COc1ccccc1-c1nc2c(C(=O)N[C@@H]3CN4CCC3CC4)cccc2o1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272016	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1ccccc1-c1nc2c(C(=O)N[C@H]3C[C@@H]4CCC[C@H](C3)N4C)cccc2o1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL3084777	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human CYP3A4	O=C(N[C@@H]1CN2CCC1CC2)c1cccc2oc(C3CC3)nc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272072	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	CN1[C@H]2CCC[C@@H]1C[C@@H](NC(=O)c1cccc3oc(C4CC4)nc13)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL3084778	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL46	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human CYP3A4	Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1110	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)OC2C3CC4CC(C3)CC2C4)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270215	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4	CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270910	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4	NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4ncccc4C(F)(F)F)C1)C(C3)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271218	=	=	IC50	nM	3300.0	IC50	nM	3300.0
Inhibition of CYP3A4	NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4ccc(C(F)(F)F)cn4)C1)C(C3)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271320	=	=	IC50	nM	7200.0	IC50	nM	7200.0
Inhibition of CYP3A4	NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@@H](Nc4cccc(C(F)(F)F)n4)C1)C(C3)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271427	=	=	IC50	nM	4800.0	IC50	nM	4800.0
Inhibition of CYP3A4	NC(=O)[C@]12CC3CC(C1)[C@H](OC(=O)N1CC[C@H](Nc4ncccc4C(F)(F)F)C1)C(C3)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271428	=	=	IC50	nM	8500.0	IC50	nM	8500.0
Inhibition of CYP3A4	NC(=O)[C@]12CC3CC(C1)[C@@H](OC(=O)N1CC[C@H](Nc4ccc(C(F)(F)F)cn4)C1)C(C3)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269894	=	=	IC50	nM	10300.0	IC50	nM	10300.0
Inhibition of CYP3A4	N#Cc1cccnc1N[C@@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269895	=	=	IC50	nM	17100.0	IC50	nM	17100.0
Inhibition of CYP3A4	N#Cc1ccc(N[C@@H]2CCN(C(=O)O[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)C2)nc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270001	=	=	IC50	nM	14200.0	IC50	nM	14200.0
Inhibition of CYP3A4	N#Cc1cccnc1N[C@H]1CCN(C(=O)O[C@H]2C3CC4CC2C[C@](C(N)=O)(C4)C3)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270002	=	=	IC50	nM	18600.0	IC50	nM	18600.0
Inhibition of CYP3A4	N#Cc1ccc(N[C@H]2CCN(C(=O)O[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)C2)nc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270110	=	=	IC50	nM	26600.0	IC50	nM	26600.0
Inhibition of CYP3A4	OC1C2CC3CC(C2)CC1C3	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1269176	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4	COc1cccc(NC(=O)Nc2cccn(Cc3c(F)cccc3Cl)c2=O)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272135	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CC#Cc1cccc([C@@]2(c3ccc(OC(F)F)cc3)N=C(N)N(C)C2=O)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270934	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4	CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2cccc(C#CC3CC3)c2)N=C1N	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271246	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4	CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2ccc(F)c(C#CC3CC3)c2)N=C1N	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270335	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1cc([C@]2(c3ccc(F)c(C#CC4CC4)c3)N=C(N)N(C)C2=O)ccc1OC(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270432	=	=	IC50	nM	4100.0	IC50	uM	4.1
Inhibition of CYP3A4	Cc1cc([C@]2(c3cccc(C#CC4CC4)c3)N=C(N)N(C)C2=O)ccc1OC(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270630	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4	CCCC#Cc1cc([C@@]2(c3ccc(OC(F)F)c(C)c3)N=C(N)N(C)C2=O)ccc1F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270834	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4	CN1C(=O)[C@@](c2ccc(OC(F)F)cc2)(c2ccc(F)c(C#CCCCF)c2)N=C1N	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270835	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4	CC#Cc1cc([C@@]2(c3ccc(OC(F)F)cc3)N=C(N)N(C)C2=O)ccc1F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1270936	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	CSc1nc(C)cc(C(=O)NCCN2CCN(c3cccc(C)c3C)CC2)n1.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271930	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 by CYPEX bactosome P450 inhibition assay	Cc1cc(C)cc(NC(=O)CSc2nnc(-c3ccoc3C)n2Cc2ccco2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271489	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 using DEF substrate by CYPEX bactosome P450 inhibition assay	Cc1cc(C)cc(NC(=O)CSc2nnc(-c3ccoc3C)n2Cc2ccco2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271489	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC4CCC(C3)N4)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271544	=	=	IC50	nM	0.5	IC50	nM	0.5
Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC[C@@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271600	=	=	IC50	nM	13.6	IC50	nM	13.6
Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CCC(CO)CC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271601	=	=	IC50	nM	13.8	IC50	nM	13.8
Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC[C@H](O)C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271651	=	=	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CC4CNCC4C3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271652	=	=	IC50	nM	6.4	IC50	nM	6.4
Inhibition of CYP3A4 after 30 mins	CC(C)[C@@H]1COC[C@H](C2(OC(=O)N3CCNCC3)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271703	=	=	IC50	nM	0.3	IC50	nM	0.3
Inhibition of CYP3A4 after 30 mins	CC(C)(C)[C@@H]1COC[C@H](COC(=O)N2CCN(C(C)(C)CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271704	=	=	IC50	nM	23.8	IC50	nM	23.8
Inhibition of CYP3A4 after 30 mins	CC(C)(C)[C@@H]1COC[C@H](COC(=O)N2CCC(CO)CC2)N1S(=O)(=O)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271762	=	=	IC50	nM	7.1	IC50	nM	7.1
Inhibition of CYP3A4 after 30 mins	CC1([C@@H]2COC[C@H](COC(=O)N3CCC(CO)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271763	=	=	IC50	nM	5.5	IC50	nM	5.5
Inhibition of CYP3A4 after 30 mins	CC1([C@@H]2COC[C@H](COC(=O)N3CCC(N4CCCCC4)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271821	=	=	IC50	nM	1.5	IC50	nM	1.5
Inhibition of CYP3A4 after 30 mins	CC1([C@@H]2COC[C@H](COC(=O)N3CCN(C(C)(C)CO)CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271822	=	=	IC50	nM	0.5	IC50	nM	0.5
Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271879	=	=	IC50	nM	0.8	IC50	nM	0.8
Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271880	=	=	IC50	nM	2.3	IC50	nM	2.3
Inhibition of CYP3A4 after 30 mins	CC(=O)N1C2CCC1CN(C(=O)OC1([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271935	>	>	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 after 30 mins	CCNC(=O)N1C2CCC1CN(C(=O)OC1([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1271991	>	>	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CC1CN2CCO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272045	=	=	IC50	nM	3.2	IC50	nM	3.2
Inhibition of CYP3A4 after 30 mins	C[C@H]1CN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)C[C@@H](C)N1CCO	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272046	=	=	IC50	nM	2.0	IC50	nM	2.0
Inhibition of CYP3A4 after 30 mins	CN1CCN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272097	=	=	IC50	nM	1.4	IC50	nM	1.4
Inhibition of CYP3A4 after 30 mins	CC[C@H]1CN(C(C)=O)[C@H](C)CN1C(=O)OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272098	>	>	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272152	>	>	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 after 30 mins	O=C(OC1([C@H]2COC[C@@H](CC3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC2(CCN2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272153	=	=	IC50	nM	11.3	IC50	nM	11.3
Inhibition of CYP3A4 after 30 mins	CN1CCC12CCN(C(=O)OC1([C@H]3COC[C@@H](CC4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)CC2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272207	=	=	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 after 30 mins	O=C1CC2(CCN(C(=O)OC3([C@H]4COC[C@@H](CC5CC5)N4S(=O)(=O)c4ccc(Cl)cc4)CC3)CC2)N1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1272208	>	>	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3CCC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL393941	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 after 30 mins	CC(C)(CO)N1CCN(C(=O)OC2([C@H]3C[C@@H](O)C[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL399507	=	=	IC50	nM	19500.0	IC50	uM	19.5
Inhibition of CYP3A4	Fc1cccc2c1CCC1(CCN(c3ccc(-c4nnc(Cc5cccnc5)o4)nn3)CC1)O2	Eur. J. Med. Chem.	2010.0	CHEMBL1276654	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4	O=C(C1=C(c2ccc(CCCOc3c(F)ccc(F)c3Cl)cc2)C[C@@H]2CNC[C@H]1N2)N(Cc1cccc(Cl)c1Cl)C1CC1	J. Med. Chem.	2010.0	CHEMBL509903	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)[C@](C)(c1ccccc1)O2	J. Med. Chem.	2010.0	CHEMBL391463	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CN(Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccncc1)c1ccccc1	J. Med. Chem.	2010.0	CHEMBL1277677	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human CYP3A4	Cc1c2c(=O)n(-c3ccccc3Cl)[nH]c2cc(=O)n1Cc1ccccn1	J. Med. Chem.	2010.0	CHEMBL1276946	=	=	IC50	nM	20900.0	IC50	uM	20.9
Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1CN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)C1	J. Med. Chem.	2010.0	CHEMBL1277312	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1=CCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)CC1	J. Med. Chem.	2010.0	CHEMBL1277126	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1CN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1	J. Med. Chem.	2010.0	CHEMBL1276948	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)[C@]12C[C@H]1CN(C1CC[C@]3(Cc4ccccc4Cc4ccccc43)C1)C2	J. Med. Chem.	2010.0	CHEMBL1276947	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1(F)CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1	J. Med. Chem.	2010.0	CHEMBL1277678	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1	J. Med. Chem.	2010.0	CHEMBL1277770	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 transfected in bactosome expression system by spectrofluorimetry	O=C(O)C1=CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1	J. Med. Chem.	2010.0	CHEMBL1277935	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1ccc(C(=O)Nc2ccon2)cc1NC(=O)c1cnn(-c2ccccc2F)c1N	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290746	>	>	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4	CN(O)C(=O)c1cc2c(CN3CCC[C@H]3C(N)=O)cn(Cc3ccc(F)cc3)c2cn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289313	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	COc1cc(-n2cnc3cc(-c4ccc(Cl)cc4)sc3c2=O)ccc1OCCN1CCCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL214957	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4	CN1CCN(CCCN(C(=O)Nc2ccc(F)c(C(F)(F)F)c2)C2CCC3(c4ccc(C#N)cc4)CC23)CC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289614	<	<	IC50	nM	50.0	IC50	uM	0.05
Inhibition of CYP3A4	O=c1cc(-c2ccc(C(F)(F)F)cc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290041	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	O=c1cc(-c2ccc(Cl)cc2Cl)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290150	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4	O=C(c1ccccc1N1Cn2c(ccc2-c2ccccc2)C1=O)N1CCCCC1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290004	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289283	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=c1cc(OCc2ccccc2)ccn1-c1ccc2c3c([nH]c2c1)CCNC3	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290155	=	=	IC50	nM	68000.0	IC50	uM	68.0
Inhibition of CYP3A4	CN1CCc2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc3n2C)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1290264	=	=	IC50	nM	67000.0	IC50	uM	67.0
Inhibition of CYP3A4	Cn1c2c(c3ccc(-n4ccc(OCc5ccccc5)cc4=O)cc31)CCNC2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289395	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	CN1CCc2c(n(C)c3cc(-n4ccc(OCc5ccccc5)cc4=O)ccc23)C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289396	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4	O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CCCC2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289283	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CCN2CC[C@H](O)C2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289515	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of CYP3A4	O=c1cc(OCc2ccccc2)ccn1-c1ccc2c(cnn2CC2=NCCN2)c1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1289053	=	=	IC50	nM	38000.0	IC50	uM	38.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins	Cl.Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2Cl)n(C)c1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1288260	=	=	IC50	nM	10200.0	IC50	uM	10.2
Inhibition of CYP3A4 in human liver microsomes after 10 mins	Cc1ccc(F)cc1Cn1c(N2CCC[C@@](C)(N)C2)cc2c1c(=O)n(C)c(=O)n2C.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1288261	=	=	IC50	nM	20200.0	IC50	uM	20.2
Inhibition of CYP3A4 in human liver microsomes after 10 mins	CCn1c(=O)n(C)c(=O)c2c1cc(N1CCC[C@@](C)(N)C1)n2Cc1cc(F)ccc1C#N.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1288288	=	=	IC50	nM	9400.0	IC50	uM	9.4
Inhibition of CYP3A4 in human liver microsomes after 10 mins	CN(C)C(=O)Cn1c(=O)n(C)c(=O)c2c1cc(N1CCC[C@@](C)(N)C1)n2Cc1cc(F)ccc1Cl.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1288289	=	=	IC50	nM	13400.0	IC50	uM	13.4
Inhibition of CYP3A4 in human liver microsomes after 10 mins	Cl.Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2Cl)n(CCCO)c1=O	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1287844	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of CYP3A4 in human liver microsomes after 10 mins	Cc1ccc(F)cc1Cn1c(N2CCC[C@@](C)(N)C2)cc2ncn(C)c(=O)c21.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1287901	=	=	IC50	nM	11900.0	IC50	uM	11.9
Inhibition of human CYP3A4	COc1cccc2c(C(=O)N3CCN4CCCC[C@H]4C3)cn(CC3CCCCC3)c12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1287846	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as probe	Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1631540	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of human recombinant CYP3A4	Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1631540	=	=	IC50	nM	67000.0	IC50	uM	67.0
Inhibition of CYP3A4 in human liver microsomes using atorvastatin as probe	Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1631540	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 in human liver microsomes using nifedipine as probe	Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1	J. Med. Chem.	2010.0	CHEMBL1631540	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of human CYP3A4	CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1	Antimicrob. Agents Chemother.	2009.0	CHEMBL264241	>	>	IC50	nM	17500.0	IC50	uM	17.5
Inhibition of CYP3A4 in human liver microsomes	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12	J. Med. Chem.	2010.0	CHEMBL221959	>	>	IC50	nM	52000.0	IC50	uM	52.0
Inhibition of CYP3A4	Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-n3ccnc3)c1)=N2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL411095	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4	Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-c3ccncc3)c1)=N2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1631858	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4	Cc1cc2c(cc1C(F)(F)F)NC(=O)CC(c1cccc(-c3cccnc3)c1)=N2	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1631876	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4	Cc1cc(-c2cccc(C3=Nc4cc(C)c(C(F)(F)F)cc4NC(=O)C3)c2)ccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1631859	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4	Cc1cc(-c2cccc(C3=Nc4cc(C)c(C(F)(F)F)cc4NC(=O)C3)c2)cc(C)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1629855	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of CYP3A4	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2ccc(Cl)cc2C1)C(F)(F)F	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1631007	>	>	IC50	nM	38000.0	IC50	uM	38.0
Inhibition of CYP3A4	NC(=O)c1cc(C(N)=O)n(-c2cccc(-c3cc(C(F)(F)F)ccc3C(F)(F)F)c2)n1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1631095	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL561132	=	=	IC50	nM	34000.0	IC50	uM	34.0
Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3cccnc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1641808	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	C[C@@H](C(=O)N(C)[C@@H]1CCc2c(CC(=O)O)c3cccnc3n2C1)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1641811	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643880	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of human CYP3A4	Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1110	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of human CYP3A4	O=C1c2cccc3[nH]nc(c23)CN1[C@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643881	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccc(N4CCOCC4)cc3OC)n1)CCN(CC(=O)N(C)C)CC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1642258	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human CYP3A4	Cn1nc2c3c(cccc31)C(=O)N([C@H]1CN3CCC1CC3)C2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643883	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)CCNC(=O)c1ccc(Cn2nc(-c3cc(Cl)cc(Cl)c3)cc2-c2ccc(OC(F)(F)F)cc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1644183	=	=	IC50	nM	39000.0	IC50	uM	39.0
Inhibition of CYP3A4	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21	Bioorg. Med. Chem.	2011.0	CHEMBL809	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4	CN[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642894	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CN[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642895	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CN[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642896	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CN[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642897	=	=	IC50	nM	17100.0	IC50	uM	17.1
Inhibition of CYP3A4	CNC[C@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642906	=	=	IC50	nM	20100.0	IC50	uM	20.1
Inhibition of CYP3A4	CNC[C@@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642907	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CNC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642908	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	NCC[C@@H]1Cc2ccccc2[C@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642912	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	NCC[C@H]1Cc2ccccc2[C@@H](c2ccc(Cl)c(Cl)c2)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1642913	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CC(C)(C)NC(=O)Cn1c(-c2ccc(OC(F)(F)F)cc2)cc2cc(C(C)(C)C(=O)NC(C)(C)C)ccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643735	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	N[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643512	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CNC1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643511	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CN[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643513	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CN(C)[C@@H]1CCN(c2ccc(Cl)c(Cl)c2)c2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643514	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL561132	=	=	IC50	nM	34000.0	IC50	uM	34.0
Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccc(F)cc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643773	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccc(F)c(F)c3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643780	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3cccc(F)c3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643783	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(O)Cc1c2n(c3ccccc13)C[C@H](N(Cc1ccc(F)cc1)S(=O)(=O)c1ccc(F)cc1)CC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1643789	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1ccccc1/C(=C\CCN1CCC[C@@H](C(=O)O)C1)c1ccccc1F	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1641613	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	CC(C)c1ccc(S(=O)(=O)n2cc(N3CCN(C)CC3)c3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1642412	=	=	IC50	nM	5540.0	IC50	uM	5.54
Inhibition of human CYP3A4	CN1CCN(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccccc23)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1642413	=	=	IC50	nM	4770.0	IC50	uM	4.77
Inhibition of human CYP3A4	CN1CCN(c2cn(S(=O)(=O)c3ccc(F)cc3)c3ccc(Br)cc23)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1642419	=	=	IC50	nM	4610.0	IC50	uM	4.61
Inhibition of CYP3A4	FC(F)(F)c1ccccc1-c1cc(C(F)(F)F)c2[nH]c(C3=NOC4(CCCCC4)C3)nc2c1	J. Med. Chem.	2011.0	CHEMBL1650511	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 uisng testosterone substrate	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651534	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 uisng testosterone substrate	O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651533	=	=	IC50	nM	23500.0	IC50	uM	23.5
Inhibition of CYP3A4 uisng testosterone substrate	Cc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651532	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 uisng testosterone substrate	O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651525	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 uisng midazolam substrate	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651534	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 uisng midazolam substrate	O=C(Nc1cnccn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651533	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 uisng midazolam substrate	Cc1ccc(NC(=O)N2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651532	=	=	IC50	nM	11800.0	IC50	uM	11.8
Inhibition of CYP3A4 uisng midazolam substrate	O=C(Nc1cccnc1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1651525	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of human CYP3A4 by fluorescence assay	CC(=O)Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1	J. Med. Chem.	2011.0	CHEMBL1649675	<=	<=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4 by fluorescence assay	CN1CCc2c(C(F)(F)F)nn(-c3ccc(CN4CCCC4=O)cc3)c2C1	J. Med. Chem.	2011.0	CHEMBL1649685	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 by fluorescence assay	O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2COCC3)cc1	J. Med. Chem.	2011.0	CHEMBL1649684	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 by fluorescence assay	O=C(c1ccc(-n2nc(C(F)(F)F)c3c2COCC3)cc1)N1CCCC1	J. Med. Chem.	2011.0	CHEMBL1649683	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 by fluorescence assay	O=C1CCCN1Cc1c(F)cc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1F	J. Med. Chem.	2011.0	CHEMBL1649682	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 by fluorescence assay	O=C1CCCN1Cc1ccc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1	J. Med. Chem.	2011.0	CHEMBL1649681	>	>	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human CYP3A4 by fluorescence assay	O=C(c1ccc(-n2nc(C(F)(F)F)c3c2CCOC3)cc1)N1CCCC1	J. Med. Chem.	2011.0	CHEMBL1649656	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 by fluorescence assay	O=C(N1CCCC1)C1(c2ccc(-n3nc(C(F)(F)F)c4c3CCCC4)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL1649667	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human CYP3A4 by fluorescence assay	O=C(Cc1ccc(-n2nc(C(F)(F)F)c3c2CCCC3)cc1)NC1CCCC1	J. Med. Chem.	2011.0	CHEMBL1649665	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of human cytochrome P450 3A4	CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O	Antimicrob. Agents Chemother.	2009.0	CHEMBL381751	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human cytochrome P450 3A4	CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](F)[C@@H]1O	Antimicrob. Agents Chemother.	2009.0	CHEMBL466624	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human cytochrome P450 3A4	CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@@H](F)[C@@H]1O	Antimicrob. Agents Chemother.	2009.0	CHEMBL443705	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human cytochrome P450 3A4	CN(C/C=C\CN)C[C@H]1O[C@@H](n2cnc3c(N)nc(Cl)nc32)[C@H](O)[C@@H]1O	Antimicrob. Agents Chemother.	2009.0	CHEMBL468092	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human cytochrome P450 3A4	Cc1nc(N)c2ncn([C@@H]3O[C@H](CN(C)C/C=C\CN)[C@@H](O)[C@H]3O)c2n1	Antimicrob. Agents Chemother.	2009.0	CHEMBL467047	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	Oc1cccc(-c2ccc3c(-c4ccccc4)c(O)ccc3c2)c1	J. Med. Chem.	2011.0	CHEMBL469227	=	=	IC50	nM	2770.0	IC50	uM	2.77
Inhibition of human CYP3A4	Oc1cccc(-c2ccc3c(-c4cccnc4)c(O)ccc3c2)c1	J. Med. Chem.	2011.0	CHEMBL1650645	=	=	IC50	nM	220.0	IC50	uM	0.22
Inhibition of human CYP3A4	Oc1cccc(-c2ccc3c(-c4cccc(O)c4)c(O)ccc3c2)c1	J. Med. Chem.	2011.0	CHEMBL1650652	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of human CYP3A4	Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1	J. Med. Chem.	2011.0	CHEMBL1650654	=	=	IC50	nM	1070.0	IC50	uM	1.07
Inhibition of human CYP3A4	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL157101	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of CYP3A4	N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)ncc(F)c1=O	J. Med. Chem.	2011.0	CHEMBL1650404	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	J. Med. Chem.	2011.0	CHEMBL376359	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O	J. Med. Chem.	2011.0	CHEMBL1650443	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL559251	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	CCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669405	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	CCCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669406	=	=	IC50	nM	4038.0	IC50	nM	4038.0
Inhibition of CYP3A4	CN(CCF)CCC1=C(Cc2cnccn2)c2ccccc2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669407	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL556506	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)CCF)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669408	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)CC#N)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669409	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)CCC#N)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669410	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)CCC(F)(F)F)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669411	>	>	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition of CYP3A4	c1ccc2c(c1)CC(CCN1CCC1)=C2Cc1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669412	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	c1ccc2c(c1)CC(CCN1CCCC1)=C2Cc1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669413	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	FC1CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669414	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	FC1(F)CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669415	=	=	IC50	nM	3871.0	IC50	nM	3871.0
Inhibition of CYP3A4	FC1(F)CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669416	=	=	IC50	nM	1405.0	IC50	nM	1405.0
Inhibition of CYP3A4	FC1CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669417	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2ccco2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669418	=	=	IC50	nM	2751.0	IC50	nM	2751.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2cccs2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669419	=	=	IC50	nM	1826.0	IC50	nM	1826.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2nccs2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669420	=	=	IC50	nM	2820.0	IC50	nM	2820.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2ncco2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669421	=	=	IC50	nM	4840.0	IC50	nM	4840.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2ncc[nH]2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669422	=	=	IC50	nM	4416.0	IC50	nM	4416.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2nccn2C)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669423	=	=	IC50	nM	1535.0	IC50	nM	1535.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2ccccn2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669424	=	=	IC50	nM	4783.0	IC50	nM	4783.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2ccncc2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669425	=	=	IC50	nM	1281.0	IC50	nM	1281.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)Cc2cnccn2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669426	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)CC2CCOCC2)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1669427	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1F)nc2[C@H]1CC[C@H](C(=O)Nc2nc3ccccc3[nH]2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1667948	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CCCCN1C(=O)C(CC(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL537424	=	=	IC50	nM	19700.0	IC50	uM	19.7
Inhibition of CYP3A4	CCCCN1C(=O)C(CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL536743	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of CYP3A4	CCCCN1C(=O)[C@@H]([C@H](O)C(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL559168	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL536754	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCCCN1C(=O)[C@H](CC2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1170878	=	=	IC50	nM	24900.0	IC50	uM	24.9
Inhibition of CYP3A4	CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668019	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCCCN1C(=O)[C@@H]([C@@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668020	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCCCN1C(=O)[C@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668021	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCCCN1C(=O)[C@H]([C@@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668022	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CCOc1ccc(-c2ccc(-c3cc(CC(=O)[O-])ccc3OC)c(CN(CC)C(=O)C3CC3)c2)cn1.[Na+]	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668898	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 by time-dependent inhibition assay	CCOc1ccc(-c2ccc(-c3cc(CC(=O)[O-])ccc3OC)c(CN(CC)C(=O)C3CC3)c2)cn1.[Na+]	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668898	=	=	IC50	nM	2.0	IC50	uM	0.002
Inhibition of CYP3A4	CCOC(=O)c1sc2cnccc2c1Nc1ccc2c(c1)CC/C2=N/O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668909	=	=	IC50	nM	50.0	IC50	nM	50.0
Inhibition of CYP3A4	CCOC(=O)c1oc2cnccc2c1Nc1ccc2c(c1)CC/C2=N/O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1667925	=	=	IC50	nM	8300.0	IC50	nM	8300.0
Inhibition of CYP3A4	O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(Cl)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1642362	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4	O=C(NC1CCCCC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668238	=	=	IC50	nM	7600.0	IC50	uM	7.6
Inhibition of CYP3A4	O=C(N[C@H]1CC[C@H](O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668239	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4	O=C(N[C@H]1CC[C@H](C(=O)O)CC1)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668240	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1615153	=	=	IC50	nM	37000.0	IC50	uM	37.0
Inhibition of CYP3A4	O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(F)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1615152	=	=	IC50	nM	39000.0	IC50	uM	39.0
Inhibition of CYP3A4	O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3cc(F)c(F)cc32)c(Cl)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668243	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1NC(=O)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1615150	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(Nc1ccc(OC2(C(=O)O)CC2)cc1F)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668249	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(Nc1ccc(-c2nnn[nH]2)cc1F)[C@H](C1CCCCC1)n1c(-c2ccc(Cl)cc2)nc2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668257	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of CYP3A4	O=C(O)c1ccc(NC(=O)[C@H](C2CCCCC2)n2c(-c3ccc(Cl)cc3)nc3ccccc32)c(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668259	=	=	IC50	nM	49000.0	IC50	uM	49.0
Inhibition of CYP3A4	COc1ccc(-c2nc3cc(F)c(F)cc3n2[C@H](C(=O)N[C@H]2CC[C@H](C(=O)O)CC2)C2CCCCC2)c(OC)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1668261	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	O=C1N[C@@H]2C(=C[C@H](O)[C@@H](O)[C@H]2O)c2cc3c(c(O)c21)OCO3	J. Nat. Prod.	2011.0	CHEMBL98745	=	=	Ki	nM	630.0	Ki	uM	0.63
Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc([C@H]2COc3ccccc3[C@@H]2O)ccc1O	J. Nat. Prod.	2011.0	CHEMBL1668108	=	=	IC50	nM	99500.0	IC50	uM	99.5
Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc([C@H]2OC[C@H]([C@@H](O)c3ccc(O)c(OC)c3)[C@@H]2CO)ccc1O	J. Nat. Prod.	2011.0	CHEMBL1668112	=	=	IC50	nM	66500.0	IC50	uM	66.5
Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc([C@H]2c3cc(O)c(OC)cc3C[C@@H](CO)[C@@H]2CO)ccc1O	J. Nat. Prod.	2011.0	CHEMBL399512	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc(C[C@H]2CO[C@H](c3ccc(O)c(O)c3)[C@H]2CO)ccc1O	J. Nat. Prod.	2011.0	CHEMBL1668114	=	=	IC50	nM	85600.0	IC50	uM	85.6
Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O	J. Nat. Prod.	2011.0	CHEMBL368347	=	=	IC50	nM	47300.0	IC50	uM	47.3
Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc(C[C@H]2CO[C@H](c3ccc(O)c(OC)c3)[C@H]2CO)ccc1O	J. Nat. Prod.	2011.0	CHEMBL518421	=	=	IC50	nM	25600.0	IC50	uM	25.6
Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc([C@@H]2Oc3cc(CCCO)ccc3O[C@H]2CO)ccc1O	J. Nat. Prod.	2011.0	CHEMBL1668115	=	=	IC50	nM	54200.0	IC50	uM	54.2
Inhibition of CYP3A4 after 30 mins by fluorometric assay	COc1cc([C@H]2c3cc(O)c(OC)cc3C[C@H]3C(=O)OC[C@H]23)ccc1O	J. Nat. Prod.	2011.0	CHEMBL463246	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 after 30 mins by fluorometric assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Nat. Prod.	2011.0	CHEMBL157101	=	=	IC50	nM	7.8	IC50	uM	0.0078
Inhibition of recombinant CYP3A4 after 30 mins	CC(C)(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	J. Med. Chem.	2011.0	CHEMBL1671922	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 after 30 mins	CC(C)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	J. Med. Chem.	2011.0	CHEMBL1671921	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 after 30 mins	CCCC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	J. Med. Chem.	2011.0	CHEMBL1671918	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 after 30 mins	CCCCC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	J. Med. Chem.	2011.0	CHEMBL1671917	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 after 30 mins	CCn1c(=O)c2c(nc(/C=C/c3ccc(OC)c(OC)c3)n2C)n(CC)c1=O	J. Med. Chem.	2011.0	CHEMBL431770	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 after 30 mins	CC(C)(C)CC(=O)Nc1c(F)cc(C(=O)Nc2nccs2)cc1F	J. Med. Chem.	2011.0	CHEMBL1671936	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 after 30 mins	Cc1ccccc1C(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	J. Med. Chem.	2011.0	CHEMBL1671916	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4	COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c(Cl)c1	J. Med. Chem.	2011.0	CHEMBL1671964	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4	COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C(F)(F)F)cc1Cl	J. Med. Chem.	2011.0	CHEMBL1671965	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C(F)(F)F)cc1Br	J. Med. Chem.	2011.0	CHEMBL1671967	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4	COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c(C(F)(F)F)c1	J. Med. Chem.	2011.0	CHEMBL1671969	=	=	IC50	nM	9800.0	IC50	uM	9.8
Inhibition of CYP3A4	COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)cc1C(F)(F)F	J. Med. Chem.	2011.0	CHEMBL1671971	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccccc1C(F)(F)F	J. Med. Chem.	2011.0	CHEMBL1671972	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4	COc1cc(/C=C2\SC(=O)NC2=O)ccc1Oc1ccc(C#N)c2ccccc12	J. Med. Chem.	2011.0	CHEMBL1671981	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4	COC(=O)c1ccc(Oc2ccc(/C=C3\SC(=O)NC3=O)cc2OC)c2ccccc12	J. Med. Chem.	2011.0	CHEMBL1671982	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2)c(-c2ccco2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672611	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2)c(-c2cccnc2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672621	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2)c(-c2ccncc2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672622	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2F)c(-c2cccnc2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672627	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2c(F)cncc2F)c(-c2cccnc2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672629	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2F)c(-c2ccncc2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672630	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2F)c(-c2ncco2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672632	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes	O=C(Nc1cnc(-c2ccncc2F)c(-c2cnco2)n1)C1CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1672633	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4	O=c1cc(CCCC2CC2)c2c(=O)[nH]c(C(F)F)nc2o1	ACS Med. Chem. Lett.	2011.0	CHEMBL1671877	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsome	Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL655	>	>	IC50	nM	33000.0	IC50	nM	33000.0
Inhibition of CYP3A4 in human liver microsome	CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1487	=	=	IC50	nM	5100.0	IC50	nM	5100.0
Inhibition of CYP3A4 in human liver microsome	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL193	=	=	IC50	nM	11000.0	IC50	nM	11000.0
Inhibition of human CYP3A4	CC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682888	=	=	IC50	nM	1400.0	IC50	nM	1400.0
Inhibition of human CYP3A4	COC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682891	=	=	IC50	nM	1400.0	IC50	nM	1400.0
Inhibition of human CYP3A4	CCCNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682895	=	=	IC50	nM	3400.0	IC50	nM	3400.0
Inhibition of human CYP3A4	CNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682893	=	=	IC50	nM	3600.0	IC50	nM	3600.0
Inhibition of human CYP3A4	CNC(=O)c1cc2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2cc1C	Bioorg. Med. Chem.	2011.0	CHEMBL1682899	=	=	IC50	nM	3600.0	IC50	nM	3600.0
Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2cc(C(N)=O)ccc2c1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682892	=	=	IC50	nM	3700.0	IC50	nM	3700.0
Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2cc3c(cc2c1)CN(C)C3=O)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682903	=	=	IC50	nM	5400.0	IC50	nM	5400.0
Inhibition of human CYP3A4	CCNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682894	=	=	IC50	nM	5700.0	IC50	nM	5700.0
Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682900	=	=	IC50	nM	6700.0	IC50	nM	6700.0
Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682900	=	=	IC50	nM	7400.0	IC50	nM	7400.0
Inhibition of human CYP3A4	CC(C)NC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682896	=	=	IC50	nM	9300.0	IC50	nM	9300.0
Inhibition of human CYP3A4	COc1ccc2cc([C@](O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682887	<	<	IC50	nM	1000.0	IC50	nM	1000.0
Inhibition of human CYP3A4	CC(=O)Nc1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682889	<	<	IC50	nM	1000.0	IC50	nM	1000.0
Inhibition of human CYP3A4	CNC(=O)Nc1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682890	<	<	IC50	nM	1000.0	IC50	nM	1000.0
Inhibition of human CYP3A4	CNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1Cl	Bioorg. Med. Chem.	2011.0	CHEMBL1682897	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4	CNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1C	Bioorg. Med. Chem.	2011.0	CHEMBL1682898	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682901	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2cc3c(cc2c1)CNC3=O)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682902	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4	CC(C)C(O)(c1ccc2c3c(ccc2c1)C(=O)NC3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682900	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4	CC(C)[C@](O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682904	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4	CC(C)[C@@](O)(c1ccc2c3c(ccc2c1)C(=O)N(C)C3)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1682905	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4	C[C@@H](C[C@@H](CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683443	=	=	IC50	nM	1.4	IC50	nM	1.4
Inhibition of CYP3A4	C[C@@H](C[C@@H](CS(=O)(=O)N1CCC(OCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c1ncc(F)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683444	<	<	IC50	nM	0.1	IC50	nM	0.1
Inhibition of CYP3A4	C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O)c1ncc(F)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683445	>	>	IC50	nM	10.0	IC50	nM	10.0
Inhibition of CYP3A4	C[C@@H](C[C@@](C)(CS(=O)(=O)N1CCC(OCc2ccc(Cl)cc2Cl)CC1)N(O)C=O)c1ncc(F)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1615186	>	>	IC50	nM	10.0	IC50	nM	10.0
Inhibition of CYP3A4	C[C@H]1CN(c2ncc(C(=O)NCc3ccc(F)c(F)c3)cc2Cl)CCN1C1CCN(Cc2ccc(Cl)cc2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1681849	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CNC(C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1684057	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CC(N(C)C)C1(c2ccc(Cl)c(Cl)c2)CCCCC1.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1684058	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CC(N(C)C)C1(c2ccc3ccccc3c2)CCCCC1.Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1684059	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	N[C@H]1CN(c2ncnc(N3CCC(F)(F)C3)n2)C[C@@H]1N1CC(F)(F)CCC1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683571	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4	Cc1c(C(=O)Nc2ccn(C)n2)ncn1Cc1cccc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683577	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1614766	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	Cc1cccc(C)c1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1682999	=	=	IC50	nM	7300.0	IC50	uM	7.3
Inhibition of CYP3A4	Cc1ccccc1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683000	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsome measured after 30 mins preincubation in presence of NADPH	Cc1cccc(C)c1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1682999	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4 in human liver microsome measured after 30 mins preincubation in presence of NADPH	Cc1ccccc1-c1nc2ccc(C(=O)Nc3ccc4ccccc4n3)cc2[nH]1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683000	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)ccn3)CC2)(C(C)C)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1683074	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CCO[C@@H]1Cc2cc(C(F)(F)F)ccc2[C@H]1N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C	ACS Med. Chem. Lett.	2010.0	CHEMBL1688243	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3F)c3c(N)ncnn32)C1	ACS Med. Chem. Lett.	2010.0	CHEMBL1667935	>	>	IC50	nM	25000.0	IC50	uM	25.0
Mechanism based inhibition of human cytochrome P450 3A4	C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CCC(O)C(C)(C)O	Curr. Drug Metab.	2005.0	CHEMBL513494	=	=	Ki	nM	59000.0	KI	uM	59.0
Mechanism based inhibition of human cytochrome P450 3A4	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Curr. Drug Metab.	2005.0	CHEMBL163	=	=	Ki	nM	100.0	KI	uM	0.1
Mechanism based inhibition of human cytochrome P450 3A4	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Curr. Drug Metab.	2005.0	CHEMBL1741	=	=	Ki	nM	5490.0	KI	uM	5.49
Mechanism based inhibition of human cytochrome P450 3A4	CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC	Curr. Drug Metab.	2005.0	CHEMBL481	=	=	Ki	nM	24000.0	KI	uM	24.0
Mechanism based inhibition of human cytochrome P450 3A4	CCc1c2c(nc3ccc(O)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC	Curr. Drug Metab.	2005.0	CHEMBL837	=	=	Ki	nM	26000.0	KI	uM	26.0
Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	COc1cc(C[C@H]2C(O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC	Curr. Drug Metab.	2005.0	CHEMBL479701	=	=	Ki	nM	82.0	KI	uM	0.082
Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc3c(c2)OCO3)cc(OC)c1OC	Curr. Drug Metab.	2005.0	CHEMBL469916	=	=	Ki	nM	54.0	KI	uM	0.054
Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	OC[C@H](Cc1ccc2c(c1)OCO2)[C@H](CO)Cc1ccc2c(c1)OCO2	Curr. Drug Metab.	2005.0	CHEMBL486597	=	=	Ki	nM	142.0	KI	uM	0.142
Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	O=C1OC[C@H](Cc2ccc3c(c2)OCO3)[C@H]1Cc1ccc2c(c1)OCO2	Curr. Drug Metab.	2005.0	CHEMBL242011	=	=	Ki	nM	373.0	KI	uM	0.373
Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	COc1cc(C[C@H]2C(=O)OC[C@@H]2Cc2ccc3c(c2)OCO3)cc(OC)c1OC	Curr. Drug Metab.	2005.0	CHEMBL471067	=	=	Ki	nM	177.0	KI	uM	0.177
Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	CC1(C)O[C@H]2CC(=O)OC[C@@]23[C@H]1CC(=O)[C@]1(C)[C@@H]3CC[C@@]2(C)[C@H](c3ccoc3)OC(=O)[C@H]3O[C@]321	Curr. Drug Metab.	2005.0	CHEMBL517449	=	=	Ki	nM	23200.0	KI	uM	23.2
Mechanism based inhibition of human cytochrome P450 3A4 measured by (14C)formaldehyde production from (N-methyl-14C)-erythromycin	O=c1c2ccccc2nc2n1CCc1c-2[nH]c2ccccc12	Curr. Drug Metab.	2005.0	CHEMBL85139	=	=	Ki	nM	107700.0	KI	uM	107.7
Mechanism based inhibition of human cytochrome P450 3A4 measured by BFC hydroxylation	COc1cc(C2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3OC2CO)ccc1O	Curr. Drug Metab.	2005.0	CHEMBL9509	=	=	Ki	nM	32000.0	KI	uM	32.0
Mechanism based inhibition of human cytochrome P450 3A4 measured by DBF fluorescence	CC(O)CCC(=O)c1ccoc1	Curr. Drug Metab.	2005.0	CHEMBL1743358	=	=	Ki	nM	20000.0	KI	uM	20.0
Mechanism based inhibition of human cytochrome P450 3A4 measured by N-demethylation of erythromycin	COc1cc2c(c(OC)c1OC)-c1c(cc3c(c1OC)OCO3)C[C@H](C)[C@](C)(O)[C@H]2OC(=O)c1ccccc1	Curr. Drug Metab.	2005.0	CHEMBL404875	=	=	Ki	nM	399.0	KI	uM	0.399
Mechanism based inhibition of human cytochrome P450 3A4 measured by midazolam 1'-hydroxylation	CC/C(=C(\c1ccccc1)c1ccc(OCCN)cc1)c1ccccc1	Curr. Drug Metab.	2005.0	CHEMBL1743350	=	=	Ki	nM	12000.0	KI	uM	12.0
Mechanism based inhibition of human cytochrome P450 3A4 measured by midazolam hydroxylase activity	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Curr. Drug Metab.	2005.0	CHEMBL23	=	=	Ki	nM	2200.0	KI	uM	2.2
Mechanism based inhibition of human cytochrome P450 3A4 measured by nifedipine oxidation, omeprazole 3-hydroxylation and omeprazole sulfoxydation	C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CCC(O)C(C)(C)O	Curr. Drug Metab.	2005.0	CHEMBL513494	=	=	Ki	nM	5560.0	KI	uM	5.56
Mechanism based inhibition of human cytochrome P450 3A4 measured by nifedipine oxidation, omeprazole 3-hydroxylation and omeprazole sulfoxydation	C=C(C)C(CC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12)OC(C)(C)C(O)CC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12	Curr. Drug Metab.	2005.0	CHEMBL1743356	=	=	Ki	nM	310.0	KI	uM	0.31
Mechanism based inhibition of human cytochrome P450 3A4 measured by nifedipine oxidation, omeprazole 3-hydroxylation and omeprazole sulfoxydation	C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CCC(OC(C)(C)C(O)CC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12)C(C)(C)O	Curr. Drug Metab.	2005.0	CHEMBL1743357	=	=	Ki	nM	130.0	KI	uM	0.13
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CC(C)CN(CC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNCc1cccc(F)c1)S(=O)(=O)c1cccc(N)c1	Curr. Drug Metab.	2005.0	CHEMBL1743352	=	=	Ki	nM	240.0	KI	uM	0.24
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cnc3occc3c2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Curr. Drug Metab.	2005.0	CHEMBL2062137	=	=	Ki	nM	7500.0	KI	uM	7.5
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C	Curr. Drug Metab.	2005.0	CHEMBL691	=	=	Ki	nM	18000.0	KI	uM	18.0
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C	Curr. Drug Metab.	2005.0	CHEMBL1276308	=	=	Ki	nM	4700.0	KI	uM	4.7
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	C=C(C)N1c2ccccc2SC1c1cc(OC)ccc1OCCCN(C)CCOc1ccc2c(c1)OCO2	Curr. Drug Metab.	2005.0	CHEMBL1743364	=	=	Ki	nM	250.0	KI	uM	0.25
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CNCCCC(C#N)(c1ccc(OC)c(OC)c1)C(C)C	Curr. Drug Metab.	2005.0	CHEMBL1743342	=	=	Ki	nM	7930.0	KI	uM	7.93
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Curr. Drug Metab.	2005.0	CHEMBL23	=	=	Ki	nM	500.0	KI	uM	0.5
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1	Curr. Drug Metab.	2005.0	CHEMBL165	=	=	Ki	nM	20000.0	KI	uM	20.0
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	Curr. Drug Metab.	2005.0	CHEMBL83	=	=	Ki	nM	200.0	KI	uM	0.2
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	CC/C(=C(\c1ccccc1)c1ccc(OCCN)cc1)c1ccccc1	Curr. Drug Metab.	2005.0	CHEMBL1743350	=	=	Ki	nM	2600.0	KI	uM	2.6
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl	Curr. Drug Metab.	2005.0	CHEMBL139	=	=	Ki	nM	1640000.0	KI	uM	1640.0
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12	Curr. Drug Metab.	2005.0	CHEMBL81	=	=	Ki	nM	9900.0	KI	uM	9.9
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation	COc1cc(C2Oc3cc([C@H]4Oc5cc(O)cc(O)c5C(=O)[C@@H]4O)ccc3OC2CO)ccc1O	Curr. Drug Metab.	2005.0	CHEMBL9509	=	=	Ki	nM	132000.0	KI	uM	132.0
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation and erythromycin N-demethylation	CC(C)=CCC/C(C)=C/COc1c2ccoc2cc2oc(=O)ccc12	Curr. Drug Metab.	2005.0	CHEMBL1078442	=	=	Ki	nM	7700.0	KI	uM	7.7
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using human liver microsomes	COc1ccc(CCNCCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL1298	=	=	Ki	nM	2110.0	KI	uM	2.11
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using human liver microsomes	COc1ccc(CCN(C)CCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL197	=	=	Ki	nM	5100.0	KI	uM	5.1
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using human liver microsomes	COc1ccc(CCN(C)CCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL36148	=	=	Ki	nM	1390.0	KI	uM	1.39
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using a recombinant system	COc1ccc(CCNCCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL1298	=	=	Ki	nM	5890.0	KI	uM	5.89
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using a recombinant system	COc1ccc(CCN(C)CCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL197	=	=	Ki	nM	6460.0	KI	uM	6.46
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using a recombinant system	COc1ccc(CCN(C)CCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL36148	=	=	Ki	nM	2970.0	KI	uM	2.97
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone beta-hydroxylation	COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2cc3c(cc2CCN1C)OCO3	Curr. Drug Metab.	2005.0	CHEMBL1256919	=	=	Ki	nM	110000.0	KI	uM	110.0
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	Curr. Drug Metab.	2005.0	CHEMBL116	=	=	Ki	nM	260.0	KI	uM	0.26
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O	Curr. Drug Metab.	2005.0	CHEMBL115	=	=	Ki	nM	480.0	KI	uM	0.48
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O	Curr. Drug Metab.	2005.0	CHEMBL729	=	=	Ki	nM	410.0	KI	uM	0.41
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O	Curr. Drug Metab.	2005.0	CHEMBL729	=	=	Ki	nM	1000.0	KI	uM	1.0
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	Curr. Drug Metab.	2005.0	CHEMBL584	=	=	Ki	nM	480.0	KI	uM	0.48
Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone hydroxylation	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	Curr. Drug Metab.	2005.0	CHEMBL114	=	=	Ki	nM	170.0	KI	uM	0.17
Mechanism based inhibition of human cytochrome P450 3A4 using expressed CYP3A4 cDNA	COc1ccc(CCNCCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Curr. Drug Metab.	2005.0	CHEMBL1298	=	=	Ki	nM	10300.0	KI	uM	10.3
Mechanism based inhibition of human cytochrome P450 3A4 was evaluated using S-mephenytoin	NNC(=O)c1ccncc1	Curr. Drug Metab.	2005.0	CHEMBL64	=	=	Ki	nM	36000.0	KI	uM	36.0
Inhibition of CYP3A4	Cn1c(-c2ccc(-c3cnccn3)cc2)nnc1C1(c2ccc(Cl)cc2)CCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760794	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cn1c(-c2ccc(-c3cnccn3)cc2Cl)nnc1C1(c2ccc(Cl)cc2)CC(F)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760809	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of CYP3A4	C[C@H]1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1Cc1ccnc2ccccc12	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1738841	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)CN3CCS(=O)(=O)CC3)CC2)no1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1762427	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)C3CCOCC3)CC2)no1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1762293	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 using fluorescent probe 7-benzyloxyquinoline and 7-benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)(C)c1cc(NC(=O)N2CCCN(C(=O)N3CCS(=O)(=O)CC3)CC2)no1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1762429	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as a substrate	CC(C)N(CCO)Cc1csc(-c2cn(CC3CCOCC3)c3c(Cl)cccc23)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1762808	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 using dibenzylfluorescein as a substrate	CC(C)N(CCO)Cc1csc(-c2cn(CC3CCOCC3)c3c(Cl)cccc23)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1762808	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CCCCN(c1cccc(-c2ccc(OC(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760005	<	>	IC50	nM	3162.28	pIC50		5.5
Inhibition of CYP3A4	CCCCN(c1cccc(-c2ccc(C(F)(F)F)cc2)c1Cl)S(=O)(=O)c1ccc(OC(C)C(=O)O)c(C)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760428	<	>	IC50	nM	3162.28	pIC50		5.5
Inhibition of CYP3A4	COc1ccccc1N1CCN(C(=O)c2cc(-c3ccccc3)n[nH]2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760200	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4	COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n[nH]2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760338	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4	COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)nn2C)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760205	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	COc1ccccc1N1CCN(C(=O)c2cc(-c3ccc(Cl)cc3)n(C)n2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1760206	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CC[C@H](NC(=O)c1c(O)c(-c2ccccc2)nc2ccccc12)c1ccccc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL10188	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4	CC(=O)N(C)C1(c2ccccc2)CCN(CCC[C@]2(c3ccc(Cl)c(Cl)c3)CCCN(C(=O)c3ccccc3)C2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL346178	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	CCN(C(C)=O)c1ccc(OC)c2nc(NC(=O)c3ccnn3C)sc12	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1170367	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC#N)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761518	=	=	IC50	nM	19600.0	IC50	uM	19.6
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761519	=	=	IC50	nM	21600.0	IC50	uM	21.6
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCN(C)C)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761520	=	=	IC50	nM	22700.0	IC50	uM	22.7
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCNS(C)(=O)=O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761521	=	=	IC50	nM	27600.0	IC50	uM	27.6
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	CCNC(=O)NCCCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761522	=	=	IC50	nM	6300.0	IC50	uM	6.3
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761523	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	CCOC(=O)[C@H]1C[C@@H]1COc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761524	=	=	IC50	nM	19300.0	IC50	uM	19.3
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761525	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC(=O)O)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761530	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761531	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761532	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761533	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	CCC(CC)(CCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1)C(=O)O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761534	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC2(C(=O)O)CCCC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761535	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC[C@](C)(OC)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761536	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)NS(C)(=O)=O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761673	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(Cc3nn[nH]n3)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761674	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC#N)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761518	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761519	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCN(C)C)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761520	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCNS(C)(=O)=O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761521	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	CCNC(=O)NCCCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761522	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761523	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	CCOC(=O)[C@H]1C[C@@H]1COc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761524	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761525	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(CC(=O)O)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761530	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761531	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761532	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCCC(C)(C)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761533	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	CCC(CC)(CCOc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)c1)C(=O)O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761534	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCCC2(C(=O)O)CCCC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761535	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC[C@](C)(OC)C(=O)O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761536	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OC[C@H]2C[C@@H]2C(=O)NS(C)(=O)=O)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761673	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccc(OCCOc3c(Cl)cc(C)cc3Cl)cc2)C2CC2)cc(OCC2(Cc3nn[nH]n3)CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761674	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC1COc2ccccc2N1C(=O)N1CCC(c2c[nH]cn2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761843	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	O=C(N1CCC(c2c[nH]cn2)CC1)N1CCCc2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761844	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	O=C(N1CCC(c2cn[nH]c2)CC1)N1CCCc2ccccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761848	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cn1cc(C2CCN(C(=O)N3CCCc4ccccc43)CC2)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1761849	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus-infected insect microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL157101	=	=	IC50	nM	57.0	IC50	nM	57.0
Inhibition of CYP3A4 in human liver microsomes	COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1	J. Med. Chem.	2011.0	CHEMBL1766005	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 in human liver microsomes	C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C	J. Med. Chem.	2011.0	CHEMBL517438	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1cccc(-c2ccccc2)c1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766169	=	=	IC50	nM	1200.0	IC50	nM	1200.0
Inhibition of human CYP3A4 after 30 mins	COc1ccc(-c2cccc(C(O)(c3c[nH]cn3)C(C)C)c2)cc1	Bioorg. Med. Chem.	2011.0	CHEMBL1765101	=	=	IC50	nM	2000.0	IC50	nM	2000.0
Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1cccc(-c2ccc(F)cc2)c1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766170	=	=	IC50	nM	2100.0	IC50	nM	2100.0
Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1cccc(-c2ccc(Cl)cc2)c1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766171	=	=	IC50	nM	2400.0	IC50	nM	2400.0
Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1ccc(-c2ccccc2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766172	=	=	IC50	nM	3700.0	IC50	nM	3700.0
Inhibition of human CYP3A4 after 30 mins	COc1ccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)cc1	Bioorg. Med. Chem.	2011.0	CHEMBL1766173	=	=	IC50	nM	4900.0	IC50	nM	4900.0
Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1ccc(-c2ccc(F)cc2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766174	=	=	IC50	nM	5300.0	IC50	nM	5300.0
Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1ccc(-c2ccc(Cl)cc2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766175	=	=	IC50	nM	7600.0	IC50	nM	7600.0
Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766176	=	=	IC50	nM	7100.0	IC50	nM	7100.0
Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1ccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)cc1	Bioorg. Med. Chem.	2011.0	CHEMBL1766177	=	=	IC50	nM	1000.0	IC50	nM	1000.0
Inhibition of human CYP3A4 after 30 mins	CNC(=O)c1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766178	=	=	IC50	nM	8100.0	IC50	nM	8100.0
Inhibition of human CYP3A4 after 30 mins	CNS(=O)(=O)c1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766179	=	=	IC50	nM	3300.0	IC50	nM	3300.0
Inhibition of human CYP3A4 after 30 mins	CNC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766180	=	=	IC50	nM	5500.0	IC50	nM	5500.0
Inhibition of human CYP3A4 after 30 mins	CC(C)C(O)(c1ccc(-c2ccccn2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766181	=	=	IC50	nM	5200.0	IC50	nM	5200.0
Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1766182	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc(C(C)(O)c3c[nH]cn3)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766183	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4 after 30 mins	CCC(O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766184	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc(C(O)(c3c[nH]cn3)C3CC3)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766185	=	=	IC50	nM	5500.0	IC50	nM	5500.0
Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc(C(O)c3c[nH]cn3)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766186	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc([C@](O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766187	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc([C@@](O)(c3c[nH]cn3)C(C)C)cc2)c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766188	=	=	IC50	nM	6700.0	IC50	nM	6700.0
Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc([C@](O)(c3c[nH]cn3)C(C)C)cc2)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1766189	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4 after 30 mins	CC(=O)Nc1cccc(-c2ccc([C@@](O)(c3c[nH]cn3)C(C)C)cc2)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1766190	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4 after 30 mins	CC[C@](O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766191	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4 after 30 mins	CC[C@@](O)(c1ccc(-c2cccc(NC(C)=O)c2)cc1)c1c[nH]cn1	Bioorg. Med. Chem.	2011.0	CHEMBL1766192	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human CYP3A4 after 30 mins	COc1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1766193	<	<	IC50	nM	1000.0	IC50	nM	1000.0
Inhibition of CYP3A4	Nc1ncc(-c2ccccc2)nc1C(=O)Nc1ccccc1	J. Med. Chem.	2011.0	CHEMBL1766759	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	Nc1ncc(-c2cccnc2)nc1C(=O)Nc1ccccc1	J. Med. Chem.	2011.0	CHEMBL1765107	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	O=C(Nc1ccc(C2CCN(C(=O)[C@H]3CC[C@H](C(=O)O)CC3)CC2)cc1)c1nc(-c2ccccc2)oc1C(F)(F)F	J. Med. Chem.	2011.0	CHEMBL1766811	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21	J. Med. Chem.	2011.0	CHEMBL1230122	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC(CCO)CCO)nc21	J. Med. Chem.	2011.0	CHEMBL1090089	>	>	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4 in human liver microsomes	O=C1CC(=O)N(CCc2ccccc2)C(=O)N1CCc1ccccc1	J. Med. Chem.	2011.0	CHEMBL1412368	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1	J. Med. Chem.	2011.0	CHEMBL1767164	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4	c1ccc(Cc2ncc3c(n2)CCNCC3)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1770373	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)n1)CN(C(=O)NC13CC(C1)C3)C2	J. Med. Chem.	2011.0	CHEMBL1774924	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)n1)CN(C(=O)NCC(F)(F)F)C2	J. Med. Chem.	2011.0	CHEMBL1774926	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC(F)(F)CNC(=O)N1Cc2nc(N)nc(-c3c(Cl)cc(Cl)cc3OCCn3cccn3)c2C1	J. Med. Chem.	2011.0	CHEMBL1738805	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Nc1nc2c(c(-c3c(Cl)cc(Cl)cc3OCCn3cc(F)cn3)n1)CN(C(=O)NCC(F)(F)F)C2	J. Med. Chem.	2011.0	CHEMBL1774930	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(F)(F)F)C2	J. Med. Chem.	2011.0	CHEMBL1774931	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC(F)(F)CNC(=O)N1Cc2nc(N)nc(-c3c(Cl)cc(Cl)cc3OCCn3cc(F)cn3)c2C1	J. Med. Chem.	2011.0	CHEMBL1774932	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of human CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(C)(F)F)C2	J. Med. Chem.	2011.0	CHEMBL1774933	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4	Cc1cc(Cl)cc(OCCn2cc(F)cn2)c1-c1nc(N)nc2c1CN(C(=O)NCC(C)(F)F)C2	J. Med. Chem.	2011.0	CHEMBL1774933	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cn1c(-c2ccoc2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778587	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of CYP3A4	Cn1c(-c2ccccn2)c(C2CCCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778481	=	=	IC50	nM	8900.0	IC50	uM	8.9
Inhibition of human CYP3A4	COC[C@H](O)Cn1c(=O)cnn(-c2ccc(Cl)c(C(=O)NCC3(O)CCCCCC3)c2)c1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1823817	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	COc1ccc(CN2CCN(C(=O)C[C@H](N)Cc3cc(F)c(F)cc3F)CC2=O)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1779699	=	=	IC50	nM	1075.0	IC50	nM	1075.0
Inhibition of CYP3A4	Cc1c(Nc2ccc(C#N)cc2Cl)ncnc1O[C@@H]1C[C@@H]2CC[C@H](C1)N2S(=O)(=O)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL3084389	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777861	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC#CC(CC(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1F	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777855	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC#C[C@@H](c1ccc(Oc2ccc(C(F)(F)F)cc2OC(F)F)cc1)[C@H]1OC(=O)NC1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777878	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 preincubated for 30 mins	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CN4CCCCC4)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777958	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 preincubated for 30 mins	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNC(C)(C)C)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777976	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 preincubated for 30 mins	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNCC(C)(C)C)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777979	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CN4CCCCC4)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777958	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNC(C)(C)C)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777976	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cc1ccc(S(=O)(=O)N2CCNC(=O)[C@H]2CC(=O)N[C@@H]2CCCc3cc(CNCC(C)(C)C)ccc32)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1777979	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL561132	=	=	IC50	nM	34000.0	IC50	uM	34.0
Inhibition of CYP3A4	C[C@@H](C(=O)N(C)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)c1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778387	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CN(C(=O)C1(c2ccc(F)cc2)CCCC1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778388	=	=	IC50	nM	37000.0	IC50	uM	37.0
Inhibition of CYP3A4	CN(C(=O)Cc1ccc(F)cc1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778506	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CN(C(=O)C1(c2ccc(F)cc2)CCC1)[C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778524	>	>	IC50	nM	50000.0	IC50	uM	50.0
Iinhibition of CYP3A4	COc1cc(F)ccc1-c1cncc(CNC2CCCC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1779003	>	>	IC50	nM	20000.0	IC50	uM	20.0
Iinhibition of CYP3A4	COc1cc(F)ccc1-c1cncc(CNCC2CC2)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778865	>	>	IC50	nM	20000.0	IC50	uM	20.0
Iinhibition of CYP3A4	COc1cc(F)ccc1-c1cncc(CNC(=O)c2cnccn2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1779012	>	>	IC50	nM	20000.0	IC50	uM	20.0
Iinhibition of CYP3A4	COc1cc(F)ccc1-c1cncc(CNC(=O)c2ccccn2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1779013	>	>	IC50	nM	20000.0	IC50	uM	20.0
Iinhibition of CYP3A4	C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL17350	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc(-c2cc(C(F)(F)F)ccc2OCC(=O)O)c(C)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1778639	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCN(C(=O)C3CCC3)CC2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784345	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCC(F)(F)CC2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784346	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCS(=O)(=O)CC2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784347	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCOC(C)(C)C2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784350	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1noc(C)c1CCC1CCN(S(=O)(=O)CC2(N(O)C=O)CCN(C)CC2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784351	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784368	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	CC(C)(CS(=O)(=O)N1CCN(c2ccc(F)cc2)CC1)N(O)C=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784354	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=CN(O)C1(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)CCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784355	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4	CN1CCC(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)(N(O)C=O)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784356	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=CN(O)C1(CS(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)CCOCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1784357	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCc1c(C)nc(-c2ccc(F)s2)nc1Nc1ccc(CC(=O)O)cc1F	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1782308	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCc1c(C)nc(-c2ccc(Cl)s2)nc1Nc1ccc(CC(=O)O)cc1	Bioorg. Med. Chem. Lett.	2009.0	CHEMBL1782306	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	O=C(O)c1cc2cc(Br)cc(NCC3CCNCC3)c2o1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1782521	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	N[C@H]1CC[C@@H](Nc2cc(Br)cc3cc(C(=O)O)oc23)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1782530	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	N[C@H]1CC[C@H](Nc2cc(Br)cc3cc(C(=O)O)oc23)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1782531	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in Escherichia coli by fluorimetric assay	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cn1	J. Med. Chem.	2009.0	CHEMBL1232887	<	>	IC50	nM	100000.0	pIC50		4.0
Inhibition of human CYP3A4 expressed in Escherichia coli by fluorimetric assay	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cn1	J. Med. Chem.	2009.0	CHEMBL1784172	<	>	IC50	nM	63095.73	pIC50		4.2
Inhibition of human CYP3A4 expressed in Escherichia coli by fluorimetric assay	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1	J. Med. Chem.	2009.0	CHEMBL1088752	<=	>=	IC50	nM	79432.82	pIC50		4.1
Inhibition of CYP3A4	O=C(NCc1ccncc1)c1ccc(Oc2ccc(C#CC3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796296	>	<	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796298	<	>	IC50	nM	10000.0	pIC50		5.0
Time dependent inhibition of CYP3A4	O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796298	<	>	IC50	nM	50118.72	pIC50		4.3
Reversible inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796063	=	=	IC50	nM	6500.0	IC50	nM	6500.0
Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone preincubated for 30 mins	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796063	=	=	IC50	nM	16000.0	IC50	nM	16000.0
Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@H]2c2ccn(C)c(=O)c2)C2CC2)cc(Br)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1796063	=	=	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of human CYP3A4	O=c1cc(Cn2c(C3CC(F)(F)C3)nc3nccnc32)c2cccc(F)c2[nH]1	J. Med. Chem.	2010.0	CHEMBL1801062	=	=	EC50	nM	23000.0	EC50	uM	23.0
Inhibition of human CYP3A4	O=c1cc(Cn2c(C3CCC3)nc3nccnc32)c2ccc(F)c(F)c2[nH]1	J. Med. Chem.	2010.0	CHEMBL1801504	>	>	EC50	nM	100000.0	EC50	uM	100.0
Inhibition of human CYP3A4	CC(C)Cc1nc2nccnc2n1Cc1cc(=O)[nH]c2c(F)c(F)ccc12	J. Med. Chem.	2010.0	CHEMBL1801506	>	>	EC50	nM	60000.0	EC50	uM	60.0
Inhibition of human CYP3A4	O=c1cc(Cn2c(C3CCC3)nc3nccnc32)c2cccc(F)c2[nH]1	J. Med. Chem.	2010.0	CHEMBL1801060	>	>	EC50	nM	60000.0	EC50	uM	60.0
Inhibition of CYP3A4	O=C(NO)c1cnc(N2C[C@H]3[C@H](NCc4ccc5cc(F)ccc5n4)[C@H]3C2)nc1	J. Med. Chem.	2010.0	CHEMBL1801250	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NO)c1cnc(N2C[C@H]3[C@H](NCc4ccc(Cl)cc4)[C@H]3C2)nc1	J. Med. Chem.	2010.0	CHEMBL1801238	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(NO)c1cnc(N2C[C@H]3[C@H](NCc4ccc5ccccc5c4)[C@H]3C2)nc1	J. Med. Chem.	2010.0	CHEMBL1801233	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(NO)c1cnc(N2C[C@H]3[C@H](NS(=O)(=O)c4ccc5ccccc5c4)[C@H]3C2)nc1	J. Med. Chem.	2010.0	CHEMBL1801172	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1	J. Med. Chem.	2011.0	CHEMBL1822792	=	=	IC50	nM	7100.0	IC50	uM	7.1
Inhibition of CYP3A4	CS(=O)(=O)Nc1ccc2ccc3ncc(-c4ccccc4)cc3c(=O)c2c1	J. Med. Chem.	2011.0	CHEMBL1803004	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 using diethoxyflourescein as a substrate	Cc1nc(-c2ccc(F)cc2F)n(C)c1CC(=O)NCc1ccc(F)cc1Cl.Cl	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1801364	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of CYP3A4	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2c(c1)NC(=O)C21CCCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1800911	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP 3A4	CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)c(F)c2)C1	J. Med. Chem.	2011.0	CHEMBL1800774	>	>	IC50	nM	8900.0	IC50	uM	8.9
Inhibition of CYP 3A4	CC(C)(N)C(=O)N1CCn2c(nc(-c3ccc(F)cc3)c2Nc2ccc(F)cc2)C1	J. Med. Chem.	2011.0	CHEMBL1800137	>	>	IC50	nM	8900.0	IC50	uM	8.9
Inhibition of CYP 3A4	NCC(=O)N1CCn2c(nc(-c3ccccc3)c2Nc2ccc3c(c2)OCO3)C1	J. Med. Chem.	2011.0	CHEMBL601821	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN1CC(Cl)=C(c2cn(S(=O)(=O)c3ccccc3)c3ccccc23)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808424	=	=	IC50	nM	14700.0	IC50	uM	14.7
Inhibition of CYP3A4	Cc1ccc(NC(=O)c2cc(F)cc(N3CCOCC3)c2)cc1Nc1ncnn2cc(C(=O)c3ccccc3)c(C)c12	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1807440	=	=	IC50	nM	470.0	IC50	nM	470.0
Inhibition of CYP3A4	O=C(CCCCCCC(=O)Nc1ccccc1)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL98	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL408513	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL27759	=	=	IC50	nM	730.0	IC50	uM	0.73
Inhibition of CYP3A4	Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cccnc3)n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL272980	=	=	IC50	nM	570.0	IC50	uM	0.57
Inhibition of CYP3A4	O=C(/C=C/c1ccc(CN(CCO)CCc2c[nH]c3ccccc23)cc1)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL356066	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4	O=C(/C=C/c1ccc2c(c1)CN(C(=O)Cc1ccccc1)C2)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808624	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(/C=C/c1ccc2c(c1)CN(S(=O)(=O)c1cccs1)C2)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808631	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1ccc(S(=O)(=O)N2Cc3ccc(/C=C/C(=O)NO)cc3C2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808640	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(/C=C/c1ccc2c(c1)CN(CCC1CCCCC1)C2)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808643	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(/C=C/c1ccc2c(c1)CN(CCc1c[nH]c3ccccc13)C2)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808644	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(/C=C/c1ccc2c(c1)CN(CCc1cnn3ccccc13)C2)NO	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1808645	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1[nH]c2ccccc2c1CCN1Cc2ccc(/C=C/C(=O)NO)cc2C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1088949	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCCCN1C(=O)C(C(C)C)NC(=O)C12CCN(Cc1ccc(Oc3ccccc3)cc1)CC2.Cl	Bioorg. Med. Chem.	2011.0	CHEMBL1813459	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813314	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813315	=	=	IC50	nM	5280.0	IC50	uM	5.28
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Clc1ccc([C@]23CCCC[C@H]2CNC3)cc1Cl	J. Med. Chem.	2011.0	CHEMBL1813471	=	=	IC50	nM	8390.0	IC50	uM	8.39
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Clc1ccc([C@@]23CCCC[C@@H]2CNC3)cc1Cl	J. Med. Chem.	2011.0	CHEMBL1813472	=	=	IC50	nM	12800.0	IC50	uM	12.8
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCN1C[C@H]2CCCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813316	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCN1C[C@@H]2CCCC[C@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813317	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CN1C[C@@H]2CCC[C@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813478	=	=	IC50	nM	12700.0	IC50	uM	12.7
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CN1C[C@H]2CCC[C@@]2(c2ccc(Cl)c(Cl)c2)C1	J. Med. Chem.	2011.0	CHEMBL1813484	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Clc1ccc([C@]23CCC[C@H]2CNC3)cc1Cl	J. Med. Chem.	2011.0	CHEMBL1813474	=	=	IC50	nM	9170.0	IC50	uM	9.17
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Clc1ccc([C@@]23CCC[C@@H]2CNC3)cc1Cl	J. Med. Chem.	2011.0	CHEMBL1813475	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	c1ccc2cc([C@]34CCC[C@H]3CNC4)ccc2c1	J. Med. Chem.	2011.0	CHEMBL1813476	=	=	IC50	nM	2650.0	IC50	uM	2.65
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	c1ccc2cc([C@@]34CCC[C@@H]3CNC4)ccc2c1	J. Med. Chem.	2011.0	CHEMBL1813477	=	=	IC50	nM	10700.0	IC50	uM	10.7
Inhibition of CYP3A4	COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(C)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090176	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(F)ccc21	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1090526	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL1092662	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL556506	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	C[C@@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12	Bioorg. Med. Chem. Lett.	2010.0	CHEMBL564144	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1.Cl	J. Med. Chem.	2011.0	CHEMBL1813067	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@]12CN(C(=O)Nc3ccnn3-c3ccccc3)CCN1C(=O)N([C@H]1C[C@@H]1c1ccccc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1813114	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CNC(=O)c2cc(-c3cccc(CN)c3)nc3ccccc23)CC1	Bioorg. Med. Chem.	2011.0	CHEMBL1818291	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay	Cc1csc(C23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1818445	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay	Cc1ccn(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1818451	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay	Cc1ccnn1CC12CNCC[C@]1(c1ccc(Cl)c(Cl)c1)C2	Bioorg. Med. Chem.	2011.0	CHEMBL1818452	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay	Cc1cc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1818455	>	>	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human CYP3A4 incubated for 10 mins before substrate addition by fluorescence assay	Cc1nc(C)n(CC23CNCC[C@]2(c2ccc(Cl)c(Cl)c2)C3)n1	Bioorg. Med. Chem.	2011.0	CHEMBL1818543	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes pre-incubated for 15 mins by LC/MS/MS analysis	Cl.Cn1c(=O)c2c(cc(N3CCC[C@@H](N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O	Bioorg. Med. Chem.	2011.0	CHEMBL1819089	=	=	Ki	nM	0.026	Ki	nM	0.026
Inhibition of CYP3A4 in human liver microsomes pre-incubated for 15 mins by LC/MS/MS analysis	CC[C@@]1(N)CCCN(c2cc3c(c(=O)n(C)c(=O)n3C)n2Cc2cc(F)ccc2C#N)C1	Bioorg. Med. Chem.	2011.0	CHEMBL1819091	=	=	Ki	nM	0.022	Ki	nM	0.022
Inhibition of CYP3A4	Cn1c(=O)c2c(cc(N3CCC[C@@](C)(N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O	Bioorg. Med. Chem.	2011.0	CHEMBL1819090	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cl.Cn1c(=O)c2c(cc(N3CCC[C@@H](N)C3)n2Cc2cc(F)ccc2C#N)n(C)c1=O	Bioorg. Med. Chem.	2011.0	CHEMBL1819089	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxy-4(trifluoromethyl)-coumarin	CS(=O)(=O)N(CCN1CCOCC1)c1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1825089	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxyquinoline	CS(=O)(=O)N(CCN1CCOCC1)c1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1825089	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxy-4(trifluoromethyl)-coumarin	CS(=O)(=O)Nc1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1825096	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using a fluorescent probe 7-benzyloxyquinoline	CS(=O)(=O)Nc1ccc(Nc2ncc3cnn(C4CCCCCC4)c3n2)cn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1825096	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using DEF substrate	CC[C@@H](NC(=O)c1ccc2c(c1)ncn2Cc1ncc(F)cc1F)c1ccccc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1821837	=	=	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	CC[C@@H](NC(=O)c1ccc2c(c1)ncn2Cc1ncc(F)cc1F)c1ccccc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1821837	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human recombinant CYP3A4 by luceferin-based assay	Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2C)CC1.Cl.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3217170	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 by luceferin-based assay	Cc1c(Cl)cccc1N1CCN(CCCNC(=O)c2nc(-c3ccccc3)n(-c3ccccc3)c2Cn2cncn2)CC1.Cl.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3215850	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 by luceferin-based assay	Cc1cccc(N2CCN(CCCNC(=O)c3nc(C)n(-c4ccc5c(c4)OCCO5)c3C)CC2)c1C.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3215864	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	Cn1nc(-c2ccc(C(=O)N3CCC[C@H]3CN3CCCC3)cc2)ccc1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1823410	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	O=C(Nc1ccccc1Cl)N1CCN(c2nc(-c3ccc4ccccc4n3)no2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1823591	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	COc1ccccc1-c1ccc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nn12	J. Med. Chem.	2011.0	CHEMBL1822515	=	=	IC50	nM	9400.0	IC50	uM	9.4
Inhibition of CYP3A4	CN1CCN(c2ccc(Nc3ncc4ccc(-c5ccccc5N(C)S(C)(=O)=O)n4n3)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL1821735	=	=	IC50	nM	14600.0	IC50	uM	14.6
Inhibition of CYP3A4	COc1cc(N2CCN(C[C@H](C)O)CC2)ccc1Nc1ncc2ccc(-c3ccccc3N(C)S(C)(=O)=O)n2n1	J. Med. Chem.	2011.0	CHEMBL1822525	>	>	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	c1cc([C@H]2CC[C@H](N3CCOCC3)CC2)ccc1OCCCN1CCCCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1824241	=	=	IC50	nM	66200.0	IC50	uM	66.2
Inhibition of CYP3A4	c1cc([C@H]2CC[C@H](N3CCCC3)CC2)ccc1OCCCN1CCCCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1824235	=	=	IC50	nM	48000.0	IC50	uM	48.0
Inhibition of CYP3A4	c1cc([C@H]2CC[C@@H](N3CCCC3)CC2)ccc1OCCCN1CCCCC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1824234	=	=	IC50	nM	41700.0	IC50	uM	41.7
Inhibition of CYP3A4	CN(C)[C@H]1CC[C@H](c2ccc(OCCCN3CCCCC3)cc2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1824231	=	=	IC50	nM	42600.0	IC50	uM	42.6
Inhibition of CYP3A4	CN(C)[C@H]1CC[C@@H](c2ccc(OCCCN3CCCCC3)cc2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1824230	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes	COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1	J. Med. Chem.	2011.0	CHEMBL1766005	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 in human liver microsomes	C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1)N(C)C	J. Med. Chem.	2011.0	CHEMBL517438	=	=	IC50	nM	350.0	IC50	uM	0.35
Inhibition of CYP3A4 in human liver microsomes	COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1cncn1	J. Med. Chem.	2011.0	CHEMBL1831092	=	=	IC50	nM	330.0	IC50	uM	0.33
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(-c3ncccn3)n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1829472	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)n2)cc1F	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1829477	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@H](COc1ccc(-c2ccc(=O)n(C)n2)cc1)CN1CCC[C@H]1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1829485	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829777	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CC(N)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829769	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829764	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829768	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829759	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNS(N)(=O)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829776	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829763	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829761	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829775	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2F)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829765	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829767	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCNS(C)(=O)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829782	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2cccc(F)c2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829766	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCNC(N)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829772	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCNC(N)=O)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829780	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCN)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829770	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	CC[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829762	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	CNC(=O)NCC[C@]1(c2ccc(F)cc2)CCN([C@@H](C)c2ccc(-c3ccc(F)cc3F)cc2)C(=O)O1	J. Med. Chem.	2011.0	CHEMBL1829773	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	CNC(=O)NCCC[C@]1(c2ccc(F)cc2)CCN([C@@H](C)c2ccc(-c3ccc(F)cc3F)cc2)C(=O)O1	J. Med. Chem.	2011.0	CHEMBL1829781	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of human CYP3A4 assessed as rate of [14C]-formaldehyde/formic acid production by liquid scintillation counting	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCN)(c2ccc(F)cc2)OC1=O	J. Med. Chem.	2011.0	CHEMBL1829779	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human recombinant CYP3A4	Cc1ccc(C(=O)N(CCCN)C(c2nc3snc(C)c3c(=O)n2Cc2ccccc2)C(C)C)cc1	J. Med. Chem.	2011.0	CHEMBL1829433	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3215861	=	=	IC50	nM	2730.0	IC50	uM	2.73
Inhibition of CYP3A4 in human liver microsomes by fluorescence assay	CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3215861	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CN(C)CC(C)(C)Cn1c(CC(C)(C)C)nc2cc(/C=C/C(=O)NO)ccc21	J. Med. Chem.	2011.0	CHEMBL1830397	=	=	IC50	nM	2280.0	IC50	uM	2.28
Inhibition of CYP3A4 in human liver microsomes by fluorescence assay	CN(C)CC(C)(C)Cn1c(CC(C)(C)C)nc2cc(/C=C/C(=O)NO)ccc21	J. Med. Chem.	2011.0	CHEMBL1830397	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of recombinant CYP3A4 after 30 mins by fluorescence assay	CCCCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(C)C	J. Med. Chem.	2011.0	CHEMBL1830424	=	=	IC50	nM	330.0	IC50	uM	0.33
Inhibition of CYP3A4 in human liver microsomes by fluorescence assay	CCCCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(C)C	J. Med. Chem.	2011.0	CHEMBL1830424	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CN1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1837037	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	COC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1837038	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CC(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1837040	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CS(=O)(=O)N1Cc2cc(Cl)ccc2-n2c(nnc2C2CCN(c3ccccn3)CC2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1837041	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CS(=O)(=O)NC[C@H]1CC[C@H](Nc2nc3c(s2)CCSc2ccccc2-3)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1836317	=	=	IC50	nM	4100.0	IC50	uM	4.1
Inhibition of CYP 3A4	CCN/C(=N\S(=O)(=O)c1cccc(Cl)c1)N1CC(C)(C)C=N1	J. Med. Chem.	2011.0	CHEMBL1834345	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	Cn1nc(NCC(=O)NC2CN([C@H]3CC[C@@H](c4cncs4)CC3)C2)c2cc(C(F)(F)F)ccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1834793	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of CYP3A4	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C[C@H](O)[C@H](Cc1ccc(-c2cncc(F)c2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	J. Med. Chem.	2011.0	CHEMBL1835487	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of CYP3A4 using vivid red as substrate	Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2	J. Med. Chem.	2011.0	CHEMBL1836215	=	=	IC50	nM	15300.0	IC50	uM	15.3
Inhibition of CYP3A4 using vivid green as substrate	Cc1c(-c2noc(-c3ccc(OC(C)C)c(C#N)c3)n2)ccc2c1CCN(C(CO)CO)C2	J. Med. Chem.	2011.0	CHEMBL1836215	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of CYP3A4 using BFC as substrate	CN1CC=C(c2c[nH]c3cc(NC(=N)c4cccs4)ccc23)CC1.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3142316	=	=	IC50	nM	74800.0	IC50	uM	74.8
Inhibition of CYP3A4 using BFC as substrate	Cl.Cl.N=C(Nc1ccc2c(C3CN4CCC3CC4)c[nH]c2c1)c1cccs1	J. Med. Chem.	2011.0	CHEMBL3142317	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 using BQ as substrate	CN1CC=C(c2c[nH]c3cc(NC(=N)c4cccs4)ccc23)CC1.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3142316	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 using BQ as substrate	Cl.Cl.N=C(Nc1ccc2c(C3CN4CCC3CC4)c[nH]c2c1)c1cccs1	J. Med. Chem.	2011.0	CHEMBL3142317	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1834184	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using DBF as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN(C)C)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834663	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 using DBF as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN4CCN(C)CC4)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834662	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using DBF as substrate	CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL1834661	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 using DBF as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(CCCN(C)C)cc3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834660	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using DBF as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(OCCN4CCCC4)cc3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834659	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 using DBF as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(N4CCN(C)CC4)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834658	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using DBF as substrate	CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O	J. Med. Chem.	2011.0	CHEMBL1834657	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using BFC as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN(C)C)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834663	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 using BFC as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(CN4CCN(C)CC4)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834662	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 using BFC as substrate	CCN1CCC(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1	J. Med. Chem.	2011.0	CHEMBL1834661	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 using BFC as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(CCCN(C)C)cc3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834660	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 using BFC as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3ccc(OCCN4CCCC4)cc3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834659	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using BFC as substrate	COc1cc(OC)c(Cl)c(NC(=O)N(C)c2cc(Nc3cccc(N4CCN(C)CC4)c3)ncn2)c1Cl	J. Med. Chem.	2011.0	CHEMBL1834658	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 using BFC as substrate	CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O	J. Med. Chem.	2011.0	CHEMBL1834657	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	NC(=O)c1cnc(N[C@H](C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3cnc(N)nc3)ccc12	J. Med. Chem.	2011.0	CHEMBL1835153	>	>	IC50	nM	75000.0	IC50	uM	75.0
Inhibition of CYP3A4	CC(C)n1nc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)c2sccc2c1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835772	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2nn(C)c(=O)c3c2CCC3)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835782	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2c(c1=O)CCC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835783	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C2=NN(C)C(=O)C3CCCC23)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835784	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CN1N=C(c2ccc(OCCCN3CCCCC3)cc2)C2CCCC2C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835785	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2nn(C)c(=O)c3c2CCCC3)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835786	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2c(c1=O)CCCC2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835787	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cn1nc(-c2ccc(OCCCN3CCCCC3)cc2)c2ccccc2c1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835706	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835918	<	>	IC50	nM	10000.0	pIC50		5.0
Time dependent inhibition of CYP3A4	Cc1ccc(N2CC(COc3ccc(-c4noc(C)n4)cc3)C2)nn1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1835918	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of CYP3A4	Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL29609	=	=	IC50	nM	6309.57	pIC50		5.2
Time dependent inhibition of CYP3A4	Cc1cc(CCCOc2c(C)cc(-c3noc(C(F)(F)F)n3)cc2C)on1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL29609	<	>	IC50	nM	50118.72	pIC50		4.3
Mechanism based inhibition of human cytochrome P450 CYP3A4 measured by 7BFC O-debenzylation	CC1(C)C=Cc2c(ccc3c2OC[C@@H](c2ccc(O)cc2O)C3)O1	Curr. Drug Metab.	2005.0	CHEMBL480477	=	=	Ki	nM	7000.0	ki	uM	7.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1			CHEMBL1016	=	=	IC50	nM	9000.0	IC50	uM	9.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12			CHEMBL493	=	=	IC50	nM	2000.0	IC50	uM	2.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12			CHEMBL1403281	=	=	IC50	nM	600.0	IC50	uM	0.6
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1			CHEMBL116	=	=	IC50	nM	1000.0	IC50	uM	1.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1.[Cl-]			CHEMBL64894	=	=	IC50	nM	3633.7	IC50	uM	3.6337
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1			CHEMBL808	=	=	IC50	nM	50.0	IC50	uM	0.05
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12			CHEMBL1385840	=	=	IC50	nM	500.0	IC50	uM	0.5
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O			CHEMBL252556	=	=	IC50	nM	7000.0	IC50	uM	7.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21			CHEMBL442	=	=	IC50	nM	1000.0	IC50	uM	1.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC			CHEMBL1729	=	=	IC50	nM	300.0	IC50	uM	0.3
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O			CHEMBL12131	=	=	IC50	nM	5000.0	IC50	uM	5.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O.CS(=O)(=O)O			CHEMBL1255837	=	=	IC50	nM	3000.0	IC50	uM	3.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1			CHEMBL104	=	=	IC50	nM	16.0	IC50	uM	0.016
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21			CHEMBL1732	=	=	IC50	nM	5000.0	IC50	uM	5.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1			CHEMBL23	=	=	IC50	nM	1836.6	IC50	uM	1.8366
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O			CHEMBL3545252	=	=	IC50	nM	2000.0	IC50	uM	2.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	NNCCc1ccccc1			CHEMBL1089	=	=	IC50	nM	2000.0	IC50	uM	2.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC			CHEMBL61	=	=	IC50	nM	600.0	IC50	uM	0.6
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1			CHEMBL1262	=	=	IC50	nM	90.0	IC50	uM	0.09
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C			CHEMBL584	=	=	IC50	nM	2000.0	IC50	uM	2.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	NNc1ccccc1			CHEMBL456807	=	=	IC50	nM	900.0	IC50	uM	0.9
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CNCCCC12CCC(c3ccccc31)c1ccccc12			CHEMBL21731	=	=	IC50	nM	4322.0	IC50	uM	4.322
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O			CHEMBL64391	=	=	IC50	nM	900.0	IC50	uM	0.9
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1			CHEMBL91	=	=	IC50	nM	100.0	IC50	uM	0.1
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS			CHEMBL1221512	=	=	IC50	nM	3000.0	IC50	uM	3.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O			CHEMBL115	=	=	IC50	nM	400.0	IC50	uM	0.4
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1			CHEMBL60889	=	=	IC50	nM	700.0	IC50	uM	0.7
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)(C(=O)c1cccnc1)c1cccnc1			CHEMBL934	=	=	IC50	nM	800.0	IC50	uM	0.8
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1			CHEMBL157101	=	=	IC50	nM	16.0	IC50	uM	0.016
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C			CHEMBL460291	=	=	IC50	nM	900.0	IC50	uM	0.9
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2			CHEMBL553025	=	=	IC50	nM	1000.0	IC50	uM	1.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C			CHEMBL413	=	=	IC50	nM	2000.0	IC50	uM	2.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC			CHEMBL269732	=	=	IC50	nM	1000.0	IC50	uM	1.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1			CHEMBL1221	=	=	IC50	nM	70.0	IC50	uM	0.07
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1			CHEMBL165	=	=	IC50	nM	600.0	IC50	uM	0.6
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	COc1cc(N)[nH]c2nc(-c3ccc(F)cc3)c(-c3ccncc3)c1-2			CHEMBL115769	=	=	IC50	nM	1000.0	IC50	uM	1.0
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1			CHEMBL163	=	=	IC50	nM	16.0	IC50	uM	0.016
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)	CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1			CHEMBL84	=	=	IC50	nM	1521.1	IC50	uM	1.5211
Inhibition of human CYP3A4	Cc1nnc(-c2ccc(C)c(-c3ccc4c(c3)NC(=O)C43CCOCC3)c2)[nH]1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911194	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)NCc1cccnc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910126	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)Nc1ccnn1C)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910125	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCOCC1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910124	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCCC1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910123	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCN(C)CC1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910122	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCN(S(C)(=O)=O)CC1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910121	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 up to 40 uM	CC(=O)N1CCN(C(=O)CN2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910120	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N1CCC(C(N)=O)CC1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910119	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 up to 40 uM	CCN(CC)C(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910118	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)N(C)C)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910117	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 up to 40 uM	CNC(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910116	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 up to 40 uM	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(N)=O)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910115	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN[C@@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911827	=	=	IC50	nM	12000.0	IC50	nM	12000.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN(C)[C@@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911826	=	=	IC50	nM	7200.0	IC50	nM	7200.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN(C)C1CN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911825	=	=	IC50	nM	5400.0	IC50	nM	5400.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCC2(C)CC2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911824	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCC(C)(C)C)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911823	=	=	IC50	nM	12000.0	IC50	nM	12000.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCc2ccnc(Cl)c2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911822	=	=	IC50	nM	11000.0	IC50	nM	11000.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCc2ccncc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911821	=	=	IC50	nM	2000.0	IC50	nM	2000.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	Cc1ncc(COC[C@@H](NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C(=O)N2CCN(C)CC2)o1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911820	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCc2ccc(F)cc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911819	=	=	IC50	nM	6300.0	IC50	nM	6300.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCc2ccc3c(c2)OCCO3)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911818	=	=	IC50	nM	3300.0	IC50	nM	3300.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN[C@H]1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)C1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911828	=	=	IC50	nM	9000.0	IC50	nM	9000.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	O=C(N[C@H](COCc1ccccc1)C(=O)N[C@@H]1CN2CCC1CC2)c1cccnc1Oc1ccc(C(F)(F)F)cc1Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911829	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	O=C(N[C@H](COCc1ccccc1)C(=O)N[C@H]1CN2CCC1CC2)c1cccnc1Oc1ccc(C(F)(F)F)cc1Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911830	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of oxidative metabolism of testosterone after 45 mins by MS analysis in the presence of 1 mmol NADPH	CN1CCN(C(=O)[C@@H](COCc2ccccc2)NC(=O)c2cccnc2Oc2ccc(C(F)(F)F)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1911817	=	=	IC50	nM	13500.0	IC50	nM	13500.0
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909987	=	=	IC50	nM	340.0	IC50	uM	0.34
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin	Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909986	=	=	IC50	nM	730.0	IC50	uM	0.73
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy resorufin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909985	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COCCN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910114	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CCO)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910113	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(CC(=O)O)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910112	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COC(=O)CN1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910111	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(C)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910110	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CNC2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909647	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(C#N)cc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910108	=	=	IC50	nM	670.0	IC50	uM	0.67
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(F)cc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910107	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccc(Cl)cc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909994	=	=	IC50	nM	390.0	IC50	uM	0.39
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1ccc(N2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909992	=	=	IC50	nM	270.0	IC50	uM	0.27
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909991	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909991	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COc1ccccc1N1Cc2c(nc(C)c(CN)c2-c2ccc(Cl)cc2Cl)C1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909991	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	COc1ccc(N2Cc3c(nc(C)c(CN)c3-c3ccc(Cl)cc3Cl)C2=O)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909989	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(c1ccccc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909988	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909987	=	=	IC50	nM	770.0	IC50	uM	0.77
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2cn(Cc3ccccc3)cc2c(-c2ccc(Cl)cc2Cl)c1CN	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909986	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 in presence of the substrate 7-bezyloxy-4-trifluoromethyl coumarin	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)CN(Cc1ccccc1)C2=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909985	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of CYP3A4	COCCCc1cc(CN(C(=O)C2CNCCC2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910294	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4	CN(C)S(=O)(=O)NCCCCCNc1nc(-c2ccccn2)cs1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1909725	>	>	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4	COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3ccnc3)cc2)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1915563	<	<	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4	COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3ccnc3)c(OC)c2)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1915564	<	<	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4	COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3cnc(C)c3)cc2)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1915565	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4	COc1ccc(Br)cc1-c1csc(Nc2ccc(-n3cnc(C)c3)c(OC)c2)n1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1915566	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of human CYP3A4	CN(C)CCN1C(=O)CCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3216770	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	CN(C)CCN1CCCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3216313	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	CN1CCC[C@H]1CCN1CCCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3142403	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	CN1CCC[C@@H]1CCN1CCCc2cc(NC(=N)c3cccs3)ccc21.Cl.Cl	J. Med. Chem.	2011.0	CHEMBL3216112	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	Cl.Cl.N=C(Nc1ccc2c(c1)CCCN2C1CCNCC1)c1cccs1	J. Med. Chem.	2011.0	CHEMBL3217198	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	Cc1ccc(S(=O)(=O)Nc2c(C(=O)N[C@@H](C)C(C)(C)C)c(C)nn2-c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916282	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	Cc1nn(-c2ccc(F)cc2)c(NS(=O)(=O)c2ccc(C#N)cc2)c1C(=O)N[C@@H](C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916288	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	CCOC(=O)N1CCC(N2CCC[C@@H](NC(=O)c3ccccc3C)C2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916224	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4	COc1ccc(CC(=O)O)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2ccccc2)[C@@H]1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916686	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	COC(=O)N(Cc1ccccc1)Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916697	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccccc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916700	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human CYP3A4	CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OC	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916704	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CCN(Cc1cc(C(F)(F)F)ccc1-c1cc(CC(=O)O)ccc1OC)C(=O)OCc1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916708	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4	N#Cc1cc(OC(F)(F)F)cc(-c2nc(-c3ccc4c(c3)CCN4C(=O)CCC(=O)O)no2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916399	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	O=C(O)CCC(=O)N1CCc2cc(-c3noc(-c4cc(C(F)(F)F)cc(C(F)(F)F)c4)n3)ccc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1916559	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC(=O)Nc1cccc2c1c(Sc1ccc(Cl)cc1)c(C)n2CC(=O)O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1914489	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCc1ccc(-c2ccc(=O)n(C)n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1917464	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCc1ccc(-c2ccc(=O)n(-c3ccc(F)cc3)n2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1917468	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)c2)cc1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923729	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	O=C(Nc1ccc(N2S(=O)(=O)c3ccccc3S2(=O)=O)cc1)c1ccccn1	J. Med. Chem.	2011.0	CHEMBL1921855	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	O=C(Nc1ccc(N2C(=O)[C@H]3[C@H]4C=C[C@H](C4)[C@H]3C2=O)c(Cl)c1)c1ccccn1	J. Med. Chem.	2011.0	CHEMBL1921961	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	O=C(Nc1ccc(N2C(=O)CC3(CCCCC3)C2=O)c(Cl)c1)c1ccccn1	J. Med. Chem.	2011.0	CHEMBL1705230	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	O=C(Nc1ccc(N2C(=O)CC(c3ccccc3)C2=O)c(Cl)c1)c1ccccn1	J. Med. Chem.	2011.0	CHEMBL1698322	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	COc1cc(NC(=O)c2ccccn2)ccc1Cl	J. Med. Chem.	2011.0	CHEMBL562551	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CNC(=O)c1ccc2cc([C@](O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921975	=	=	IC50	nM	7800.0	IC50	nM	7800.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc(C(O)(c3c[nH]cn3)C(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1682893	=	=	IC50	nM	3600.0	IC50	nM	3600.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921977	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc(C3(O)c4cncn4CC3(C)C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921978	=	=	IC50	nM	3200.0	IC50	nM	3200.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc(C3CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921979	<	<	IC50	nM	1000.0	IC50	nM	1000.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc(C(C)(O)c3cncn3C)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921980	=	=	IC50	nM	6900.0	IC50	nM	6900.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	NC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921981	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CCNC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921982	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	O=C(NC1CC1)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921983	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CC(C)NC(=O)c1ccc2cc(C3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921984	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921976	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant human CYP3A4 assessed as conversion of testosterone into 6-hydroxytestosterone after 30 mins by HPLC analysis	CNC(=O)c1ccc2cc([C@]3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921985	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of human B-lymphoblastoid cell microsomal CYP3A4 assessed as testosterone 6beta-hydroxylation preincubated for 5 mins with substrate	CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1	Bioorg. Med. Chem.	2011.0	CHEMBL1921976	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4	CNc1nc2[nH]c(-c3cccc(CNC(=O)COC)n3)cc2c2c1ncn2C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923983	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4	CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1	J. Med. Chem.	2011.0	CHEMBL1922660	>	>	IC50	nM	50.0	IC50	nM	50.0
Inhibition of human CYP3A4	Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(C)cn3)cc2)nc1	J. Med. Chem.	2011.0	CHEMBL1922662	=	=	IC50	nM	8.5	IC50	nM	8.5
Inhibition of human CYP3A4	Cc1ccc(COc2ccc3c(c2)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n3Cc2ccc(-c3ccc(F)cn3)cc2)nc1	J. Med. Chem.	2011.0	CHEMBL1922663	=	=	IC50	nM	5.5	IC50	nM	5.5
Inhibition of human CYP3A4	COc1cnc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)nc1	J. Med. Chem.	2011.0	CHEMBL1229205	=	=	IC50	nM	8.8	IC50	nM	8.8
Inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910292	=	=	IC50	nM	900.0	IC50	uM	0.9
Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@]2(O)c2ccccc2)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1910286	=	=	IC50	nM	2600.0	IC50	uM	2.6
Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2ccccc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923106	=	=	IC50	nM	6000.0	IC50	uM	6.0
Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC(=O)c2ccccc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923107	=	=	IC50	nM	7200.0	IC50	uM	7.2
Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCCc2ccccc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923108	=	=	IC50	nM	6400.0	IC50	uM	6.4
Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC=Cc2ccccc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923109	=	=	IC50	nM	1100.0	IC50	uM	1.1
Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OC(=O)Cc2ccccc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923110	=	=	IC50	nM	5600.0	IC50	uM	5.6
Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)cc(OCCOC)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923111	=	=	IC50	nM	13000.0	IC50	uM	13.0
Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccccc1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923112	=	=	IC50	nM	5000.0	IC50	uM	5.0
Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc(Cl)c1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923113	=	=	IC50	nM	5600.0	IC50	uM	5.6
Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccc(Cl)cc1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923114	=	=	IC50	nM	1900.0	IC50	uM	1.9
Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cc(Cl)ccc1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923115	=	=	IC50	nM	1600.0	IC50	uM	1.6
Reversible inhibition of CYP3A4	Cc1cccc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1C	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923116	=	=	IC50	nM	5000.0	IC50	uM	5.0
Reversible inhibition of CYP3A4	Cc1c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)cccc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923117	=	=	IC50	nM	2300.0	IC50	uM	2.3
Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc(C(F)(F)F)c1Cl)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923118	=	=	IC50	nM	3600.0	IC50	uM	3.6
Reversible inhibition of CYP3A4	COCCCc1cc(C)c(C)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923119	=	=	IC50	nM	3500.0	IC50	uM	3.5
Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc2ccccc12)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923120	=	=	IC50	nM	6000.0	IC50	uM	6.0
Reversible inhibition of CYP3A4	COCCCc1cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c2ccccc2c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923121	=	=	IC50	nM	1600.0	IC50	uM	1.6
Reversible inhibition of CYP3A4	COCCCc1cccc2cccc(CN(C(=O)[C@H]3CNCC[C@@]34OCc3cc(F)c(F)cc34)C3CC3)c12	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923122	=	=	IC50	nM	15000.0	IC50	uM	15.0
Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1nccc2ccccc12)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923123	=	=	IC50	nM	9300.0	IC50	uM	9.3
Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1ccnc2ccccc12)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923124	=	=	IC50	nM	31000.0	IC50	uM	31.0
Reversible inhibition of CYP3A4	O=C([C@H]1CNCC[C@@]12OCc1cc(F)c(F)cc12)N(Cc1cccc2cccnc12)C1CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923125	=	=	IC50	nM	8900.0	IC50	uM	8.9
Reversible inhibition of CYP3A4	O=C1O[C@@]2(CCNC[C@@H]2C(=O)N(Cc2cccc(C(F)(F)F)c2Cl)C2CC2)c2cc(F)c(F)cc21	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923126	=	=	IC50	nM	700.0	IC50	uM	0.7
Reversible inhibition of CYP3A4	COCCCc1cc(CCCN2CCOCC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923127	=	=	IC50	nM	2600.0	IC50	uM	2.6
Reversible inhibition of CYP3A4	CCN(CC)CCCc1cc(CCCOC)cc(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1Cl	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923128	=	=	IC50	nM	5800.0	IC50	uM	5.8
Reversible inhibition of CYP3A4	COCCCc1cc(CCCCNS(C)(=O)=O)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923129	=	=	IC50	nM	2200.0	IC50	uM	2.2
Reversible inhibition of CYP3A4	COCCCc1cc(CCCNS(C)(=O)=O)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923130	=	=	IC50	nM	2000.0	IC50	uM	2.0
Reversible inhibition of CYP3A4	COCCCc1cc(CCCN2CCS(=O)(=O)CC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923131	=	=	IC50	nM	2400.0	IC50	uM	2.4
Reversible inhibition of CYP3A4	COCCCc1cc(CCC(=O)N2CCOCC2)c(Cl)c(CN(C(=O)[C@H]2CNCC[C@@]23OCc2cc(F)c(F)cc23)C2CC2)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1923132	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of human CYP3A4	C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccccc2O1.Cl.O	J. Med. Chem.	2011.0	CHEMBL1923502	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of human CYP3A4	C[C@@H]1C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)NCCCc2ccc(F)cc2OCCN[C@@H](C2CC2)C(=O)N1C	J. Med. Chem.	2011.0	CHEMBL1923642	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4	CCCCC[C@@H](Cc1ccc(C(=O)NCCC(=O)O)cc1)C(=O)c1cc2cc(Cl)ccc2n1-c1cccc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1922933	>	>	IC50	nM	11000.0	IC50	nM	11000.0
Inhibition of CYP3A4	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1929238	=	=	IC50	nM	550.0	IC50	uM	0.55
Inhibition of CYP3A4	Cc1cc2ncc(C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N)cn2n1.Cl	Bioorg. Med. Chem.	2011.0	CHEMBL1929387	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	CC(C)(C)CC(c1ccc(CC(=O)O)cc1-c1ccc(C(F)(F)F)cc1)N1CCC(C(F)(F)F)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL1928243	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 by mass spectrophotometry	Cl.O=c1c2c3n(c(=O)cc2[nH]n1-c1ccccc1Cl)CCCN(Cc1ccccc1)C3	Bioorg. Med. Chem.	2011.0	CHEMBL1927147	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4	COc1ccc(-c2sc(/N=C/c3ccc(N(C)CCC#N)cc3)c(C#N)c2C)cc1OC	Eur. J. Med. Chem.	2012.0	CHEMBL1928092	=	=	IC50	nM	33200.0	IC50	uM	33.2
Inhibition of human recombinant CYP3A4	COc1ccc(-c2sc(/N=C/c3ccc(-c4ccccc4)cc3)c(C#N)c2C)cc1OC	Eur. J. Med. Chem.	2012.0	CHEMBL1928095	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CS(=O)(=O)CCCOc1ccc2c(c1)CCC1(CCN(C3CCC3)CC1)O2	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935416	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CN1CCC[C@@H](c2nc3ccccc3n2Cc2ccc(F)cc2)C1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1095819	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	Cc1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935441	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	Fc1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935442	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935443	=	=	IC50	nM	4900.0	IC50	uM	4.9
Inhibition of CYP3A4	Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935443	=	=	IC50	nM	7600.0	IC50	uM	7.6
Inhibition of CYP3A4	Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935444	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4	Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935444	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of CYP3A4	Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935444	=	=	IC50	nM	9500.0	IC50	uM	9.5
Inhibition of CYP3A4	Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935445	=	=	IC50	nM	16700.0	IC50	uM	16.7
Inhibition of CYP3A4	Fc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935446	=	=	IC50	nM	15600.0	IC50	uM	15.6
Inhibition of CYP3A4	Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935445	=	=	IC50	nM	10600.0	IC50	uM	10.6
Inhibition of CYP3A4	COc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935447	=	=	IC50	nM	5800.0	IC50	uM	5.8
Inhibition of CYP3A4	COc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935448	=	=	IC50	nM	15800.0	IC50	uM	15.8
Inhibition of CYP3A4	Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL556450	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	O=S(=O)(c1cccc(F)c1)c1ccc2c3c(oc2c1)C1(CCCOC1)NCC3	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935601	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	COCCCS(=O)(=O)c1ccc(-c2ccc(CCN3CCC[C@H]3C)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1934523	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	CO[C@H]1CC[C@@H](n2nc(C)c(C(=O)N[C@@H](C)C(C)(C)C)c2NS(=O)(=O)c2ccc(C)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1934424	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	Cc1nn(C2CCOCC2)c(NS(=O)(=O)c2ccc(C3CC3)cc2)c1C(=O)N[C@@H](C)C(C)(C)C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1934426	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)CC2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935100	>	>	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)C(C)(C)C2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935114	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CC1CC(=O)NN=C1c1ccc(OCCCN2CCC[C@H]2C)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935111	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CC1CC(=O)NN=C1c1ccc(OCCCN2CCC[C@H]2C)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1935111	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cc1cc(=O)[nH]nc1-c1ccc(OCCCN2CCC[C@H]2C)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1829475	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins by fluorimetry	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1	J. Med. Chem.	2011.0	CHEMBL1939876	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(Cl)cc1)N(CC1CCS(=O)(=O)CC1)C(=O)Cc1ccc(F)c(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1939559	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(Cl)cc1)N(CC1CCS(=O)(=O)CC1)C(=O)Cc1ccc(C(F)(F)F)c(F)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1939560	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(NC1CCCS(=O)(=O)C1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1940315	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CN1CCC(NC(=O)c2ccc(Oc3ccc(C#C[C@]4(O)CN5CCC4CC5)cc3)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1940308	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CNC(=O)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1940296	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	O=C(NCc1ccncn1)c1ccc(Oc2ccc(C#C[C@]3(O)CN4CCC3CC4)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1796298	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1	J. Med. Chem.	2012.0	CHEMBL1944698	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	COc1ccc2c(-n3c(=O)n(Cc4cccc([C@@]5(C)OC(=O)NC5=O)c4)c4ccccc43)noc2c1	J. Med. Chem.	2011.0	CHEMBL1947144	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1cc2nnc(-c3c(F)cccc3Cl)n2n(C)c1=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1945721	=	=	IC50	nM	25800.0	IC50	uM	25.8
Inhibition of CYP3A4	CCn1c(=O)c(-c2cc(C(=O)NC3CC3)ccc2C)cc2nnc(-c3c(F)cccc3Cl)n21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1945723	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4	CCn1c(=O)c(-c2cc(C(=O)NC3CC3)cc(F)c2C)cc2nnc(-c3c(F)cccc3Cl)n21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1945726	=	=	IC50	nM	11800.0	IC50	uM	11.8
Inhibition of CYP3A4	O=c1ccc(-c2ccc(OC3CCN(C4CCC4)CC3)cc2)n[nH]1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950643	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CC1(C)CC(c2ccc(OC3CCN(C4CCC4)CC3)cc2)=NNC1=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950743	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCOCC2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951055	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(Cl)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951320	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(Br)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951321	=	=	IC50	nM	210.0	IC50	uM	0.21
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951322	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(F)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951323	=	=	IC50	nM	710.0	IC50	uM	0.71
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951324	=	=	IC50	nM	480.0	IC50	uM	0.48
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(Br)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951325	=	=	IC50	nM	92.0	IC50	uM	0.092
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccccc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951326	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	Cc1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951327	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc([N+](=O)[O-])c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951328	=	=	IC50	nM	61.0	IC50	uM	0.061
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	COC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951329	=	=	IC50	nM	82.0	IC50	uM	0.082
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	COc1ccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951330	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccccc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951331	=	=	IC50	nM	26.0	IC50	uM	0.026
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CCOC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951332	=	=	IC50	nM	44.0	IC50	uM	0.044
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CNC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951334	=	=	IC50	nM	98.0	IC50	uM	0.098
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CCNC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951335	=	=	IC50	nM	55.0	IC50	uM	0.055
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951336	=	=	IC50	nM	90.0	IC50	uM	0.09
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CN(C)C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951337	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CCN(CC)C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951338	=	=	IC50	nM	47.0	IC50	uM	0.047
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)N(C(=O)c1cccc(NC(=O)Nc2ccc(-c3ccnc4[nH]cnc34)cc2)c1)C(C)C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951339	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)Nc2ccccc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951340	=	=	IC50	nM	53.0	IC50	uM	0.053
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)NC2CCCC2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951341	=	=	IC50	nM	70.0	IC50	uM	0.07
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)N2CCCCC2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951342	=	=	IC50	nM	79.0	IC50	uM	0.079
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccnc3[nH]cnc23)cc1)Nc1cccc(C(=O)N2CCOCC2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951343	=	=	IC50	nM	290.0	IC50	uM	0.29
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]ccc34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951344	=	=	IC50	nM	560.0	IC50	uM	0.56
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4c3ccn4C)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951345	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951346	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CCc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951347	=	=	IC50	nM	4600.0	IC50	uM	4.6
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ncnc4[nH]cc(Cl)c34)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951348	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CCn1c(=O)[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951350	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	CC(C)NC(=O)c1cccc(NC(=O)Nc2ccc(-c3ccncc3)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951443	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	N#Cc1ccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5[nH]cnc45)cc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951444	=	=	IC50	nM	11.0	IC50	uM	0.011
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccc(O)cc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951445	=	=	IC50	nM	30.0	IC50	uM	0.03
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	Nc1ccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5[nH]cnc45)cc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951446	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	COc1cccc(-c2ccc(NC(=O)Nc3ccc(-c4ccnc5[nH]cnc45)cc3)cc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951447	=	=	IC50	nM	48.0	IC50	uM	0.048
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2cccc3ccccc23)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951448	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2cccnc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951449	=	=	IC50	nM	220.0	IC50	uM	0.22
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(Nc1ccc(-c2ccncc2)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951450	=	=	IC50	nM	360.0	IC50	uM	0.36
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(NCc1ccc(F)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951451	=	=	IC50	nM	280.0	IC50	nM	280.0
Inhibition of recombinant human CYP3A4 in supersomes using midazolam as substrate after 5 mins by LC-MS/MS analysis	O=C(NCc1ccc(Br)cc1)Nc1ccc(-c2ccnc3[nH]cnc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951452	=	=	IC50	nM	270.0	IC50	nM	270.0
Inhibition of human CYP3A4 using midazolam as substrate by LC-MS/MS analysis	CCCOc1sc(C(=O)N2CCC(c3cccc(CN)c3)CC2)c(C)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951453	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of human CYP3A4 using midazolam as substrate by LC-MS/MS analysis	CCCOc1sc(C(=O)N2[C@H]3CC[C@H]2CC(c2cc(CN)ccc2F)C3)c(C)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951454	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of CYP3A4	COc1ccc([C@]2(O)CC[C@H](N3CC[C@@H](NC(=O)CNC(=O)c4cccc(C(F)(F)F)c4)C3)CC2)cn1.CS(=O)(=O)O	ACS Med. Chem. Lett.	2011.0	CHEMBL1951778	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2ncn(Cc3nccc4ccccc34)c(=O)c21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951432	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4	Cn1c(=O)n(Cc2nccc3ccccc23)c(=O)c2c1c(C#N)c(N1CCC[C@H](N)C1)n2Cc1ccccc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951596	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCC[C@H](N)C4)n3Cc3ccccc3)n(C)c2=O)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951595	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	Cn1c(=O)c2c(c(C#N)c(N3CCC[C@H](N)C3)n2Cc2ccccc2)n(C)c1=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951597	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951599	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCC[C@H](N)C4)n3CC=C(C)C)n(C)c2=O)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951598	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951600	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1ncccc1C#N)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951602	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2c1c(=O)n(Cc1cnc3ccccc3n1)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951601	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	COc1cccc(C(=O)Cn2c(=O)c3c(c(C#N)c(N4CCCNCC4)n3CC=C(C)C)n(C)c2=O)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951607	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951609	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951608	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1cn3ccccc3n1)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951610	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1c(C#N)cnc3ccccc13)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949693	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1ncc3ccccc3c1C#N)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951611	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1nccc3ccccc13)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951612	>=	>=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC#CCn1c(N2CCCNCC2)c(C#N)c2c1c(=O)n(Cc1c(C#N)cnc3ccccc13)c(=O)n2C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951614	>=	>=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCN(S(C)(=O)=O)CC2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951914	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of human CYP3A4 by luminescent assay	COc1cc(NCC2CCNCC2)nc2c1nnn2-c1cccc(OC(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1952142	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4	CC(C)=CCn1c(N2CCC[C@H](N)C2)c(C#N)c2ncn(Cc3ccnc4ccccc34)c(=O)c21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951431	<=	<=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	O=C(N1CCCCC1)N1CC(O[C@@H](c2ccc(Cl)cc2)c2cccnc2Cl)C1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL555563	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCS(=O)(=O)n1c2c(c3cc(C(=O)N4CCC(C)CC4)ccc31)CN(C1CCOCC1)CC2	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950351	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP 3A4	COc1cc(OC(C)C)cc(S(=O)(=O)c2ccc3c(c2)O[C@H]2CNCC[C@@H]32)c1.Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949930	>	>	IC50	nM	5900.0	IC50	uM	5.9
Reversible inhibition of CYP3A4	Cc1ncc(C(O)c2c3cc(Cl)cc(C)c3nc3[nH]nc(C)c23)cn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950091	=	=	IC50	nM	7900.0	IC50	uM	7.9
Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3cncn3C)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950090	=	=	IC50	nM	300.0	IC50	uM	0.3
Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ncco3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950089	=	=	IC50	nM	7400.0	IC50	uM	7.4
Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccnc(F)c3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950088	>	>	IC50	nM	20000.0	IC50	uM	20.0
Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccccn3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950087	=	=	IC50	nM	1800.0	IC50	uM	1.8
Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3cccnc3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950086	=	=	IC50	nM	1100.0	IC50	uM	1.1
Reversible inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccncc3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950085	=	=	IC50	nM	300.0	IC50	uM	0.3
Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(F)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950084	=	=	IC50	nM	300.0	IC50	uM	0.3
Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(C)(O)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950082	=	=	IC50	nM	7100.0	IC50	uM	7.1
Reversible inhibition of CYP3A4	COc1ccc(C(C#N)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950081	=	=	IC50	nM	300.0	IC50	uM	0.3
Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(C#N)c3ccccc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950080	=	=	IC50	nM	800.0	IC50	uM	0.8
Reversible inhibition of CYP3A4	COc1ccc(C(O)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950078	<	<	IC50	nM	200.0	IC50	uM	0.2
Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncs3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949942	<	<	IC50	nM	200.0	IC50	uM	0.2
Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncn3C)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949941	=	=	IC50	nM	1200.0	IC50	uM	1.2
Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ncco3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949940	=	=	IC50	nM	4400.0	IC50	uM	4.4
Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccnc(F)c3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949939	=	=	IC50	nM	600.0	IC50	uM	0.6
Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccccn3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949938	=	=	IC50	nM	4600.0	IC50	uM	4.6
Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cccnc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949937	<	<	IC50	nM	200.0	IC50	uM	0.2
Reversible inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949936	=	=	IC50	nM	2900.0	IC50	uM	2.9
Time dependent inhibition of CYP3A4	Cc1ncc(C(O)c2c3cc(Cl)cc(C)c3nc3[nH]nc(C)c23)cn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950091	>	>	IC50	nM	20000.0	IC50	uM	20.0
Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3cncn3C)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950090	=	=	IC50	nM	800.0	IC50	uM	0.8
Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ncco3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950089	=	=	IC50	nM	1000.0	IC50	uM	1.0
Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccnc(F)c3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950088	>	>	IC50	nM	20000.0	IC50	uM	20.0
Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccccn3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950087	=	=	IC50	nM	12200.0	IC50	uM	12.2
Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3cccnc3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950086	=	=	IC50	nM	2100.0	IC50	uM	2.1
Time dependent inhibition of CYP3A4	Cc1cc(Cl)cc2c(C(O)c3ccncc3)c3c(C)n[nH]c3nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950085	=	=	IC50	nM	500.0	IC50	uM	0.5
Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(F)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950084	=	=	IC50	nM	12000.0	IC50	uM	12.0
Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(C)(O)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950082	=	=	IC50	nM	14200.0	IC50	uM	14.2
Time dependent inhibition of CYP3A4	COc1ccc(C(C#N)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950081	=	=	IC50	nM	12900.0	IC50	uM	12.9
Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(C#N)c3ccccc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950080	=	=	IC50	nM	20000.0	IC50	uM	20.0
Time dependent inhibition of CYP3A4	COc1ccc(C(O)c2c3cc(OC)cc(C)c3nc3[nH]nc(C)c23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1950078	=	=	IC50	nM	1200.0	IC50	uM	1.2
Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncs3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949942	=	=	IC50	nM	700.0	IC50	uM	0.7
Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cncn3C)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949941	=	=	IC50	nM	4900.0	IC50	uM	4.9
Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ncco3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949940	=	=	IC50	nM	7800.0	IC50	uM	7.8
Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccnc(F)c3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949939	=	=	IC50	nM	4200.0	IC50	uM	4.2
Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccccn3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949938	=	=	IC50	nM	10600.0	IC50	uM	10.6
Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3cccnc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949937	=	=	IC50	nM	2700.0	IC50	uM	2.7
Time dependent inhibition of CYP3A4	COc1cc(C)c2nc3[nH]nc(C)c3c(C(O)c3ccncc3)c2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1949936	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4	CN1CC=C(c2c[nH]c3ccc(NC(=N)c4ccco4)cc23)CC1.Cl.Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL3216551	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes	O=C(c1cccn2ccnc12)N1CCN(CCc2ccc(F)cc2F)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1957816	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(-c2cnn(-c3ccccn3)c(=O)c2)cc1	J. Med. Chem.	2012.0	CHEMBL1945843	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant CYP3A4	FC(F)(F)c1ccccc1-c1ccc2[nH]c(/C=C/C3CCCCC3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1955989	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 in human liver microsomes	FC(F)(F)c1ccccc1-c1ccc2[nH]c(/C=C/C3CCCCC3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1955989	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human microsome	NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1956397	=	=	IC50	nM	139000.0	IC50	uM	139.0
Inhibition of CYP3A4 in human microsome	NC(=O)C[S+]([O-])Cc1ccccc1-c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1956397	=	=	IC50	nM	159000.0	IC50	uM	159.0
Inhibition of CYP3A4 after 30 mins by fluorescence assay	C/C(=C\COc1c2ccoc2cc2oc(=O)ccc12)CC[C@@H](O)C(C)(C)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1079119	=	=	IC50	nM	810.0	IC50	uM	0.81
Inhibition of CYP3A4 after 30 mins by fluorescence assay	C/C(=C\COc1c(CCC(=O)O)c(O)cc2occc12)CCC(O)C(C)(C)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1957148	>	>	IC50	nM	172000.0	IC50	uM	172.0
Inhibition of CYP3A4	Nc1cncc(Nc2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)n1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2010816	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4	COc1ccc(-c2nc(C(=O)NCc3ccc(F)cc3F)c([C@H](C)N)o2)c2ccc(C(F)(F)F)nc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2012228	>	>	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human CYP3A4 using midazolam as substrate after 5 mins by LC-MS/MS analysis	Cc1nc2c(OC(F)F)cccc2n1-c1ccc(C(=O)NC2CC2)s1	ACS Med. Chem. Lett.	2011.0	CHEMBL2012951	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 using midazolam as substrate after 5 mins by LC-MS/MS analysis	Cc1nc2c(C#N)cccc2n1-c1ccc(C(=O)NC2CC2)s1	ACS Med. Chem. Lett.	2011.0	CHEMBL2012958	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)S(=O)(=O)NC[C@H]1CC[C@H](NC(=O)CN2CCc3cc(Cl)ccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013012	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 by HTRF assay	CN(C(=O)Cc1ccc(-n2cnnn2)cc1)C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1	Bioorg. Med. Chem. Lett.	2011.0	CHEMBL2010836	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CS(=O)(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013045	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	O=S(=O)(C1CC1)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013050	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CC(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013051	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CC(C)C(=O)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013052	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	O=C(C1CC1)N1CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013053	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3	J. Med. Chem.	2012.0	CHEMBL2010872	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 co-incubated with substrate	Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(F)ccc3F)c2cc1F	J. Med. Chem.	2012.0	CHEMBL2011266	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 preincubated prior to substrate addition	Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(F)ccc3F)c2cc1F	J. Med. Chem.	2012.0	CHEMBL2011266	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	Oc1ccc2[nH]c(-c3ccccc3)nc2c1CN1CCCCC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2013195	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	c1ccc(-c2nc3c(CN4CCCCC4)cccc3[nH]2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2010880	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Fc1ccc2[nH]c(-c3ccccc3)nc2c1CN1CCCC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2010883	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes co-incubated with testosterone	O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1	ACS Med. Chem. Lett.	2011.0	CHEMBL1938681	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 30 mins prior to substrate addition	O=C(c1ccc(-c2ccc(Cl)cc2)o1)N(Cc1ccccn1)c1ccc(N2CCNCC2)cc1	ACS Med. Chem. Lett.	2011.0	CHEMBL1938681	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	COc1nc(C(=O)N[C@H]2COc3ccc(Cl)c(F)c32)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2018331	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(C(F)(F)F)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL1938952	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cc1cnc[nH]1	J. Med. Chem.	2012.0	CHEMBL2018481	=	=	IC50	nM	7146.0	IC50	nM	7146.0
Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](c2ccccc2)CN1C(=O)Cc1cnc[nH]1	J. Med. Chem.	2012.0	CHEMBL2018482	=	=	IC50	nM	301.0	IC50	nM	301.0
Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccccc2)CN1C(=O)Cn1cncn1	J. Med. Chem.	2012.0	CHEMBL2018484	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1	J. Med. Chem.	2012.0	CHEMBL2018485	=	=	IC50	nM	12605.0	IC50	nM	12605.0
Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@H](Cc2ccc(F)cc2)CN1C(=O)Cn1cncn1	J. Med. Chem.	2012.0	CHEMBL2018486	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1ccnn1	J. Med. Chem.	2012.0	CHEMBL2018571	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of human CYP3A4 using testosterone as substrate by LC/MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)[C@@H]1C[C@@H](Cc2ccc(F)cc2)CN1C(=O)Cn1nccn1	J. Med. Chem.	2012.0	CHEMBL2018573	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018906	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018905	=	=	IC50	nM	27100.0	IC50	uM	27.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCCCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018903	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCCCCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018904	=	=	IC50	nM	26300.0	IC50	uM	26.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCCCCCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018907	=	=	IC50	nM	5330.0	IC50	uM	5.33
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCCCCCCSc1nc2cc(OC)ccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2018908	=	=	IC50	nM	15700.0	IC50	uM	15.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCC(C)C)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018909	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCC(C)(C)C)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018910	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCC3CC3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018911	=	=	IC50	nM	16400.0	IC50	uM	16.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCC3CCCCC3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018912	=	=	IC50	nM	6230.0	IC50	uM	6.23
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCCCO)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018913	=	=	IC50	nM	5490.0	IC50	uM	5.49
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCCCC(=O)O)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018914	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccccc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018915	>	>	IC50	nM	80.0	IC50	uM	0.08
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(C)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018916	=	=	IC50	nM	8860.0	IC50	uM	8.86
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(C(C)C)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018917	=	=	IC50	nM	8340.0	IC50	uM	8.34
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(C(C)(C)C)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018918	=	=	IC50	nM	12300.0	IC50	uM	12.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(Cl)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018919	=	=	IC50	nM	4860.0	IC50	uM	4.86
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(Br)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018920	=	=	IC50	nM	4230.0	IC50	uM	4.23
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(I)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018921	=	=	IC50	nM	4910.0	IC50	uM	4.91
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(C(=O)O)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018922	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1cc(CSc2nc3ccc(OC)cc3[nH]2)cc(OC)c1	J. Med. Chem.	2012.0	CHEMBL488400	=	=	IC50	nM	720.0	IC50	uM	0.72
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3cccc(-c4ccccc4)c3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018923	=	=	IC50	nM	1870.0	IC50	uM	1.87
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2nc(SCc3ccc4ccccc4c3)[nH]c2c1	J. Med. Chem.	2012.0	CHEMBL502335	=	=	IC50	nM	3110.0	IC50	uM	3.11
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc4ccccc4n3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018924	=	=	IC50	nM	2810.0	IC50	uM	2.81
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3cccc(Oc4ccccc4)c3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018925	=	=	IC50	nM	2490.0	IC50	uM	2.49
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccc(OCc4ccccc4)cc3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2018926	=	=	IC50	nM	3560.0	IC50	uM	3.56
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	COc1ccc2[nH]c(SCc3ccccn3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2019022	=	=	IC50	nM	4010.0	IC50	uM	4.01
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	CCOc1ccc2[nH]c(SCc3ccccn3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2019023	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	c1ccc(CSc2nc3ccccc3[nH]2)nc1	J. Med. Chem.	2012.0	CHEMBL296580	>	>	IC50	nM	3750.0	IC50	uM	3.75
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	Cc1ccc2[nH]c(SCc3ccccn3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2019024	=	=	IC50	nM	3610.0	IC50	uM	3.61
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	FC(F)Oc1ccc2[nH]c(SCc3ccccn3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2019025	=	=	IC50	nM	10700.0	IC50	uM	10.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins by LC-MS/MS analysis	Nc1ccc2[nH]c(SCc3ccccn3)nc2c1	J. Med. Chem.	2012.0	CHEMBL2019026	=	=	IC50	nM	520.0	IC50	uM	0.52
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1ccc([C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)c(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1957676	=	=	IC50	nM	20000.0	IC50	uM	20.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2ccc(F)cc2Br)no1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2016935	=	=	IC50	nM	3000.0	IC50	uM	3.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2c(Cl)cccc2Cl)no1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2016936	=	=	IC50	nM	8000.0	IC50	uM	8.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2ccc(F)cc2Cl)no1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2016937	=	=	IC50	nM	7000.0	IC50	uM	7.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2ccccc2Cl)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2016938	=	=	IC50	nM	18000.0	IC50	uM	18.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2cccc(Cl)c2Cl)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017097	=	=	IC50	nM	19000.0	IC50	uM	19.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	Cc1cccc(-c2noc([C@H]3CNCC[C@]3(O)c3ccc(F)c(F)c3)c2Br)c1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017098	=	=	IC50	nM	20000.0	IC50	uM	20.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2c(Cl)cccc2Cl)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017099	=	=	IC50	nM	15000.0	IC50	uM	15.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1onc(-c2cccc3ccccc23)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017100	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1noc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017101	=	=	IC50	nM	45000.0	IC50	uM	45.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017102	=	=	IC50	nM	33000.0	IC50	uM	33.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	O[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1cc(-c2c(Cl)cccc2Cl)on1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017103	=	=	IC50	nM	17000.0	IC50	uM	17.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1cc(F)ccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017104	=	=	IC50	nM	45000.0	IC50	uM	45.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1cc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)no1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017105	=	=	IC50	nM	32000.0	IC50	uM	32.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017106	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1C(C)=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017107	=	=	IC50	nM	8000.0	IC50	uM	8.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(O)c2ccc(F)c(F)c2)c1C(C)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017108	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017109	=	=	IC50	nM	13000.0	IC50	uM	13.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CO[C@]1(c2ccc(F)c(F)c2)CCNC[C@@H]1c1noc(-c2ccccc2CCNC(C)=O)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017110	=	=	IC50	nM	28000.0	IC50	uM	28.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(C(N)=O)c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017111	=	=	IC50	nM	36000.0	IC50	uM	36.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	CC(=O)NCCc1ccccc1-c1onc([C@H]2CNCC[C@]2(OCC(O)CO)c2ccc(F)c(F)c2)c1Br	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017112	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1ccc(-n2c(SCc3nc(-c4ccc(C)cc4)no3)nnc2-c2ccncc2)cc1	J. Med. Chem.	2012.0	CHEMBL1552719	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4	Oc1nc(-c2ccc(C(F)(F)F)cc2)nc2c1CSCC2	J. Med. Chem.	2012.0	CHEMBL1086580	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1ccc(-n2c(C)nnc2SCc2nc(-c3ccc(OC)c(OC)c3)no2)cc1	J. Med. Chem.	2012.0	CHEMBL1867804	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of CYP3A4	COc1ccc(-c2noc(CSc3nnc(C)n3-c3ccc(OC)cc3)n2)cc1	J. Med. Chem.	2012.0	CHEMBL1898239	=	=	IC50	nM	5700.0	IC50	uM	5.7
Inhibition of CYP3A4	Fc1ccc(-c2nnc(SCc3nc(-c4ccccc4)no3)n2-c2ccccc2)cc1	J. Med. Chem.	2012.0	CHEMBL2016639	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4-mediated conversion of testosterone to 6-beta-hydroxy-testosterone after 30 mins	COC[C@H](C)COCc1ccc([C@@]2(O)CCNC[C@@H]2c2noc(-c3ccccc3CCNC(C)=O)c2Br)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017113	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4	Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(N)=O)cnc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017089	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4	Cc1noc(C)c1-c1ccc2c(Nc3ccccc3)c(C(=O)O)cnc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017091	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4	Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017268	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017269	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017273	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3C(C)(C)C)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017274	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3CCN3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017275	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3C(=O)c3ccccn3)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017276	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3N3CCOCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017279	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4	COc1cc2c(Nc3ccccc3C(=O)N3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017280	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4	COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017281	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017283	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3OC(F)(F)F)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017284	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017285	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017286	=	=	IC50	nM	12900.0	IC50	uM	12.9
Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(C(C)c3ccccc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017287	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017288	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4	CC[C@H](c1ccccc1)n1c(=O)[nH]c2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017290	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017291	=	=	IC50	nM	9700.0	IC50	uM	9.7
Inhibition of CYP3A4	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1970317	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of CYP3A4	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1980297	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 preincubated for 15 mins	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1970317	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	CNC[C@H](C[C@H]1CCCOC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1	ACS Med. Chem. Lett.	2011.0	CHEMBL2024248	=	=	IC50	nM	28000.0	IC50	nM	28000.0
Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	CNC[C@H](CC1CCOCC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1	ACS Med. Chem. Lett.	2011.0	CHEMBL2023124	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	CNC[C@@H](NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1)[C@@H](O)C1CCCCC1	ACS Med. Chem. Lett.	2011.0	CHEMBL2023123	=	=	IC50	nM	7100.0	IC50	nM	7100.0
Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	CN[C@H](CNC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1)C[C@H]1CCCOC1	ACS Med. Chem. Lett.	2011.0	CHEMBL1276678	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	COCCCC[C@@](O)(c1cccc(Cl)c1F)[C@@H]1CCCN(C(=O)NC[C@@H](N)CC2CCCCC2)C1	ACS Med. Chem. Lett.	2011.0	CHEMBL2024249	=	=	IC50	nM	2910.0	IC50	nM	2910.0
Inhibition of CYP3A4 using testosterone as substrate in human liver microsome for 20 mins by HPLC analysis	CNC[C@H](CC1CCCCC1)NC(=O)N1CCC[C@@H]([C@@H](OCCNC(=O)OC)c2cccc(Cl)c2)C1	ACS Med. Chem. Lett.	2011.0	CHEMBL591578	=	=	IC50	nM	4600.0	IC50	nM	4600.0
Inhibition of human CYP3A4	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl	ACS Med. Chem. Lett.	2011.0	CHEMBL119385	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	CCOc1cc2nccc(Oc3cnc(CC(=O)Nc4n[nH]c(CC)c4C)c(OC)c3)c2cc1OC	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2023802	>	>	IC50	nM	8600.0	IC50	uM	8.6
Inhibition of CYP3A4	COc1ccc2c(Oc3ccc(CC(=O)Nc4cn(C)nc4C)c(OC)c3)ccnc2c1.O=S(=O)(O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2023803	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2022495	=	=	IC50	nM	48000.0	IC50	uM	48.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	COc1cc(NC(=O)c2ccccc2F)ccc1-c1nnc(NCCCN2CCCCC2)o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2022495	=	=	IC50	nM	76000.0	IC50	uM	76.0
Inhibition of CYP3A4	Cc1n[nH]c(C(=O)O)c1Cc1cccc(-c2ccc(F)cc2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2022570	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1n[nH]c(C(=O)O)c1Cc1cc2ccccc2s1	ACS Med. Chem. Lett.	2011.0	CHEMBL2022571	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using diethoxyfluorescein as substrate	O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)c(F)c1)c1ccccc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2022739	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 using 7-benzyloxyquinoline as substrate	O=C(Nc1ccc(-c2nnc(NCCCCN3CCOCC3)o2)c(F)c1)c1ccccc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2022739	=	=	IC50	nM	64000.0	IC50	uM	64.0
Inhibition of CYP3A4	Cc1cccc(C(CC[C@H](N)C(=O)O)(c2ccccc2)c2ccccc2)c1	J. Med. Chem.	2012.0	CHEMBL2022995	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	Cc1cccc(C(CC[C@@H](N)C(=O)O)(c2ccccc2)c2ccccc2)c1	J. Med. Chem.	2012.0	CHEMBL2022996	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	Cc1cccc(C(CCCN)(c2ccccc2)c2ccccc2)c1	J. Med. Chem.	2012.0	CHEMBL2022997	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of CYP3A4	Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1	J. Med. Chem.	2012.0	CHEMBL228814	=	=	IC50	nM	4100.0	IC50	uM	4.1
Inhibition of CYP3A4	O=C(NCC(=O)N1CC[C@H](N[C@H]2CC[C@@](O)(c3ccc(-c4ncccn4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2029422	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC	J. Med. Chem.	2012.0	CHEMBL2029988	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=c1[nH]c([C@@H]2CCCN2)nc2c1oc1ccc(Cl)cc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2030402	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc2c(c1)CCc1cc(=O)n(C)nc1-2	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2031470	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	O=C(Nc1ccc(Cl)c(Cl)c1)N1CCN(C[C@@H]2CCCN(C3CC3)C2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2036757	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4	CN[C@H]1CC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc32)CC1.Cl	J. Med. Chem.	2012.0	CHEMBL2036268	=	=	IC50	nM	57300.0	IC50	uM	57.3
Inhibition of CYP3A4	CCN[C@H]1CC[C@@H](c2c[nH]c3ccc(NC(=N)c4cccs4)cc32)CC1.Cl	J. Med. Chem.	2012.0	CHEMBL2036270	=	=	IC50	nM	23100.0	IC50	uM	23.1
Inhibition of CYP3A4	CNC1CCCC(c2c[nH]c3ccc(NC(=N)c4cccs4)cc23)C1.Cl	J. Med. Chem.	2012.0	CHEMBL2036273	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4	CC(C)C1(c2ccc(-c3ccc4ccccc4c3)[nH]c2=O)OC(=O)NC1=O	ACS Med. Chem. Lett.	2010.0	CHEMBL1770317	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCC(=O)N(Cc1cccc(C(F)(F)F)c1)c1cccc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036208	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cccc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036209	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cc(F)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036210	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCCCC(=O)N(Cc1ccc(C(F)(F)F)cc1)c1cc(F)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036211	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCCCC(=O)N(Cc1cccc(OC(F)(F)F)c1)c1cc(F)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036212	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(F)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036213	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCCCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(F)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036214	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 incubated for 15 mins prior to substrate addition measured after 30 mins by spectrophotometry	CCCCC(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1cc(Cl)cc(-c2nnn[nH]2)c1	ACS Med. Chem. Lett.	2011.0	CHEMBL2036215	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCOCC2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1951055	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCN(C(=O)c3ccccc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2036635	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	COC(=O)N1CCN(CC(=O)c2ccc(OCCCN3CCC[C@H]3C)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2036653	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@@H]1CCCN1CCCOc1ccc(C(=O)CN2CCC(F)(F)CC2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2036643	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	O=c1[nH]c(CN2CC[C@@H](O)C2)nc2c1oc1ccc(Br)cc12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2030386	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CC1(CCCc2cc(=O)oc3[nH]c(=O)[nH]c(=O)c23)CC1	ACS Med. Chem. Lett.	2012.0	CHEMBL2036958	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COCn1ncc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)cc1=O	Bioorg. Med. Chem.	2012.0	CHEMBL2037608	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	C[C@H](COc1ccc(-c2cn[nH]c(=O)c2)cc1)CN1CCC[C@H]1C	Bioorg. Med. Chem.	2012.0	CHEMBL2037604	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate	CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C	J. Med. Chem.	2012.0	CHEMBL2037511	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F	J. Med. Chem.	2012.0	CHEMBL377414	=	=	IC50	nM	31000.0	IC50	uM	31.0
Inhibition of human CYP3A4 using diethoxyfluorescein as substrate	CC[C@H](C)[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N1CCOCC1)c1ccc(C)nc1C	J. Med. Chem.	2012.0	CHEMBL2037511	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 using diethoxyfluorescein as substrate	CC(C)C[C@@H]1C(=O)N[C@H](C2Cc3ccccc3C2)C(=O)N1[C@@H](C(=O)N(C)C)c1ccc(F)cc1F	J. Med. Chem.	2012.0	CHEMBL377414	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	Cc1cnc2nc1-c1ccnc(c1)OCC/C=C/COCc1cc(ccc1OCCN1CCCC1)N2	J. Med. Chem.	2012.0	CHEMBL2035053	=	=	IC50	nM	970.0	IC50	uM	0.97
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(s2)COC/1	J. Med. Chem.	2012.0	CHEMBL2035183	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1	J. Med. Chem.	2012.0	CHEMBL2035185	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2coc(c2)COC/1	J. Med. Chem.	2012.0	CHEMBL2035186	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by fluorescence detection assay	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2ccc(o2)COC/1	J. Med. Chem.	2012.0	CHEMBL2035185	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(O)C[C@H]1CC[C@H](c2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2036730	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CN1C(=O)N(Cc2cc(Cl)ccc2F)C(=O)[C@]12C(=O)N(CC(=O)O)c1ccc(Cl)cc12	ACS Med. Chem. Lett.	2011.0	CHEMBL2042239	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 3 mins prior to NAPDH-addition measured after 30 mins by RP-HPLC analysis	O=C(O)/C(O)=C/C(=O)c1cc(Cc2ccc(F)cc2F)cn(Cc2ccccc2F)c1=O	ACS Med. Chem. Lett.	2011.0	CHEMBL2043144	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human liver microsomes using triazolam as substrate incubated for 3 mins prior to NAPDH-addition measured after 30 mins by RP-HPLC analysis	O=C(O)/C(O)=C/C(=O)c1cc(Cc2ccc(F)cc2F)cn(Cc2ccccc2F)c1=O	ACS Med. Chem. Lett.	2011.0	CHEMBL2043144	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4	CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1	ACS Med. Chem. Lett.	2012.0	CHEMBL2043437	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 in liver microsomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL157101	=	=	IC50	nM	70.0	IC50	uM	0.07
Inhibition of human CYP3A4 in liver microsomes	CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL105592	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human CYP3A4 in liver microsomes	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL163	=	=	IC50	nM	100.0	IC50	uM	0.1
Reversible inhibition of human CYP3A4 in liver microsomes by Dixon and Cornish-Bowden plot analysis	CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL105592	=	=	Ki	nM	80.0	Ki	uM	0.08
Inhibition of CYP3A4	NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1	Eur. J. Med. Chem.	2012.0	CHEMBL2043240	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	NC(=O)C[S+]([O-])Cc1ccccc1Oc1ccc(Cl)c(Cl)c1	Eur. J. Med. Chem.	2012.0	CHEMBL2043240	=	=	IC50	nM	32000.0	IC50	uM	32.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2043011	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043168	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4cccc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043169	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccccc4C(=O)O)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043170	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4Cl)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043171	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(Cl)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043172	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4F)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043324	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043325	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)c(C)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2043326	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(C3CCCCC3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2043327	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(N3CCC3=O)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2043328	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COCc1nc(-c2ccc(N3C(=O)N(c4cc(O)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)no1	J. Med. Chem.	2012.0	CHEMBL2040894	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-n3cccn3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2040895	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccno3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2040896	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1nc(C)c(-c2ccc(N3C(=O)N(c4cc(O)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)s1	J. Med. Chem.	2012.0	CHEMBL2040897	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)s4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041010	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4csc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041164	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4coc(C(=O)O)c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041165	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3cnc(O)nc3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2041167	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5ccn[nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041168	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(-c4ccn[nH]4)cc3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2041169	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(N4CCOCC4)cc3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2041170	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(-c5cc(=O)[nH][nH]5)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041171	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc5cn[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041172	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc5[nH]ncc5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041173	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc5nc[nH]c5c4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041174	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc4scnc4c3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2041175	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C#N)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041176	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(N)=O)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041177	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CNC(=O)c1ccc(-c2ccc(N3C(=O)N(c4cc(OC)ncn4)C4(CCN(Cc5ncccc5C)CC4)C3=O)cc2)cc1	J. Med. Chem.	2012.0	CHEMBL2041178	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)N(C)C)cc4)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041179	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041180	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)nc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041181	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(O)ncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1	J. Med. Chem.	2012.0	CHEMBL2040854	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)ncn1	J. Med. Chem.	2012.0	CHEMBL2041182	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cc(C(F)(F)F)ncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1	J. Med. Chem.	2012.0	CHEMBL2041183	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1nccc(N2C(=O)N(c3ccc(-c4ccc(C(=O)O)cc4C)cc3)C(=O)C23CCN(Cc2ncccc2C)CC3)n1	J. Med. Chem.	2012.0	CHEMBL2041184	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	COc1nccnc1N1C(=O)N(c2ccc(-c3ccc(C(=O)O)cc3C)cc2)C(=O)C12CCN(Cc1ncccc1C)CC2	J. Med. Chem.	2012.0	CHEMBL2041185	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3nccnc3C)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1	J. Med. Chem.	2012.0	CHEMBL2041186	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ncccn1	J. Med. Chem.	2012.0	CHEMBL2041187	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ncccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1	J. Med. Chem.	2012.0	CHEMBL2041188	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1cnccn1	J. Med. Chem.	2012.0	CHEMBL2041189	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1	J. Med. Chem.	2012.0	CHEMBL2041190	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3cnccn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cn1	J. Med. Chem.	2012.0	CHEMBL2041191	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccc(C(=O)O)cc3)cc1)C(=O)N2c1ccncn1	J. Med. Chem.	2012.0	CHEMBL2041192	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cc(C(=O)O)ccc1-c1ccc(N2C(=O)N(c3ccncn3)C3(CCN(Cc4ncccc4C)CC3)C2=O)cc1	J. Med. Chem.	2012.0	CHEMBL2041193	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	Cc1cccnc1CN1CCC2(CC1)C(=O)N(c1ccc(-c3ccccc3)cc1)C(=O)N2c1cc(O)ncn1	J. Med. Chem.	2012.0	CHEMBL2043004	=	=	IC50	nM	69000.0	IC50	uM	69.0
Inhibition of CYP3A4 using midazolam as substrate	COc1ccc(C(C)=O)cc1CSc1nc2ccccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048183	=	=	IC50	nM	37000.0	IC50	uM	37.0
Inhibition of CYP3A4 using midazolam as substrate	COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048187	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 using midazolam as substrate	CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048199	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 using midazolam as substrate	COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048204	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 using testosterone as substrate	COc1ccc(C(C)=O)cc1CSc1nc2ccccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048183	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 using testosterone as substrate	COc1ccc(C(C)=O)cc1CSc1nc2cc(F)ccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048187	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 using testosterone as substrate	CCCCNC(=O)c1ccc(OC)c(CSc2nc3cc(F)ccc3n2CC(=O)O)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048199	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 using testosterone as substrate	COc1ccc(C(=O)N2CCc3ccccc32)cc1CSc1nc2cc(F)ccc2n1CC(=O)O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048204	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes	Cc1csc(N(C)C(=O)CSc2ccc(-c3ccccc3)nn2)n1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048846	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Cc1csc(N(C(=O)CSc2ccc(-c3ccccc3)nn2)C2CC2)n1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048855	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3c(c2Cl)CCN(C(=O)c2ccc4ccoc4c2)C3)C(=O)O)c1	ACS Med. Chem. Lett.	2012.0	CHEMBL2048028	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2023898	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(Cl)c(-c2ccc(-c3ccc(-c4[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)nc4Cl)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2047188	=	=	IC50	nM	13800.0	IC50	uM	13.8
Inhibition of CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(F)c(-c2ccc(-c3ccc(-c4[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)nc4F)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2047191	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4	CC(C)(C)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1	J. Med. Chem.	2012.0	CHEMBL2048047	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4	CC(C)(C)c1ccnc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1	J. Med. Chem.	2012.0	CHEMBL2048057	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4	CC(C)(O)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1	J. Med. Chem.	2012.0	CHEMBL2048058	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4	CC(C)(CO)c1cccc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)c1	J. Med. Chem.	2012.0	CHEMBL2048059	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4	CC1(C)OCc2ccc(CN[C@H]3CS(=O)(=O)C[C@@H](Cc4cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c4)[C@@H]3O)cc21	J. Med. Chem.	2012.0	CHEMBL2048060	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4	Nc1c(F)cc(C[C@@H]2CS(=O)(=O)C[C@H](NCc3cccc(OC(F)(F)F)c3)[C@H]2O)cc1OC(C(F)(F)F)C(F)(F)F	J. Med. Chem.	2012.0	CHEMBL2048061	=	=	IC50	nM	9200.0	IC50	uM	9.2
Inhibition of CYP3A4	CC(C)(C)Cn1cc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)cn1	J. Med. Chem.	2012.0	CHEMBL2048062	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of CYP3A4	CC(C)(C)Cc1cc(CN[C@H]2CS(=O)(=O)C[C@@H](Cc3cc(F)c(N)c(OC(C(F)(F)F)C(F)(F)F)c3)[C@@H]2O)no1	J. Med. Chem.	2012.0	CHEMBL2048063	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4	N#Cc1cc(OC(F)(F)F)cc(-c2nc(-c3ccc4c(c3)cc3n4CCC3CC(=O)O)no2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2048293	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	COc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048485	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	CCc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048486	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	OC[C@H]1C[C@@H](c2cccc(Cc3ccc(C4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	Bioorg. Med. Chem.	2012.0	CHEMBL2048487	=	=	IC50	nM	76000.0	IC50	uM	76.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	CCc1ccc(Cc2ccc(OC)c([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048490	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	CCOc1ccc(Cc2ccc(CC)cc2)cc1[C@@H]1C[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Bioorg. Med. Chem.	2012.0	CHEMBL2048492	=	=	IC50	nM	36600.0	IC50	uM	36.6
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	CCc1ccc(Cc2cc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048496	=	=	IC50	nM	25700.0	IC50	uM	25.7
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture simultaneously with BFC substrate by fluorometric assay	CCc1ccc(Cc2cc([C@]3(O)C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048497	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	COc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048485	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	CCc1ccc(Cc2cccc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048486	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	OC[C@H]1C[C@@H](c2cccc(Cc3ccc(C4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	Bioorg. Med. Chem.	2012.0	CHEMBL2048487	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	CCc1ccc(Cc2ccc(OC)c([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048490	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	CCOc1ccc(Cc2ccc(CC)cc2)cc1[C@@H]1C[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Bioorg. Med. Chem.	2012.0	CHEMBL2048492	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	CCc1ccc(Cc2cc([C@@H]3C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048496	=	=	IC50	nM	40300.0	IC50	uM	40.3
Inhibition of CYP3A4 using BFC substrate in which compound added to reaction mixture before addition of BFC substrate by fluorometric assay	CCc1ccc(Cc2cc([C@]3(O)C[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c(OC)cc2OC)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2048497	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N)sc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059114	=	=	IC50	nM	19.0	IC50	uM	0.019
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cccnc3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058906	=	=	IC50	nM	22.0	IC50	uM	0.022
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058665	=	=	IC50	nM	22.0	IC50	uM	0.022
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncsc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059115	=	=	IC50	nM	23.0	IC50	uM	0.023
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccc(F)cc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058900	=	=	IC50	nM	23.0	IC50	uM	0.023
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(-c3ccccc3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058905	=	=	IC50	nM	24.0	IC50	uM	0.024
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(-c3ccncc3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058664	=	=	IC50	nM	24.0	IC50	uM	0.024
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CC1CCCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057522	=	=	IC50	nM	26.0	IC50	uM	0.026
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC3CCCCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057523	=	=	IC50	nM	26.0	IC50	uM	0.026
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057527	=	=	IC50	nM	27.0	IC50	uM	0.027
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCNc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057518	=	=	IC50	nM	28.0	IC50	uM	0.028
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CC1CCC(F)(F)CC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057791	=	=	IC50	nM	30.0	IC50	uM	0.03
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	C#CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057792	=	=	IC50	nM	30.0	IC50	uM	0.03
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058910	=	=	IC50	nM	31.0	IC50	uM	0.031
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCCn3ccnc3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057790	=	=	IC50	nM	31.0	IC50	uM	0.031
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059117	=	=	IC50	nM	33.0	IC50	uM	0.033
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(C(C)C)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058663	=	=	IC50	nM	37.0	IC50	uM	0.037
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)C)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057788	=	=	IC50	nM	37.0	IC50	uM	0.037
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCOCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059120	=	=	IC50	nM	38.0	IC50	uM	0.038
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	C#CCNc1nc2ccc(C(=O)N(CC#C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057787	=	=	IC50	nM	38.0	IC50	uM	0.038
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057786	=	=	IC50	nM	39.0	IC50	uM	0.039
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	C#CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057524	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CNc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057517	=	=	IC50	nM	41.0	IC50	uM	0.041
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058901	=	=	IC50	nM	42.0	IC50	uM	0.042
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3ccc4c(c3)OCO4)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058903	=	=	IC50	nM	44.0	IC50	uM	0.044
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	Cc1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058904	=	=	IC50	nM	52.0	IC50	uM	0.052
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)C)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059119	=	=	IC50	nM	53.0	IC50	uM	0.053
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncoc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057528	=	=	IC50	nM	55.0	IC50	uM	0.055
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057521	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@H](O)[C@H](Cc3cccnc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057794	=	=	IC50	nM	69.0	IC50	uM	0.069
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)CC)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057520	=	=	IC50	nM	79.0	IC50	uM	0.079
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057514	=	=	IC50	nM	84.0	IC50	uM	0.084
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1cccnc1)NC(=O)OCc1cncs1)C(=O)c1ccc2ncsc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059116	=	=	IC50	nM	90.0	IC50	uM	0.09
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCN(C)CC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059123	=	=	IC50	nM	92.0	IC50	uM	0.092
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCNc1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)O)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057789	=	=	IC50	nM	97.0	IC50	uM	0.097
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059126	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CCN1CCOCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059127	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	O=C(N[C@@H](Cc1ccccc1)[C@H](O)CN(CCN1CCCC1)C(=O)c1ccc2nc(N3CCCC3)oc2c1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059122	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CCN3CCOCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058909	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CCN3CCCC3)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059121	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)CC(C)(C)O)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057525	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N(C)CCN(C)C)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057516	=	=	IC50	nM	180.0	IC50	uM	0.18
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3ccncc3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058907	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCN(C)C)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059124	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NCCCN(C)C)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057515	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CN(C)CCN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(N3CCCC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059125	=	=	IC50	nM	230.0	IC50	uM	0.23
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CCN(C)c1nc2ccc(C(=O)N(CCN(C)C)C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)cc2o1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058908	=	=	IC50	nM	410.0	IC50	uM	0.41
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)c1ccc2nc(NC3CCN(C)CC3)oc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2058902	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	CC(C)C[C@@H](NC(=O)N1CCC(n2c(=O)[nH]c3ccccc32)CC1)C(=O)N1CCC(N2CCCCC2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059786	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1ccc(O)cc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059790	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1cc(Br)c(O)c(Br)c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059794	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1cccc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059798	=	=	IC50	nM	30.0	IC50	uM	0.03
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1ccc2ccccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059799	=	=	IC50	nM	30.0	IC50	uM	0.03
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059800	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059801	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	Cn1cc(C[C@@H](NC(=O)N2CCC(n3c(=O)[nH]c4ccccc43)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059802	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(NC(Cc1ccc2[nH]ccc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059803	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(NC(Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059804	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059852	=	=	IC50	nM	7300.0	IC50	uM	7.3
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059853	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C1Cc2cc(C[C@@H](NC(=O)N3CCC(N4Cc5ccccc5NC4=O)CC3)C(=O)N3CCC(N4CCCCC4)CC3)ccc2N1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059877	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1ccc2[nH]nnc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059878	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using benzyloxyresorufin as substrate after 45 mins by fluorescence detection assay	O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059880	=	=	IC50	nM	84.0	IC50	uM	0.084
Inhibition of human recombinant CYP3A4 expressed in baculo-virus infected insect microsomes using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 20 mins by fluorescence detection assay	O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059880	=	=	IC50	nM	870.0	IC50	uM	0.87
Inhibition of CYP3A4	O=C(N[C@H](Cc1csc2ccccc12)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC2(CC1)N=C(c1ccccc1)NC2=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059900	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	O=C1Nc2ccccc2C2(CCN(C(=O)N[C@H](Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)O1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059905	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	O=C1Nc2ccccc2C2(CCN(C(=O)N[C@H](Cc3csc4ccccc34)C(=O)N3CCC(N4CCCCC4)CC3)CC2)N1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2059906	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4	CCc1c(CCCC(=O)O)cccc1-c1noc(-c2ccc(OC(C)C)c(C#N)c2)n1	J. Med. Chem.	2012.0	CHEMBL2059515	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	CCc1c(CCCC(=O)O)cccc1-c1nnc(-c2ccc(OC(C)C)c(C#N)c2)s1	J. Med. Chem.	2012.0	CHEMBL2059516	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(OC(C)C)c(Cl)c2)n1	J. Med. Chem.	2012.0	CHEMBL2057282	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4	CCc1c(CCN2CCC(C(=O)O)CC2)cccc1-c1nsc(-c2ccc(CC(C)C)c(C#N)c2)n1	J. Med. Chem.	2012.0	CHEMBL2057285	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of human CYP3A4	CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN	J. Med. Chem.	2012.0	CHEMBL2058833	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CPY3A4	O=C(C1CN(S(=O)(=O)c2cccc3cnccc23)C1)N1CC2CN(c3ccncc3)CC2C1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2057776	<	<	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4	CS(=O)(=O)c1ccc(-c2cccn3nc(Nc4cccc(N5CCC(N6CCOCC6)CC5)c4)nc23)cc1	J. Med. Chem.	2012.0	CHEMBL2062808	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4	CN1CCN(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1	J. Med. Chem.	2012.0	CHEMBL2062804	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4	CN1CCC(c2cccc(Nc3nc4c(-c5ccc(S(C)(=O)=O)cc5)cccn4n3)c2)CC1	J. Med. Chem.	2012.0	CHEMBL2062809	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)c(F)ccc3o2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064417	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccs4)cccc3o2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064413	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cccc(-c4ccccc4)c3o2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064412	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3o2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064352	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cccc(-c3ccccc3)c21	J. Med. Chem.	2012.0	CHEMBL2064348	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2c(-c3ccccc3)cccc21	J. Med. Chem.	2012.0	CHEMBL2064347	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)cccc3[nH]2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064346	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2-c2ccccc2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064344	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2C2CCCCC2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064343	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3n2C2CC2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064341	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	CCn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21	J. Med. Chem.	2012.0	CHEMBL2064340	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cc(Cl)ccc3[nH]2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064336	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cc(Br)ccc3[nH]2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064335	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(F)ccc21	J. Med. Chem.	2012.0	CHEMBL2064333	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3[nH]2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064331	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21	J. Med. Chem.	2012.0	CHEMBL2064330	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CPY3A4	O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3o2)[nH]1	J. Med. Chem.	2012.0	CHEMBL2064418	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	O=C(O)c1cc(NC(=O)[C@H](Cc2ccccc2)NCc2cscn2)cc(-c2ccncc2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069579	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cc1cc(-c2c[nH]c(=O)c(NC(=O)[C@H](Cc3ccccc3)NCc3cscn3)c2)ccn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069588	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	Cc1cccc(-c2noc(C3CC(=O)N(c4ccc(F)cc4)C3)n2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069398	>	>	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	c1ccc(CN2CCN(Cc3nnc(-c4ccccc4)o3)CC2)cc1	J. Med. Chem.	2012.0	CHEMBL1504335	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	c1ccc(CN2CCN(Cc3nc(-c4ccccc4)no3)CC2)cc1	J. Med. Chem.	2012.0	CHEMBL2069921	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	O=C(NC1CCCCC1)c1nnc(CS(=O)(=O)c2ccccc2)o1	J. Med. Chem.	2012.0	CHEMBL2069806	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	O=C(NC1CCCCC1)c1nc(CS(=O)(=O)c2ccccc2)no1	J. Med. Chem.	2012.0	CHEMBL2069805	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	c1cc(-c2nnc(C3CCCCC3)o2)ccn1	J. Med. Chem.	2012.0	CHEMBL2069804	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	c1cc(-c2noc(C3CCCCC3)n2)ccn1	J. Med. Chem.	2012.0	CHEMBL2069803	=	=	IC50	nM	10200.0	IC50	uM	10.2
Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	O=C(NCc1ccncc1)c1nnc(CS(=O)(=O)c2ccccc2)o1	J. Med. Chem.	2012.0	CHEMBL2069802	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	O=C(NCc1ccncc1)c1nc(CS(=O)(=O)c2ccccc2)no1	J. Med. Chem.	2012.0	CHEMBL2069801	=	=	IC50	nM	14600.0	IC50	uM	14.6
Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	Clc1cc(-c2nnc(CSc3nnc(-c4ccncc4)n3C3CC3)o2)ccn1	J. Med. Chem.	2012.0	CHEMBL2069800	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli	Clc1cc(-c2nc(CSc3nnc(-c4ccncc4)n3C3CC3)no2)ccn1	J. Med. Chem.	2012.0	CHEMBL2069799	=	=	IC50	nM	14200.0	IC50	uM	14.2
Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccccc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069838	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(F)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069839	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(O)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069840	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(OC(F)(F)F)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069841	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(C(F)(F)F)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069842	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(S(N)(=O)=O)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069843	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2ccc(C(=O)O)cc2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069844	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	N[C@@H](CC(=O)N1CCN(C(=O)c2cccc(C(=O)O)c2)CC1)Cc1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069845	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	CN1CCN(c2ccc(C(=O)N3CCN(C(=O)C[C@H](N)Cc4cc(F)c(F)cc4F)CC3)cc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069846	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4ccccc4s3)CC2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070937	<	>	IC50	nM	31622.78	pIC50		4.5
Inhibition of CYP3A4	CS(=O)(=O)c1ccc2nc(N3CCN(C(=O)[C@@H]4CCCC[C@H]4C(=O)NC4(C#N)CC4)CC3)sc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070947	=	=	IC50	nM	630.96	pIC50		6.2
Inhibition of CYP3A4	CC(C)(C#N)c1cnc(N2CCN(C(=O)[C@@H]3CCCC[C@H]3C(=O)NC3(C#N)CC3)CC2)s1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070948	=	=	IC50	nM	3981.07	pIC50		5.4
Inhibition of CYP3A4	N#CC1(NC(=O)[C@@H]2CCCC[C@H]2C(=O)N2CCN(c3nc4cccnc4s3)CC2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070949	<	>	IC50	nM	31622.78	pIC50		4.5
Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3cn(-c4ccccc4)ccc3=O)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070162	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	O=c1ccc(-c2nc3cc(S(=O)(=O)CC(F)(F)F)ccc3[nH]2)cn1-c1ccccc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070161	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	O=c1ccc(-c2nc3cc(S(=O)(=O)C(F)(F)F)ccc3[nH]2)cn1-c1ccccc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070160	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of CYP3A4	CC(C)(C)S(=O)(=O)c1ccc2[nH]c(-c3ccc(=O)n(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070159	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3ccc(=O)n(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070158	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3ccnc(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070157	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cncc(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070156	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccn3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070155	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)n3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070154	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(C)c(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2069316	=	=	IC50	nM	5700.0	IC50	uM	5.7
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3C)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070153	=	=	IC50	nM	5900.0	IC50	uM	5.9
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3C)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070152	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(Cl)c(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070151	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3Cl)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070150	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3Cl)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070149	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3ccc(F)c(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070148	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cc(-c4ccccc4)ccc3F)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070147	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3F)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070146	=	=	IC50	nM	6600.0	IC50	uM	6.6
Inhibition of CYP3A4	CCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070137	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(OC(F)(F)F)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070143	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(C(F)(F)F)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070142	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3ccc(-c4ccccc4)cc3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070141	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3cccc(-c4ccccc4)c3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070140	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3ccccc3-c3ccccc3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070139	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3ccccc3)nc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070138	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	O=S(=O)(c1ccc2[nH]c(SCc3cccc(Cl)c3)nc2c1)N1CCOCC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL1585484	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4	CCCS(=O)(=O)c1ccc2[nH]c(-c3cccn(-c4ccccc4)c3=O)nc2c1.Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2070163	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4	CCCCCCc1c(O)ccc2c1O[C@]1(C2=O)C(Cl)=C(Cl)C(=O)N1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2087639	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CC(C)n1cnc2c(NCc3ccc(-c4ccccn4)cc3)nc(NC[C@@H](O)CO)nc21	Eur. J. Med. Chem.	2012.0	CHEMBL2089032	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 by high-throughput fluorescence assay	CC(C)c1nc(N2CCN(c3ncc(OCc4ccncc4C#N)cn3)[C@H](C)C2)no1	J. Med. Chem.	2012.0	CHEMBL2086690	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2nc4cc(OC)ccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086751	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2nc4ccccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086753	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(C)cc2)c2nc4ccccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086754	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(OC)cc2)c2nc4ccccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086755	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2nc4ccccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086756	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2cc(F)cc(F)c2)c2nc4ccccc4[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086757	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccccc2)c2ncc[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086758	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2ncc[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086759	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2ccc(Cl)cc2)c2ncc[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2086760	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2087167	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2cc(F)cc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2087168	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCN1CCC(Nc2ccc3c(c2)C(=C(c2nc(C)c[nH]2)c2ccccc2F)C(=O)N3)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2087169	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4	Cn1cc(S(=O)(=O)[C@H]2CC[C@](CNC(=O)c3ccc(Cl)cc3Cl)(CC3CC3)CC2)nn1	ACS Med. Chem. Lett.	2010.0	CHEMBL520648	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	CC1CCN([C@H](c2ccc(F)cc2)c2ccc([C@@H](C)C(=O)O)cc2-c2ccc(C(F)(F)F)cc2)CC1	ACS Med. Chem. Lett.	2011.0	CHEMBL2146750	>	>	IC50	nM	35000.0	IC50	uM	35.0
Inhibition of CYP3A4	Cl.Cn1c(=O)c2c(nc(N3CCC[C@@H](N)C3)n2Cc2cc(F)ccc2Cl)c2ccc(C(=O)O)cc21	Bioorg. Med. Chem.	2012.0	CHEMBL2147070	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4-catalyzed midazolam 1'-hydroxylation in human liver microsomes	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1	J. Med. Chem.	2011.0	CHEMBL565612	=	=	Ki	nM	2900.0	Ki	uM	2.9
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli	c1ccc([C@@H]([C@H](c2ccccc2)N2CCCCC2)N2CCCCC2)cc1	ACS Med. Chem. Lett.	2012.0	CHEMBL2152522	=	=	IC50	nM	15848.93	pIC50		4.8
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli	c1ccc([C@H]([C@@H](c2ccccc2)N2CCCCC2)N2CCCCC2)cc1	ACS Med. Chem. Lett.	2012.0	CHEMBL2152523	=	=	IC50	nM	19952.62	pIC50		4.7
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli	c1ccc([C@@H]([C@H](c2ccccc2)N2CCCC2)N2CCCC2)cc1	ACS Med. Chem. Lett.	2012.0	CHEMBL2152524	=	=	IC50	nM	12589.25	pIC50		4.9
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli	c1ccc([C@H]([C@@H](c2ccccc2)N2CCCC2)N2CCCC2)cc1	ACS Med. Chem. Lett.	2012.0	CHEMBL2152525	=	=	IC50	nM	12589.25	pIC50		4.9
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	COc1ccc(NC(=O)c2cc(-c3ccccc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152010	=	=	Ki	nM	3100.0	Ki	uM	3.1
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	CN(C)c1ccc(NC(=O)c2cc(-c3ccccc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152011	=	=	Ki	nM	14400.0	Ki	uM	14.4
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	O=C(Nc1ccccc1)c1cc(-c2ccccc2)nc2ccccc12	J. Med. Chem.	2012.0	CHEMBL2152012	=	=	Ki	nM	4100.0	Ki	uM	4.1
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	Cc1ccc(NC(=O)c2cc(-c3ccccc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152013	=	=	Ki	nM	3970.0	Ki	uM	3.97
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	COc1ccc(NC(=O)c2cc(-c3ccncc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152014	=	=	Ki	nM	540.0	Ki	uM	0.54
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	CN(C)c1ccc(NC(=O)c2cc(-c3ccncc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152015	=	=	Ki	nM	800.0	Ki	uM	0.8
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	O=C(Nc1ccccc1)c1cc(-c2ccncc2)nc2ccccc12	J. Med. Chem.	2012.0	CHEMBL463976	=	=	Ki	nM	700.0	Ki	uM	0.7
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	Cc1ccc(NC(=O)c2cc(-c3ccncc3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152016	=	=	Ki	nM	540.0	Ki	uM	0.54
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	COc1ccc(NC(=O)c2cc(-c3ccccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152017	=	=	Ki	nM	11900.0	Ki	uM	11.9
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	CN(C)c1ccc(NC(=O)c2cc(-c3ccccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152018	=	=	Ki	nM	32900.0	Ki	uM	32.9
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	O=C(Nc1ccccc1)c1cc(-c2ccccn2)nc2ccccc12	J. Med. Chem.	2012.0	CHEMBL513115	=	=	Ki	nM	14500.0	Ki	uM	14.5
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	Cc1ccc(NC(=O)c2cc(-c3ccccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152019	=	=	Ki	nM	3900.0	Ki	uM	3.9
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	COc1ccc(NC(=O)c2cc(-c3cnccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152020	=	=	Ki	nM	20100.0	Ki	uM	20.1
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	CN(C)c1ccc(NC(=O)c2cc(-c3cnccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152021	=	=	Ki	nM	15930.0	Ki	uM	15.93
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	O=C(Nc1ccccc1)c1cc(-c2cnccn2)nc2ccccc12	J. Med. Chem.	2012.0	CHEMBL2152022	=	=	Ki	nM	6900.0	Ki	uM	6.9
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	Cc1ccc(NC(=O)c2cc(-c3cnccn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152023	=	=	Ki	nM	2700.0	Ki	uM	2.7
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	COc1ccc(NC(=O)c2cc(-c3ccncn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152024	=	=	Ki	nM	2200.0	Ki	uM	2.2
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	CN(C)c1ccc(NC(=O)c2cc(-c3ccncn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2152025	=	=	Ki	nM	8400.0	Ki	uM	8.4
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	O=C(Nc1ccccc1)c1cc(-c2ccncn2)nc2ccccc12	J. Med. Chem.	2012.0	CHEMBL2152026	=	=	Ki	nM	2200.0	Ki	uM	2.2
Inhibition of recombinant CYP3A4 NF-14 expressed in Escherichia coli assessed as formation of 6-beta-hydroxytestosterone using testosterone as substrate after 5 mins by HPLC based UV method	Cc1ccc(NC(=O)c2cc(-c3ccncn3)nc3ccccc23)cc1	J. Med. Chem.	2012.0	CHEMBL2151049	=	=	Ki	nM	3000.0	Ki	uM	3.0
Inhibition of CYP3A4	O=C(C1CCC(F)(F)CC1)N1CC(c2nc(-c3cccc(Cl)c3)no2)C1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151497	=	=	IC50	nM	25000000.0	IC50	mM	25.0
Inhibition of CYP3A4	CC1CCCCC1C(=O)N1CC(c2nc(-c3cccc(F)c3)no2)C1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151616	=	=	IC50	nM	25000000.0	IC50	mM	25.0
Inhibition of human CYP3A4 using midazolam as substrate after 15 mins by LC/MS/MS analysis	CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N	J. Med. Chem.	2012.0	CHEMBL2152252	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of human CYP3A4 using testosterone as substrate after 15 mins by LC/MS/MS analysis	CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N	J. Med. Chem.	2012.0	CHEMBL2152252	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2064419	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151821	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151921	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	COc1cccc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151922	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1cccc(Br)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151923	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	Cc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151925	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151926	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	COc1cc(NC(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)ccc1F	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151927	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccc(F)c(Br)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151048	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	Cn1c(CC(=O)Nc2ccc(F)c(Cl)c2)nc(N2CCOCC2)cc1=O	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2151935	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	NC(=O)c1ccccc1Nc1cccc(OCCc2ccccc2)c1	J. Med. Chem.	2012.0	CHEMBL2152613	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@H](C)c2nc(-c3ccccc3)c[nH]2)cc1C(=O)O.Cl.Cl	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL4299173	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCSC)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159130	=	=	IC50	nM	1330.0	IC50	uM	1.33
Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCN(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159131	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N/c2ccc(OC)cc2)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159136	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159135	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159134	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(OC)C[C@@H](C)NC(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159133	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159132	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C	J. Med. Chem.	2012.0	CHEMBL2159140	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C	J. Med. Chem.	2012.0	CHEMBL2159139	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of human recombinant CYP3A4 using DEF as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL529	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCSC)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159130	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\CCCN(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159131	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N/c2ccc(OC)cc2)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159136	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)(C)C)N3C)[C@](C)(OC)C[C@@H](C)C(=O)N[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159135	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159134	=	=	IC50	nM	9800.0	IC50	uM	9.8
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(OC)C[C@@H](C)NC(=O)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159133	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H]3[C@H]2O/C(=N\C(C)C)N3C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL2159132	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C	J. Med. Chem.	2012.0	CHEMBL2159140	=	=	IC50	nM	5700.0	IC50	uM	5.7
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@]3(C)O)O[C@H](C)C[C@@H]2N1C	J. Med. Chem.	2012.0	CHEMBL2159139	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC/N=C1\O[C@H]2[C@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]4C[C@@](C)(OC)[C@@H](O)[C@H](C)O4)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]3(C)OC)O[C@H](C)C[C@@H]2N1C	J. Med. Chem.	2012.0	CHEMBL2159138	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of human recombinant CYP3A4 using 7-BQ as substrate preincubated for 5 to 10 mins before substrate addition	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	J. Med. Chem.	2012.0	CHEMBL529	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 using midazolam as substrate	Cc1nc2cnc3[nH]ccc3c2n1[C@@H]1CCC[C@@H](O)C1	J. Med. Chem.	2012.0	CHEMBL2159210	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 using testosterone as substrate	Cc1nc2cnc3[nH]ccc3c2n1[C@@H]1CCC[C@@H](O)C1	J. Med. Chem.	2012.0	CHEMBL2159210	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate	Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2159071	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate	Cc1ccc(C2(C(=O)N(C)Cc3cccs3)CC2)cc1	Bioorg. Med. Chem.	2012.0	CHEMBL2159071	=	=	IC50	nM	7300.0	IC50	uM	7.3
Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate	CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem.	2012.0	CHEMBL2159084	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate	CN(Cc1cccn1C)C(=O)C12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem.	2012.0	CHEMBL2159084	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate	CN(Cc1cccs1)C(=O)CC12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem.	2012.0	CHEMBL2158890	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl) coumarin as substrate	CN(Cc1cccs1)C(=O)C12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem.	2012.0	CHEMBL2159075	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCNCC3)cc2C2=CCCCC2)n1.O=C(O)C(F)(F)F	J. Med. Chem.	2011.0	CHEMBL2158221	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(c4ccccn4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158222	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(Cc4ccccn4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158224	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4	N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCO)CC3)cc2C2=CCCCC2)[nH]1	J. Med. Chem.	2011.0	CHEMBL2158225	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CS(=O)(=O)CCN1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1	J. Med. Chem.	2011.0	CHEMBL2158227	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(CC(N)=O)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158228	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	N#Cc1cnc(C(=O)Nc2ccc(C3CCN(CCN4CCOCC4)CC3)cc2C2=CCCCC2)[nH]1	J. Med. Chem.	2011.0	CHEMBL2158230	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4	CC(=O)N1CCC(c2ccc(NC(=O)c3ncc(C#N)[nH]3)c(C3=CCCCC3)c2)CC1	J. Med. Chem.	2011.0	CHEMBL256712	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4cccnc4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158231	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of CYP3A4	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1	J. Med. Chem.	2011.0	CHEMBL1908842	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)[C@H](O)CO)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158287	=	=	IC50	nM	8200.0	IC50	uM	8.2
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CNCCO)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158288	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of CYP3A4	CN(CCO)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1	J. Med. Chem.	2011.0	CHEMBL2158289	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4ccc[n+]([O-])c4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158291	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)c4cc[n+]([O-])cc4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158292	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cn1cnc(CC(=O)N2CCC(c3ccc(NC(=O)c4nc(C#N)c[nH]4)c(C4=CCCCC4)c3)CC2)c1	J. Med. Chem.	2011.0	CHEMBL2158294	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccccn4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158295	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)Cc4ccncc4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158297	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)CN4CCOCC4)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158299	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4	CC(C)(N)C(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1	J. Med. Chem.	2011.0	CHEMBL2158301	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	N#Cc1c[nH]c(C(=O)Nc2ccc(C3CCN(C(=O)NCCO)CC3)cc2C2=CCCCC2)n1	J. Med. Chem.	2011.0	CHEMBL2158302	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of human CYP3A4 in liver microsomes assessed as testosterone 6beta-hydroxylation after 48 hrs	COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	J. Med. Chem.	2012.0	CHEMBL1933349	=	=	IC50	nM	60000.0	IC50	uM	60.0
Inhibition of CYP3A4 using midazolam as substrate	O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1	J. Med. Chem.	2012.0	CHEMBL1939222	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 using testosterone as substrate	O=c1cc(COc2cc(Cl)cc(Cl)c2)[nH][nH]1	J. Med. Chem.	2012.0	CHEMBL1939222	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4	CC[C@H](C(=O)Nc1ccccc1N1CCCC1)c1ccccc1	J. Med. Chem.	2012.0	CHEMBL2164048	=	=	IC50	nM	3900.0	IC50	uM	3.9
inhibition of CYP3A4	O=S(=O)(NCCO)c1ccc(-c2ccnc3[nH]c(C4CC4)cc23)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2164422	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(OC(F)(F)F)cc2)CC1	J. Med. Chem.	2012.0	CHEMBL2163828	=	=	IC50	nM	2900.0	IC50	nM	2900.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(OC(F)(F)F)cc2)CC1	J. Med. Chem.	2012.0	CHEMBL2163827	=	=	IC50	nM	2400.0	IC50	nM	2400.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1	J. Med. Chem.	2012.0	CHEMBL2163826	=	=	IC50	nM	600.0	IC50	nM	600.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1C[C@@H]2CC[C@H](C1)N2C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1	J. Med. Chem.	2012.0	CHEMBL2163825	=	=	IC50	nM	430.0	IC50	nM	430.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1CCCC(NC(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)C1	J. Med. Chem.	2012.0	CHEMBL2163824	=	=	IC50	nM	420.0	IC50	nM	420.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	NC1CCN(C(=O)[C@H](Cc2ccc(Br)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163823	=	=	IC50	nM	8000.0	IC50	nM	8000.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	O=C([C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1)N1CCC(O)CC1	J. Med. Chem.	2012.0	CHEMBL2163822	=	=	IC50	nM	1300.0	IC50	nM	1300.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN(C)CCN(C)C(=O)[C@H](Cc1ccc(Br)cc1)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1	J. Med. Chem.	2012.0	CHEMBL2163839	=	=	IC50	nM	7800.0	IC50	nM	7800.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN(C)CCN(C)C(=O)[C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1	J. Med. Chem.	2012.0	CHEMBL2163838	=	=	IC50	nM	1530.0	IC50	nM	1530.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	C[C@H]1CN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CCN1	J. Med. Chem.	2012.0	CHEMBL2163837	=	=	IC50	nM	400.0	IC50	nM	400.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	C[C@@H]1CN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CCN1	J. Med. Chem.	2012.0	CHEMBL2163836	=	=	IC50	nM	450.0	IC50	nM	450.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	O=C([C@H](Cc1ccc(Cl)cc1Cl)NC(=O)C1(c2ccc(Cl)cc2Cl)CC1)N1CCNCC1	J. Med. Chem.	2012.0	CHEMBL2163835	<	<	IC50	nM	200.0	IC50	nM	200.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](Cc2ccc(Br)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163834	=	=	IC50	nM	480.0	IC50	nM	480.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163833	=	=	IC50	nM	760.0	IC50	nM	760.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2Cl)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163832	=	=	IC50	nM	1030.0	IC50	nM	1030.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](Cc2ccccc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163831	=	=	IC50	nM	1360.0	IC50	nM	1360.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](COCc2ccccc2)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163830	=	=	IC50	nM	2200.0	IC50	nM	2200.0
Inhibition of human CYP3A4 using testosterone as substrate after 45 mins	CN1CCN(C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)C2(c3ccc(Cl)cc3Cl)CC2)CC1	J. Med. Chem.	2012.0	CHEMBL2163829	=	=	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of hepatic CYP3A4	CCOc1cc2c(cc1-c1cccnc1)CCC(=O)N2C	J. Med. Chem.	2012.0	CHEMBL2165317	=	=	IC50	nM	90000.0	IC50	uM	90.0
Inhibition of hepatic CYP3A4	COc1cc2c(cc1-c1cccnc1)CCC(=O)N2C	J. Med. Chem.	2012.0	CHEMBL2165315	=	=	IC50	nM	90000.0	IC50	uM	90.0
Inhibition of human CYP3A4	NC(=O)c1cc2cc(Br)c(C(F)(F)F)nc2nc1N	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2163365	>	>	IC50	nM	50000.0	IC50	uM	50.0
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2sc(CN3CCN4CCOC[C@H]4C3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165505	=	=	Ki	nM	78000.0	Ki	uM	78.0
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165504	=	=	Ki	nM	6600.0	Ki	uM	6.6
Inhibition of CYP3A4	Cc1cc(-c2cc(=O)[nH]c(NCc3cccc4ccccc34)n2)ccn1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2165175	=	=	IC50	nM	700.0	IC50	uM	0.7
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C4COC4)CC3(C)C)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165502	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCC(C(C)(C)O)CC3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165501	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CCc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(S(C)(=O)=O)CC3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165500	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCN(C(C)(C)C(N)=O)CC3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165499	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Cc1nc2ccccc2n1-c1nc(N2CCOCC2)c2sc(CN3CCC(N(C)C)CC3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165498	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CN(C)C1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165666	=	=	IC50	nM	9100.0	IC50	uM	9.1
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4ccnc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165513	<	<	IC50	nM	100.0	IC50	uM	0.1
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cncc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165512	=	=	IC50	nM	3200.0	IC50	uM	3.2
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4nccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165511	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Cn1ccc2c(-c3nc(N4CCOCC4)c4sc(CN5CCN(C(C)(C)C(N)=O)CC5)cc4n3)cccc21	J. Med. Chem.	2012.0	CHEMBL2165510	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Cc1cc2c(-c3nc(N4CCOCC4)c4sc(CN5CCN(C(C)(C)C(N)=O)CC5)cc4n3)cccc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2165509	<	<	IC50	nM	100.0	IC50	uM	0.1
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)cc(F)c5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165508	=	=	IC50	nM	600.0	IC50	uM	0.6
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cc(C#N)cc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165507	=	=	IC50	nM	1200.0	IC50	uM	1.2
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4cc(F)cc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165506	=	=	IC50	nM	510.0	IC50	uM	0.51
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	Fc1ccc2[nH]ccc2c1-c1nc(N2CCOCC2)c2sc(CN3CCN4CCOC[C@H]4C3)cc2n1	J. Med. Chem.	2012.0	CHEMBL2165505	=	=	IC50	nM	7000.0	IC50	uM	7.0
Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins	CC(C)(C(N)=O)N1CCN(Cc2cc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3s2)CC1	J. Med. Chem.	2012.0	CHEMBL2165504	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 in human liver microsomes	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1	J. Med. Chem.	2012.0	CHEMBL2001019	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	COc1cc(C(=O)N[C@@H](CC(=O)O)c2ccccc2C)nn1-c1ccccc1F	J. Med. Chem.	2012.0	CHEMBL2171396	=	=	IC50	nM	26.0	IC50	nM	26.0
Inhibition of CYP3A4	Cc1ccccc1[C@H](CC(=O)O)NC(=O)c1cc(OCC2CC2)n(-c2ccccc2F)n1	J. Med. Chem.	2012.0	CHEMBL2171398	=	=	IC50	nM	15.0	IC50	nM	15.0
Inhibition of CYP3A4	CCOc1cc(C(=O)N[C@@H](CC(=O)O)c2ccccc2C)nn1-c1ccccc1F	J. Med. Chem.	2012.0	CHEMBL2171397	=	=	IC50	nM	15.0	IC50	nM	15.0
Inhibition of CYP3A4	Cc1ccccc1[C@H](CC(=O)O)NC(=O)c1cc(=O)n(-c2ccccc2F)[nH]1	J. Med. Chem.	2012.0	CHEMBL3145341	=	=	IC50	nM	38.0	IC50	nM	38.0
Inhibition of human CYP3A4 using 7-benzyloxyquinoline as substrate incubated for 30 mins prior to substrate addition measured up to 10 mins by fluorimetry	COc1cc2c(cc1C(F)(F)F)N(C(=O)Nc1cc(OC(F)(F)F)cc(-c3cccnc3)c1)CC2	ACS Med. Chem. Lett.	2012.0	CHEMBL586213	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	O=C(Nc1nc2ccc(O)cc2s1)c1c(F)ccc(O)c1F	J. Med. Chem.	2012.0	CHEMBL2170747	=	=	IC50	nM	54000.0	IC50	uM	54.0
Inhibition of human CYP3A4	Cc1ccc(C(=O)c2nc3ccc(O)cc3s2)cc1O	J. Med. Chem.	2012.0	CHEMBL2170754	=	=	IC50	nM	54000.0	IC50	uM	54.0
Inhibition of human CYP3A4	O=C(c1ccc(F)c(O)c1)c1nc2ccc(O)cc2s1	J. Med. Chem.	2012.0	CHEMBL2170750	=	=	IC50	nM	54000.0	IC50	uM	54.0
Inhibition of human recombinant CYP3A4	Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	J. Med. Chem.	2012.0	CHEMBL2170062	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	J. Med. Chem.	2012.0	CHEMBL2170062	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170610	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CCC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170609	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	COCC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170608	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)C3CC3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170607	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CC(C)C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170606	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CC(C)(C)C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170605	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	Cn1cncc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170618	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	Cn1ccnc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170617	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(S(N)(=O)=O)cc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170615	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(O)nc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170639	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(C(N)=O)cc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170638	=	=	IC50	nM	24500.0	IC50	uM	24.5
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccccn3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170637	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3cccnc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170636	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 using midazolam as substrate	Cc1ccccc1-n1nc(-c2c(-c3ccc(F)cc3)nn3c2NC[C@@H](CO)C3)ccc1=O	J. Med. Chem.	2012.0	CHEMBL2170294	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccncc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170635	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CS(=O)(=O)c1cccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)c1	J. Med. Chem.	2012.0	CHEMBL2170633	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	CS(=O)(=O)c1ccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)cc1	J. Med. Chem.	2012.0	CHEMBL2170632	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N#Cc1ccccc1C(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1	J. Med. Chem.	2012.0	CHEMBL2170631	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N#Cc1cccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)c1	J. Med. Chem.	2012.0	CHEMBL2170630	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N#Cc1ccc(C(=O)N2CCC(c3ccc(C(=O)NC(=N)N)cc3C(F)(F)F)CC2)cc1	J. Med. Chem.	2012.0	CHEMBL2170629	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccc(F)cc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170643	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(C2CCN(C(=O)c3ccccc3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2170642	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by LC/MS/MS analysis	N=C(N)NC(=O)c1ccc(N2CCN(C(=O)c3ccc[nH]3)CC2)c(C(F)(F)F)c1	J. Med. Chem.	2012.0	CHEMBL2105423	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method	CN1C[C@@H](C(=O)Nc2ccc(Cl)cc2)[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)C1	J. Med. Chem.	2012.0	CHEMBL2177588	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method	CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2F)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1	J. Med. Chem.	2012.0	CHEMBL2177582	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method	CC(C)(O)CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1	J. Med. Chem.	2012.0	CHEMBL2178223	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method	Nc1ccccc1NC(=O)/C=C/c1ccc([C@H]2CN(CCO)C[C@@H]2C(=O)Nc2ccc(Cl)cc2)cc1	J. Med. Chem.	2012.0	CHEMBL2178221	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS method	CN1C[C@H](c2ccc(/C=C/C(=O)Nc3ccccc3N)cc2)[C@@H](C(=O)Nc2ccc(Cl)cc2)C1	J. Med. Chem.	2012.0	CHEMBL2177587	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	CO[C@H](C)C(=O)N[C@@H](Cc1ccc2c(c1)OCO2)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181880	=	=	IC50	nM	50.0	IC50	nM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	C#Cc1ccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)cc1	J. Med. Chem.	2012.0	CHEMBL2181899	=	=	IC50	nM	100.0	IC50	nM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1ccc(-c2nccs2)cc1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181898	=	=	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	CC#Cc1cccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)c1	J. Med. Chem.	2012.0	CHEMBL2181897	=	=	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	C#Cc1cccc(C[C@H](NC(=O)COC)[C@H](O)CN[C@H]2CC3(CCC3)Oc3ncc(CC(C)(C)C)cc32)c1	J. Med. Chem.	2012.0	CHEMBL2181896	=	=	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2nc(C)cs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181895	=	=	IC50	nM	100.0	IC50	nM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2cscn2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181894	=	=	IC50	nM	100.0	IC50	nM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2cncs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181893	=	=	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2nccs2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181892	=	=	IC50	nM	100.0	IC50	nM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2nccn2C)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181891	=	=	IC50	nM	50.0	IC50	nM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2ncco2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181890	=	=	IC50	nM	100.0	IC50	nM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2ccccn2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181889	=	=	IC50	nM	400.0	IC50	nM	400.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by HPLC-MS analysis	COCC(=O)N[C@@H](Cc1cccc(-c2ccncc2)c1)[C@H](O)CN[C@H]1CC2(CCC2)Oc2ncc(CC(C)(C)C)cc21	J. Med. Chem.	2012.0	CHEMBL2181888	=	=	IC50	nM	160.0	IC50	nM	160.0
Inhibition of CYP3A4	CNc1ccn2ncc(C(=O)Nc3cc(C)nn3-c3cccc(Cl)c3)c2n1	J. Med. Chem.	2012.0	CHEMBL2178247	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1cc(NC(=O)c2cnn3ccc(N)nc23)n(-c2cccc(Cl)c2)n1	J. Med. Chem.	2012.0	CHEMBL2178807	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time dependent inhibition of CYP3A4	Cn1cc(NC(=O)c2cnn3ccc(N)nc23)c(-c2cc(Cl)ccc2Cl)n1	J. Med. Chem.	2012.0	CHEMBL2178804	=	=	IC50	nM	5800.0	IC50	uM	5.8
Inhibition of CYP3A4 preincubated with substrate	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J. Med. Chem.	2012.0	CHEMBL2178718	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 coincubated with substrate	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J. Med. Chem.	2012.0	CHEMBL2178718	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cn3)C[C@H]2C1=O	J. Med. Chem.	2012.0	CHEMBL2178714	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4	Cc1nc(-c2cccc(Cl)c2)c(NC(=O)c2cnn3ccc(N)nc23)s1	J. Med. Chem.	2012.0	CHEMBL2178258	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of CYP3A4	Cn1cc(NC(=O)c2cnn3ccc(N)nc23)c(-c2cccc(Cl)c2)n1	J. Med. Chem.	2012.0	CHEMBL2178254	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(Nc1c[nH]nc1-c1cccc(Cl)c1)c1cnn2cccnc12	J. Med. Chem.	2012.0	CHEMBL2178253	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4	Cn1cc(NC(=O)c2cnn3cccnc23)c(-c2cccc(Cl)c2)n1	J. Med. Chem.	2012.0	CHEMBL2178252	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cn1cc(-c2cccc(Cl)c2)c(NC(=O)c2cnn3cccnc23)n1	J. Med. Chem.	2012.0	CHEMBL2178251	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1cc(NC(=O)c2cnn3cccnc23)c(-c2cccc(Cl)c2)cn1	J. Med. Chem.	2012.0	CHEMBL2178250	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	O=C(Nc1ccncc1-c1cccc(Cl)c1)c1cnn2cccnc12	J. Med. Chem.	2012.0	CHEMBL2178249	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4	O=C(Nc1cccnc1-c1cccc(Cl)c1)c1cnn2cccnc12	J. Med. Chem.	2012.0	CHEMBL2178248	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	Cc1cc(NC(=O)c2cnn3cccnc23)n(-c2cccc(Cl)c2)n1	J. Med. Chem.	2012.0	CHEMBL2178806	=	=	IC50	nM	4600.0	IC50	uM	4.6
Inhibition of CYP3A4	CS(=O)(=O)c1ccc(F)cc1C(=O)N1CCC(N(C2CC2)S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1	J. Med. Chem.	2012.0	CHEMBL2180905	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH	COc1ccc(S(=O)(=O)N2CCOc3ccc(Cl)cc32)cc1NC1CCN(C)CC1	J. Med. Chem.	2012.0	CHEMBL2178742	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH	COc1ccc(S(=O)(=O)n2nc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1.O=C(O)[C@H](O)[C@@H](O)C(=O)O	J. Med. Chem.	2012.0	CHEMBL3436346	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH	COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)cnc32)cc1NC1CCN(C)CC1	J. Med. Chem.	2012.0	CHEMBL2179222	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins by LC-MS/MS analysis in presence of NADPH	COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1	J. Med. Chem.	2012.0	CHEMBL2179217	=	=	IC50	nM	6460.0	IC50	uM	6.46
Inhibition of CYP3A4	FC(F)(F)c1c(N2CCC(c3ccccc3)CC2)ccn2c(CC3CC3)nnc12	J. Med. Chem.	2012.0	CHEMBL2179319	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human recombinant CYP3A4 using benzoylresorufin as substrate after 45 mins by fluorescence assay	N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F	J. Med. Chem.	2012.0	CHEMBL2178422	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 20 mins by fluorescence assay	N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F	J. Med. Chem.	2012.0	CHEMBL2178422	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CNC(=O)c5cccc(F)c5)cc4)c3n2)c1	J. Med. Chem.	2012.0	CHEMBL2177836	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins	Nc1ncccc1-c1nc2cc(-c3cccnc3)cnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1	J. Med. Chem.	2012.0	CHEMBL2177831	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CNC(=O)c2ccccc2)cc1	J. Med. Chem.	2012.0	CHEMBL2177819	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins	Nc1ncccc1-c1nc2cccnc2n1-c1ccc(CC(=O)Nc2ccccc2)cc1	J. Med. Chem.	2012.0	CHEMBL2177818	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl	J. Med. Chem.	2012.0	CHEMBL1651219	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1	J. Med. Chem.	2012.0	CHEMBL2151164	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1	J. Med. Chem.	2012.0	CHEMBL2151164	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of recombinant CYP3A4 expressed in baculovirus-infected insect cells using fluorogeinc substrate	CC(C)[C@@H](NC(=O)c1ccccc1)C(=O)N1CCC(c2ccc(Cl)cc2)CC1	J. Med. Chem.	2012.0	CHEMBL2180528	>	>	IC50	nM	40000.0	IC50	nM	40000.0
Inhibition of CYP3A4	Cc1nc(C)c(-c2ccc([C@H]3CC[C@H](CC(=O)O)CC3)cc2)nc1C(N)=O	J. Med. Chem.	2012.0	CHEMBL2178953	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS	COc1ccc2cc1COCC=CCOCc1cc(ccc1OCCN1CCCC1)Nc1nccc-2n1	J. Med. Chem.	2011.0	CHEMBL2181313	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS	Cc1cnc2nc1-c1cccc(c1)COCC=CCOCc1cc(ccc1OCCN1CCCC1)N2	J. Med. Chem.	2011.0	CHEMBL2181088	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS	C1=CCOCc2cc(ccc2OCCN2CCCCC2)Nc2nccc(n2)-c2cccc(c2)COC1	J. Med. Chem.	2011.0	CHEMBL2181331	=	=	IC50	nM	370.0	IC50	uM	0.37
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1	J. Med. Chem.	2011.0	CHEMBL2035187	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 1-hydroxymidazolam from midazolam substrate after 5 mins by LC-MS/MS	CCN(CC)CCOc1ccc2cc1COCC=CCOCc1cccc(c1)-c1ccnc(n1)N2	J. Med. Chem.	2011.0	CHEMBL2181329	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of CYP3A4	Cn1c(-c2ccncc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181629	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP3A4	Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181621	=	=	IC50	nM	10700.0	IC50	uM	10.7
Inhibition of CYP3A4	Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181618	=	=	IC50	nM	6300.0	IC50	uM	6.3
Inhibition of CYP3A4	Cn1c(-c2cnccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181643	=	=	IC50	nM	10600.0	IC50	uM	10.6
Inhibition of CYP3A4	COc1ccc(-c2c(C3CCCC3)c3ccc(C(=O)NC4(C(=O)Nc5ccc(/C=C/C(=O)O)cc5)CCC4)cc3n2C)cn1	J. Med. Chem.	2012.0	CHEMBL2181641	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4	Cn1c(-c2cccc(N)n2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181638	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4	Cn1c(-c2ccc(F)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181635	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of CYP3A4	Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181634	=	=	IC50	nM	10900.0	IC50	uM	10.9
Inhibition of CYP3A4	Cc1ccc(-c2c(C3CCCC3)c3ccc(C(=O)NC4(C(=O)Nc5ccc(/C=C/C(=O)O)cc5)CCC4)cc3n2C)nc1	J. Med. Chem.	2012.0	CHEMBL2181777	=	=	IC50	nM	5800.0	IC50	uM	5.8
Inhibition of CYP3A4	Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181776	=	=	IC50	nM	9500.0	IC50	uM	9.5
Inhibition of CYP3A4	Cn1c(-c2ccc(Cl)cc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181775	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of CYP3A4	Cn1c(-c2ccoc2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2012.0	CHEMBL2181765	=	=	IC50	nM	9200.0	IC50	uM	9.2
Inhibition of CYP3A4	Cn1c(-c2ccc(Cl)cn2)c(C2CCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21	J. Med. Chem.	2012.0	CHEMBL2181789	=	=	IC50	nM	9400.0	IC50	uM	9.4
Inhibition of CYP3A4	Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC(C)(C)C(=O)Nc3ccc(/C=C/C(=O)O)cc3)cc21	J. Med. Chem.	2012.0	CHEMBL2181786	=	=	IC50	nM	7900.0	IC50	uM	7.9
Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	J. Med. Chem.	2012.0	CHEMBL114	=	=	Ki	nM	650.0	Ki	uM	0.65
Time dependent inhibition of CYP3A4 in human liver microsomes	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O	J. Med. Chem.	2012.0	CHEMBL1084546	=	=	Ki	nM	12000.0	Ki	uM	12.0
Time dependent inhibition of CYP3A4	CC(C)(C)NC(=O)C1(C2CCCCC2)CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2)NC(=O)[C@H]2CCc3ccccc3[C@H]2N)CC1	J. Med. Chem.	2012.0	CHEMBL433764	=	=	Ki	nM	23000.0	Ki	uM	23.0
Reversible inhibition of CYP3A4	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	J. Med. Chem.	2012.0	CHEMBL45816	=	=	IC50	nM	300.0	IC50	uM	0.3
Time dependent inhibition of CYP3A4	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	J. Med. Chem.	2012.0	CHEMBL45816	=	=	Ki	nM	2300.0	Ki	uM	2.3
Inhibition of CYP3A4 in human liver microsomes	O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12	J. Med. Chem.	2012.0	CHEMBL81	=	=	Ki	nM	9900.0	Ki	uM	9.9
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	COc1cc(CC(=O)O)ccc1Oc1ccc2[nH]c(C)cc2c1NS(=O)(=O)c1ccc(Cl)cc1Cl	J. Med. Chem.	2012.0	CHEMBL2181816	=	=	Ki	nM	18000.0	Ki	uM	18.0
Time dependent inhibition of CYP3A4	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1	J. Med. Chem.	2012.0	CHEMBL553	=	=	Ki	nM	6300.0	Ki	uM	6.3
Time dependent inhibition of CYP3A4 in human liver microsomes assessed as quasi-irreversible complex formation	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1	J. Med. Chem.	2012.0	CHEMBL554	=	=	Ki	nM	1700.0	Ki	uM	1.7
Time dependent inhibition of CYP3A4 in human liver microsomes	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1	J. Med. Chem.	2012.0	CHEMBL1421	=	=	Ki	nM	6300.0	Ki	uM	6.3
Inhibition of CYP3A4-mediated midazolam 1'-hydroxylation	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1	J. Med. Chem.	2012.0	CHEMBL941	=	=	Ki	nM	14300.0	Ki	uM	14.3
Time dependent inhibition of CYP3A4	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1	J. Med. Chem.	2012.0	CHEMBL623	=	=	Ki	nM	1000.0	Ki	uM	1.0
Time dependent inhibition of CYP3A4 in human liver microsomes	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1	J. Med. Chem.	2012.0	CHEMBL623	=	=	IC50	nM	15.0	IC50	uM	0.015
Competitive inhibition of CYP3A4 in human liver microsomes	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1	J. Med. Chem.	2012.0	CHEMBL623	=	=	IC50	nM	1500.0	IC50	uM	1.5
Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	J. Med. Chem.	2012.0	CHEMBL163	=	=	Ki	nM	170.0	Ki	uM	0.17
Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	J. Med. Chem.	2012.0	CHEMBL584	=	=	Ki	nM	1000.0	Ki	uM	1.0
Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	J. Med. Chem.	2012.0	CHEMBL116	=	=	Ki	nM	370.0	Ki	uM	0.37
Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome	Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O	J. Med. Chem.	2012.0	CHEMBL729	=	=	Ki	nM	1000.0	Ki	uM	1.0
Inhibition of CYP3A4-mediated N-demethylation in human liver microsomes	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	J. Med. Chem.	2012.0	CHEMBL23	=	=	Ki	nM	100.0	Ki	uM	0.1
Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017291	=	=	IC50	nM	9700.0	IC50	uM	9.7
Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017288	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccn3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017286	=	=	IC50	nM	12900.0	IC50	uM	12.9
Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(Cc3ccccc3)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017285	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n(-c3ccccc3C(C)(C)C)c12	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017283	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(NC3CCCCC3)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017277	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(Nc3cccc4cccnc34)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017281	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of CYP3A4 using diethoxyfluoresin as substrate	COc1cc2c(Nc3ccccc3F)c(C(N)=O)cnc2cc1-c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017273	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 using diethoxyfluoresin as substrate	Cc1noc(C)c1-c1ccc2c(Nc3ccccc3C(C)(C)C)c(C(=O)O)cnc2c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2017269	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1.Cl	J. Med. Chem.	2011.0	CHEMBL2204363	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1.Cl	J. Med. Chem.	2011.0	CHEMBL2204360	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)c(Cl)c1	J. Med. Chem.	2011.0	CHEMBL2204359	=	=	IC50	nM	4400.0	IC50	uM	4.4
Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cc1cccc(Sc2ccccc2N2CCNCC2)c1C.Cl	J. Med. Chem.	2011.0	CHEMBL2204357	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cl.Clc1cccc(Sc2ccccc2N2CCNCC2)c1Cl	J. Med. Chem.	2011.0	CHEMBL2204356	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cc1ccc(Sc2ccccc2N2CCNCC2)cc1C.Cl	J. Med. Chem.	2011.0	CHEMBL2205054	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cc1ccc(Sc2ccccc2N2CCNCC2)cc1.Cl	J. Med. Chem.	2011.0	CHEMBL2205045	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of human recombinant CYP3A4 using resorufin benzyl ether after 30 mins by fluorescence spectrophotometric analysis	Cl.Clc1ccc(Sc2ccccc2N2CCNCC2)cc1	J. Med. Chem.	2011.0	CHEMBL2205043	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of human liver microsome CYP3A4 by LC-MS-MS analysis	Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ccc(Cl)cc4)CC3)c(Cl)cnc2[nH]1	J. Med. Chem.	2012.0	CHEMBL2207503	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4	CCN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C	ACS Med. Chem. Lett.	2012.0	CHEMBL2206278	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	CN1C(C)(C)CC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1(C)C	ACS Med. Chem. Lett.	2012.0	CHEMBL2206277	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4	CCN1CCC(Oc2ccc(C(=O)Nc3ccc(NC(=O)Nc4cc(C(C)(C)C)on4)cc3)nc2)CC1	ACS Med. Chem. Lett.	2012.0	CHEMBL2203434	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of cytochrome P450 3A4	O=S(=O)(Nc1cc(Cl)ccc1Cn1ccnn1)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2207081	=	=	IC50	nM	3981.07	pIC50		5.4
Inhibition of cytochrome P450 3A4	O=S(=O)(Nc1cc(Cl)c(Cl)cc1Cn1ccnn1)c1ccc(Cl)s1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2207100	=	=	IC50	nM	5011.87	pIC50		5.3
Inhibition of cytochrome P450 3A4	Cn1nnnc1Cc1ncc(Cl)cc1NS(=O)(=O)c1ccc(Cl)c(Cl)c1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2207099	=	=	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 in human liver microsomes	COc1ccc(C#Cc2ccc(C(=O)N3CCC[C@@H](CO)C3)cc2)cc1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2204445	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	COC(=O)C(C)(C)C(c1ccc(Nc2ccccc2)cc1)n1cncn1	Bioorg. Med. Chem.	2012.0	CHEMBL2205775	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4	Cc1c(Cc2ccc(=O)n(Cc3ccc(F)cc3F)n2)c2cc(F)ccc2n1CC(=O)O	J. Med. Chem.	2012.0	CHEMBL2204469	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4	CS(=O)(=O)NCc1nc2cnc3[nH]ccc3c2n1[C@@H]1C[C@H]2CC[C@@H]1C2	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2206059	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH	CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2207388	=	=	IC50	nM	30500.0	IC50	uM	30.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH	CN1CCN(Cc2cccc3c2ccn3S(=O)(=O)c2ccccc2Br)CC1	Bioorg. Med. Chem. Lett.	2012.0	CHEMBL2207386	=	=	IC50	nM	35970.0	IC50	uM	35.97
Inhibition of Homo sapiens (human) recombinant CYP3A4 by fluorogenic assay	COc1ccc2c(n1)C1(CO2)C(=O)N(Cc2ccc(C(F)(F)F)o2)c2ccccc21	Med Chem Res	2013.0	CHEMBL2296321	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in Trichoplusia ni BTI-TN-5B1-4 cells preincubated for 15 mins measured after 30 mins by spectrofluorimetry	N=C(N)c1ccc(CNC(=O)[C@@H]2Cc3ccc(cc3)NC(=O)CCN3CCN(CCC(=O)Nc4ccc(cc4)C[C@@H](NS(=O)(=O)Cc4ccccc4)C(=O)N2)CC3)cc1.O=C(O)C(F)(F)F	J. Med. Chem.	2013.0	CHEMBL2315243	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in Trichoplusia ni BTI-TN-5B1-4 cells preincubated for 15 mins measured after 30 mins by spectrofluorimetry	N=C(N)c1ccc(CNC(=O)[C@@H]2Cc3ccc(cc3)NC(=O)CN3CCN(CC3)CC(=O)Nc3ccc(cc3)C[C@@H](NS(=O)(=O)Cc3ccccc3)C(=O)N2)cc1.O=C(O)C(F)(F)F	J. Med. Chem.	2013.0	CHEMBL2315239	>	>	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	C[S+]([O-])Cc1ccc(C(=O)Nc2ccc(OCCOCCO)nc2C(=O)NCC2CCC2)c2ccccc12	J. Med. Chem.	2013.0	CHEMBL2316386	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	C[S+]([O-])Cc1ccc(C(=O)Nc2nccnc2C(=O)NCC2CCC2)c2ccccc12	J. Med. Chem.	2013.0	CHEMBL2316385	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	C[S+]([O-])Cc1ccc(C(=O)Nc2cccnc2C(=O)NCC2CCOCC2)c2ccccc12	J. Med. Chem.	2013.0	CHEMBL2316383	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	COc1ccc(NC(=O)c2ccc(C[S+](C)[O-])c3ccccc23)c(C(=O)NCC2CCOCC2)n1	J. Med. Chem.	2013.0	CHEMBL2316382	=	=	IC50	nM	8800.0	IC50	uM	8.8
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	O=C(NCC1CCOCC1)c1ncccc1NC(=O)c1ccc(Cn2ccnn2)c2ccccc12	J. Med. Chem.	2013.0	CHEMBL2316379	=	=	IC50	nM	610.0	IC50	uM	0.61
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli cells	COc1ccc(NC(=O)c2ccc(Cn3ccnn3)c3ccccc23)c(C(=O)NCC2CCOCC2)n1	J. Med. Chem.	2013.0	CHEMBL2316378	=	=	IC50	nM	360.0	IC50	uM	0.36
Inhibition of CYP3A4 (unknown origin)	COc1cc(/C=C2\CCCN3C2=NOCC[C@@H]3c2cc(F)c(F)c(F)c2)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2312555	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CO[C@@H]1COCC[C@@H]1N[C@@H]1C[C@H]2CCC[C@@]2(C(=O)N2CCc3ncc(C(F)(F)F)cc3C2)C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2313764	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc(-c2nnc(/C=C/c3nnc(-c4ccc(C#N)cc4)o3)n2-c2ccccc2Cl)nc1	J. Med. Chem.	2013.0	CHEMBL2325503	>	>	IC50	nM	25000.0	IC50	uM	25.0
Competitive inhibition of CYP3A4 (unknown origin)	COc1cc(N2CCN(C(=O)Cn3nc(C(F)(F)F)c(Cl)c3C)CC2)ccc1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2322875	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS-MS analysis	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1	J. Med. Chem.	2013.0	CHEMBL2323775	=	=	IC50	nM	11580.0	IC50	nM	11580.0
Inhibition of CYP3A4 (unknown origin)	CCCS(=O)(=O)N1CCN(C2(CNC(=O)c3c(F)cccc3F)CCC(F)(F)CC2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2324491	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(NCCN1CCC2(CC1)C(=O)NCN2c1cccc(F)c1)c1ccc(F)c(F)c1	J. Med. Chem.	2013.0	CHEMBL1907089	=	=	IC50	nM	17600.0	IC50	uM	17.6
Inhibition of CYP3A4 (unknown origin)	Cc1cccc(N2CNC(=O)C23CCN(C[C@H](C)NC(=O)c2ccc(Br)cc2)CC3)c1	J. Med. Chem.	2013.0	CHEMBL2325485	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of CYP3A4 (unknown origin)	COc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2325940	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1	J. Med. Chem.	2013.0	CHEMBL2325697	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338479	=	=	IC50	nM	10.0	IC50	uM	0.01
Inhibition of CYP3A4 (unknown origin)	Cc1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338480	=	=	IC50	nM	1.0	IC50	uM	0.001
Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CN(C2COC2)CC3)cc1	J. Med. Chem.	2013.0	CHEMBL2334760	=	=	IC50	nM	2500.0	IC50	uM	2.5
Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)C[C@@H]2CC[C@H]3N2S(C)(=O)=O)cc1	J. Med. Chem.	2013.0	CHEMBL2334764	=	=	IC50	nM	5000.0	IC50	uM	5.0
Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)C[C@@H]2CC[C@H]3N2C2COC2)cc1	J. Med. Chem.	2013.0	CHEMBL2334763	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2S(C)(=O)=O)cc1	J. Med. Chem.	2013.0	CHEMBL2334758	=	=	IC50	nM	5000.0	IC50	uM	5.0
Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2C(C)=O)cc1	J. Med. Chem.	2013.0	CHEMBL2334759	=	=	IC50	nM	7300.0	IC50	uM	7.3
Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)[C@H]2CC[C@@H](C3)N2C2COC2)cc1	J. Med. Chem.	2013.0	CHEMBL2334756	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCNc1nc2c(c(C(N)=O)n1)CN(C(=O)CCc1ccc(OC(F)(F)F)cc1)CC2	ACS Med. Chem. Lett.	2013.0	CHEMBL2331648	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL450668	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2nn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336411	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Br)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336412	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Cl)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336413	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1cc(I)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336415	=	=	IC50	nM	32000.0	IC50	uM	32.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1cc(Br)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336416	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1cc(Cl)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336417	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c(Cl)c2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336418	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2c(C)n[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336419	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336421	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(NC(Cc1cc(Cl)c2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336422	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL454791	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336424	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL454751	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4cccc(F)c4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL450668	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2nn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336411	=	=	IC50	nM	7300.0	IC50	uM	7.3
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Br)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336412	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1cc2oc(=O)[nH]c2cc1Cl)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336413	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1cc(I)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336415	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1cc(Br)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336416	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1cc(Cl)c2[nH]c(=O)oc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336417	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)c(Cl)c2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336418	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2c(C)n[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336419	=	=	IC50	nM	6900.0	IC50	uM	6.9
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	CC(C)c1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336420	=	=	IC50	nM	370.0	IC50	uM	0.37
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	CCc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336421	=	=	IC50	nM	450.0	IC50	uM	0.45
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(NC(Cc1cc(Cl)c2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336422	=	=	IC50	nM	180.0	IC50	uM	0.18
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	Cc1cc(C[C@@H](NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL454791	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	Cc1cc(CC(NC(=O)N2CCC(N3Cc4ccccc4NC3=O)CC2)C(=O)N2CCC(N3CCCCC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2336424	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-resorufin as substrate	O=C(N[C@H](Cc1ccc2[nH]ncc2c1)C(=O)N1CCC(N2CCCCC2)CC1)N1CCC(N2Cc3ccccc3NC2=O)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL454751	=	=	IC50	nM	4000.0	IC50	uM	4.0
Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C2COC2)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331680	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C(C)C)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331678	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2nccn2C)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331677	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2cc(C)ncn2)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331676	=	=	IC50	nM	8400.0	IC50	uM	8.4
Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ccnc(C)n2)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331689	=	=	IC50	nM	3300.0	IC50	uM	3.3
Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ncc(F)cn2)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2331688	=	=	IC50	nM	1400.0	IC50	uM	1.4
Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay	CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(c2ncccn2)C3)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2181522	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cccc(OCC2CCN(c3ccc(NC(=O)c4cccc(Oc5ccccc5)c4)cn3)CC2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2334082	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human recombinant CYP3A4	CC(C)(C)NC(=O)NCCN1CCC(CO)(CNC(=O)c2cc(Cl)cc(Cl)c2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2337981	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4	CC(C)CCOc1ccc2c(c1)[C@H]1OCCC[C@H]1[C@@H](C1CCOCC1)N2	J. Med. Chem.	2013.0	CHEMBL2338343	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)NCCC1CCN(c2ncnc3cc(C(N)=O)sc23)CC1	J. Med. Chem.	2013.0	CHEMBL2332055	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1cn([C@H]2CCCN(S(=O)(=O)c3ccc(O)c(Oc4cccc(Cl)c4)c3)C2)c(=O)[nH]c1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2331747	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam	COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1	J. Med. Chem.	2013.0	CHEMBL2332068	=	=	IC50	nM	80000.0	IC50	uM	80.0
Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam	COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1	J. Med. Chem.	2013.0	CHEMBL2332065	=	=	IC50	nM	35000.0	IC50	uM	35.0
Inhibition of CYP3A4 (unknown origin)-mediated midazolam hydroxylation to 1'-Hydroxymidazolam	COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1	J. Med. Chem.	2013.0	CHEMBL2332097	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL1236924	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(F)c1)c1ccc(Cl)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL2338473	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)c1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cnc2ccccc2c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338475	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1ccc(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL2338472	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cc(Cl)c(Oc2cnc3ccccc3c2)c(Cl)c1)c1ccc(C(F)(F)F)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL2338474	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cc(Cl)c(Oc2cncc(Cl)c2)c(Cl)c1)c1ccc(Cl)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL2331772	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cc(Cl)c(Oc2ccc3ncccc3c2)c(Cl)c1)c1ccc(Cl)cc1Cl	Bioorg. Med. Chem.	2013.0	CHEMBL2338477	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1Oc1cncc(Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338484	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4 (unknown origin)	CC(=O)c1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338482	=	=	IC50	nM	360.0	IC50	uM	0.36
Inhibition of CYP3A4 (unknown origin)	CCNC(=O)c1cc(NS(=O)(=O)c2cc(C)c(Cl)cc2Cl)ccc1Oc1cncc(Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2331785	=	=	IC50	nM	360.0	IC50	uM	0.36
Inhibition of CYP3A4 (unknown origin)	NC(=O)c1cncc(Oc2c(Cl)cc(NS(=O)(=O)c3ccc(Cl)cc3Cl)cc2Cl)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2338481	=	=	IC50	nM	30.0	IC50	uM	0.03
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3ncn4c3CCCC4)nc12	J. Med. Chem.	2013.0	CHEMBL2347996	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(C4CCNCC4)c4cc(F)ccc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347994	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc2c(-c3cnc4[nH]cc(C(=O)NC(C)(C)CO)c4n3)nn(CCCN(C)C)c2c1	J. Med. Chem.	2013.0	CHEMBL2347993	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(CO)NC(=O)c1c[nH]c2ncc(-c3nn(CCCS(C)(=O)=O)c4cc(F)ccc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347992	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCC(O)CO)c4cc(F)ccc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347991	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(CO)NC(=O)c1c[nH]c2ncc(-c3nn(CCC(O)CO)c4cc(F)ccc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347990	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3nn(CCCS(C)(=O)=O)c4cc(F)ccc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347989	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CN(C)CCCn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2cc(OC(F)F)ccc21	J. Med. Chem.	2013.0	CHEMBL2347415	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@]4(C)C[C@@H](N)C4)c3n2)c2ccc(F)cc21	J. Med. Chem.	2013.0	CHEMBL2347414	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)NC4COCC(N)C4)c3n2)c2ccc(F)cc21	J. Med. Chem.	2013.0	CHEMBL2347410	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)NC4(C)CCNCC4)c3n2)c2ccc(F)cc21	J. Med. Chem.	2013.0	CHEMBL2347408	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)NC(=O)c1c[nH]c2ncc(-c3n[nH]c4ccc(OC(F)F)cc34)nc12	J. Med. Chem.	2013.0	CHEMBL2347405	>	>	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2cc(OC(F)F)ccc21	J. Med. Chem.	2013.0	CHEMBL2346686	>	>	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)N[C@H]4C[C@H](O)C4)c3n2)c2ccc(F)cc21	J. Med. Chem.	2013.0	CHEMBL2348857	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)CO)c3n2)c2ccc(Cl)cc21	J. Med. Chem.	2013.0	CHEMBL2348856	>	>	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)c2ccc(Cl)cc21	J. Med. Chem.	2013.0	CHEMBL2348853	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cnc3[nH]cc(C(=O)NC(C)CO)c3n2)cc1OC	J. Med. Chem.	2013.0	CHEMBL2348851	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(Nc2nc(-c3cccc(C(=O)Nc4ccc(C(=O)O)cc4)c3)nc3scnc23)cc1OC	J. Med. Chem.	2013.0	CHEMBL2177737	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	NC(=O)c1cnc(N[C@@H]2CCCC[C@@H]2N)nc1Nc1cccc(-n2nccn2)c1	J. Med. Chem.	2013.0	CHEMBL2177736	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC	J. Med. Chem.	2013.0	CHEMBL2103830	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cccnc2)Cc2ccccc2)C(C)C)cs1	J. Med. Chem.	2013.0	CHEMBL2347183	=	=	IC50	nM	130.0	IC50	nM	130.0
Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnco2)Cc2ccccc2)C(C)C)cs1	J. Med. Chem.	2013.0	CHEMBL2347184	=	=	IC50	nM	3400.0	IC50	nM	3400.0
Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cnc[nH]2)Cc2ccccc2)C(C)C)cs1	J. Med. Chem.	2013.0	CHEMBL2347185	=	=	IC50	nM	280.0	IC50	nM	280.0
Inhibition of C-terminal His-tagged wild type CYP3A4 (unknown origin)-mediated hydroxylation of 7-benzyloxy-4-trifluoromethylcoumarin expressed in Escherichia coli after 5 mins by fluorimetric analysis	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	J. Med. Chem.	2013.0	CHEMBL163	=	=	IC50	nM	550.0	IC50	nM	550.0
Inhibition of human CYP3A4	C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C[C@@H](C(F)(F)F)OC(N)=N1	J. Med. Chem.	2013.0	CHEMBL2347208	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(CO)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2347337	=	=	IC50	nM	6900.0	IC50	uM	6.9
Inhibition of human CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2347328	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of human CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(Br)c(-c2ccc(N=[N+]=[N-])cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2347323	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of human CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(N=[N+]=[N-])cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2347159	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of human CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2023898	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO	Bioorg. Med. Chem.	2013.0	CHEMBL2348780	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(S(=O)(=O)Nc2cc(Oc3ccccc3)ccc2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2376562	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(Oc2ccccc2)ccc1NS(=O)(=O)c1ccc(Br)cc1F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2375371	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(S(=O)(=O)Nc2ccc(Oc3ccccc3)cc2C(=O)O)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2376577	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human recombinant CYP3A4	O[C@H]1CC[C@H](c2ccc(OCCCN3CCCCC3)cc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2375587	=	=	IC50	nM	30300.0	IC50	uM	30.3
Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	COC(=S)NC[C@H]1CN(c2cc(F)c(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1	Eur. J. Med. Chem.	2013.0	CHEMBL2377663	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)CO)CC3)c(F)c2)C(=O)O1	Eur. J. Med. Chem.	2013.0	CHEMBL2377662	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	CC(=O)NC[C@H]1CN(c2ccc(N3CCN(C(=O)CO)CC3)c(F)c2)C(=O)O1	Eur. J. Med. Chem.	2013.0	CHEMBL47955	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1	Eur. J. Med. Chem.	2013.0	CHEMBL126	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cnccc1COc1cnc(N2CC3CCC(C2)N3C(=O)OCC(F)(F)F)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2382415	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CN(C(=O)OCC(F)(F)F)CCN1c1ncc(OCc2ccncc2C#N)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2086687	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cnccc1COc1cnc(N2CCN(C(=O)OCC(F)(F)F)CC2)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2382414	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)OC(=O)N([C@H]2CC[C@H](n3c(=O)[nH]c4c(F)c(C#N)ccc43)CC2)[C@H]1c1ccccc1	J. Med. Chem.	2013.0	CHEMBL2381946	=	=	IC50	nM	5400.0	IC50	uM	5.4
Inhibition of CYP3A4 (unknown origin)	CC1(C)OC(=O)N([C@H]2CC[C@H](n3c(=O)[nH]c4cc(C#N)c(F)cc43)CC2)[C@H]1c1ccccc1	J. Med. Chem.	2013.0	CHEMBL2381945	=	=	IC50	nM	7600.0	IC50	uM	7.6
Inhibition of CYP3A4 (unknown origin)	CC1(C)OC(=O)N([C@H]2CC[C@H](NC(=O)c3ccnc4cc(F)cnc34)CC2)[C@H]1c1ccccc1	J. Med. Chem.	2013.0	CHEMBL2381936	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) by fluorescence detection method	CC[C@H](NC(=O)[C@@H]1C[C@@H](S(=O)(=O)c2ccccc2)CN1C(C)=O)C(=O)c1nc2ccccc2o1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380735	=	=	IC50	nM	9950.0	IC50	uM	9.95
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cnc(N3CCN(C(=O)N4CCC(c5cn[nH]c5)C4)c4ccccc43)nc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL1761869	<	<	IC50	nM	300.0	IC50	nM	300.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cnc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](O)(C6)C5)c4ccccc43)nc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380637	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cnc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](C(N)=O)(C6)C5)c4ccccc43)nc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380639	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cnc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](OC(N)=O)(C6)C5)c4ccccc43)nc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380640	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)N1CCN(c2cnc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](O)(C6)C5)c4ccccc43)nc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380641	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)N1CCN(c2ccc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](O)(C6)C5)c4ccccc43)nc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380642	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)N1CCN(c2ccc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](O)(C6)C5)c4ccccc43)cc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380643	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)N1CCN(c2ccc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](C(N)=O)(C6)C5)c4ccccc43)cc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380644	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](O)(C6)C5)c4ccccc43)nc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380646	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(N[C@H]1C2CC3CC1C[C@](O)(C3)C2)N1CCN(c2ccc(N3CCN(S(=O)(=O)C4CC4)CC3)cn2)c2ccccc21	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380647	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)N1CCN(c2ccc(N3CCN(C(=O)N[C@H]4C5CC6CC4C[C@](C(N)=O)(C6)C5)c4ccccc43)nc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380648	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	NC(=O)[C@]12CC3CC(C1)[C@@H](NC(=O)N1CCN(c4ccc(N5CCN(S(=O)(=O)C6CC6)CC5)cn4)c4ccccc41)C(C3)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2380649	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay	Cc1ccc(-c2ccccc2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381076	=	=	IC50	nM	64000.0	IC50	uM	64.0
Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay	Cc1ccc(-c2ncccn2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381074	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay	Cc1cc(C)nc(NC[C@@H]2CC3(CC3)CN2C(=O)c2nc(C)sc2-c2ccccc2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381071	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of human recombinant CYP3A4 using BFC as substrate by fluorimetric assay	Cc1nc(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)c(-c2ccccc2)s1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381100	>	>	IC50	nM	100000.0	IC50	uM	100.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using 6beta-hydroxylase as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by LC-MS/MS analysis	COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381116	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 6beta-hydroxylase as substrate by LC-MS/MS analysis	COc1ccc2c(c1)C(=O)N(c1nc(C(=O)Nc3cnccc3N3CCNCC3)cs1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2381116	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 15 mins prior to NADPH addition measured after 8 mins by LC/MS/MS analysis	COc1ccc(C#Cc2ccc(C(=O)N3CCC[C@@H](O)C3)c(F)c2)cc1	J. Med. Chem.	2013.0	CHEMBL2385886	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	CCc1ccc(-c2ccc(C(=O)N3CCc4c(c5ccccc5n4CC(=O)O)C3)cc2)cc1	J. Med. Chem.	2013.0	CHEMBL2385904	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)Cc1c[nH]c3ccccc13)CC2	J. Med. Chem.	2013.0	CHEMBL2385902	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)Cc1cccc3ccccc13)CC2	J. Med. Chem.	2013.0	CHEMBL2385901	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc3ccccc13)CC2	J. Med. Chem.	2013.0	CHEMBL2386081	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1cccc3ccccc13)CC2	J. Med. Chem.	2013.0	CHEMBL2386079	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccc(Cl)c1)CC2	J. Med. Chem.	2013.0	CHEMBL2386077	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1cccc(Cl)c1)CC2	J. Med. Chem.	2013.0	CHEMBL2386076	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3cc(F)ccc31)CN(C(=O)c1cccs1)CC2	J. Med. Chem.	2013.0	CHEMBL2386075	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam-1'-hydroxylation by LC-MS/MS analysis	O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1ccccc1)CC2	J. Med. Chem.	2013.0	CHEMBL2385906	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccc(Cl)cc3)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387588	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3cccc(Cl)c3)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387587	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccccc3Cl)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387507	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	Cc1ccc(-c2ccc3c(c2)[nH]c(=O)c2nc(-c4c(F)cccc4Cl)[nH]c23)cc1	Bioorg. Med. Chem.	2013.0	CHEMBL2387506	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	Cc1cccc(-c2ccc3c(c2)[nH]c(=O)c2nc(-c4c(F)cccc4Cl)[nH]c23)c1	Bioorg. Med. Chem.	2013.0	CHEMBL2387505	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	Cc1ccccc1-c1ccc2c(c1)[nH]c(=O)c1nc(-c3c(F)cccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387504	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3c(F)cccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387503	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3c(Cl)cccc3[N+](=O)[O-])nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387502	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3c(Cl)cccc3C(F)(F)F)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387501	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	Cc1cccc(Cl)c1-c1nc2c(=O)[nH]c3cc(-c4ccccc4)ccc3c2[nH]1	Bioorg. Med. Chem.	2013.0	CHEMBL2387500	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccncc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387606	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3cccnc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387605	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccco3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387604	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3cccs3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387603	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccc4ccccc4c3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387602	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(CCc3ccccc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387601	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(Cc3ccccc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387600	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(-c3ccccc3)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387599	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	CCCCCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387598	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	CCCCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387597	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	CCCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387596	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	CCCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387595	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	CCc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387594	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	Cc1ccc2c(c1)[nH]c(=O)c1nc(-c3ccccc3Cl)[nH]c12	Bioorg. Med. Chem.	2013.0	CHEMBL2387593	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2ccc(Cl)cc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387592	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2ccc(Br)cc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387591	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(Cl)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387590	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2ccccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL2387589	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS/MS analysis	O=c1[nH]c2cc(Br)ccc2c2[nH]c(-c3ccccc3Cl)nc12	Bioorg. Med. Chem.	2013.0	CHEMBL1934810	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(O[C@@H](CC(C)C)[C@H]2CCNC2)c(C)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2386162	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)[C@H]1C[C@@H]1c1ccc(-c2ncn(C)c2Sc2ccc(Cl)cn2)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2386558	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CCC#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386636	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386635	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](C#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386633	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@@H](NCC(F)(F)F)C1	J. Med. Chem.	2013.0	CHEMBL2385096	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](NCC(F)(F)F)CC1	J. Med. Chem.	2013.0	CHEMBL2386629	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CCCOC1	J. Med. Chem.	2013.0	CHEMBL2386653	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CCC#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386636	=	=	IC50	nM	6700.0	IC50	uM	6.7
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386635	=	=	IC50	nM	8800.0	IC50	uM	8.8
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](C#N)CC1	J. Med. Chem.	2013.0	CHEMBL2386633	=	=	IC50	nM	7900.0	IC50	uM	7.9
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@@H](NCC(F)(F)F)C1	J. Med. Chem.	2013.0	CHEMBL2385096	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](NCC(F)(F)F)CC1	J. Med. Chem.	2013.0	CHEMBL2386629	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC/MS/MS analysis	C[C@@H](O)c1nc2cnc3[nH]ccc3c2n1[C@H]1CCCOC1	J. Med. Chem.	2013.0	CHEMBL2386653	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)Nc1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2387312	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)Cn1c2c(c3ccccc31)CN(C(=O)c1ccccc1)CC2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2385906	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	N#C/C(=C\c1cn(CC(=O)O)c2ccccc12)C(=O)N1CCCc2ccccc21	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2391518	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Nc1ccc(CNC(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2393183	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2(C)CC2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397199	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(c1cc(-c2cnc(NC(=O)N3CCC[C@H]3C(N)=O)s2)ccn1)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397196	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2CCC2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397194	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)C)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397193	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C2(C#N)CC2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397192	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2396661	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397187	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397186	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2c(C)nn3c(NCCN4CCOCC4)cc(C)nc23)cc1OC	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397317	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)C(C)(C)CC(F)(F)F)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397316	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)[C@@H](C)CC(F)(F)F)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397315	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)[C@H](C)CC(F)(F)F)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397314	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)Cc2nc(-c3ccccc3)c(C)o2)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397313	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)C(C)CC(F)(F)F)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397312	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)C2(C)CCCCC2)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397311	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)[C@H]2CC[C@@H](C(F)(F)F)CC2)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397310	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CO[C@H]1CC[C@@H](C(=O)Nc2nc(C)c(-c3ccc(N)nc3)s2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397309	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(C(=O)N(CC(=O)Nc2ncc(-c3ccc(N)cc3)s2)Cc2ccccc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397308	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1[C@H](C(=O)Nc2ncc(-c3ccc(N)cc3)s2)CC[C@@H]1c1ccccc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397307	=	=	IC50	nM	980.0	IC50	uM	0.98
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)CN2C(=O)OC[C@H]2C(C)C)sc1-c1ccc(N)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397306	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(NC(=O)CN(Cc2ccccc2)C(=O)c2ccncc2)sc1-c1ccc(N)nc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397305	=	=	IC50	nM	710.0	IC50	uM	0.71
Inhibition of CYP3A4 (unknown origin)	Nc1ccc(-c2cnc(NC(=O)CN(Cc3ccccc3)C(=O)c3ccncc3)s2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397304	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 (unknown origin)	Nc1ccc(-c2cnc(NC(=O)CN(Cc3ccccc3)C(=O)c3ccncc3)s2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397303	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus-infected insect cell microsomes assessed as benzoylresorufin conversion to resorufin metabolites after 45 mins by fluorescence assay	Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397415	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus-infected insect cell microsomes assessed as 7-benzyloxy-4-trifluoromethylcoumarin conversion to 7-hydroxy-4-trifluoromethylcoumarin after 20 mins by fluorescence assay	Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397415	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CC[C@@H](N3CCC[C@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2403551	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2403550	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CC[C@@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2403549	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CC[C@H](N3CCC[C@H]3C)C2)ccc1NC(=O)c1cc(F)ccc1C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2403548	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	Cc1ccccc1[C@@H]1[C@@H](O[C@H](CO)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC[C@@H]2CN(C3=NC(=O)CO3)C[C@H]21	J. Med. Chem.	2013.0	CHEMBL2402572	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-Hydroxymidazolam after 7 mins by LC-MS/MS analysis	CN1CCN(CCC(=O)Nc2ccc3ncnc(Nc4ccc(NC(=O)Nc5cc(C(C)(C)C)nn5-c5cccc(N)c5)cc4)c3c2)CC1	J. Med. Chem.	2013.0	CHEMBL2403820	=	=	IC50	nM	1950.0	IC50	uM	1.95
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation to 1'-Hydroxymidazolam after 7 mins by LC-MS/MS analysis	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4ccccc34)cc2)n(-c2cccc(N)c2)n1	J. Med. Chem.	2013.0	CHEMBL2403816	=	=	IC50	nM	14800.0	IC50	uM	14.8
Inhibition of CP3A4 (unknown origin)	C#CCC(Oc1c(N)ncc2c(-c3cnn(C4CCNCC4)c3)coc12)c1c(Cl)ccc(F)c1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2401818	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CP3A4 (unknown origin)	CC(Oc1c(N)ncc2c(-c3cnn(C4CCNCC4)c3)coc12)c1c(Cl)ccc(F)c1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2401834	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	COc1ccnc(Oc2ccc3c(c2)c(=O)ncn3Cc2c(F)cc(F)cc2F)c1C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2403317	=	=	IC50	nM	18000.0	IC50	uM	18.0
Induction of CYP3A4 (unknown origin)	O=C(O)CC1CCC(c2ccc(-c3nc4cc(NC(=O)c5nc(-c6ccccc6)oc5C(F)(F)F)ccc4[nH]3)cc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409564	>	>	EC50	nM	100000.0	EC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC(c2ccc(-c3nc4cc(NC(=O)c5nc(-c6ccccc6)oc5C(F)(F)F)ccc4[nH]3)cc2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409564	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	O=CN(O)[C@@H](CCCc1ncccn1)CS(=O)(=O)N1CCN(c2ccc(C(F)(F)F)cn2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409667	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4	C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(OCc4ccccn4)cc3)CC2)NC(=O)NC1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409691	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(C(F)(F)F)cc3)CC2)NC(=O)NC1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409710	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4	C[C@]1(CS(=O)(=O)N2CCN(c3ncc(OCc4ccc(C(F)(F)F)o4)cn3)CC2)NC(=O)NC1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409676	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	C[C@]1(CS(=O)(=O)N2CCC(Oc3ccc(OC(F)(F)C(F)F)cc3)CC2)NC(=O)NC1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2409707	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1	ACS Med. Chem. Lett.	2013.0	CHEMBL2408045	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using vivid green as substrate	Nc1ccccc1NC(=O)c1ccc(CNC2=N[C@@H](c3ccccc3)CS2)cc1	J. Med. Chem.	2013.0	CHEMBL2407717	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 (unknown origin) using vivid red as substrate	Nc1ccccc1NC(=O)c1ccc(CNC2=N[C@@H](c3ccccc3)CS2)cc1	J. Med. Chem.	2013.0	CHEMBL2407717	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay	COc1ccc2c(c1)/C(=C\c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2013.0	CHEMBL2407900	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay	CN1CCN(c2ccc(/C=C/c3n[nH]c4cc(/C=C5/C(=O)Nc6ccccc65)ccc34)cn2)CC1	J. Med. Chem.	2013.0	CHEMBL2407899	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc(/C=C4/C(=O)Nc5ccccc54)ccc23)cc1	J. Med. Chem.	2013.0	CHEMBL2407897	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) after 10 mins by fluorescence assay	O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1	J. Med. Chem.	2013.0	CHEMBL2407749	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CN(C)c1ccc(C(C/C(=N\O)c2ccncc2)c2ccccc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407936	<	<	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cc(/C(CC(c2ccc(-c3cccc(C(=O)O)c3)cc2)c2ccccc2C)=N/O)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407955	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cc(/C(CC(c2ccc(-c3ccc(C(=O)O)cc3)cc2)c2ccccc2C)=N/O)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407954	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cc(/C(CC(c2ccc(CC(=O)O)cc2)c2ccccc2C)=N/O)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407953	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cc(/C(CC(c2ccc(C(=O)O)cc2)c2ccccc2C)=N/O)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407952	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1ccccc1C(C/C(=N\O)c1ccc(=O)n(C)c1)c1ccc(Br)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407951	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cc(/C(CC(c2ccc(Br)cc2)c2ccccc2C)=N/O)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407950	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1ccccc1C(C/C(=N\O)c1ccncc1)c1ccc(Br)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2407949	<	<	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 (unknown origin)	COCc1c(C(=O)NCc2ccncc2)cnn1-c1ncc(C)c(-c2cccs2)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2409024	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 (unknown origin)	CCOCc1c(C(=O)NCc2cncn2C)cnn1-c1ncc(C)c(N2CCCCC2)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2409007	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 20 mins by LCMS analysis	CC(C)(C)n1nnnc1C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)N1CCCC1	Bioorg. Med. Chem.	2013.0	CHEMBL2413882	=	=	IC50	nM	1450.0	IC50	uM	1.45
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 20 mins by LCMS analysis	CCN(CC)C(c1cccc(Nc2ccnc3cc(Cl)ccc23)c1)c1nnnn1C(C)(C)C	Bioorg. Med. Chem.	2013.0	CHEMBL2413881	=	=	IC50	nM	6.0	IC50	uM	0.006
Inhibition of CYP3A4 (unknown origin) using nifedipine as substrate	Cc1ccc2[nH]c(C(=O)N3CCC(CC(C)(C)O)CC3)cc2c1	Bioorg. Med. Chem.	2013.0	CHEMBL2413849	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	COc1nc(-c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2415099	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2nc3n(n2)CCO[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2415098	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2415097	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2nc3n(n2)CCC[C@H]3c2ccc(F)cc2C)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2415095	=	=	IC50	nM	6940.0	IC50	uM	6.94
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	C[C@@H]1CN(c2cccnc2C#N)CCN1C(=O)C12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2397347	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)N1CCC2(CCCC2)C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2418359	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(N1C[C@@H]2CN(c3ccccn3)C[C@@H]2C1)C12CC3CC(CC(C3)C1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2418364	=	=	IC50	nM	6200.0	IC50	uM	6.2
Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1cn2cc(-c3cnc(N)c(C(F)(F)F)c3)ccc2n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2418954	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1nc2ccc(-c3cnc(N)c(C(F)(F)F)c3)cc2s1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2418948	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1nc2ccc(-c3ccc(N)nc3)cc2s1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2418946	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of CYP3A4 (unknown origin)	O=C(CN1CCN(CCO)CC1)Nc1ccc(-c2cccc3c(=O)cc(N4CCOCC4)oc23)c2sc3ccccc3c12	J. Med. Chem.	2013.0	CHEMBL2420310	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1	J. Med. Chem.	2013.0	CHEMBL1086377	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1	J. Med. Chem.	2013.0	CHEMBL2420425	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCc1ccc(-c2nc3c(=O)n(C)c(=O)nc-3n(C)n2)cc1	J. Med. Chem.	2013.0	CHEMBL2420615	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	J. Med. Chem.	2013.0	CHEMBL254328	=	=	IC50	nM	2700.0	IC50	nM	2700.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cncc4ccccc34)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420688	=	=	IC50	nM	1739.0	IC50	nM	1739.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cncc4ccccc34)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420687	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cncnc3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420686	=	=	IC50	nM	2145.0	IC50	nM	2145.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cncnc3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420685	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1cncc(-c2ccc3ccc(O)cc3c2Cl)c1	J. Med. Chem.	2013.0	CHEMBL2420684	=	=	IC50	nM	5046.0	IC50	nM	5046.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cncc(O)c3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420683	=	=	IC50	nM	6720.0	IC50	nM	6720.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1cncc(-c2ccc3ccc(O)cc3c2Cl)c1	J. Med. Chem.	2013.0	CHEMBL2420682	=	=	IC50	nM	4196.0	IC50	nM	4196.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1cncc(-c2ccc3ccc(OC)cc3c2Cl)c1	J. Med. Chem.	2013.0	CHEMBL2420681	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cncc(F)c3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420680	=	=	IC50	nM	3581.0	IC50	nM	3581.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cncc(F)c3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420679	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cccnc3)c(Cl)c2c1F	J. Med. Chem.	2013.0	CHEMBL2420678	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cccnc3)c(Cl)c2c1F	J. Med. Chem.	2013.0	CHEMBL2420677	=	=	IC50	nM	1009.0	IC50	nM	1009.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cccnc3)c(F)c2c1	J. Med. Chem.	2013.0	CHEMBL2420676	=	=	IC50	nM	1262.0	IC50	nM	1262.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cccnc3)c(F)c2c1	J. Med. Chem.	2013.0	CHEMBL2420675	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	Oc1ccc2ccc(-c3cccnc3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL2420674	=	=	IC50	nM	1759.0	IC50	nM	1759.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculovirus-infected insect microsomes	COc1ccc2ccc(-c3cccnc3)c(Cl)c2c1	J. Med. Chem.	2013.0	CHEMBL371430	=	=	IC50	nM	3560.0	IC50	nM	3560.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccnc(NC(=O)C2CC2)c1)c1c(Cl)cccc1Cl	Eur. J. Med. Chem.	2013.0	CHEMBL2387224	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccncc1)c1c(Cl)cccc1Cl	Eur. J. Med. Chem.	2013.0	CHEMBL1327969	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3F)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419495	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(C(C)C)cc3)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419494	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419493	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(OC)cc3)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419492	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419491	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CCC(C(=O)NS(=O)(=O)Cc3ccccc3)CC2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419490	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(C)cc3)C2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419487	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(F)cc3)C2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419486	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccc(Cl)cc3)C2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419485	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of human recombinant CYP3A4	CCOC(=O)c1cc(C#N)c(N2CC(C(=O)NS(=O)(=O)Cc3ccccc3)C2)nc1C	J. Med. Chem.	2013.0	CHEMBL2419501	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy trifluoromethylcoumarin as substrate	Cc1cncc(Cc2ccc(-c3ccccc3)nc2)c1	J. Med. Chem.	2013.0	CHEMBL2417553	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419525	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3COC3)CC2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419524	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419518	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419516	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419515	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419505	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419525	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3COC3)CC2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419524	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419518	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	Nc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419516	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419515	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2ccccc2)cc1)N1Cc2ccncc2C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2419505	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(OCc4ccccc4)nc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425161	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)cn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425160	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(OC)nc(-c2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)cc2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425159	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccncc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425158	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3ccc(N)nc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425157	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cccnc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425156	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nncn3C)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425155	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnn3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425154	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3cnco3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425153	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3nnnc3C)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425152	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3csnn3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425151	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cncc3C)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425150	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(Cl)c3Cl)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425149	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-c3nnc(S)n3C)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425148	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnnc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425147	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3ccnc3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425146	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc(C)c3)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425145	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(-n3cnc4c(N)ncnc43)cc2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425144	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A (unknown origin)	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL376359	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425886	=	=	IC50	nM	97900.0	IC50	uM	97.9
Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(Cl)ccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425889	=	=	IC50	nM	91930.0	IC50	uM	91.93
Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(Br)ccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425888	=	=	IC50	nM	79360.0	IC50	uM	79.36
Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(F)ccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425890	=	=	IC50	nM	58280.0	IC50	uM	58.28
Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccc(F)cc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425894	=	=	IC50	nM	54650.0	IC50	uM	54.65
Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(C)ccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425891	=	=	IC50	nM	46240.0	IC50	uM	46.24
Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3ccc(Cl)cc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425893	=	=	IC50	nM	46180.0	IC50	uM	46.18
Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2ccc3cc(OC)ccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425892	=	=	IC50	nM	42190.0	IC50	uM	42.19
Inhibition of CYP3A (unknown origin)	CC#CCn1c(N2CCC[C@@H](N)C2)cc(=O)n(Cc2cc(Cl)c3ccccc3n2)c1=O	Eur. J. Med. Chem.	2013.0	CHEMBL2425895	=	=	IC50	nM	14080.0	IC50	uM	14.08
Inhibition of CYP3A4 (unknown origin) using Vivid BOMR as substrate	CCc1nc2c(Cc3ccc(C(=O)NO)cc3)cccc2c(=O)n1CCc1ccccc1	J. Med. Chem.	2013.0	CHEMBL2425952	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin) using Vivid BOMR as substrate	Cc1nc2cc(/C=C/C(=O)NO)ccc2c(=O)n1CCc1ccccc1	J. Med. Chem.	2013.0	CHEMBL2425958	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(C(C)(C)C)ccn3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425607	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(CC(C)(C)C)on3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425606	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cnn(CC(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425605	=	=	IC50	nM	3600.0	IC50	uM	3.6
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(OC(F)(F)F)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425604	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(OC(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425603	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)O)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425602	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)CO)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425601	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cc(C(C)(C)C)ccc3F)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425600	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](N[C@H](C)c3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425599	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425618	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 (unknown origin)	[2H]C([2H])(N[C@H]1C[S@+]([O-])C[C@@H](Cc2cc(F)c(N)c(O[C@H](COC)C(F)(F)F)c2)[C@@H]1O)c1cccc(C(C)(C)C)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425617	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S+]([O-])C[C@H](N)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425615	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(O)c(N)c(F)c3)[C@@H]2O)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425614	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(F)c(N)c(O[C@H](CO)C(F)(F)F)c3)[C@@H]2O)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425613	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 (unknown origin)	COC[C@@H](Oc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N)C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425612	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cccc(CN[C@H]2C[S@+]([O-])C[C@@H](Cc3cc(F)c(N)c(OCC(F)(F)F)c3)[C@@H]2O)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425611	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin)	COc1cc(C[C@@H]2C[S@@+]([O-])C[C@H](NCc3cccc(C(C)(C)C)c3)[C@H]2O)cc(F)c1N	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2425610	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of human CYP3A4	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21	J. Med. Chem.	2013.0	CHEMBL1232461	>=	>=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin)	Cn1nc(-c2ccncc2)cc1NC(=O)[C@H](Cc1ccccc1)NCC(=O)O	ACS Med. Chem. Lett.	2013.0	CHEMBL2430983	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CC1(NC(=O)c2ccc(C#Cc3cccc(F)c3)cn2)COC1	J. Med. Chem.	2013.0	CHEMBL2431173	>	>	IC50	nM	30000.0	IC50	uM	30.0
Reversible inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2cc(F)c[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431365	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(CCc2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431456	=	=	IC50	nM	340.0	IC50	uM	0.34
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2cc(F)c[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431365	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(C2CC2c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431463	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(/C=C/c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431462	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(CCN2CCC(NS(C)(=O)=O)CC2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431460	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of midazolam turnover preincubated for 3 mins followed by midazolam and NADPH addition measured after 5 mins by HPLC-MS/MS analysis	COc1c(NC(=O)c2ccc(NS(C)(=O)=O)cc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C	J. Med. Chem.	2013.0	CHEMBL2431457	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes	Cn1c2c(c3ccccc31)CCN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CC2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436632	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccc(F)cc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436630	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436629	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	N#Cc1ccc2c(c1)CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CC2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436628	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCc5ccccc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436627	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCNc5ccccc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436626	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	COc1ccc2c(c1)CCCN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436625	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	COc1ccc2c(c1)CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)CCC2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436624	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCCc5ccccc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436623	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4CCc5ccccc5CC4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436622	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Cc1nnc2n1-c1sccc1C(=O)N(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436621	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Cc1nnc2n1-c1sccc1CN(C1CCN(C(=O)C3(F)CCN(Cc4ccnc(N)c4)CC3)CC1)C2	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436620	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4c5ccccc5Sc5ccccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436617	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5Cc5ccccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436616	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(F)(C(=O)N3CCC(N4Cc5ccccc5-c5ccccc5C4)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436633	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin)	CCc1nc(N[C@@H]2CCC[C@@H]2C#N)c2cc[nH]c(=O)c2n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2436945	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	COc1cc(-c2cnc3[nH]cc(-c4cnc(N)nc4)c3c2)cc(OC)c1OC	J. Med. Chem.	2013.0	CHEMBL2436976	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	COc1cc(-c2cnc3[nH]cc(-c4ccc(N)nc4)c3c2)cc(OC)c1OC	J. Med. Chem.	2013.0	CHEMBL2436982	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	COc1cc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cc(OC)c1OC	J. Med. Chem.	2013.0	CHEMBL2436980	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	Nc1ncc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1	J. Med. Chem.	2013.0	CHEMBL2436983	=	=	IC50	nM	21800.0	IC50	uM	21.8
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	CN1CCN(Cc2ccc(-c3cnc4[nH]cc(-c5ccc6[nH]ccc6c5)c4c3)cc2)CC1	J. Med. Chem.	2013.0	CHEMBL2436978	=	=	IC50	nM	16200.0	IC50	uM	16.2
Inhibition of CYP3A4 in human liver microsomes assessed as inhibition of dextromethorphan metabolism by HPLC/MS analysis	Nc1ccc(-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)cn1	J. Med. Chem.	2013.0	CHEMBL2436981	=	=	IC50	nM	4200.0	IC50	uM	4.2
Inhibition of CYP3A4 (unknown origin)	CCc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1	J. Med. Chem.	2013.0	CHEMBL2435856	>	>	IC50	nM	73000.0	IC50	uM	73.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1ccc(Sc2ccc(CN3CCC(N4C(=O)N(C5CCOCC5)C[C@H]4c4ccccc4)CC3)cn2)cc1	J. Med. Chem.	2013.0	CHEMBL2434978	>	>	IC50	nM	60000.0	IC50	uM	60.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1	J. Med. Chem.	2013.0	CHEMBL2435852	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(Oc2ccc(C(N)=O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2ccccc2)CC1	J. Med. Chem.	2013.0	CHEMBL2435858	>	>	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(Oc2ccc(C(=O)O)cc2)ccc1CN1CCC(N2C(=O)N(C3CCOCC3)C[C@H]2c2cccc(Cl)c2)CC1	J. Med. Chem.	2013.0	CHEMBL2435853	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	CNC(=O)N1CCN(c2ccc(N3C[C@H](CNC(=S)OC)OC3=O)cc2F)CCN1	Eur. J. Med. Chem.	2013.0	CHEMBL2437199	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as terfenadine hydroxylation after 20 mins by LC/MS/MS analysis	COC(=S)NC[C@H]1CN(c2ccc(N3CCNN(C(=O)C(F)F)CC3)c(F)c2)C(=O)O1	Eur. J. Med. Chem.	2013.0	CHEMBL2437330	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2cccc3ccccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436321	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5cnccn5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437433	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ncccn5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437432	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ccccn5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437431	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5cc(F)cc(F)c5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437430	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(-c5ccc(F)c(F)c5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437429	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC5CCCCC5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437428	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(C5CCCC5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437427	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC5CC5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437426	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CC(F)(F)F)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437425	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)Cn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccnc(N)c4)CC3)CC2)c2ccc(F)cc21	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437424	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCCC(F)(F)F)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437423	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCN5CCOCC5)c5cc(F)ccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437422	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCN5CCOCC5)c5ccccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437421	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	COCCn1c(=O)n(C2CCN(C(=O)C3CCN(Cc4ccnc(N)c4)CC3)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437420	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)n(CCCC(F)(F)F)c5ccccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437417	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	Nc1cc(CN2CCC(C(=O)N3CCC(n4c(=O)[nH]c5ccccc54)CC3)CC2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2437416	>	>	IC50	nM	30000.0	IC50	uM	30.0
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2nn(-c3ccccc3C#N)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436222	=	=	Ki	nM	83300.0	Ki	uM	83.3
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436225	=	=	Ki	nM	50000.0	Ki	uM	50.0
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436224	=	=	Ki	nM	50000.0	Ki	uM	50.0
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436223	=	=	Ki	nM	50000.0	Ki	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436224	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436223	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2nn(C)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436221	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2noc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436220	=	=	IC50	nM	38000.0	IC50	uM	38.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2nn(-c3ccccc3C#N)c3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436222	=	=	IC50	nM	37000.0	IC50	uM	37.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436219	=	=	IC50	nM	32000.0	IC50	uM	32.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436225	=	=	IC50	nM	18000.0	IC50	uM	18.0
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436226	=	=	Ki	nM	16700.0	Ki	uM	16.7
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436226	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2ccccc2)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436324	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(N)cc2)c2ccccc2N(Cc2c(OC)ccc3ccccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436208	=	=	IC50	nM	10200.0	IC50	uM	10.2
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CS(C)(=O)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436215	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436218	=	=	IC50	nM	9700.0	IC50	uM	9.7
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436219	=	=	Ki	nM	8500.0	Ki	uM	8.5
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436218	=	=	Ki	nM	7100.0	Ki	uM	7.1
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3cc(Br)ccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436216	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(CCc2ccccc2)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436325	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(C)=O)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436214	=	=	IC50	nM	3200.0	IC50	uM	3.2
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)Cc2cccnc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436210	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)C2CCOCC2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436213	=	=	IC50	nM	2300.0	IC50	uM	2.3
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2noc3ccccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436220	=	=	Ki	nM	2100.0	Ki	uM	2.1
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(S(C)(=O)=O)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436205	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C)o2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436212	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C(C)=O)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436206	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C#N)n(-c3ccccc3C#N)c3ccccc23)c2ccccc2OC12CCOCC2	J. Med. Chem.	2013.0	CHEMBL2436227	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(OC)ccc3c(Br)cccc23)c2ccccc2N(C(=O)CS(C)(=O)=O)[C@H]1C.Cl	J. Med. Chem.	2013.0	CHEMBL2436217	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cnccn2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436211	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(F)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436331	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(OC)ccc3ccccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436328	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccc(C)cc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436334	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(C)ccc3ccccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436327	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cccnc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436209	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2cccc(F)c2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436332	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccccc2)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436330	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)CC(C)C)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436329	=	=	IC50	nM	1100.0	IC50	uM	1.1
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C#N)n(-c3ccccc3C#N)c3ccccc23)c2ccccc2OC12CCOCC2	J. Med. Chem.	2013.0	CHEMBL2436227	=	=	Ki	nM	1000.0	Ki	uM	1.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H]1CN(C(=O)c2ccccc2F)c2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl	J. Med. Chem.	2013.0	CHEMBL2436333	=	=	IC50	nM	860.0	IC50	uM	0.86
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis	Cc1cc(C)n(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2441346	=	=	IC50	nM	20500.0	IC50	uM	20.5
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis	Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2441342	=	=	IC50	nM	7400.0	IC50	uM	7.4
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2441340	=	=	IC50	nM	19700.0	IC50	uM	19.7
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate after 5 to 60 mins by LC-MS/MS analysis	Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2171124	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis	Cc1cc(C)n(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2441346	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis	Cn1cc(-c2ccc3c(c2F)CCN3C(=O)Cc2cccc(C(F)(F)F)n2)c2c(N)ncnc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2441342	=	=	IC50	nM	9090.0	IC50	uM	9.09
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	ACS Med. Chem. Lett.	2013.0	CHEMBL2441340	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 60 mins by LC-MS/MS analysis	Cn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(C(F)(F)F)c2)c2c(N)ncnc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2171124	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of human recombinant CYP3A4 after 20 mins by LC/MS/MS analysis	CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3cc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2441567	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 after 20 mins by LC/MS/MS analysis	CN(C)C/C=C/C(=O)N1CCOc2cc3ncnc(Nc4ccc(F)c(Cl)c4)c3cc21	ACS Med. Chem. Lett.	2013.0	CHEMBL2441565	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N1CCCCC1)C2	J. Med. Chem.	2013.0	CHEMBL2441955	=	=	IC50	nM	8200.0	IC50	uM	8.2
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N1CCCC1)C2	J. Med. Chem.	2013.0	CHEMBL2441954	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CCCN(C)C(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441953	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N(C)C)C2	J. Med. Chem.	2013.0	CHEMBL2441952	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)N(C)C)C2	J. Med. Chem.	2013.0	CHEMBL2441952	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CNC(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441951	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(N)=O)C2	J. Med. Chem.	2013.0	CHEMBL2441950	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CCN(CC)C(=O)[C@@H](C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441848	=	=	IC50	nM	9600.0	IC50	uM	9.6
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CCN(CC)C(=O)CCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441847	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CCN(CC)C(=O)CN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441846	=	=	IC50	nM	6600.0	IC50	uM	6.6
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CCC(=O)O)C2	J. Med. Chem.	2013.0	CHEMBL2441845	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(CC(=O)O)C2	J. Med. Chem.	2013.0	CHEMBL2441844	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	CCOC(=O)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441843	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)NC2	J. Med. Chem.	2013.0	CHEMBL2441842	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCN1S(=O)(=O)C1CC1)C2	J. Med. Chem.	2013.0	CHEMBL2441841	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCN1)C2	J. Med. Chem.	2013.0	CHEMBL2441840	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@@H]1CCCO1)C2	J. Med. Chem.	2013.0	CHEMBL2441839	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(C[C@H]1CCCO1)C2	J. Med. Chem.	2013.0	CHEMBL2441838	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COC[C@H](C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441837	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COC[C@H](C)N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441837	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441836	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441836	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COCCN1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441836	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1cc(CN2Cc3nc(C)c(CN)c(-c4ccc(Cl)cc4Cl)c3C2=O)no1	J. Med. Chem.	2013.0	CHEMBL2441835	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ncco1)C2	J. Med. Chem.	2013.0	CHEMBL2441834	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ccn(C)n1)C2	J. Med. Chem.	2013.0	CHEMBL2441833	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(Cc1ccccc1)C2	J. Med. Chem.	2013.0	CHEMBL2441832	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	Cc1nc2c(c(-c3ccc(Cl)cc3Cl)c1CN)C(=O)N(c1ccn(C)n1)C2	J. Med. Chem.	2013.0	CHEMBL2441831	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441830	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441830	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COc1ccccc1N1Cc2nc(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2C1=O	J. Med. Chem.	2013.0	CHEMBL2441830	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethyl coumarin as substrate	COc1ccc(N2Cc3nc(C)c(CN)c(-c4ccc(Cl)cc4Cl)c3C2=O)cc1	J. Med. Chem.	2013.0	CHEMBL2441829	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	N#Cc1cncc(Oc2cc(Cl)cc(C(=O)Nc3ccc(F)cn3)c2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440639	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	Cc1cccc(NC(=O)c2cc(Cl)cc(Oc3cncc(F)c3)c2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440638	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(Nc1ccc(F)cn1)c1cc(Cl)cc(Oc2cncc(F)c2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440637	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	Cc1cccc(NC(=O)c2cc(Cl)cc(Oc3cncnc3)c2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440626	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(Nc1cccc(Cl)n1)c1cc(Cl)cc(Oc2cncnc2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440625	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(Nc1cccc(F)n1)c1cc(Cl)cc(Oc2cncnc2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440624	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	O=C(Nc1ccc(F)cn1)c1cc(Cl)cc(Oc2cncnc2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440663	=	=	IC50	nM	6200.0	IC50	uM	6.2
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	Cc1csc(NC(=O)c2cc(Cl)cc(Oc3cncnc3)c2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440660	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	Cc1csc(NC(=O)c2cc(F)cc(Oc3cncnc3)c2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2440659	=	=	IC50	nM	22300.0	IC50	uM	22.3
Inhibition of human CYP3A4	Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1	Bioorg. Med. Chem.	2013.0	CHEMBL2442750	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP2D6 (unknown origin) coincubated with substrate	O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441208	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP2D6 (unknown origin) coincubated with substrate	CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441200	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) coincubated with substrate	O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441208	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) coincubated with substrate	CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441200	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) preincubated prior to substrate addition	O=C(Nc1ccc(N2CCN(C(=O)Nc3ccccc3Cl)CC2)nc1)c1oc(N2CCCCC2)nc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441208	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) preincubated prior to substrate addition	CC(C)OC(=O)N1CCN(c2ccc(NC(=O)c3oc(N4CCCCC4)nc3C(F)(F)F)cn2)CC1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2441200	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	Cl.OC(COc1ccc2cc(Br)ccc2c1)Cn1ccnc1			CHEMBL2448692	=	=	IC50	nM	700.0	IC50	uM	0.7
DNDI: CYP Inhibition	O=c1c2ccccc2nc(-c2ccc(-c3ccccc3)cc2)n1Cc1cccnc1			CHEMBL2448693	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCOC(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448694	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(c1ccccc1)S(=O)(=O)c1ccc(NC(=O)CN(C)C2CCN(C)CC2)c(Cl)c1.Cl			CHEMBL2448695	=	=	IC50	nM	19000.0	IC50	uM	19.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(c1ccccc1)S(=O)(=O)c1ccc(Cl)c(NC(=O)c2ccc3c(c2)CCNC3)c1			CHEMBL2448696	=	=	IC50	nM	5830.0	IC50	uM	5.83
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCOC(COc1ccc2cc(Br)ccc2c1)Cn1ccnc1.O=CO			CHEMBL2448697	<	<	IC50	nM	250.0	IC50	uM	0.25
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(CC)S(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448698	=	=	IC50	nM	20000.0	IC50	uM	20.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	N#Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448699	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(c1ccccc1)S(=O)(=O)c1ccc(Cl)c(NC(=O)CNC2CCCN(C)C2)c1.O=CO			CHEMBL2448700	=	=	IC50	nM	16300.0	IC50	uM	16.3
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CS(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448701	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(NCCc1cnc[nH]1)c1ccc2cc(Br)ccc2c1			CHEMBL2448703	=	=	IC50	nM	3280.0	IC50	uM	3.28
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448704	=	=	IC50	nM	18000.0	IC50	uM	18.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(NCCc1cnc[nH]1)c1cnc(-c2ccccc2)cn1			CHEMBL2448705	=	=	IC50	nM	16000.0	IC50	uM	16.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CN(CC(O)COc1ccc2cc(Br)ccc2c1)C1CCCCC1			CHEMBL2448706	>	>	IC50	nM	10000.0	IC50	uM	10.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(C)N(C)CC(O)COc1ccc2cc(Br)ccc2c1			CHEMBL2448707	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1			CHEMBL2448708	=	=	IC50	nM	1000.0	IC50	uM	1.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CN1CCC(NCC(O)COc2ccc3cc(Br)ccc3c2)CC1			CHEMBL2448709	=	=	IC50	nM	44400.0	IC50	uM	44.4
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(C1CC1)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1			CHEMBL2448711	=	=	IC50	nM	1400.0	IC50	uM	1.4
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	N#Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1			CHEMBL2448712	=	=	IC50	nM	4500.0	IC50	uM	4.5
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CN(C)S(=O)(=O)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1			CHEMBL2448713	=	=	IC50	nM	10000.0	IC50	uM	10.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCS(=O)(=O)N(Cc1cccnc1)c1cccc(-c2nc3ccccc3s2)c1			CHEMBL2448714	<	<	IC50	nM	250.0	IC50	uM	0.25
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1			CHEMBL2448715	=	=	IC50	nM	790.0	IC50	uM	0.79
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1			CHEMBL2448716	=	=	IC50	nM	1000.0	IC50	uM	1.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3cccs3)nc2)c1			CHEMBL2448717	=	=	IC50	nM	1400.0	IC50	uM	1.4
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccc3)nc2)c1			CHEMBL2448689	=	=	IC50	nM	4000.0	IC50	uM	4.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccc3)cc2)c1			CHEMBL2448718	=	=	IC50	nM	3000.0	IC50	uM	3.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2ccc(-c3ccccn3)s2)c1			CHEMBL2448719	=	=	IC50	nM	2000.0	IC50	uM	2.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(C1CC1)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1			CHEMBL2448720	=	=	IC50	nM	1120.0	IC50	uM	1.12
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnn(-c3ccccn3)c2)c1			CHEMBL2448721	=	=	IC50	nM	1400.0	IC50	uM	1.4
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448722	=	=	IC50	nM	2900.0	IC50	uM	2.9
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448722	=	=	IC50	nM	1520.0	IC50	uM	1.52
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCS(=O)(=O)N(Cc1cccnc1)c1cncc(-c2nc3ccccc3s2)c1			CHEMBL2448723	=	=	IC50	nM	1040.0	IC50	uM	1.04
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)s1			CHEMBL2448724	=	=	IC50	nM	2000.0	IC50	uM	2.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(Nc1ccccc1-n1ccnc1)c1cnc(-c2ccccc2)nc1			CHEMBL2448725	>	>	IC50	nM	10000.0	IC50	uM	10.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1			CHEMBL2448727	=	=	IC50	nM	775.0	IC50	uM	0.775
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	O=C(C1CC1)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1			CHEMBL2448728	=	=	IC50	nM	1110.0	IC50	uM	1.11
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2sc(-c3ccccc3)nc2C)c1			CHEMBL2448729	<	<	IC50	nM	1000.0	IC50	uM	1.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	Cl.NCC(=O)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1			CHEMBL2448730	<	<	IC50	nM	1000.0	IC50	uM	1.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	Cl.NCC(=O)N(Cc1cccnc1)c1cc(F)cc(-c2nc3ccccc3s2)c1			CHEMBL2448730	=	=	IC50	nM	1010.0	IC50	uM	1.01
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F			CHEMBL2448733	=	=	IC50	nM	1000.0	IC50	uM	1.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(=O)N(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F			CHEMBL2448734	=	=	IC50	nM	470.0	IC50	uM	0.47
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CS(=O)(=O)N(Cc1cnc[nH]1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448735	=	=	IC50	nM	1500.0	IC50	uM	1.5
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccn3)s2)c1			CHEMBL2448736	=	=	IC50	nM	3000.0	IC50	uM	3.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)nc2)c1			CHEMBL2448737	>	>	IC50	nM	10000.0	IC50	uM	10.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)cn2)c1			CHEMBL2448738	=	=	IC50	nM	8000.0	IC50	uM	8.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1			CHEMBL2448739	<	<	IC50	nM	1000.0	IC50	uM	1.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1c[nH]cn1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448740	=	=	IC50	nM	4000.0	IC50	uM	4.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CS(=O)(=O)N(Cc1cccnc1)c1ccc(-c2ccc(F)cc2)cc1F			CHEMBL2448741	=	=	IC50	nM	612.0	IC50	uM	0.612
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(=O)N(Cc1c[nH]cn1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448742	>	>	IC50	nM	10000.0	IC50	uM	10.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1cnc[nH]1)c1cc(F)cc(-c2nc3ccccc3s2)c1			CHEMBL2448743	=	=	IC50	nM	576.0	IC50	uM	0.576
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	NCC(=O)N(Cc1cccnc1)c1ccc(-c2nc3ccccc3s2)cc1			CHEMBL2448744	=	=	IC50	nM	13040.0	IC50	uM	13.04
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CS(=O)(=O)N(Cc1c[nH]cn1)c1ccc(-c2ccc(F)cc2)cc1F			CHEMBL2448745	<	<	IC50	nM	1000.0	IC50	uM	1.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CC(C)Cc1ccc(-n2ccnc2)c(NC(=O)c2cnc(-c3ccccc3)s2)c1			CHEMBL2448747	<	<	IC50	nM	1000.0	IC50	uM	1.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CCN(Cc1c[nH]cn1)c1ccc(-c2ccc(F)cc2)cc1F			CHEMBL2448748	=	=	IC50	nM	4000.0	IC50	uM	4.0
DNDI: Human CYP3A4 inhibition determined using 6b-hydroxylation of testosterone	CO/N=C(\C)c1ccc(-n2ccnc2)c(NC(=O)c2cncc(-c3ccccc3)n2)c1			CHEMBL2448752	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	Cc1csc(C(C)(O)c2nnc(NC(=O)Cc3c(F)cccc3F)s2)n1	J. Med. Chem.	2013.0	CHEMBL3088176	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1csc(C(C)(O)c2nnc(Nc3ncn(Cc4c(F)cccc4F)n3)s2)n1	J. Med. Chem.	2013.0	CHEMBL3088175	=	=	IC50	nM	48000.0	IC50	uM	48.0
Inhibition of CYP3A4 (unknown origin)	Cc1csc([C@](C)(O)c2nnc(Nc3ccn(Cc4c(F)cccc4F)n3)s2)n1	J. Med. Chem.	2013.0	CHEMBL3088172	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NC(=O)[C@@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087343	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NC(=O)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087342	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NC(=O)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087341	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NC(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087340	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NC(=O)c3cc(Cl)cc(Cl)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087339	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	CCCc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087043	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	CCc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087042	=	=	IC50	nM	12200.0	IC50	uM	12.2
Inhibition of CYP3A4 (unknown origin) after 5 mins	C=Cc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087041	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4 (unknown origin) after 5 mins	COc1cc(-c2ccnc(C)c2)ccc1NS(=O)(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087040	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NS(=O)(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087038	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1cc(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2)ccn1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087037	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2cncnc2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087036	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2ncccn2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087035	=	=	IC50	nM	16200.0	IC50	uM	16.2
Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2ccncc2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087355	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1nccn1-c1ccc(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)cc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087353	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-n2ccnc2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087352	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2cc[nH]n2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087351	=	=	IC50	nM	15300.0	IC50	uM	15.3
Inhibition of CYP3A4 (unknown origin) after 5 mins	Cc1noc(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3)cc2)n1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087350	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2nnco2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087349	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2ccco2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087348	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) after 5 mins	O=S(=O)(Nc1ccc(-c2cnco2)cc1)c1cc(Cl)cc(Cl)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087347	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 (unknown origin) after 4 hrs	Cc1cc(N2CC[C@H](N3CCC[C@@H]3C)C2)ccc1NC(=O)c1c(C)noc1C	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3087669	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccccc1[C@H]1C[C@@H](NCc2ccc(Cl)cc2)CC[C@@H]1C(=O)N1CC(c2ccccc2)(c2ccccc2)C1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3086045	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins post NADPH addition followed by substrate addition measured after 5 mins by LC/MS/MS analysis	Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3086078	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by NADPH and substrate addition measured after 5 mins by LC/MS/MS analysis	Cc1c(Cc2cccc(NS(N)(=O)=O)c2F)c(=O)oc2cc(OC(=O)N(C)C)c(F)cc12	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3086078	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of recombinant human CYP3A4	Cn1c(NCC(=O)c2ccccc2)nc(-c2ccncc2)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091545	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	COc1cccc([C@H]2CN(c3nc(-c4ccncn4)cc(=O)n3C)CCO2)c1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091464	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncn2)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091536	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncc2F)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091531	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091529	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	Cn1c(N2CCOC(c3ccc(F)cc3)C2)nc(-c2ccncc2)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091547	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	Cn1c(N2CCOC(c3ccccc3)C2)nc(-c2ccncc2)cc1=O	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3091546	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes measured after compound pre-incubation	Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)O)n(Cc3cc4ccccc4nc3Cl)c2cc1F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3092124	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes measured after concurrent incubation	Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)O)n(Cc3cc4ccccc4nc3Cl)c2cc1F	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3092124	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	Nc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3092130	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	Cc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL2442495	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC[C@@H](Cn1cc(C#N)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3093463	=	=	IC50	nM	5800.0	IC50	nM	5800.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC[C@@H](Cn1cc(C)c2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3093462	=	=	IC50	nM	940.0	IC50	nM	940.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC[C@@H](Cn1ccc2ccccc21)NS(=O)(=O)c1c(N)cc(Cl)cc1Cl	Bioorg. Med. Chem. Lett.	2013.0	CHEMBL3093461	=	=	IC50	nM	570.0	IC50	nM	570.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C1CCN(C(=O)c2cc(F)ccc2S(C)(=O)=O)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092198	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C1CCN(C(=O)c2ccc(S(C)(=O)=O)cc2OC(F)(F)F)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092197	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis	O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccn3ncnc3c2)c(F)c1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092423	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis	O=C1O[C@@H](Cn2ccnn2)CN1c1ccc(-c2ccn3ccnc3c2)c(F)c1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092421	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis	CC(=O)NC[C@H]1CN(c2ccc(-c3ccn4ncnc4c3)c(F)c2)C(=O)O1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092419	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis	CC(=O)NC[C@H]1CN(c2ccc(-c3ccn4ccnc4c3)c(F)c2)C(=O)O1	ACS Med. Chem. Lett.	2013.0	CHEMBL3092417	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as terfenadine hydroxylation after 20 mins by LC-MS/MS analysis	CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1	ACS Med. Chem. Lett.	2013.0	CHEMBL126	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation and testosterone 6beta-hydroxylation after 20 mins by LC-MS/MS analysis	CC(C)(C)n1nnnc1C(NCCNc1ccnc2cc(Cl)ccc12)c1ccc(Cl)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL2414256	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation and testosterone 6beta-hydroxylation after 20 mins by LC-MS/MS analysis	Cc1ccc(C(NCCNc2ccnc3cc(Cl)ccc23)c2nnnn2C(C)(C)C)cc1	ACS Med. Chem. Lett.	2013.0	CHEMBL3099819	=	=	IC50	nM	170.0	IC50	uM	0.17
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104374	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104490	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1	J. Med. Chem.	2013.0	CHEMBL3104489	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1	J. Med. Chem.	2013.0	CHEMBL3104488	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1	J. Med. Chem.	2013.0	CHEMBL3104487	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104486	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1	J. Med. Chem.	2013.0	CHEMBL3104485	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104479	=	=	IC50	nM	6300.0	IC50	uM	6.3
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104478	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104476	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104473	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(Cl)cc3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104472	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	N#Cc1ccccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104537	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104534	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	O=C([C@@H](c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104526	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	O=C([C@H](c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104525	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1	J. Med. Chem.	2013.0	CHEMBL3104376	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6beta-hydroxylation of testosterone	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1	J. Med. Chem.	2013.0	CHEMBL3104375	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	O=C(c1ccc(F)c(F)c1)N1CCN2C(=O)c3ccccc3[C@@]12c1ccc(Cl)cc1	J. Med. Chem.	2013.0	CHEMBL3105228	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 (unknown origin)	C/C(=N\NC(=O)c1cccc(S(=O)(=O)N2CCOCC2)c1)c1cc(Cl)ccc1O	J. Med. Chem.	2013.0	CHEMBL3104250	=	=	IC50	nM	2610.0	IC50	uM	2.61
Inhibition of CYP3A4 (unknown origin)	c1ccc(-c2ccc(C3(Cc4nnn[nH]4)C4CC5CC(C4)CC3C5)cc2)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3103437	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5F)c4n3)cnc2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3109337	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4 (unknown origin)	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@@H]5F)c4n3)cnc2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3109356	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4 (unknown origin)	COCCOc1ccn2c(-c3ccc4cccc(O[C@H]5CCNC[C@@H]5F)c4n3)cnc2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3109338	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4 (unknown origin)	COCCOc1ccn2c(-c3ccc4cccc(O[C@@H]5CCNC[C@H]5F)c4n3)cnc2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3109337	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4 (unknown origin)	COCCOc1ccn2c(-c3ccc4cccc(OC5CCNCC5)c4n3)cnc2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3109340	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2014.0	CHEMBL157101	=	=	IC50	nM	24.0	IC50	uM	0.024
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	C[C@]12CC[C@@H]3c4ccc(CCBr)cc4CC[C@H]3[C@@H]1C[C@H](Cc1cccc(C(N)=O)c1)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL2203397	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@H](Cc1cccc(C(N)=O)c1)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL410242	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of human CYP3A4	CCOc1ccc(N2CCN(c3noc(C4(NC(C)=O)CCC4)n3)[C@@H](C)C2)c(C)c1	J. Med. Chem.	2013.0	CHEMBL3110076	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	CN1C[C@H]2[C@@H](C1)[C@@H]2CN(Cc1ccc(Cl)c(F)c1)C(=O)c1cn(C)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114787	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)[C@]3(CNC(=O)c2ccccc2C(F)(F)F)CC2CC2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114971	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)[C@]3(CNC(=O)c2ccccc2C(F)(F)F)c2ccccn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114968	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cn1cnc(S(=O)(=O)N2C[C@H]3[C@@H](C2)[C@]3(CNC(=O)c2ccc(Cl)cc2Cl)c2ccccn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114967	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CCS(=O)(=O)N1CCC(CNC(=O)c2ccc(Cl)cc2Cl)(CC2CC2)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL472757	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCCS(=O)(=O)N1CCC(c2ccccc2)([C@H](C)NC(=O)c2ccc(Cl)cc2Cl)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114792	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cn1cncc1[C@@](C)(O)C1=Cc2cccnc2[C@@H](N2CCN(C(=O)OC(C)(C)C)CC2)c2ccc(Cl)cc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115253	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) compound preincubated with substrate	COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3112778	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) compound co-incubated with substrate	COCCOc1ccccc1N1CCN(C(=O)C2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3112778	=	=	IC50	nM	4900.0	IC50	uM	4.9
Inhibition of CYP3A4 (unknown origin)	COc1cccc(OC)c1C1CCCC(=O)N1Cc1ccc2ccccc2n1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3112601	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) after 10 to 30 mins	Cl.O=C1N[C@H](C(=O)O)Cc2cn(cn2)C/C=C/COc2ccc(Cl)c1c2	ACS Med. Chem. Lett.	2014.0	CHEMBL3115061	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4	C[C@@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1	J. Med. Chem.	2014.0	CHEMBL3112867	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1	J. Med. Chem.	2014.0	CHEMBL3112866	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	CC1(C)CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21	J. Med. Chem.	2014.0	CHEMBL3112865	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	CC1CN(C(=O)Cc2nc(N3CCOCC3)cc(=O)[nH]2)c2ccccc21	J. Med. Chem.	2014.0	CHEMBL3112864	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	Cn1c(CC(=O)N2CCc3ccccc32)nc(N2CCOCC2)cc1=O	J. Med. Chem.	2014.0	CHEMBL3112861	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccncc3)cccc21	J. Med. Chem.	2014.0	CHEMBL3112858	=	=	IC50	nM	31000.0	IC50	uM	31.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3cccnc3)cccc21	J. Med. Chem.	2014.0	CHEMBL3112857	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccn3)cccc21	J. Med. Chem.	2014.0	CHEMBL3112856	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(-c3ccccc3)cccc21	J. Med. Chem.	2014.0	CHEMBL3112855	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(OC(F)(F)F)cccc21	J. Med. Chem.	2014.0	CHEMBL3112854	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c1cccc2C(F)(F)F	J. Med. Chem.	2014.0	CHEMBL3112853	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	COc1cccc2c1CCN2C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1	J. Med. Chem.	2014.0	CHEMBL3112852	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Br)cccc21	J. Med. Chem.	2014.0	CHEMBL3112850	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(Cl)cccc21	J. Med. Chem.	2014.0	CHEMBL3112849	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2c(F)cccc21	J. Med. Chem.	2014.0	CHEMBL3112848	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(Cl)ccc21	J. Med. Chem.	2014.0	CHEMBL3112592	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2cc(F)ccc21	J. Med. Chem.	2014.0	CHEMBL3112847	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4	O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)N1CCc2ccccc21	J. Med. Chem.	2014.0	CHEMBL3112690	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)NC(Cc2ccccc2)CN(Cc2ccccc2)C(=O)OCc2cncs2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114739	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)NC(Cc2ccccc2)CN(Cc2ccccc2)C(=O)OCc2cncs2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114739	=	=	IC50	nM	460.0	IC50	uM	0.46
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114738	=	=	IC50	nM	220.0	IC50	uM	0.22
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N2CCN(C(=O)OCc3cncs3)CC2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114737	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCNC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114736	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)CN(CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)C(=O)[C@H](CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114735	=	=	IC50	nM	270.0	IC50	uM	0.27
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)CN(CC[C@H](Cc1ccccc1)NC(=O)[C@H](CCN1CCOCC1)NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)OCc1cncs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114734	=	=	IC50	nM	350.0	IC50	uM	0.35
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccccc2Cl)C(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114733	=	=	IC50	nM	340.0	IC50	uM	0.34
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccc(Cl)cc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114732	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114731	=	=	IC50	nM	340.0	IC50	uM	0.34
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114730	=	=	IC50	nM	320.0	IC50	uM	0.32
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(CCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114729	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NC2CCN(C(=O)OCc3cncs3)CC2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3112611	=	=	IC50	nM	1670.0	IC50	uM	1.67
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N2CCC(NC(=O)OCc3cncs3)CC2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114728	=	=	IC50	nM	1840.0	IC50	uM	1.84
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCCNC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114727	=	=	IC50	nM	1260.0	IC50	uM	1.26
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCN(Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114726	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CCNNC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114725	=	=	IC50	nM	630.0	IC50	uM	0.63
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(CCCCN(Cc2ccccc2)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114724	=	=	IC50	nM	240.0	IC50	uM	0.24
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)NCCCCNC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114723	=	=	IC50	nM	870.0	IC50	uM	0.87
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114722	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)[C@H]2OC(C)(C)O[C@@H]2[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114721	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](C)CC[C@H](C)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114720	=	=	IC50	nM	510.0	IC50	uM	0.51
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC[C@@H](CC[C@H](CC)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114719	=	=	IC50	nM	190.0	IC50	uM	0.19
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CCC[C@@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114718	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CCC[C@@H](CC[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(C)C)NC(=O)OCc1cncs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114717	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N(C)[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114740	=	=	IC50	nM	410.0	IC50	uM	0.41
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)N(C)C(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114716	=	=	IC50	nM	710.0	IC50	uM	0.71
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](/C=C/[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114715	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC(=O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114714	=	=	IC50	nM	280.0	IC50	uM	0.28
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114713	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of human CYP3A4-mediated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL163	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc(Oc2ncnc3c2cnn3C2CCN(Cc3ccc(C(F)(F)F)cc3)CC2)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114894	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 (unknown origin)	CC(C)CC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114886	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	CC(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114880	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)OC(=O)N1CCC(n2ncc3c(Oc4ccc(S(C)(=O)=O)cc4)ncnc32)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114905	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)OC(=O)N1CCC(n2ncc3c(Nc4ccc(S(C)(=O)=O)cc4F)ncnc32)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3114896	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115191	=	=	IC50	nM	90.0	IC50	uM	0.09
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	O=C(N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)N(Cc1cncs1)C1CC1)Cc1ccccc1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115190	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)[C@H](NC(=O)N(C)Cc1cscn1)C(=O)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115189	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(=O)NCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@@H](CC[C@@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115188	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115187	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](Cn2cccn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115186	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2cn(C)cn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115185	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115184	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCNS(C)(=O)=O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115183	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(=O)NCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115182	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115181	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115180	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2095208	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN(C)C)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115179	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CNCC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115178	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115177	=	=	IC50	nM	210.0	IC50	uM	0.21
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115176	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)NC(CN(C)C)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115175	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115174	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115173	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](COCc2ccccc2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115172	=	=	IC50	nM	170.0	IC50	uM	0.17
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	COC[C@H](NC(=O)N(C)Cc1csc(C(C)C)n1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115171	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	O=C(N[C@H](CC[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)N(Cc1cncs1)C1CC1)Cc1ccccc1)OCc1cncs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115170	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CN(Cc1cncs1)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115169	=	=	IC50	nM	170.0	IC50	uM	0.17
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C2CC2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115168	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C)C(=O)N[C@@H](CO)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115167	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CN(Cc1cncs1)C(=O)NCCC(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115166	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)[C@H](NC(=O)N(C)Cc1cncs1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115165	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)[C@H](NC(=O)N(Cc1cscn1)C1CC1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115164	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)[C@H](NC(=O)N(C)Cc1cscn1)C(=O)N[C@H](CC[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115163	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	Cc1nc(CN(C)C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115162	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human CYP3A4-mdiated midazolam 1'-hydroxylase activity	CC(C)c1nc(CN(C(=O)N[C@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)C(C)C)C2CC2)cs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3115161	=	=	IC50	nM	210.0	IC50	uM	0.21
Inhibition of human CYP3A4	O=C(Nc1ccc(F)c(-c2nc3cc(-c4ccccc4)cnc3[nH]2)c1)N1CCCC1	J. Med. Chem.	2014.0	CHEMBL3115821	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1sc(N[C@](Cc2ccccc2)(c2cc(F)cc(OC(F)(F)C(F)F)c2)c2ccc(Cl)cn2)nc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116157	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)cs2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116158	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)c(Br)s2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116160	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)cc(F)c3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116154	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)ccc3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116155	=	=	IC50	nM	32000.0	IC50	uM	32.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116156	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2152165	=	=	IC50	nM	8800.0	IC50	uM	8.8
Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Cc1sc(N[C@](Cc2ccccc2)(c2cc(F)cc(OC(F)(F)C(F)F)c2)c2ccc(Cl)cn2)nc1C(F)(F)F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116157	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)cs2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116158	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc(C(F)(F)F)c(Br)s2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116160	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)cc(F)c3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116154	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3cc(F)ccc3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116155	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Fc1cc(OC(F)(F)C(F)F)cc([C@@](Cc2ccccc2)(Nc2nc3ccccc3[nH]2)c2ccc(Cl)cn2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3116156	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	O=C(NC1CCCC1)N[C@@](Cc1ccccc1)(c1cc(F)cc(OC(F)(F)C(F)F)c1)c1ccc(Cl)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2152165	=	=	IC50	nM	3600.0	IC50	uM	3.6
Inhibition of CYP3A4 in human liver microsomes	CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncc(F)cn1	J. Med. Chem.	2014.0	CHEMBL3121804	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ccccn1	J. Med. Chem.	2014.0	CHEMBL3121800	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	CCc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccn1	J. Med. Chem.	2014.0	CHEMBL3120505	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccc1F	J. Med. Chem.	2014.0	CHEMBL3121798	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncc(F)cn1	J. Med. Chem.	2014.0	CHEMBL3121694	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1cc2c(cc1F)c(C#N)c(-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)cn1)n2-c1ncccn1	J. Med. Chem.	2014.0	CHEMBL3121811	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@@H]2C[C@H]12	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3121096	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C1NN=C(c2ccc(OC3CCN(C4CCC4)CC3)cc2)[C@H]2C[C@@H]12	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3121095	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CC6(CN5C(=O)[C@@H](NC(=O)OC)C(C)C)OCCO6)[nH]4)cc3)cc2)[nH]1)C(C)C	J. Med. Chem.	2014.0	CHEMBL3121951	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin)	C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1	J. Med. Chem.	2014.0	CHEMBL2403888	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	Cc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1	J. Med. Chem.	2014.0	CHEMBL3128180	=	=	IC50	nM	41800.0	IC50	uM	41.8
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2ccnn21	J. Med. Chem.	2014.0	CHEMBL3128188	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2scnc21	J. Med. Chem.	2014.0	CHEMBL3128178	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	Nc1nc(CC(=O)Nc2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1	J. Med. Chem.	2014.0	CHEMBL1684585	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	Nc1nc2c(s1)CC[C@H]2C(=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1	J. Med. Chem.	2014.0	CHEMBL3128194	=	=	IC50	nM	86000.0	IC50	uM	86.0
Inhibition of human recombinant CYP3A4	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125375	=	=	IC50	nM	40.0	IC50	nM	40.0
Inhibition of human recombinant CYP3A4	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125395	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125394	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125391	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125390	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125389	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	NC(=O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2ccccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125385	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125384	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125384	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Br)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125383	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	CC1Cc2cc(F)ccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125381	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2cc(F)ccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125380	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	CC1Cc2c(Cl)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(=O)O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125379	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	O=C(O)c1sc(N2CCOCC2)nc1CC(=O)N1CCc2c(Cl)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125378	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	CC1Cc2c(Br)cccc2N1C(=O)Cc1nc(N2CCOCC2)sc1C(N)=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3125395	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes after 7 mins by LC/MS/MS analysis	O=C(c1nn2c(C(F)(F)F)cc(C3CC3)cc2c1Cl)N1CCN([C@H]2C[C@@H]3C[C@@H]3[C@@H]2O)C(=O)C1	J. Med. Chem.	2014.0	CHEMBL3125655	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 by fluorescence assay	CCc1cc(C(=O)N[C@@H]2C[C@@H](C(N)=O)N(C(=O)c3coc4ccccc34)C2)n(CC)n1	J. Med. Chem.	2014.0	CHEMBL3125270	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 by fluorescence assay	CCNC(=O)[C@@H]1C[C@@H](NC(=O)c2cc(CC)nn2C)CN1C(=O)c1coc2ccccc12	J. Med. Chem.	2014.0	CHEMBL3125272	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1csc(-n2nc(-c3ccccc3)c3ccc(C(F)(F)F)cc32)n1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3127163	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in Escherichia coli using 7-benzyloxyquinoline as substrate	CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCC1	J. Med. Chem.	2014.0	CHEMBL3126382	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein as substrate	CC(=O)O.O=S(=O)(c1cccc(CCCCOCCCCCCNC[C@H](O)c2ccc(O)c(CO)c2)c1)C1CCCC1	J. Med. Chem.	2014.0	CHEMBL3126382	=	=	IC50	nM	1600.0	IC50	uM	1.6
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127494	=	=	IC50	nM	1800.0	IC50	uM	1.8
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127510	=	=	IC50	nM	1900.0	IC50	uM	1.9
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127509	=	=	IC50	nM	960.0	IC50	uM	0.96
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127507	=	=	IC50	nM	1500.0	IC50	uM	1.5
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127506	=	=	IC50	nM	3000.0	IC50	uM	3.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127501	=	=	IC50	nM	890.0	IC50	uM	0.89
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)c1	J. Med. Chem.	2014.0	CHEMBL3127500	=	=	IC50	nM	890.0	IC50	uM	0.89
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)C2CCOCC2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127526	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127525	=	=	IC50	nM	8900.0	IC50	uM	8.9
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1ccc([C@@H]2C[C@H]2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127522	=	=	IC50	nM	3500.0	IC50	uM	3.5
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127521	=	=	IC50	nM	680.0	IC50	uM	0.68
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127520	=	=	IC50	nM	1200.0	IC50	uM	1.2
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2cnn(C3CCOCC3)c2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127494	=	=	IC50	nM	1400.0	IC50	uM	1.4
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127510	=	=	IC50	nM	200.0	IC50	uM	0.2
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127509	=	=	IC50	nM	300.0	IC50	uM	0.3
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@H]3C[C@@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127507	=	=	IC50	nM	140.0	IC50	uM	0.14
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CCCn1cc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127506	=	=	IC50	nM	270.0	IC50	uM	0.27
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2cccc(OC(F)(F)F)c2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127501	=	=	IC50	nM	65.0	IC50	uM	0.065
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CS(=O)(=O)c1cccc(S(=O)(=O)c2ccc(NC(=O)[C@@H]3C[C@H]3c3cccnc3)cc2)c1	J. Med. Chem.	2014.0	CHEMBL3127500	=	=	IC50	nM	180.0	IC50	uM	0.18
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)C2CCOCC2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127526	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127525	=	=	IC50	nM	2500.0	IC50	uM	2.5
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	Nc1ccc([C@@H]2C[C@H]2C(=O)Nc2ccc(S(=O)(=O)c3ccccc3)cc2)cn1	J. Med. Chem.	2014.0	CHEMBL3127522	=	=	IC50	nM	2000.0	IC50	uM	2.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127521	=	=	IC50	nM	90.0	IC50	uM	0.09
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@@H]1C[C@H]1c1cccnc1	J. Med. Chem.	2014.0	CHEMBL3127520	=	=	IC50	nM	110.0	IC50	uM	0.11
Inhibition of CYP3A4 (unknown origin)	COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21	J. Med. Chem.	2014.0	CHEMBL3126842	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human liver microsomes using benzyloxyresorufin as substrate after 30 mins in presence of NADPH	COc1ccc2c(c1)C1CC1(C(=O)N1C3CC1CN(Cc1ccccc1)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21	J. Med. Chem.	2014.0	CHEMBL3126836	=	=	EC50	nM	13000.0	EC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes using benzyloxyresorufin as substrate after 30 mins in presence of NADPH	CCN1CC2CC(C1)N2C(=O)[C@]12C[C@H]1c1cc(OC)ccc1-c1c(C3CCCCC3)c3ccc(C(=O)NS(=O)(=O)N(C)C)cc3n1C2	J. Med. Chem.	2014.0	CHEMBL3126835	=	=	EC50	nM	9000.0	EC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes using benzyloxyresorufin as substrate after 30 mins in presence of NADPH	COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21	J. Med. Chem.	2014.0	CHEMBL3126834	=	=	EC50	nM	14000.0	EC50	uM	14.0
Inhibition of CYP3A4 in human liver microsomes using benzyloxyresorufin as substrate after 30 mins in presence of NADPH	COc1ccc2c(c1)C1CC1(C(=O)N1C3CNCC1C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21	J. Med. Chem.	2014.0	CHEMBL3126657	>	>	EC50	nM	40000.0	EC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)Cc1cc2c(cc1Br)OCO2	Eur. J. Med. Chem.	2014.0	CHEMBL3127992	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2ccc3n(c2=O)CCN(CCOc2ccc(Cl)cc2C(F)(F)F)C3=O)cn1	J. Med. Chem.	2014.0	CHEMBL3127906	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2ccc3n(c2=O)CCN(CCOc2ccc(F)cc2C(F)(F)F)C3=O)cn1	J. Med. Chem.	2014.0	CHEMBL3127905	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CCC1(C)NC(=O)c2cc(S(=O)(=O)Nc3ccc(F)cc3F)cc(Cl)c2NC1=O	MedChemComm	2013.0	CHEMBL3134098	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)C[C@H]1CC[C@@H](Oc2ccc(NC(=O)c3nnc(Nc4ccc(F)c(F)c4)o3)cn2)CC1	MedChemComm	2013.0	CHEMBL3133005	>	>	IC50	nM	10000.0	IC50	uM	10.0
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1			CHEMBL3104376	=	=	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1			CHEMBL3104376	=	=	IC50	nM	1200.0	IC50	uM	1.2
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1			CHEMBL3104376	=	=	IC50	nM	7400.0	IC50	uM	7.4
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1			CHEMBL3104488	=	=	IC50	nM	7000.0	IC50	uM	7.0
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1			CHEMBL3104488	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1			CHEMBL3104488	=	=	IC50	nM	6600.0	IC50	uM	6.6
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1			CHEMBL3104490	=	=	IC50	nM	4000.0	IC50	uM	4.0
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1			CHEMBL3104490	=	=	IC50	nM	19000.0	IC50	uM	19.0
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1			CHEMBL3104490	=	=	IC50	nM	7100.0	IC50	uM	7.1
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1			CHEMBL3104486	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1			CHEMBL3104486	=	=	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1			CHEMBL3104486	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1			CHEMBL3104374	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1			CHEMBL3104374	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1			CHEMBL3104374	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1			CHEMBL3104487	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1			CHEMBL3104487	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)nc3)CC2)c2cccnc2)cc1			CHEMBL3104487	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1			CHEMBL3104485	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1			CHEMBL3104485	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)c2cccnc2)cc1			CHEMBL3104485	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1			CHEMBL3104489	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1			CHEMBL3104489	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1ccc(C(C(=O)N2CCN(c3ccc(C(F)(F)F)cn3)CC2)c2cccnc2)cc1			CHEMBL3104489	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cncnc3)CC2)cc1			CHEMBL3137389	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cncnc3)CC2)cc1			CHEMBL3137389	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCN(C(=O)C(c3ccc(Cl)cc3)c3cncnc3)CC2)cc1			CHEMBL3137389	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)nc2)CC1			CHEMBL3137390	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)cn2)CC1			CHEMBL3137391	=	=	IC50	nM	18000.0	IC50	uM	18.0
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cncnc1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1			CHEMBL3137392	=	=	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	O=C(C(c1ccc(Cl)cc1)c1cccnc1)N1CCN(Cc2ccccc2C(F)(F)F)CC1			CHEMBL3137394	=	=	IC50	nM	15000.0	IC50	uM	15.0
DNDI: CYP Inhibition	CS(=O)(=O)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1			CHEMBL3137466	=	=	IC50	nM	2600.0	IC50	uM	2.6
DNDI: CYP Inhibition	CC(C)(C)CC(=O)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1			CHEMBL3104528	=	=	IC50	nM	800.0	IC50	uM	0.8
DNDI: CYP Inhibition	O=C(C1CC1)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1			CHEMBL3137467	=	=	IC50	nM	1500.0	IC50	uM	1.5
DNDI: CYP Inhibition	O=C(c1ccccc1)N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1			CHEMBL3137468	=	=	IC50	nM	1900.0	IC50	uM	1.9
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104479	=	=	IC50	nM	6300.0	IC50	uM	6.3
DNDI: CYP Inhibition	CC(C)(C)C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3104529	=	=	IC50	nM	1900.0	IC50	uM	1.9
DNDI: CYP Inhibition	O=C(c1ccccc1C(F)(F)F)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3104531	=	=	IC50	nM	1700.0	IC50	uM	1.7
DNDI: CYP Inhibition	Cc1noc(C)c1C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137441	=	=	IC50	nM	2100.0	IC50	uM	2.1
DNDI: CYP Inhibition	Cc1ncsc1C(=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137442	=	=	IC50	nM	2900.0	IC50	uM	2.9
DNDI: CYP Inhibition	O=C(c1ccc(F)cc1)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137443	=	=	IC50	nM	4400.0	IC50	uM	4.4
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3104536	>	>	IC50	nM	100000.0	IC50	uM	100.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3104536	=	=	IC50	nM		IC50	uM	
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(Cl)cc3)CC2)cc1			CHEMBL3104472	=	=	IC50	nM		IC50	uM	
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccccc3)CC2)cc1			CHEMBL3137445	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1			CHEMBL3137446	>	>	IC50	nM	100000.0	IC50	uM	100.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1			CHEMBL3137446	=	=	IC50	nM		IC50	uM	
DNDI: CYP Inhibition	FC(F)(F)c1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3137448	=	=	IC50	nM		IC50	uM	
DNDI: CYP Inhibition	COc1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3137450	=	=	IC50	nM	15000.0	IC50	uM	15.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3ccccc3C(F)(F)F)CC2)cc1			CHEMBL3104532	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3nccs3)CC2)cc1			CHEMBL3137452	=	=	IC50	nM		IC50	uM	
DNDI: CYP Inhibition	Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3104534	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	=	=	IC50	nM		IC50	uM	
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	=	=	IC50	nM		IC50	uM	
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	>	>	IC50	nM	100000.0	IC50	uM	100.0
DNDI: CYP Inhibition	Fc1cnc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)nc1			CHEMBL3137455	=	=	IC50	nM		IC50	uM	
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ncccn3)CC2)cc1			CHEMBL3137456	=	=	IC50	nM		IC50	uM	
DNDI: CYP Inhibition	N#Cc1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3104538	=	=	IC50	nM		IC50	uM	
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3104536	=	=	IC50	nM	30200.0	IC50	uM	30.2
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(Cl)cc3)CC2)cc1			CHEMBL3104472	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccccc3)CC2)cc1			CHEMBL3137445	=	=	IC50	nM	11000.0	IC50	uM	11.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1			CHEMBL3137446	=	=	IC50	nM	10700.0	IC50	uM	10.7
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3cccc(C(F)(F)F)c3)CC2)cc1			CHEMBL3137446	=	=	IC50	nM	18000.0	IC50	uM	18.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3137448	=	=	IC50	nM	10000.0	IC50	uM	10.0
DNDI: CYP Inhibition	COc1ccc(CN2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3137450	=	=	IC50	nM	8000.0	IC50	uM	8.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(Cc3ccccc3C(F)(F)F)CC2)cc1			CHEMBL3104532	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3nccs3)CC2)cc1			CHEMBL3137452	=	=	IC50	nM	1700.0	IC50	uM	1.7
DNDI: CYP Inhibition	Cc1ccccc1CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3104534	=	=	IC50	nM	18000.0	IC50	uM	18.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	=	=	IC50	nM	6000.0	IC50	uM	6.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	=	=	IC50	nM	12100.0	IC50	uM	12.1
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	Fc1cnc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)nc1			CHEMBL3137455	=	=	IC50	nM	700.0	IC50	uM	0.7
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ncccn3)CC2)cc1			CHEMBL3137456	=	=	IC50	nM	1800.0	IC50	uM	1.8
DNDI: CYP Inhibition	N#Cc1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)cc1			CHEMBL3104538	=	=	IC50	nM	4000.0	IC50	uM	4.0
DNDI: CYP Inhibition	N#Cc1ccccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3104537	=	=	IC50	nM	5200.0	IC50	uM	5.2
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1			CHEMBL3104473	=	=	IC50	nM	16000.0	IC50	uM	16.0
DNDI: CYP Inhibition	Cc1cncc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)c1			CHEMBL3137458	=	=	IC50	nM	600.0	IC50	uM	0.6
DNDI: CYP Inhibition	N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1			CHEMBL3104476	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)cc1			CHEMBL3104478	=	=	IC50	nM	12000.0	IC50	uM	12.0
DNDI: CYP Inhibition	CS(=O)(=O)c1ccc(N2CCC(N(c3ccc(Cl)cc3)c3cccnc3)CC2)cc1			CHEMBL3104477	=	=	IC50	nM	2000.0	IC50	uM	2.0
DNDI: CYP Inhibition	N#Cc1ccc(N(c2cccnc2)C2CCN(c3ccc(F)c(F)c3)CC2)cc1			CHEMBL3137459	=	=	IC50	nM	4300.0	IC50	uM	4.3
DNDI: CYP Inhibition	CC(C)(O)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137460	=	=	IC50	nM	5300.0	IC50	uM	5.3
DNDI: CYP Inhibition	CN(C)S(=O)(=O)c1ccccc1N1CCC(N(c2ccc(C#N)cc2)c2cccnc2)CC1			CHEMBL3137461	=	=	IC50	nM	2000.0	IC50	uM	2.0
DNDI: CYP Inhibition	CN(C)S(=O)(=O)c1cccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cccnc3)CC2)c1			CHEMBL3137462	=	=	IC50	nM	7000.0	IC50	uM	7.0
DNDI: CYP Inhibition	CN(C)S(=O)(=O)c1cccc(N2CCC(N(c3ccc(C#N)cc3)c3cccnc3)CC2)c1			CHEMBL3137463	=	=	IC50	nM	6000.0	IC50	uM	6.0
DNDI: CYP Inhibition	CCC(C(C)=O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137464	=	=	IC50	nM	10000.0	IC50	uM	10.0
DNDI: CYP Inhibition	CC(=O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137471	=	=	IC50	nM	5000.0	IC50	uM	5.0
DNDI: CYP Inhibition	CC(O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137472	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CC(O)C(C)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137472	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1cc(C(F)(F)F)ccc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137473	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	N#Cc1cc(C(F)(F)F)ccc1N1CCC(N(c2ccc(Cl)cc2)c2cccnc2)CC1			CHEMBL3137474	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	Cn1nc(C2CC2)cc1N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137475	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CC(C)(O)CN1CCC(N(c2ccc(C#N)cc2)c2cccnc2)CC1			CHEMBL3137476	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CCC(C(C)O)N1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137477	=	=	IC50	nM	17000.0	IC50	uM	17.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N2CCC(N(c3ccc(C(F)(F)F)cc3)c3cncnc3)CC2)cc1			CHEMBL3137479	=	=	IC50	nM	16000.0	IC50	uM	16.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cncnc2)C2CCN(c3ccc(C(F)(F)F)nc3)CC2)cc1			CHEMBL3137480	=	=	IC50	nM	9000.0	IC50	uM	9.0
DNDI: CYP Inhibition	CC(C)C(O)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137481	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	CC(C)(F)CN1CCC(N(c2ccc(C(F)(F)F)cc2)c2cccnc2)CC1			CHEMBL3137482	=	=	IC50	nM	16000.0	IC50	uM	16.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(C(c3ccccc3)C(F)(F)F)CC2)cc1			CHEMBL3137483	>	>	IC50	nM	20000.0	IC50	uM	20.0
DNDI: CYP Inhibition	FC(F)(F)c1ccc(N(c2cccnc2)C2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1			CHEMBL3104375	=	=	IC50	nM		IC50	uM	
Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(N2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218854	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(N2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218855	=	=	IC50	nM	8500.0	IC50	uM	8.5
Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(N2CCC(N3CCOCC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218856	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218857	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(CN2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218858	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate by LC/MS/MS analysis	COc1cc(CN2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218859	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(N2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218854	=	=	IC50	nM	5400.0	IC50	uM	5.4
Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(N2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218855	=	=	IC50	nM	13700.0	IC50	uM	13.7
Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(N2CCC(N3CCOCC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218856	=	=	IC50	nM	14200.0	IC50	uM	14.2
Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218857	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(CN2CCOCC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218858	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate by LC/MS/MS analysis	COc1cc(CN2CCN(C)CC2)ccc1-c1nc2c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)c(Cl)cnc2[nH]1	MedChemComm	2012.0	CHEMBL3218859	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Br.CN(C)Cc1cc2c([nH]c(=O)c3cccc(O)c32)s1	MedChemComm	2011.0	CHEMBL3219283	<	<	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccccc1-c1nc2ccc(-c3ccc(Cl)cc3)cc2c(=O)n1C[C@H]1CCCN(C(C)C)C1	MedChemComm	2013.0	CHEMBL3218645	=	=	IC50	nM	680.0	IC50	uM	0.68
Inhibition of CYP3A4 (unknown origin)	COc1cc(OC)cc(-c2nnc([C@@]3(Cc4ccccc4)OC(=O)N([C@H](C)c4ccccc4)C3=O)o2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3234858	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](c1ccccc1)N1C(=O)O[C@](Cc2ccccc2)(c2nnc(C3(c4ccccc4)CC3)o2)C1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3234863	>	>	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CCN(C)CC2)nc(N2CCC[C@@H](C(=O)NCCc3ccc(C#N)cc3)C2)n1	J. Med. Chem.	2014.0	CHEMBL3234564	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(C(F)(F)F)nc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)cc4)C3)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234565	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(N2CCC[C@@H](C(=O)NCCc3ccc(C#N)cc3)C2)nc(N2CCN(C)CC2)c1F	J. Med. Chem.	2014.0	CHEMBL3234566	=	=	IC50	nM	7600.0	IC50	uM	7.6
Inhibition of CYP3A4 (unknown origin)	Cc1nc(N2CCN(C)CC2)cc(N2CCC[C@@H](C(=O)NCCc3ccc(C#N)cc3)C2)n1	J. Med. Chem.	2014.0	CHEMBL3234567	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)cc4)C3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234568	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(CCNC(=O)[C@@H]2CCCN(c3cc(N4CCNCC4)nc(C(F)(F)F)n3)C2)cc1	J. Med. Chem.	2014.0	CHEMBL3234569	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(CCNC(=O)[C@@H]2CCCN(c3cc(N4CCN(C5COC5)CC4)nc(C(F)(F)F)n3)C2)cc1	J. Med. Chem.	2014.0	CHEMBL3234570	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4ccc(C#N)nc4)C3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234571	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(CCNC(=O)[C@@H]2CCCN(c3cc(N4CCNCC4)nc(C(F)(F)F)n3)C2)cn1	J. Med. Chem.	2014.0	CHEMBL3234572	<	<	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin)	CCN1CCN(c2cc(N3CCC[C@@H](C(=O)NCCc4cnc(C#N)nc4)C3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234573	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CCCC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234574	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CCC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234575	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CCC[C@@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234576	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CC[C@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234577	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2cc(N3CC[C@@H]3C(=O)NCCc3ccc(C#N)cc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234578	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 (unknown origin)	CCN1CCN(c2cc(N3CC[C@H]3C(=O)NCCc3ccc(C#N)nc3)nc(C(F)(F)F)n2)CC1	J. Med. Chem.	2014.0	CHEMBL3234579	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(CCNC(=O)[C@@H]2CCN2c2cc(-c3ccc([C@H]4CC[C@H](C(=O)O)CC4)cc3)nc(C(F)(F)F)n2)cc1	J. Med. Chem.	2014.0	CHEMBL3234871	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis	Cc1cccc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)n1	J. Med. Chem.	2014.0	CHEMBL3233058	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis	Cc1nc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)ccc1F	J. Med. Chem.	2014.0	CHEMBL3237560	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis	Cc1ccc(Nc2cc(N[C@@H]3CCCC[C@@H]3N)nnc2C(N)=O)nc1C	J. Med. Chem.	2014.0	CHEMBL3237561	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomal fraction assessed as midazolam-1'-hydroxylation preincubated for 10 mins followed by NADPH addition measured after 5 to 20 mins by RF-MS analysis	NC(=O)c1nnc(N[C@@H]2CCCC[C@@H]2N)cc1Nc1ccc2c(n1)CCC2	J. Med. Chem.	2014.0	CHEMBL3237564	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nccn2)c(C(=O)N2C[C@H](C#Cc3ccc(F)cn3)CC[C@H]2C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3235253	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-n2nccn2)c(C(=O)N2C[C@H](C#Cc3cccc(CO)c3)CC[C@H]2C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3235265	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 (unknown origin)	c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2cn1	J. Med. Chem.	2014.0	CHEMBL3237442	=	=	IC50	nM	550.0	IC50	uM	0.55
Inhibition of CYP3A4 (unknown origin)	Fc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12	J. Med. Chem.	2014.0	CHEMBL3237443	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Clc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12	J. Med. Chem.	2014.0	CHEMBL3237444	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nccc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c12	J. Med. Chem.	2014.0	CHEMBL3237445	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	c1cc2c3cnc(Nc4ccc(N5CCNCC5)cn4)nc3n(C3CCCC3)c2nn1	J. Med. Chem.	2014.0	CHEMBL3237448	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H](CO)n1c2cnccc2c2cnc(Nc3ccc(N4CCNCC4)cn3)nc21	J. Med. Chem.	2014.0	CHEMBL3237449	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1CC[C@H](n2c3cnccc3c3cnc(Nc4ccc(N5CCNCC5)cn4)nc32)CC1	J. Med. Chem.	2014.0	CHEMBL3237703	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)CCC(n2c3cnccc3c3cnc(Nc4ccc(N5CCNCC5)cn4)nc32)CC1	J. Med. Chem.	2014.0	CHEMBL3237704	=	=	IC50	nM	9500.0	IC50	uM	9.5
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3125527	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(Cc2nnn[nH]2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236358	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(Cc2noc(=O)[nH]2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236359	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)NS(=O)(=O)C(F)(F)F)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236360	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3125537	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)C(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236361	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(=O)CO)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236362	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC[C@@H](CS(=O)(=O)C(C)(C)C)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236363	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236364	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CS(N)(=O)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236365	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)N2CC[C@@H](C(=O)O)C2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236635	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)N2CC[C@H](C(=O)O)C2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236636	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ccccn2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236637	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ccccc2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236638	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2cc(C(=O)O)ccn2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236639	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2ncc(C(=O)CO)s2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236654	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2cn(C(C)C)c(=O)c3ccccc23)c2cc(F)ccc2n1CC(=O)O	J. Med. Chem.	2014.0	CHEMBL3236948	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(Cc2nc(CC(=O)O)cs2)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1	J. Med. Chem.	2014.0	CHEMBL3236640	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C)n(-c2cc(NC(=O)CN3CCN(C)CC3)nc(-c3nccs3)n2)n1	J. Med. Chem.	2014.0	CHEMBL271202	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3263640	=	=	IC50	nM	9800.0	IC50	uM	9.8
Inhibition of CYP3A4 (unknown origin) using benzyloxyresorufin as substrate	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1nc(Nc2ccc(C(=O)N3CCOCC3)cc2)c2nc[nH]c2n1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3263640	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	Cn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260740	=	=	IC50	nM	6600.0	IC50	uM	6.6
Inhibition of human recombinant CYP3A4	Cc1nc(C(F)(F)F)ccc1Cn1c(=O)c(-c2ccncc2)c(-c2ccc(Cl)cc2)c2nn(C)c(=O)n21	J. Med. Chem.	2013.0	CHEMBL3260741	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260742	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3C)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260744	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccc(C#N)cc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260745	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnc(C)nc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260753	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3F)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260754	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnn(C)c3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260755	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of human recombinant CYP3A4	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3cnc(N(C)C)nc3)c(=O)n(Cc3ccc(C#N)cc3)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260756	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human hepatocytes	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260743	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 in human liver microsomes	CCn1nc2c(-c3ccc(Cl)cc3)c(-c3ccncc3)c(=O)n(Cc3ccc(C(F)(F)F)nc3C)n2c1=O	J. Med. Chem.	2013.0	CHEMBL3260743	=	=	IC50	nM	9100.0	IC50	uM	9.1
Inhibition of CYP3A4 (unknown origin)	N[C@H]1CC[C@H](Nc2ccc3ncc(-c4cnc(Nc5ncccc5F)nc4)n3n2)CC1	J. Med. Chem.	2014.0	CHEMBL3264059	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	ACS Med. Chem. Lett.	2014.0	CHEMBL3264002	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH	CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	ACS Med. Chem. Lett.	2014.0	CHEMBL3092195	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH	CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3092189	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH	CNS(=O)(=O)Nc1cc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)ccn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3263996	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	ACS Med. Chem. Lett.	2014.0	CHEMBL3264002	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH	CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	ACS Med. Chem. Lett.	2014.0	CHEMBL3092195	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH	CNS(=O)(=O)Nc1cccc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3092189	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH	CNS(=O)(=O)Nc1cc(Cc2c(C)c3ccc(OC(=O)N(C)C)cc3oc2=O)ccn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3263996	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1[C@H](OC(C)(C)C)C(=O)O	ACS Med. Chem. Lett.	2014.0	CHEMBL3259907	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(C(F)(F)F)cc(SC)c1C(=O)N[C@@]1(c2ccccc2)CCCN(C)C1	ACS Med. Chem. Lett.	2014.0	CHEMBL3259928	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O	J. Med. Chem.	2014.0	CHEMBL3261331	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins prior to substrate addition measured after 10 mins by LC/MS/MS analysis	Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1	J. Med. Chem.	2014.0	CHEMBL3260567	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C)c(S(=O)(=O)N[C@@H](C)CNc2cccc3c2cnn3-c2ccc(F)cc2)c(C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261407	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCCC2)c(C)c1S(=O)(=O)N[C@@H](C)CNc1cccc2c1cnn2-c1ccc(F)nc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261425	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4 (unknown origin)	O=C1c2cccc3ccn(c23)CCN1[C@@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261479	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C1c2cccc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261481	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C1c2cc(F)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261482	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C1c2cc(Cl)cc3cnn(c23)CCN1[C@@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261483	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1cc2c3c(cnn3CCN([C@@H]3CN4CCC3CC4)C2=O)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261485	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C1c2cccc3[nH]c(=O)n(c23)CCN1[C@@H]1CN2CCC1CC2	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3261486	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL1110	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4 (unknown origin)	COCCn1cc(-c2c(C)nc3c(N4CCOCC4)nccn23)cn1	J. Med. Chem.	2014.0	CHEMBL3262028	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cncs3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264599	=	=	IC50	nM	770.0	IC50	uM	0.77
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3c[nH]cn3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264604	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cc[nH]n3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264595	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3ccncc3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264602	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cnco3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264600	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cccnc3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264601	=	=	IC50	nM	9400.0	IC50	uM	9.4
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(OC(F)F)ccc2c1)c1c[nH]nn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264608	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3ccncn3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264603	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cnn[nH]1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264605	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(OCC(F)(F)F)c(OCC(F)(F)F)cc2c1)c1c[nH]nn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264606	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cn[nH]c3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264596	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3cnn[nH]3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264597	=	=	IC50	nM	57000.0	IC50	uM	57.0
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(-c3cccs3)ccc2c1)c1c[nH]nn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3259868	=	=	IC50	nM	81000.0	IC50	uM	81.0
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	COc1cc2ccc(C(O)(c3nc[nH]n3)C(C)C)cc2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264598	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(-c3cnco3)ccc2c1)c1cnn[nH]1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264607	=	=	IC50	nM	102000.0	IC50	uM	102.0
Inhibition of human hepatocyte microsome CYP3A4 using testosterone as substrate by HPLC/MS/MS method	CC(C)C(O)(c1ccc2cc(OCC(F)(F)F)ccc2c1)c1c[nH]nn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3264609	>=	>=	IC50	nM	195000.0	IC50	uM	195.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(NC(=O)N2CCNC[C@@H]2COc2cccnc2)cc1.Cl	J. Med. Chem.	2014.0	CHEMBL3262163	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1	J. Med. Chem.	2014.0	CHEMBL3265032	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2014.0	CHEMBL157101	=	=	IC50	nM	280.0	IC50	uM	0.28
Inhibition of CYP3A4 (unknown origin)	Cc1cc2nn(Cc3cc([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)ccc3Cl)c(=O)n2cc1Cl	Bioorg. Med. Chem.	2014.0	CHEMBL3288752	>	>	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin)	CCN1C(=O)CN(c2ccc(Cc3cc([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)ccc3Cl)cc2)C1=O	Bioorg. Med. Chem.	2014.0	CHEMBL3288755	>	>	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291118	=	=	IC50	nM	1250.0	IC50	uM	1.25
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cccc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291120	=	=	IC50	nM	1950.0	IC50	uM	1.95
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291124	=	=	IC50	nM	242.0	IC50	uM	0.242
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(N)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291127	=	=	IC50	nM	135.0	IC50	uM	0.135
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291394	=	=	IC50	nM	1080.0	IC50	uM	1.08
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291395	=	=	IC50	nM	1890.0	IC50	uM	1.89
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291398	=	=	IC50	nM	4650.0	IC50	uM	4.65
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291118	=	=	IC50	nM	1360.0	IC50	uM	1.36
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cccc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291120	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(CO)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291124	=	=	IC50	nM	216.0	IC50	uM	0.216
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(N)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291127	=	=	IC50	nM	44.4	IC50	uM	0.0444
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCCC(O)C3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291394	=	=	IC50	nM	1240.0	IC50	uM	1.24
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2cncc(NC(=O)CN3CCC(O)CC3)c2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291395	=	=	IC50	nM	1630.0	IC50	uM	1.63
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 15 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2CC[C@@H](N)C[C@H]2O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	J. Med. Chem.	2014.0	CHEMBL3291398	=	=	IC50	nM	4430.0	IC50	uM	4.43
Inhibition of CYP3A4 (unknown origin)	Cn1c2c(c(=O)n1Cc1ccccc1C(F)(F)F)[C@H]1CC[C@]2(C)C1(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291357	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of CYP3A4 (unknown origin)	CC1(C)[C@@H]2CC[C@@]1(C)c1c2c(=O)n(-c2ccc(F)cc2F)n1Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291346	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of CYP3A4 (unknown origin)	CC1(C)[C@@H]2CC[C@@]1(C)c1c2c(=O)n(-c2ccccc2)n1Cc1ccccc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291340	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of CYP3A4 (unknown origin)	Cn1c2c(c(=O)n1-c1ccccc1C(F)(F)F)[C@H]1CC[C@]2(C)C1(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291345	=	=	IC50	nM	22600.0	IC50	uM	22.6
Inhibition of CYP3A4 (unknown origin)	Cn1c2c(c(=O)n1-c1cc(Cl)ccc1Cl)[C@H]1CC[C@]2(C)C1(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291348	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	Cn1c2c(c(=O)n1-c1ccccc1)[C@H]1CC[C@]2(C)C1(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291337	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cn1c2c(c(=O)n1-c1ccccc1Cl)[C@H]1CC[C@]2(C)C1(C)C	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3291354	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	N=C(N)c1ccc(Oc2cc(Oc3ccc(C(=N)N)cc3)cc(C(=O)N[C@H]3CC[C@H](N)CC3)c2)cc1	Bioorg. Med. Chem.	2014.0	CHEMBL3289023	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	N=C(N)c1ccc(Oc2cc(NC(=O)[C@H]3CC[C@H](N)CC3)cc(Oc3ccc(C(=N)N)cc3)c2)cc1	Bioorg. Med. Chem.	2014.0	CHEMBL3289034	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	N=C(N)c1ccc(Oc2cc(Oc3ccc(C(=N)N)cc3)cc(C(=O)O[C@H]3CC[C@H](N)CC3)c2)cc1	Bioorg. Med. Chem.	2014.0	CHEMBL3289038	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	COc1ncnc(Cn2cc(C(=O)NCCF)c3ncc(C)cc32)c1C	J. Med. Chem.	2014.0	CHEMBL3109801	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc32)c1C	J. Med. Chem.	2014.0	CHEMBL3109802	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1ncnc(Cn2cc(C(=O)NCC(F)F)c3ncc(C)cc32)c1C	J. Med. Chem.	2014.0	CHEMBL3291422	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	Cc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(N(C)C)c3C)c2c1	J. Med. Chem.	2014.0	CHEMBL3291423	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	Cc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(OC(F)F)c3C)c2c1	J. Med. Chem.	2014.0	CHEMBL3291424	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(OC)c3C)c2c1	J. Med. Chem.	2014.0	CHEMBL3291427	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	COc1cnc2c(C(=O)NCCO)cn(Cc3ncnc(N(C)C)c3C)c2c1	J. Med. Chem.	2014.0	CHEMBL3291430	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Nc1ccc(-c2cccs2)cc1NC(=O)c1ccc(N2CCC3(CC2)CNC(=O)O3)nc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3286732	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Nc1nc2ccc(C(F)(F)F)cc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl	J. Med. Chem.	2014.0	CHEMBL3289803	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Nc1nc2cccnc2n1CC(O)c1cccc(Cl)c1Cl	J. Med. Chem.	2014.0	CHEMBL3289805	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Nc1nc2ccc(OC3CCOC3)nc2n1CC(O)c1ccc(C(F)(F)F)cc1Cl	J. Med. Chem.	2014.0	CHEMBL3289811	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4 (unknown origin)	CN1CCN(c2ccc3nc(N)n(CC(O)c4ccc(C(F)(F)F)cc4Cl)c3n2)CC1	J. Med. Chem.	2014.0	CHEMBL3289806	=	=	IC50	nM	14100.0	IC50	uM	14.1
Inhibition of CYP3A4 (unknown origin)	CC(Oc1ccc2nc(N)n(CC(O)c3ccc(C(F)(F)F)cc3Cl)c2n1)C(F)(F)F	J. Med. Chem.	2014.0	CHEMBL3289813	=	=	IC50	nM	20300.0	IC50	uM	20.3
Inhibition of CYP3A4 in human liver microsomes after 2 to 45 mins by LC-MS/MS analysis	CCC(=O)N1CCc2cc(-c3cncc4ccccc34)ccc21	J. Med. Chem.	2014.0	CHEMBL3287179	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes after 2 to 45 mins by LC-MS/MS analysis	CC(=O)N1CCc2cc(-c3cnccc3C)ccc21	J. Med. Chem.	2014.0	CHEMBL3287188	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone conversion to 6-hydroxy testosterone preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis	Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287548	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam conversion to 1'-hydroxy midazolam preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis	Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287548	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	Cc1noc(C)c1-c1ccc(-c2nc(C)c([C@H](OC(C)(C)C)C(=O)O)c(-c3ccc(Cl)cc3)c2C)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287925	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc2ccccc2c(-c2ccc3c4c(ccnc24)CCO3)c1[C@H](OC(C)(C)C)C(=O)O	ACS Med. Chem. Lett.	2014.0	CHEMBL3259907	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of CYP3A4 (unknown origin)	Cc1cccc2nc(C(=O)N[C@H]3CC[C@@H](NC(=O)c4cc(F)cnc4Oc4cccc(-c5ccc(CN6CCC(N7CCCC7)CC6)cc5)c4)CC3)cn12	J. Med. Chem.	2014.0	CHEMBL3288009	<	>	IC50	nM	1000.0	pIC50		6.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1CN(Cc2ccc(-c3cccc(Oc4ncc(F)cc4C(=O)N[C@H]4CC[C@@H](NC(=O)c5cc6ccccn6n5)CC4)c3)cc2)C[C@@H](C)N1	J. Med. Chem.	2014.0	CHEMBL3288010	=	=	IC50	nM	398.11	pIC50		6.4
Inhibition of CYP3A4 (unknown origin)	Cc1cccc2nc(C(=O)N[C@H]3CC[C@@H](NC(=O)c4cc(F)cnc4Oc4cccc(-c5ccc(CN6C[C@H](C)N[C@H](C)C6)cc5)c4)CC3)cn12	J. Med. Chem.	2014.0	CHEMBL3288011	<	>	IC50	nM	1000.0	pIC50		6.0
Inhibition of CYP3A4 (unknown origin)	O=c1cc([C@H]2CCN[C@@H](Cc3ccccc3)C2)o[nH]1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287849	>	>	IC50	nM	20000000.0	IC50	mM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C[C@H]1C[C@@H](c2cc(=O)[nH]o2)CCN1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287851	>	>	IC50	nM	20000000.0	IC50	mM	20.0
Inhibition of CYP3A4 (unknown origin)	O=c1cc([C@H]2CCN[C@@H](CCc3ccccc3)C2)o[nH]1	ACS Med. Chem. Lett.	2014.0	CHEMBL3287854	>	>	IC50	nM	20000000.0	IC50	mM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)N[C@H]2CC[C@@H](NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(CCCN5C[C@H](C)N[C@H](C)C5)cc4)c3)CC2)nn1C	J. Med. Chem.	2014.0	CHEMBL3288027	<	>	IC50	nM	1000.0	pIC50		6.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)N[C@H]2CC[C@@H](NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(CCN5CCC(N6CCCC6)CC5)cc4)c3)CC2)nn1C	J. Med. Chem.	2014.0	CHEMBL3288028	<	>	IC50	nM	1000.0	pIC50		6.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)N[C@H]2CC[C@@H](NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(O)cc4CN4CCOCC4)c3)CC2)nn1C	J. Med. Chem.	2014.0	CHEMBL3287739	=	=	IC50	nM	501.19	pIC50		6.3
Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288447	=	=	IC50	nM	4900.0	IC50	uM	4.9
Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme	C=CC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288448	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CC(O)CO)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288450	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) co-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CCO)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288451	=	=	IC50	nM	13300.0	IC50	uM	13.3
Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)C2)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288447	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme	C=CC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCN(c2ccccc2OCCOC)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288448	<	<	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CC(O)CO)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288450	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 (unknown origin) pre-incubated with enzyme	COCCOc1ccccc1N1CCN(C(=O)[C@]2(Oc3ccc(C(F)(F)F)cc3)CCCN(C(=O)c3cnccc3C(F)(F)F)[C@@H]2CCO)CC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3288451	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3109797	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298835	=	=	IC50	nM	2070.0	IC50	uM	2.07
Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298836	=	=	IC50	nM	490.0	IC50	uM	0.49
Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298837	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCN(c3ccc(OC(F)(F)F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298905	=	=	IC50	nM	11540.0	IC50	uM	11.54
Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298906	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(Cl)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298907	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(Cl)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298908	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2cc(Cl)ccn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298909	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant CYP3A4 (unknown origin) by LC/MS/MS analysis	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(N2CCC(c3ccc(OC(F)(F)F)cc3)CC2)cc1	J. Med. Chem.	2014.0	CHEMBL3298910	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(C[C@@H](NC(=O)C[C@H]2CNC(=O)c3cc(-c4cccc(Cl)c4)cn32)C2CCCCC2)CC1	Bioorg. Med. Chem.	2013.0	CHEMBL3297762	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay	COc1cc2ccnc(Oc3ccc(F)cc3)c2cc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3298322	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay	Fc1ccc(Oc2ncnc3[nH]ccc23)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3298431	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay	Fc1ccc(Oc2nccc3[nH]ccc23)c(F)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3298760	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS/competitive screening assay	Fc1ccc(Oc2nccc3[nH]ccc23)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3297778	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C)CCn1c(CC(C)(C)C)nc2cc(S(=O)(=O)C3CN(CCO)C3)ccc21	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3357391	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of recombinant CYP3A4 (unknown origin) after 3 mins by LC-MS/MS analysis	COc1ccc(-c2nc(CS(=O)(=O)c3cccc(Cl)c3)nc3ccsc23)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3354313	=	=	IC50	nM	6710.0	IC50	uM	6.71
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cc(NC(=O)[C@@H]2CCCN2c2ccc(C(F)(F)F)cc2)no1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3353862	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cc(NC(=O)[C@@H]2CCCN2c2ccc(Cl)cc2)no1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3353863	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cc(NC(=O)[C@@H]2CCC(=O)N2c2ccc(C(F)(F)F)cc2)on1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3353881	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	CC(C)(C)c1cc(NC(=O)[C@@H]2CCCCN2C(=O)N2CCS(=O)(=O)CC2)no1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3354553	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1COCCN1c1nc(-c2cncc3[nH]ccc23)cc2c1ncn2[C@@H](C)S(C)(=O)=O	ACS Med. Chem. Lett.	2015.0	CHEMBL3355474	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1COCCN1c1nc(-c2nncc3[nH]ccc23)cc2c1ncn2C	ACS Med. Chem. Lett.	2015.0	CHEMBL3355480	>	>	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cccc(Cl)c4Cl)cc3)cnc12	ACS Med. Chem. Lett.	2015.0	CHEMBL3092460	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)cnc12	ACS Med. Chem. Lett.	2015.0	CHEMBL3092468	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 midazolam site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	COc1ccc(Cl)c(S(=O)(=O)Nc2ccc(-c3cnc4c(C)n[nH]c4n3)cc2)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3092467	=	=	IC50	nM	26800.0	IC50	uM	26.8
Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cccc(Cl)c4Cl)cc3)cnc12	ACS Med. Chem. Lett.	2015.0	CHEMBL3092460	=	=	IC50	nM	14500.0	IC50	uM	14.5
Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1n[nH]c2nc(-c3ccc(NS(=O)(=O)c4cc(Cl)ccc4F)cc3)cnc12	ACS Med. Chem. Lett.	2015.0	CHEMBL3092468	=	=	IC50	nM	28600.0	IC50	uM	28.6
Inhibition of human CYP3A4 testosterone site in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	COc1ccc(Cl)c(S(=O)(=O)Nc2ccc(-c3cnc4c(C)n[nH]c4n3)cc2)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3092467	=	=	IC50	nM	18600.0	IC50	uM	18.6
Inhibition of CYP3A4 (unknown origin)	O=C(O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(C(F)(F)F)c3)cc21	ACS Med. Chem. Lett.	2014.0	CHEMBL3358920	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@]1(F)CCC[C@H]1Nc1c(C(N)=O)cnn2cccc12	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3359927	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2ccncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL1254079	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358921	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2c(C)cncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358922	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1cc2cc(CC(O)(CC(C)(C)c3cc(F)ccc3C)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358923	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C)nc(C)c2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358924	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(-c3ccccc3)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358925	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358926	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N(C)C)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358927	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(OC(C)C)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358928	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358929	=	=	IC50	nM	10.0	IC50	uM	0.01
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(C(N)=O)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358930	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358931	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358932	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(F)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358933	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358934	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	COc1ccc(F)cc1C(C)(C)CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358935	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358936	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3352882	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358937	=	=	IC50	nM	10.0	IC50	uM	0.01
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358938	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(C(N)=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358939	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(C)(=O)=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358940	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(N3CCOCC3)ncc2[nH]1)C(F)(F)F)c1cccc(S(N)(=O)=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358941	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1C(N)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358942	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(C)(=O)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358944	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccccc1S(N)(=O)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358945	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(F)cc1C(N)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358946	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1ccc(Cl)cc1C(N)=O	ACS Med. Chem. Lett.	2014.0	CHEMBL3358947	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(C(C)(C)CC(O)(Cc2cc3cc(S(C)(=O)=O)ncc3[nH]2)C(F)(F)F)c(C(N)=O)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358948	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358949	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CCS(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358950	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)S(=O)(=O)c1cc2cc(CC(O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358951	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CC(C)(CC(O)(Cc1cc2cc(S(C)(=O)=O)ncc2[nH]1)C(F)(F)F)c1cccc2c1S(=O)(=O)CC2	ACS Med. Chem. Lett.	2014.0	CHEMBL3358952	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccccc3C(N)=O)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358953	=	=	IC50	nM	34000.0	IC50	uM	34.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1	ACS Med. Chem. Lett.	2014.0	CHEMBL3358954	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)-coumarin as substrate after 30 mins by fluorescence assay	Cc1ccc(F)cc1C(C)(C)CC(O)(Cc1[nH]c2cnccc2c1C)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3358921	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 (unknown origin)	CC(C)Oc1ccc(COc2ccc3c(c2)c(Cl)c2n3CC[C@@H]2CC(=O)O)cc1C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3359523	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2151164	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	COc1nc(Nc2cccc3c2nc(-c2ccc(F)cc2)n3C)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2151164	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	COc1nc(-c2nc(Nc3cc(C(F)(F)F)ccc3F)n(C)n2)ccc1-n1cnc(C)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3353099	=	=	IC50	nM	25400.0	IC50	uM	25.4
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay	COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL502	=	=	IC50	nM	54680.0	IC50	uM	54.68
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes preincubated for 10 mins by fluorescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL157101	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3cccnc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353342	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353348	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353354	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353355	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccc(F)cc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353356	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	CN1CCN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3353359	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH	N#CC1(c2cc(C[C@H](O)CO)cc(-c3ccnc4[nH]nc(C(F)(F)F)c34)c2)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310294	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH	N#CC1(c2cc(C[C@@H](O)CO)cc(-c3ccnc4[nH]nc(C(F)(F)F)c34)c2)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310295	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 using testosterone as substrate after 10 mins by SPE-MS analysis in presence of NADPH	CS(=O)(=O)NCCc1cc(-c2ccnc3[nH]nc(C(F)(F)F)c23)cc(C2(C#N)CC2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310285	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL1175	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	Clc1ccc(C23CNCC2C3)cc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL528995	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310483	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310484	=	=	IC50	nM	710.0	IC50	uM	0.71
Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310485	=	=	IC50	nM	510.0	IC50	uM	0.51
Inhibition of recombinant human CYP3A4 preincubated for 5 mins before fluorescent substrate addition by fluorescence assay	Fc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310486	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins	CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1	Bioorg. Med. Chem.	2014.0	CHEMBL3330260	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1	Bioorg. Med. Chem.	2014.0	CHEMBL3330410	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in supersomes (unknown origin) using Dibenzylfluorescein as substrate after 10 mins	CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C	Bioorg. Med. Chem.	2014.0	CHEMBL3330409	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins	CCc1cccc(CC)c1NC(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1	Bioorg. Med. Chem.	2014.0	CHEMBL3330260	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins	NS(=O)(=O)c1cccc(-c2n[nH]c3ccc(NC(=O)C(c4ccsc4)N4CCCC4)cc23)c1	Bioorg. Med. Chem.	2014.0	CHEMBL3330410	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in supersomes (unknown origin) using 7-benzyloxy-4-trifluoromethylcoumarin as substrate after 30 mins	CCc1ccccc1C(C(=O)Nc1ccc2[nH]nc(-c3cccc(S(N)(=O)=O)c3)c2c1)N(C)C	Bioorg. Med. Chem.	2014.0	CHEMBL3330409	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1ccnn1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310992	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1cnnn1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310993	=	=	IC50	nM	32000.0	IC50	uM	32.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1ccnc1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310994	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1ncnn1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3309278	=	=	IC50	nM	46000.0	IC50	uM	46.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL638	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccccn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3310995	=	=	IC50	nM	136000.0	IC50	uM	136.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(Cl)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3358962	=	=	IC50	nM	74000.0	IC50	uM	74.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(OCC(F)(F)F)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311221	=	=	IC50	nM	72000.0	IC50	uM	72.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311222	=	=	IC50	nM	53000.0	IC50	uM	53.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	N#Cc1ccc(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cc1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311223	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311224	>	>	IC50	nM	60000.0	IC50	uM	60.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(Cl)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311225	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311226	=	=	IC50	nM	54000.0	IC50	uM	54.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311227	=	=	IC50	nM	79000.0	IC50	uM	79.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3311228	=	=	IC50	nM	65000.0	IC50	uM	65.0
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL64391	=	=	IC50	nM	70.0	IC50	uM	0.07
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL1397	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of CYP3A4 in human hepatocytes using testosterone as substrate by HPLC/MS/MS method	C[C@@H](c1ncncc1F)[C@](O)(Cn1cnnc1)c1ccc(F)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3358963	=	=	IC50	nM	51000.0	IC50	uM	51.0
Inhibition of CYP3A4 (unknown origin)	Nc1ccc(S(=O)(=O)N2CCN(c3ncc(C(O)(C(F)(F)F)C(F)(F)F)cc3-c3cccnc3)CC2)cn1	J. Med. Chem.	2014.0	CHEMBL3319549	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin)	Cn1cc(-c2cc(C(O)(C(F)(F)F)C(F)(F)F)cnc2N2CCN(S(=O)(=O)c3ccc(N)nc3)CC2)cn1	J. Med. Chem.	2014.0	CHEMBL3319533	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) using Vivid OOMR substrate	COc1ccc(C(=O)NC(=O)Nc2ccc3c(c2)NC(=O)/C3=C\c2[nH]c(C)c(C(=O)NCCN3CCCC3)c2C)c(F)c1	Eur. J. Med. Chem.	2014.0	CHEMBL3329684	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C(=O)NC(N)=O)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3315061	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C(=O)Nc1nncs1)[C@@H]1c2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)nc2Oc2c(F)cccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3315062	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) using Vivid OOMR substrate	O=C1Nc2cc(NC(=O)c3c[nH]cc(-c4ccccc4F)c3=O)ccc2/C1=C/c1ccc[nH]1	Eur. J. Med. Chem.	2014.0	CHEMBL3322590	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsome	CN1CCN(C(=O)c2cncnc2Oc2cc(Cl)ccc2Cl)c2ccccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3321845	=	=	IC50	nM	250.0	IC50	uM	0.25
Inhibition of CYP3A4 in human liver microsome	CN1CCN(C(=O)c2cnc(O)nc2Oc2cc(Cl)ccc2Cl)c2ccccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3321846	=	=	IC50	nM	260.0	IC50	uM	0.26
Inhibition of CYP3A4 in human liver microsome	CN1CCN(C(=O)C2(C(=O)Nc3cc(Cl)ccc3Cl)CC2)c2ccccc21	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3321850	=	=	IC50	nM	270.0	IC50	uM	0.27
Inhibition of CYP3A4 in human liver microsome	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL157101	<	<	IC50	nM	62.0	IC50	uM	0.062
Inhibition of CYP3A4 (unknown origin)	C[C@H](c1ccc(Cl)cc1)N1Cc2cncn2C(C[C@H](O)c2ccccc2)S1(=O)=O	J. Med. Chem.	2014.0	CHEMBL3313972	<	<	IC50	nM	68.0	IC50	nM	68.0
Inhibition of CYP3A4 (unknown origin)	CCOC[C@@H](CC(C)C)NC(=O)[C@@H]1CNC[C@H](C(=O)N(c2ccc(C(C)C)cn2)C2CC2)[C@@H]1O	ACS Med. Chem. Lett.	2014.0	CHEMBL3318957	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A3	Clc1ccc(C2(c3nnc4c(C5CC5)cccn34)CC2)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3318978	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	COc1cnc2ccc(=O)n(CCN3CCC(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3318997	=	=	IC50	nM	9400.0	IC50	uM	9.4
Inhibition of CYP3A4 (unknown origin)	COc1cnc2ccc(=O)n(CCN3CCN(c4nc5cc(C#N)c(C)cc5[nH]4)CC3)c2c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3318998	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in pooled human liver microsomes in presence of NADPH	O=C(Nc1cncc(Oc2cncnc2)n1)c1cc(Cl)ccn1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3314850	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C1CC(c2ccccc2)CC(O)=C1Sc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318415	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1SC1=C(O)CC(c2ccccc2)CC1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318423	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	O=C1CC(c2c(Cl)cccc2Cl)CC(O)=C1Sc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318469	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	O=C1CC(c2c(Cl)cccc2C(F)(F)F)CC(O)=C1Sc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318472	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	O=C1CC(c2c(C(F)(F)F)cccc2C(F)(F)F)CC(O)=C1Sc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318477	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1SC1=C(O)CC(c2c(Cl)cccc2Cl)CC1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318481	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1SC1=C(O)CC(c2c(Cl)cccc2Br)CC1=O	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3318482	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2cc(F)ccc2O1	J. Med. Chem.	2014.0	CHEMBL3326569	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2ccc(F)cc2O1	J. Med. Chem.	2014.0	CHEMBL3326570	=	=	IC50	nM	660.0	IC50	uM	0.66
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CC1(C)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2ccc(OC(F)(F)F)cc2O1	J. Med. Chem.	2014.0	CHEMBL3326576	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CCC1(CC)C[C@@H](NC(=O)Nc2cccc3cnccc23)c2cc(F)ccc2O1	J. Med. Chem.	2014.0	CHEMBL3326577	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CCC1(CC)C[C@@H](NC(=O)Nc2cccc3cnc(C)cc23)c2cc(F)ccc2O1	J. Med. Chem.	2014.0	CHEMBL3326578	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CCC1(CC)C[C@@H](NC(=O)Nc2cccc3cnc(C)cc23)c2cccc(F)c2O1	J. Med. Chem.	2014.0	CHEMBL3326579	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	CCCC1(CCC)C[C@@H](NC(=O)Nc2cccc3cnc(C)cc23)c2cccc(F)c2O1	J. Med. Chem.	2014.0	CHEMBL3326580	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4cc(F)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326581	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4cc(C(F)(F)F)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3325460	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4c3ccc(F)c4F)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326582	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4c(F)cc(F)cc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326583	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4c3ccc(C(F)(F)F)c4F)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326584	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(C)(C)Oc4cc(OC(F)(F)F)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326585	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4ccc(F)cc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326586	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4cc(F)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326587	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4cc(Cl)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326588	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4cc(C5CC5)ccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326589	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using 7-benzyloxyquiniline substrate and NADPH incubated up to 2 hrs	Cc1cc2c(NC(=O)N[C@@H]3CC(CF)(CF)Oc4c(F)cccc43)cccc2cn1	J. Med. Chem.	2014.0	CHEMBL3326909	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2/C1=C\c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL2407749	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc(/C=C4/C(=O)Nc5ccccc54)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL2407897	=	=	IC50	nM	940.0	IC50	uM	0.94
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	COc1ccc2c(c1)/C(=C\c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL2407900	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2/C1=C/c1ccc2cn[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353337	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2cn[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353338	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccncc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353340	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353341	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 (unknown origin) using BFC substrate after 30 mins by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL3353347	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	O=C1NCCc2nc(OCc3cccc(F)c3)ccc21	J. Med. Chem.	2014.0	CHEMBL3298273	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1cc(C(C)(C)C)c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O	J. Med. Chem.	2014.0	CHEMBL2010601	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	COC(=O)c1ccc(CSc2nc3c(c(=O)[nH]2)CCC3)cc1	J. Med. Chem.	2014.0	CHEMBL1515648	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	COC(=O)c1ccc(CSc2nc3c(c(=O)[nH]2)CCC3)cc1	J. Med. Chem.	2014.0	CHEMBL1515648	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)ncn2)ccc1F	J. Med. Chem.	2014.0	CHEMBL514794	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)ncn2)ccc1F	J. Med. Chem.	2014.0	CHEMBL514794	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	Cn1c(=O)n(Cc2ccc(C(=O)O)cc2)c(=O)c2cc(C#CCc3ccccc3)ccc21	J. Med. Chem.	2014.0	CHEMBL496942	>	>	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	Cn1c(=O)n(Cc2ccc(C(=O)O)cc2)c(=O)c2cc(C#CCc3ccccc3)ccc21	J. Med. Chem.	2014.0	CHEMBL496942	>	>	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(Cl)cc2)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3325526	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	CN1CC[C@H](c2ccc(Cl)cc2)[C@@H](COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3325537	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=S(=O)(Nc1ncc(F)cn1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(Cl)cc2)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3325551	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) by high throughput fluorescence assay	C[C@@H]1CN(c2nc(C(F)(F)F)no2)CCN1c1ncc(OCc2ccc(CS(C)(=O)=O)cc2F)cn1	J. Med. Chem.	2014.0	CHEMBL3358006	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human liver CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C	J. Med. Chem.	2014.0	CHEMBL2023898	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of human liver CYP3A4	COC(=O)N[C@H](C(=O)N1CCC[C@@H]1c1ncc(C#CC#Cc2ccc(-c3cnc([C@H]4CCCN4C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]3)cc2)[nH]1)C(C)C.Cl	J. Med. Chem.	2014.0	CHEMBL3341815	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cn1c(-c2ccccn2)c(C2CCCC2)c2ccc(C(=O)NC3(C(=O)Nc4ccc(/C=C/C(=O)O)cc4)CCC3)cc21	J. Med. Chem.	2014.0	CHEMBL2181776	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CCOc1cc(NC(=O)C2(NC(=O)c3ccc4c(C5CCCC5)c(-c5ncc(Cl)cn5)n(C)c4c3)CCC2)ccc1/C=C/C(=O)O	J. Med. Chem.	2014.0	CHEMBL3355225	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(NC[C@@H]1OC(=O)N2c3ccc(N4CCOCC4=O)cc3OC[C@@H]12)c1ccc(Cl)s1	J. Med. Chem.	2014.0	CHEMBL3330442	=	=	IC50	nM	85120.0	IC50	uM	85.12
Reversible inhibition of CYP3A4 (unknown origin)	COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3338865	=	=	IC50	nM	17000.0	IC50	uM	17.0
Time dependent inhibition of CYP3A4 (unknown origin)	COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2ccccc2)nc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3338848	=	=	Ki	nM	5600.0	Ki	uM	5.6
Time dependent inhibition of CYP3A4 (unknown origin)	COc1ccc(CNC(=O)c2cc(-c3cncc(C)c3)ncc2-c2nccs2)nc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3338865	=	=	Ki	nM	19400.0	Ki	uM	19.4
Time dependent inhibition of CYP3A4 (unknown origin)	COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3338866	=	=	Ki	nM	9500.0	Ki	uM	9.5
Inhibition of CYP3A4 (unknown origin)	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](C)C(=O)N(C)[C@@H]([C@@H](C)CN2CCN(CCOC)CC2)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	J. Med. Chem.	2014.0	CHEMBL3344501	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using 7-benzloxyquinolone as substrate after 10 mins by fluorescence assay	CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2[C@H](Nc2ccccc2)C[C@@H]1C	J. Med. Chem.	2014.0	CHEMBL3353992	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using 7-benzloxyquinolone as substrate after 10 mins by fluorescence assay	CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C	J. Med. Chem.	2014.0	CHEMBL2177300	=	=	IC50	nM	32000.0	IC50	uM	32.0
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate after 10 mins by fluorescence assay	CC(=O)N1c2ccc(-c3ccc(CN4CCCCC4)cc3)cc2[C@H](Nc2ccccc2)C[C@@H]1C	J. Med. Chem.	2014.0	CHEMBL3353992	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate after 10 mins by fluorescence assay	CC(=O)N1c2ccc(-c3ccc(C(=O)O)cc3)cc2[C@H](Nc2ccc(Cl)cc2)C[C@@H]1C	J. Med. Chem.	2014.0	CHEMBL2177300	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 (unknown origin)	N#C[C@@H]1C[C@H](F)CN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F	Eur. J. Med. Chem.	2014.0	CHEMBL3330060	=	=	IC50	nM	56490.0	IC50	uM	56.49
Inhibition of CYP3A4 (unknown origin)	N#C[C@@H]1C[C@@H]2CCC[C@@H]2N1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F	Eur. J. Med. Chem.	2014.0	CHEMBL3330073	=	=	IC50	nM	2250.0	IC50	uM	2.25
Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Cl.c1ccc(N(Cc2ccc3ccccc3c2)C2CNC2)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3331469	=	=	IC50	nM	1330.0	IC50	uM	1.33
Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Clc1ccc(CN(C2CC2)C2CNC2)cc1Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3331484	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Clc1cccc(CN(CC2CNC2)c2ccccc2)c1Cl.O=C(O)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3331502	=	=	IC50	nM	32700.0	IC50	uM	32.7
Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	CC(C)N(Cc1ccc(Cl)c(Cl)c1)CC1CNC1.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3331503	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	ACS Med. Chem. Lett.	2014.0	CHEMBL1175	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Clc1ccc(CN(C2CCCCC2)C2CNC2)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3331504	=	=	IC50	nM	810.0	IC50	uM	0.81
Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Fc1ccccc1N(Cc1ccc(Cl)cc1)C1CNC1	ACS Med. Chem. Lett.	2014.0	CHEMBL3331506	=	=	IC50	nM	3640.0	IC50	uM	3.64
Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Clc1cccc(N(Cc2ccc3ccccc3c2)C2CNC2)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3331507	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	Clc1ccccc1CN(CC1CNC1)c1ccccc1.O=C(O)C(F)(F)F	ACS Med. Chem. Lett.	2014.0	CHEMBL3331508	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of human recombinant CYP3A4 incubated for 5 mins by fluorescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	ACS Med. Chem. Lett.	2014.0	CHEMBL157101	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method	CN(C)C/C=C(\F)C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	J. Med. Chem.	2014.0	CHEMBL3357641	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method	CCOc1cc2ncnc(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C	J. Med. Chem.	2014.0	CHEMBL3357637	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN1CCCCC1	J. Med. Chem.	2014.0	CHEMBL3357635	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human hepatic microsomes after 20 mins by LC/MS/MS method	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C(F)=C/CN(C)C	J. Med. Chem.	2014.0	CHEMBL3357634	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem.	2014.0	CHEMBL157101	=	=	IC50	nM	25.0	IC50	uM	0.025
Inhibition of CYP3A4 (unknown origin) using AMMC by fluorescence assay	C#C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@@H](N5CCN(C(=O)[C@@H]6CCCN6C(=O)c6ccc7ccccc7n6)CC5)C[C@]4(C)[C@H]3CC[C@@]21C	Bioorg. Med. Chem.	2014.0	CHEMBL3344121	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1ccccc1NC(=O)N1CCC(c2ccccc2C(F)(F)F)CC1	J. Med. Chem.	2014.0	CHEMBL1230001	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1ccccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359014	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(F)ccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359017	=	=	IC50	nM	53000.0	IC50	uM	53.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)c1	J. Med. Chem.	2014.0	CHEMBL3359018	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(Cl)ccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359019	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)c1	J. Med. Chem.	2014.0	CHEMBL3359020	=	=	IC50	nM	42000.0	IC50	uM	42.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cccnc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359021	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cnccc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359022	<	<	IC50	nM	46.0	IC50	uM	0.046
Inhibition of CYP3A4 (unknown origin)	Cc1cc(NC(=O)N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)c(C(=O)O)cn1	J. Med. Chem.	2014.0	CHEMBL3359023	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cnncc1NC(=O)N1C[C@H]2C[C@@H](c3ccccc3C(F)(F)F)C[C@H]2C1	J. Med. Chem.	2014.0	CHEMBL3359024	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in human liver microsomes	CCCCOc1cncc(-c2nnc3c(C)nc4ccc(CN5CCOCC5)cc4n23)c1	ACS Med. Chem. Lett.	2014.0	CHEMBL3331521	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	J. Med. Chem.	2014.0	CHEMBL3301607	>	>	IC50	nM	70000.0	IC50	uM	70.0
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	O=C(NOCCO)c1ccn2cncc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330652	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330650	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	O=C(NOCCO)c1ccc2cnsc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2087461	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	O=C(NOCCO)c1oc2ccncc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330649	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=C(NOCCO)c1ccn2cncc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330652	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=C(NOCCO)c1ccc2cncn2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330650	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=C(NOCCO)c1ccc2cnsc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL2087461	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	O=C(NOCCO)c1oc2ccncc2c1Nc1ccc(I)cc1F	Bioorg. Med. Chem. Lett.	2014.0	CHEMBL3330649	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 by electrospray ionization	c1ccc(CC[C@@H]2CN(Cc3nc4ccccc4[nH]3)CCO2)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3335537	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 by electrospray ionization	Clc1ccc(CN2CCO[C@H](CCc3ccccc3)C2)cc1	ACS Med. Chem. Lett.	2014.0	CHEMBL3335556	=	=	IC50	nM	15600.0	IC50	uM	15.6
Inhibition of CYP3A4 (unknown origin)	CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3ccccc3[nH]c12.Cl	ACS Med. Chem. Lett.	2014.0	CHEMBL3326224	>=	>=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	Oc1nc(SCc2ccc(Cl)cc2)nc2c1CCC2	J. Med. Chem.	2014.0	CHEMBL473326	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	Oc1nc(SCc2ccc(Cl)cc2)nc2c1CCC2	J. Med. Chem.	2014.0	CHEMBL473326	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	Cc1ccc(CSc2nc(O)c3c(n2)CCC3)cc1	J. Med. Chem.	2014.0	CHEMBL1371684	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using testosterone substrate	Cc1ccc(CSc2nc(O)c3c(n2)CCC3)cc1	J. Med. Chem.	2014.0	CHEMBL1371684	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CCN1CCC[C@H]1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C	J. Med. Chem.	2014.0	CHEMBL3359270	=	=	IC50	nM	3200.0	IC50	uM	3.2
Inhibition of CYP3A4 (unknown origin)	CC(C)N1CCC[C@H]1CNC(=O)c1cn(C2CCCC2)c(=O)c2c1c1ccccc1n2C	J. Med. Chem.	2014.0	CHEMBL3359272	=	=	IC50	nM	10100.0	IC50	uM	10.1
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncn(-c3ccc(Nc4nccc(-c5cccc(N6CCOCC6)c5)n4)cc3)n2)cn1	J. Med. Chem.	2015.0	CHEMBL2144409	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5s4)s3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3393730	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5s4)cc3)cc2)[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3120454	>	>	IC50	nM	30000.0	IC50	uM	30.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CC(C)CN1CCC(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394719	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394721	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2cnccc2[nH]1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394722	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CC(C)CN1CCC([S+]([O-])c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394724	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394729	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394730	=	=	IC50	nM	5700.0	IC50	uM	5.7
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394734	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	O=C(NCc1ccc([S+]([O-])c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394736	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394738	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394741	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CC(C)CN1CCC(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394719	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394721	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	O=C(NCc1ccc(S(=O)(=O)C2CCN(C3CCOCC3)CC2)cc1)c1cc2cnccc2[nH]1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394722	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CC(C)CN1CCC([S+]([O-])c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394724	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394729	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394730	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394734	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	O=C(NCc1ccc([S+]([O-])c2cc(F)cc(F)c2)cn1)c1cc2ccncc2o1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394736	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394738	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CCCn1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394741	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5cc(C)ncn5)ccc42)C3)c(C(N)=O)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3394201	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(CC(=O)N2CCC3(CC2)CN([C@@H]2CCc4cc(-c5ncccn5)ccc42)C3)cc1	ACS Med. Chem. Lett.	2015.0	CHEMBL2426677	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CC[C@@H](Oc2ccnc3c(F)cccc23)CN1C(=O)c1ccccc1-n1nccn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394842	=	=	IC50	nM	25400.0	IC50	uM	25.4
Inhibition of CYP3A4 (unknown origin)	COC(=O)N[C@H](C(=O)N1C[C@@H](C)C[C@H]1c1nc(-c2ccc(-c3ccc(-c4ccc5[nH]c([C@@H]6C[C@H](C)CN6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)cc3)cc2)c[nH]1)C(C)C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3394868	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(NCc1ccncc1)c1ccc(Oc2ccccc2)cc1	J. Med. Chem.	2015.0	CHEMBL1607077	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(Oc2ccc(C(=O)NCc3ccncc3)cc2)cc1	J. Med. Chem.	2015.0	CHEMBL1427458	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	O=C(NCc1ccncc1)c1ccc(Oc2ccc(Cl)cc2)cc1	J. Med. Chem.	2015.0	CHEMBL3393290	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	O=C(NCc1ccncc1)c1ccc(Oc2ccc(F)cc2)cc1	J. Med. Chem.	2015.0	CHEMBL3393291	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccncc2)cc1	J. Med. Chem.	2015.0	CHEMBL1796293	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccccc2)cc1	J. Med. Chem.	2015.0	CHEMBL3393294	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1Oc1ccc(C(=O)NCc2cccnc2)cc1	J. Med. Chem.	2015.0	CHEMBL3393295	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccccc1Oc1ccc(C(=O)NCc2ccncn2)cc1	J. Med. Chem.	2015.0	CHEMBL3393063	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393469	=	=	IC50	nM	190.0	IC50	uM	0.19
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CNC1)C2c1ccc(Sc2nc3ccccc3[nH]2)o1.Cl.O	J. Med. Chem.	2015.0	CHEMBL3393472	=	=	IC50	nM	170.0	IC50	uM	0.17
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cc(F)ccc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393473	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cccc(F)c3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393474	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)cc(F)cc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393475	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cc(F)c(F)cc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393476	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3ccc(F)c(F)c3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393477	=	=	IC50	nM	34000.0	IC50	uM	34.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(F)c(F)c(F)cc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393478	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3cccc(Cl)c3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393479	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(O)cccc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393482	=	=	IC50	nM	490.0	IC50	uM	0.49
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)C2c1ccc(Sc2nc3c(N)cccc3[nH]2)o1	J. Med. Chem.	2015.0	CHEMBL3393483	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase/human b5 reductase using 7-benzyloxyquinoline substrate	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CN(C(=O)CN)C1)[C@H]2c1ccc(Sc2nc3ccccc3[nH]2)o1.Cl	J. Med. Chem.	2015.0	CHEMBL3393485	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of human recombinant CYP3A4 in liver microsomes by mechanism based inhibition assay	CCOC(=O)c1[nH]cc2c1NC1=C(C(=O)CCC1)[C@H]2c1cccc(Oc2nc3ccccc3[nH]2)c1	J. Med. Chem.	2015.0	CHEMBL3393498	=	=	Ki	nM	990.0	Ki	uM	0.99
Inhibition of human recombinant CYP3A4 in liver microsomes by mechanism based inhibition assay	Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2	J. Med. Chem.	2015.0	CHEMBL655	=	=	Ki	nM	2470.0	Ki	uM	2.47
Inhibition of CYP3A4 (unknown origin)	COc1cc([C@H]2CCN(CCO)C[C@@H]2O)ccc1Nc1ncc2ccc(-c3ccccc3OC)n2n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3398175	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in pooled mixed-gender human liver microsomes using triazolam substrate in presence of NADPH pre-incubated for 3 mins by HPLC-UV detection method	O=C(/C=C(\O)C(=O)N1CCN(c2ccc(-n3cccc3)cc2)CC1)c1cc(Cc2cc(F)cc(F)c2)cn(Cc2ccccc2F)c1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3398252	>	>	IC50	nM	85000.0	IC50	uM	85.0
Inhibition of CYP3A4 in pooled mixed-gender human liver microsomes using testosterone substrate in presence of NADPH pre-incubated for 3 mins by HPLC-UV detection method	O=C(/C=C(\O)C(=O)N1CCN(c2ccc(-n3cccc3)cc2)CC1)c1cc(Cc2cc(F)cc(F)c2)cn(Cc2ccccc2F)c1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3398252	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL2206994	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CCOC)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL2207044	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403817	=	=	IC50	nM	100000.0	IC50	uM	100.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403817	=	=	IC50	nM	54000.0	IC50	uM	54.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403818	=	=	IC50	nM	12000.0	IC50	uM	12.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403818	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403819	=	=	IC50	nM	5300.0	IC50	uM	5.3
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403819	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403820	=	=	IC50	nM	3000.0	IC50	uM	3.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403820	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403821	=	=	IC50	nM	4900.0	IC50	uM	4.9
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403821	=	=	IC50	nM	3200.0	IC50	uM	3.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403822	=	=	IC50	nM	15000.0	IC50	uM	15.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403822	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403823	=	=	IC50	nM	13000.0	IC50	uM	13.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7CCC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403823	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403824	=	=	IC50	nM	6600.0	IC50	uM	6.6
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C7COC7)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403824	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403825	=	=	IC50	nM	22000.0	IC50	uM	22.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCOC)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403825	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403826	=	=	IC50	nM	14000.0	IC50	uM	14.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CC(C)(C)O)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403826	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403827	=	=	IC50	nM	17000.0	IC50	uM	17.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(CCO)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403827	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403816	=	=	IC50	nM	37000.0	IC50	uM	37.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C(C)C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403816	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403815	=	=	IC50	nM	25000.0	IC50	uM	25.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403815	=	=	IC50	nM	25000.0	IC50	uM	25.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis	CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL2206994	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of CYP3A4 (unknown origin)	CC(CCN1CCOCC1)CC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3402641	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4	O=C1N(c2ccc(F)cc2)CCc2nc(COc3ccccc3)cn21	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401195	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4	CC(C)C1CN(c2nc(-c3ccncc3F)cc(=O)n2C)CCO1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401115	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	CCCCC1CN(c2nc(-c3ccncc3F)cc(=O)n2C)CCO1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401116	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	Cn1c(N2CCOC(C3CCC3)C2)nc(-c2ccncc2F)cc1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401117	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	C[C@@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401118	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	C[C@H]1COCCN1c1nc(-c2ccncc2F)cc(=O)n1C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401121	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H](c3ccc(F)cc3)C2)nc(-c2ccncn2)cc1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3091536	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	C[C@H]1OCCN(c2nc(-c3ccncc3F)cc(=O)n2C)[C@@H]1C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401127	=	=	IC50	nM	485000.0	IC50	uM	485.0
Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H]3CCC[C@H]32)nc(-c2ccncc2F)cc1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401129	=	=	IC50	nM	445000.0	IC50	uM	445.0
Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H]3CCCC[C@H]32)nc(-c2ccncc2F)cc1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401131	=	=	IC50	nM	418000.0	IC50	uM	418.0
Inhibition of recombinant human CYP3A4	Cn1c(N2CCO[C@@H]3COC[C@H]32)nc(-c2ccncc2F)cc1=O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401132	=	=	IC50	nM	545000.0	IC50	uM	545.0
Inhibition of human recombinant CYP3A4 assessed as effect on conversion of beetle D-luciferin derivative into D-luciferin by firefly luciferase based luminescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg. Med. Chem.	2015.0	CHEMBL157101	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)Cc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401541	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400450	=	=	IC50	nM	14800.0	IC50	uM	14.8
Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCC2CCCCC2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400449	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NCc2ccc3ccccc3c2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400435	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)Cc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3401541	=	=	IC50	nM	4400.0	IC50	uM	4.4
Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400450	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)OCC2CCCCC2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400449	=	=	IC50	nM	3200.0	IC50	uM	3.2
Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)CCc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400445	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 (unknown origin) using midazolam fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NCc2ccc3ccccc3c2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400435	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)C2CCOCC2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400440	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NC(=O)CC2CCOCC2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400443	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using DBF fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2NS(=O)(=O)CC2CCOCC2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3400459	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OC(=O)NCc2ccccc2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403995	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OCc2cccc(-n3cccc3)c2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403987	<=	<=	IC50	nM	200.0	IC50	nM	200.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OCc2cccc(-c3ccccc3)c2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403986	<=	<=	IC50	nM	200.0	IC50	nM	200.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyl-4-trifluoromethylcoumarin as fluorometric substrate	COCCCOc1cc(C(=O)N(C[C@@H]2CNC[C@H]2OCc2cccc(OC)c2)C(C)C)ccc1OC	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3403984	<=	<=	IC50	nM	200.0	IC50	nM	200.0
Inhibition of human CYP3A4	COc1ccc(C(=O)NCc2csc(C)n2)cc1OC1CCN(C(C)C)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3187348	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C(C)C)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL1872483	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CCn1nc(C)c(CNC(=O)c2ccc(OC)c(OC3CCN(C(C)C)CC3)c2)c1C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3182315	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	COc1ccc(C(=O)NC(C)Cc2ccccn2)cc1OC1CCN(C(C)C)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3188567	=	=	IC50	nM	28200.0	IC50	uM	28.2
Inhibition of human CYP3A4	COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3304438	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OCCN1CCCCC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3303792	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353341	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	CN1CCN(c2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1	J. Med. Chem.	2015.0	CHEMBL3408940	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(N4CCNCC4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3408941	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL3353347	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN(C)C)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353348	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)N(C)c4ccccc45)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL3408942	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CC[C@@H](F)C4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3408943	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCCCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408944	=	=	IC50	nM	5400.0	IC50	uM	5.4
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353354	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	Cc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353357	=	=	IC50	nM	6200.0	IC50	uM	6.2
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353355	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408945	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	C[C@H]1CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)C[C@@H](C)O1	J. Med. Chem.	2015.0	CHEMBL3408946	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408947	=	=	IC50	nM	4600.0	IC50	uM	4.6
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408948	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc([C@H](C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408951	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5[C@@H](C)CN(C)C[C@H]5C)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408955	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 (unknown origin) using DBF as substrate by fluorescence assay	CC(C)N1CCC(Oc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3408957	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353341	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	CN1CCN(c2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)N(C)c5ccccc56)ccc34)cn2)CC1	J. Med. Chem.	2015.0	CHEMBL3408940	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)Nc4ccccc45)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL3353347	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	CN(C)Cc1ccc(/C=C/c2n[nH]c3cc([C@@H]4C[C@@]45C(=O)N(C)c4ccccc45)ccc23)cc1	J. Med. Chem.	2015.0	CHEMBL3408942	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CC[C@@H](F)C4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3408943	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCCCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408944	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	O=C1Nc2ccccc2[C@]12C[C@H]2c1ccc2c(/C=C/c3ccc(CN4CCOCC4)cc3)n[nH]c2c1	J. Med. Chem.	2015.0	CHEMBL3353354	=	=	IC50	nM	6300.0	IC50	uM	6.3
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	Cc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353357	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3353355	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408945	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	C[C@H]1CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)C[C@@H](C)O1	J. Med. Chem.	2015.0	CHEMBL3408946	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408947	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408948	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc([C@H](C)N5CCOCC5)cc4)n[nH]c3c1)C(=O)N2C	J. Med. Chem.	2015.0	CHEMBL3408951	=	=	IC50	nM	450.0	IC50	uM	0.45
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5[C@@H](C)CN(C)C[C@H]5C)cc4)n[nH]c3c1)C(=O)N2	J. Med. Chem.	2015.0	CHEMBL3408955	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate by fluorescence assay	CC(C)N1CCC(Oc2ccc(/C=C/c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccccc56)ccc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3408957	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis	CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4cnccn4)nc31)[C@H](O)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL3407774	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis	CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccco4)nc31)[C@H](O)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL3407778	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis	CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(Cl)s4)nc31)[C@H](O)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL3407784	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human microsomes preincubated for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis	CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(Br)s4)nc31)[C@H](O)[C@@H]2O	J. Med. Chem.	2014.0	CHEMBL3407785	>	>	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay	Cl.Fc1cccc(CCCNCCc2ccnc(-n3ccnc3)n2)c1	J. Med. Chem.	2015.0	CHEMBL3407810	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay	Cl.c1cncc(CCCNCCc2ccnc(-n3ccnc3)n2)c1	J. Med. Chem.	2015.0	CHEMBL3407814	=	=	IC50	nM	70000.0	IC50	uM	70.0
Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay	Cc1cncn1-c1nccc(CCNCCCc2cccc(F)c2)n1.Cl	J. Med. Chem.	2015.0	CHEMBL3407821	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of human CYP3A4 using 7-benzyloxy-4-(trifluoromethyl)coumarin as substrate assessed as formation of 7-hydroxy-4-trifluoromethylcoumarin incubated for 2 mins prior to NADPH addition by fluorimetric assay	Cl.Fc1cccc(C[C@@H]2C[C@H]2NCCc2ccnc(-n3ccnc3)n2)c1	J. Med. Chem.	2015.0	CHEMBL3407822	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@H](C)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3113764	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@H](Cl)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409853	=	=	IC50	nM	6600.0	IC50	uM	6.6
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409855	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1C1CC(F)(F)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409857	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409859	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@H](OC)C(=O)N1Cc1ccc(OC(F)(F)F)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409860	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1C1CCC(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409869	=	=	IC50	nM	6900.0	IC50	uM	6.9
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409870	=	=	IC50	nM	8800.0	IC50	uM	8.8
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(OC)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409872	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(F)c1[C@@H]1C[C@H](F)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409873	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(F)c1C1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409875	=	=	IC50	nM	46000.0	IC50	uM	46.0
Inhibition of CYP3A4 (unknown origin) using testosterone as marker substrate	COc1cccc(F)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409876	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1cccc(F)c1[C@@H]1C[C@@H](O)C(=O)N1Cc1ccc2oc3ccccc3c2c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3409876	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=c1cc(-c2ccnc(NC3CCOCC3)n2)ccn1[C@H](CO)c1ccc(Cl)c(F)c1	J. Med. Chem.	2015.0	CHEMBL3409588	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	NC(=O)C1CCN(c2c(Cl)cncc2Cl)CC1	J. Med. Chem.	2015.0	CHEMBL1673059	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 (unknown origin)	O=C1NCCC12CCN(c1c(Cl)cncc1-c1ccc(N3CCOCC3)cc1)CC2	J. Med. Chem.	2015.0	CHEMBL3408192	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of human recombinant CYP3A4 using midazolam substrate by LC-MS/MS method	Cc1nnc2n1-c1c(F)cc(-c3cncc(F)c3)cc1CC2	J. Med. Chem.	2015.0	CHEMBL2331699	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human recombinant CYP3A4 using midazolam substrate by LC-MS/MS method	Cc1ccncc1-c1cc(F)c2c(c1)CCc1nnc(C)n1-2	J. Med. Chem.	2015.0	CHEMBL3313969	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis	C[C@]1(Nc2ccc(C(=O)NO)cc2)CCN(c2ccc(Cl)cc2)C1=O	J. Med. Chem.	2015.0	CHEMBL3415629	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins	CC(C)(O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CCC3)no2)cn1	J. Med. Chem.	2015.0	CHEMBL3417511	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1	J. Med. Chem.	2015.0	CHEMBL3417525	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins	CN(C)CCn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1	J. Med. Chem.	2015.0	CHEMBL3417530	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 6 mins	CC(C)(O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1	J. Med. Chem.	2015.0	CHEMBL3417531	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)C3CC23)cc1	Eur. J. Med. Chem.	2015.0	CHEMBL3417504	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](COc1ccc(C2=NNC(=O)C3CC23)cc1)CN1CCC[C@H]1C	Eur. J. Med. Chem.	2015.0	CHEMBL3417505	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@@H]3C[C@H]23)cc1	Eur. J. Med. Chem.	2015.0	CHEMBL3417585	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@H]3C[C@@H]23)cc1	Eur. J. Med. Chem.	2015.0	CHEMBL3417586	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	O=C(c1ccc(F)cc1)N1CCn2c(nnc2-c2ccccn2)C1	J. Med. Chem.	2015.0	CHEMBL3421983	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1	J. Med. Chem.	2015.0	CHEMBL3422000	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	O=C(c1ccc(F)cc1)N1CCn2c(nnc2-c2cccc(C(F)(F)F)n2)C1	J. Med. Chem.	2015.0	CHEMBL3422004	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)cs1	J. Med. Chem.	2015.0	CHEMBL3422005	=	=	IC50	nM	63000.0	IC50	uM	63.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	C[C@@H]1c2nnc(-c3csc(-c4ccccc4)n3)n2CCN1C(=O)c1ccc(F)cc1	J. Med. Chem.	2015.0	CHEMBL3422006	=	=	IC50	nM	67000.0	IC50	uM	67.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1cccc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	J. Med. Chem.	2015.0	CHEMBL3422007	=	=	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1cncc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	J. Med. Chem.	2015.0	CHEMBL3422008	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	C[C@@H]1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1	J. Med. Chem.	2015.0	CHEMBL3422009	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1	J. Med. Chem.	2015.0	CHEMBL3422010	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)C3)cs1	J. Med. Chem.	2015.0	CHEMBL3422012	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	C[C@@H]1c2nnc(-c3csc(C(F)(F)F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1	J. Med. Chem.	2015.0	CHEMBL3422013	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1	J. Med. Chem.	2015.0	CHEMBL3422014	=	=	IC50	nM	35000.0	IC50	uM	35.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	CC(C)c1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)co1	J. Med. Chem.	2015.0	CHEMBL3422015	=	=	IC50	nM	43000.0	IC50	uM	43.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1csc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	J. Med. Chem.	2015.0	CHEMBL3422016	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	J. Med. Chem.	2015.0	CHEMBL3422017	=	=	IC50	nM	55000.0	IC50	uM	55.0
Inhibition of CYP3A4 (unknown origin) by luciferase reporter assay in presence of NADPH regeneration system	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	J. Med. Chem.	2015.0	CHEMBL3422018	=	=	IC50	nM	80000.0	IC50	uM	80.0
Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay	CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccccc1	J. Med. Chem.	2015.0	CHEMBL2386285	=	=	IC50	nM	285.0	IC50	nM	285.0
Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay	CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccc(O)cc1	J. Med. Chem.	2015.0	CHEMBL3422028	=	=	IC50	nM	1880.0	IC50	nM	1880.0
Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay	CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccccc1	J. Med. Chem.	2015.0	CHEMBL2386285	=	=	Ki	nM	375.0	Ki	nM	375.0
Inhibition of human recombinant CYP3A4 assessed as metabolism of 7-benzyloxy-4-trifluoromethylcoumarin to HFC after 30 mins by fluorescence assay	CC/C(=C(/c1ccc(O)cc1)c1ccc(OCCN)cc1)c1ccc(O)cc1	J. Med. Chem.	2015.0	CHEMBL3422028	=	=	Ki	nM	1640.0	Ki	nM	1640.0
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=CN1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3422072	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=CN1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccn5)C5CC5)cc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3422073	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CN(C)CC(=O)N1CCC(Oc2ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL3422074	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CN1[C@H]2CC[C@@H]1C[C@H](Oc1ccc(-c3n[nH]c4ccc(C(=O)NC(c5ccccc5)C5CC5)cc34)cc1)C2	J. Med. Chem.	2015.0	CHEMBL3422075	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CC(C)CC(NC(=O)c1ccc2[nH]nc(-c3ccc(O[C@@H]4C[C@@H]5CC[C@H](C4)N5C=O)cc3)c2c1)c1ccccn1	J. Med. Chem.	2015.0	CHEMBL3422078	=	=	IC50	nM	410.0	IC50	uM	0.41
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccc1F)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422082	=	=	IC50	nM	240.0	IC50	uM	0.24
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CC(C)[C@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1)c1ccccc1Cl	J. Med. Chem.	2015.0	CHEMBL3422083	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422085	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422086	=	=	IC50	nM	930.0	IC50	uM	0.93
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4C5CCC4COC5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422087	=	=	IC50	nM	360.0	IC50	uM	0.36
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422091	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422092	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422093	=	=	IC50	nM	820.0	IC50	uM	0.82
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422094	=	=	IC50	nM	230.0	IC50	uM	0.23
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ncccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422095	=	=	IC50	nM	940.0	IC50	uM	0.94
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CC(C)C[C@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1)c1ccccn1	J. Med. Chem.	2015.0	CHEMBL3422097	=	=	IC50	nM	320.0	IC50	uM	0.32
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	CC(C)C[C@@H](NC(=O)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1)c1ccccn1	J. Med. Chem.	2015.0	CHEMBL3422098	=	=	IC50	nM	290.0	IC50	uM	0.29
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](CC1CC1)c1ccccn1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422099	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5COC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422102	=	=	IC50	nM	330.0	IC50	uM	0.33
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422091	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@@H](c1ccccn1)C1CC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422092	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human CYP3A4 using BFC as substrate preincubated for 10 mins followed by enzyme/substrate addition measured after 30 mins by fluorescence assay	O=C(N[C@H](c1ccccn1)C1CCCC1)c1ccc2[nH]nc(-c3ccc(N4[C@H]5CC[C@H]4CC(O)C5)cc3)c2c1	J. Med. Chem.	2015.0	CHEMBL3422093	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 (unknown origin)	NC1=N[C@@]2(c3ccc(F)cc3F)CO[C@@H](c3ncco3)C[C@H]2CS1	J. Med. Chem.	2015.0	CHEMBL3422235	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1coc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1	J. Med. Chem.	2015.0	CHEMBL3422236	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1	J. Med. Chem.	2015.0	CHEMBL3422237	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cn1cc([C@H]2C[C@H]3CSC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)cn1	J. Med. Chem.	2015.0	CHEMBL3422238	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1coc([C@H]2C[C@H]3[C@@H](C)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1	J. Med. Chem.	2015.0	CHEMBL3422241	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc([C@H]2C[C@H]3[C@@H](C)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1	J. Med. Chem.	2015.0	CHEMBL3422242	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1SC(N)=N[C@@]2(c3ccc(F)cc3F)CO[C@@H](c3cnn(C)c3)C[C@@H]12	J. Med. Chem.	2015.0	CHEMBL3422243	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1coc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)n1	J. Med. Chem.	2015.0	CHEMBL3422244	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)on1	J. Med. Chem.	2015.0	CHEMBL3422245	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cn1cc([C@H]2C[C@H]3[C@@H](CF)SC(N)=N[C@@]3(c3ccc(F)cc3F)CO2)cn1	J. Med. Chem.	2015.0	CHEMBL3422246	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	O=c1n(Cc2nc3ccccc3n2CCCCO)c2cnccc2n1C1CC1	ACS Med. Chem. Lett.	2015.0	CHEMBL243876	=	=	IC50	nM	27500.0	IC50	uM	27.5
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	O=C(O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12	ACS Med. Chem. Lett.	2015.0	CHEMBL3427272	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12	ACS Med. Chem. Lett.	2015.0	CHEMBL3427276	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCS(=O)(=O)CCc1c(Cn2c(=O)n(C3CC3)c3ccncc32)nc2cc(Cl)ccn12	ACS Med. Chem. Lett.	2015.0	CHEMBL3427277	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)(O)c1ccccc1-c1ccc2[nH]c(/C=C/c3ccc(C(F)(F)F)cc3)nc2c1	J. Med. Chem.	2015.0	CHEMBL2364618	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human His-tagged CYP3A4 expressed in Escherichia coli TOPP3 using BFC as substrate after 15 mins by double reciprocal plot analysis in presence of NADPH and cytochrome b5	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12	Drug Metab. Dispos.	2011.0	CHEMBL1614710	=	=	Ki	nM	24000.0	Ki	uM	24.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	Cl.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1708	=	=	IC50	nM	24100.0	IC50	uM	24.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Drug Metab. Dispos.	2012.0	CHEMBL6966	=	=	IC50	nM	17600.0	IC50	uM	17.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1	Drug Metab. Dispos.	2012.0	CHEMBL296419	=	=	IC50	nM	10600.0	IC50	uM	10.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL54	=	=	IC50	nM	8200.0	IC50	uM	8.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12	Drug Metab. Dispos.	2012.0	CHEMBL50	=	=	IC50	nM	2110.0	IC50	uM	2.11
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	O[C@@H](c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)[C@H]1CCCCN1	Drug Metab. Dispos.	2012.0	CHEMBL172	=	=	IC50	nM	667.0	IC50	uM	0.667
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	Drug Metab. Dispos.	2012.0	CHEMBL83	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21	Drug Metab. Dispos.	2012.0	CHEMBL1064	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	Drug Metab. Dispos.	2012.0	CHEMBL1423	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	Cc1ccccc1C(OCCN(C)C)c1ccccc1	Drug Metab. Dispos.	2012.0	CHEMBL900	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1	Drug Metab. Dispos.	2012.0	CHEMBL1484	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1	Drug Metab. Dispos.	2012.0	CHEMBL998	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1	Drug Metab. Dispos.	2012.0	CHEMBL480	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O	Drug Metab. Dispos.	2012.0	CHEMBL1200633	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12	Drug Metab. Dispos.	2012.0	CHEMBL1648	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C	Drug Metab. Dispos.	2012.0	CHEMBL1479	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	Drug Metab. Dispos.	2012.0	CHEMBL1008	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1	Drug Metab. Dispos.	2012.0	CHEMBL1483	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Drug Metab. Dispos.	2012.0	CHEMBL157101	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 8 mins by LC-MS/MS analysis	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Drug Metab. Dispos.	2012.0	CHEMBL104	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin)	CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835951	=	=	IC50	nM	4.0	IC50	nM	4.0
Inhibition of CYP3A4 (unknown origin)	CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835950	=	=	IC50	nM	4.0	IC50	nM	4.0
Inhibition of CYP3A4 (unknown origin)	CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835949	=	=	IC50	nM	4.0	IC50	nM	4.0
Inhibition of CYP3A4 (unknown origin)	CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL454471	=	=	IC50	nM	4.0	IC50	nM	4.0
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method	CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1O	Drug Metab. Dispos.	2011.0	CHEMBL3526984	=	=	IC50	nM	8220.0	IC50	uM	8.22
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method	CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1	Drug Metab. Dispos.	2011.0	CHEMBL1672054	=	=	IC50	nM	9860.0	IC50	uM	9.86
Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method	CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1	Drug Metab. Dispos.	2011.0	CHEMBL1672054	=	=	IC50	nM	9720.0	IC50	uM	9.72
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by HPLC-MS/MS method	CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1	Drug Metab. Dispos.	2011.0	CHEMBL1672054	=	=	Ki	nM	4930.0	Ki	uM	4.93
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1	Drug Metab. Dispos.	2013.0	CHEMBL161	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21	Drug Metab. Dispos.	2013.0	CHEMBL71	=	=	IC50	nM	23300.0	IC50	uM	23.3
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	Drug Metab. Dispos.	2013.0	CHEMBL6966	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	Clc1ccccc1CN1CCc2sccc2C1	Drug Metab. Dispos.	2013.0	CHEMBL833	=	=	IC50	nM	32700.0	IC50	uM	32.7
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21	Drug Metab. Dispos.	2013.0	CHEMBL809	=	=	IC50	nM	13600.0	IC50	uM	13.6
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1	Drug Metab. Dispos.	2013.0	CHEMBL42	=	=	IC50	nM	46300.0	IC50	uM	46.3
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	Drug Metab. Dispos.	2013.0	CHEMBL1008	=	=	IC50	nM	23600.0	IC50	uM	23.6
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1	Drug Metab. Dispos.	2013.0	CHEMBL567	=	=	IC50	nM	13900.0	IC50	uM	13.9
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO	Drug Metab. Dispos.	2013.0	CHEMBL1451	=	=	IC50	nM	49100.0	IC50	uM	49.1
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COCCc1ccc(OCC(O)CNC(C)C)cc1	Drug Metab. Dispos.	2013.0	CHEMBL13	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1	Drug Metab. Dispos.	2013.0	CHEMBL54	=	=	IC50	nM	33100.0	IC50	uM	33.1
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	Drug Metab. Dispos.	2013.0	CHEMBL388590	=	=	IC50	nM	29200.0	IC50	uM	29.2
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1	Drug Metab. Dispos.	2013.0	CHEMBL1428	=	=	IC50	nM	1780.0	IC50	uM	1.78
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]	Drug Metab. Dispos.	2013.0	CHEMBL193	=	=	IC50	nM	5620.0	IC50	uM	5.62
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21	Drug Metab. Dispos.	2013.0	CHEMBL9	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	Drug Metab. Dispos.	2013.0	CHEMBL45816	=	=	IC50	nM	470.0	IC50	uM	0.47
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1	Drug Metab. Dispos.	2013.0	CHEMBL1484	=	=	IC50	nM	380.0	IC50	uM	0.38
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	Drug Metab. Dispos.	2013.0	CHEMBL682	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1	Drug Metab. Dispos.	2013.0	CHEMBL30008	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method	CCCc1nc2c(C)cc(-c3nc4ccccc4n3C)cc2n1Cc1ccc(-c2ccccc2C(=O)O)cc1	Drug Metab. Dispos.	2013.0	CHEMBL1017	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	Drug Metab. Dispos.	2011.0	CHEMBL45816	=	=	Ki	nM	280.0	Ki	uM	0.28
Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH	CC(C)[C@H]1c2ccc(F)cc2CC[C@]1(O)CCN(C)CCCc1nc2ccccc2[nH]1	Drug Metab. Dispos.	2011.0	CHEMBL3526662	=	=	Ki	nM	820.0	Ki	uM	0.82
Reversible inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A4 harboring human P450 oxidoreductase and b5	Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1	Drug Metab. Dispos.	2012.0	CHEMBL3527048	=	=	IC50	nM	300.0	IC50	uM	0.3
Reversible inhibition of testosterone 6beta-hydroxylase activity of human recombinant CYP3A4 in presence of human P450 oxidoreductase and b5	Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1	Drug Metab. Dispos.	2012.0	CHEMBL3527048	=	=	IC50	nM	690.0	IC50	uM	0.69
Inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A4 harboring human P450 oxidoreductase and b5 assessed as decrease in enzyme activity preincubated for 30 mins by LC-MS/MS analysis	Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1	Drug Metab. Dispos.	2012.0	CHEMBL3527048	=	=	Ki	nM	120.0	Ki	uM	0.12
Inhibition of testosterone 6beta-hydroxylase activity of human recombinant CYP3A4 in presence of human P450 oxidoreductase and b5 assessed as decrease in enzyme activity preincubated for 30 mins by LC-MS/MS analysis	Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1	Drug Metab. Dispos.	2012.0	CHEMBL3527048	=	=	Ki	nM	170.0	Ki	uM	0.17
Inhibition of CYP3A4 in human liver microsomes using nifedipine substrate by HPLC-MS/MS method	CC(=O)N1CCN([C@H]2CCN(C(=O)N(C)[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)[C@@H](c3ccc(F)cc3C)C2)CC1O	Drug Metab. Dispos.	2011.0	CHEMBL3526984	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 activity in human liver microsomes using testosterone as a substrate by LC/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Drug Metab. Dispos.	2013.0	CHEMBL157101	=	=	Ki	nM	49.0	Ki	uM	0.049
Inhibition of CYP3A4 activity in human liver microsomes using testosterone as a substrate by LC/MS analysis	CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)N[C@@H](C(N)=O)C(C)C)CO2	Drug Metab. Dispos.	2013.0	CHEMBL3527358	=	=	Ki	nM	287000.0	Ki	uM	287.0
Inhibition of CYP3A4 activity in human liver microsomes using nifedipine as a substrate by LC/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Drug Metab. Dispos.	2013.0	CHEMBL157101	=	=	Ki	nM	11.0	Ki	uM	0.011
Inhibition of CYP3A4 activity in human liver microsomes using nifedipine as a substrate by LC/MS analysis	CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)N[C@@H](C(N)=O)C(C)C)CO2	Drug Metab. Dispos.	2013.0	CHEMBL3527358	=	=	Ki	nM	403000.0	Ki	uM	403.0
Inhibition of CYP3A4 activity in human liver microsomes using midazolam as a substrate by LC/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Drug Metab. Dispos.	2013.0	CHEMBL157101	=	=	Ki	nM	7.0	Ki	uM	0.007
Inhibition of CYP3A4 activity in human liver microsomes using midazolam as a substrate by LC/MS analysis	CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)N[C@@H](C(N)=O)C(C)C)CO2	Drug Metab. Dispos.	2013.0	CHEMBL3527358	=	=	Ki	nM	58000.0	Ki	uM	58.0
Inhibition of CYP3A4 activity in human liver microsomes assessed as dibenzo fluuorescene oxidation up to 40 uM	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Drug Metab. Dispos.	2013.0	CHEMBL157101	=	=	IC50	nM	9.8	IC50	nM	9.8
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL1951575	>	>	Ki	nM	30000.0	Ki	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL1951575	>=	>=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL3526979	>	>	Ki	nM	30000.0	Ki	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL1951575	>	>	Ki	nM	30000.0	Ki	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL1951575	>=	>=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 to 30 mins by LC-MS/MS analysis	CC(C)(C)NC(=O)c1ccc(Oc2cc(F)c(CC(=O)O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)cc2Cl)c(NS(=O)(=O)c2ccc(C3CC3)cc2Cl)c1	Drug Metab. Dispos.	2012.0	CHEMBL3526979	>	>	Ki	nM	30000.0	Ki	uM	30.0
Inhibition of CYP3A4 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy	CC(C)c1cc2c(c(O)c1O)[C@@]1(C(=O)O)CCCC(C)(C)[C@@H]1CC2	Drug Metab. Dispos.	2012.0	CHEMBL484853	=	=	Ki	nM	4300.0	Ki	uM	4.3
Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated with compound before substrate addition by LC-MS method	C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC	Drug Metab. Dispos.	2012.0	CHEMBL269732	=	=	IC50	nM	120.0	IC50	uM	0.12
Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation by LC-MS method	C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC	Drug Metab. Dispos.	2012.0	CHEMBL269732	=	=	IC50	nM	620.0	IC50	uM	0.62
Reversible competitive inhibition of human CYP3A4-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study	C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC	Drug Metab. Dispos.	2012.0	CHEMBL269732	=	=	Ki	nM	2660.0	Ki	uM	2.66
Competitive inhibition of recombinant CYP3A4 (unknown origin) expressed in supersomes	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Drug Metab. Dispos.	2012.0	CHEMBL160	=	=	Ki	nM	7600.0	Ki	uM	7.6
Competitive inhibition of CYP3A4 in human liver microsomes	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Drug Metab. Dispos.	2012.0	CHEMBL160	=	=	Ki	nM	300.0	Ki	uM	0.3
Reversible competitive inhibition of human CYP3A4-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Drug Metab. Dispos.	2012.0	CHEMBL160	=	=	Ki	nM	890.0	Ki	uM	0.89
Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated for 15 mins before substrate addition by LC-MS method	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Drug Metab. Dispos.	2012.0	CHEMBL160	=	=	IC50	nM	1450.0	IC50	uM	1.45
Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation after 7.5 mins by LC-MS method	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C	Drug Metab. Dispos.	2012.0	CHEMBL160	=	=	IC50	nM	2060.0	IC50	uM	2.06
Induction of CYP3A4 in human hepatocytes after 72 hrs relative to vehicle-treated control	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4	Drug Metab. Dispos.	2012.0	CHEMBL567597	=	=	EC50	nM	5900.0	EC50	uM	5.9
Inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4	Drug Metab. Dispos.	2012.0	CHEMBL252518	>	>	IC50	nM	125000.0	IC50	uM	125.0
Inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4	Drug Metab. Dispos.	2012.0	CHEMBL567597	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4	Drug Metab. Dispos.	2012.0	CHEMBL252518	>	>	IC50	nM	125000.0	IC50	uM	125.0
Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4	Drug Metab. Dispos.	2012.0	CHEMBL567597	=	=	IC50	nM	50000.0	IC50	uM	50.0
Competitive inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4	Drug Metab. Dispos.	2012.0	CHEMBL567597	=	=	Ki	nM	25000.0	Ki(app)	uM	25.0
Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21	Drug Metab. Dispos.	2013.0	CHEMBL1229211	=	=	IC50	nM	65000.0	IC50	uM	65.0
Metabolism-dependent inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with NADPH prior to initiation of reaction with probe substrate by HPLC analysis	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21	Drug Metab. Dispos.	2013.0	CHEMBL1229211	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21	Drug Metab. Dispos.	2013.0	CHEMBL1229211	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21	Drug Metab. Dispos.	2013.0	CHEMBL1229211	=	=	IC50	nM	54000.0	IC50	uM	54.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysis	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL385517	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 3 mins by LC-MS/MS analysis	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL3350936	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL385517	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 3 mins by LC-MS/MS analysis in presence of NADPH	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL3350936	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL385517	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation preincubated for 15 mins by LC-MS/MS analysis	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL3350936	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL385517	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation preincubated for 15 mins by LC-MS/MS analysis in presence of NADPH	N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(O)(CC(O)(C3)C1)C2	Drug Metab. Dispos.	2012.0	CHEMBL3350936	>	>	IC50	nM	200000.0	IC50	uM	200.0
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as unbound inhibitor concentration required for half maximal enzyme inactivation after 2 to 10 mins by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	Ki	nM	740.0	Ki	uM	0.74
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as unbound inhibitor concentration required for half maximal enzyme inactivation after 2 to 10 mins by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	Ki	nM	730.0	Ki	uM	0.73
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	80000.0	IC50	uM	80.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as residual enzyme activity after 2 to 10 mins by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	Ki	nM	1900.0	Ki	uM	1.9
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	110000.0	IC50	uM	110.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as residual enzyme activity after 2 to 10 mins by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	Ki	nM	1900.0	Ki	uM	1.9
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	20000.0	IC50	uM	20.0
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	9200.0	IC50	uM	9.2
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	146000.0	IC50	uM	146.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	30000.0	IC50	uM	30.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	220000.0	IC50	uM	220.0
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	5700.0	IC50	uM	5.7
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	62000.0	IC50	uM	62.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	22000.0	IC50	uM	22.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	36000.0	IC50	uM	36.0
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	2900.0	IC50	uM	2.9
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	19000.0	IC50	uM	19.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	27000.0	IC50	uM	27.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	9600.0	IC50	uM	9.6
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	7000.0	IC50	uM	7.0
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	100000.0	IC50	uM	100.0
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	IC50	nM	650.0	IC50	uM	0.65
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	26000.0	IC50	uM	26.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	190000.0	IC50	uM	190.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	IC50	nM	2100.0	IC50	uM	2.1
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	8000.0	IC50	uM	8.0
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	110000.0	IC50	uM	110.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	30000.0	IC50	uM	30.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	220000.0	IC50	uM	220.0
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	5200.0	IC50	uM	5.2
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	12000.0	IC50	uM	12.0
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	IC50	nM	27.0	IC50	uM	0.027
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	25000.0	IC50	uM	25.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	8100.0	IC50	uM	8.1
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	C[C@H](c1nc2ncccc2c(=O)n1-c1ccc(O)cc1)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Drug Metab. Dispos.	2012.0	CHEMBL1939697	=	=	IC50	nM	68.0	IC50	uM	0.068
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	2700.0	IC50	uM	2.7
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	100.0	IC50	uM	0.1
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	CCOc1ccc(-n2c([C@@H](C)N(Cc3cccnc3)C(=O)Cc3ccc(OC(F)(F)F)cc3)nc3ncccc3c2=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL397983	=	=	IC50	nM	21000.0	IC50	uM	21.0
Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH	COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1	Drug Metab. Dispos.	2012.0	CHEMBL23	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH	CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835955	=	=	IC50	nM	26.0	IC50	nM	26.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH	CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835954	=	=	IC50	nM	20.0	IC50	nM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH	CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835953	=	=	IC50	nM	16.0	IC50	nM	16.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH	CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Drug Metab. Dispos.	2012.0	CHEMBL1835952	=	=	IC50	nM	17.0	IC50	nM	17.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrates after 5 mins by LC/MS analysis in presence of NADPH	O=C(Cn1cncn1)c1ccc(Cl)cc1Cl	Drug Metab. Dispos.	2012.0	CHEMBL2063494	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins by LC-MS/MS method	CC12CCC(C(NC(=O)[C@@H](CC3CCCCC3)NC(=O)N[C@@H](CCCCN)C(=O)O)C1)C2(C)C.Cl	J. Med. Chem.	2015.0	CHEMBL3577447	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate incubated for 30 mins by LC-MS/MS method	CC12CCC(C(NC(=O)[C@@H](CC3CCCCC3)NC(=O)N[C@@H](CCCCN)C(=O)O)C1)C2(C)C.Cl	J. Med. Chem.	2015.0	CHEMBL3577447	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin)	CC(C)N1CCN(C(=O)c2ccc(CN3CCOCC3)cc2)CC1.O=C(O)/C=C\C(=O)O	ACS Med. Chem. Lett.	2015.0	CHEMBL3577955	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4 assessed as remaining enzyme activity by measuring conversion of luciferin-PPXE into D-luciferin by luminescence CYP3A4 P450-Glo assay relative to untreated control	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2015.0	CHEMBL157101	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human recombinant CYP3A4 using midazolam as substrate after 1 hr by LC-MS/MS analysis	CC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2	J. Med. Chem.	2015.0	CHEMBL3582243	=	=	IC50	nM	4780.0	IC50	uM	4.78
Inhibition of human recombinant CYP3A4 using testosterone as substrate after 1 hr by LC-MS/MS analysis	CC1(C)CC[C@]23CC[C@]4(C)[C@](C(=O)C=C5[C@@]6(C)C=C(C#N)C(=O)C(C)(C)[C@@H]6CC[C@]54C)([C@@H]2C1)N(C1CCCCC1)C3=O	J. Med. Chem.	2015.0	CHEMBL3582240	=	=	IC50	nM	2535.0	IC50	uM	2.535
Inhibition of human recombinant CYP3A4 using testosterone as substrate after 1 hr by LC-MS/MS analysis	CC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@](C)(CC[C@H]4C(C)(C)C(=O)C(C#N)=C[C@]34C)[C@]1(C)CC2	J. Med. Chem.	2015.0	CHEMBL3582243	=	=	IC50	nM	2740.0	IC50	uM	2.74
Inhibition of human recombinant CYP3A4 using midazolam as substrate after 1 hr by LC-MS/MS analysis	CC1(C)CC[C@]23CC[C@]4(C)[C@](C(=O)C=C5[C@@]6(C)C=C(C#N)C(=O)C(C)(C)[C@@H]6CC[C@]54C)([C@@H]2C1)N(C1CCCCC1)C3=O	J. Med. Chem.	2015.0	CHEMBL3582240	=	=	IC50	nM	932.0	IC50	uM	0.932
Inhibition of CYP3A4 (unknown origin)	CCn1cc([C@@]2(c3nn(C)c(=O)o3)N[C@@H](c3nc(-c4ccc(F)cn4)c[nH]3)Cc3c2[nH]c2ccccc32)cn1	ACS Med. Chem. Lett.	2015.0	CHEMBL3582336	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl	J. Med. Chem.	2015.0	CHEMBL3581693	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Fc1cncc(-c2nc3cc(F)c(F)cc3n2C2CC2)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3582472	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(O)c1cncc(-c2nc3cc(F)c(F)cc3n2C2CC2)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3582477	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3582478	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(F)cncc1-c1nc2cc(F)c(F)cc2n1C1CC1	ACS Med. Chem. Lett.	2015.0	CHEMBL3582481	=	=	IC50	nM	8235.0	IC50	nM	8235.0
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccncc3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581121	=	=	IC50	nM	750.0	IC50	uM	0.75
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2cc(-c3ccncc3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581132	=	=	IC50	nM	480.0	IC50	uM	0.48
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccncn3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581137	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2cc(-c3ccncn3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581138	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(C)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581139	=	=	IC50	nM	7400.0	IC50	uM	7.4
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(N)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581140	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 (unknown origin)	CNc1cc(-c2csc(NC(=O)Cc3cccc(OC)c3)n2)ccn1	J. Med. Chem.	2015.0	CHEMBL3581141	=	=	IC50	nM	11400.0	IC50	uM	11.4
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(N(C)C)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581142	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(OC)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581143	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(F)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581144	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(Cl)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581145	=	=	IC50	nM	3600.0	IC50	uM	3.6
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581146	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(F)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3580669	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581147	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(Cl)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581148	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581149	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3ccnc(N)c3)cs2)c1	J. Med. Chem.	2015.0	CHEMBL3581150	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Cc1cc(C)nc(N2C[C@H]3CN(C(=O)c4c(F)cccc4-n4nccn4)C[C@H]3C2)n1	J. Med. Chem.	2015.0	CHEMBL3586436	>	>	IC50	nM	10000.0	IC50	uM	10.0
Competitive inhibition of CYP3A4 (unknown origin)	Cl.O=C(c1cc(S(=O)(=O)Nc2ccccc2F)c(F)cc1Cl)N1CCN2CCC[C@@H]2C1	ACS Med. Chem. Lett.	2015.0	CHEMBL3589557	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)O)nc(N2C[C@H]3C[C@@H](c4ccccc4C(F)(F)F)C[C@H]3C2)n1	J. Med. Chem.	2015.0	CHEMBL3594232	>	>	IC50	nM	34000.0	IC50	uM	34.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2ncc(-c3nc(-c4ccccc4)cs3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)cc(C)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601185	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2ncc(-c3nc(-c4ccccc4)cs3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601186	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601189	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	OC[C@H]1C[C@@H](Nc2nc(Nc3ccnc(OC4CC4)c3)ncc2-c2ccc3ccccc3n2)[C@H](O)[C@@H]1O	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601190	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)Oc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)ccn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601070	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2ncc(-c3ccc4ccccc4n3)c(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)n2)cc(C)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601192	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(N[C@@H]3C[C@H](CO)[C@@H](O)[C@H]3O)c(-c3nc4ccccc4s3)cn2)cc(C)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601196	>	>	IC50	nM	50000.0	IC50	uM	50.0
Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N(C)C)CC3)cc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601323	=	=	IC50	nM	9400.0	IC50	uM	9.4
Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCNC(=O)C4)CC3)cc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601397	=	=	IC50	nM	11300.0	IC50	uM	11.3
Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N(C)C)CC3)nc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601399	=	=	IC50	nM	5000.0	IC50	uM	5.0
Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CC(=O)N(C)C4)CC3)nc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601400	=	=	IC50	nM	13200.0	IC50	uM	13.2
Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)nc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601401	>	>	IC50	nM	20000.0	IC50	uM	20.0
Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cn1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601402	>	>	IC50	nM	20000.0	IC50	uM	20.0
Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1cnc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cn1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601403	>	>	IC50	nM	20000.0	IC50	uM	20.0
Time dependent inhibition of CYP3A4 in human liver microsomes	COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2	J. Med. Chem.	2015.0	CHEMBL3601398	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](NC(=O)[C@H]1CCCCN1CCOc1ccccc1)c1ccc(C(=O)O)cc1.Cl	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3115074	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(COc2cnn(CC(=O)c3ccc(CN(C)C)cc3C)c(=O)c2)nc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3601377	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin)	O=C(c1ccc(F)cc1)N1CCc2nc(COc3cccc(F)c3)oc2C1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3605277	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(c1n[nH]c2ncccc12)N1CCc2nc(COc3ccccc3)oc2C1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3605296	>=	>=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	O=C(Nc1ccc(Cl)cc1Cl)c1cn[nH]n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3604174	=	=	IC50	nM	58100.0	IC50	uM	58.1
Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method	CCn1c([C@@H](C)NS(=O)(=O)c2cccnc2)nc2ccc(C(F)(F)F)cc21	J. Med. Chem.	2015.0	CHEMBL3605542	=	=	IC50	nM	830.0	IC50	uM	0.83
Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method	CCn1c([C@@H](C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C(F)(F)F)cc21	J. Med. Chem.	2015.0	CHEMBL3605557	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes incubated for 5 mins in presence of NADPH and specific substrates by LC/MS/MS method	CCn1c([C@@H](C)NS(=O)(=O)c2ccc(C#N)nc2)nc2cnc(C3CC3)cc21	J. Med. Chem.	2015.0	CHEMBL3605558	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(F)ccc(Cl)c2Cl)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604739	=	=	IC50	nM	3981.07	pIC50		5.4
Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604734	=	=	IC50	nM	12589.25	pIC50		4.9
Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(C)cccc2Cl)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604733	=	=	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(Cl)cccc2Cl)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604722	=	=	IC50	nM	7943.28	pIC50		5.1
Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2cccc(Cl)c2Cl)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604717	=	=	IC50	nM	3981.07	pIC50		5.4
Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2ccccc2C(F)(F)F)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604713	=	=	IC50	nM	12589.25	pIC50		4.9
Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(C)cccc2C)c2cccc(C(N)=O)c2n1	J. Med. Chem.	2015.0	CHEMBL3604701	=	=	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(Cl)cc(-c2cc(-c3ccc(F)cn3)ncn2)c1	J. Med. Chem.	2015.0	CHEMBL3603923	<	>	IC50	nM	15848.93	pIC50		4.8
Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method	COc1cccc2nc(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)[nH]c12	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3609819	=	=	IC50	nM	34000.0	IC50	uM	34.0
Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL45816	=	=	IC50	nM	140000.0	IC50	uM	140.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1'-hydroxylation by LC-MS/MS method	COc1cccc2nc(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)[nH]c12	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3609819	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation by LC-MS/MS method	COc1cccc2nc(CCCN(C)CC[C@]3(OC(=O)C(C)C)C[C@H]4CCC[C@@H]3c3ccccc34)[nH]c12	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3609819	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccccc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608740	=	=	IC50	nM	31000.0	IC50	uM	31.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1c2nnc(-c3nc(C(F)(F)F)ns3)n2CCN1C(=O)c1ccc(F)cc1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608688	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(Cl)cc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608687	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3(C)C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608686	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)C3)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608684	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CC(C)c1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608683	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cc1noc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608682	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3422018	=	=	IC50	nM	79000.0	IC50	uM	79.0
Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3C)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608680	=	=	IC50	nM	90000.0	IC50	uM	90.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(-c2nnc3n2CCN(C(=O)c2ccc(-c4cccs4)cc2)[C@@H]3C)cs1	ACS Med. Chem. Lett.	2015.0	CHEMBL3422010	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1c2nnc(-c3csc(-c4ccc(F)cc4F)n3)n2CCN1C(=O)c1ccc(-c2cccs2)cc1	ACS Med. Chem. Lett.	2015.0	CHEMBL3422009	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin)	Cc1nsc(-c2nnc3n2CCN(C(=O)c2ccc(F)cc2)[C@@H]3CCO)n1	ACS Med. Chem. Lett.	2015.0	CHEMBL3608741	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	CN[C@@H](C)C(=O)N[C@H](C(=O)N1C[C@@H]2C[C@H]1C(=O)N[C@@H](Cc1ccc3ccccc3c1)C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)OCCCC[C@H]1C[C@@H](C(=O)N[C@@H](Cc3ccc4ccccc4c3)C(=O)N[C@H](NS(=O)(=O)C3CC3)Cc3ccc(cc3)OCc3cn2nn3)N(C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)C1)C(C)(C)C	ACS Med. Chem. Lett.	2015.0	CHEMBL3609325	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 by luminometry	COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(-c2ccc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)cc2C(F)(F)F)c(C(F)(F)F)c1)c1ccccc1	Eur. J. Med. Chem.	2015.0	CHEMBL3608913	=	=	EC50	nM	4640.0	EC50	uM	4.64
Inhibition of human CYP3A4 by luminometry	COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(-c2ccc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)cc2F)c(F)c1)c1ccccc1	Eur. J. Med. Chem.	2015.0	CHEMBL3608915	=	=	EC50	nM	2460.0	EC50	uM	2.46
Inhibition of human CYP3A4 by luminometry	COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(-c2ccc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)cc2Cl)c(Cl)c1)c1ccccc1	Eur. J. Med. Chem.	2015.0	CHEMBL3608916	=	=	EC50	nM	3990.0	EC50	uM	3.99
Inhibition of human CYP3A4 by luminometry	COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc2c(c1)C(C)(C)c1cc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)ccc1-2)c1ccccc1	Eur. J. Med. Chem.	2015.0	CHEMBL3608920	=	=	EC50	nM	1030.0	EC50	uM	1.03
Inhibition of human CYP3A4 by luminometry	COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc2c(c1)C(F)(F)c1cc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)ccc1-2)c1ccccc1	Eur. J. Med. Chem.	2015.0	CHEMBL3608921	=	=	EC50	nM	976.0	EC50	uM	0.976
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C1c2cc(-c3ccnc(N[C@@H]4C[C@H](O)[C@@H](F)C4)n3)cn2CCCN1[C@H](CO)c1ccccc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3608458	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	O=C1c2cc(-c3ccnc(N[C@@H]4C[C@H](O)[C@@H](F)C4)n3)cn2CCCN1[C@H](CO)c1ccccc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3608458	=	=	IC50	nM	38800.0	IC50	uM	38.8
Inhibition of CYP3A4 (unknown origin)	COc1cc([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ncc1C#N	ACS Med. Chem. Lett.	2015.0	CHEMBL3612810	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL157101	=	=	IC50	nM	180.0	IC50	umol/L	0.18
Inhibition of CYP3A4 (unknown origin)	O=C(Cn1cnc([N+](=O)[O-])n1)Nc1cccc(-c2ccccc2)c1	Bioorg. Med. Chem.	2015.0	CHEMBL3612341	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	O=C(NCCCCNC(=O)c1cccnc1O)c1cc(-c2ccccc2)on1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3618396	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay	COC(=O)C(Cn1ccnc1)NC(=O)c1c(C)nn(-c2ccccc2)c1Cl	Bioorg. Med. Chem.	2015.0	CHEMBL3617983	=	=	IC50	nM	1170.0	IC50	uM	1.17
Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay	Cc1nn(-c2ccccc2)c(Cl)c1C(=O)NC(Cn1ccnc1)C(=O)OC(C)C	Bioorg. Med. Chem.	2015.0	CHEMBL3617986	=	=	IC50	nM	4920.0	IC50	uM	4.92
Inhibition of CYP3A4 (unknown origin) incubated for 45 mins using NADPH by fluorescence assay	Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1	Bioorg. Med. Chem.	2015.0	CHEMBL389433	=	=	IC50	nM	690.0	IC50	uM	0.69
Inhibition of CYP3A4 in human liver microsomes by cocktail assay	C[C@@H]1CN(c2cccnc2F)C(=O)c2cc(COc3ccc(Cl)cn3)nn21	J. Med. Chem.	2015.0	CHEMBL3617655	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CCS(=O)(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12	ACS Med. Chem. Lett.	2015.0	CHEMBL3623127	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	COCc1cnc(N2CCC([C@H]3C[C@H]3COCc3ccc(S(C)(=O)=O)cc3F)CC2)nc1	ACS Med. Chem. Lett.	2015.0	CHEMBL3622175	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C)cc(Nc2nccc(-n3cc(C)c(CN4CC[C@@H](O)C4)c3)n2)c1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3622924	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2ccnc(Nc3cc(C)c(OCCO)c(C)c3)n2)cc1CN1CC[C@@H](O)C1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3622939	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21	J. Med. Chem.	2015.0	CHEMBL3623823	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCC(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21	J. Med. Chem.	2015.0	CHEMBL3623824	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)C(=O)NC1CCCc2c(-c3ccc(C#N)cc3)cncc21	J. Med. Chem.	2015.0	CHEMBL3623825	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCC(=O)N[C@@H]1CCCc2c(-c3ccc(C#N)cc3)cncc21	J. Med. Chem.	2015.0	CHEMBL3623830	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCC(=O)N[C@H]1CCCc2c(-c3ccc(C#N)cc3)cncc21	J. Med. Chem.	2015.0	CHEMBL3623831	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3nc(C)c(C)s3)nc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3622137	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1CN1CCOCC1	J. Med. Chem.	2015.0	CHEMBL3623278	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C	J. Med. Chem.	2015.0	CHEMBL3623290	>	>	IC50	nM	50.0	IC50	nM	50.0
Inhibition of CYP3A4 in human liver microsomes	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3545215	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4	c1ccc(-c2nnc3n2-c2ccc(-c4cccnc4)cc2CC3)cc1	ACS Med. Chem. Lett.	2015.0	CHEMBL3622434	=	=	IC50	nM	36510.0	IC50	nM	36510.0
Inhibition of human CYP3A4	COC(=O)c1cncc(-c2ccc3c(c2)CCc2nnc(C)n2-3)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL3622437	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of human CYP3A4	COC(C)(C)c1cncc(-c2ccc3c(c2)CCc2nnc(C)n2-3)c1	ACS Med. Chem. Lett.	2015.0	CHEMBL2331704	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of human CYP3A4	Cc1nnc2n1-c1ccc(-c3cncc([C@](C)(O)C(F)(F)F)c3)cc1CC2	ACS Med. Chem. Lett.	2015.0	CHEMBL3622445	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4c(F)ccc(C)c4c(=O)[nH]3)c(Cl)c2)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3627899	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4ccc(Cl)cc4[nH]3)c(Cl)c2)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3627895	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3ccc4[nH]c(C)nc4c3)c(Cl)c2)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3627897	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	Cc1ncn(-c2cc(Cl)c(C(=O)NC[C@@H](c3cccc(F)c3)c3nc4c(C)cc(Cl)cc4[nH]3)c(Cl)c2)n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3627896	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	COc1cc2nc([C@@H](CNC(=O)c3c(Cl)cc(-n4cnc(C)n4)cc3Cl)c3cccc(F)c3)[nH]c2cc1Cl	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3627894	=	=	IC50	nM	33260.0	IC50	nM	33260.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(Cl)cc3C2=O)c(Cl)c1	J. Med. Chem.	2015.0	CHEMBL3628112	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(F)c3C2=O)c(Cl)c1	J. Med. Chem.	2015.0	CHEMBL3628113	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccncc3C2=O)c(Cl)c1	J. Med. Chem.	2015.0	CHEMBL3628115	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	O=C(Nc1nc(C(F)(F)F)co1)C1c2ccccc2Oc2ccccc21	J. Med. Chem.	2015.0	CHEMBL521982	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	O=C(Nc1ccc(N2C(=O)c3cccc(Cl)c3C2=O)c(Cl)c1)c1ncccc1Cl	J. Med. Chem.	2015.0	CHEMBL3628116	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncccc3c2)C2CCCC2)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL592646	=	=	IC50	nM	260.0	IC50	uM	0.26
Inhibition of CYP3A4 (unknown origin)	CC(C)[C@](C)(NCc1ccc2ncccc2c1)c1cn(C(CCS(C)(=O)=O)C(=O)COc2c(F)c(F)cc(F)c2F)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3628591	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin)	CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncccc3c2)C(C)C)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL600002	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 (unknown origin)	CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccn3nccc3n2)C(C)C)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3628942	=	=	IC50	nM	314.0	IC50	uM	0.314
Inhibition of CYP3A4 (unknown origin)	CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccn3nccc3n2)C2CCCC2)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3628943	=	=	IC50	nM	263.0	IC50	uM	0.263
Inhibition of CYP3A4 (unknown origin)	CCCCC(C(=O)COc1c(F)c(F)cc(F)c1F)n1cc([C@@](C)(NCc2ccc3ncsc3c2)C(C)C)nn1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3628934	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin)	C[C@@](NCc1ccc2ncsc2c1)(c1cn(C(CCS(C)(=O)=O)C(=O)COc2c(F)c(F)cc(F)c2F)nn1)C1CCCC1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3628939	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(N[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL372199	=	=	IC50	nM	16600.0	IC50	uM	16.6
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCCC(CO)(CO)[C@@H]1COc1c(F)ccc(F)c12	J. Med. Chem.	2015.0	CHEMBL3629736	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCC[C@]3(CCOC3)[C@@H]1COc1c(F)ccc(F)c12	J. Med. Chem.	2015.0	CHEMBL3629738	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=C1OCC[C@]12CCC[C@@]1(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]21	J. Med. Chem.	2015.0	CHEMBL3629740	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S1(=O)CCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CC1	J. Med. Chem.	2015.0	CHEMBL3629741	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(N1CC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)C1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL3629743	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	CP1(=O)OCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1	J. Med. Chem.	2015.0	CHEMBL3629744	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	CP1(=O)OCC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1	J. Med. Chem.	2015.0	CHEMBL3629745	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL1090209	=	=	IC50	nM	9600.0	IC50	uM	9.6
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate and protein	O=S(=O)(NC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL3627955	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(N[C@H]1CC[C@@](c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL372199	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCCC(CO)(CO)[C@@H]1COc1c(F)ccc(F)c12	J. Med. Chem.	2015.0	CHEMBL3629736	=	=	IC50	nM	11500.0	IC50	uM	11.5
Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(c1ccc(Cl)cc1)[C@@]12CCC[C@]3(CCOC3)[C@@H]1COc1c(F)ccc(F)c12	J. Med. Chem.	2015.0	CHEMBL3629738	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=C1OCC[C@]12CCC[C@@]1(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]21	J. Med. Chem.	2015.0	CHEMBL3629740	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S1(=O)CCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CC1	J. Med. Chem.	2015.0	CHEMBL3629741	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(N1CC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)C1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL3629743	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	CP1(=O)OCC2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1	J. Med. Chem.	2015.0	CHEMBL3629744	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	CP1(=O)OCC[C@]2(CCC[C@@]3(S(=O)(=O)c4ccc(Cl)cc4)c4c(F)ccc(F)c4OC[C@@H]23)CO1	J. Med. Chem.	2015.0	CHEMBL3629745	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@H]2C1)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL1090209	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 (unknown origin) preincubated with protein for 30 mins followed by substrate addition	O=S(=O)(NC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C(F)(F)F	J. Med. Chem.	2015.0	CHEMBL3627955	=	=	IC50	nM	21400.0	IC50	uM	21.4
Inhibition of human recombinant CYP3A4 assessed as conversion of luciferin-PPXE to D-luciferin by luminescence Glo assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL157101	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human CYP3A4	COc1ccc2c(O[C@H]3CCN4C(=O)N(C)CCCC/C=C/[C@@H]5C[C@@]5(C(=O)NS(=O)(=O)C5(C)CC5)NC(=O)[C@@H]4C3)cc(-c3nc(C(F)(F)F)cs3)nc2c1C	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3634394	>=	>=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition	O=C(Nc1cc2ncncc2cc1OCc1cccc(Cl)c1)Nc1cccc2ccccc12	Eur. J. Med. Chem.	2015.0	CHEMBL3634101	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL157101	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of CYP3A4 (unknown origin)	CCOC(=O)N1[C@H]2CC[C@@H]1C[C@@H](CN1CC[C@@H](N3Cc4ccccc4NC3=O)C1)C2	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3633184	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human Liver microsomes after 5 mins by LC-MS/MS method	O=C(Cn1cnc([N+](=O)[O-])n1)N1CCN(Cc2ccc(C(F)(F)F)cc2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL3633320	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human Liver microsomes after 5 mins by LC-MS/MS method	O=C(Cn1cnc([N+](=O)[O-])n1)N1CCN(Cc2ccc(Cl)c(Cl)c2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL3633321	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL558752	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cc1cnc(-c2cc(Oc3ccc4c(c3)nc(Nc3cc(C(F)(F)F)ccc3F)n4C)ccn2)[nH]1	ACS Med. Chem. Lett.	2015.0	CHEMBL3632724	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cc(C(F)(F)F)ccc2F)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632723	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cccc(C(F)(F)F)c2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632722	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cc(C(C)(C)C)ccc2F)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632721	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2ccc(C(C)(C)C)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632720	=	=	IC50	nM	34000.0	IC50	uM	34.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632719	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc(-c5ccccc5)[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632718	=	=	IC50	nM	7100.0	IC50	uM	7.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Cn1c(Nc2cccc(C(C)(C)C)c2)nc2cc(Oc3ccnc(-c4ncc[nH]4)c3)ccc21	ACS Med. Chem. Lett.	2015.0	CHEMBL3632717	=	=	IC50	nM	1800.0	IC50	uM	1.8
Reversible inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O	J. Med. Chem.	2015.0	CHEMBL3633460	>	>	IC50	nM	100000.0	IC50	uM	100.0
Time-dependent inhibition of CYP3A4 in human liver microsomes	COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O	J. Med. Chem.	2015.0	CHEMBL3633460	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCCn2nc(COc3ccccc3)cc21	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3633943	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc([C@H](C)NC(=O)COc2cc(C(F)(F)F)c3c(-c4ccccc4)nn(C)c3n2)cc1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3634013	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 (unknown origin)	Cc1n[nH]c(C)c1[C@H](C)NC(=O)COc1cc(C(F)(F)F)c2c(-c3ccccc3)nn(C)c2n1	Bioorg. Med. Chem. Lett.	2015.0	CHEMBL3634015	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition Assay: Inhibition assay using P450 CYP enzymes.	CS(=O)(=O)Nc1cccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)c1		2013.0	CHEMBL1650658	=	=	IC50	nM	1070.0	IC50	nM	1070.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		2015.0	CHEMBL3673964	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCCC5)n4)nc3)c2c1		2015.0	CHEMBL3669004	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1		2015.0	CHEMBL3673980	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F		2015.0	CHEMBL3673971	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)cc1F		2015.0	CHEMBL3673978	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Clc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3)c2c1		2015.0	CHEMBL3673980	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(Cl)cc23)cn1		2015.0	CHEMBL3673935	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1		2015.0	CHEMBL3669002	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(C)c4)nc3F)c2c1		2015.0	CHEMBL3673968	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c2c1		2015.0	CHEMBL3673948	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1		2015.0	CHEMBL3673973	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cc1F		2015.0	CHEMBL3673963	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Fc1cc(Cc2c[nH]c3ncc(Cl)cc23)cnc1NCc1ccc(C(F)(F)F)nc1		2015.0	CHEMBL3673979	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Assay: Inhibition assay using P450 CYP enzymes.	COc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cn1		2013.0	CHEMBL1650646	=	=	IC50	nM	2050.0	IC50	nM	2050.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.	CC(C)C(c1ccc2cc(OC(F)F)ccc2c1)n1ncnn1		2015.0	CHEMBL3682507	>	>	IC50	nM	200000.0	IC50	nM	200000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C#N)cc23)c(F)n1		2015.0	CHEMBL3673982	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cc1F		2015.0	CHEMBL3673971	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.	OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OC(F)(F)F)cc2)cn1		2014.0	CHEMBL3680985	=	=	IC50	nM	3800.0	IC50	nM	3800.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F		2014.0	CHEMBL638	=	=	IC50	nM	13000.0	IC50	nM	13000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1		2015.0	CHEMBL3669005	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1		2015.0	CHEMBL3673972	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1		2015.0	CHEMBL3673973	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Assay: Inhibition assay using P450 CYP enzymes.	O=C(O)CCC(=O)Nc1ccc(-c2c(O)ccc3cc(-c4cccc(O)c4)ccc23)cc1		2013.0	CHEMBL3645217	=	=	IC50	nM	221.0	IC50	nM	221.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1		2015.0	CHEMBL3673950	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(NC(C)=O)cc23)c(F)n1		2015.0	CHEMBL3673953	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1		2015.0	CHEMBL3673967	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12		2015.0	CHEMBL3673958	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1		2015.0	CHEMBL3673939	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.	OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)cc2)cn1		2014.0	CHEMBL3680983	=	=	IC50	nM	1400.0	IC50	nM	1400.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(F)c4)nc3F)c2c1		2015.0	CHEMBL3673939	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1		2015.0	CHEMBL3673934	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1		2015.0	CHEMBL3673957	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1		2015.0	CHEMBL3673938	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1		2015.0	CHEMBL3673974	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1		2015.0	CHEMBL3673943	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Assay: Inhibition assay using P450 CYP enzymes.	CCOC(=O)/C=C/c1c(OC)ccc2cc(-c3cccc(OC)c3)ccc12		2013.0	CHEMBL3645215	=	=	IC50	nM	1580.0	IC50	nM	1580.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)nc1		2015.0	CHEMBL3673940	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3cnc(NCc4ccc(C(F)(F)F)nc4)c(F)c3)c2c1		2015.0	CHEMBL3673974	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1		2015.0	CHEMBL3673945	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cn1		2015.0	CHEMBL3673945	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)nc1		2015.0	CHEMBL3673940	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1		2015.0	CHEMBL3673962	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	CCS(=O)(=O)Nc1ccccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		2015.0	CHEMBL3673941	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	FC(F)(F)c1ccncc1CNc1ccc(Cc2c[nH]c3ncc(Cl)cc23)cn1		2015.0	CHEMBL3673967	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1		2015.0	CHEMBL3673947	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.	COc1cc2ccc(C(C(C)C)n3ncnn3)cc2cc1OC		2015.0	CHEMBL3682506	>	>	IC50	nM	200000.0	IC50	nM	200000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCCC5)n4)nc3)c2c1		2015.0	CHEMBL3669004	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)cc1F		2015.0	CHEMBL3673978	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3F)c2c1		2015.0	CHEMBL3673947	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.	CC(C)C(c1ccc2cc(OCC(F)(F)F)ccc2c1)n1ncnn1		2015.0	CHEMBL3682505	>	>	IC50	nM	60000.0	IC50	nM	60000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4cncc(F)c4)nc3F)c2c1		2015.0	CHEMBL3673944	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(Cl)nc4)nc3)c2c1		2015.0	CHEMBL3669001	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	CS(=O)(=O)Nc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1		2015.0	CHEMBL3673954	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.	OC(Cn1cncn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1		2014.0	CHEMBL3680984	=	=	IC50	nM	5800.0	IC50	nM	5800.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(Cl)cc23)cn1		2015.0	CHEMBL3673935	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Assay: In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4.	COc1cc2cnc(C(O)(c3cnn[nH]3)C(C)C)cc2cc1OC		2014.0	CHEMBL3689756	=	=	IC50	nM	23000.0	IC50	nM	23000.0
Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(C(F)(F)F)cc2)cn1		2014.0	CHEMBL3311224	>	>	IC50	nM	60000.0	IC50	nM	60000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4ccc(Cl)nc4)nc3)c2c1		2015.0	CHEMBL3669001	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1		2015.0	CHEMBL3673934	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1		2015.0	CHEMBL3673966	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Assay: In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4.	CC(C)C(O)(c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1)c1cnn[nH]1		2014.0	CHEMBL3264605	=	=	IC50	nM	23000.0	IC50	nM	23000.0
Inhibition Assay: Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 5 mM. Separate stock solutions of each substrate were prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution.	N#Cc1ccc(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cc1		2014.0	CHEMBL3311223	=	=	IC50	nM	16000.0	IC50	nM	16000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cc2F)cn1		2015.0	CHEMBL3673957	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		2015.0	CHEMBL3673959	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1		2015.0	CHEMBL3673952	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)cc1F		2015.0	CHEMBL3673963	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4cnccc4C(F)(F)F)nc3F)c2c1		2015.0	CHEMBL3673966	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		2015.0	CHEMBL3673981	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(F)cc34)c(F)n2)cn1		2015.0	CHEMBL3673950	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4cncc(F)c4)nc3F)c2c1		2015.0	CHEMBL3673944	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c2c1		2015.0	CHEMBL3673948	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	150.0	IC50	nM	150.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)ccn1		2015.0	CHEMBL3673972	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1		2015.0	CHEMBL3673937	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Assay: In the design of clinically safe and effective metalloenzyme inhibitors, use of the most appropriate metal-binding group for the particular target and clinical indication is critical. If a weakly binding metal-binding group is utilized, potency may be suboptimal. On the other hand, if a very tightly binding metal-binding group is utilized, selectivity for the target enzyme versus related metalloenzymes may be suboptimal. The lack of optimal selectivity can be a cause for clinical toxicity due to unintended inhibition of these off-target metalloenzymes. One example of such clinical toxicity is the unintended inhibition of human drug metabolizing enzymes such as CYP2C9, CYP2C19 and CYP3A4 by the currently-available prostate anticancer agent ketoconazole. It is believed that this off-target inhibition is caused primarily by the indiscriminate binding of the currently utilized 1-imidazole to iron in the active site of CYP2C9, CYP2C19 and CYP3A4.	COc1cc2ccc(C(O)(c3cnn[nH]3)C(C)C)cc2cc1OC		2014.0	CHEMBL3264597	=	=	IC50	nM	57000.0	IC50	nM	57000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.	OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1ccc2cc(Br)ccc2n1		2014.0	CHEMBL3699081	=	=	IC50	nM	11000.0	IC50	nM	11000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O		2015.0	CHEMBL3673976	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cn1		2015.0	CHEMBL3673965	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cn1cc(F)cc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)c1=O		2015.0	CHEMBL3673976	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccnc(C)c4)nc3F)c2c1		2015.0	CHEMBL3673968	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(OC)n1		2015.0	CHEMBL3673937	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1		2015.0	CHEMBL3673936	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		2015.0	CHEMBL3673964	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		2015.0	CHEMBL3639728	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(C)cc34)cn2)cn1		2015.0	CHEMBL3673965	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1		2015.0	CHEMBL3669003	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1		2015.0	CHEMBL3673970	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Assay: Inhibition assay using P450 CYP enzymes.	CNC(=O)/C=C/c1cc(OC)cc(-c2ccc3cc(OC)ccc3c2)c1		2013.0	CHEMBL3645225	=	=	IC50	nM	2250.0	IC50	nM	2250.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C#N)cc23)c(F)n1		2015.0	CHEMBL3673982	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ccc(Cc2c[nH]c3ncccc23)c(F)n1		2015.0	CHEMBL3673962	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1		2015.0	CHEMBL3673960	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)cc4)nc3F)c12		2015.0	CHEMBL3673958	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1		2015.0	CHEMBL3673946	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(C)n4)nc3)c2c1		2015.0	CHEMBL3669002	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cc(CNc2ccc(Cc3c[nH]c4ncc(C)cc34)c(F)n2)c(F)cn1		2015.0	CHEMBL3673970	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4ccc(OC)nc4)nc3F)c2c1		2015.0	CHEMBL3673946	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncccc1CNc1ncc(Cc2c[nH]c3ncc(C)cc23)cn1		2015.0	CHEMBL3669005	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1		2015.0	CHEMBL3639728	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F		2014.0	CHEMBL106	=	=	IC50	nM	8000.0	IC50	nM	8000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Fc1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		2015.0	CHEMBL3673981	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 μM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 μM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 μM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 μM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.	OC(Cn1cnnc1)(c1ccc(F)cc1F)C(F)(F)c1cnc2cc(Cl)ccc2n1		2014.0	CHEMBL3699082	=	=	IC50	nM	45000.0	IC50	nM	45000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 uM. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:ACN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v.Pooled human liver microsome suspension (20 mg/mL) was determined.	CC(C)C(O)c1ccc2cc(OCC(F)(F)F)ccc2c1		2015.0	CHEMBL3682508	>	>	IC50	nM	200000.0	IC50	nM	200000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4OC)nc3F)c2c1		2015.0	CHEMBL3673960	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4cccnc4F)nc3F)c2c1		2015.0	CHEMBL3673938	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	COc1ccc(CNc2ncc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		2015.0	CHEMBL3673959	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(Cl)nc4)nc3F)c2c1		2015.0	CHEMBL3673936	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Fc1cncc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)c(F)n2)c1		2015.0	CHEMBL3673943	=	=	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3ccc(NCc4ccc(C(F)(F)F)nc4)nc3)c2c1		2015.0	CHEMBL3673952	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition Enzyme Assay: CYP (Cytochrome P450) enzymes are the major drug metabolizing enzymes present in the liver. The inhibition of CYP enzyme activity (IC50) for each of CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4(BFC) and CYP3A4(BQ) is determined for compounds, where inhibition of metabolism of a known substrate leads to a decrease in the fluorescence of the metabolized product. The fluorescence of the product is monitored as a function of compound concentration.Compounds are dissolved in DMSO to a concentration of 100 mM. These are diluted 1 uL into 82 uL of acetonitrile. An 11 uL aliquot of this solution is then added to 204 uL of cofactor mix (1.3% NADPH Regeneration system Solution A, 1.04% NADPH Regeneration system Solution B from BD Biosciences, 5% acetonitrile and 0.05% DMSO). These are then serially diluted 1:1 (160 uL to 160 uL co-factor mix) for a total of 10 points. A 10 uL aliquot of this final mixture is dispensed into 384 well assay plates.	Cc1cnc2[nH]cc(Cc3cnc(NCc4cccc(N5CCOCC5)n4)nc3)c2c1		2015.0	CHEMBL3669003	<	<	IC50	nM	5000.0	IC50	nM	5000.0
Inhibition of CYP3A4 (unknown origin)	Cc1noc([C@H]2C[C@@H]2C(=O)NCc2ccc(-c3cccc(OC(F)(F)F)c3)c3c2CN(C(=O)NC(C)(C)C)CC3)n1	J. Med. Chem.	2015.0	CHEMBL3734797	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of human CYP3A4 by LC-MS analysis	CC(C)NCC(O)COc1cccc2ccccc12	J. Med. Chem.	2015.0	CHEMBL27	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of human CYP3A4 by LC-MS analysis	CB1C=Cc2cccc(OCC(O)CN(C)C)c2N1	J. Med. Chem.	2015.0	CHEMBL3736433	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of human CYP3A4 by LC-MS analysis	CB1C=Cc2c(cccc2OCC(O)CN(C)C)N1	J. Med. Chem.	2015.0	CHEMBL3736156	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NCC2CCN(CC3CCOCC3)CC2)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3741608	=	=	IC50	nM	25500.0	IC50	uM	25.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	COCCCN1CCC(CNC(=O)c2nc(C(C)C)n3ccccc23)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL3741821	=	=	IC50	nM	27200.0	IC50	uM	27.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC2CCN(C(C)C)CC2)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3739521	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC2CCN(CC3CC3)CC2)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3739470	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	COCCCN1CCC(NC(=O)c2nc(C(C)C)n3ccccc23)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL3741776	=	=	IC50	nM	16300.0	IC50	uM	16.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC2CCN(CCF)CC2)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3740908	=	=	IC50	nM	27300.0	IC50	uM	27.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	COCCCN1C[C@H]2[C@H](CNC(=O)c3nc(C(C)C)n4ccccc34)[C@H]2C1	Eur. J. Med. Chem.	2015.0	CHEMBL3740472	=	=	IC50	nM	0.0	IC50	uM	0.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC[C@H]2[C@@H]3CN(CC4CCOCC4)C[C@H]23)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3739647	=	=	IC50	nM	41400.0	IC50	uM	41.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	COC(=O)N1CCC(CN2C[C@H]3[C@H](CNC(=O)c4nc(C(C)C)n5ccccc45)[C@H]3C2)CC1	Eur. J. Med. Chem.	2015.0	CHEMBL3740669	=	=	IC50	nM	54300.0	IC50	uM	54.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC[C@H]2[C@@H]3CN(CC(C)(C)F)C[C@H]23)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3741595	=	=	IC50	nM	44700.0	IC50	uM	44.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis in presence of NADPH regeneration system	CC(C)c1nc(C(=O)NC[C@H]2[C@@H]3CN(CC(C)(C)O)C[C@H]23)c2ccccn12	Eur. J. Med. Chem.	2015.0	CHEMBL3741377	=	=	IC50	nM	18900.0	IC50	uM	18.9
Inhibition of CYP3A4 (unknown origin)	COc1cc(N2C(=O)N(Cc3c(F)cc(F)cc3F)c3ncccc3S2(=O)=O)cnc1OC	MedChemComm	2015.0	CHEMBL3740099	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of human CYP3A4 by fluorescence assay	Cc1cc(F)c(-c2ccnn(C)c2=O)cc1NC(=O)C1=CN(C)C(=O)C[C@H]1c1ccc(F)cc1	J. Med. Chem.	2015.0	CHEMBL3740684	>	>	IC50	nM	32000.0	IC50	uM	32.0
Inhibition of human CYP3A4 by fluorescence assay	COC[C@H](O)Cn1c(=O)cnn(-c2ccc(C)c(NC(=O)C3=CN(C)C(=O)C[C@H]3c3ccc(F)cc3)c2)c1=O	J. Med. Chem.	2015.0	CHEMBL3739741	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) assessed as testosterone-6beta hydroxylation	CCn1cc(C(=O)N2CCc3ccsc3C2Cc2ccc(OC)c(OC)c2)c2ccccc21	MedChemComm	2015.0	CHEMBL3742341	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin)	CC(C)Cc1cc(O)c(-c2ccccc2)c(=O)[nH]1	Eur. J. Med. Chem.	2015.0	CHEMBL3597017	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(S(=O)(=O)N(C)C2(C(=O)N[C@H]3C4CC5CC3C[C@](C(N)=O)(C5)C4)CC2)cc1F	MedChemComm	2015.0	CHEMBL3741915	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(C(=O)O)c(C)c1NC(=O)c1cc(-c2cccc(Cl)c2)cc2ccccc12	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3740325	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 by fluorescence assay	O=C(c1sc2c([N+](=O)[O-])cc(C(F)(F)F)cc2[n+]1[O-])N1CCCCC1	Bioorg. Med. Chem.	2015.0	CHEMBL3742347	=	=	IC50	nM	3910.0	IC50	uM	3.91
Inhibition of human recombinant CYP3A4 by fluorescence assay	COCCN1CCN(C(=O)c2nc3cc(C(F)(F)F)cc([N+](=O)[O-])c3s2)CC1	Bioorg. Med. Chem.	2015.0	CHEMBL3742122	=	=	IC50	nM	19500.0	IC50	uM	19.5
Inhibition of human recombinant CYP3A4 by fluorescence assay	COCCN1CCN(C(=O)c2nc3cc(C(F)(F)F)c(C)c([N+](=O)[O-])c3s2)CC1	Bioorg. Med. Chem.	2015.0	CHEMBL3741545	=	=	IC50	nM	95000.0	IC50	uM	95.0
Inhibition of human recombinant CYP3A4 by fluorescence assay	O=C([C@@H]1COC(c2nc3cc(C(F)(F)F)cc([N+](=O)[O-])c3s2)=N1)N1CCCC1	Bioorg. Med. Chem.	2015.0	CHEMBL3739863	=	=	IC50	nM	18600.0	IC50	uM	18.6
Inhibition of human recombinant CYP3A4 by fluorescence assay	Cc1c(C(F)(F)F)cc2nc(C3=N[C@H](C(=O)N4CCCC4)CO3)sc2c1[N+](=O)[O-]	Bioorg. Med. Chem.	2015.0	CHEMBL3739831	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cn1cc(CNc2cc(OC[C@H]3C[C@@H]3c3ccccn3)nc3ccnn23)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3695713	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(C)c(CNc2cc(C3CC3)nc3ccnn23)s1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3695718	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(Cl)nc(OC[C@H]2C[C@@H]2c2ccccn2)nc1NCc1cnn(C)c1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3665949	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 (unknown origin)	Cc1nc(C)c(CNc2nc(C3CC3)nc(Cl)c2C)s1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3622879	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(C)c(CNc2nc(OCCCc3ccc4ccccc4n3)nc(Cl)c2C)s1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3622898	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 (unknown origin)	O=C1c2cc(COc3ccccc3)nn2CCN1c1ccc(F)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3746457	>=	>=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2cccc(CO)c2)nc1C(=O)Nc1c(C)ccc(C(=O)O)c1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3754085	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 after 2 mins by LC-MS/MS analysis	CC(C)N1CCC(Oc2ccc(C(=O)NC3CCN(C(C)C)C3)cc2)CC1	Eur. J. Med. Chem.	2016.0	CHEMBL3753093	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of human CYP3A4 after 2 mins by LC-MS/MS analysis	CC(C)N1CCC(NC(=O)c2ccc(OC3CCN(C4CCC4)CC3)cc2)C1	Eur. J. Med. Chem.	2016.0	CHEMBL3754205	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(C)n1nc(-c2cc(C3CC3)on2)c2c(N)ncnc21	J. Med. Chem.	2016.0	CHEMBL3753341	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc2c(c1)C(=O)N(c1ccc(NC(=O)c3occc3C)c(F)c1)C2=O	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3758746	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(C)c3C2=O)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3758305	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(Cl)cc3C2=O)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3759901	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3ccc(F)cc3C2=O)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3758435	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccoc1C(=O)Nc1ccc(N2C(=O)c3cccc(F)c3C2=O)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3758465	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(CNC(=O)c2cc(-c3nnn(C[C@H]4CO[C@H](CO)CO4)n3)nc(C)n2)ccc1F	J. Med. Chem.	2016.0	CHEMBL3759468	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=S(=O)(Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(-c2nc(-c3ccc(C(F)(F)F)cc3)cs2)cc1	J. Med. Chem.	2016.0	CHEMBL111201	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	Nc1nc(CC(=O)Nc2ccc(C[C@@H]3CC[C@H]([C@H](O)c4ccccc4)N3)cc2)cs1	J. Med. Chem.	2016.0	CHEMBL1684585	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2scnc21	J. Med. Chem.	2016.0	CHEMBL3128178	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3cccnc3)N2)cc1)[C@@H]1CCc2ccnn21	J. Med. Chem.	2016.0	CHEMBL3128188	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Cn1cnc2ccccc2c1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1	J. Med. Chem.	2016.0	CHEMBL3764774	=	=	IC50	nM	96000.0	IC50	uM	96.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Cn1ncccc1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1	J. Med. Chem.	2016.0	CHEMBL3764088	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Cn1cccnc1=O)Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1	J. Med. Chem.	2016.0	CHEMBL3763594	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation	O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21	J. Med. Chem.	2016.0	CHEMBL2107826	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cl.NOCc1ccc(I)cc1	Eur. J. Med. Chem.	2016.0	CHEMBL3763688	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4 (unknown origin)	Cl.NOCc1cccc(Cl)c1	Eur. J. Med. Chem.	2016.0	CHEMBL3765807	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human CYP3A4 expressed in bactosome using DBOMF as substrate	Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3765754	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 expressed in bactosome using DBOMF as substrate	Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3764557	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human CYP3A4 expressed in bactosome using DBOMF as substrate	Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3765426	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 expressed in bactosome using DBOMF as substrate	Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3764143	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4 expressed in bactosome using 7BQ as substrate	Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3765754	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 expressed in bactosome using 7BQ as substrate	Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)n1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3764557	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human CYP3A4 expressed in bactosome using 7BQ as substrate	Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3765426	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 expressed in bactosome using 7BQ as substrate	Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3764143	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis	O=C(O)CN(C1(c2ccc(-c3ccccc3OC(F)(F)F)cc2)CCC1)S(=O)(=O)c1ccc(OC(F)F)cc1	Bioorg. Med. Chem.	2016.0	CHEMBL3765022	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis	CC1(C)CCc2cc(S(=O)(=O)N(CC(=O)O)C3(c4cccc(-c5cc(Cl)cc(Cl)c5)c4)CCC3)ccc2O1	Bioorg. Med. Chem.	2016.0	CHEMBL3764017	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis	CC1(C)CCc2cc(S(=O)(=O)N(CC(=O)O)Cc3cccc(-c4ccccc4)c3)ccc2O1	Bioorg. Med. Chem.	2016.0	CHEMBL3764044	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS analysis	O=C(O)CN(Cc1cccc(-c2ccccc2OC(F)(F)F)c1)S(=O)(=O)c1ccc(OC(F)F)cc1	Bioorg. Med. Chem.	2016.0	CHEMBL3764377	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(C)n1ncnc1-c1cn2c(n1)-c1ccc(O[C@@H](C)C(N)=O)cc1OCC2	J. Med. Chem.	2016.0	CHEMBL3771364	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 by VG metabolism assay	Cc1c2c(nn1-c1nnc(-c3ccc(OC(C)C)c(Cl)c3)s1)CCN(CCC(=O)O)C2	J. Med. Chem.	2016.0	CHEMBL3769933	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 by VR metabolism assay	Cc1c2c(nn1-c1nnc(-c3ccc(OC(C)C)c(Cl)c3)s1)CCN(CCC(=O)O)C2	J. Med. Chem.	2016.0	CHEMBL3769933	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	Cc1nc2c([N+](=O)[O-])c(Cl)c(Cl)cc2n1Cc1ccc(B2OC(=O)CN(C)CC(=O)O2)cc1	J. Med. Chem.	2016.0	CHEMBL3771105	=	=	IC50	nM	28120.0	IC50	uM	28.12
Inhibition of CYP3A4 (unknown origin) using testostrone as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	Cc1nc2c([N+](=O)[O-])c(Cl)c(Cl)cc2n1Cc1ccc(B2OC(=O)CN(C)CC(=O)O2)cc1	J. Med. Chem.	2016.0	CHEMBL3771105	=	=	IC50	nM	21940.0	IC50	uM	21.94
Inhibition of recombinant human CYP3A4 by luminescence -based microplate reader assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2016.0	CHEMBL157101	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1cn(-c2ccc3c(c2)CCc2sc(Cc4ccccc4)nc2N3)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3769671	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1ncn(-c2ccc3c(c2)CCc2cn(Cc4ccccc4)nc2N3)n1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3770314	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Clc1cn(-c2ccc3c(c2)CCc2cn(Cc4ccccc4)nc2N3)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3771055	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	COc1ccc(Cc2nc3c(o2)CCc2cc(-c4ccnc(C)c4)ccc2C3=O)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3769445	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	COc1ccc(Cc2nc3c(n2C)CCc2cc(-n4cnc(C)c4)ccc2C3=O)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3769523	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	COc1ccc(Cc2nc3c(n2C)CCc2cc(-c4ccnc(C)c4)ccc2C3=O)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3769470	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1cn(-c2ccc3c(c2)CCc2ccc(Cc4ccc(F)cc4)nc2C3=O)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3770902	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1cn(-c2ccc3c(c2)NC(=O)c2ccc(Cc4ccccc4)nc2N3)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3769926	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	O=C1Nc2cc(-n3cnc(Cl)c3)ccc2Nc2nc(Cc3ccccc3)ccc21	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3770111	>	>	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1ncn(-c2ccc3c(c2)NC(=O)c2ccc(Cc4ccccc4)nc2N3)n1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3771031	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1cn(-c2cc3c(cc2F)Nc2nc(Cc4ccccc4)ccc2C(=O)N3)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3771295	=	=	IC50	nM	30.0	IC50	uM	0.03
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Cc1cn(-c2ccc3c(c2)NC(=O)c2ccc(C(C)c4ccccc4)nc2N3)cn1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3770105	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	CC(c1ccccc1)c1ccc2c(n1)Nc1ccc(-n3cnc(Cl)c3)cc1NC2=O	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3770272	>	>	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)Nc2cccc(SC)c2)cc1	J. Med. Chem.	2016.0	CHEMBL3667554	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(S(=O)(=O)N2CCC[C@H]2C(=O)Nc2cc(C)cc(C)c2)cc1	J. Med. Chem.	2016.0	CHEMBL3597952	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(CNC(=O)c2cc(-c3cncc(Cl)c3)cnc2-c2ccccn2)nc1OC	J. Med. Chem.	2016.0	CHEMBL3338866	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3774588	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cnccn1	Bioorg. Med. Chem.	2016.0	CHEMBL3774683	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4F)C3C2)nnc1-c1cnccn1	Bioorg. Med. Chem.	2016.0	CHEMBL3774591	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cccnc1	Bioorg. Med. Chem.	2016.0	CHEMBL3775197	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774769	>	>	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cc[nH]c(=O)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774411	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4c(F)cc(F)cc4F)C3C2)nnc1-c1ccn(C)c(=O)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3775350	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccccc4)C3C2)nnc1C1CCOCC1	Bioorg. Med. Chem.	2016.0	CHEMBL3774649	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccccc4)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3775589	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4F)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3775226	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3774588	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cnccn1	Bioorg. Med. Chem.	2016.0	CHEMBL3774683	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	CC(C)Oc1ccccc1N1CCC2CN(CCCSc3nnc(-c4cnccn4)n3C)CC21	Bioorg. Med. Chem.	2016.0	CHEMBL3775598	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4F)C3C2)nnc1-c1cnccn1	Bioorg. Med. Chem.	2016.0	CHEMBL3774591	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	CC(C)Oc1ccccc1N1CCC2CN(CCCSc3nnc(-c4cnccn4)n3C)CC21	Bioorg. Med. Chem.	2016.0	CHEMBL3775598	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cccnc1	Bioorg. Med. Chem.	2016.0	CHEMBL3775197	=	=	IC50	nM	920.0	IC50	uM	0.92
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cc[nH]c(=O)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774411	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774769	>	>	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774769	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4c(F)cc(F)cc4F)C3C2)nnc1-c1ccn(C)c(=O)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3775350	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using 7-benzyloxyquinoline as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccccc4)C3C2)nnc1C1CCOCC1	Bioorg. Med. Chem.	2016.0	CHEMBL3774649	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccccc4)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3775589	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4F)C3C2)n1C	Bioorg. Med. Chem.	2016.0	CHEMBL3775226	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins using diethoxyflourescein as substrate by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1	Bioorg. Med. Chem.	2016.0	CHEMBL3774769	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes preincubated for 10 mins followed by cofactor addition measured every minute for 10 mins by CYPEX assay	Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cnccn1	Bioorg. Med. Chem.	2016.0	CHEMBL3774783	=	=	IC50	nM	980.0	IC50	uM	0.98
Inhibition of human CYP3A4	CCn1c(CCC(=O)Nc2ccc(C)cc2C)nnc1CCC1CCCCC1	ACS Med. Chem. Lett.	2016.0	CHEMBL3775930	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of human CYP3A4	CCn1c(SCC(=O)Nc2cccc3ccccc23)nnc1C1Cc2ccccc2C1	ACS Med. Chem. Lett.	2016.0	CHEMBL3775765	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with substrate for 5 mins followed by NADPH addition measured after 20 mins by HPLC analysis	CC(=O)N1C[C@H](C(=O)Nc2ccc(C)cc2C)[C@@H](c2nnc([C@H]3C[C@@H](CC(C)C)C3)n2C2CC2)C1	ACS Med. Chem. Lett.	2016.0	CHEMBL3774855	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with substrate for 5 mins followed by NADPH addition measured after 20 mins by HPLC analysis	Cc1ccc(NC(=O)[C@H]2C[C@@H](O)C[C@@H]2c2nnc([C@H]3C[C@@H](CC(C)C)C3)n2C2CC2)c(C)c1	ACS Med. Chem. Lett.	2016.0	CHEMBL3775807	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with substrate for 5 mins followed by NADPH addition measured after 20 mins by HPLC analysis	Cc1ccc(NC(=O)CCc2nnc([C@H]3C[C@@H](CC(C)C)C3)n2C2CC2)c(C)c1	ACS Med. Chem. Lett.	2016.0	CHEMBL3775828	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	CN1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12	Bioorg. Med. Chem.	2016.0	CHEMBL3774871	=	=	IC50	nM	7040.0	IC50	nM	7040.0
Inhibition of CYP3A4 (unknown origin)	C[N+]1([O-])CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12	Bioorg. Med. Chem.	2016.0	CHEMBL3774852	=	=	IC50	nM	26139.0	IC50	nM	26139.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CCN1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12	Bioorg. Med. Chem.	2016.0	CHEMBL3775464	=	=	IC50	nM	25988.0	IC50	nM	25988.0
Inhibition of CYP3A4 (unknown origin)	CN(C)CC(=O)N1CCC2(CC1)C(=O)Nc1cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc12	Bioorg. Med. Chem.	2016.0	CHEMBL3775389	=	=	IC50	nM	4778.0	IC50	nM	4778.0
Inhibition of CYP3A4 (unknown origin)	O=C1COc2ccc(CN3c4ccccc4COc4cc(F)ccc43)cc2N1	Bioorg. Med. Chem.	2016.0	CHEMBL3775476	=	=	IC50	nM	5544.0	IC50	nM	5544.0
Inhibition of CYP3A4 (unknown origin)	O=C1COc2ccc(S(=O)(=O)N3c4ccccc4COc4cc(F)ccc43)cc2N1	Bioorg. Med. Chem.	2016.0	CHEMBL3775370	=	=	IC50	nM	6697.0	IC50	nM	6697.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)OC(=S)Nc2ccc(S(=O)(=O)N3c4ccccc4COc4cc(F)ccc43)cc21	Bioorg. Med. Chem.	2016.0	CHEMBL3775473	=	=	IC50	nM	363.0	IC50	nM	363.0
Inhibition of CYP3A4 (unknown origin)	O=c1[nH]c2cc(/C=C3\c4ccccc4COc4cc(F)ccc43)ccc2n1[C@@H]1C[C@@H]2COCCN2C1	Bioorg. Med. Chem.	2016.0	CHEMBL3775798	=	=	IC50	nM	5810.0	IC50	nM	5810.0
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1ccc(Oc2nc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)n2)cc1	ACS Med. Chem. Lett.	2015.0	CHEMBL3775504	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)[C@H]1CC[C@H](Oc2nc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)n2)CC1	ACS Med. Chem. Lett.	2015.0	CHEMBL3775875	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)N1CCC(Oc2nc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)n2)CC1	ACS Med. Chem. Lett.	2015.0	CHEMBL3774827	>	>	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin)	CC[C@@H](C[C@H]1COC(N)=N1)c1ccccc1	ACS Med. Chem. Lett.	2016.0	CHEMBL3684869	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(F)cccc1[C@H]1COC(N)=N1	ACS Med. Chem. Lett.	2016.0	CHEMBL3781694	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) in presence of NADPH	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	J. Med. Chem.	2016.0	CHEMBL494979	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4 (unknown origin) in presence of NADPH	COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	J. Med. Chem.	2016.0	CHEMBL566685	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) in presence of NADPH	COCCOc1cnc2ccc([C@H](C)n3nnc4ccn(-c5cc(C)ns5)c(=O)c43)cc2c1	J. Med. Chem.	2016.0	CHEMBL2029678	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 (unknown origin) in presence of NADPH	COCCOc1cnc2ccc([C@H](C)c3nnc4c(F)cc(-c5cc(C)no5)cn34)cc2c1	J. Med. Chem.	2016.0	CHEMBL3414926	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) in absence of NADPH	COc1ccc2c(OCc3nnc4ccc(-c5cc(F)c(F)c(F)c5)nn34)ccnc2c1	J. Med. Chem.	2016.0	CHEMBL494979	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin) in absence of NADPH	COc1cnc2c(NCc3nnc4ccc(-c5cc(C)ns5)nn34)ccnc2c1	J. Med. Chem.	2016.0	CHEMBL566685	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 (unknown origin) in absence of NADPH	COCCOc1cnc2ccc([C@H](C)n3nnc4ccn(-c5cc(C)ns5)c(=O)c43)cc2c1	J. Med. Chem.	2016.0	CHEMBL2029678	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 (unknown origin) in absence of NADPH	COCCOc1cnc2ccc([C@H](C)c3nnc4c(F)cc(-c5cc(C)no5)cn34)cc2c1	J. Med. Chem.	2016.0	CHEMBL3414926	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	CC1(C)CCC(Nc2ncnc3c2nn2ccccc32)CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3787247	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(CN1C(=O)c2ccccc2C1C(=O)NCCCF)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3785768	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCCNC(=O)C1c2ccccc2C(=O)N1CC(C)c1ccc(Cl)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3786344	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 by HPLC analysis	O=C(NCc1cc(Cl)ccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)[C@H](O)c1ccccc1	MedChemComm	2016.0	CHEMBL3787458	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of human CYP3A4 by HPLC analysis	O=C(NCc1cc(Cl)ccc1-n1cnnn1)[C@@H]1C[C@H]2C[C@H]2N1C(=O)[C@H](O)c1ccccc1	MedChemComm	2016.0	CHEMBL3785556	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 by HPLC analysis	O=C(NCc1cc(Cl)ccc1-n1cnnn1)[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@H](O)c1ccccc1	MedChemComm	2016.0	CHEMBL3785177	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4 by HPLC analysis	CC(C)(C)[C@@H](O)C(=O)N1C[C@@H]2C[C@@H]2[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1	MedChemComm	2016.0	CHEMBL3785476	=	=	IC50	nM	47000.0	IC50	uM	47.0
Inhibition of human CYP3A4 by HPLC analysis	CCCC[C@@H](O)C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1	MedChemComm	2016.0	CHEMBL3786799	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 by HPLC analysis	O=C(NCc1cc(Cl)ccc1-n1cnnn1)[C@@H]1CC=NN1C(=O)[C@H](O)c1ccc(F)cc1	MedChemComm	2016.0	CHEMBL3787587	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 by HPLC analysis	CCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1	MedChemComm	2016.0	CHEMBL3786896	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human CYP3A4 by HPLC analysis	CC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1	MedChemComm	2016.0	CHEMBL3785257	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 by HPLC analysis	CCCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1	MedChemComm	2016.0	CHEMBL3787339	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of human CYP3A4 by HPLC analysis	CCCCC(=O)O[C@@H](C(=O)N1N=CC[C@H]1C(=O)NCc1cc(Cl)ccc1-n1cnnn1)c1ccc(F)cc1	MedChemComm	2016.0	CHEMBL3787686	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis in presence of NADPH	CC1(C)CCC(C)(C)c2cc(C3(c4ccc(/C=C/C(=O)O)cc4)OCCO3)ccc21	J. Med. Chem.	2016.0	CHEMBL3786581	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis in presence of NADPH	CC1(C)CCC(C)(C)c2cc(C3(c4ccc(CCC(=O)O)cc4)SCCS3)ccc21	J. Med. Chem.	2016.0	CHEMBL3787323	=	=	IC50	nM	7500.0	IC50	uM	7.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis in presence of NADPH	Cn1cnc2ncn(Cc3nc(CCc4ccc(Cl)cc4)no3)c(=O)c21	J. Med. Chem.	2016.0	CHEMBL3785736	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP34A (unknown origin)	Cc1ccoc1C(=O)Nc1ccc(N2Cc3c(Cl)cccc3C2=O)c(Cl)c1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3785321	>	>	IC50	nM	30000.0	IC50	uM	30.0
Time-dependent inhibition of CYP3A4 (unknown origin)	Cc1c2cc(-n3ccc(OCc4csc(C(F)(F)F)c4)cc3=O)ccc2nn1C1CC1	Bioorg. Med. Chem.	2016.0	CHEMBL3578244	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)C1CN(Cc2ccc(-c3noc(-c4onc(-c5ccccn5)c4C(F)(F)F)n3)cc2)C1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3794145	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(CCN2CCN(C(=O)Cc3ccc(-n4cnnn4)nc3)CC2)ccc2c1COC2=O	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3692706	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(N2CCC(O)CC2)nc1C(=O)Nc1c(C)cc(C(=O)O)cc1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3686863	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1cc(CN2CCOc3c(F)cccc32)c2oc(N3CCOCC3)cc(=O)c2c1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3799831	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1nc(C(F)(F)F)co1)C1c2ccccc2Oc2ccccc21	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL521982	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1csc(NC(=O)C2c3ccccc3Oc3ccccc32)n1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3797793	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(C)c1csc(NC(=O)C2c3ccccc3Oc3ccccc32)n1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3799685	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)C1CN(Cc2ccc(-c3noc(-c4onc(-c5ccccc5)c4C(F)(F)F)n3)cc2)C1	J. Med. Chem.	2016.0	CHEMBL3794064	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)cc(F)c(F)c3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640275	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)ccc(F)c3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640286	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3c(F)cccc3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640258	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cc(F)c(F)cc3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640255	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3cc(F)ccc3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3261082	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccc(F)cc3)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640263	=	=	IC50	nM	34100.0	IC50	uM	34.1
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640262	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(N)=N[C@@]3(c3ccccc3)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640259	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(Cl)s3)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3798199	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(C#N)s3)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3798544	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3ccc(F)cc3F)C2)nc(C)c1F	J. Med. Chem.	2016.0	CHEMBL3640290	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J. Med. Chem.	2016.0	CHEMBL3800286	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncccc3C#N)C[C@H]2C1=O	J. Med. Chem.	2016.0	CHEMBL2178713	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone and midazolam as substrate preincubated for 30 mins followed substrate addition by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J. Med. Chem.	2016.0	CHEMBL2178718	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin)	CCC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1ccc(C(F)(F)F)cc1)C(=O)N1CCC(Oc2cccc(C(=O)O)n2)CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3797513	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate incubated for 30 mins by fluorescence analysis in presence of NADPH	CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCN(C)CC3)nc21	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3797717	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human recombinant CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate incubated for 30 mins by fluorescence analysis in presence of NADPH	CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCNCC3)nc21	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3799529	<	<	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	Nc1cccnc1C(=O)Nc1ccc(N2C(=O)c3ccccc3C2=O)c(Cl)c1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3798234	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using 1-hydroxymidazolam as substrate	CCc1cnc(Oc2ccc(NC(=O)c3ncccc3N)cc2Cl)nc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3798517	=	=	IC50	nM	21100.0	IC50	uM	21.1
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect cells using BFC as susbtrate incubated for 45 mins by plate reader analysis in presence of NADP+	COc1cnc(C(=O)Nc2cc(F)c(F)c([C@]3(C)C[C@@H](c4c(C)noc4C)SC(N)=N3)c2)cn1	ACS Med. Chem. Lett.	2016.0	CHEMBL3805852	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect cells using benzyloxyresorufin as susbtrate incubated for 45 mins by plate reader analysis in presence of NADP+	COc1cnc(C(=O)Nc2cc(F)c(F)c([C@]3(C)C[C@@H](c4c(C)noc4C)SC(N)=N3)c2)cn1	ACS Med. Chem. Lett.	2016.0	CHEMBL3805852	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC/MS/MS analysis	Nc1noc2ccc(-c3cc(Cl)ccc3Oc3cc(F)c(S(=O)(=O)Nc4ncns4)cc3F)cc12	ACS Med. Chem. Lett.	2016.0	CHEMBL3341983	=	=	IC50	nM	77.0	IC50	uM	0.077
Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC/MS/MS analysis	Nc1noc2ccc(-c3cc(Cl)ccc3Oc3cc(F)c(S(=O)(=O)Nc4ncccn4)cc3F)cc12	ACS Med. Chem. Lett.	2016.0	CHEMBL3804898	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 using BFC as substrate incubated for 30 mins by fluorimetry	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur. J. Med. Chem.	2016.0	CHEMBL157101	=	=	IC50	nM	280.0	IC50	uM	0.28
Inhibition of CYP3A4 (unknown origin)	Cc1cc2ncc3c(n2n1)CN([C@H]1CC[C@H](c2cc(F)c(F)cc2F)[C@@H](N)C1)C3	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3805966	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc2ncc3c(n2n1)CN([C@H]1CO[C@H](c2cc(F)c(F)cc2F)[C@@H](N)C1)C3	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3806029	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	N[C@H]1C[C@@H](N2Cc3cnc4nnc(C5CC5)n4c3C2)CC[C@@H]1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3806041	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	N[C@H]1C[C@@H](N2Cc3nn4cccnc4c3C2)CC[C@@H]1c1cc(F)c(F)cc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3806003	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccn2nc3c(c2n1)CN([C@H]1CO[C@H](c2cc(F)ccc2F)[C@@H](N)C1)C3	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3805400	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccnc2c3c(nn12)CN([C@H]1CO[C@H](c2cc(F)ccc2F)[C@@H](N)C1)C3	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3804950	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	N[C@H]1C[C@@H](N2Cc3nn4nccnc4c3C2)CO[C@@H]1c1cc(F)ccc1F	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3806052	>	>	IC50	nM	50000.0	IC50	uM	50.0
Time dependent inhibition of CYP3A4 in human liver microsomes	Cn1c(=O)n(CC(C)(C)C)c2ccc(N3C[C@@H]4CC[C@H]3CN4C(=O)c3ccon3)nc21	ACS Med. Chem. Lett.	2016.0	CHEMBL3806137	=	=	Ki	nM	540.0	Ki	nM	540.0
Inhibition of CYP3A4 (unknown origin)	CCC[C@H]1N(C(=O)c2cnccc2C(F)(F)F)CCC[C@@]1(Oc1csc(C(F)(F)F)c1)C(=O)N1CCN(c2ccccc2OCCCC(=O)O)CC1	ACS Med. Chem. Lett.	2016.0	CHEMBL3805372	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1cccc(-c2cccc(-c3cn[nH]c3N)c2)c1	J. Med. Chem.	2016.0	CHEMBL3806191	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Nc1cccc(-c2cccc(-c3c(-c4ccc(O)cc4)n[nH]c3N)c2)c1	J. Med. Chem.	2016.0	CHEMBL3806115	=	=	IC50	nM	11300.0	IC50	uM	11.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	Oc1ccc(CNc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1	J. Med. Chem.	2016.0	CHEMBL3805279	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	CCN1CCN(Cc2ccc(NC(=O)CNc3ccc(-c4ccc(NC(C)=O)nc4)cc3)cc2C(F)(F)F)CC1	J. Med. Chem.	2016.0	CHEMBL3805891	=	=	IC50	nM	3200.0	IC50	uM	3.2
Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1ccc(-c2ccc(NCC(=O)Nc3ccc(CN4CCNCC4)c(C(F)(F)F)c3)cc2)cn1	J. Med. Chem.	2016.0	CHEMBL3804921	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4 (unknown origin)	O=C(CNc1ccc(-c2ccc(NC(=O)C3CC3)nc2)cc1)Nc1ccc(CN2CCNCC2)c(C(F)(F)F)c1	J. Med. Chem.	2016.0	CHEMBL3805330	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 (unknown origin)	CCN1CCN(Cc2ccc(NC(=O)CNc3ccc(-c4ccc(NC(=O)C5CC5)nc4)cc3)cc2C(F)(F)F)CC1	J. Med. Chem.	2016.0	CHEMBL3805771	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(Cc2ccc(NC(=O)CNc3ccc(-c4ccc(NC(=O)C5CC5)nc4)cc3F)cc2C(F)(F)F)CC1	J. Med. Chem.	2016.0	CHEMBL3806189	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins by LC/MS/MS analysis	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	J. Med. Chem.	2016.0	CHEMBL64391	=	=	IC50	nM	50.4	IC50	nM	50.4
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins by LC/MS/MS analysis	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(C)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	J. Med. Chem.	2016.0	CHEMBL3809786	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cccc(C(=O)Nc2ccc(NC(=O)c3ccco3)cc2)c1	ACS Med. Chem. Lett.	2016.0	CHEMBL3808895	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccn(-c2cn(Cc3cccc(C(F)(F)F)c3)cn2)c(=O)c1)c1cscn1	ACS Med. Chem. Lett.	2016.0	CHEMBL3809896	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 (unknown origin)	CC(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1	ACS Med. Chem. Lett.	2016.0	CHEMBL3810245	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccn(-c2c[nH]c(C(O)c3cccc(C(F)(F)F)c3)n2)c(=O)c1)c1cscn1	ACS Med. Chem. Lett.	2016.0	CHEMBL3809890	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(O)(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1	ACS Med. Chem. Lett.	2016.0	CHEMBL3808805	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cccc(C(C)(O)c2nc(-n3ccc(NC(=O)c4cscn4)cc3=O)c[nH]2)c1	ACS Med. Chem. Lett.	2016.0	CHEMBL3810414	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(C(C)(O)c2nc(-n3ccc(NC(=O)c4cscn4)cc3=O)c[nH]2)cc1	ACS Med. Chem. Lett.	2016.0	CHEMBL3809367	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(C)CC(O)(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1	ACS Med. Chem. Lett.	2016.0	CHEMBL3808401	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(C)OC(c1cccc(C(F)(F)F)c1)c1nc(-n2ccc(NC(=O)c3cscn3)cc2=O)c[nH]1	ACS Med. Chem. Lett.	2016.0	CHEMBL3810042	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cn1cc(-c2cc3cnc(Nc4ccc(-c5cncn5C)cc4Cl)cc3n2C(=O)OC(C)(C)C)cn1	J. Med. Chem.	2016.0	CHEMBL3109945	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	Cc1sc2ncnc(N3CCC(C(=O)Nc4ccc(S(N)(=O)=O)cc4)CC3)c2c1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL1357034	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12	J. Med. Chem.	2016.0	CHEMBL3814877	=	=	IC50	nM	210.0	IC50	uM	0.21
Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)Cc1ccccc1	J. Med. Chem.	2016.0	CHEMBL3814479	=	=	IC50	nM	520.0	IC50	uM	0.52
Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)CC1CCCCC1	J. Med. Chem.	2016.0	CHEMBL3814345	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	NCCCCCC(=O)NCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL3814729	=	=	IC50	nM	1000000.0	IC50	uM	1000.0
Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	CC(C)(C)OC(=O)NCCCCCC(=O)NCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL3814075	=	=	IC50	nM	75000.0	IC50	uM	75.0
Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	NCCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL1256004	=	=	IC50	nM	5000000.0	IC50	uM	5000.0
Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in presence of rat cytochrome P450 reductase	c1ccncc1	J. Med. Chem.	2016.0	CHEMBL266158	=	=	IC50	nM	4000000.0	IC50	uM	4000.0
Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12	J. Med. Chem.	2016.0	CHEMBL3814877	=	=	Kd	nM	500.0	Kd	uM	0.5
Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)Cc1ccccc1	J. Med. Chem.	2016.0	CHEMBL3814479	=	=	Kd	nM	900.0	Kd	uM	0.9
Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	CC(C)(C)OC(=O)N[C@H](CSCCC(=O)NCc1cccnc1)CC1CCCCC1	J. Med. Chem.	2016.0	CHEMBL3814345	=	=	Kd	nM	10000.0	Kd	uM	10.0
Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	NCCCCCC(=O)NCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL3814729	=	=	Kd	nM	10000.0	Kd	uM	10.0
Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	CC(C)(C)OC(=O)NCCCCCC(=O)NCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL3814075	=	=	Kd	nM	105000.0	Kd	uM	105.0
Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	NCCc1cccnc1	J. Med. Chem.	2016.0	CHEMBL1256004	=	=	Kd	nM	2500000.0	Kd	uM	2500.0
Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method	c1ccncc1	J. Med. Chem.	2016.0	CHEMBL266158	=	=	Kd	nM	4500000.0	Kd	uM	4500.0
Inhibition of recombinant CYP3A4 (unknown origin)	CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1	J. Med. Chem.	2016.0	CHEMBL3814206	=	=	IC50	nM	29430.0	IC50	nM	29430.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1	J. Med. Chem.	2016.0	CHEMBL3814206	=	=	IC50	nM	6600.0	IC50	nM	6600.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CCOC1(c2ccccc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3819185	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CC1=CSC(OCC(F)(F)F)(c2ccccc2)c2noc(=O)n21	J. Med. Chem.	2016.0	CHEMBL3819606	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CCOC1(c2ccc(OC)cc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3818643	=	=	IC50	nM	15500.0	IC50	uM	15.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CCOC1(c2ccc(OC)cc2)Sc2ccccc2-n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3818560	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	COc1ccc(C2(OCC(F)(F)F)Sc3ccccc3-n3c2noc3=O)cc1	J. Med. Chem.	2016.0	CHEMBL3819349	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2016.0	CHEMBL157101	=	=	IC50	nM	4.0	IC50	uM	0.004
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CCOC1(c2ccc(Br)cc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL211204	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CC1=CSC(OCC(F)(F)F)(c2ccc(Br)cc2)c2noc(=O)n21	J. Med. Chem.	2016.0	CHEMBL3408523	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	CCOC1(c2ccc(Br)cc2)Sc2ccccc2-n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3408526	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 4 mins by LC-MS analysis	O=c1onc2n1-c1ccccc1SC2(OCC(F)(F)F)c1ccc(Br)cc1	J. Med. Chem.	2016.0	CHEMBL3408529	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccccc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3819185	=	=	IC50	nM	19100.0	IC50	uM	19.1
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CC1=CSC(OCC(F)(F)F)(c2ccccc2)c2noc(=O)n21	J. Med. Chem.	2016.0	CHEMBL3819606	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccc(OC)cc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3818643	=	=	IC50	nM	19400.0	IC50	uM	19.4
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccccc2)Sc2ccccc2-n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3819226	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccc(OC)cc2)Sc2ccccc2-n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3818560	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	COc1ccc(C2(OCC(F)(F)F)Sc3ccccc3-n3c2noc3=O)cc1	J. Med. Chem.	2016.0	CHEMBL3819349	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2016.0	CHEMBL157101	=	=	IC50	nM	1.0	IC50	uM	0.001
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccc(Br)cc2)SC=C(C)n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL211204	=	=	IC50	nM	19200.0	IC50	uM	19.2
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CC1=CSC(OCC(F)(F)F)(c2ccc(Br)cc2)c2noc(=O)n21	J. Med. Chem.	2016.0	CHEMBL3408523	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	CCOC1(c2ccc(Br)cc2)Sc2ccccc2-n2c1noc2=O	J. Med. Chem.	2016.0	CHEMBL3408526	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 5 mins by LC-MS analysis	O=c1onc2n1-c1ccccc1SC2(OCC(F)(F)F)c1ccc(Br)cc1	J. Med. Chem.	2016.0	CHEMBL3408529	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(NC4CCCC4)nc23)ccc1C(=O)NC1CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3819637	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Oc4ccccc4)nc23)ccc1C(=O)NC1CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3819210	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Oc4cccc(F)c4F)nc23)ccc1C(=O)NC1CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3818646	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Nc4cccc(F)c4)nc23)ccc1C(=O)NC1CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3819019	=	=	IC50	nM	470.0	IC50	uM	0.47
Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cnn3c(NCC4CCOCC4)nc(Nc4ccccc4F)nc23)ccc1C(=O)NC1CC1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3819328	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of CYP3A4 (unknown origin)	CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)CC1	ACS Med. Chem. Lett.	2016.0	CHEMBL3819521	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 (unknown origin)	CN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1	ACS Med. Chem. Lett.	2016.0	CHEMBL3819512	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 (unknown origin)	CCN1CCC(S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(F)c3Cl)c2O)CC1	ACS Med. Chem. Lett.	2016.0	CHEMBL3818331	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 (unknown origin)	CN1CC[C@H](S(=O)(=O)c2c(Cl)ccc(NC(=O)Nc3cccc(Cl)c3Cl)c2O)C1	ACS Med. Chem. Lett.	2016.0	CHEMBL3818179	<	>	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1-hydroxylation/testosterone 6beta-hydroxylation by LC-MS/MS analysis	Cc1sc2ccccc2c1[C@@H]1C=CN=CN1	MedChemComm	2016.0	CHEMBL3823832	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1-hydroxylation/testosterone 6beta-hydroxylation by LC-MS/MS analysis	Cc1cc(C2C=CN=CN2)c(C)s1.Cl	MedChemComm	2016.0	CHEMBL3823354	=	=	IC50	nM	19800.0	IC50	uM	19.8
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH using midazolam as substrate measured within 2.5 mins by LC-MS/MS analysis	COc1cc(-c2cn(C)c(=O)c3cnccc23)cc(OC)c1CN(C)C	J. Med. Chem.	2016.0	CHEMBL3823478	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH using midazolam as substrate measured within 2.5 mins by LC-MS/MS analysis	COc1cc(-c2cn(C)c(=O)c3cnccc23)c(OC)cc1CN(C)C	J. Med. Chem.	2016.0	CHEMBL3823101	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay	COc1cccc(-c2nc(OC)c3ccccc3n2)c1	J. Med. Chem.	2016.0	CHEMBL3822473	=	=	IC50	nM	12860.0	IC50	uM	12.86
Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay	COc1cccc(-c2nc(SC)c3ccccc3n2)c1	J. Med. Chem.	2016.0	CHEMBL3822867	=	=	IC50	nM	22940.0	IC50	uM	22.94
Inhibition of recombinant human CYP3A4 by P450-Glo luminescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J. Med. Chem.	2016.0	CHEMBL157101	=	=	IC50	nM	240.0	IC50	uM	0.24
Inhibition of CYP3A4 (unknown origin)	COc1cc(N2CCN(C(C)=O)CC2)ccc1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3823297	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCNCC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3824296	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1	J. Med. Chem.	2016.0	CHEMBL3823914	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(CCO)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3824323	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CNC(=O)CN1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1	J. Med. Chem.	2016.0	CHEMBL3823962	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(CC(=O)N(C)C)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3823095	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)CO)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3822587	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COCC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1	J. Med. Chem.	2016.0	CHEMBL3822651	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)[C@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3822947	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)[C@@H](C)O)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3823030	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)CN)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3823154	=	=	IC50	nM	500.0	IC50	uM	0.5
Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)[C@H](C)N)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3824103	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin)	Cc1nn(C2CCN(C(=O)[C@@H](C)N)CC2)c(C)c1Nc1ncc(Cl)c(-c2cnn3ccccc23)n1	J. Med. Chem.	2016.0	CHEMBL3822644	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	CNCC(=O)N1CCC(n2nc(C)c(Nc3ncc(Cl)c(-c4cnn5ccccc45)n3)c2C)CC1	J. Med. Chem.	2016.0	CHEMBL3822976	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nc2ccccc2nc1SCC(=O)NC(=O)Nc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3828067	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1ccccc1NC(=O)NC(=O)CSc1nc2ccccc2nc1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3828353	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1ccc(NC(=O)NC(=O)CSc2nc3ccccc3nc2C)cc1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3828283	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1ccc(C)c(NC(=O)NC(=O)CSc2nc3ccccc3nc2C)c1	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3827067	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nc2ccccc2nc1SCC(=O)NC(=O)Nc1cccc(F)c1C	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3828651	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(CSc1nc2ccccc2nc1C(F)(F)F)NC(=O)Nc1ccccc1Cl	Bioorg. Med. Chem. Lett.	2016.0	CHEMBL3828537	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin)	COC(=O)N(CC(=O)O)Cc1cc(OCc2nc(-c3ccc(Cl)cc3)oc2C)ccc1F	ACS Med. Chem. Lett.	2016.0	CHEMBL3828718	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human TC5 cells	COC(=O)N(CC(=O)O)Cc1cc(OCc2nc(-c3ccc(Cl)cc3)oc2C)ccc1F	ACS Med. Chem. Lett.	2016.0	CHEMBL3828718	>	>	IC50	nM	150000.0	IC50	uM	150.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ccc(F)cn2)ccc1Oc1ccc(CO)c(Cl)c1	MedChemComm	2016.0	CHEMBL3688197	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(Oc2ccc(S(=O)(=O)Nc3ccc(F)cn3)cc2C#N)cc1Cl	MedChemComm	2016.0	CHEMBL3683287	=	=	IC50	nM	17500.0	IC50	uM	17.5
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1ccc(C(F)(F)F)nc1)c1ccccc1C(F)(F)F	MedChemComm	2016.0	CHEMBL3924161	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cncc(C(F)(F)F)c1)c1ccccc1C(F)(F)F	MedChemComm	2016.0	CHEMBL3929544	=	=	IC50	nM	620.0	IC50	uM	0.62
Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3935692	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3913607	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccccc3)C2)n1C	J Med Chem	2016.0	CHEMBL3983937	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccc(F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3963783	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3F)C2)n1C	J Med Chem	2016.0	CHEMBL3901587	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1	J Med Chem	2016.0	CHEMBL3899125	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccc(C(N)=O)c1	J Med Chem	2016.0	CHEMBL3970323	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(CC(N)=O)cc1	J Med Chem	2016.0	CHEMBL3981856	>	>	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1	J Med Chem	2016.0	CHEMBL3941818	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3F)C2)nnc1-c1cccnc1	J Med Chem	2016.0	CHEMBL3949662	>	>	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	CC(=O)NC1CCC(c2nnc(SCCCN3CC[C@]4(C[C@@H]4c4ccc(C(F)(F)F)cc4)C3)n2C)CC1	J Med Chem	2016.0	CHEMBL3912801	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCOCC1	J Med Chem	2016.0	CHEMBL3948167	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cc1ncccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3968272	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccnc1C(F)(F)F	J Med Chem	2016.0	CHEMBL3946313	>	>	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)nc1	J Med Chem	2016.0	CHEMBL3950254	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cc1nc(C(N)=O)ccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3941520	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cc1nc(C(=O)O)ccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C	J Med Chem	2016.0	CHEMBL3964649	>	>	IC50	nM	38000.0	IC50	uM	38.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1=CCC(=O)N=C1	J Med Chem	2016.0	CHEMBL3964512	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(=O)n(C)c1	J Med Chem	2016.0	CHEMBL3922838	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccn(C)c(=O)c1	J Med Chem	2016.0	CHEMBL3894853	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCNC(=O)C1	J Med Chem	2016.0	CHEMBL3913849	>	>	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of human CYP3A4 expressed in microsomes using DEF as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCN(C(N)=O)CC1	J Med Chem	2016.0	CHEMBL3963243	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human CYP3A4 expressed in microsomes using 7BQ as substrate after 10 mins by P450 cypex assay	Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCN(C(N)=O)CC1	J Med Chem	2016.0	CHEMBL3963243	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Nc1ccc(F)cc1)N1N=C(c2ccncc2)CC1c1ccc(F)cc1	J Med Chem	2016.0	CHEMBL3892579	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	O=C(Nc1ccc(F)cc1)N1N=C(c2ccncc2)CC1c1ccc(F)cc1	J Med Chem	2016.0	CHEMBL3892579	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1CN(c2ccc(CO)c(S(C)(=O)=O)c2)CCN1c1ncc(CO)c(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3814206	=	=	IC50	nM	29450.0	IC50	nM	29450.0
Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1c2nn(-c3ccc(CO)c(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3978980	=	=	IC50	nM	7700.0	IC50	nM	7700.0
Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ncc(CO)c(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3932169	=	=	IC50	nM	3050.0	IC50	nM	3050.0
Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1nccc(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3959681	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1ccnc(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3933543	=	=	IC50	nM	12800.0	IC50	nM	12800.0
Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H]1c2nn(-c3cccc(S(C)(=O)=O)c3)cc2CN1c1cc(C(F)(F)F)ncn1	Bioorg Med Chem Lett	2016.0	CHEMBL3960195	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C(F)(F)F)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3985591	=	=	IC50	nM	21100.0	IC50	nM	21100.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)nc(C)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3914727	=	=	IC50	nM	12920.0	IC50	nM	12920.0
Inhibition of CYP3A4 (unknown origin)	COc1ncc(F)c(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3972392	=	=	IC50	nM	15400.0	IC50	nM	15400.0
Inhibition of CYP3A4 (unknown origin)	COc1ncnc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)c1F	Bioorg Med Chem Lett	2016.0	CHEMBL3905741	=	=	IC50	nM	2500.0	IC50	nM	2500.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)cc(C)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3976470	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)C)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL3913348	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(N2Cc3cn(-c4cccc(S(C)(=O)=O)c4)nc3[C@H]2C(C)(C)C)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL3940521	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 in human liver microsomes after 5 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1	ACS Med Chem Lett	2016.0	CHEMBL3984425	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(C)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3975000	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(OC)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3933716	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccccc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3891198	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(N3CCOCC3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3913765	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(Cl)ccc3c(=O)n2C)nc1	Bioorg Med Chem Lett	2016.0	CHEMBL3941754	=	=	IC50	nM	7400.0	IC50	uM	7.4
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(OC(F)(F)F)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3904766	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccccc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3932777	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3895821	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1ccc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3923823	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3984607	=	=	IC50	nM	5800.0	IC50	uM	5.8
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3914795	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3949480	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3939202	=	=	IC50	nM	5400.0	IC50	uM	5.4
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3957699	=	=	IC50	nM	9900.0	IC50	uM	9.9
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3930206	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1cnc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)nc1	Bioorg Med Chem Lett	2016.0	CHEMBL3976743	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-n3cccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3905160	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(Oc3ccc(Cl)cc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3948762	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(Oc3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3905463	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(N)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3973340	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as 6-beta-hydroxytestosterone metabolite formation using testosterone as substrate incubated for 30 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(Cl)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3976702	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(Cl)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3976702	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(C)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3975000	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(OC)ccc3c(=O)n2C)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3933716	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccccc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3891198	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(N3CCOCC3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3913765	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1ccc(CCNc2nc3cc(Cl)ccc3c(=O)n2C)nc1	Bioorg Med Chem Lett	2016.0	CHEMBL3941754	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(OC(F)(F)F)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3904766	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccccc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3932777	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3895821	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1ccc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3923823	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3984607	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3914795	=	=	IC50	nM	41000.0	IC50	uM	41.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3949480	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3939202	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncc(F)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3957699	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ncc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3930206	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	COc1cnc(-c2ccc(CCNc3nc4cc(Cl)ccc4c(=O)n3C)cc2)nc1	Bioorg Med Chem Lett	2016.0	CHEMBL3976743	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-n3cccn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3905160	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-n3cc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3977242	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(Oc3ccc(Cl)cc3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3948762	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(Oc3ccc(Cl)cn3)cc2)nc2cc(Cl)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3905463	=	=	IC50	nM	9800.0	IC50	uM	9.8
Inhibition of CYP3A4 in human liver microsomes assessed as 1'-hydroxymidazolam metabolite formation using midazolam as substrate incubated for 10 mins by HPLC-MS method	Cn1c(NCCc2ccc(-c3ccc(F)cc3)cc2)nc2cc(N)ccc2c1=O	Bioorg Med Chem Lett	2016.0	CHEMBL3973340	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate in presence of NADPH by LC/MS/MS analysis	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2	J Med Chem	2016.0	CHEMBL2064666	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate in presence of NADPH by LC/MS/MS analysis	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC[C@H](N1CCN(C)CC1)C2	J Med Chem	2016.0	CHEMBL3936443	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate in presence of NADPH by LC/MS/MS analysis	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CCC[C@@H](N1CCN(C)CC1)C2	J Med Chem	2016.0	CHEMBL3980825	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate in presence of NADPH by LC/MS/MS analysis	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@@H](N2CCN(CCO)CC2)C3)ncc1Cl	J Med Chem	2016.0	CHEMBL3972653	>	>	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate in presence of NADPH by LC/MS/MS analysis	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3c(c2OC)CCC[C@H](N2CCN(CCO)CC2)C3)ncc1Cl	J Med Chem	2016.0	CHEMBL3951811	>	>	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by HPLC analysis	C[C@@H]1c2ncn(-c3ccc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2016.0	CHEMBL3895947	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation by LC/MS/MS analysis	C[C@@H]1c2ncn(-c3ccc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2016.0	CHEMBL3895947	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 1-OH-midazolam formation by LC/MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2016.0	CHEMBL157101	=	=	IC50	nM	9.1	IC50	nM	9.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation by LC/MS/MS analysis	C[C@@H]1c2ncn(-c3ccc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2016.0	CHEMBL3895947	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as reduction in 4-OH-midazolam formation by LC/MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2016.0	CHEMBL157101	=	=	IC50	nM	7.4	IC50	nM	7.4
Inhibition of CYP3A4 (unknown origin)	Fc1ccc(N2CCN(Cc3ccn4c(CC5CC5)nnc4c3C(F)(F)F)CC2)c(F)c1	J Med Chem	2016.0	CHEMBL3926416	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O	J Med Chem	2016.0	CHEMBL3900554	=	=	IC50	nM	8500.0	IC50	uM	8.5
Inhibition of CYP3A4 (unknown origin)	C=CC(=O)N1CCCC[C@@H](n2c(NC(=O)c3cccc(C(F)(F)F)c3)nc3cccc(C)c32)C1	J Med Chem	2016.0	CHEMBL3972316	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 (unknown origin)	Cc1cccc2nc(NC(=O)c3cccc(C(F)(F)F)c3)n([C@@H]3CCCCN(C(=O)/C=C/CN(C)C)C3)c12	J Med Chem	2016.0	CHEMBL3951434	=	=	IC50	nM	22200.0	IC50	uM	22.2
Inhibition of CYP3A4 (unknown origin)	Cc1cccc2nc(NC(=O)c3ccnc(C(F)(F)F)c3)n([C@@H]3CCCCN(C(=O)/C=C/CN(C)C)C3)c12	J Med Chem	2016.0	CHEMBL3939913	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)Nc2nc3cccc(C)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1	J Med Chem	2016.0	CHEMBL3960167	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1	J Med Chem	2016.0	CHEMBL3787344	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4	CC(C)c1cc(CNC(=O)c2ccc(Cl)c(OC3CCN(C)CC3)c2)on1	Bioorg Med Chem Lett	2016.0	CHEMBL3933906	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	COc1ccc(C(=O)NCc2cc(C(C)C)no2)cc1OC1CCN(C)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3304438	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in pooled human hepatic microsomes using testosterone substrate in presence of NADPH	Cc1nnc(C)n1-c1ccc(O[C@H]2c3cc(Cl)cc(Cl)c3C[C@@H]2N2CC[C@@H](O)C2)c(F)c1	J Med Chem	2016.0	CHEMBL3949677	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in pooled human hepatic microsomes using testosterone substrate in presence of NADPH	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2016.0	CHEMBL157101	=	=	IC50	nM	28.5	IC50	uM	0.0285
Inhibition of CYP3A4 (unknown origin)	Cc1nc2ccc(Cl)cc2c(-c2ccccc2)c1C(=O)O	Bioorg Med Chem Lett	2016.0	CHEMBL1738980	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)c1nc2ccc(Cl)cc2c(-c2ccccc2)c1C(=O)O	Bioorg Med Chem Lett	2016.0	CHEMBL3947458	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1c(N2CCCCC2)nc2ccc(Cl)cc2c1-c1ccccc1	Bioorg Med Chem Lett	2016.0	CHEMBL3941588	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1c(N2CCCCC2)nc2c(Cl)cc(Cl)cc2c1-c1ccccc1	Bioorg Med Chem Lett	2016.0	CHEMBL3971182	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Cl)cc2c(-c3ccccc3)c(C(=O)O)c(N3CCCCC3)nc12	Bioorg Med Chem Lett	2016.0	CHEMBL3950316	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 (unknown origin)	CC(C)c1cccc(-c2c(C(=O)O)c(N(C)C)nc3ccc(Cl)cc23)c1	Bioorg Med Chem Lett	2016.0	CHEMBL3979347	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Clc1ccc2nc(N3CCCCC3)c(-c3nnn[nH]3)c(-c3ccccc3)c2c1	Bioorg Med Chem Lett	2016.0	CHEMBL3959018	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=c1[nH]nc(-c2c(N3CCCCC3)nc3ccc(Cl)cc3c2-c2ccccc2)o1	Bioorg Med Chem Lett	2016.0	CHEMBL3889982	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	S=c1[nH]nc(-c2c(N3CCCCC3)nc3ccc(Cl)cc3c2-c2ccccc2)o1	Bioorg Med Chem Lett	2016.0	CHEMBL3970105	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as suppression of 6beta-hydroxytestosterone formation after 30 mins by LC-MS/MS analysis	CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](NC(=O)[C@H](CC1CCCCC1)NS(=O)(=O)N[C@@H](CCCCN)C(=O)O)C2.Cl	J Med Chem	2016.0	CHEMBL3982647	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as suppression of 1'-hydroxymidazolam formation after 10 mins by LC-MS/MS analysis	CC1(C)[C@@H]2CC[C@@]1(C)[C@@H](NC(=O)[C@H](CC1CCCCC1)NS(=O)(=O)N[C@@H](CCCCN)C(=O)O)C2.Cl	J Med Chem	2016.0	CHEMBL3982647	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis	C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2n[nH]c(=O)o2)CC1(F)F	ACS Med Chem Lett	2016.0	CHEMBL3940415	=	=	IC50	nM	21800.0	IC50	uM	21.8
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis	C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2nnc(N)o2)CC1(F)F	ACS Med Chem Lett	2016.0	CHEMBL3929336	=	=	IC50	nM	9900.0	IC50	uM	9.9
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis	C[C@H]1[C@H](/C=C/c2ccc(-c3cccc(F)c3)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2n[nH]c(=O)o2)CC1(F)F	ACS Med Chem Lett	2016.0	CHEMBL3968866	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by rapidfire/MS analysis	C[C@H]1[C@H](/C=C/c2ccc(-c3ccccc3C#N)cn2)[C@@H]2[C@@H](C)OC(=O)[C@]2(c2cc[nH]n2)CC1(F)F	ACS Med Chem Lett	2016.0	CHEMBL3939323	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4 (unknown origin) expressed in Escherichia coli co-expressing human NADPH reductase using both 7-benzyloxyquinolone and diethoxyfluorescein substrate in presence of NADPH regenerating system incubated for 10 mins by spectrofluorometry	CN1CCC(C)(C2CC(=O)N(CCOc3ccc(F)c(C#N)c3)C2)CC1	J Med Chem	2016.0	CHEMBL3897162	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) expressed in Escherichia coli co-expressing human NADPH reductase using both 7-benzyloxyquinolone and diethoxyfluorescein substrate in presence of NADPH regenerating system incubated for 10 mins by spectrofluorometry	CC1([C@@H]2CC(=O)N(CCOc3ccc(F)c(C#N)c3)C2)CCS(=O)(=O)CC1	J Med Chem	2016.0	CHEMBL3922315	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) expressed in Escherichia coli co-expressing human NADPH reductase using both 7-benzyloxyquinolone and diethoxyfluorescein substrate in presence of NADPH regenerating system incubated for 10 mins by spectrofluorometry	CC1([C@@H]2CC(=O)N(CCOc3ccc(F)c(F)c3)C2)CCS(=O)(=O)CC1	J Med Chem	2016.0	CHEMBL3957888	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) expressed in Escherichia coli co-expressing human NADPH reductase using both 7-benzyloxyquinolone and diethoxyfluorescein substrate in presence of NADPH regenerating system incubated for 10 mins by spectrofluorometry	CC1(C2CC(=O)N(CCOc3ccc(F)c(C#N)c3)C2)CCNCC1.Cl	J Med Chem	2016.0	CHEMBL3899527	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3C3CC3)N(C(=O)[C@@H](NC(=O)O[C@@H]3C[C@@H]4C[C@@H]4C3)C(C)(C)C)C2)c2cc(Cl)ccc12	J Med Chem	2016.0	CHEMBL3941014	=	=	EC50	nM	2000.0	EC50	uM	2.0
Inhibition of CYP3A4 (unknown origin)	CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O	J Med Chem	2016.0	CHEMBL3976121	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC(C4CC4)C4CC4)nc(Cl)nc31)[C@H](O)[C@@H]2O	J Med Chem	2016.0	CHEMBL3970041	>=	>=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1c2ccncc2N(Cc2ccccc2)C[C@@H](C)N1C(=O)NCc1ccccc1	J Med Chem	2016.0	CHEMBL3895005	=	=	IC50	nM	23.0	IC50	nM	23.0
Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2ccc(-c3cn(CC(=O)Nc4cccc(Cl)c4Cl)nn3)cc2F)cn1	ACS Med Chem Lett	2016.0	CHEMBL3903475	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1nccn1-c1ccc(-c2cn(CC(=O)Nc3cccc(Cl)c3Cl)nn2)cc1	ACS Med Chem Lett	2016.0	CHEMBL3905835	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin)	Cc1nccn1-c1ccc(-c2cn(CC(=O)Nc3cccc(Cl)c3Cl)nn2)cn1	ACS Med Chem Lett	2016.0	CHEMBL3965469	=	=	IC50	nM	43000.0	IC50	uM	43.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cc1)c1ccc2nccn2c1	J Med Chem	2016.0	CHEMBL2420629	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1	J Med Chem	2016.0	CHEMBL2391568	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2cccc(C(F)(F)F)c2)cc1)c1cnc2[nH]ncc2c1	J Med Chem	2016.0	CHEMBL3260358	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1	J Med Chem	2016.0	CHEMBL3127521	=	=	IC50	nM	90.0	IC50	uM	0.09
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	J Med Chem	2016.0	CHEMBL2419515	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	J Med Chem	2016.0	CHEMBL3394738	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	N#CN/C(=N\CCCCCCOc1ccc(Cl)cc1)Nc1ccncc1	J Med Chem	2016.0	CHEMBL17289	=	=	IC50	nM	220.0	IC50	uM	0.22
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1	J Med Chem	2016.0	CHEMBL566757	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2cc(F)cc(F)c2)cc1)c1ccc2nccn2c1	J Med Chem	2016.0	CHEMBL2420629	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1cccnc1)Nc1ccc(S(=O)(=O)N2CC3CCC(C2)O3)cc1	J Med Chem	2016.0	CHEMBL2391568	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	O=C(NCc1ccc(S(=O)(=O)c2cccc(C(F)(F)F)c2)cc1)c1cnc2[nH]ncc2c1	J Med Chem	2016.0	CHEMBL3260358	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)[C@H]1C[C@@H]1c1cccnc1	J Med Chem	2016.0	CHEMBL3127521	=	=	IC50	nM	680.0	IC50	uM	0.68
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	Cc1ccc(S(=O)(=O)c2ccc(CNC(=O)N3Cc4ccncc4C3)cc2)cn1	J Med Chem	2016.0	CHEMBL2419515	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CC(C)n1cc(S(=O)(=O)c2ccc(CNC(=O)c3cc4ccncc4o3)nc2)cn1	J Med Chem	2016.0	CHEMBL3394738	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	N#CN/C(=N\CCCCCCOc1ccc(Cl)cc1)Nc1ccncc1	J Med Chem	2016.0	CHEMBL17289	=	=	IC50	nM	320.0	IC50	uM	0.32
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	O=C(/C=C/c1cccnc1)NCCCCC1CCN(C(=O)c2ccccc2)CC1	J Med Chem	2016.0	CHEMBL566757	=	=	IC50	nM	540.0	IC50	uM	0.54
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	CC1(OC(=O)N2CCC3(CC2)C[C@@H]3CNC(=O)N2Cc3ccncc3C2)COC1	J Med Chem	2016.0	CHEMBL3916438	>	>	IC50	nM	10000.0	IC50	uM	10.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CC1(OC(=O)N2CCC3(CC2)C[C@@H]3CNC(=O)N2Cc3ccncc3C2)COC1	J Med Chem	2016.0	CHEMBL3916438	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3983734	=	=	IC50	nM	158.0	IC50	nM	158.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CCS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3913908	=	=	IC50	nM	162.0	IC50	nM	162.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CC(C)S(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3894912	=	=	IC50	nM	198.0	IC50	nM	198.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(C1CC1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3922888	=	=	IC50	nM	185.0	IC50	nM	185.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	COCCS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3964421	=	=	IC50	nM	185.0	IC50	nM	185.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(C1CCOCC1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3931836	=	=	IC50	nM	226.0	IC50	nM	226.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1)C(F)(F)F	Bioorg Med Chem Lett	2016.0	CHEMBL3938615	=	=	IC50	nM	336.0	IC50	nM	336.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(C(F)F)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3968178	=	=	IC50	nM	99.0	IC50	nM	99.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	N#CCS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3952032	=	=	IC50	nM	153.0	IC50	nM	153.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CS(=O)(=O)CS(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3980889	=	=	IC50	nM	151.0	IC50	nM	151.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(c1cccs1)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3960724	=	=	IC50	nM	87.0	IC50	nM	87.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	Cn1ccnc1S(=O)(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3891718	=	=	IC50	nM	145.0	IC50	nM	145.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL75	=	=	IC50	nM	136.0	IC50	nM	136.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL157101	=	=	IC50	nM	146.0	IC50	nM	146.0
Inhibition of human Cyp3A4 using testosterone as substrate by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL157101	=	=	IC50	nM	133.0	IC50	nM	133.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CCCOc1ccc(-c2cc(OC(F)(F)F)ccc2Cl)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3968947	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2cc(OC(F)(F)F)ccc2Cl)cc(C)c1OCCCC(=O)O	Bioorg Med Chem Lett	2016.0	CHEMBL3909872	=	=	IC50	nM	3280.0	IC50	nM	3280.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CCc1cc2cc(-c3cc(OC(F)(F)F)ccc3F)ccc2o1	Bioorg Med Chem Lett	2016.0	CHEMBL3896657	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	NCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3966450	=	=	IC50	nM	15100.0	IC50	uM	15.1
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	CNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3904067	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	CCNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3974964	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@H]1CCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3892856	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@@H]1CCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3911925	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@H]1CCNC1	Bioorg Med Chem Lett	2016.0	CHEMBL3981876	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@@H]1CCNC1	Bioorg Med Chem Lett	2016.0	CHEMBL3902914	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	CN(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3928270	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CCN1CCNCC1	Bioorg Med Chem Lett	2016.0	CHEMBL3903590	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	CNC(C)(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3920870	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CC1=NCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3916230	=	=	IC50	nM	13200.0	IC50	uM	13.2
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	CN(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3928270	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CCN1CCNCC1	Bioorg Med Chem Lett	2016.0	CHEMBL3903590	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	CNC(C)(C)CCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3920870	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)CC1=NCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3916230	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	NCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3966450	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	CNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3904067	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	CCNCCS(=O)(=O)CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12	Bioorg Med Chem Lett	2016.0	CHEMBL3974964	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@H]1CCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3892856	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)C[C@@H]1CCCN1	Bioorg Med Chem Lett	2016.0	CHEMBL3911925	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@H]1CCNC1	Bioorg Med Chem Lett	2016.0	CHEMBL3981876	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins after 30 secs by LC/MS/MS analysis	O=S(=O)(CC[C@@H]1OCC[C@@]2(S(=O)(=O)c3ccc(Cl)cc3)c3c(F)ccc(F)c3OC[C@@H]12)[C@@H]1CCNC1	Bioorg Med Chem Lett	2016.0	CHEMBL3902914	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of CYP3A4 (unknown origin)	Cc1c([C@@H]2CN3CCN(C(=O)Cc4ccc(-n5cnnn5)cn4)C[C@H]3CO2)ccc(F)c1C#N	Bioorg Med Chem Lett	2016.0	CHEMBL3933749	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	CC(C)(CO)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Eur J Med Chem	2016.0	CHEMBL3976597	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1C2CCC1CC(N1CCCCC1)C2	Eur J Med Chem	2016.0	CHEMBL3947332	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO	Eur J Med Chem	2016.0	CHEMBL3940770	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2	Eur J Med Chem	2016.0	CHEMBL3912780	=	=	IC50	nM	9900.0	IC50	uM	9.9
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Eur J Med Chem	2016.0	CHEMBL3979311	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(C(O)C1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2	Eur J Med Chem	2016.0	CHEMBL3909015	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(C(O)C1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1C2CCC1CC(N1CCCCC1)C2	Eur J Med Chem	2016.0	CHEMBL3889928	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1)N1CCC(N2CCCCC2)CC1	Eur J Med Chem	2016.0	CHEMBL3917946	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	CC(=O)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(F)cc3)CC2)CC1	Eur J Med Chem	2016.0	CHEMBL3898853	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1)N1CCN(CCO)CC1	Eur J Med Chem	2016.0	CHEMBL3926905	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	C[C@H]1CN(C(C)(C)CO)CCN1C(=O)CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1	Eur J Med Chem	2016.0	CHEMBL3907874	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(CO)CC1	Eur J Med Chem	2016.0	CHEMBL3935840	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(N2CCCCC2)CC1	Eur J Med Chem	2016.0	CHEMBL3942592	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3CO[C@H]4CCC[C@H]4N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Eur J Med Chem	2016.0	CHEMBL3972189	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC[C@@H](O)C1	Eur J Med Chem	2016.0	CHEMBL3907872	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC[C@@H](CO)C1	Eur J Med Chem	2016.0	CHEMBL3984859	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	CC(C)(CO)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC2)CC1	Eur J Med Chem	2016.0	CHEMBL3976597	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1C2CCC1CC(N1CCCCC1)C2	Eur J Med Chem	2016.0	CHEMBL3947332	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2CCO	Eur J Med Chem	2016.0	CHEMBL3940770	<	<	IC50	nM	400.0	IC50	uM	0.4
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2	Eur J Med Chem	2016.0	CHEMBL3912780	<	<	IC50	nM	300.0	IC50	uM	0.3
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Eur J Med Chem	2016.0	CHEMBL3979311	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(C(O)C1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC2CCC(C1)N2	Eur J Med Chem	2016.0	CHEMBL3909015	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(C(O)C1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1C2CCC1CC(N1CCCCC1)C2	Eur J Med Chem	2016.0	CHEMBL3889928	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1)N1CCC(N2CCCCC2)CC1	Eur J Med Chem	2016.0	CHEMBL3917946	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	CC(=O)N1CCN(C(=O)CC2([C@H]3COC[C@@H](C4CC4)N3S(=O)(=O)c3ccc(F)cc3)CC2)CC1	Eur J Med Chem	2016.0	CHEMBL3898853	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1)N1CCN(CCO)CC1	Eur J Med Chem	2016.0	CHEMBL3926905	=	=	IC50	nM	6900.0	IC50	uM	6.9
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	C[C@H]1CN(C(C)(C)CO)CCN1C(=O)CC1([C@H]2COC[C@@H](C3CC3)N2S(=O)(=O)c2ccc(F)cc2)CC1	Eur J Med Chem	2016.0	CHEMBL3907874	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(CO)CC1	Eur J Med Chem	2016.0	CHEMBL3935840	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CCC(N2CCCCC2)CC1	Eur J Med Chem	2016.0	CHEMBL3942592	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	CC(=O)N1C2CCC1CN(C(=O)CC1([C@H]3CO[C@H]4CCC[C@H]4N3S(=O)(=O)c3ccc(Cl)cc3)CC1)C2	Eur J Med Chem	2016.0	CHEMBL3972189	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC[C@@H](O)C1	Eur J Med Chem	2016.0	CHEMBL3907872	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells preincubated for 30 mins using fluorescent substrate	O=C(CC1([C@H]2CO[C@H]3CCC[C@H]3N2S(=O)(=O)c2ccc(Cl)cc2)CC1)N1CC[C@@H](CO)C1	Eur J Med Chem	2016.0	CHEMBL3984859	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(N[C@@H](C)CCCC(C)(C)O)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL1778663	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccc3)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3966303	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccc3F)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3903916	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccc3Cl)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3974799	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3cccnc3)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3912923	<	<	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccccn3)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3922893	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3ccncc3)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3921905	<	<	IC50	nM	400.0	IC50	uM	0.4
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)cn1	Bioorg Med Chem Lett	2016.0	CHEMBL3893914	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2cc(C)c(C#N)c(NCCOc3cccnc3C)n2)n[nH]1	Bioorg Med Chem Lett	2016.0	CHEMBL3937431	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)c(C)n1	Bioorg Med Chem Lett	2016.0	CHEMBL3967136	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 (unknown origin)	CCc1ccc(OCCNc2nc(Nc3cc(C)[nH]n3)cc(C)c2C#N)cn1	Bioorg Med Chem Lett	2016.0	CHEMBL3928420	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of hepatic CYP3A4 (unknown origin)	C[C@](O)(c1cncc(-c2nc3ccc(F)cn3c2C2CC2)c1)C(F)(F)F	Bioorg Med Chem Lett	2017.0	CHEMBL3923127	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of hepatic CYP3A4 (unknown origin)	Fc1cncc(-c2nc3ccc(F)cn3c2C2CC2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL3893614	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of hepatic CYP3A4 (unknown origin)	Fc1ccc2nc(-c3cncc4ccccc34)c(C3CC3)n2c1	Bioorg Med Chem Lett	2017.0	CHEMBL3948337	=	=	IC50	nM	3500.0	IC50	nM	3500.0
Inhibition of hepatic CYP3A4 (unknown origin)	Fc1cncc(-c2nc3cc(F)c(Cl)cn3c2C2CC2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL3951973	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of hepatic CYP3A4 (unknown origin)	Cc1c(F)cncc1-c1nc2ccc(F)cn2c1C1CC1	Bioorg Med Chem Lett	2017.0	CHEMBL3924257	=	=	IC50	nM	11000.0	IC50	nM	11000.0
Inhibition of hepatic CYP3A4 (unknown origin)	CCc1c(F)cncc1-c1nc2ccc(F)cn2c1C1CC1	Bioorg Med Chem Lett	2017.0	CHEMBL3919759	=	=	IC50	nM	2800.0	IC50	nM	2800.0
Inhibition of human CYP3A4	CO[C@H]1C[C@H](Oc2cc(F)c(F)c(-c3ccc4c(c3)CC[C@H](CCC(=O)O)O4)n2)C1	ACS Med Chem Lett	2017.0	CHEMBL3980898	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(S(=O)(=O)C(F)F)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL3963788	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(S(=O)(=O)C(F)(F)F)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL3915634	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(S(F)(F)(F)(F)F)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL3942511	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS method	CC(C)COC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2F)cc1	Bioorg Med Chem	2017.0	CHEMBL3984743	=	=	IC50	nM	155.0	IC50	uM	0.155
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS method	CC(C)COC(=O)[C@@H](Cn1cncn1)NC(=O)c1ccc(-c2ccccc2F)cc1	Bioorg Med Chem	2017.0	CHEMBL3892576	=	=	IC50	nM	227.0	IC50	uM	0.227
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in nifedipine oxidation incubated for 10 mins	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Bioorg Med Chem	2017.0	CHEMBL64391	=	=	IC50	nM	32.6	IC50	nM	32.6
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in nifedipine oxidation incubated for 10 mins	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2017.0	CHEMBL157101	=	=	IC50	nM	31.7	IC50	nM	31.7
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation at 1 to 25 uM by UPLC-MS/MS analysis	C[C@H](Nc1ncnc(N)c1C#N)c1nn2ccc(C#N)c2c(=O)n1-c1ccccc1	ACS Med Chem Lett	2017.0	CHEMBL3910904	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 using BFC as substrate	c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1	J Med Chem	2016.0	CHEMBL3918431	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4 using BZR as substrate	c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1	J Med Chem	2016.0	CHEMBL3918431	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3918722	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3971789	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3903656	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3957835	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3941703	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3939013	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3986998	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1		2012.0	CHEMBL3948750	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2ccccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3899101	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3896422	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccc(F)c2)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3981313	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12		2012.0	CHEMBL3934437	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12		2012.0	CHEMBL3951586	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12		2012.0	CHEMBL3949599	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12		2012.0	CHEMBL3956565	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3904681	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3968497	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c12		2012.0	CHEMBL3966021	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3928847	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12		2012.0	CHEMBL3926189	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c12		2012.0	CHEMBL3890797	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12		2012.0	CHEMBL3979607	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5ccccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3895266	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5cc(F)ccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3904980	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5c(F)cccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3940360	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5cccc(F)c5)c4F)c3c2)cn1		2012.0	CHEMBL3942988	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4)c3F)c2c1		2012.0	CHEMBL3916725	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3919462	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3954395	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1		2012.0	CHEMBL3956999	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3944290	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4ccccc4)c3F)c2c1		2012.0	CHEMBL3931676	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3977421	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccnc2)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3968167	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3967303	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12		2012.0	CHEMBL3914107	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccnc2)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3893235	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12		2012.0	CHEMBL3890467	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3980636	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NCC)nc4)cc23)c1F		2012.0	CHEMBL3928507	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)nc4)cc23)c1F		2012.0	CHEMBL3912374	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(F)nc4)cc23)c1F		2012.0	CHEMBL3964025	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncnc4)cc23)c1F		2012.0	CHEMBL3921859	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NS(C)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3979361	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)N5CCOCC5)cc4)cc23)c1F		2012.0	CHEMBL3981784	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC)cc4)cc23)c1F		2012.0	CHEMBL3904645	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC5CC5)cc4)cc23)c1F		2012.0	CHEMBL3907402	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cn[nH]c4)cc23)c1F		2012.0	CHEMBL3968460	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnn(CCN5CCOCC5)c4)cc23)c1F		2012.0	CHEMBL3952336	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN(C)C)nc4)cc23)c1F		2012.0	CHEMBL3954978	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NC)nc4)cc23)c1F		2012.0	CHEMBL3971807	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NC5CC5)nc4)cc23)c1F		2012.0	CHEMBL3969082	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(C)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3981425	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OC)nc4OC)cc23)c1F		2012.0	CHEMBL3979042	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)N(C)C)cc4)cc23)c1F		2012.0	CHEMBL3935100	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(SC)nc4)cc23)c1F		2012.0	CHEMBL3932389	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncc(S(C)(=O)=O)c4)cc23)c1F		2012.0	CHEMBL3968095	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(SC)nc4)cc23)c1F		2012.0	CHEMBL3985076	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnn(Cc5ccccc5)c4)cc23)c1F		2012.0	CHEMBL3913674	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccnc(F)c4)cc23)c1F		2012.0	CHEMBL3920821	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NC(C)=O)nc4)cc23)c1F		2012.0	CHEMBL3904333	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(N)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3907089	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3942381	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3945059	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(OC)nc4OC)cc23)c1F		2012.0	CHEMBL3911079	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(C)nc4)cc23)c1F		2012.0	CHEMBL3899027	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C)nc4)cc23)c1F		2012.0	CHEMBL3933168	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N)nc4)cc23)c1F		2012.0	CHEMBL3896589	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)CC)cc4)cc23)c1F		2012.0	CHEMBL3899285	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3928075	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C#CCN(CC)CC)nc4)cc23)c1F		2012.0	CHEMBL3949992	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)C(C)C)cc4)cc23)c1F		2012.0	CHEMBL3947313	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCc1ccc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)CCC)c4F)c3c2)cn1		2012.0	CHEMBL3897700	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(CCCOC)cc4)cc23)c1F		2012.0	CHEMBL3985717	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cccc(S(C)(=O)=O)c4)cc23)c1F		2012.0	CHEMBL3935744	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3955478	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3919966	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCN5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3917210	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCN5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3958968	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3941565	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3896039	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(C#CCOC)cc23)c1F		2012.0	CHEMBL3945707	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	C#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)CCC)c3F)c2c1		2012.0	CHEMBL3948349	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1cccc(C(=O)c2c[nH]c3ncc(-c4cnc(OC)nc4)cc23)c1F		2012.0	CHEMBL3917962	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate after 30 mins	CCCS(=O)(=O)Nc1cccc(C(=O)c2c[nH]c3ncc(-c4cnc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3923610	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3918722	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3971789	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3903656	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3957835	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3941703	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3939013	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3986998	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1		2012.0	CHEMBL3948750	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2ccccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3899101	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cc(F)ccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3896422	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccc(F)c2)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3981313	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12		2012.0	CHEMBL3934437	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4F)c3F)c12		2012.0	CHEMBL3951586	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12		2012.0	CHEMBL3949599	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12		2012.0	CHEMBL3956565	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3904681	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3968497	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c12		2012.0	CHEMBL3966021	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2c(F)cccc2F)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3928847	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c12		2012.0	CHEMBL3926189	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c12		2012.0	CHEMBL3890797	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccc(F)c4)c3F)c12		2012.0	CHEMBL3979607	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5ccccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3895266	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5cc(F)ccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3904980	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5c(F)cccc5F)c4F)c3c2)cn1		2012.0	CHEMBL3940360	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ncc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)c5cccc(F)c5)c4F)c3c2)cn1		2012.0	CHEMBL3942988	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4ccccc4)c3F)c2c1		2012.0	CHEMBL3916725	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4ccccc4F)c3F)c2c1		2012.0	CHEMBL3919462	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cc(F)ccc4F)c3F)c2c1		2012.0	CHEMBL3954395	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccc(F)c4)c3F)c2c1		2012.0	CHEMBL3956999	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3F)c2c1		2012.0	CHEMBL3944290	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4ccccc4)c3F)c2c1		2012.0	CHEMBL3931676	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3977421	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccnc2)c1F)c1c[nH]c2ncc(Cl)cc12		2012.0	CHEMBL3968167	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3967303	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	COc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12		2012.0	CHEMBL3914107	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	O=C(c1c(F)ccc(NS(=O)(=O)c2cccnc2)c1F)c1c[nH]c2nccc(Cl)c12		2012.0	CHEMBL3893235	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1ccnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)c4cccnc4)c3F)c12		2012.0	CHEMBL3890467	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	N#Cc1cnc2[nH]cc(C(=O)c3cccc(NS(=O)(=O)c4cccnc4)c3F)c2c1		2012.0	CHEMBL3980636	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NCC)nc4)cc23)c1F		2012.0	CHEMBL3928507	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)nc4)cc23)c1F		2012.0	CHEMBL3912374	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(F)nc4)cc23)c1F		2012.0	CHEMBL3964025	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncnc4)cc23)c1F		2012.0	CHEMBL3921859	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NS(C)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3979361	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)N5CCOCC5)cc4)cc23)c1F		2012.0	CHEMBL3981784	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC)cc4)cc23)c1F		2012.0	CHEMBL3904645	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)NC5CC5)cc4)cc23)c1F		2012.0	CHEMBL3907402	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cn[nH]c4)cc23)c1F		2012.0	CHEMBL3968460	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnn(CCN5CCOCC5)c4)cc23)c1F		2012.0	CHEMBL3952336	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN(C)C)nc4)cc23)c1F		2012.0	CHEMBL3954978	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NC)nc4)cc23)c1F		2012.0	CHEMBL3971807	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C(=O)NC5CC5)nc4)cc23)c1F		2012.0	CHEMBL3969082	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(C)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3981425	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OC)nc4OC)cc23)c1F		2012.0	CHEMBL3979042	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)N(C)C)cc4)cc23)c1F		2012.0	CHEMBL3935100	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(SC)nc4)cc23)c1F		2012.0	CHEMBL3932389	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cncc(S(C)(=O)=O)c4)cc23)c1F		2012.0	CHEMBL3968095	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(SC)nc4)cc23)c1F		2012.0	CHEMBL3985076	<	<	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnn(Cc5ccccc5)c4)cc23)c1F		2012.0	CHEMBL3913674	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccnc(F)c4)cc23)c1F		2012.0	CHEMBL3920821	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(NC(C)=O)nc4)cc23)c1F		2012.0	CHEMBL3904333	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(N)(=O)=O)cc4)cc23)c1F		2012.0	CHEMBL3907089	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3942381	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3945059	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(OC)nc4OC)cc23)c1F		2012.0	CHEMBL3911079	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(C)nc4)cc23)c1F		2012.0	CHEMBL3899027	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C)nc4)cc23)c1F		2012.0	CHEMBL3933168	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N)nc4)cc23)c1F		2012.0	CHEMBL3896589	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)CC)cc4)cc23)c1F		2012.0	CHEMBL3899285	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cnc(N5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3928075	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(C#CCN(CC)CC)nc4)cc23)c1F		2012.0	CHEMBL3949992	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(=O)(=O)C(C)C)cc4)cc23)c1F		2012.0	CHEMBL3947313	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCc1ccc(-c2cnc3[nH]cc(C(=O)c4c(F)ccc(NS(=O)(=O)CCC)c4F)c3c2)cn1		2012.0	CHEMBL3897700	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(CCCOC)cc4)cc23)c1F		2012.0	CHEMBL3985717	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4cccc(S(C)(=O)=O)c4)cc23)c1F		2012.0	CHEMBL3935744	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3955478	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(N5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3919966	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCN5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3917210	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCN5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3958968	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCCC5)nc4)cc23)c1F		2012.0	CHEMBL3941565	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(OCCCN5CCOCC5)nc4)cc23)c1F		2012.0	CHEMBL3896039	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(C#CCOC)cc23)c1F		2012.0	CHEMBL3945707	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	C#Cc1cnc2[nH]cc(C(=O)c3c(F)ccc(NS(=O)(=O)CCC)c3F)c2c1		2012.0	CHEMBL3948349	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1cccc(C(=O)c2c[nH]c3ncc(-c4cnc(OC)nc4)cc23)c1F		2012.0	CHEMBL3917962	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate after 30 mins	CCCS(=O)(=O)Nc1cccc(C(=O)c2c[nH]c3ncc(-c4cnc(N(C)C)nc4)cc23)c1F		2012.0	CHEMBL3923610	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) expressed in baculosomes containing NADPH reductase by fluorescence based Pan-Vera VividC450 assay	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		2013.0	CHEMBL3544960	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) expressed in baculosomes containing NADPH reductase by fluorescence based Pan-Vera VividC450 assay	NC[C@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		2013.0	CHEMBL3942454	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).	Cc1nc(CN2CCN(c3c(Cl)cnc4[nH]c(-c5cn(C)nc5C)nc34)CC2)no1		2016.0	CHEMBL2207501	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O		2013.0	CHEMBL3645534	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3645512	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1nc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O		2013.0	CHEMBL3645513	=	=	IC50	nM	32700.0	IC50	nM	32700.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(CC(F)(F)F)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645515	=	=	IC50	nM	15600.0	IC50	nM	15600.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)nn(C)c1=O		2013.0	CHEMBL3645516	=	=	IC50	nM	31000.0	IC50	nM	31000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	Cc1cc(=O)n(C)nc1-c1ccc([C@H](C)N2CC[C@](CC(C)(C)O)(c3ccccc3)OC2=O)cc1		2013.0	CHEMBL3645517	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(CC3CC3)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645518	=	=	IC50	nM	5700.0	IC50	nM	5700.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C3CC3)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645519	=	=	IC50	nM	15700.0	IC50	nM	15700.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL1829763	=	=	IC50	nM	7400.0	IC50	nM	7400.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL1829768	=	=	IC50	nM	9900.0	IC50	nM	9900.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3645523	=	=	IC50	nM	4400.0	IC50	nM	4400.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2F)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O		2013.0	CHEMBL1829759	=	=	IC50	nM	5300.0	IC50	nM	5300.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O		2013.0	CHEMBL1829761	=	=	IC50	nM	7000.0	IC50	nM	7000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CCC(N)=O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645524	=	=	IC50	nM	14100.0	IC50	nM	14100.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(F)cc2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645525	=	=	IC50	nM	4900.0	IC50	nM	4900.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3645526	=	=	IC50	nM	4400.0	IC50	nM	4400.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3645527	=	=	IC50	nM	19700.0	IC50	nM	19700.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3645528	=	=	IC50	nM	3100.0	IC50	nM	3100.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C3CC3)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664694	=	=	IC50	nM	44000.0	IC50	nM	44000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C(F)F)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664695	=	=	IC50	nM	21000.0	IC50	nM	21000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C(F)F)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664696	=	=	IC50	nM	29000.0	IC50	nM	29000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2cc[nH]c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O		2013.0	CHEMBL3664643	=	=	IC50	nM	25000.0	IC50	nM	25000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O		2013.0	CHEMBL3664706	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(CCF)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664707	=	=	IC50	nM	33000.0	IC50	nM	33000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O		2013.0	CHEMBL3664646	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O		2013.0	CHEMBL3664710	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3664711	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3664712	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664715	=	=	IC50	nM	48000.0	IC50	nM	48000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCO)(c2ccccc2)OC1=O		2013.0	CHEMBL3664651	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664717	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O		2013.0	CHEMBL3664657	=	=	IC50	nM	32000.0	IC50	nM	32000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccccc2)OC1=O		2013.0	CHEMBL3639635	=	=	IC50	nM	14000.0	IC50	nM	14000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC[C@@H](c1ccc(-c2ccc(=O)n(CC)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664659	=	=	IC50	nM	48000.0	IC50	nM	48000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O		2013.0	CHEMBL3664660	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664661	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664662	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC)(c2ccccc2)OC1=O		2013.0	CHEMBL3664665	=	=	IC50	nM	8000.0	IC50	nM	8000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC(C)n1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)ccc1=O		2013.0	CHEMBL3664718	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn(C)c1=O		2013.0	CHEMBL3664667	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccc(F)cc4)OC3=O)cc2)ccc1=O		2013.0	CHEMBL3664668	=	=	IC50	nM	48000.0	IC50	nM	48000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(=O)n1C		2013.0	CHEMBL3664670	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664671	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(CC(F)(F)F)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664672	=	=	IC50	nM	18000.0	IC50	nM	18000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(CC(F)(F)F)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664673	=	=	IC50	nM	28000.0	IC50	nM	28000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC(C)n1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664674	=	=	IC50	nM	43000.0	IC50	nM	43000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)C#N)(c2ccc(F)cc2)OC1=O		2013.0	CHEMBL3664675	=	=	IC50	nM	23000.0	IC50	nM	23000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(C)c1=O		2013.0	CHEMBL3664676	=	=	IC50	nM	28000.0	IC50	nM	28000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C#CC(C)(C)C[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccc(=O)[nH]c3)cc2)C(=O)O1		2013.0	CHEMBL3664719	=	=	IC50	nM	6000.0	IC50	nM	6000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CCn1c(C)cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664677	=	=	IC50	nM	41000.0	IC50	nM	41000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664679	=	=	IC50	nM	23000.0	IC50	nM	23000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccc(=O)n(CC3CC3)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664680	=	=	IC50	nM	10000.0	IC50	nM	10000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	COC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccc(=O)n(C)c3)cc2)C(=O)O1		2013.0	CHEMBL3664681	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	COC[C@]1(c2ccccc2)CCN([C@@H](C)c2ccc(-c3ccn(C)c(=O)c3)cc2)C(=O)O1		2013.0	CHEMBL3664682	=	=	IC50	nM	47000.0	IC50	nM	47000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2cc(=O)n(C)cc2F)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664683	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(CC(C)(C)O)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O		2013.0	CHEMBL3664684	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	COCC(C)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664685	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	CC(CO)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664686	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	COC(C)(C)Cn1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc1=O		2013.0	CHEMBL3664687	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Biological Assay Example 6: The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37° C with human recombinant cytochrome P450 3A4.	C[C@@H](c1ccc(-c2ccn(C3CC3)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2F)OC1=O		2013.0	CHEMBL3664689	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCc1ccc(-c2cccnc2)s1		2013.0	CHEMBL359657	=	=	IC50	nM	58720.0	IC50	nM	58720.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCc1ccc(-c2cccnc2)s1		2013.0	CHEMBL359657	=	=	IC50	nM	15330.0	IC50	nM	15330.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCc1ccc(-c2cccnc2)o1		2013.0	CHEMBL178090	=	=	IC50	nM	47170.0	IC50	nM	47170.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCC#Cc1cccnc1		2013.0	CHEMBL360541	=	=	IC50	nM	365000.0	IC50	nM	365000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCC#Cc1cccnc1		2013.0	CHEMBL360541	=	=	IC50	nM	128000.0	IC50	nM	128000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1ccsc1-c1cccnc1		2013.0	CHEMBL179669	=	=	IC50	nM	5990.0	IC50	nM	5990.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cn1cnc(-c2cccnc2)c1		2013.0	CHEMBL360999	=	=	IC50	nM	261900.0	IC50	nM	261900.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	c1cncc(-n2ccnc2)c1		2013.0	CHEMBL179477	=	=	IC50	nM	109000.0	IC50	nM	109000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1ccsc1-c1ccc(F)nc1		2013.0	CHEMBL179621	=	=	IC50	nM	39080.0	IC50	nM	39080.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	c1cncc(-c2ccsc2)c1		2013.0	CHEMBL361153	=	=	IC50	nM	55910.0	IC50	nM	55910.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1nccn1-c1cccnc1		2013.0	CHEMBL368883	=	=	IC50	nM	152000.0	IC50	nM	152000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	c1cncc(-c2c[nH]cn2)c1		2013.0	CHEMBL178516	=	=	IC50	nM	139900.0	IC50	nM	139900.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1cscc1-c1cccnc1		2013.0	CHEMBL179704	<	<	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	O=NCc1ccc(-c2cccnc2)s1		2013.0	CHEMBL3640786	=	=	IC50	nM	12980.0	IC50	nM	12980.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Nc1ccc(-c2cccnc2)s1		2013.0	CHEMBL3640762	=	=	IC50	nM	1590.0	IC50	nM	1590.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	c1cncc(-n2ccnc2)c1		2013.0	CHEMBL179477	=	=	IC50	nM	77540.0	IC50	nM	77540.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	O=NCc1ccc(-c2cccnc2)o1		2013.0	CHEMBL3640785	>	>	IC50	nM	400000.0	IC50	nM	400000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	O=Cc1ccc(-c2cccnc2)s1		2013.0	CHEMBL179398	=	=	IC50	nM	23930.0	IC50	nM	23930.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Fc1ccc(-c2ccsc2)cn1		2013.0	CHEMBL179005	=	=	IC50	nM	114000.0	IC50	nM	114000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCC1CCC(c2cccnc2)O1		2013.0	CHEMBL3640764	=	=	IC50	nM	64710.0	IC50	nM	64710.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	NCc1ccc(-c2cccnc2)s1		2013.0	CHEMBL359657	=	=	IC50	nM	56990.0	IC50	nM	56990.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	CC(=O)c1ccc(-c2cccnc2)s1		2013.0	CHEMBL362702	=	=	IC50	nM	26900.0	IC50	nM	26900.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	O=NCc1ccc(-c2cccnc2)o1		2013.0	CHEMBL3640785	>	>	IC50	nM	400000.0	IC50	nM	400000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	c1cnc(-c2cccnc2)nc1		2013.0	CHEMBL178878	>	>	IC50	nM	400000.0	IC50	nM	400000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1cscc1-c1ccc(F)nc1		2013.0	CHEMBL425519	=	=	IC50	nM	114000.0	IC50	nM	114000.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	Cc1ccc(-c2cccnc2)nc1		2013.0	CHEMBL179589	=	=	IC50	nM	84230.0	IC50	nM	84230.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	CN1CCCC1c1cccnc1		2013.0	CHEMBL440464	=	=	IC50	nM	142400.0	IC50	nM	142400.0
Inhibition Assay (Testosterone Hydroxylase): To gain insight into the selectivity of the synthetic compounds, nicotine, nicotine related alkaloids and nicotine metabolites for inhibition of other CYPs, we examined the major CYP present in human liver (i.e., CYP 3A4). That the CYP2A6 inhibitors showed low or no inhibitory activity against CYP3A4 suggests that the inhibitors examined selectively inhibited CYP2A6.	O=NCc1ccc(-c2cccnc2)o1		2013.0	CHEMBL3640785	>	>	IC50	nM	400000.0	IC50	nM	400000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		2014.0	CHEMBL1980297	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		2014.0	CHEMBL1980297	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		2014.0	CHEMBL1980297	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		2014.0	CHEMBL1980297	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](C)O)c5)cnc(N)c34)cc2)c1		2014.0	CHEMBL3646210	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](C)O)c5)cnc(N)c34)cc2)c1		2014.0	CHEMBL3646210	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		2014.0	CHEMBL2004290	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		2014.0	CHEMBL2004290	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](O)CO)c5)cnc(N)c34)cc2)cc1		2014.0	CHEMBL3646211	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C[C@H](O)CO)c5)cnc(N)c34)cc2)cc1		2014.0	CHEMBL3646211	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		2014.0	CHEMBL1969102	=	=	IC50	nM	300.0	IC50	nM	300.0
Inhibtion Assay: Assays (200 μL final volume) were carried out in NUNC polypropylene deep well plates in 50 mM potassium phosphate buffer, pH 7.4, using a microtiter plate shaker in a 37° C. incubator. Pooled human liver microsomes (BD Gentest, 50 μg/mL) were incubated with 5 concentrations of test compound (from 0.1 μM to 10 μM), 1 mM NADPH (Sigma), and 2 μM midazolam (Sigma). A constant amount of dimethylsulfoxide (1%) was added to the incubations with the test compounds, and each analysis was performed in duplicate. For preincubation experiments (Pre), the microsomes, test compounds, and NADPH were mixed and incubated 30 minutes before addition of midazolam. For coincubation experiments (Co), the compounds, microsomes, and midazolam were mixed and the reaction initiated by addition of NADPH to the wells.	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		2014.0	CHEMBL1969102	=	=	IC50	nM	760.0	IC50	nM	760.0
Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	150.0	IC50	nM	150.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699315	=	=	IC50	nM	14700.0	IC50	nM	14700.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699316	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699317	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCSCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699318	=	=	IC50	nM	1760.0	IC50	nM	1760.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCN(C(C)=O)CC7)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699319	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCN(C)CC7)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699320	=	=	IC50	nM	7040.0	IC50	nM	7040.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N7CCOCC7)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699321	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cccc(C(=O)Nc6ccccc6)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699322	=	=	IC50	nM	2130.0	IC50	nM	2130.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(C(N)=O)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699323	=	=	IC50	nM	15970.0	IC50	nM	15970.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(O)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699324	=	=	IC50	nM	8070.0	IC50	nM	8070.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699325	=	=	IC50	nM	7630.0	IC50	nM	7630.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(N)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699326	=	=	IC50	nM	2420.0	IC50	nM	2420.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OCc7ccccc7)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699327	=	=	IC50	nM	17200.0	IC50	nM	17200.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OC)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699328	=	=	IC50	nM	6530.0	IC50	nM	6530.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699329	=	=	IC50	nM	19500.0	IC50	nM	19500.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6ccc(OCCCC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699330	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cccc(C(=O)Nc6ccc(N7CCN(c8ccc(OC)cc8)CC7)cc6)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699331	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)Nc6cccc(OC(C)C)c6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699332	=	=	IC50	nM	13700.0	IC50	nM	13700.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NC6CCC(NC(=O)OC(C)(C)C)CC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699333	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NNC(C)(C)C)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699334	=	=	IC50	nM	3410.0	IC50	nM	3410.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NN6CCN(c7ccccn7)CC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699335	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)NN6CCN(C)CC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699336	=	=	IC50	nM	2510.0	IC50	nM	2510.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699337	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699338	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699339	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N(C)C)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699340	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)CCCCCCC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699341	=	=	IC50	nM	21700.0	IC50	nM	21700.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(CN(CC)CC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699342	=	=	IC50	nM	2260.0	IC50	nM	2260.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(NC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699343	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N(CC)CC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699344	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCOCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702672	=	=	IC50	nM	2190.0	IC50	nM	2190.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)c6ccc(N)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702673	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)CCCNCCC(C)=O)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3640015	=	=	IC50	nM	2780.0	IC50	nM	2780.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702674	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCCCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702675	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCCc6ccccc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702676	=	=	IC50	nM	10500.0	IC50	nM	10500.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)cc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702677	=	=	IC50	nM	9480.0	IC50	nM	9480.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccc(OC)nc6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699316	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCCC6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702678	=	=	IC50	nM	7800.0	IC50	nM	7800.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ncccn6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702679	=	=	IC50	nM	8520.0	IC50	nM	8520.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6cnccn6)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702680	=	=	IC50	nM	4610.0	IC50	nM	4610.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)Nc6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699317	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCOCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702681	=	=	IC50	nM	10200.0	IC50	nM	10200.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702682	=	=	IC50	nM	6960.0	IC50	nM	6960.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N6CCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702683	=	=	IC50	nM	6510.0	IC50	nM	6510.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCc6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702684	=	=	IC50	nM	20390.0	IC50	nM	20390.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NCC(C)(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702685	=	=	IC50	nM	2190.0	IC50	nM	2190.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702686	=	=	IC50	nM	6400.0	IC50	nM	6400.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)NC6CCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702687	=	=	IC50	nM	2920.0	IC50	nM	2920.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)N(C)C)o5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702688	=	=	IC50	nM	3420.0	IC50	nM	3420.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCOC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702694	=	=	IC50	nM	9120.0	IC50	nM	9120.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702695	=	=	IC50	nM	11300.0	IC50	nM	11300.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702696	=	=	IC50	nM	9300.0	IC50	nM	9300.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCCN(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702697	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C(C)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702698	=	=	IC50	nM	10900.0	IC50	nM	10900.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(S(C)(=O)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702699	=	=	IC50	nM	11200.0	IC50	nM	11200.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(S(=O)(=O)CC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702700	=	=	IC50	nM	2820.0	IC50	nM	2820.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N6CCN(C)CC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702701	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC6CCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702702	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC6CCNCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702703	=	=	IC50	nM	8170.0	IC50	nM	8170.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCN6CCCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702704	=	=	IC50	nM	5530.0	IC50	nM	5530.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCN6CCOCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702705	=	=	IC50	nM	6090.0	IC50	nM	6090.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCN(c6ccccn6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702706	=	=	IC50	nM	2480.0	IC50	nM	2480.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702707	=	=	IC50	nM	3630.0	IC50	nM	3630.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCCC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702708	=	=	IC50	nM	6600.0	IC50	nM	6600.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C(C)=O)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702709	=	=	IC50	nM	15000.0	IC50	nM	15000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(CC(C)C)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702710	=	=	IC50	nM	3980.0	IC50	nM	3980.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C(=O)OC(C)(C)C)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702711	=	=	IC50	nM	2200.0	IC50	nM	2200.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(C=O)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702712	=	=	IC50	nM	12100.0	IC50	nM	12100.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN6CCN(CC)CC6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702713	=	=	IC50	nM	5040.0	IC50	nM	5040.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702714	=	=	IC50	nM	10700.0	IC50	nM	10700.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(OC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702715	=	=	IC50	nM	3300.0	IC50	nM	3300.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(C(=O)OCC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702716	=	=	IC50	nM	3860.0	IC50	nM	3860.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(C(=O)N(C)CCN(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702717	=	=	IC50	nM	4970.0	IC50	nM	4970.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702718	=	=	IC50	nM	7650.0	IC50	nM	7650.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)c6ccc(N(C)C)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702719	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(NC(=O)c6ccc(N7CCN(C)CC7)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702720	=	=	IC50	nM	6020.0	IC50	nM	6020.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702721	=	=	IC50	nM	2230.0	IC50	nM	2230.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C6CCN(C)CC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702722	=	=	IC50	nM	8550.0	IC50	nM	8550.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC(N6CCOCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702723	=	=	IC50	nM	2110.0	IC50	nM	2110.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC6CCN(C)C6C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702724	=	=	IC50	nM	2450.0	IC50	nM	2450.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCC6CN(C)CC65)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702725	=	=	IC50	nM	4490.0	IC50	nM	4490.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(O)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702726	=	=	IC50	nM	18300.0	IC50	nM	18300.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCN(C)CC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702727	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCOCC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702728	=	=	IC50	nM	5990.0	IC50	nM	5990.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CC(N6CCC(OC)CC6)C5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702729	=	=	IC50	nM	11800.0	IC50	nM	11800.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702689	=	=	IC50	nM	3900.0	IC50	nM	3900.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702690	=	=	IC50	nM	12200.0	IC50	nM	12200.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CC)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702691	=	=	IC50	nM	8040.0	IC50	nM	8040.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(C(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702692	=	=	IC50	nM	2240.0	IC50	nM	2240.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N5CCN(CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702693	=	=	IC50	nM	6820.0	IC50	nM	6820.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702730	=	=	IC50	nM	3160.0	IC50	nM	3160.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702731	=	=	IC50	nM	2510.0	IC50	nM	2510.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702732	=	=	IC50	nM	16180.0	IC50	nM	16180.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702733	=	=	IC50	nM	3680.0	IC50	nM	3680.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCOC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702734	=	=	IC50	nM	3840.0	IC50	nM	3840.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCOCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702735	=	=	IC50	nM	16360.0	IC50	nM	16360.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CC5(CO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702736	=	=	IC50	nM	2530.0	IC50	nM	2530.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCCOC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702737	=	=	IC50	nM	2010.0	IC50	nM	2010.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702738	=	=	IC50	nM	7870.0	IC50	nM	7870.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN(CC)CC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702739	=	=	IC50	nM	3640.0	IC50	nM	3640.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN(C)C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702740	=	=	IC50	nM	17890.0	IC50	nM	17890.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(CCO)CCNCCO)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702741	=	=	IC50	nM	2890.0	IC50	nM	2890.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N[C@H](C)C(=O)OC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702742	=	=	IC50	nM	10890.0	IC50	nM	10890.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCC(=O)OCC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702743	=	=	IC50	nM	3580.0	IC50	nM	3580.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCC(=O)OC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702744	=	=	IC50	nM	3460.0	IC50	nM	3460.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCC(=O)O)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702745	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702746	=	=	IC50	nM	8500.0	IC50	nM	8500.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702747	=	=	IC50	nM	2860.0	IC50	nM	2860.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702748	=	=	IC50	nM	11510.0	IC50	nM	11510.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702749	=	=	IC50	nM	7800.0	IC50	nM	7800.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702750	=	=	IC50	nM	1100.0	IC50	nM	1100.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCCCN5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702751	=	=	IC50	nM	2540.0	IC50	nM	2540.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CC(=O)N5CCN(C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702752	=	=	IC50	nM	5040.0	IC50	nM	5040.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)CCn5ccnc5C)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702753	=	=	IC50	nM	2480.0	IC50	nM	2480.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCc5ccc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702754	=	=	IC50	nM	2050.0	IC50	nM	2050.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NCc5ccnc(N(C)C)c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702755	=	=	IC50	nM	2180.0	IC50	nM	2180.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)N(C)NC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702756	=	=	IC50	nM	2330.0	IC50	nM	2330.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NNCC(=O)OCC)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702757	=	=	IC50	nM	6150.0	IC50	nM	6150.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702758	=	=	IC50	nM	17440.0	IC50	nM	17440.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCCCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702759	=	=	IC50	nM	4780.0	IC50	nM	4780.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCOCC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702760	=	=	IC50	nM	22290.0	IC50	nM	22290.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NN5CCN(C6CCCC6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702761	=	=	IC50	nM	2390.0	IC50	nM	2390.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NNc5ccccc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702762	=	=	IC50	nM	6800.0	IC50	nM	6800.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)OC(C)(C)C)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702763	=	=	IC50	nM	5650.0	IC50	nM	5650.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(CCCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702764	=	=	IC50	nM	9710.0	IC50	nM	9710.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(C)=O)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702765	=	=	IC50	nM	5120.0	IC50	nM	5120.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)CCO)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702766	=	=	IC50	nM	6870.0	IC50	nM	6870.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)c6ccc(N(C)C)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702767	=	=	IC50	nM	6150.0	IC50	nM	6150.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)NC5CCN(C(=O)c6ccc(N7CCN(C)CC7)cc6)CC5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702768	=	=	IC50	nM	9650.0	IC50	nM	9650.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(F)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702769	=	=	IC50	nM	2970.0	IC50	nM	2970.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702770	=	=	IC50	nM	2610.0	IC50	nM	2610.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(OC)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702771	=	=	IC50	nM	2160.0	IC50	nM	2160.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OC(C)(C)C)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702772	=	=	IC50	nM	19100.0	IC50	nM	19100.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(CCO)cc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3640016	=	=	IC50	nM	7400.0	IC50	nM	7400.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCOC)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702773	=	=	IC50	nM	7620.0	IC50	nM	7620.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702774	=	=	IC50	nM	10100.0	IC50	nM	10100.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702775	=	=	IC50	nM	13030.0	IC50	nM	13030.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702776	=	=	IC50	nM	6750.0	IC50	nM	6750.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(C)CCO)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702777	=	=	IC50	nM	3450.0	IC50	nM	3450.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCC(O)CO)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702778	=	=	IC50	nM	2550.0	IC50	nM	2550.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCC(C)(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702779	=	=	IC50	nM	2380.0	IC50	nM	2380.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702780	=	=	IC50	nM	6750.0	IC50	nM	6750.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCCN(CC)CC)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702781	=	=	IC50	nM	4530.0	IC50	nM	4530.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN(C(C)C)C(C)C)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702782	=	=	IC50	nM	4050.0	IC50	nM	4050.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N(CCN(CC)CC)CCN(CC)CC)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702783	=	=	IC50	nM	5350.0	IC50	nM	5350.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702784	=	=	IC50	nM	2530.0	IC50	nM	2530.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCOCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702785	=	=	IC50	nM	2320.0	IC50	nM	2320.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(NCCN6CCC(O)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702786	=	=	IC50	nM	5800.0	IC50	nM	5800.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(OCCCN6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702787	=	=	IC50	nM	7670.0	IC50	nM	7670.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NCCCN6CCCC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702788	=	=	IC50	nM	2570.0	IC50	nM	2570.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCCC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3699315	=	=	IC50	nM	12240.0	IC50	nM	12240.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCOCC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702789	=	=	IC50	nM	21060.0	IC50	nM	21060.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702790	=	=	IC50	nM	6950.0	IC50	nM	6950.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(OC)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702791	=	=	IC50	nM	2210.0	IC50	nM	2210.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCNCC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702792	=	=	IC50	nM	2730.0	IC50	nM	2730.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702793	=	=	IC50	nM	7600.0	IC50	nM	7600.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CC)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702794	=	=	IC50	nM	5730.0	IC50	nM	5730.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CCC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702795	=	=	IC50	nM	6940.0	IC50	nM	6940.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(CCO)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702796	=	=	IC50	nM	6040.0	IC50	nM	6040.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)C)CC6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702797	=	=	IC50	nM	6120.0	IC50	nM	6120.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5cnc(N6CCN(C(C)C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702798	=	=	IC50	nM	3670.0	IC50	nM	3670.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)(C)C)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702799	=	=	IC50	nM	4190.0	IC50	nM	4190.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C7CC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702800	=	=	IC50	nM	6940.0	IC50	nM	6940.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C7CCCC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702801	=	=	IC50	nM	17240.0	IC50	nM	17240.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702802	=	=	IC50	nM	3970.0	IC50	nM	3970.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(NC6CC(C)(C)N(C)C(C)(C)C6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702803	=	=	IC50	nM	7100.0	IC50	nM	7100.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(C(C)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702804	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702805	=	=	IC50	nM	3290.0	IC50	nM	3290.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCCCC7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702806	=	=	IC50	nM	2370.0	IC50	nM	2370.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCC(N7CCN(C)CC7)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702807	=	=	IC50	nM	6320.0	IC50	nM	6320.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(c7ccc(C(F)(F)F)cc7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702808	=	=	IC50	nM	23670.0	IC50	nM	23670.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(c7ccccc7OC)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702809	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCN(Cc7ccc(OC)cc7)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702810	=	=	IC50	nM	21520.0	IC50	nM	21520.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(O)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702811	=	=	IC50	nM	4870.0	IC50	nM	4870.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(N7CCN(C)CC7)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702812	=	=	IC50	nM	4100.0	IC50	nM	4100.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC(N7CCC(OC)CC7)C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702813	=	=	IC50	nM	2560.0	IC50	nM	2560.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CC7CCN(C)C7C6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702814	=	=	IC50	nM	7640.0	IC50	nM	7640.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCC7(CCN(CC)C7)C6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702815	=	=	IC50	nM	3910.0	IC50	nM	3910.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc(N6CCC7CCCN7C6)nc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702816	=	=	IC50	nM	4600.0	IC50	nM	4600.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(C(=O)Nc5ccc(N6CCCN(C)CC6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702817	=	=	IC50	nM	11240.0	IC50	nM	11240.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=O)N6CCN(S(C)(=O)=O)CC6)nc5)cn(C)c34)CC2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702818	=	=	IC50	nM	6400.0	IC50	nM	6400.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(C(=O)Nc5ccc6c(c5)OCCO6)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702819	=	=	IC50	nM	2630.0	IC50	nM	2630.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C(=O)OC)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702820	=	=	IC50	nM	3850.0	IC50	nM	3850.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(C#N)cc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702821	=	=	IC50	nM	9330.0	IC50	nM	9330.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2C(CN(Cc3cccc4c(-c5ccc(S(C)(=O)=O)cc5)cn(C)c34)C(=O)[C@@H]2Cc2ccc(O)cc2)N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702822	=	=	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=S)NC(=O)OCC)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702823	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5ccc(NC(=S)NC(=O)c6ccccc6)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702824	>	>	IC50	nM	25000.0	IC50	nM	25000.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cnc6ccccc6c5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702825	=	=	IC50	nM	2090.0	IC50	nM	2090.0
Inhibition Assay: This assay was performed in a 200 l volume in 96-well microtiter plates using cDNA-expressed human hepatic CYP3A4 (supersome, BD Gentest #456202). As a substrate for CYP3A4, 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) was used. The compounds of Examples 1 to 5 and the substrate BFC were dissolved in 100% acetonitrile. The final volume of acetonitrile of the incubation mixture was less than 1% (volume/volume). A potassium phosphate buffer (pH 7.4, final concentration 0.1M), MgCl2 (final concentration 8.3 mM), EDTA (final concentration 1.67 mM), an inventive compound stock solution, CYP3A4 supersome, and NADPH (final concentration 0.25 mM) were added to each well. The reaction was initiated by adding the substrate (BFC, final concentration 30 M) at 37. The incubation was performed for 20 minutes and then the reaction was terminated by the addition of 75 ul of acetonitrile: 0.5 M tris-base=4:1 (volume/volume).Then, a fluorescent signal was measured using a fluorometer.	C=CCN1CC(=O)N2[C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3cccc4c(-c5cnc(N(C)C)nc5)cn(C)c34)C[C@@H]2N1C(=O)NCc1ccccc1		2015.0	CHEMBL3702826	=	=	IC50	nM	6410.0	IC50	nM	6410.0
Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1		2015.0	CHEMBL3125537	=	=	IC50	nM	0.0962	IC50	nM	0.0962
Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)c(F)c1		2015.0	CHEMBL3407554	=	=	IC50	nM	0.102	IC50	nM	0.102
Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.	COc1cc(NC(=O)C[C@@]2(C)C[C@H](c3cccc(Cl)c3)[C@@H](c3ccc(Cl)cc3)N([C@H](CS(=O)(=O)C(C)(C)C)C3CC3)C2=O)ccc1C(=O)O		2015.0	CHEMBL3407558	=	=	IC50	nM	0.0503	IC50	nM	0.0503
Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.	CC(C)(C)S(=O)(=O)C[C@H](C1CC1)N1C(=O)[C@@](C)(CC(N)=O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1		2015.0	CHEMBL3236364	=	=	IC50	nM	1.83	IC50	nM	1.83
Homogenous Time-Resolved Fluorescence Assay (HTRF): The standard assay conditions for the in vitro HTRF assay consisted of a 50 ul total reaction volume in black 384-well Costar polypropylene plates in 1PBS buffer pH 7.4, 1 mM DTT, 0.1% BSA, 2.5 nM GST-hMDM2 (aa 1-188), 5 nM biotinylated-p53 (aa 1-83), 1.8 nM SA-XLent (Cisbio; Bedford, Mass.), 0.6 nM anti-GST cryptate monoclonal antibody (Cisbio; Bedford, Mass.) and 200 mM KF. Amino acid residues 1-188 of human MDM2 were expressed as an amino-terminal glutathione S-transferase (GST) fusion protein (GST-hMDM2) in Escherichia coli. Residues 1-83 of human p53 were expressed as an amino-terminal AviTag-TrxA-6His fusion protein (biotinylated p53) in E. coli. Each protein was purified from cell paste by affinity chromatography.Specifically, 10 uL of GST-hMDM2 was incubated with 10 ul of diluted compound (various concentrations, serially diluted) in 10% DMSO for 20 minutes at room temperature. 20 uL of biotinylated-p53 was added to the GST-hMDM2+compound mixture.	COc1cc(NC(=O)C[C@@]2(C)C[C@H](c3cccc(Cl)c3)[C@@H](c3ccc(Cl)c(F)c3)N([C@H](CS(=O)(=O)C(C)(C)C)C3CC3)C2=O)ccc1C(=O)O		2015.0	CHEMBL3407575	=	=	IC50	nM	0.33	IC50	nM	0.33
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672572	=	=	IC50	nM	160.0	IC50	nM	160.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672573	=	=	IC50	nM	170.0	IC50	nM	170.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672574	=	=	IC50	nM	120.0	IC50	nM	120.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CSC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672575	=	=	IC50	nM	200.0	IC50	nM	200.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CS(=O)(=O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672576	=	=	IC50	nM	160.0	IC50	nM	160.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCN(C)CC2)cs1		2015.0	CHEMBL3672577	=	=	IC50	nM	190.0	IC50	nM	190.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCNCC2)cs1		2015.0	CHEMBL3672585	=	=	IC50	nM	150.0	IC50	nM	150.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCN(C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3639714	=	=	IC50	nM	140.0	IC50	nM	140.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672578	=	=	IC50	nM	190.0	IC50	nM	190.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CN[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1		2015.0	CHEMBL3672586	=	=	IC50	nM	170.0	IC50	nM	170.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N(C)C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672587	=	=	IC50	nM	150.0	IC50	nM	150.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N3CCOCC3)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672579	=	=	IC50	nM	120.0	IC50	nM	120.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](N3CCOCC3)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672580	<	<	IC50	nM	100.0	IC50	nM	100.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(=O)N[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1		2015.0	CHEMBL3672581	<	<	IC50	nM	100.0	IC50	nM	100.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672582	=	=	IC50	nM	130.0	IC50	nM	130.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672583	=	=	IC50	nM	110.0	IC50	nM	110.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2Cc3nc[nH]c3C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672584	=	=	IC50	nM	190.0	IC50	nM	190.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672572	=	=	IC50	nM	230.0	IC50	nM	230.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672573	=	=	IC50	nM	240.0	IC50	nM	240.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672574	=	=	IC50	nM	300.0	IC50	nM	300.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CSC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672575	=	=	IC50	nM	300.0	IC50	nM	300.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CS(=O)(=O)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672576	=	=	IC50	nM	260.0	IC50	nM	260.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCN(C)CC2)cs1		2015.0	CHEMBL3672577	=	=	IC50	nM	340.0	IC50	nM	340.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)NC2(C(=O)N[C@H](CC[C@H](Cc3ccccc3)NC(=O)OCc3cncs3)Cc3ccccc3)CCNCC2)cs1		2015.0	CHEMBL3672585	=	=	IC50	nM	340.0	IC50	nM	340.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCN(C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3639714	=	=	IC50	nM	300.0	IC50	nM	300.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672578	=	=	IC50	nM	310.0	IC50	nM	310.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CN[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1		2015.0	CHEMBL3672586	=	=	IC50	nM	360.0	IC50	nM	360.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N(C)C)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672587	=	=	IC50	nM	330.0	IC50	nM	330.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@@H](N3CCOCC3)C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672579	=	=	IC50	nM	350.0	IC50	nM	350.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2C[C@H](N3CCOCC3)C[C@H]2C(=O)N[C@@H](CC[C@@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672580	=	=	IC50	nM	150.0	IC50	nM	150.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(=O)N[C@H]1C[C@@H](C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)N(C(=O)N(C)Cc2csc(C(C)C)n2)C1		2015.0	CHEMBL3672581	=	=	IC50	nM	370.0	IC50	nM	370.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCC[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672582	=	=	IC50	nM	260.0	IC50	nM	260.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2CCC[C@@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672583	=	=	IC50	nM	250.0	IC50	nM	250.0
Inhibition Assay: The potencies of the compounds as inhibitors of human hepatic cytochromes P450 of the CYP3A subfamily (particularly CYP3A4) were assessed using well-characterized selective activities: midazolam 1'-hydroxylase (Kronbach, T., et al. Mol. Pharmacol. 36, 89-96 [1989]) and testosterone 6beta -hydroxylase (Waxman, D. J., et al. Arch. Biochem. Biophys. 263, 424-436, [1988]). For midazolam hydroxylase determination the final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/mL and 2.5 uM, respectively, and the LC-MS internal standard was 1alpha -hydroxytriazolam. For testosterone hydroxylase activity the final microsomal protein concentration was 0.5 mg/mL, the substrate concentration was 50 uM and the LC-MS internal standard was D7-labeled 6beta -hydroxytestosterone. After incubation at 37 C. for 5 minutes, metabolic reactions were terminated by treatment with quench solution containing the appropriate internal standard.	CC(C)c1nc(CN(C)C(=O)N2Cc3nc[nH]c3C[C@H]2C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1		2015.0	CHEMBL3672584	=	=	IC50	nM	370.0	IC50	nM	370.0
Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	12.0	IC50	nM	12.0
null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	8800.0	IC50	nM	8800.0
null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1		2015.0	CHEMBL1437764	=	=	IC50	nM	47500.0	IC50	nM	47500.0
null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL275066	=	=	IC50	nM	52500.0	IC50	nM	52500.0
null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	c1ccc(-c2c[nH]cn2)cc1		2015.0	CHEMBL14145	=	=	IC50	nM	58800.0	IC50	nM	58800.0
null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	c1ccc(Cn2ccnc2)cc1		2015.0	CHEMBL14192	=	=	IC50	nM	77500.0	IC50	nM	77500.0
null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	c1ccc(-c2nc[nH]c2-c2ccccc2)cc1		2015.0	CHEMBL224554	=	=	IC50	nM	100000.0	IC50	nM	100000.0
null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	Cc1nccn1Cc1ccccc1		2015.0	CHEMBL1269154	=	=	IC50	nM	307500.0	IC50	nM	307500.0
null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1		2015.0	CHEMBL104	>	>	IC50	nM	500000.0	IC50	nM	500000.0
null: Microsomal preparation: One lobe of fresh pig liver is obtained (e.g., at about the time of slaughter from a food-processing company) and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver is minced and homogenized in 30 mL of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer or equivalent by pulsing 3 times with 20 second pulses. This procedure is repeated for a total of 8x10 g samples of pig liver. The remaining pig liver may be stored at -80 C. The homogenates from the 8 samples are pooled and centrifuged at 13,000xg for 20 minutes at 4 C. to remove crude debris. The supernatant is further centrifuged at 100,000xg for 70 minutes at 4° C. The microsomal pellets are re-suspended into 50 mL of 150 mM KH2PO4/1 mM DTT (pH 7.4) and 1 mL aliquots are stored at -80 C.100-150 ug of pig liver microsomal protein in 150 mM KH2PO4 is incubated at 37° C.	c1ccc(-c2ncc[nH]2)cc1		2015.0	CHEMBL14189	>	>	IC50	nM	500000.0	IC50	nM	500000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1		2015.0	CHEMBL389433	<	<	IC50	nM	100.0	IC50	nM	100.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1		2015.0	CHEMBL1437764	=	=	IC50	nM	100.0	IC50	nM	100.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	500.0	IC50	nM	500.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1		2015.0	CHEMBL104	=	=	IC50	nM	300.0	IC50	nM	300.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL275066	=	=	IC50	nM	1000.0	IC50	nM	1000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc(-c2c[nH]cn2)cc1		2015.0	CHEMBL14145	=	=	IC50	nM	1500.0	IC50	nM	1500.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	C=CN(C=N)C(c1ccccc1)c1ccc(-c2ccccc2)cc1		2015.0	CHEMBL3961189	=	=	IC50	nM	800.0	IC50	nM	800.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(=O)c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL528463	=	=	IC50	nM	800.0	IC50	nM	800.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(C)(C(=O)c1cccnc1)c1cccnc1		2015.0	CHEMBL934	=	=	IC50	nM	3000.0	IC50	nM	3000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2		2015.0	CHEMBL1201131	=	=	IC50	nM	3000.0	IC50	nM	3000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1		2015.0	CHEMBL91	=	=	IC50	nM	5000.0	IC50	nM	5000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1		2015.0	CHEMBL91	=	=	IC50	nM	5000.0	IC50	nM	5000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F		2015.0	CHEMBL106	=	=	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCN(CC)C(=O)/C=C/C=C/c1ccc2c(c1)OCO2		2015.0	CHEMBL3889591	=	=	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	NCCCn1ccnc1		2015.0	CHEMBL3984871	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1		2015.0	CHEMBL25105	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Nc1nc(Cc2ccccc2)nc2nc[nH]c12		2015.0	CHEMBL3913781	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	N[C@@H](Cc1c[nH]cn1)C(=O)O		2015.0	CHEMBL17962	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CN/C(=N/CCSCc1nc[nH]c1C)NC#N		2015.0	CHEMBL30	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3		2015.0	CHEMBL40583	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		2015.0	CHEMBL261454	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCc1cccc(C)c1N(C(=O)CCl)C(C)CCO		2015.0	CHEMBL3963505	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCc1nc(C)c[nH]1		2015.0	CHEMBL1367804	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1ncnc2[nH]cnc12		2015.0	CHEMBL140037	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	NC(=O)CC[C@H](N)C(=O)O		2015.0	CHEMBL930	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O		2015.0	CHEMBL54976	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc2[nH]cnc2c1		2015.0	CHEMBL306226	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc(-c2ncc[nH]2)cc1		2015.0	CHEMBL14189	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1ccc(-c2nc3ccccc3[nH]2)cc1		2015.0	CHEMBL153535	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cn1ccnc1		2015.0	CHEMBL543	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O		2015.0	CHEMBL8	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCOC(=O)[C@H](C)[C@@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@H](C)[C@@H](O[C@H](OC(C)C)[C@H](O)CN(C)C)[C@](C)(O)C[C@@H](C)C(O)[C@H](C)[C@@H](O)[C@H](C)O		2015.0	CHEMBL4111332	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	C=Cn1ccnc1		2015.0	CHEMBL3929571	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Clc1ccccc1-c1nc2ccccc2[nH]1		2015.0	CHEMBL473162	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Nc1nc[nH]n1		2015.0	CHEMBL232801	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	O=S(=O)(O)c1ccc2[nH]c(-c3ccccc3)nc2c1		2015.0	CHEMBL1987518	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	COc1ccc([C@@H]2Sc3ccccc3N(C(C)N(C)C)C(=O)[C@@H]2OC(C)=O)cc1		2015.0	CHEMBL4107351	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1c[nH]cn1		2015.0	CHEMBL540	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cc1ncc[nH]1		2015.0	CHEMBL293391	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	NC(=O)CC[C@@H](N)C(=O)O		2015.0	CHEMBL1232207	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCCc1nc(Cl)cn1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1		2015.0	CHEMBL3913946	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cc1cccc(C)c1N(Cn1cccn1)C(=O)CCl		2015.0	CHEMBL2272118	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	N=C(N)NCCC[C@H](N)C(=O)O		2015.0	CHEMBL1485	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	O=c1ncnc2[nH][nH]cc1-2		2015.0	CHEMBL1467	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(NC(=O)[C@@H](N)CCC(=O)O)c1ncc[nH]1		2015.0	CHEMBL3928334	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	O=C(n1ccnc1)n1ccnc1		2015.0	CHEMBL3903881	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCc1ncc[nH]1		2015.0	CHEMBL303797	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cn1c(=O)c2nc[nH]c2n(C)c1=O		2015.0	CHEMBL190	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(=O)n1ccnc1		2015.0	CHEMBL1592087	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	NC(=O)C[C@H](N)C(=O)O		2015.0	CHEMBL58832	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCCc1nc(C=O)c(Cl)[nH]1		2015.0	CHEMBL3933368	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(=O)/C=C/C1=C(C)CCCC1(C)C		2015.0	CHEMBL559945	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC1=N[C@H](C(=O)O)CCN1		2015.0	CHEMBL1230264	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)C(C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O		2015.0	CHEMBL3184688	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1		2015.0	CHEMBL623	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	NC(=O)N1c2ccccc2C=Cc2ccccc21		2015.0	CHEMBL108	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCCCNC(=O)n1c(NC(=O)OC)nc2ccccc21		2015.0	CHEMBL327919	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1nc(CC2CCCNC2)c[nH]1		2015.0	CHEMBL151467	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CC(=O)O[C@@H]1[C@H](C)[C@@H](CO)/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@H]1C		2015.0	CHEMBL4111819	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C		2015.0	CHEMBL160	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCC[C@H](NC)[C@@H](O)[C@@H](O)OCCC[C@](C)(O)C1O[C@H]([C@H](CC)OCC[C@H](OC)[C@@H](O)[C@H](C)O)C(O)OC[C@H](C)[C@H](OC(C)O)[C@H]1C		2015.0	CHEMBL3923392	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Cn1cc[nH]c1=S		2015.0	CHEMBL1515	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21		2015.0	CHEMBL5	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	Nc1ncnc2[nH]cnc12		2015.0	CHEMBL226345	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1coc(-c2nc3ccccc3[nH]2)c1		2015.0	CHEMBL201094	>	>	IC50	nM	10000.0	IC50	nM	10000.0
null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	c1coc(CNc2ncnc3[nH]cnc23)c1		2015.0	CHEMBL228792	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	8800.0	IC50	nM	8800.0
In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1		2015.0	CHEMBL1437764	=	=	IC50	nM	47500.0	IC50	nM	47500.0
In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL275066	=	=	IC50	nM	52500.0	IC50	nM	52500.0
In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	c1ccc(-c2c[nH]cn2)cc1		2015.0	CHEMBL14145	=	=	IC50	nM	58800.0	IC50	nM	58800.0
In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	c1ccc(Cn2ccnc2)cc1		2015.0	CHEMBL14192	=	=	IC50	nM	77500.0	IC50	nM	77500.0
In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	c1ccc(-c2nc[nH]c2-c2ccccc2)cc1		2015.0	CHEMBL224554	=	=	IC50	nM	100000.0	IC50	nM	100000.0
In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	Cc1nccn1Cc1ccccc1		2015.0	CHEMBL1269154	=	=	IC50	nM	307500.0	IC50	nM	307500.0
In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	ClC1CC=CC=C1C(c1ccccc1)(c1ccccc1)n1ccnc1		2015.0	CHEMBL3952468	>	>	IC50	nM	500000.0	IC50	nM	500000.0
In vitro ATRA 4-Hydroxylase Activity Assay: All procedures were carried out under minimal light in order to prevent degradation of the retinoid samples.Microsomal preparation: one lobe of fresh pig liver was obtained at the time of slaughter from a food-processing company and immediately placed in ice cold 15 mM KH2PO4/250 mM sucrose (pH 7.4) and kept on ice during transportation. A 10 g sample of liver was minced and homogenized in 30 mls of homogenization buffer (15 mM KH2PO4/250 mM sucrose) using a Tekmar homoginizer by pulsing 3 times 20 second pulses. This procedure was repeated for a total of 8x10 g samples of pig liver. The remaining pig liver was cut into 10-g pieces and wrapped in aluminum foil and stored at -80 °C. The homogenates from the 8 samples were pooled and centrifuged at 13,000xg for 20 minutes at 4 °C. to remove crude debris and the supernatant was further centrifuged at 100,000xg for 70 minutes at 4 °C. The microsomal pellets were resuspended into 50 mls of 150 mM KH2PO4/1 mM DTT (pH 7.4).	c1ccc(-c2ncc[nH]2)cc1		2015.0	CHEMBL14189	>	>	IC50	nM	500000.0	IC50	nM	500000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Clc1cccc(C(c2ccc3nc[nH]c3c2)n2ccnc2)c1		2015.0	CHEMBL389433	<	<	IC50	nM	100.0	IC50	nM	100.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(C)(C)C(=O)C(Oc1ccc(Cl)cc1)n1ccnc1		2015.0	CHEMBL1437764	=	=	IC50	nM	100.0	IC50	nM	100.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	500.0	IC50	nM	500.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	ClC1CC=CC=C1C(c1ccccc1)(c1ccccc1)n1ccnc1		2015.0	CHEMBL3952468	=	=	IC50	nM	300.0	IC50	nM	300.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL275066	=	=	IC50	nM	1000.0	IC50	nM	1000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-c2c[nH]cn2)cc1		2015.0	CHEMBL14145	=	=	IC50	nM	1500.0	IC50	nM	1500.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1		2015.0	CHEMBL277535	=	=	IC50	nM	800.0	IC50	nM	800.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(=O)c1ccc(-n2ccnc2)cc1		2015.0	CHEMBL528463	=	=	IC50	nM	800.0	IC50	nM	800.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(C)(C(=O)c1cccnc1)c1cccnc1		2015.0	CHEMBL934	=	=	IC50	nM	3000.0	IC50	nM	3000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCCCOCCOCCOCc1cc2c(cc1CCC)OCO2		2015.0	CHEMBL1201131	=	=	IC50	nM	3000.0	IC50	nM	3000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1		2015.0	CHEMBL91	=	=	IC50	nM	5000.0	IC50	nM	5000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1		2015.0	CHEMBL91	=	=	IC50	nM	5000.0	IC50	nM	5000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F		2015.0	CHEMBL106	=	=	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCCN(CC)C(=O)/C=C/C=C/c1ccc2c(c1)OCO2		2015.0	CHEMBL3889591	=	=	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	NCCCn1ccnc1		2015.0	CHEMBL3984871	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2)cc1		2015.0	CHEMBL25105	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Nc1nc(Cc2ccccc2)nc2nc[nH]c12		2015.0	CHEMBL3913781	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	N[C@@H](Cc1c[nH]cn1)C(=O)O		2015.0	CHEMBL17962	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CN/C(=N/CCSCc1nc[nH]c1C)NC#N		2015.0	CHEMBL30	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3		2015.0	CHEMBL40583	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		2015.0	CHEMBL261454	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCc1cccc(C)c1N(C(=O)CCl)[C@@H](C)COC		2015.0	CHEMBL2251445	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCc1nc(C)c[nH]1		2015.0	CHEMBL1367804	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Clc1ncnc2[nH]cnc12		2015.0	CHEMBL140037	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	NC(=O)CC[C@H](N)C(=O)O		2015.0	CHEMBL930	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O		2015.0	CHEMBL54976	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc2[nH]cnc2c1		2015.0	CHEMBL306226	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-c2ncc[nH]2)cc1		2015.0	CHEMBL14189	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1ccc(-c2nc3ccccc3[nH]2)cc1		2015.0	CHEMBL153535	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cn1ccnc1		2015.0	CHEMBL543	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O		2015.0	CHEMBL8	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](C)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O		2015.0	CHEMBL1237043	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	C=Cn1ccnc1		2015.0	CHEMBL3929571	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Clc1ccccc1-c1nc2ccccc2[nH]1		2015.0	CHEMBL473162	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Nc1nc[nH]n1		2015.0	CHEMBL232801	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	O=S(=O)(O)c1ccc2[nH]c(-c3ccccc3)nc2c1		2015.0	CHEMBL1987518	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCOO[C@H]1C(=O)N(CCN(C)C)c2ccccc2S[C@H]1c1ccc(OC)cc1		2015.0	CHEMBL4106906	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1c[nH]cn1		2015.0	CHEMBL540	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cc1ncc[nH]1		2015.0	CHEMBL293391	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	NC(=O)CC[C@H](N)C(=O)O		2015.0	CHEMBL930	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCCCc1nc(Cl)c(COC(c2ccccc2)(c2ccccc2)c2ccccc2)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1		2015.0	CHEMBL3968740	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cc1cccc(C)c1N(Cn1cccn1)C(=O)CCl		2015.0	CHEMBL2272118	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	N=C(N)NCCC[C@H](N)C(=O)O		2015.0	CHEMBL1485	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	O=c1ncnc2[nH][nH]cc1-2		2015.0	CHEMBL1467	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(NC(=O)[C@@H](N)CCC(=O)O)c1ncc[nH]1		2015.0	CHEMBL3928334	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	O=C(n1ccnc1)n1ccnc1		2015.0	CHEMBL3903881	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCc1ncc[nH]1		2015.0	CHEMBL303797	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cn1c(=O)c2nc[nH]c2n(C)c1=O		2015.0	CHEMBL190	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(=O)n1ccnc1		2015.0	CHEMBL1592087	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	NC(=O)C[C@H](N)C(=O)O		2015.0	CHEMBL58832	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCCCc1nc(C=O)c(Cl)[nH]1		2015.0	CHEMBL3933368	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(=O)/C=C/C1=C(C)CCCC1(C)C		2015.0	CHEMBL559945	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC1=N[C@H](C(=O)O)CCN1		2015.0	CHEMBL1230264	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC[C@@H]1OC(=O)[C@@H](C)[C@H](O[C@@H]2C[C@](C)(OC)[C@H](O)[C@@H](C)O2)C(C)[C@H](O[C@H]2O[C@@H](C)C[C@@H](N(C)C)[C@@H]2O)[C@@](C)(OC)C[C@H](C)C(=O)[C@@H](C)[C@H](O)[C@@]1(C)O		2015.0	CHEMBL3937847	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1		2015.0	CHEMBL623	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	NC(=O)N1c2ccccc2C=Cc2ccccc21		2015.0	CHEMBL108	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCCCNC(=O)n1c(NC(=O)OC)nc2ccccc21		2015.0	CHEMBL327919	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1nc(CC2CCCNC2)c[nH]1		2015.0	CHEMBL151467	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CC(=O)O[C@@H]1[C@H](C)[C@@H](CO)/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@H]1C		2015.0	CHEMBL4111819	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C		2015.0	CHEMBL4108227	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCC[C@@H]([C@@H](OC(C)=O)[C@@H](O)OCCCC(C)(O)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)COC(=O)[C@H](C)[C@H](CC)OCC[C@H](OC)[C@@H](OC(C)=O)[C@H](C)O)N(C)C		2015.0	CHEMBL3930201	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Cn1cc[nH]c1=S		2015.0	CHEMBL1515	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	CCn1cc(C(=O)O)c(=O)c2ccc(C)nc21		2015.0	CHEMBL5	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	Nc1ncnc2[nH]cnc12		2015.0	CHEMBL226345	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1coc(-c2nc3ccccc3[nH]2)c1		2015.0	CHEMBL201094	>	>	IC50	nM	10000.0	IC50	nM	10000.0
In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	c1coc(CNc2ncnc3[nH]cnc23)c1		2015.0	CHEMBL228792	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition Assay: CYP17 activity was assayed according to the following procedure. Solutions of each test compound and isozyme inhibitor (ketoconazole) were separately prepared at concentrations of 2700, 540, 90, 18, 3, 0.6 and 0.1 uM by serial dilution with DMSO:ACN (50:50 v/v). The individual test compound and isozyme inhibitor solutions were then diluted 20-fold with deionized water (50:950 v/v) to concentrations of 135, 27, 4.5, 0.9, 0.15, 0.03 and 0.005 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture is 1%. Pooled rat testicular microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 1.25 mg/mL suspension. A solution of NADPH was prepared in phosphate buffer at a concentration of 2.5x. A stock solution of the substrate was prepared in DMSO:MeCN (50:50 v/v), mixed, and diluted in phosphate buffer to obtain a single solution containing the substrate at 5 uM.	COc1cc2ccc(C(O)(c3cncs3)C(C)C)cc2cc1OC		2015.0	CHEMBL3264599	=	=	IC50	nM	770.0	IC50	nM	770.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1		2015.0	CHEMBL3964719	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c1		2015.0	CHEMBL3929240	=	=	IC50	nM	43000.0	IC50	nM	43000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ccccn1		2015.0	CHEMBL3906541	=	=	IC50	nM	21000.0	IC50	nM	21000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1cccnc1		2015.0	CHEMBL3920320	=	=	IC50	nM	1200.0	IC50	nM	1200.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncccn1		2015.0	CHEMBL3919273	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1cnccn1		2015.0	CHEMBL3922632	=	=	IC50	nM	26000.0	IC50	nM	26000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1cccnn1		2015.0	CHEMBL3937551	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1nccs1		2015.0	CHEMBL3912376	=	=	IC50	nM	3200.0	IC50	nM	3200.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncco1		2015.0	CHEMBL3946411	=	=	IC50	nM	8400.0	IC50	nM	8400.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3951681	=	=	IC50	nM	43000.0	IC50	nM	43000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3901346	=	=	IC50	nM	30000.0	IC50	nM	30000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-n1cccn1		2015.0	CHEMBL3936446	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3ccnn3)c2)c1		2015.0	CHEMBL3974746	=	=	IC50	nM	14000.0	IC50	nM	14000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1		2015.0	CHEMBL3932552	=	=	IC50	nM	43000.0	IC50	nM	43000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncccn3)c2)c1		2015.0	CHEMBL3922611	=	=	IC50	nM	33000.0	IC50	nM	33000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1		2015.0	CHEMBL3962055	=	=	IC50	nM	39000.0	IC50	nM	39000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)c1		2015.0	CHEMBL3982154	=	=	IC50	nM	32000.0	IC50	nM	32000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(F)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2cccn2)c1		2015.0	CHEMBL3943785	=	=	IC50	nM	25000.0	IC50	nM	25000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)c1F		2015.0	CHEMBL3921296	=	=	IC50	nM	20000.0	IC50	nM	20000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3962710	=	=	IC50	nM	41000.0	IC50	nM	41000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cncn3)c2)c1		2015.0	CHEMBL3933744	=	=	IC50	nM	6000.0	IC50	nM	6000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ccccn3)c2)c1		2015.0	CHEMBL3957752	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(F)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3969984	=	=	IC50	nM	24000.0	IC50	nM	24000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3892369	=	=	IC50	nM	31000.0	IC50	nM	31000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ccncc3)c2)c1		2015.0	CHEMBL3967139	=	=	IC50	nM	300.0	IC50	nM	300.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1F		2015.0	CHEMBL3981412	=	=	IC50	nM	39000.0	IC50	nM	39000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3952666	=	=	IC50	nM	17000.0	IC50	nM	17000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	N#Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3945071	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3949919	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1F		2015.0	CHEMBL3890222	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1OC		2015.0	CHEMBL3917412	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1C		2015.0	CHEMBL3913869	=	=	IC50	nM	20000.0	IC50	nM	20000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3960556	=	=	IC50	nM	36000.0	IC50	nM	36000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1C		2015.0	CHEMBL3942262	=	=	IC50	nM	17000.0	IC50	nM	17000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3nccc(C)n3)c2)c1		2015.0	CHEMBL3947571	=	=	IC50	nM	18000.0	IC50	nM	18000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncco2)c1		2015.0	CHEMBL3956147	=	=	IC50	nM	5100.0	IC50	nM	5100.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3nccs3)c2)c1		2015.0	CHEMBL3941085	=	=	IC50	nM	1200.0	IC50	nM	1200.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2nccs2)c1		2015.0	CHEMBL3967251	=	=	IC50	nM	2000.0	IC50	nM	2000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3cccnn3)c2)c1		2015.0	CHEMBL3950355	=	=	IC50	nM	6000.0	IC50	nM	6000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2cccnn2)c1		2015.0	CHEMBL3926167	=	=	IC50	nM	9600.0	IC50	nM	9600.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncccn3)c2)c1F		2015.0	CHEMBL3941635	=	=	IC50	nM	21000.0	IC50	nM	21000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncccn3)c2)c1		2015.0	CHEMBL3913644	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncccn2)c1		2015.0	CHEMBL3936154	=	=	IC50	nM	20000.0	IC50	nM	20000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)n1		2015.0	CHEMBL3932799	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3cccn3)c2)n1		2015.0	CHEMBL3954973	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(F)c1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3927349	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1		2015.0	CHEMBL3942815	=	=	IC50	nM	33000.0	IC50	nM	33000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F		2015.0	CHEMBL3968722	=	=	IC50	nM	20000.0	IC50	nM	20000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2cc(C)ccc2-n2nccn2)cc1-c1ncon1		2015.0	CHEMBL3959904	=	=	IC50	nM	42000.0	IC50	nM	42000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncon1		2015.0	CHEMBL3975507	=	=	IC50	nM	32000.0	IC50	nM	32000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccc(C)cc2-n2nccn2)cc1-c1ncon1		2015.0	CHEMBL3947761	=	=	IC50	nM	41000.0	IC50	nM	41000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C[C@@H]2COCCN2C(=O)c2ccc(F)cc2-n2nccn2)cc1-c1ncon1		2015.0	CHEMBL3977023	=	=	IC50	nM	42000.0	IC50	nM	42000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3938981	=	=	IC50	nM	29000.0	IC50	nM	29000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1-n1nccn1		2015.0	CHEMBL3933467	=	=	IC50	nM	33000.0	IC50	nM	33000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2ccc(C)c(-n3nccn3)c2)c1		2015.0	CHEMBL4115063	=	=	IC50	nM	22000.0	IC50	nM	22000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-n1nccn1		2015.0	CHEMBL3972999	=	=	IC50	nM	36000.0	IC50	nM	36000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2ccc(C)c(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3895130	=	=	IC50	nM	25000.0	IC50	nM	25000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1COC[C@@H](Cc2cccc(-n3nccn3)c2)N1C(=O)c1ccccc1-n1nccn1		2015.0	CHEMBL3951941	=	=	IC50	nM	24000.0	IC50	nM	24000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2[C@@H](C)COC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3936704	=	=	IC50	nM	14000.0	IC50	nM	14000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2[C@@H](C)COC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3909876	=	=	IC50	nM	6800.0	IC50	nM	6800.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cc(C)c(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3915231	=	=	IC50	nM	15000.0	IC50	nM	15000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(C(F)(F)F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3959470	=	=	IC50	nM	7500.0	IC50	nM	7500.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3946888	=	=	IC50	nM	16000.0	IC50	nM	16000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1F		2015.0	CHEMBL3968942	=	=	IC50	nM	22000.0	IC50	nM	22000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3895786	=	=	IC50	nM	33000.0	IC50	nM	33000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c1-n1nccn1		2015.0	CHEMBL3932131	=	=	IC50	nM	25000.0	IC50	nM	25000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1		2015.0	CHEMBL3909701	=	=	IC50	nM	21000.0	IC50	nM	21000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-c3ncon3)c2)c(-n2nccn2)cc1C		2015.0	CHEMBL3963262	=	=	IC50	nM	25000.0	IC50	nM	25000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(C(F)(F)F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-c2ncon2)c1		2015.0	CHEMBL3938822	=	=	IC50	nM	15000.0	IC50	nM	15000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1ccc(Cl)c(-c2ncon2)c1		2015.0	CHEMBL3936592	=	=	IC50	nM	21000.0	IC50	nM	21000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(F)c(F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3901849	=	=	IC50	nM	17000.0	IC50	nM	17000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1C		2015.0	CHEMBL3952970	=	=	IC50	nM	44000.0	IC50	nM	44000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3930115	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1C		2015.0	CHEMBL3944222	=	=	IC50	nM	30000.0	IC50	nM	30000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3916290	=	=	IC50	nM	49000.0	IC50	nM	49000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3946474	=	=	IC50	nM	28000.0	IC50	nM	28000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c1-n1nccn1		2015.0	CHEMBL3943141	=	=	IC50	nM	11000.0	IC50	nM	11000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1C		2015.0	CHEMBL3910117	=	=	IC50	nM	9700.0	IC50	nM	9700.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1C		2015.0	CHEMBL3953726	=	=	IC50	nM	9600.0	IC50	nM	9600.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3976034	=	=	IC50	nM	13000.0	IC50	nM	13000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3915416	=	=	IC50	nM	9700.0	IC50	nM	9700.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@@]2(C)Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3914317	=	=	IC50	nM	17000.0	IC50	nM	17000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)cc1Cl		2015.0	CHEMBL3901878	=	=	IC50	nM	13000.0	IC50	nM	13000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(Cl)cc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3904485	=	=	IC50	nM	21000.0	IC50	nM	21000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(Cl)cc(-n3nccn3)c2)c1-n1nccn1		2015.0	CHEMBL3982996	=	=	IC50	nM	14000.0	IC50	nM	14000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3916665	=	=	IC50	nM	22000.0	IC50	nM	22000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cccc(-c3ncccn3)c2)CO1		2015.0	CHEMBL3922707	=	=	IC50	nM	46000.0	IC50	nM	46000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-c3ncccn3)c2)c1		2015.0	CHEMBL3894723	=	=	IC50	nM	43000.0	IC50	nM	43000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-c3ncccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3931654	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-c3ncccn3)c2)c1-n1nccn1		2015.0	CHEMBL3900153	=	=	IC50	nM	40000.0	IC50	nM	40000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cccc(-c3ncccn3)c2)c(-n2nccn2)c1C		2015.0	CHEMBL3937108	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cccc(-c3ncccn3)c2)CO1		2015.0	CHEMBL3909195	=	=	IC50	nM	26000.0	IC50	nM	26000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cccc(-c3ncccn3)c2)CO1		2015.0	CHEMBL3946019	=	=	IC50	nM	35000.0	IC50	nM	35000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1		2015.0	CHEMBL3921658	=	=	IC50	nM	24000.0	IC50	nM	24000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1		2015.0	CHEMBL3914896	=	=	IC50	nM	21000.0	IC50	nM	21000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3984705	=	=	IC50	nM	23000.0	IC50	nM	23000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1-n1nccn1		2015.0	CHEMBL3940721	=	=	IC50	nM	23000.0	IC50	nM	23000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2C)c1		2015.0	CHEMBL3936519	=	=	IC50	nM	19000.0	IC50	nM	19000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c(-n2nccn2)c1		2015.0	CHEMBL3936920	=	=	IC50	nM	19000.0	IC50	nM	19000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)cc1C[C@@H]1COCCN1C(=O)c1ccccc1-n1nccn1		2015.0	CHEMBL3978573	=	=	IC50	nM	18000.0	IC50	nM	18000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c1-n1nccn1		2015.0	CHEMBL3954756	=	=	IC50	nM	18000.0	IC50	nM	18000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2C)c(-n2nccn2)c1		2015.0	CHEMBL3963023	=	=	IC50	nM	27000.0	IC50	nM	27000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)cc1C[C@@H]1COCCN1C(=O)c1cccc(C)c1-n1nccn1		2015.0	CHEMBL3939510	=	=	IC50	nM	22000.0	IC50	nM	22000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c1		2015.0	CHEMBL3965827	=	=	IC50	nM	22000.0	IC50	nM	22000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1Cl		2015.0	CHEMBL3950474	=	=	IC50	nM	17000.0	IC50	nM	17000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1-n1nccn1		2015.0	CHEMBL3977521	=	=	IC50	nM	30000.0	IC50	nM	30000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F		2015.0	CHEMBL3968141	=	=	IC50	nM	26000.0	IC50	nM	26000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F		2015.0	CHEMBL3912674	=	=	IC50	nM	20000.0	IC50	nM	20000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1		2015.0	CHEMBL3957620	=	=	IC50	nM	35000.0	IC50	nM	35000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1F		2015.0	CHEMBL3907193	=	=	IC50	nM	19000.0	IC50	nM	19000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c1F		2015.0	CHEMBL3974582	=	=	IC50	nM	37000.0	IC50	nM	37000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)cc1C		2015.0	CHEMBL3902291	=	=	IC50	nM	19000.0	IC50	nM	19000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F		2015.0	CHEMBL3924060	=	=	IC50	nM	30000.0	IC50	nM	30000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(C(F)(F)F)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1F		2015.0	CHEMBL3961204	=	=	IC50	nM	7400.0	IC50	nM	7400.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	COc1cc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2F)c(-n2nccn2)cc1Cl		2015.0	CHEMBL3933736	=	=	IC50	nM	13000.0	IC50	nM	13000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-n3ccnn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3939249	=	=	IC50	nM	19000.0	IC50	nM	19000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	CC[C@@H]1CN(C(=O)c2cc(C)ccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3977273	=	=	IC50	nM	9200.0	IC50	nM	9200.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	CC[C@@H]1CN(C(=O)c2ccccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3909380	=	=	IC50	nM	9100.0	IC50	nM	9100.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	CC[C@@H]1CN(C(=O)c2ccc(C)cc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3956556	=	=	IC50	nM	9600.0	IC50	nM	9600.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(F)cc(-n2nccn2)c1		2015.0	CHEMBL3932544	=	=	IC50	nM	22000.0	IC50	nM	22000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(F)cc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3971116	=	=	IC50	nM	40000.0	IC50	nM	40000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c1		2015.0	CHEMBL3909223	=	=	IC50	nM	28000.0	IC50	nM	28000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3962902	=	=	IC50	nM	31000.0	IC50	nM	31000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c1-n1nccn1		2015.0	CHEMBL3901113	=	=	IC50	nM	32000.0	IC50	nM	32000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cc(-c3ncccn3)ccc2F)CO1		2015.0	CHEMBL3925326	=	=	IC50	nM	15000.0	IC50	nM	15000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cc(-c3ncccn3)ccc2F)CO1		2015.0	CHEMBL3949593	=	=	IC50	nM	18000.0	IC50	nM	18000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cccc(Cl)c2-n2nccn2)[C@H](Cc2cc(-c3ncccn3)ccc2F)CO1		2015.0	CHEMBL3940958	=	=	IC50	nM	24000.0	IC50	nM	24000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c1		2015.0	CHEMBL3970504	=	=	IC50	nM	30000.0	IC50	nM	30000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3939766	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncccn3)ccc2F)c(-n2nccn2)c1C		2015.0	CHEMBL3932708	=	=	IC50	nM	40000.0	IC50	nM	40000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncccn2)ccc1F		2015.0	CHEMBL3901217	=	=	IC50	nM	17000.0	IC50	nM	17000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncccn2)ccc1F		2015.0	CHEMBL3923760	=	=	IC50	nM	17000.0	IC50	nM	17000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncccn2)ccc1F		2015.0	CHEMBL3895759	=	=	IC50	nM	33000.0	IC50	nM	33000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCO[C@@H](C)[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3922678	=	=	IC50	nM	14000.0	IC50	nM	14000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2C[C@@H](C)OC[C@H]2Cc2cc(-c3cccnn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3910286	=	=	IC50	nM	20000.0	IC50	nM	20000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3cccnn3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3907310	=	=	IC50	nM	19000.0	IC50	nM	19000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCO[C@H](C)[C@H]2Cc2cccc(-n3nccn3)c2)c(-n2nccn2)c1		2015.0	CHEMBL3957175	=	=	IC50	nM	8500.0	IC50	nM	8500.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3nccn3)ccc2Cl)c(-n2nccn2)c1C		2015.0	CHEMBL3985846	=	=	IC50	nM	29000.0	IC50	nM	29000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1Cl		2015.0	CHEMBL3942007	=	=	IC50	nM	9800.0	IC50	nM	9800.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-n2nccn2)ccc1Cl		2015.0	CHEMBL3897210	=	=	IC50	nM	13000.0	IC50	nM	13000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cccc(Cl)c2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3943170	=	=	IC50	nM	23000.0	IC50	nM	23000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cccc(Cl)c2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1		2015.0	CHEMBL3972733	=	=	IC50	nM	21000.0	IC50	nM	21000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c1		2015.0	CHEMBL3948499	=	=	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c(-n2nccn2)c1		2015.0	CHEMBL3980766	=	=	IC50	nM	35000.0	IC50	nM	35000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cc(Cl)ccc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncon2)ccc1F		2015.0	CHEMBL3967125	=	=	IC50	nM	22000.0	IC50	nM	22000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccc(Cl)cc1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncon2)ccc1F		2015.0	CHEMBL3946045	=	=	IC50	nM	24000.0	IC50	nM	24000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1cc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c(-n2nccn2)cc1C		2015.0	CHEMBL3968480	=	=	IC50	nM	29000.0	IC50	nM	29000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(Cl)c1-n1nccn1)N1CCOC[C@H]1Cc1cc(-c2ncon2)ccc1F		2015.0	CHEMBL3954732	=	=	IC50	nM	36000.0	IC50	nM	36000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-c3ncon3)ccc2F)c(-n2nccn2)c1C		2015.0	CHEMBL3930630	=	=	IC50	nM	36000.0	IC50	nM	36000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1cccc(C(F)(F)F)c1-n1nccn1)N1CCOC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3931693	=	=	IC50	nM	14000.0	IC50	nM	14000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cccc(-n3nccn3)c2F)c(-n2nccn2)c1		2015.0	CHEMBL3964366	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3940700	=	=	IC50	nM	19000.0	IC50	nM	19000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cccc(-n3nccn3)c2)CO1		2015.0	CHEMBL3909224	=	=	IC50	nM	20000.0	IC50	nM	20000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2cc(Cl)ccc2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1		2015.0	CHEMBL3938386	=	=	IC50	nM	19000.0	IC50	nM	19000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	C[C@@H]1CN(C(=O)c2ccc(Cl)cc2-n2nccn2)[C@H](Cc2cc(-n3nccn3)ccc2F)CO1		2015.0	CHEMBL3910447	=	=	IC50	nM	14000.0	IC50	nM	14000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCOC[C@H]2Cc2cc(-n3cccn3)ccc2C)c1		2015.0	CHEMBL3923356	=	=	IC50	nM	14000.0	IC50	nM	14000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(-n3cccn3)ccc2C)c(-n2nccn2)c1		2015.0	CHEMBL3947667	=	=	IC50	nM	17000.0	IC50	nM	17000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2cccn2)cc1C[C@@H]1COCCN1C(=O)c1cccc(C)c1-n1nccn1		2015.0	CHEMBL3910932	=	=	IC50	nM	26000.0	IC50	nM	26000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)cc1C[C@@H]1COCCN1C(=O)c1ccc(Cl)cc1-n1nccn1		2015.0	CHEMBL3938872	=	=	IC50	nM	14000.0	IC50	nM	14000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncccn1		2015.0	CHEMBL3901915	>	>	IC50	nM	50000.0	IC50	nM	50000.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1nccs1		2015.0	CHEMBL3907374	=	=	IC50	nM	600.0	IC50	nM	600.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3905808	=	=	IC50	nM	5500.0	IC50	nM	5500.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3917550	=	=	IC50	nM	3300.0	IC50	nM	3300.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	O=C(c1ccccc1-n1nccn1)N1CCCC[C@H]1Cc1cccc(-n2nccn2)c1		2015.0	CHEMBL3905303	=	=	IC50	nM	6100.0	IC50	nM	6100.0
CYP3A4 Inhibition Assay: The CYP3A4 inhibition assay was performed using human liver microsomes and testosterone 6'-hydroxylation as a P450 isoform-specific marker. In a total volume of 150 uL, 14C-testosterone at a final concentration of 40 uM in a 100 mM phosphate buffer (pH 7.4) was incubated in a 96-well plate with 0.3 mg/mL of human liver microsomes in an Eppendorf thermomixer at 37° C. and 400 rpm. A 1.0 uL-aliquot of the 150-fold concentrated compound stock solution, prepared in DMSO, was added to yield final inhibitor concentrations of 0, 0.1, 0.5, 1.0, 5.0, 10, 25, and 50 uM. The reaction was initiated by addition of 15 uL of the NADPH-regenerating system containing the glucose-6-phosphate dehydrogenase and terminated after 7 min with a 75 uL-aliquot of methanol. After centrifugation at 465 g and 4° C. for 20 min, a 50 uL-aliquot of the supernatant was submitted to HPLC according to the method described below.	Cc1ccc(-n2nccn2)c(C(=O)N2CCCC[C@H]2Cc2cccc(-n3nccn3)c2)c1		2015.0	CHEMBL3981385	=	=	IC50	nM	7700.0	IC50	nM	7700.0
Fluorescent High Throughput P450 Assay: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5). Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths. Concentration-response curves performed in duplicate for known inhibitors for each isoenzyme were tested in ever	CCCCCCCCCCCC(=O)OCC(CCP(=O)(O)OCCNC(=O)c1ccc(Cn2c(=O)[nH]c3c(N)nc(OCCOC)nc32)cc1)OC(=O)CCCCCCCCCCC		2015.0	CHEMBL4107005	=	=	IC50	nM	13600.0	IC50	nM	13600.0
Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths.	CCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCCNC(=O)c1ccc(Cn2c(=O)[nH]c3c(N)nc(OCCOC)nc32)cc1)OC(=O)CCCCCCCCCCC		2015.0	CHEMBL4106421	=	=	IC50	nM	13600.0	IC50	nM	13600.0
Fluorescent High Throughput P450 Assays: The interaction of SC12 with cytochrome P450 enzymes was tested using Fluorescent High Throughput P450 assays (Gentest); The IC50s of the compounds was calculated on isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2C8, CYP2B6, CYP2D6, CYP2E1, CYP3A4 and CYP3A5).Materials and Methods: Inhibition of the P450 isoforms was measured in specific assays using specific substrates that become fluorescent upon CYP metabolism. Compounds, dissolved in ACN (acetonitrile) (CYP2E1, CYP2C8, CYP2B6, CYP3A5) or DMSO (all remaining isoforms), were tested in duplicate (n=2) in concentration-response curves (eight concentrations) in a 96-well plate containing incubation/NADPH regenerating buffer. Specific isoenzymes and substrates were added and incubated at 37° C. Reactions were terminated at different times, depending on the assays, and plates read on a Fluoroskan Ascent at the appropriate emission/excitation wavelengths.	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1		2015.0	CHEMBL157101	=	=	IC50	nM	12.0	IC50	nM	12.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	CCOC(=O)/C=C/c1ccc(C(F)(F)C(O)(Cn2cnnn2)c2ccc(F)cc2F)nc1		2015.0	CHEMBL3891460	=	=	IC50	nM	83000.0	IC50	nM	83000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(/C=C/COCC(F)(F)F)cn1		2015.0	CHEMBL3954501	=	=	IC50	nM	81000.0	IC50	nM	81000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(Cl)nc2)cn1		2015.0	CHEMBL3918756	=	=	IC50	nM	17000.0	IC50	nM	17000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(F)nc2)cn1		2015.0	CHEMBL3945322	=	=	IC50	nM	33000.0	IC50	nM	33000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F		2015.0	CHEMBL106	=	=	IC50	nM	8000.0	IC50	nM	8000.0
Inhibition Assay: Solutions of each test compound were separately prepared at concentrations of 20000, 6000, 2000, 600, 200, and 60 uM by serial dilution with DMSO:MeCN (50:50 v/v). The individual test compound solutions were then diluted 20-fold with DMSO:MeCN:deionized water (5:5:180 v/v/v) to concentrations of 1000, 300, 100, 30, 10, and 3 Î¼M. Mixtures of isozyme inhibitors (sulfaphenazole, tranylcypromine, and ketoconazole as specific inhibitors of isozymes 2C9, 2C19, and 3A4, respectively) were prepared containing each inhibitor at concentrations of 6000, 2000, 600, 200, 60, 20, 6, and 2 uM by serial dilution with DMSO:CH3CN (50:50 v/v). The mixed inhibitor solutions were then diluted 20-fold with DMSO: CH3CN:deionized water (5:5:180 v/v/v) to concentrations of 300, 100, 30, 10, 3, 1, 0.3, and 0.1 uM. The percent of organic solvent attributable to the test compound or inhibitor mixture in the final reaction mixture was 2% v/v. Pooled human liver microsome suspension (20 mg/mL) was diluted with phosphate buffer to obtain a 5 mg/mL suspension.	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F		2015.0	CHEMBL638	=	=	IC50	nM	13000.0	IC50	nM	13000.0
Inhibition Assay: Inhibition of cytochromes P450 (CYPs) 2C9, 2D6 and 3A4 was assessed using human liver microsomes and CYP-selective substrate metabolism reactions. 50 μl incubations were made up containing (finally) 0.2 mg/ml pooled human liver microsomes, 5 μM substrate (diclofenac for CYP2C9 [4' hydroxylase], dextromethorphan for CYP2D6 [O-demethylase] or midazolam for CYP3A4 [1' hydroxylase]), 0.25 μl, DMSO containing test inhibitor and NADPH regenerating system. Test inhibitor concentrations of 50, 16.7, 5.6, 1.9, 0.6 and 0.2 μM were assessed in singlicate. Incubations were prewarmed to 37° C. for 10 minutes before initiation by addition of NADPH regenerating system. Incubations were quenched after 5 minutes (20 minutes for dextromethorphan) by addition of 50 μl cold acetonitrile containing 20 ng/ml 4-OH-diclofenac-13C6, 20 ng/mL dextrorphan-D3 and 20 ng/mL 1-OH-midazolam-D4. Quenched incubates were stored at -20° C. for at least 1 hour before centrifugation (20,000xg, 20 minutes). Supernatants were removed and diluted 1:1 with water prior to analysis using a RapidFire sample injector system and API4000 mass spectrometer.	C[C@@]1(c2cc(Nc3cc(Cl)cc4cc(Cl)cnc34)ccc2F)COCC(N)=N1		2016.0	CHEMBL3969614	=	=	IC50	nM	33000.0	IC50	nM	33000.0
Inhibition Assay: Inhibition of cytochromes P450 (CYPs) 2C9, 2D6 and 3A4 was assessed using human liver microsomes and CYP-selective substrate metabolism reactions. 50 μl incubations were made up containing (finally) 0.2 mg/ml pooled human liver microsomes, 5 μM substrate (diclofenac for CYP2C9 [4' hydroxylase], dextromethorphan for CYP2D6 [O-demethylase] or midazolam for CYP3A4 [1' hydroxylase]), 0.25 μl, DMSO containing test inhibitor and NADPH regenerating system. Test inhibitor concentrations of 50, 16.7, 5.6, 1.9, 0.6 and 0.2 μM were assessed in singlicate. Incubations were prewarmed to 37° C. for 10 minutes before initiation by addition of NADPH regenerating system. Incubations were quenched after 5 minutes (20 minutes for dextromethorphan) by addition of 50 μl cold acetonitrile containing 20 ng/ml 4-OH-diclofenac-13C6, 20 ng/mL dextrorphan-D3 and 20 ng/mL 1-OH-midazolam-D4. Quenched incubates were stored at -20° C. for at least 1 hour before centrifugation (20,000xg, 20 minutes). Supernatants were removed and diluted 1:1 with water prior to analysis using a RapidFire sample injector system and API4000 mass spectrometer.	Cn1nc(Nc2ccc(F)c([C@@]3(C)COCC(N)=N3)c2)c2ccc(Cl)cc21		2016.0	CHEMBL4111354	=	=	IC50	nM	25000.0	IC50	nM	25000.0
CYP Inhibition Assay (Without Preincubation): Without Preincubation: To a 96 deep well plate was added 2.5 uL, of the test substance solution (x200 concentration), 442.5 uL of Incubation Mixture, and 5 uL of the substrate solution, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added to start the reaction, and incubated at 37° C. for 5 minutes. After the incubation, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.	CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)OC)[C@@](O)(CCOC)C(=O)O		2016.0	CHEMBL4107824	=	=	IC50	nM	23800.0	IC50	nM	23800.0
CYP Inhibition Assay (Without Preincubation): Without Preincubation: To a 96 deep well plate was added 2.5 uL, of the test substance solution (x200 concentration), 442.5 uL of Incubation Mixture, and 5 uL of the substrate solution, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added to start the reaction, and incubated at 37° C. for 5 minutes. After the incubation, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.	CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)O)[C@@](O)(CCOC)C(=O)O		2016.0	CHEMBL4106646	=	=	IC50	nM	16200.0	IC50	nM	16200.0
CYP Inhibition Assay (With Preincubation): With Preincubation: To a 96 deep well plate was added 2.5 uL of the test substance solution (x200 concentration), and 442.5 uL of Incubation Mixture, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added and preincubated at 37° C. for 30 minutes. After the preincubation, 5 uL of the substrate solution was added and the solution was mixed and further incubated at 37° C. for 5 minutes for the reaction. After the reaction, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.	CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)OC)[C@@](O)(CCOC)C(=O)O		2016.0	CHEMBL4107824	=	=	IC50	nM	11900.0	IC50	nM	11900.0
CYP Inhibition Assay (With Preincubation): With Preincubation: To a 96 deep well plate was added 2.5 uL of the test substance solution (x200 concentration), and 442.5 uL of Incubation Mixture, and the solution was mixed and warmed to 37° C. for 5 minutes. To this incubation solution 50 uL of 10 mM NADPH was added and preincubated at 37° C. for 30 minutes. After the preincubation, 5 uL of the substrate solution was added and the solution was mixed and further incubated at 37° C. for 5 minutes for the reaction. After the reaction, 100 uL of the Incubation Mixture was removed, added to 150 uL of isopropanol containing IS and mixed. This mixture was transferred onto a multi-screen filter, centrifuged at 500xg at 4° C. for 10 minutes. The filtrate was used for LC-MS/MS analysis.	CCCCCCCC(F)(F)CCCCCC/C=C/[C@H](C(O)N[C@@H](Cc1ccc(OCCCC)cc1)C(=O)O)[C@@](O)(CCOC)C(=O)O		2016.0	CHEMBL4106646	=	=	IC50	nM	11800.0	IC50	nM	11800.0
In Vitro CYP Inhibition Assay: P450 enzyme inhibition was measured using human cDNA-expressed CYP3A4, 2D6, 2C19, 2C9, and 1A2 recombinant enzymes and fluorogenic substrates (coumarin analogues) that are converted to fluorescent products. The analogues utilized for each isoenzyme are as follows: 7-benzyloxy-trifluoromethylcoumarin, (BFC) for 3A4; 3-[2-(N,N-diethyl-N-methyl amino)ethyl]7-methoxy-4-methylcoumarin, (AMMC) for 2D6; 3-cyano-7-ethoxycoumarin, (CEC) for 2C19 and 1 A2; and 7-methoxy-4-trifluoro-methylcoumarin, (MFC) for 2C9. These substrates were utilized at a single concentration (either 50 uM or 75 uM) at or near the apparent Km for each substrate. Fluorescence intensity was measured using a Wallac 1420 Victor3 Multi-label Counter Model (PerkinElmer, Wellesley, Mass.), with an excitation wavelength filter of 405 nm, and an emission filter of 460 nm (535 nm for the 3A4 and 2C9 substrates). Compound stocks (10 mM in a 4:1 ratio of acetonitrile:DMSO) were tested in this study using an 8-point dose response curve in duplicate (ranging from 0.15 uM-20.0 uM). The concentration of acetonitrile was kept constant at 0.4%, and the reaction was carried out at 37° C. for 30 minutes.	C[C@](O)(COc1ccc(Cl)c(F)c1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1		2016.0	CHEMBL512283	>	>	IC50	nM	20000.0	IC50	nM	20000.0
CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.	Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1		2016.0	CHEMBL3545241	=	=	IC50	nM	10900.0	IC50	nM	10900.0
CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.	Cc1cc(Nc2nc([C@@H](O)c3ccc(F)cc3)nc3ccccc23)n[nH]1		2016.0	CHEMBL3939800	=	=	IC50	nM	10500.0	IC50	nM	10500.0
CYP450 Inhibition Assay: The ability of the R and S enantiomers of (4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol to inhibit the common drug metabolizing isoforms of cytochrome P450 (CYP) was evaluated against the following isoforms: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The compounds were incubated in duplicate with eight test compound concentrations (final DMSO concentration of 0.20%) with human liver microsomes (0.25 or 0.50 mg/mL) and NADPH (1 mM) in the presence of CYP isoform specific probe substrates (phenacetin, bupropion, taxol, diclofenac, mephenyloin, dextromethorphan, testosterone) at the Km for 10-20 minutes at 37° C. Selective CYP isoform inhibitors (furafulline, ticlopidine, quercetin, sulfaphenazole, ticlopidine, quinidine, ketoconazole) were screened alongside the test compounds as positive controls.	Cc1cc(Nc2nc([C@H](O)c3ccc(F)cc3)nc3ccccc23)n[nH]1		2016.0	CHEMBL3962269	=	=	IC50	nM	14800.0	IC50	nM	14800.0
Inhibition Assay: Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO; final DMSO concentration=0.26%) are incubated with human liver microsomes (0.1 mg/mL) and NADPH (1 mM) in the presence of the probe substrate midazolam (2.5 μM) for 5 min at 37° C. The selective CYP3A4 inhibitor, ketoconazole, is screened alongside the test compounds as a positive control.	OCc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2		2016.0	CHEMBL1188	=	=	IC50	nM	2700.0	IC50	nM	2700.0
Inhibition Assay: Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO; final DMSO concentration=0.275%) are incubated with human liver microsomes (0.5 mg/mL) and NADPH (1 mM) in the presence of the probe substrate testosterone (50 μM) for 5 min at 37° C. The selective CYP3A4 inhibitor, ketoconazole, is screened alongside the test compounds as a positive control.	C[C@]12CC[C@H]3[C@@H](C[C@@H](O)C4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O		2016.0	CHEMBL2074878	=	=	IC50	nM	10500.0	IC50	nM	10500.0
Inhibitory Assay: The cytochrome P450 inhibitory potentials of compounds for human recombinant CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A were determined using Vivid CYP450 blue screening kits (Invitrogen, USA). All of the procedures were performed according the instruction provided by the manufacturer. Briefly, serials of diluted compounds were incubated the vivid CYP450 reaction systems including CYP450 BACULOSOMES with different recombinant human CYP450 isozymes and the appropriate vivid CYP450 substrates, and rabbit NADPH-P450 reductase, and the regeneration system. Ketoconazole was used as reference CYP450 inhibitor. After 30 minutes incubation at room temperature, the fluorescence was measured with an excitation at 400 nm and an emission at 460 nm using Envision 2104 multi-label Reader (Perkin Elmer, USA).	COc1ccc(C2(c3ccc(OC)cc3)NC(=N)N(C3CCCCC3)C2=O)cc1		2016.0	CHEMBL3109542	=	=	IC50	nM	449.0	IC50	nM	449.0
CYP Inhibition Assay: Incubation of phenacetin, diclofenac, dextromethorphan, mephenotoin, albendazole and testosterone with human liver microsomes in the presence of in each case eight different concentrations of a compound formula (B) (as potential inhibitor) is carried out on a incubator shaker at 37 C. Standard incubation mixtures comprise NADPH and substrates in 100 mM phosphate buffer (pH 7.4) in a total volume of 200 μl. Test compound are dissolved in acetonitrile. Incubated with pooled human liver microsomes at 37° C. for a defined time. The reactions are stopped by adding 100 μl of acetonitrile in which a suitable internal standard is always present. Precipitated proteins are removed by centrifugation, and the supernatants analyzed by LC-MS/MS.	O=CN(C[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)C(=O)c1ccc(Cl)s1		2016.0	CHEMBL3975957	=	=	IC50	nM	5700.0	IC50	nM	5700.0
CYP Inhibition Assay: Incubation of phenacetin, diclofenac, dextromethorphan, mephenotoin, albendazole and testosterone with human liver microsomes in the presence of in each case eight different concentrations of a compound formula (B) (as potential inhibitor) is carried out on a incubator shaker at 37 C. Standard incubation mixtures comprise NADPH and substrates in 100 mM phosphate buffer (pH 7.4) in a total volume of 200 μl. Test compound are dissolved in acetonitrile. Incubated with pooled human liver microsomes at 37° C. for a defined time. The reactions are stopped by adding 100 μl of acetonitrile in which a suitable internal standard is always present. Precipitated proteins are removed by centrifugation, and the supernatants analyzed by LC-MS/MS.	Cc1ccc(C(=O)NC[C@H]2CN(c3ccc(N4CCOCC4=O)cc3)C(=O)O2)s1		2016.0	CHEMBL370614	=	=	IC50	nM	9700.0	IC50	nM	9700.0
Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.	Cc1cnc(C(=O)c2ccnc3[nH]ncc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1		2016.0	CHEMBL3951306	=	=	IC50	nM	3000.0	IC50	nM	3000.0
Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.	Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1		2016.0	CHEMBL2178573	=	=	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.	COC1=C(C(=O)c2ncc(C)cc2NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)C2C=CNC2N=C1		2016.0	CHEMBL3944846	=	=	IC50	nM	3000.0	IC50	nM	3000.0
Inhibition Assay: The test compounds were incubated with pooled human liver microsomes at 37° C. in the presence of NADPH and appropriate concentrations of substrates specific for CYP2C9 and 3A4. 120 μL of a mixture of human liver microsomes (HLM) in 50 mM potassium phosphate/5 mM MgCl2 buffer was added into all wells of row A in a 96-well plate. The concentration of microsomal protein was 2-fold the intended protein concentration for the particular isozyme assay recorded in Table 4. In addition, 80 μL of this human liver microsome preparation spiked with 1% DMSO was dispensed into all wells of rows B through H. 1.2 μL of each individual test compound in DMSO (10 mM) was added to the first 10 wells of row A (5 different test compounds each in duplicate). Additionally, 1.2 μL of the DMSO stock of the control inhibitor for the isozyme under study was added into the final two wells of row A to give a concentration two-fold above the highest final concentration. Three-fold serial dilutions were performed by taking 40 μL from each solution in wells of row A (wells 1-12, both compounds and controls) and diluting into the wells of row B. After thorough mixing, 40 μL from each solution in wells of row B were dispensed with a multichannel pipette (12 channels) into the wells of row C and the controls and test compounds hence further diluted. This process was repeated for rows D through G. After mixing, 40 μL was removed and discarded from the wells of row G. This procedure resulted in 80 μL of solution being present in all wells of all rows A through H, with protein concentrations being twice the final intended concentrations in all wells of rows, and test compound and control concentration being twice the final intended concentrations in rows A through G. Row H was not spiked with a test compound or positive control. The plate was covered and pre-incubated for 10 minutes in a 37° C. incubator. The reaction was initiated by adding 80 μL of a solution of the substrate for the isozyme under investigation in 50 mM potassium phosphate/5 mM MgCl2 buffer solution with 4 mM NADPH present, at a substrate concentration two-fold the intended final substrate concentrations using a multichannel pipette. The substrate solution was added to all wells rows A to H excluding wells 95 and 96 (microsomal blanks). The plate was covered and incubated at 37° C. for the time listed in Table 4 for the isoform under investigation. The reaction was stopped by dispensing 120 μL of internal standard (200 ng/mL CCX915-6A) in acetonitrile to all wells. 80 μL of the specific substrate/NADPH solution described above was added into the well 95 and 96 after stopping the reaction to provide the blank. The plate was vortexed for 10 min and spun in a centrifuge at 4,450 rpm and 4° C. for 10 min. With a multichannel pipette, 80 μL of the supernatant was transferred into a sample plate wells containing 80 μL of 0.1% formic acid/water and mixed well for analysis on LC-MS/MS as described in sections E and F.	Cc1cnc(C(=O)c2ncnc3[nH]ccc23)c(NS(=O)(=O)c2ccc(Cl)c(C(F)(F)F)c2)c1		2016.0	CHEMBL2178573	=	=	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).	Cn1cc(-c2nc3c(N4CCN(Cc5cccnc5)CC4)c(Br)cnc3[nH]2)cn1		2016.0	CHEMBL3898132	<	<	IC50	nM	1000.0	IC50	nM	1000.0
Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).	Cc1nn(C)c(C)c1-c1nc2c(N3CCN(Cc4cccnc4)CC3)c(Br)cnc2[nH]1		2016.0	CHEMBL3891461	<	<	IC50	nM	1000.0	IC50	nM	1000.0
Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).	Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ccc(Cl)cc4)CC3)c(Cl)cnc2[nH]1		2016.0	CHEMBL2207503	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: Inhibition of CYP isozymes was determined using a mixture of probe substrates. The samples were incubated for 10 minutes followed by protein precipitation with methanol. The substrate metabolites in each sample were measured by LC/MS/MS using reverse-phase liquid chromatography and positive ion mode ESI with multiple reaction monitoring (MRM).	Cc1nn(C)cc1-c1nc2c(N3CCN(Cc4ncon4)CC3)c(Cl)cnc2[nH]1		2016.0	CHEMBL2207500	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccccc12		2016.0	CHEMBL3926686	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(Cl)cc12		2016.0	CHEMBL3915393	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3942519	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)ccc12		2016.0	CHEMBL3951269	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(F)cc12		2016.0	CHEMBL3927059	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cccc(F)c12		2016.0	CHEMBL3926432	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)ccc12		2016.0	CHEMBL3900133	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(O)cc12		2016.0	CHEMBL3930161	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1cccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c12		2016.0	CHEMBL3905553	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3942519	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1		2016.0	CHEMBL3947939	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	Cc1cccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c12		2016.0	CHEMBL3941986	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	Cc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1		2016.0	CHEMBL3960725	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	Cc1cccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3945113	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Br)ccc12		2016.0	CHEMBL3934554	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(Br)cc12		2016.0	CHEMBL3957026	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cccc(Br)c12		2016.0	CHEMBL3899367	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2c(Cl)cccc12		2016.0	CHEMBL3889611	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)ccc12		2016.0	CHEMBL3951766	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2ccc(Cl)cc12		2016.0	CHEMBL3915393	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	N#Cc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3923510	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(OC(F)(F)F)ccc12		2016.0	CHEMBL3906058	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc3c(cc12)OCCO3		2016.0	CHEMBL3930595	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(OC(F)F)ccc12		2016.0	CHEMBL3932173	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2cc1F		2016.0	CHEMBL3907721	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1cc(F)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3923223	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1C		2016.0	CHEMBL3962437	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cccc(Cl)c12		2016.0	CHEMBL3910483	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Cytochrome P450 Inhibition: Protocol 2: Stock solution for NCEs (test articles) and standard inhibitors were prepared at a concentration of 20 mM in DMSO. Stock solutions were diluted with DMSO to get substocks which were further diluted 10-fold in 80:20 MeCN:water to obtain intermediate substocks. Working stocks were prepared by diluting the intermediate substocks 50-fold in buffer.	COc1cccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3895257	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(C)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3969361	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(Cl)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3980571	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1Cl		2016.0	CHEMBL3917789	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1OC		2016.0	CHEMBL3892761	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)cc(Br)c12		2016.0	CHEMBL3961768	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)cc(Br)c12		2016.0	CHEMBL3916144	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1c(F)ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3891650	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(F)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3907175	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3984048	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)cc(Cl)c12		2016.0	CHEMBL3910048	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1Br		2016.0	CHEMBL3977772	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(Br)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3967401	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(Br)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3906051	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(Cl)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3920876	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)c(F)cc12		2016.0	CHEMBL3908841	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)c(F)cc12		2016.0	CHEMBL3979166	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)cc(Br)c12		2016.0	CHEMBL3941189	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(C)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3945612	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2cc1O		2016.0	CHEMBL3898625	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2cc1C		2016.0	CHEMBL3973221	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2cc1F		2016.0	CHEMBL3939590	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)c(F)cc12		2016.0	CHEMBL3944958	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(C#N)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3923319	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(O)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3918191	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(C)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3969361	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(Cl)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3980571	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1Cl		2016.0	CHEMBL3917789	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1OC		2016.0	CHEMBL3892761	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)cc(Br)c12		2016.0	CHEMBL3961768	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)cc(Br)c12		2016.0	CHEMBL3916144	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1c(F)ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3891650	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(F)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3907175	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1ccc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3984048	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)cc(Cl)c12		2016.0	CHEMBL3910048	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1ccc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2c1Br		2016.0	CHEMBL3977772	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc(Br)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3967401	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(Br)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3906051	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(Cl)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3920876	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(F)c(F)cc12		2016.0	CHEMBL3908841	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(Cl)c(F)cc12		2016.0	CHEMBL3979166	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)cc(Br)c12		2016.0	CHEMBL3941189	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(C)c2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2c1		2016.0	CHEMBL3945612	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2cc1O		2016.0	CHEMBL3898625	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c2cc1C		2016.0	CHEMBL3973221	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	COc1cc2c(C(=O)OCC34CCN(CC3)CC4)c[nH]c2cc1F		2016.0	CHEMBL3939590	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	O=C(OCC12CCN(CC1)CC2)c1c[nH]c2cc(O)c(F)cc12		2016.0	CHEMBL3944958	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(C#N)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3923319	>	>	IC50	nM	10000.0	IC50	nM	10000.0
"Cytochrome P450 Inhibition: Protocol 1: Studies were carried out in human liver microsomes. Human liver microsomes were purchased from BD Gentest. DMSO stocks were prepared for the test compounds. Aliquots of the DMSO solutions were diluted 1:3 by acetonitrile:ACN mixture (v/v: 40:60) to ""400×"" intermediate solutions, then further diluted by liver microsomes/buffer to ""2×"" intermediate solutions. ""2×"" intermediate solutions were mixed with ""2×"" NADPH/substrate solutions, which had been pre-warmed to 37° C. (final test compound concentrations were 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, 0.0136 μM, and 0 μM). The plates were kept in a 37° C. water bath for the duration of the experiment. At the end of incubation (5 minutes for 3A4; 45 minutes for 2C19; 10 minutes for 1A2, 2C9, 2D6), 120 μL of acetonitrile was added into corresponding wells. After the final time point was sampled, the plates were shaken at a vibrator (IKA, MTS 2/4) for 10 mM (600 rpm/min) and then centrifuged at 5594 g for 15 mM (Thermo Multifuge×3R). Aliquots of the supernatant were removed, diluted 1:1 into distilled water, and analyzed by LC-MS/MS. The peak area response ratio to internal standard (PARR) of the compounds at 10 μM, 3.3 μM, 1.1 μM, 0.37 μM, 0.122 μM, 0.041 μM, and 0.0136 μM was compared to the PARR at 0 μM to determine the percent of metabolite generation from substrate at each test compound concentration."	Cc1cc(O)cc2[nH]cc(C(=O)OCC34CCN(CC3)CC4)c12		2016.0	CHEMBL3918191	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Luciferase-Based P450-Glo Assay: Five CYP isoforms (0.5 pmol) were tested, namely 1A2, 2C9, 2C19, 2D6 and 3A4 (each isoform was assayed in a separate assay plate). Each assay plate contained several compounds at 2 concentrations (10 uM and 1 uM), with 2 replicates at each concentration or a small number of compounds per plate in dose response by duplicate (50, 16.5, 5.4, 1.8, 0.6, 0.2, 0.066, 0.022, 0.007 uM). In addition, each assay plate contained 8 different concentrations of an isoform-specific inhibitor (Furafylline, Sulfaphenazole, N-3-benzylnirvanol, Quinidine and Ketoconazole as inhibitors of CYP 1A2, 2C9, 2C19, 2D6 and 3A4, respectively), with two replicates at each concentration. The test compounds and the reference inhibitors were tested at a final DMSO concentration of 0.5%. The assay plate included also 8 replicates a vehicle control containing 0.5% DMSO/H2O. The membranes containing the CYPs, test compound and the probe substrate were pre-incubated 10 min at 37°C. in the absence of NADPH, NADPH was then added following incubation for 60 minutes at 37°C., the reaction was terminated by the addition of Luciferin detection reagent. After 20 min incubation at 37°C., the assay plate was read in the Envision 2104 Multilable reader. Values were normalized against the control activity included for each CYP. These values were plotted against the inhibitor concentration and were fitted to a sigmoid dose-response curve by using the model sigmoidal Four-Parameter Logistc inplement for Activity baseÂ  software.	CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCOCC1		2016.0	CHEMBL3921669	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Luciferase-Based P450-Glo Assay: Five CYP isoforms (0.5 pmol) were tested, namely 1A2, 2C9, 2C19, 2D6 and 3A4 (each isoform was assayed in a separate assay plate). Each assay plate contained several compounds at 2 concentrations (10 uM and 1 uM), with 2 replicates at each concentration or a small number of compounds per plate in dose response by duplicate (50, 16.5, 5.4, 1.8, 0.6, 0.2, 0.066, 0.022, 0.007 uM). In addition, each assay plate contained 8 different concentrations of an isoform-specific inhibitor (Furafylline, Sulfaphenazole, N-3-benzylnirvanol, Quinidine and Ketoconazole as inhibitors of CYP 1A2, 2C9, 2C19, 2D6 and 3A4, respectively), with two replicates at each concentration. The test compounds and the reference inhibitors were tested at a final DMSO concentration of 0.5%. The assay plate included also 8 replicates a vehicle control containing 0.5% DMSO/H2O. The membranes containing the CYPs, test compound and the probe substrate were pre-incubated 10 min at 37°C. in the absence of NADPH, NADPH was then added following incubation for 60 minutes at 37°C., the reaction was terminated by the addition of Luciferin detection reagent. After 20 min incubation at 37°C., the assay plate was read in the Envision 2104 Multilable reader. Values were normalized against the control activity included for each CYP. These values were plotted against the inhibitor concentration and were fitted to a sigmoid dose-response curve by using the model sigmoidal Four-Parameter Logistc inplement for Activity baseÂ  software.	CNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21		2016.0	CHEMBL3985847	=	=	IC50	nM	39000.0	IC50	nM	39000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3ncccc3c2)n1		2016.0	CHEMBL3925961	=	=	IC50	nM	3700.0	IC50	nM	3700.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3nc(C)ccc3c2)n1		2016.0	CHEMBL3910478	=	=	IC50	nM	2100.0	IC50	nM	2100.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1		2016.0	CHEMBL3934839	=	=	IC50	nM	4000.0	IC50	nM	4000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc(-c3ccon3)cc2)n1		2016.0	CHEMBL3969750	=	=	IC50	nM	2300.0	IC50	nM	2300.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(c2)OCC(=O)N3C)n1		2016.0	CHEMBL3947193	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CNC(C)C(=O)Nc1ccc(-c2c(-c3ccncc3)nc3cc(C)ccn23)c(C#Cc2ccccc2)n1		2016.0	CHEMBL3970302	=	=	IC50	nM	3000.0	IC50	nM	3000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3895473	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(C)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3911035	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cnn(C)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3981054	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cncn3C)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3905467	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3C)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3973040	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccc(C)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3896543	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cnc(C)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3967713	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(OC)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3928571	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccc(OC)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3964219	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1		2016.0	CHEMBL3930510	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(C)c3)nc3cc(C)ccn23)c(C#Cc2ccccc2)n1		2016.0	CHEMBL3958007	=	=	IC50	nM	46000.0	IC50	nM	46000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cnc(C)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1		2016.0	CHEMBL3935923	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccnc(OC)c3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1		2016.0	CHEMBL3969059	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3ccc(OC)nc3)nc3cc(C)ccn23)c(C#Cc2ccc3c(ccc(=O)n3C)c2)n1		2016.0	CHEMBL3929505	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3cc(Cl)ccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3974300	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition Assays: The final incubation volume contains TRIS buffer (0.1 M), MgCl2 (5 mM), a certain concentration of human liver microsomes dependent on the P450 isoenzyme measured (P450 2C9, P450 3A4: 0.1 mg/ml; P450 2D6: 0.2 mg/ml; P450 2C19: 0.5 mg/ml; P450 2C8: 0.05 mg/ml) and a certain concentration of the individual substrate for each isoenzyme (P450 2C9: Diclofenac 10 μM; P450 3A4: Midazolam 5 μM; P450 2D6: Dextromethorphan 5 μM; P450 2C19: S-Mephenytoin 70 μM; P450 2C8: Amodiaquine 1 μM).	CN[C@@H](C)C(=O)Nc1ccc(-c2c(-c3cccnc3OC)nc3ccccn23)c(C#Cc2ccc3c(C)nccc3c2)n1		2016.0	CHEMBL3956933	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	CCC(C)(C)C(=O)N(O)Cc1ccccc1	J Med Chem	2017.0	CHEMBL4092421	>	>	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1cccc(C2=NC(C(F)(F)F)(C(F)(F)F)c3c(n(-c4ccc(Cl)cc4)c(=O)[nH]c3=O)N2)c1	J Med Chem	2017.0	CHEMBL4095693	=	=	IC50	nM	16440.0	IC50	uM	16.44
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	Cn1c2c(c(=O)n(C)c1=O)C(C(F)(F)F)(C(F)(F)F)N=C(c1cccc([N+](=O)[O-])c1)N2	J Med Chem	2017.0	CHEMBL4079193	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	Cn1c2c(c(=O)n(C)c1=O)C(C(F)(F)F)(C(F)(F)F)NC(c1ccc(Cl)cc1)=N2	J Med Chem	2017.0	CHEMBL1341270	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC[C@@H]1c2c(C#N)ncn2-c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1	Bioorg Med Chem Lett	2017.0	CHEMBL4074778	>	<	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 (unknown origin)	CC[C@@H]1c2c(C#N)ncn2-c2cnc(Nc3cc(F)c(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1	Bioorg Med Chem Lett	2017.0	CHEMBL4066163	>	<	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 (unknown origin)	CC[C@@H]1c2c(C#N)ncn2-c2cnc(Nc3cc(F)c(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCCC1	Bioorg Med Chem Lett	2017.0	CHEMBL4078098	>	<	IC50	nM	10000.0	pIC50		5.0
Inhibition of CYP3A4 (unknown origin)	COCc1cnc(N2CCC([C@H]3C[C@H]3CCOc3cc(F)c(CC(=O)N4CCC4)c(F)c3)CC2)nc1	Bioorg Med Chem Lett	2017.0	CHEMBL4093284	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	NCc1ccnc(Cl)c1	ACS Med Chem Lett	2017.0	CHEMBL4068784	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 expressed in baculovirus-infected insect cells using Luciferin-PFBE as substrate in presence of NADPH by P450-Glo luminescence assay	COc1cccc(/C=C/C(=O)c2cc(OC)c(OC)cc2O)c1	Eur J Med Chem	2017.0	CHEMBL4071093	=	=	IC50	nM	27400.0	IC50	uM	27.4
Inhibition of human CYP3A4 expressed in baculovirus-infected insect cells using Luciferin-PFBE as substrate in presence of NADPH by P450-Glo luminescence assay	N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1	Eur J Med Chem	2017.0	CHEMBL55	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F	ACS Med Chem Lett	2017.0	CHEMBL3137332	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	O=C(COc1ccc(-n2ccnc2)cc1)Nc1ccc(-c2ccccc2)cc1	J Med Chem	2015.0	CHEMBL4097104	=	=	IC50	nM	20.0	IC50	uM	0.02
Inhibition of CYP3A4 (unknown origin)	O=C(COc1ccc(-c2cnco2)cc1)Nc1ccc(-c2ccccc2)cc1	J Med Chem	2015.0	CHEMBL4063419	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1nccn1-c1ccc(OCC(=O)Nc2ccc(-c3ccccc3)cc2)cc1	J Med Chem	2015.0	CHEMBL4070649	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1ccc(OCC(=O)Nc2ccc(-c3ccccc3)cc2)cc1	J Med Chem	2015.0	CHEMBL4099279	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](Nc1ccc(-c2ccnn2C)nc1)C(=O)Nc1ccc(-c2ccccc2)cn1	J Med Chem	2015.0	CHEMBL4080842	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](Nc1ccc(-c2ccnn2C)nc1)C(=O)Nc1ccc(-c2cccnc2)nc1	J Med Chem	2015.0	CHEMBL4098880	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](Nc1ccc(-c2ccnn2C)nc1)C(=O)Nc1ccc(-c2cccnc2)cn1	J Med Chem	2015.0	CHEMBL4088716	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	CC(C)(C)c1ccccc1Oc1ccc(-c2cccc(C(=O)O)c2)cc1NC(=O)Nc1ccc(OC(F)(F)F)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4097275	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3cccc(C)c3)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4060679	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3ccccc3C)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4082553	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3ccccc3Cl)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4060089	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin) using BZR as substrate	CC(C)(C)c1ccccc1Oc1ccc(-c2cccc(C(=O)O)c2)cc1NC(=O)Nc1ccc(OC(F)(F)F)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4097275	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using BZR as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3cccc(C)c3)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4060679	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin) using BZR as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3ccccc3C)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4082553	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin) using BZR as substrate	COc1ccc(-c2ccc(Oc3cccc4c3CCCC4)c(NC(=O)Nc3ccccc3Cl)c2)cc1C(=O)O	Bioorg Med Chem Lett	2017.0	CHEMBL4060089	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4	Cl.NCCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(F)cc1	Bioorg Med Chem	2017.0	CHEMBL4070447	=	=	IC50	nM	74.0	IC50	uM	0.074
Inhibition of human CYP3A4	Cl.NCCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(Cl)cc1	Bioorg Med Chem	2017.0	CHEMBL4097622	=	=	IC50	nM	70.0	IC50	uM	0.07
Inhibition of human CYP3A4	CCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(Cl)cc1	Bioorg Med Chem	2017.0	CHEMBL4092343	=	=	IC50	nM	11900.0	IC50	uM	11.9
Inhibition of human CYP3A4	Cl.NCCN(C(=O)c1ccc(Cl)cc1Cl)c1ccc(OCc2ccc(Cl)cc2)cc1	Bioorg Med Chem	2017.0	CHEMBL4089012	=	=	IC50	nM	179.0	IC50	uM	0.179
Inhibition of human CYP3A4	Cl.NCCN(C(=O)c1ccc(F)cc1C(F)(F)F)c1ccc(OCc2ccc(Cl)cc2)cc1	Bioorg Med Chem	2017.0	CHEMBL4065918	=	=	IC50	nM	10.0	IC50	uM	0.01
Inhibition of human CYP3A4	CC(C)c1ccc(COc2ccc(N(CCN)C(=O)c3ccc(Cl)cc3Cl)cc2)cc1.Cl	Bioorg Med Chem	2017.0	CHEMBL4095951	=	=	IC50	nM	15.0	IC50	uM	0.015
Inhibition of human CYP3A4	CC(C)c1ccc(COc2ccc(N(CCN)C(=O)c3cccnc3C(F)(F)F)cc2)cc1.Cl	Bioorg Med Chem	2017.0	CHEMBL4080366	=	=	IC50	nM	144.0	IC50	uM	0.144
Inhibition of human CYP3A4	Cc1cc(C)cc(COc2ccc(N(CCN)C(=O)c3ccc(Cl)cc3Cl)cc2)c1.Cl	Bioorg Med Chem	2017.0	CHEMBL4088945	=	=	IC50	nM	3.0	IC50	uM	0.003
Inhibition of CYP3A4 (unknown origin)	O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	ACS Med Chem Lett	2017.0	CHEMBL2105720	=	=	IC50	nM	74400.0	IC50	uM	74.4
Inhibition of CYP3A4 (unknown origin)	O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	ACS Med Chem Lett	2017.0	CHEMBL2105720	=	=	IC50	nM	32400.0	IC50	uM	32.4
Inhibition of CYP3A4 (unknown origin)	O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	ACS Med Chem Lett	2017.0	CHEMBL2105720	=	=	IC50	nM	31000.0	IC50	uM	31.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by HPLC-MS/MS method	CCCCCc1ccc(NC(=O)COc2cc(C)nc3ccc(OC)cc23)cc1	Eur J Med Chem	2017.0	CHEMBL4094462	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 using in human liver microsomes using testosterone as substrate after 5 to 15 mins	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	ACS Med Chem Lett	2017.0	CHEMBL157101	=	=	IC50	nM	15.0	IC50	uM	0.015
Inhibition of CYP3A4 using in human liver microsomes using midazolam as substrate after 5 to 15 mins	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	ACS Med Chem Lett	2017.0	CHEMBL157101	=	=	IC50	nM	18.0	IC50	uM	0.018
Inhibition of CYP3A4 using in human liver microsomes using midazolam as substrate after 5 to 15 mins	CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	ACS Med Chem Lett	2017.0	CHEMBL4101807	=	=	IC50	nM	81900.0	IC50	uM	81.9
Inhibition of CYP3A4 using in human liver microsomes using testosterone as substrate after 5 to 15 mins	CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	ACS Med Chem Lett	2017.0	CHEMBL4101807	=	=	IC50	nM	12500.0	IC50	uM	12.5
Inhibition of recombinant human CYP3A4 using fluorogenic substrate BFC preincubated for 30 mins and measured after 20 to 60 mins in presence of NADPH regenerating system by fluorescence assay	c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1	ACS Med Chem Lett	2017.0	CHEMBL3918431	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4 using fluorogenic substrate BFC preincubated for 30 mins and measured after 20 to 60 mins in presence of NADPH regenerating system by fluorescence assay	c1cn(-c2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncn2)cn1	ACS Med Chem Lett	2017.0	CHEMBL4084621	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 using fluorogenic substrate BZR preincubated for 30 mins and measured after 20 to 60 mins in presence of NADPH regenerating system by fluorescence assay	c1ccc2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncc2c1	ACS Med Chem Lett	2017.0	CHEMBL3918431	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of recombinant human CYP3A4 using fluorogenic substrate BZR preincubated for 30 mins and measured after 20 to 60 mins in presence of NADPH regenerating system by fluorescence assay	c1cn(-c2cc(NC3=NC[C@@]4(CN5CCC4CC5)O3)ncn2)cn1	ACS Med Chem Lett	2017.0	CHEMBL4084621	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1	J Med Chem	2017.0	CHEMBL3301604	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2cccc(F)c2)CC1	J Med Chem	2017.0	CHEMBL3933704	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	Cc1nc(NC2CCCC2)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cn2)n1	J Med Chem	2017.0	CHEMBL4081497	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of microsomal CYP3A4 (unknown origin) using midazolam as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)[C@H]1CCCN1.Cl	Eur J Med Chem	2017.0	CHEMBL4093614	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of microsomal CYP3A4 (unknown origin) using testosterone as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1NC(=O)[C@H]1CCCN1.Cl	Eur J Med Chem	2017.0	CHEMBL4093614	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes	N#Cc1cccc(S(=O)(=O)c2cnc3cc(F)ccc3c2-c2ccc(Cl)cc2)c1	J Med Chem	2017.0	CHEMBL3765114	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CN1CCN(Cc2cn(S(=O)(=O)c3ccccc3)c3ccccc23)CC1.Cl.Cl	J Med Chem	2017.0	CHEMBL4062687	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CN1CCN(Cc2cn(S(=O)(=O)c3ccc(F)cc3)c3ccccc23)CC1	J Med Chem	2017.0	CHEMBL4070284	=	=	IC50	nM	1820.0	IC50	uM	1.82
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CC(C)c1ccc(S(=O)(=O)n2cc(CN3CCN(C)CC3)c3cc(F)ccc32)cc1.Cl.Cl	J Med Chem	2017.0	CHEMBL4093699	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	COc1cccc2c1c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccc(C(C)C)cc1.Cl.Cl	J Med Chem	2017.0	CHEMBL4085003	=	=	IC50	nM	7100.0	IC50	uM	7.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br.CS(=O)(=O)O.O	J Med Chem	2017.0	CHEMBL4082473	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccc(C(C)C)cc1.CS(=O)(=O)O.CS(=O)(=O)O	J Med Chem	2017.0	CHEMBL4100484	=	=	IC50	nM	1850.0	IC50	uM	1.85
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccc(F)cc1.CS(=O)(=O)O.CS(=O)(=O)O	J Med Chem	2017.0	CHEMBL4073586	=	=	IC50	nM	1710.0	IC50	uM	1.71
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	COc1ccc2c(c1)c(CN1CCCN(C)CC1)cn2S(=O)(=O)c1ccc(C(C)C)cc1.Cl.Cl	J Med Chem	2017.0	CHEMBL4101284	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br.CS(=O)(=O)O.O	J Med Chem	2017.0	CHEMBL4082473	=	=	IC50	nM	2640.0	IC50	uM	2.64
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1ccc(C(=O)/C=C/c2cccnc2)c(OC)c1	Eur J Med Chem	2017.0	CHEMBL427692	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccnc1)c1cccc(Cl)c1	Eur J Med Chem	2017.0	CHEMBL4065284	=	=	IC50	nM	12500.0	IC50	uM	12.5
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccnc1)c1cccc(Br)c1	Eur J Med Chem	2017.0	CHEMBL4084977	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccnc1)c1ccc2ccccc2c1	Eur J Med Chem	2017.0	CHEMBL4063333	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1ccc2cc(C(=O)/C=C/c3cccnc3)ccc2c1	Eur J Med Chem	2017.0	CHEMBL4092737	=	=	IC50	nM	10600.0	IC50	uM	10.6
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccnc1)c1cccc2ccccc12	Eur J Med Chem	2017.0	CHEMBL4071959	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccnc1)c1ccc2ccc3ccccc3c2c1	Eur J Med Chem	2017.0	CHEMBL4080095	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc2c(c1)OCO2)c1cccnc1	Eur J Med Chem	2017.0	CHEMBL1413330	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1cccc(/C=C/C(=O)c2cccnc2)c1	Eur J Med Chem	2017.0	CHEMBL4099058	=	=	IC50	nM	1280.0	IC50	uM	1.28
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1ccccc1/C=C/C(=O)c1cccnc1	Eur J Med Chem	2017.0	CHEMBL4072091	=	=	IC50	nM	1520.0	IC50	uM	1.52
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2cccnc2)cc1OC	Eur J Med Chem	2017.0	CHEMBL4063471	=	=	IC50	nM	53000.0	IC50	uM	53.0
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2cccnc2)c(OC)c1OC	Eur J Med Chem	2017.0	CHEMBL2237709	=	=	IC50	nM	11800.0	IC50	uM	11.8
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc(Cl)c(Cl)c1)c1cccnc1	Eur J Med Chem	2017.0	CHEMBL4068333	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc2ccccc2c1)c1cccnc1	Eur J Med Chem	2017.0	CHEMBL4059677	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human liver CYP3A4 expressed in Saccharomyces cerevisiae YY7 microsomal membranes using DBF as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccccc1)c1cccnc1	Eur J Med Chem	2017.0	CHEMBL4087973	=	=	IC50	nM	11100.0	IC50	uM	11.1
Inhibition of CYP3A4 (unknown origin)	COc1nc(C2=NOC[C@H](c3cc4ccccc4o3)N2)ccc1-n1cnc(C)c1	J Med Chem	2017.0	CHEMBL4101809	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccc(Cl)cc2)CC1	J Med Chem	2017.0	CHEMBL4094887	=	=	IC50	nM	280.0	IC50	uM	0.28
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4102633	=	=	IC50	nM	430.0	IC50	uM	0.43
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4062566	=	=	IC50	nM	680.0	IC50	uM	0.68
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2Cl)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4098912	=	=	IC50	nM	270.0	IC50	uM	0.27
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2Cl)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4098978	=	=	IC50	nM	580.0	IC50	uM	0.58
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	CN[C@H]1CC[C@](CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4072007	=	=	IC50	nM	450.0	IC50	uM	0.45
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1ncns1)c1cc(F)c(OCC[C@]2(c3ccccc3)CC[C@H](NC3CC3)CC2)cc1F	J Med Chem	2017.0	CHEMBL4063378	=	=	IC50	nM	90.0	IC50	uM	0.09
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4101437	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)(c2ccccc2)CC1	J Med Chem	2017.0	CHEMBL4077266	=	=	IC50	nM	9800.0	IC50	uM	9.8
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	C[C@]1(CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)CC[C@@H](N)CC1	J Med Chem	2017.0	CHEMBL4093720	=	=	IC50	nM	780.0	IC50	uM	0.78
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	C[C@]1(CCOc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)CC[C@H](N)CC1	J Med Chem	2017.0	CHEMBL4087898	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@H](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	J Med Chem	2017.0	CHEMBL4060154	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@H](CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	J Med Chem	2017.0	CHEMBL4080712	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@H](CNc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2Cl)CC1	J Med Chem	2017.0	CHEMBL4076627	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	N[C@H]1CC[C@@H](CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	J Med Chem	2017.0	CHEMBL4078268	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCNCC2)cc1F	J Med Chem	2017.0	CHEMBL4096299	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCNC2)cc1F	J Med Chem	2017.0	CHEMBL4078252	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1ncns1)c1cc(Cl)c(NCCC2CCCCN2)cc1F	J Med Chem	2017.0	CHEMBL4088581	=	=	IC50	nM	5900.0	IC50	uM	5.9
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCCN2)cc1F	J Med Chem	2017.0	CHEMBL4076444	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	CN1CCC(CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	J Med Chem	2017.0	CHEMBL4091922	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCNC2)cc1F	J Med Chem	2017.0	CHEMBL4071098	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CNC2)cc1F	J Med Chem	2017.0	CHEMBL4103940	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCNC2)cc1F	J Med Chem	2017.0	CHEMBL4085278	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@@H]2CCCNC2)cc1F	J Med Chem	2017.0	CHEMBL4062380	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CNCCO2)cc1F	J Med Chem	2017.0	CHEMBL4089010	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCN(O)C2)cc1F	J Med Chem	2017.0	CHEMBL4096711	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@@H]2CCCN(O)C2)cc1F	J Med Chem	2017.0	CHEMBL4072107	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CNC2)cc1F	J Med Chem	2017.0	CHEMBL4071551	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	CN1C(C)(C)CC(Nc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1(C)C	J Med Chem	2017.0	CHEMBL4064193	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 assessed as inhibition of dealkylation	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2(CN3CCCC3)CC2)cc1F	J Med Chem	2017.0	CHEMBL4092078	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1	J Med Chem	2017.0	CHEMBL4098877	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis	Cc1ccc(-c2ccc(C(=O)NC(CN)c3ncc(CO)s3)[nH]2)cc1F	J Med Chem	2017.0	CHEMBL4075766	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis	NCC(NC(=O)c1ccc(-c2cc(F)c(Cl)c(F)c2)[nH]1)c1ncc(CO)s1	J Med Chem	2017.0	CHEMBL4083672	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis	Cc1nc(C(NC(=O)c2ccc(-c3ccc(Cl)cc3)[nH]2)C2CCCCN2)sc1CO	J Med Chem	2017.0	CHEMBL4096918	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 5 mins in presence of NADPH by LC-MS/MS analysis	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	J Med Chem	2017.0	CHEMBL3301620	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins	CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL549472	=	=	IC50	nM	7100.0	IC50	uM	7.1
Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid DBOMF substrate green measured every 30 sec for 30 mins by fluorescence assay	CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL549472	=	=	IC50	nM	21800.0	IC50	uM	21.8
Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay	CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL549472	=	=	IC50	nM	24900.0	IC50	uM	24.9
Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMCC substrate blue measured every 30 sec for 30 mins by fluorescence assay	CCCCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL549472	=	=	IC50	nM	20800.0	IC50	uM	20.8
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL402978	=	=	IC50	nM	73400.0	IC50	uM	73.4
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins	CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL402978	=	=	IC50	nM	37400.0	IC50	uM	37.4
Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid DBOMF substrate green measured every 30 sec for 30 mins by fluorescence assay	CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL402978	=	=	IC50	nM	32000.0	IC50	uM	32.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay	CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL402978	=	=	IC50	nM	42900.0	IC50	uM	42.9
Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMCC substrate blue measured every 30 sec for 30 mins by fluorescence assay	CCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL402978	=	=	IC50	nM	21800.0	IC50	uM	21.8
Inhibition of CYP3A4 in human liver microsomes assessed as enzyme-mediated metabolite formation using midazolam as substrate incubated for 5 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis	CCCCCCCC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL2071440	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes assessed as enzyme-mediated metabolite formation using testosterone as substrate incubated for 5 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis	CCCCCCCC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL2071440	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins in presence of NADPH by LC-MS/MS analysis	CCCCCCCC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL2071440	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 20 mins followed by substrate addition measured after 30 mins in presence of NADPH by LC-MS/MS analysis	CCCCCCCC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL2071440	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins	CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL25948	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 5 mins	CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL25948	=	=	IC50	nM	65200.0	IC50	uM	65.2
Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay	CCCCC/C=C/C(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL25948	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins	CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL1095671	=	=	IC50	nM	8100.0	IC50	uM	8.1
Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid DBOMF substrate green measured every 30 sec for 30 mins by fluorescence assay	CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL1095671	=	=	IC50	nM	11600.0	IC50	uM	11.6
Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMR substrate red measured every 30 sec for 30 mins by fluorescence assay	CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL1095671	=	=	IC50	nM	10500.0	IC50	uM	10.5
Inhibition of recombinant human CYP3A4 expressed in baculosomes using Vivid BOMCC substrate blue measured every 30 sec for 30 mins by fluorescence assay	CCCCCCC[C@H](O)CC(=O)CCc1ccc(O)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL1095671	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of CYP3A4 (unknown origin)	COC(=O)C1=C(CN2CCOC[C@H]2C(=O)O)NC(c2nccs2)=N[C@H]1c1ccc(F)cc1Cl	J Med Chem	2017.0	CHEMBL4064672	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(C(F)(F)F)ccc1-c1ncnc2cc(S(=O)(=O)Nc3nccs3)ccc12	J Med Chem	2017.0	CHEMBL3687538	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(C(F)(F)F)ccc1-c1nccc2cc(S(=O)(=O)Nc3ccncn3)ccc12	J Med Chem	2017.0	CHEMBL3692139	=	=	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)ccc1-c1nccc2cc(S(=O)(=O)Nc3ccncn3)ccc12	J Med Chem	2017.0	CHEMBL3682789	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ccncn3)ccc12	J Med Chem	2017.0	CHEMBL3687606	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ncccn3)ccc12	J Med Chem	2017.0	CHEMBL4078593	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3cccnn3)ccc12	J Med Chem	2017.0	CHEMBL4096614	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ncns3)ccc12	J Med Chem	2017.0	CHEMBL3687604	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ccon3)ccc12	J Med Chem	2017.0	CHEMBL3687608	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ncco3)ccc12	J Med Chem	2017.0	CHEMBL4092695	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(F)c2)c(Cl)cc1-c1nccc2cc(S(=O)(=O)Nc3ncon3)ccc12	J Med Chem	2017.0	CHEMBL4071917	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(-c2cccc(C(F)(F)F)c2)c(F)cc1-c1nccc2cc(S(=O)(=O)Nc3ccon3)ccc12	J Med Chem	2017.0	CHEMBL4060568	>	>	IC50	nM	15000.0	IC50	uM	15.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3949600	=	=	IC50	nM	45000.0	IC50	uM	45.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cc(C(F)(F)F)ccc2C)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3949474	=	=	IC50	nM	2200.0	IC50	uM	2.2
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cccc(C(F)(F)F)c2)c(C)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3956563	=	=	IC50	nM	2800.0	IC50	uM	2.8
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3cnccn3)ccc21	J Med Chem	2017.0	CHEMBL3953660	=	=	IC50	nM	4600.0	IC50	uM	4.6
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21	J Med Chem	2017.0	CHEMBL3941727	=	=	IC50	nM	32000.0	IC50	uM	32.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cccc(OC(F)F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3921528	>	>	IC50	nM	50000.0	IC50	uM	50.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cc(OC)c(-n3c(=O)ccc4cc(S(=O)(=O)Nc5ncccn5)ccc43)cc2F)ccc1Cl	J Med Chem	2017.0	CHEMBL3937744	>	>	IC50	nM	50000.0	IC50	uM	50.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21	J Med Chem	2017.0	CHEMBL3979498	>	>	IC50	nM	50000.0	IC50	uM	50.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition	COc1cc(-c2ccc(F)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3961163	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3949600	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cc(C(F)(F)F)ccc2C)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3949474	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cccc(C(F)(F)F)c2)c(C)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3956563	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3cnccn3)ccc21	J Med Chem	2017.0	CHEMBL3953660	=	=	IC50	nM	3600.0	IC50	uM	3.6
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2ccc(Cl)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21	J Med Chem	2017.0	CHEMBL3941727	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cccc(OC(F)F)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3921528	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cc(OC)c(-n3c(=O)ccc4cc(S(=O)(=O)Nc5ncccn5)ccc43)cc2F)ccc1Cl	J Med Chem	2017.0	CHEMBL3937744	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2cccc(C(F)(F)F)c2)ccc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ncccn3)ccc21	J Med Chem	2017.0	CHEMBL3979498	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	COc1cc(-c2ccc(F)c(C)c2)c(F)cc1-n1c(=O)ccc2cc(S(=O)(=O)Nc3ccon3)ccc21	J Med Chem	2017.0	CHEMBL3961163	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(Cl)ccc2F)cc1Nc1ccnc2cn[nH]c12	Bioorg Med Chem Lett	2017.0	CHEMBL4084771	=	=	IC50	nM	3162.28	pIC50		5.5
Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(F)ccc2F)cc1Nc1ccnc2cn[nH]c12	Bioorg Med Chem Lett	2017.0	CHEMBL4102696	=	=	IC50	nM	1584.89	pIC50		5.8
Inhibition of CYP3A4 (unknown origin)	COc1cccc2nccc(Nc3cc(-c4nc(C)ccc4F)ncc3C)c12	Bioorg Med Chem Lett	2017.0	CHEMBL4094958	=	=	IC50	nM	6309.57	pIC50		5.2
Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(Cl)ccc2F)cc1Nc1ccnc2cnn(CC(N)=O)c12	Bioorg Med Chem Lett	2017.0	CHEMBL4072325	=	=	IC50	nM	12589.25	pIC50		4.9
Inhibition of CYP3A4 (unknown origin)	NC(=O)Cn1cc2nccc(Nc3ccnc(-c4cc(Cl)ccc4F)c3)c2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4067488	=	=	IC50	nM	12589.25	pIC50		4.9
Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(Cl)ccc2F)cc1Nc1ccnc2cn(CC(N)=O)nc12	Bioorg Med Chem Lett	2017.0	CHEMBL4069101	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of CYP3A4 (unknown origin)	NC(=O)n1cc(NC(=O)N2CCC[C@H]2C(=O)Nc2cccc(OC(F)(F)F)c2)c2ccccc21	J Med Chem	2017.0	CHEMBL3908849	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	NC(=O)c1nn(CC(=O)N2[C@H](C(=O)Nc3cccc(Br)n3)C[C@H]3C[C@H]32)c2ccccc12	J Med Chem	2017.0	CHEMBL3683753	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 in human microsomes in presence of NADPH	O=c1c2ccccc2oc2c(Cc3ccc4c(c3)OCO4)[nH]c(-c3nccs3)c12	J Med Chem	2017.0	CHEMBL4099219	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	O=c1[nH]c(-c2ccc(Br)cc2)nc2ccccc12	Eur J Med Chem	2017.0	CHEMBL2058057	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	COc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1O	Eur J Med Chem	2017.0	CHEMBL3289112	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	COc1cc(-c2nc3ccccc3c(=O)[nH]2)ccc1O	Eur J Med Chem	2017.0	CHEMBL4081914	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	C#CCOc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1	Eur J Med Chem	2017.0	CHEMBL4074105	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	O=c1[nH]c(-c2ccc(Oc3ccc(Cl)cc3Cl)cc2)nc2ccccc12	Eur J Med Chem	2017.0	CHEMBL4100866	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	O=c1[nH]c(-c2ccc(OCc3ccc(F)cc3F)cc2)nc2ccccc12	Eur J Med Chem	2017.0	CHEMBL4084413	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Eur J Med Chem	2017.0	CHEMBL283196	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1	Bioorg Med Chem Lett	2017.0	CHEMBL4060768	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ncccn5)CC4)ccc3C)c(F)c12	J Med Chem	2017.0	CHEMBL4093031	>	>	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ncccn5)CC4)ccc3C)cc12	J Med Chem	2017.0	CHEMBL4104000	=	=	IC50	nM	11400.0	IC50	uM	11.4
Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccncc5)CC4)ccc3C)cc12	J Med Chem	2017.0	CHEMBL4086080	=	=	IC50	nM	73.0	IC50	uM	0.073
Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5cccnc5)CC4)ccc3C)cc12	J Med Chem	2017.0	CHEMBL4096241	=	=	IC50	nM	63.0	IC50	uM	0.063
Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccccn5)CC4)ccc3C)cc12	J Med Chem	2017.0	CHEMBL4078188	=	=	IC50	nM	4100.0	IC50	uM	4.1
Inhibition of microsomal CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3cc(C(=O)NC4(c5ccccc5)CC4)ccc3C)cc12	J Med Chem	2017.0	CHEMBL4088517	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 (unknown origin)	O=C(CC1(c2ccccc2)C2CC3CC1CC(C2)C3O)N1CC(O)C1	J Med Chem	2017.0	CHEMBL4080667	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2cccc(-c3cc(-c4ccnn4CC(F)(F)F)c4c(N)ncnn34)c2)C(=O)C1(C)C	J Med Chem	2017.0	CHEMBL4059848	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2cc(-c3cc(C(F)(F)F)c4c(N)ncnn34)ccc2C#N)C(=O)C1(C)C	J Med Chem	2017.0	CHEMBL4064666	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate preincubated with compound followed by substrate addition	COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N	J Med Chem	2017.0	CHEMBL4066936	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate	COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N	J Med Chem	2017.0	CHEMBL4066936	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human liver microsomes CYP3A4 using midazolam as substrate preincubated with compound followed by substrate addition	COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N	J Med Chem	2017.0	CHEMBL4066936	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human liver microsomes CYP3A4 using midazolam as substrate	COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N	J Med Chem	2017.0	CHEMBL4066936	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	O=C(NC1CCCCCC1)c1cc2c(Cl)cc(Cl)cc2[nH]1	J Med Chem	2017.0	CHEMBL4090593	<=	<=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 using ketoconazole as substrate	CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](F)(Cl)[C@@H]1O)Oc1ccccc1	J Med Chem	2017.0	CHEMBL4081718	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of human CYP3A4 using ketoconazole as substrate	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	J Med Chem	2017.0	CHEMBL1259059	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4102132	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	O=S(=O)(Nc1ncc(F)s1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4079748	=	=	IC50	nM	37500.0	IC50	uM	37.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	O=S(=O)(Nc1nc(Cl)cs1)c1cc(Cl)c(NC[C@H]2NCCC=C2c2ccc(F)cc2)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4090203	=	=	IC50	nM	40100.0	IC50	uM	40.1
Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate after 30 mins in presence of NADPH by LC-MS/MS analysis	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CCCN2CCC3)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4061793	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate after 30 mins in presence of NADPH by LC-MS/MS analysis	CC1(C)CN2CCC[C@]2(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)C1	Bioorg Med Chem Lett	2017.0	CHEMBL4062780	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay	COc1ccc(CNc2c3c(nc4ccccc24)CCCC3)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4076034	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay	COc1ccc(CNc2c3c(nc4cc(Cl)ccc24)CCCC3)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4070182	=	=	IC50	nM	13800.0	IC50	uM	13.8
Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay	Clc1ccc2c(NCc3ccccn3)c3c(nc2c1)CCCC3	Bioorg Med Chem Lett	2017.0	CHEMBL4075061	=	=	IC50	nM	9100.0	IC50	uM	9.1
Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2017.0	CHEMBL157101	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of recombinant human CYP3A4 expressed in insect cells using DBOMF as substrate pretreated for 10 mins followed by substrate addition measured every minute for 15 mins in presence of NADP+ by fluorescence assay	Nc1c2c(nc3ccccc13)CCCC2	Bioorg Med Chem Lett	2017.0	CHEMBL95	=	=	IC50	nM	96900.0	IC50	uM	96.9
Inhibition of CYP3A4 in liver microsomes (unknown origin) assessed as formation of 1-hydroxymidazolam from midazolam in presence of NADPH by LC-MS/MS analysis	Cc1ncn(-c2ccc(C(=O)N[C@H]3[C@H]4CC[C@H]3N(c3ncc(Cl)c5cnoc35)C4)c(Cl)c2)n1	Bioorg Med Chem Lett	2017.0	CHEMBL4096341	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method	C=CC(=O)Nc1cccc(C)c1Nc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)ccc2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4068896	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method	C=CC(=O)Nc1cccc(C)c1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4089245	=	=	IC50	nM	6900.0	IC50	uM	6.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS method	C=CC(=O)N[C@H]1COC[C@H]1Nc1ncc(OCc2c(F)c(OC)cc(OC)c2F)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4077859	=	=	IC50	nM	13300.0	IC50	uM	13.3
Inhibition of CYP3A4 (unknown origin)	C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1	J Med Chem	2018.0	CHEMBL4065122	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 6beta-hydroxytestosterone from testosterone after 10 mins by LC-MS/MS analysis	O=[N+]([O-])c1cn2c(n1)OC[C@H](Oc1ccc(OC(F)(F)F)cc1)C2	J Med Chem	2018.0	CHEMBL4078293	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1[C@@H](C)OC(C)(C)C(=O)N1c1cc(-c2cc(C(F)(F)F)c3c(N)ncnn23)ccc1C#N	Bioorg Med Chem Lett	2017.0	CHEMBL4091875	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human hepatic CYP3A4	COc1cncc(CN2CCc3c(sc4ccc(F)cc34)C2)c1	Eur J Med Chem	2017.0	CHEMBL4063960	=	=	IC50	nM	6526.0	IC50	nM	6526.0
Inhibition of human hepatic CYP3A4	Fc1cncc(CN2CCc3c(sc4ccc(F)cc34)C2)c1	Eur J Med Chem	2017.0	CHEMBL4091726	=	=	IC50	nM	9032.0	IC50	nM	9032.0
Inhibition of human hepatic CYP3A4	Cc1ccncc1CN1CCc2c(sc3ccc(F)cc23)C1	Eur J Med Chem	2017.0	CHEMBL4059780	=	=	IC50	nM	8561.0	IC50	nM	8561.0
Inhibition of human hepatic CYP3A4	Oc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3	Eur J Med Chem	2017.0	CHEMBL4064141	=	=	IC50	nM	5282.0	IC50	nM	5282.0
Inhibition of human hepatic CYP3A4	Fc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3	Eur J Med Chem	2017.0	CHEMBL4101612	=	=	IC50	nM	7897.0	IC50	nM	7897.0
Inhibition of human hepatic CYP3A4	Fc1ccc2sc3c(c2c1)CCN(Cc1c[nH]cn1)C3	Eur J Med Chem	2017.0	CHEMBL4068802	=	=	IC50	nM	685.0	IC50	nM	685.0
Inhibition of human hepatic CYP3A4	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	Eur J Med Chem	2017.0	CHEMBL254328	=	=	IC50	nM	2700.0	IC50	nM	2700.0
Reversible inhibition of CYP3A4 in human liver microsomes	Cc1ccc(Oc2nc3cc(-c4ccc(-c5ccccc5)cc4)c(Cl)cc3[nH]2)cc1C(=O)O	J Med Chem	2017.0	CHEMBL4082745	>	>	IC50	nM	50000.0	IC50(app)	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)Cc2c(sc(NC(=O)c3ccn[nH]3)c2C(N)=O)C(C)(C)O1	J Med Chem	2018.0	CHEMBL4075348	>	>	EC50	nM	100000.0	EC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes	c1nc(N[C@H]2CC[C@H](N3CCOCC3)CC2)c2c(C3CCOCC3)c[nH]c2n1	J Med Chem	2017.0	CHEMBL4064608	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(C)[nH]c(=O)c1CN1CCc2c(Cl)cc([C@H](OC)C3COC3)c(Cl)c2C1=O	J Med Chem	2018.0	CHEMBL4080228	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	CC#C[C@@H](CC(=O)O)c1ccc(OCc2ccc3nc(-c4c(C)cccc4C)nn3c2)cc1	J Med Chem	2018.0	CHEMBL3927519	>	>	IC50	nM	60000.0	IC50	uM	60.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate upto 10 uM after 5 mins in presence of NADPH by LC-MS/MS analysis	CN(C/C=C/c1ccc(-c2ccccc2)cc1)Cc1coc2ccccc12.Cl	J Med Chem	2018.0	CHEMBL4086008	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate upto 10 uM after 5 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	80000.0	IC50	uM	80.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate upto 10 uM after 5 mins in presence of NADPH by LC-MS/MS analysis	CN(C/C=C/c1ccc(-c2ccccc2)cc1)Cc1coc2ccccc12.Cl	J Med Chem	2018.0	CHEMBL4086008	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate upto 10 uM after 5 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	80000.0	IC50	uM	80.0
Inhibition of CYP3A4 (unknown origin) expressed in baculosomes	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of CYP3A4 (unknown origin)	COc1cc(C(=O)NC(c2nc(C(=O)Nc3ccccc3C(=O)c3ccccc3)cs2)C(C)C)cc(OC)c1OC	J Med Chem	2018.0	CHEMBL4076355	=	=	IC50	nM	8230.0	IC50	uM	8.23
Inhibition of human liver microsomal CYP3A4	Cc1cc(NC2CCN(C(=O)CCNCC(=O)O)CC2)nc(NCc2cn(CCCNCCCNC3CCCCC3)nn2)n1	J Med Chem	2018.0	CHEMBL4064397	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by LC-MS/MS analysis	OC12CC3CC(C1)CC(NCc1cc(C4CC4)on1)(C3)C2	J Med Chem	2018.0	CHEMBL4077296	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes expression system using fluorogenic-BOMCC as substrate by fluorescent homogeneous assay	N#Cc1c(-c2cccs2)nc(SCc2cccc(CC(=O)O)c2)[nH]c1=O	J Med Chem	2018.0	CHEMBL4071212	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS analysis	CCOC(=O)C1=C(CN2CCO[C@H](CCC(=O)O)C2)NC(c2nccs2)=N[C@H]1c1ccc(F)cc1Br	J Med Chem	2018.0	CHEMBL4085181	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BQ as substrate	CC(=O)O[C@H]1C[C@H]2[C@H]([C@@H]3CC[C@H]([C@H](C)CCCNCCCCNc4ccnc5cc(Cl)ccc45)[C@@]13C)[C@H](OC(C)=O)C[C@@H]1C[C@H](N)CC[C@@]12C	J Med Chem	2018.0	CHEMBL4092633	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 (unknown origin) using DBF as substrate	CC(=O)O[C@H]1C[C@H]2[C@H]([C@@H]3CC[C@H]([C@H](C)CCCNCCCCNc4ccnc5cc(Cl)ccc45)[C@@]13C)[C@H](OC(C)=O)C[C@@H]1C[C@H](N)CC[C@@]12C	J Med Chem	2018.0	CHEMBL4092633	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	CC(=O)O[C@H]1C[C@H]2[C@H]([C@@H]3CC[C@H]([C@H](C)CCCNCCCCNc4ccnc5cc(Cl)ccc45)[C@@]13C)[C@H](OC(C)=O)C[C@@H]1C[C@H](N)CC[C@@]12C	J Med Chem	2018.0	CHEMBL4092633	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of hepatic CYP3A4 (unknown origin)	Cc1nn(-c2cncc([C@](C)(O)C(F)(F)F)c2)c2ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL4098297	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of hepatic CYP3A4 (unknown origin)	Cc1nn(-c2cncc([C@@](C)(O)C(F)(F)F)c2)c2ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL4080256	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of hepatic CYP3A4 (unknown origin)	C[C@](O)(c1cncc(-n2nc(C(F)(F)F)c3ccccc32)c1)C(F)(F)F	Bioorg Med Chem Lett	2017.0	CHEMBL4071689	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of hepatic CYP3A4 (unknown origin)	Cc1nn(-c2cncc(C(C)(C)O)c2)c2cccc(F)c12	Bioorg Med Chem Lett	2017.0	CHEMBL4080420	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of hepatic CYP3A4 (unknown origin)	CC(C)(O)c1cncc(-n2ncc3c(C(F)(F)F)cccc32)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4067000	=	=	IC50	nM	43000.0	IC50	nM	43000.0
Time dependent inhibition of CYP3A4 (unknown origin) in absence of NADPH	Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3=O)ccc2c1COC2=O	Bioorg Med Chem Lett	2017.0	CHEMBL4069245	>	>	IC50	nM	50000.0	IC50	uM	50.0
Time dependent inhibition of CYP3A4 (unknown origin) in presence of NADPH	Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3=O)ccc2c1COC2=O	Bioorg Med Chem Lett	2017.0	CHEMBL4069245	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1c([C@@H](O)CN2CCC3(CC2)CCN(c2ccc(=O)n(C)n2)C3=O)ccc2c1COC2=O	Bioorg Med Chem Lett	2017.0	CHEMBL4069245	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(-c4ccncc4)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4070692	=	=	IC50	nM	340.0	IC50	uM	0.34
Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(-c4ccnc(F)c4)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4094439	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(-c4ccc(F)nc4)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4102040	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NCc3ccc(-c4cccnc4F)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4091821	>	>	IC50	nM	30000.0	IC50	uM	30.0
Induction of CYP3A4 in cryopreserved human hepatocytes measured after 48 hrs	Cc1nnc2sc(C(=O)NCc3ccc(-c4cccnc4F)cc3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4091821	>	>	EC50	nM	50000.0	EC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS analysis	O=C(N/N=C/c1ccc2no[n+]([O-])c2c1)c1ccncc1	J Med Chem	2017.0	CHEMBL2338421	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 30 mins by LC-MS/MS analysis	N#Cc1ccc2c(c1)[nH]c(=O)n2[C@H]1C[C@H](c2nnc(-c3ccncn3)n2-c2ccccc2Cl)C1	J Med Chem	2017.0	CHEMBL4095003	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 in human liver microsomes preincubated for 5 mins followed by addition of NADPH generating system measured after 20 mins by LC-MS/MS analysis	COCCCc1ccc2oc(-c3ccc(OC)c(OC)c3)cc2c1	J Med Chem	2018.0	CHEMBL4066961	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone, midozolam or nifedipine as substrates	C[C@H]1Cc2c(nnn2-c2ncc(F)cn2)CN1C(=O)c1cccc(C(F)(F)F)c1F	J Med Chem	2018.0	CHEMBL3919664	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone, midozolam or nifedipine as substrates	C[C@H]1Cc2c(nnn2-c2ncc(F)cn2)CN1C(=O)c1ccnc(C(F)(F)F)c1F	J Med Chem	2018.0	CHEMBL3914857	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone, midozolam or nifedipine as substrates	Cc1c(C(=O)N2Cc3nnn(-c4ncc(F)cn4)c3C[C@@H]2C)ccnc1C(F)(F)F	J Med Chem	2018.0	CHEMBL3936866	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in baculosomes using BOMR as substrate preincubated for 10 mins followed by substrate/NADP+ addition measured for 1 hr	Cc1cc(C(=O)N/N=C/c2ccc(Cl)cc2)c2c(C)nn(-c3ccccc3)c2n1	Eur J Med Chem	2017.0	CHEMBL4084418	=	=	IC50	nM	94600.0	IC50	uM	94.6
Inhibition of recombinant human CYP3A4 expressed in baculosomes using BOMR as substrate preincubated for 10 mins followed by substrate/NADP+ addition measured for 1 hr	Cc1cc(C(=O)N/N=C/c2ccc(Br)cc2)c2c(C)nn(-c3ccccc3)c2n1	Eur J Med Chem	2017.0	CHEMBL4062734	=	=	IC50	nM	137800.0	IC50	uM	137.8
Inhibition of recombinant human CYP3A4 expressed in baculosomes using BOMR as substrate preincubated for 10 mins followed by substrate/NADP+ addition measured for 1 hr	Cc1cc(C(=O)N/N=C/c2ccc([N+](=O)[O-])cc2)c2c(C)nn(-c3ccccc3)c2n1	Eur J Med Chem	2017.0	CHEMBL4099918	=	=	IC50	nM	155700.0	IC50	uM	155.7
Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NC3CN(c4cccc(F)c4F)C3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4062319	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin)	Cc1nnc2sc(C(=O)NC3CN(c4ccc(C(F)(F)F)nc4)C3)c(N)c2c1C	Bioorg Med Chem Lett	2017.0	CHEMBL4083081	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(Br)cc1)N1CC[C@](CCO)(c2ccc(F)cc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4102254	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(Br)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL3645526	=	=	IC50	nM	3500.0	IC50	uM	3.5
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(Br)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4099792	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCC(N)=O)(c2ccc(F)cc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4100755	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CCC(N)=O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4076820	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CC(C)(C)O)(c2ccc(F)cc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4079355	=	=	IC50	nM	6600.0	IC50	uM	6.6
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(OC(F)F)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4103620	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccccn2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4060843	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2cccnc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4070571	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccncc2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4101787	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of recombinant CYP3A4 (unknown origin)	Cc1cc(-c2ccc([C@H](C)N3CC[C@](CCCO)(c4ccccc4)OC3=O)cc2)cc(C)n1	Bioorg Med Chem	2017.0	CHEMBL4075665	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2cncc(F)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4075869	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of recombinant CYP3A4 (unknown origin)	COc1ccc(-c2ccc([C@H](C)N3CC[C@](CCCO)(c4ccccc4)OC3=O)cc2)cn1	Bioorg Med Chem	2017.0	CHEMBL4066654	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CCCO)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL3664710	=	=	IC50	nM	10500.0	IC50	uM	10.5
Inhibition of recombinant CYP3A4 (unknown origin)	Cc1cc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cc(C)n1	Bioorg Med Chem	2017.0	CHEMBL4072112	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant CYP3A4 (unknown origin)	COc1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn1	Bioorg Med Chem	2017.0	CHEMBL4069717	=	=	IC50	nM	11600.0	IC50	uM	11.6
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(F)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4096179	=	=	IC50	nM	24100.0	IC50	uM	24.1
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(C#N)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4090128	=	=	IC50	nM	12700.0	IC50	uM	12.7
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(C(N)=O)cn2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4076599	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant CYP3A4 (unknown origin)	Cc1cnc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn1	Bioorg Med Chem	2017.0	CHEMBL4064441	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant CYP3A4 (unknown origin)	Cc1ccc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)nn1	Bioorg Med Chem	2017.0	CHEMBL4075178	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant CYP3A4 (unknown origin)	Cc1ncc(-c2ccc([C@H](C)N3CC[C@](CC(C)(C)O)(c4ccccc4)OC3=O)cc2)cn1	Bioorg Med Chem	2017.0	CHEMBL4105041	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(=O)n(C)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL3664715	=	=	IC50	nM	48000.0	IC50	uM	48.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccn(C)c(=O)c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL3664717	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc(=O)n(C)n2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL4063121	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@@H](c1ccc(-c2ccc3ncnn3c2)cc1)N1CC[C@](CC(C)(C)O)(c2ccccc2)OC1=O	Bioorg Med Chem	2017.0	CHEMBL3660140	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(O)CC(=O)N1CCC(c2ccc(NC(=O)N3Cc4ccccc4C3)cc2)CC1	Bioorg Med Chem Lett	2017.0	CHEMBL4082366	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 (unknown origin)	O=C(NC[C@@H]1CCOC1)c1ccc(NC(=O)N2Cc3ccccc3C2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL3929298	>	>	IC50	nM	20000.0	IC50	uM	20.0
Competitive inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2nc(CCC(F)(F)F)c(-c3cc(C(=O)NC(C)(C)c4ncon4)c(=O)n(C)c3)cc12	ACS Med Chem Lett	2017.0	CHEMBL4061621	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of CYP3A4 (unknown origin)	COc1cnc(-n2cncn2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	J Med Chem	2018.0	CHEMBL4104608	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using 7-benzyloxy-4-trifluoromethylcoumarin as substrate measured after 45 mins in presence of NADPH by spectrofluorometric method	O=c1cc(-c2ccccc2)oc2cc(O)c(O)c(O)c12	Eur J Med Chem	2017.0	CHEMBL8260	=	=	IC50	nM	9200.0	IC50	uM	9.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cccc(NC(=O)c2cc(Oc3cncnc3)cc(C)n2)n1	J Med Chem	2017.0	CHEMBL4103707	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cccc(NC(=O)c2cc(Oc3cncc(F)c3)cc(C)n2)n1	J Med Chem	2017.0	CHEMBL4076771	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	CCc1cccc(NC(=O)c2cc(Oc3cncnc3)cc(C)n2)n1	J Med Chem	2017.0	CHEMBL2386772	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2cccc(F)n2)n1	J Med Chem	2017.0	CHEMBL4095685	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2cccc(F)n2)n1	J Med Chem	2017.0	CHEMBL4077672	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL2386850	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL2386849	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(Cl)cn2)n1	J Med Chem	2017.0	CHEMBL4082854	=	=	IC50	nM	16400.0	IC50	uM	16.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(Cl)cn2)n1	J Med Chem	2017.0	CHEMBL4100830	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2cc(F)ccn2)n1	J Med Chem	2017.0	CHEMBL4090661	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2cc(F)ccn2)n1	J Med Chem	2017.0	CHEMBL4062697	=	=	IC50	nM	27400.0	IC50	uM	27.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cnc(C)nc2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL2386771	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis	Cc1cc(Oc2cncc(Cl)c2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL4096818	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins measured after 8 mins in presence or absence of NADPH by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL2386850	=	=	IC50	nM	133000.0	IC50	uM	133.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 15 mins measured after 8 mins in presence or absence of NADPH by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1	J Med Chem	2017.0	CHEMBL2386850	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 (unknown origin)	CN1C(=O)C2=C(C1=O)N(CC(=O)Nc1ccc(-c3nccs3)cc1)CCC2	J Med Chem	2017.0	CHEMBL4094309	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4 (unknown origin)	CN1C(=O)C2=C(C1=O)N(CC(=O)Nc1ccc(-c3cccnc3)nn1)CCC2	J Med Chem	2017.0	CHEMBL4104257	=	=	IC50	nM	6200.0	IC50	uM	6.2
Inhibition of CYP3A4 (unknown origin)	O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cccnc2)nn1	J Med Chem	2017.0	CHEMBL4087906	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 (unknown origin)	CN1C(=O)C2=C(C1=O)N(CC(=O)Nc1ccc(-c3cncc(F)c3)nn1)CCC2	J Med Chem	2017.0	CHEMBL4066589	=	=	IC50	nM	7100.0	IC50	uM	7.1
Inhibition of CYP3A4 (unknown origin)	O=C(CN1CCCC2=C1C(=O)N(C1CC1)C2=O)Nc1ccc(-c2cncc(F)c2)nn1	J Med Chem	2017.0	CHEMBL4095609	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ccc(NC(=O)CN3CCCC4=C3C(=O)N(C)C4=O)nn2)cn1	J Med Chem	2017.0	CHEMBL4075204	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ccc(NC(=O)CN3CCCC4=C3C(=O)N(C3CC3)C4=O)nn2)cn1	J Med Chem	2017.0	CHEMBL4103356	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1ccc(S(=O)(=O)Nc2ncns2)cc1C#N	J Med Chem	2017.0	CHEMBL2324753	=	=	IC50	nM	556.0	IC50	nM	556.0
Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2ncns2)cc1F	J Med Chem	2017.0	CHEMBL2325350	<	<	IC50	nM	30.0	IC50	nM	30.0
Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2nncs2)cc1Cl	J Med Chem	2017.0	CHEMBL2324755	=	=	IC50	nM	11068.0	IC50	nM	11068.0
Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1ccc(S(=O)(=O)Nc2cscn2)cc1C#N	J Med Chem	2017.0	CHEMBL2322421	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl	J Med Chem	2017.0	CHEMBL2324405	=	=	IC50	nM	26588.0	IC50	nM	26588.0
Inhibition of CYP3A4 (unknown origin)	Cn1nccc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl	J Med Chem	2017.0	CHEMBL2324391	=	=	IC50	nM	1058.0	IC50	nM	1058.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1ccn[nH]1	J Med Chem	2017.0	CHEMBL2324742	=	=	IC50	nM	400.0	IC50	nM	400.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1cn[nH]c1	J Med Chem	2017.0	CHEMBL2325330	=	=	IC50	nM	505.0	IC50	nM	505.0
Inhibition of CYP3A4 (unknown origin)	Cc1[nH]ncc1-c1cc(C(F)(F)F)ccc1Oc1ccc(S(=O)(=O)Nc2ncns2)cc1C#N	J Med Chem	2017.0	CHEMBL2325619	=	=	IC50	nM	737.0	IC50	nM	737.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1cn[nH]c1N	J Med Chem	2017.0	CHEMBL2325038	=	=	IC50	nM	827.0	IC50	nM	827.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(Cl)cc1-c1ccnc(N)c1	J Med Chem	2017.0	CHEMBL2325013	=	=	IC50	nM	205.0	IC50	nM	205.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1ccncn1	J Med Chem	2017.0	CHEMBL2323074	=	=	IC50	nM	910.0	IC50	nM	910.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1cccnn1	J Med Chem	2017.0	CHEMBL2323073	=	=	IC50	nM	616.0	IC50	nM	616.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(C(F)(F)F)cc1-c1ccnnc1	J Med Chem	2017.0	CHEMBL2325021	=	=	IC50	nM	1271.0	IC50	nM	1271.0
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1nncs1)c1cc(Cl)c(Oc2ccc(C(F)(F)F)cc2-c2ccnnc2)cc1F	J Med Chem	2017.0	CHEMBL2324776	>	>	IC50	nM	11248.0	IC50	nM	11248.0
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(Nc1cscn1)c1cc(Cl)c(Oc2ccc(C(F)(F)F)cc2-c2ccnnc2)cc1F	J Med Chem	2017.0	CHEMBL2324396	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 (unknown origin)	Nc1n[nH]cc1-c1cc(C(F)(F)F)ccc1Oc1cc(F)c(S(=O)(=O)Nc2nncs2)cc1Cl	J Med Chem	2017.0	CHEMBL2325627	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 (unknown origin)	Nc1n[nH]cc1-c1cc(C(F)(F)F)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl	J Med Chem	2017.0	CHEMBL2325601	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 (unknown origin)	Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl	J Med Chem	2017.0	CHEMBL2325014	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 (unknown origin)	CN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1	J Med Chem	2017.0	CHEMBL2325622	=	=	IC50	nM	427.0	IC50	nM	427.0
Inhibition of CYP3A4 (unknown origin)	CCN1CC(n2nccc2-c2cc(Cl)ccc2Oc2ccc(S(=O)(=O)Nc3cscn3)cc2C#N)C1	J Med Chem	2017.0	CHEMBL2324748	=	=	IC50	nM	12239.0	IC50	nM	12239.0
Inhibition of CYP3A4 (unknown origin)	CN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3cscn3)cc2F)C1	J Med Chem	2017.0	CHEMBL2325317	=	=	IC50	nM	15124.0	IC50	nM	15124.0
Inhibition of CYP3A4 (unknown origin)	CCN1CC(n2nccc2-c2cc(Cl)ccc2Oc2cc(F)c(S(=O)(=O)Nc3cscn3)cc2F)C1	J Med Chem	2017.0	CHEMBL2325020	>	>	IC50	nM	30000.0	IC50	nM	30000.0
Inhibition of CYP3A4 (unknown origin)	C[C@]12CC[C@@H]3[C@H]4CC[C@@](C)(O)C[C@H]4CC[C@H]3[C@@H]1CC[C@@H]2C(=O)Cn1cc(C#N)cn1	J Med Chem	2017.0	CHEMBL4105630	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	CCOC(=O)/C=C/c1ccc(/C=C/c2cc(O)c(O)c(O)c2)cc1	J Med Chem	2017.0	CHEMBL4062993	=	=	IC50	nM	36200.0	IC50	uM	36.2
Inhibition of CYP3A4 in human liver microsomes	CCOC(=O)/C=C/c1cc(O)c(O)cc1-c1cc2ccccc2o1	J Med Chem	2017.0	CHEMBL4090305	=	=	IC50	nM	11200.0	IC50	uM	11.2
Inhibition of CYP3A4 in human liver microsomes	CCOC(=O)/C=C/c1cc(O)c2oc(-c3cc(O)c(O)c(O)c3)cc2c1	J Med Chem	2017.0	CHEMBL3409195	=	=	IC50	nM	21700.0	IC50	uM	21.7
Inhibition of CYP3A4 in human liver microsomes	Oc1ccc(-c2cc3cc(Br)cc(O)c3o2)cc1O	J Med Chem	2017.0	CHEMBL3409192	=	=	IC50	nM	23500.0	IC50	uM	23.5
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CCCN2CCC3)cc1F	Bioorg Med Chem	2017.0	CHEMBL4061793	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@]23CCO[C@H]2OCC3)cc1F	Bioorg Med Chem	2017.0	CHEMBL4104727	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@]23CCC[C@@]2(O)CCC3)cc1F	Bioorg Med Chem	2017.0	CHEMBL4071736	=	=	IC50	nM	6300.0	IC50	uM	6.3
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC23CC4CC(CC(O)(C4)C2)C3)cc1F	Bioorg Med Chem	2017.0	CHEMBL4061129	=	=	IC50	nM	6300.0	IC50	uM	6.3
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCOC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4101414	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCCC2CCOC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4073353	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2OCCO2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4083744	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCOCC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4102647	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCOCC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4064762	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCCCO2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4092463	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2COCCO2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4087220	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCCO2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4065798	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCOC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4072883	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	CC(C)(C)[C@H]1OCCC[C@@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl	Bioorg Med Chem	2017.0	CHEMBL4064295	=	=	IC50	nM	4900.0	IC50	uM	4.9
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	CC(C)(C)[C@@H]1OCCC[C@@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl	Bioorg Med Chem	2017.0	CHEMBL4084268	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCCO[C@@H]2c2ccccc2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4102233	=	=	IC50	nM	3600.0	IC50	uM	3.6
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCCC2CCCOC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4094490	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=C1CCCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)C1	Bioorg Med Chem	2017.0	CHEMBL4102624	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCC[C@H](O)C2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4084685	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CCC[C@@H](O)C2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4094879	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NCC2CCCC3(C2)OCCO3)cc1F	Bioorg Med Chem	2017.0	CHEMBL4074392	=	=	IC50	nM	16500.0	IC50	uM	16.5
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=C1CCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	Bioorg Med Chem	2017.0	CHEMBL4073324	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	CON=C1CCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	Bioorg Med Chem	2017.0	CHEMBL4100176	=	=	IC50	nM	13700.0	IC50	uM	13.7
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CC[C@H](O)CC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4092435	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S(=O)(Nc1nccs1)c1cc(Cl)c(NC[C@H]2CC[C@@H](O)CC2)cc1F	Bioorg Med Chem	2017.0	CHEMBL4068484	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S1(=O)CCC(CCNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)CC1	Bioorg Med Chem	2017.0	CHEMBL4075332	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using 7-Benzoyloxy-4-trifluoromethyl coumarin substrate in presence of NADP+ by fluorescence based assay	O=S1(=O)CCC(CNc2cc(F)c(S(=O)(=O)Nc3nccs3)cc2Cl)C1	Bioorg Med Chem	2017.0	CHEMBL4082252	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC-MS/MS analysis	O=C(c1ccccc1)N1CCc2oc(-c3ccc(F)cn3)nc2C1	Bioorg Med Chem Lett	2017.0	CHEMBL4060556	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC-MS/MS analysis	O=C(c1cccc(F)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1	Bioorg Med Chem Lett	2017.0	CHEMBL4102181	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC-MS/MS analysis	O=C(c1cc(F)cc(Cl)c1)N1CCc2oc(-c3ccc(F)cn3)nc2C1	Bioorg Med Chem Lett	2017.0	CHEMBL4087545	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC-MS/MS analysis	O=C(c1cc(F)cc(Cl)c1)N1CCn2nc(-c3ccc(F)cn3)cc2C1	Bioorg Med Chem Lett	2017.0	CHEMBL4098822	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@@H]3CCCNC3)c2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4086461	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@H]3CCCNC3)c2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4104355	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@@H]3CCCNC3)c2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4086461	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	NC(=O)c1cc(Cl)c2c(Cl)c(C3CC3)n([C@H]3CCCNC3)c2n1	Bioorg Med Chem Lett	2017.0	CHEMBL4104355	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of human CYP3A4	CCCCc1cc(OC2CCN(CCCCNS(=O)(=O)CC)CC2)c2ncccc2c1.Cl.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4088036	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	N#Cc1cncc(Oc2cc(C(=O)Nc3ccc(F)cn3)c3ncnn3c2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4089606	=	=	IC50	nM	10600.0	IC50	uM	10.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cnc(F)c(F)c2)cn2ncnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4081733	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2F)cn2ncnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4092008	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncnc2)cn2ncnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4085919	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2ncnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4089114	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2cnnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4071447	=	=	IC50	nM	17800.0	IC50	uM	17.8
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1ccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)nc1	Bioorg Med Chem Lett	2017.0	CHEMBL4104546	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	Cc1ccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)nc1	Bioorg Med Chem Lett	2017.0	CHEMBL4080316	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2ccnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4066902	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	Cc1cccc(NC(=O)c2cc(Oc3cncc(F)c3)cn3ccnc23)n1	Bioorg Med Chem Lett	2017.0	CHEMBL4088174	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	O=C(Nc1cccc(F)n1)c1cc(Oc2cncc(F)c2)cn2ccnc12	Bioorg Med Chem Lett	2017.0	CHEMBL4077770	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	Cc1cc(Oc2cncc(F)c2)cc(C(=O)Nc2ccc(F)cn2)n1	Bioorg Med Chem Lett	2017.0	CHEMBL2386849	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP3A4 (unknown origin)	CN1[C@H]2CC[C@@H]1Cc1sc(NC(=O)Nc3ccc(Cl)cc3)c(C(N)=O)c12.Cl	J Med Chem	2018.0	CHEMBL4096279	=	=	IC50	nM	46000.0	IC50	uM	46.0
Inhibition of human CYP3A4 using fluorogenic substrate preincubated with co-factor for 10 mins followed by enzyme-substrate addition by fluorometric method	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(/C=C/c4c(Cl)cccc4Cl)oc23)[C@H](O)C1	J Med Chem	2018.0	CHEMBL4079206	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	N#CC1(NC(=O)[C@@H]2Cc3ccc(c(Cl)c3)OCCCCOc3cc(C(F)(F)F)ccc3C(=O)N2)CC1	J Med Chem	2018.0	CHEMBL3917415	=	=	IC50	nM	43000.0	IC50	uM	43.0
Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)cc3)n2)CC1	J Med Chem	2018.0	CHEMBL4104507	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)nc3)n2)CC1	J Med Chem	2018.0	CHEMBL4060895	=	=	IC50	nM	47000.0	IC50	uM	47.0
Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	N#CC1(NC(=O)[C@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)NC(=O)c2cnn(-c3cccnc3)n2)CC1	J Med Chem	2018.0	CHEMBL4081213	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	Cn1ncc(C(=O)N[C@@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)C(=O)NC2(C#N)CC2)n1	J Med Chem	2018.0	CHEMBL4093444	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	CC(C)(C)n1ncc(C(=O)N[C@@H](Cc2ccc(OC(F)(F)F)c(Cl)c2)C(=O)NC2(C#N)CC2)n1	J Med Chem	2018.0	CHEMBL4065483	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using DBF as substrate by fluorescence assay	N#CC1(NC(=O)[C@H](Cc2ccc(Cl)c(Cl)c2)NC(=O)c2cnn(-c3ccc(F)cc3)n2)CC1	J Med Chem	2018.0	CHEMBL4073014	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CC1)CCN(c1ccc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)cn1)CC2	J Med Chem	2017.0	CHEMBL4100640	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of CYP3A4 (unknown origin)	O=C(O)CN1CCC2(CC1)CCN(c1ccc(-c3nc4cc(C(F)(F)F)ccc4[nH]3)cn1)CC2	J Med Chem	2017.0	CHEMBL4105361	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)C1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1	J Med Chem	2017.0	CHEMBL4069786	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4075203	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1	J Med Chem	2017.0	CHEMBL4060355	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)O1	J Med Chem	2017.0	CHEMBL4082282	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4087688	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)C[C@@H]1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4066339	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)C[C@H]1COC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4079801	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4075203	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCOC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)C1	J Med Chem	2017.0	CHEMBL4075203	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1	J Med Chem	2017.0	CHEMBL4060355	=	=	IC50	nM	19500.0	IC50	uM	19.5
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)OC1	J Med Chem	2017.0	CHEMBL4060355	=	=	IC50	nM	13300.0	IC50	uM	13.3
Inhibition of CYP3A4 (unknown origin)	O=C(O)CC1CCC2(CCN(c3ccc(-c4nc5cc(C(F)(F)F)ccc5[nH]4)cn3)CC2)O1	J Med Chem	2017.0	CHEMBL4082282	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1	J Med Chem	2017.0	CHEMBL4068611	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 (unknown origin)	Cc1cn2cc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)nc2c(C)n1	J Med Chem	2017.0	CHEMBL4081789	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 6beta-hydroxytestosterone from testosterone after 10 mins by LC-MS/MS analysis	O=[N+]([O-])c1cn2c(n1)O[C@@H](COc1ccc(-c3ccc(F)cc3)nc1)CC2	J Med Chem	2017.0	CHEMBL4069220	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in formation of 6beta-hydroxytestosterone from testosterone after 10 mins by LC-MS/MS analysis	C[C@]1(COc2ccc(OC(F)(F)F)cc2)Cn2cc([N+](=O)[O-])nc2O1	J Med Chem	2017.0	CHEMBL218974	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes after 10 mins by LC-MS/MS analysis	Cl.NCc1ccnc(Oc2cccc(C(=O)N3C[C@@H](O)[C@H](F)C3)c2)c1	J Med Chem	2017.0	CHEMBL4063337	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(F)c(-c2ccc(Cc3ccc(N4C[C@H](C(F)(F)F)C[C@@H]4CC(=O)O)cc3)c(C)c2)c1	J Med Chem	2017.0	CHEMBL4083365	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	C[C@@H]1c2nnn(-c3cc(F)ccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2017.0	CHEMBL4094806	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	C[C@@H]1c2nnn(-c3cnccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2017.0	CHEMBL4074304	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	C[C@@H]1c2nnn(-c3ncccn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2017.0	CHEMBL4068397	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	Cc1ccnc(-n2nnc3c2CCN(C(=O)c2cccc(C(F)(F)F)c2Cl)[C@@H]3C)n1	J Med Chem	2017.0	CHEMBL4095741	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	C[C@@H]1c2nnn(-c3ncc(F)cn3)c2CCN1C(=O)c1cccc(C(F)(F)F)c1Cl	J Med Chem	2017.0	CHEMBL4079239	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N	Bioorg Med Chem Lett	2017.0	CHEMBL4096145	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4080797	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4068343	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4068343	=	=	IC50	nM	198000.0	IC50	uM	198.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(Cl)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4087982	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(C(F)(F)F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4059686	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2cccc(F)c2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4100049	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2cccc(Cl)c2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4073194	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCC(F)F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4063185	=	=	IC50	nM	60000.0	IC50	uM	60.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(NCC(F)(F)F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4096118	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	Bioorg Med Chem Lett	2017.0	CHEMBL1397	=	=	IC50	nM	75.0	IC50	uM	0.075
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL106	=	=	IC50	nM	32000.0	IC50	uM	32.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	O[C@@](Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL3311228	=	=	IC50	nM	65000.0	IC50	uM	65.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCc3ccc(OC(F)(F)F)cc3)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4080531	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCc3ccc(C(F)(F)F)cc3)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4097031	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	CNC(=O)c1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4069838	=	=	IC50	nM	122000.0	IC50	uM	122.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCc3ccc(F)cc3)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4063357	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCc3ccc(CC(F)F)cc3)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4064340	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(C#Cc2ccc(OCc3ccc(CC(F)F)cc3)cc2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4064340	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4077246	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4077246	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1cccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4067180	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4073979	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1F	Bioorg Med Chem Lett	2017.0	CHEMBL4073979	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)c(F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4102268	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(Cl)cc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4084305	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(COc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4cc(F)ccc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4075382	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human hepatocyte microsomes using testosterone substrate by HPLC/MS/MS method	N#Cc1ccc(OCc2ccc(C#Cc3ccc(C(F)(F)C(O)(Cn4cnnn4)c4ccc(F)cc4F)nc3)cc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4086421	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1cccc(/C=C/C(=O)c2ccc[nH]2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL1586994	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1cccc(OC)c1/C=C/C(=O)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL2299166	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cc([N+](=O)[O-])ccc1Cl)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL2299167	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1cccc(/C=C/C(=O)c2ccc[nH]2)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL2236657	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc2c(c1)OCO2)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL1477453	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccc[nH]2)c(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL2299353	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/C=C/c1ccccc1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4065261	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccc[nH]2)cc(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4086703	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccccc1F)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4081406	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1ccccc1/C=C/C(=O)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4105559	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C=C/C(=O)c2ccc[nH]2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL3745717	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	CN(C)c1ccc(/C=C/C(=O)c2ccc[nH]2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL2299165	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccc[nH]2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL2299354	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccccc1Cl)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL1335197	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccc(Br)c1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4061752	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccc[nH]2)cc1Br	Bioorg Med Chem Lett	2017.0	CHEMBL4089828	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	CCc1ccc(/C=C/C(=O)c2ccc[nH]2)o1	Bioorg Med Chem Lett	2017.0	CHEMBL4076533	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccc[nH]2)cc(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4090207	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc(OC(F)(F)F)cc1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4081017	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(O)c1ccc(/C=C/C(=O)c2ccc[nH]2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4105268	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1c2ccccc2cc2ccccc12)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4070384	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1cccc(Cl)c1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL3735451	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=C(/C=C/c1ccc(Br)cc1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL2299352	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 bound to yeast microsomal membrane using dibenzylfluorescein as substrate after 10 mins by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL283196	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in HEK293 cells using fluorogenic dibenzylfluorescein as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1ccccc1/C=C/C(=O)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4105559	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in HEK293 cells using fluorogenic dibenzylfluorescein as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	O=C(/C=C/c1ccccc1Cl)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL1335197	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in HEK293 cells using fluorogenic dibenzylfluorescein as substrate preincubated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	O=C(/C=C/c1ccc(OC(F)(F)F)cc1)c1ccc[nH]1	Bioorg Med Chem Lett	2017.0	CHEMBL4081017	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4	CC(C)N1CCN(c2nc(-c3ccncn3)cc(=O)n2C)[C@H](C)C1	Bioorg Med Chem Lett	2017.0	CHEMBL4064440	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	C[C@@H]1CN(Cc2ccccc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4082198	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2ccccc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL3719193	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	Cc1ccc(S(=O)(=O)N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4102920	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2cccc(F)c2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4095848	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2ccc(F)cc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4076060	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2ccc(Cl)cc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4077048	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	COc1ccccc1N1CCN(c2nc(-c3ccncn3)cc(=O)n2C)[C@H](C)C1	Bioorg Med Chem Lett	2017.0	CHEMBL4065818	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	COc1cccc(N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4063206	=	=	IC50	nM	9600.0	IC50	uM	9.6
Inhibition of recombinant human CYP3A4	COc1ccc(N2CCN(c3nc(-c4ccncn4)cc(=O)n3C)[C@H](C)C2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL4084855	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2cccc(C#N)c2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4074586	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2ccncc2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4065956	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	C[C@@H]1CN(c2ccccn2)CCN1c1nc(-c2ccncn2)cc(=O)n1C	Bioorg Med Chem Lett	2017.0	CHEMBL4093930	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	COc1ccccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4085821	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	COc1cccc(C2CN(c3nc(-c4ccncc4)cc(=O)n3C)CCN2)c1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4061578	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	COc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4087402	>	>	IC50	nM	53000.0	IC50	uM	53.0
Inhibition of recombinant human CYP3A4	COc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4087402	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	COc1cc(F)ccc1C1CN(c2nc(-c3ccncc3)cc(=O)n2C)CCN1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4087402	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	COc1cc(F)ccc1C1CN(c2nc(-c3ccncn3)cc(=O)n2C)CCN1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4076186	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes	COc1ccc(C2CN(c3nc(-c4ccncc4)cc(=O)n3C)CCN2)cc1.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4078436	>	>	IC50	nM	53000.0	IC50	uM	53.0
Inhibition of CYP3A4 (unknown origin)	CNC(=O)N1CCc2c(c(N3CCCc4cc(-c5cnn(C)c5)c(C(F)F)cc43)nn2C2CCOCC2)C1	J Med Chem	2017.0	CHEMBL4097025	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C1CC(c2c[nH]c3ccc(F)cc23)C(=O)N1	J Med Chem	2017.0	CHEMBL4086143	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	O=C1C[C@H](c2c[nH]c3ccccc23)C(=O)N1	J Med Chem	2017.0	CHEMBL4087106	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL3091687	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1ccc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2ccccn2)nc1	J Med Chem	2018.0	CHEMBL4086739	=	=	IC50	nM	6010.0	IC50	uM	6.01
Inhibition of CYP3A4 (unknown origin)	c1cncc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2cccnc2)c1	J Med Chem	2018.0	CHEMBL4081338	=	=	IC50	nM	1290.0	IC50	uM	1.29
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCN(Cc1ccncc1)Cc1ccncc1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4105591	=	=	IC50	nM	622.0	IC50	uM	0.622
Inhibition of CYP3A4 (unknown origin)	c1ccc(CN(CCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)Cc2ccccc2)cc1	J Med Chem	2018.0	CHEMBL4082134	=	=	IC50	nM	2240.0	IC50	uM	2.24
Inhibition of CYP3A4 (unknown origin)	c1ccc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)nc1	J Med Chem	2018.0	CHEMBL3091683	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4 (unknown origin)	c1cncc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)c1	J Med Chem	2018.0	CHEMBL4071612	=	=	IC50	nM	8450.0	IC50	uM	8.45
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNCc1ccncc1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4092405	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4 (unknown origin)	c1ccc(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)cc1	J Med Chem	2018.0	CHEMBL4062981	=	=	IC50	nM	6150.0	IC50	uM	6.15
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCCCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4084652	=	=	IC50	nM	2780.0	IC50	uM	2.78
Inhibition of CYP3A4 (unknown origin)	FC1(F)CCC(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4101106	=	=	IC50	nM	19200.0	IC50	uM	19.2
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCOCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4074366	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCNCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4076841	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNCC1CCSCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4065751	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	O=S1(=O)CCC(CNCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4070843	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCCCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4097946	=	=	IC50	nM	11700.0	IC50	uM	11.7
Inhibition of CYP3A4 (unknown origin)	FC1(F)CCC(NCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4062223	=	=	IC50	nM	11300.0	IC50	uM	11.3
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCOCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4090235	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCNCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4089307	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCNC1CCSCC1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4068122	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	O=S1(=O)CCC(NCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4081436	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)CCC(NCCCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4059462	=	=	IC50	nM	12900.0	IC50	uM	12.9
Inhibition of CYP3A4 (unknown origin)	NCc1ccccc1CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4084920	=	=	IC50	nM	15200.0	IC50	uM	15.2
Inhibition of CYP3A4 (unknown origin)	NCc1cccc(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)c1	J Med Chem	2018.0	CHEMBL4075694	=	=	IC50	nM	4630.0	IC50	uM	4.63
Inhibition of CYP3A4 (unknown origin)	NCc1ccc(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)cc1	J Med Chem	2018.0	CHEMBL4078260	=	=	IC50	nM	7440.0	IC50	uM	7.44
Inhibition of CYP3A4 (unknown origin)	NC/C=C\CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4096305	=	=	IC50	nM	12700.0	IC50	uM	12.7
Inhibition of CYP3A4 (unknown origin)	NC/C=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4086147	=	=	IC50	nM	9290.0	IC50	uM	9.29
Inhibition of CYP3A4 (unknown origin)	CC(C)(CCN)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4104056	=	=	IC50	nM	10800.0	IC50	uM	10.8
Inhibition of CYP3A4 (unknown origin)	CC(C)(CN)CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4104948	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(N)CCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4080718	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNCC3CCOCC3)cc1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4059622	=	=	IC50	nM	994.0	IC50	uM	0.994
Inhibition of CYP3A4 (unknown origin)	FC1(F)CCC(NCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)CC1	J Med Chem	2018.0	CHEMBL4088588	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNC3CCOCC3)cc1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4089531	=	=	IC50	nM	442.0	IC50	uM	0.442
Inhibition of CYP3A4 (unknown origin)	CC1(C)CCC(NCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)CC1	J Med Chem	2018.0	CHEMBL4061381	=	=	IC50	nM	334.0	IC50	uM	0.334
Inhibition of CYP3A4 (unknown origin)	c1ccc(CNCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)nc1	J Med Chem	2018.0	CHEMBL4072645	=	=	IC50	nM	109.0	IC50	uM	0.109
Inhibition of CYP3A4 (unknown origin)	c1cncc(CNCc2ccc(CN(C[C@H]3Cc4ccccc4CN3)[C@H]3CCCc4cccnc43)cc2)c1	J Med Chem	2018.0	CHEMBL4099550	=	=	IC50	nM	58.0	IC50	uM	0.058
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(Cc1ccc(CNCc3ccncc3)cc1)[C@H]1CCCc3cccnc31)C2	J Med Chem	2018.0	CHEMBL4083122	=	=	IC50	nM	59.0	IC50	uM	0.059
Inhibition of CYP3A4 (unknown origin)	C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCC1CCOCC1	J Med Chem	2018.0	CHEMBL4070320	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	FC1(F)CCC(NC/C=C/CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4094123	=	=	IC50	nM	839.0	IC50	uM	0.839
Inhibition of CYP3A4 (unknown origin)	C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNC1CCOCC1	J Med Chem	2018.0	CHEMBL4075205	=	=	IC50	nM	7730.0	IC50	uM	7.73
Inhibition of CYP3A4 (unknown origin)	CC1(C)CCC(NC/C=C/CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4098635	=	=	IC50	nM	990.0	IC50	uM	0.99
Inhibition of CYP3A4 (unknown origin)	C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1ccccn1	J Med Chem	2018.0	CHEMBL4081958	=	=	IC50	nM	1560.0	IC50	uM	1.56
Inhibition of CYP3A4 (unknown origin)	C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1cccnc1	J Med Chem	2018.0	CHEMBL4066459	=	=	IC50	nM	1250.0	IC50	uM	1.25
Inhibition of CYP3A4 (unknown origin)	C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)\CNCc1ccncc1	J Med Chem	2018.0	CHEMBL4090772	=	=	IC50	nM	350.0	IC50	uM	0.35
Inhibition of CYP3A4 (unknown origin)	CC(C)(CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CNCC1CCOCC1	J Med Chem	2018.0	CHEMBL4073818	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CNC1CCC(F)(F)CC1	J Med Chem	2018.0	CHEMBL4094400	=	=	IC50	nM	5580.0	IC50	uM	5.58
Inhibition of CYP3A4 (unknown origin)	CC(C)(CCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CNC1CCOCC1	J Med Chem	2018.0	CHEMBL4065224	=	=	IC50	nM	17700.0	IC50	uM	17.7
Inhibition of CYP3A4 (unknown origin)	CC1(C)CCC(NCC(C)(C)CCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4086662	=	=	IC50	nM	7830.0	IC50	uM	7.83
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis	CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1cc(-c2ccccc2F)on1	Eur J Med Chem	2017.0	CHEMBL4127941	=	=	IC50	nM	5810.0	IC50	uM	5.81
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis	CC(C)COC(=O)[C@H](Cn1ccnc1)NC(=O)c1cc(-c2ccccc2F)on1	Eur J Med Chem	2017.0	CHEMBL4126548	=	=	IC50	nM	8380.0	IC50	uM	8.38
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC/MS/MS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2017.0	CHEMBL157101	=	=	IC50	nM	35.9	IC50	uM	0.0359
Inhibition of CYP3A4 (unknown origin) by CYP3A4 P450-Glo assay	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of CYP3A4 (unknown origin)	Cc1cc(N2CCOc3ncnc(N)c3C2=O)cc(C)c1C#CC(C)(C)CC(=O)O	Bioorg Med Chem Lett	2018.0	CHEMBL4126331	=	=	IC50	nM	45500.0	IC50	uM	45.5
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate in presence of NADPH by LC-MS/MS analysis	CCn1ncc2c1CC[C@@H](Nc1nc3c(-c4ccc(F)cc4C)cccn3n1)C2	Bioorg Med Chem	2018.0	CHEMBL4127978	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis	c1cc(C2CCC3(CC2)OOC2(OO3)C3CC4CC(C3)CC2C4)ccc1CN1CCOCC1	Bioorg Med Chem	2018.0	CHEMBL4127539	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	22.0	IC50	uM	0.022
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis	c1cc(C2CCC3(CC2)OOC2(OO3)C3CC4CC(C3)CC2C4)ccc1CN1CCOCC1	Bioorg Med Chem	2018.0	CHEMBL4127539	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6beta-hydroxylation after 4 to 40 mins in presence of NADPH by LCMS analysis	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2018.0	CHEMBL157101	=	=	IC50	nM	13.0	IC50	uM	0.013
Inhibition of human CYP3A4	Cn1cc(-c2ccc(-c3ccc(C4=NC5(CC5)C(=O)N4C[C@@H]4CCN(C(=O)C5CC5)C4)cc3)cc2)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4125752	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	CC1(C)OCCn2c1nc(C(=O)NCc1ccc(F)cc1)c(O)c2=O	Bioorg Med Chem Lett	2018.0	CHEMBL4126289	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4 using testosterone as substrate by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2018.0	CHEMBL75	=	=	IC50	nM	146.0	IC50	nM	146.0
Inhibition of human CYP3A4 using testosterone as substrate by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1	Bioorg Med Chem Lett	2018.0	CHEMBL4129721	=	=	IC50	nM	695.0	IC50	nM	695.0
Inhibition of human CYP3A4 using testosterone as substrate by LC-MS/MS analysis	CCS(=O)(=O)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1	Bioorg Med Chem Lett	2018.0	CHEMBL4126284	=	=	IC50	nM	243.0	IC50	nM	243.0
Inhibition of human CYP3A4 using testosterone as substrate by LC-MS/MS analysis	O=S(=O)(N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1)C(F)(F)F	Bioorg Med Chem Lett	2018.0	CHEMBL4128368	=	=	IC50	nM	9360.0	IC50	nM	9360.0
Inhibition of CYP3A4 (unknown origin)	O=C(c1ccc(-n2nnc3cccnc32)cc1)N(c1ncccc1Cl)[C@@H]1CCCNC1	J Med Chem	2018.0	CHEMBL4109308	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cncc(-c2ccc(C(=O)N(c3ncccc3Cl)[C@@H]3CCCNC3)cc2)n1	J Med Chem	2018.0	CHEMBL4127458	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 (unknown origin)	C=CC(=O)Nc1cccc(-n2c(=O)n(C(C)C)c(=O)c3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1	J Med Chem	2018.0	CHEMBL4127317	=	=	IC50	nM	23900.0	IC50	uM	23.9
Inhibition of CYP3A4 in human liver microsomes preincubated for 5 mins followed by NADPH/substrate addition measured after 20 mins by LC-MS/MS analysis	Cc1cccc2c(Nc3cccc(-c4nc5c(C(N)=O)cccc5[nH]4)c3)c3ccccc3nc12	Eur J Med Chem	2017.0	CHEMBL4175440	=	=	IC50	nM	6800.0	IC50	uM	6.8
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1nn(Cc2nc3cc(Cl)ccc3n2CC2COC2)c2cnccc12	Eur J Med Chem	2017.0	CHEMBL4177457	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins in presence of NADPH by LC/MS/MS analysis	CC(COc1ccn(-c2ccc(F)cc2)c(=O)c1)Oc1ccccc1	ACS Med Chem Lett	2017.0	CHEMBL4164219	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins in presence of NADPH by LC/MS/MS analysis	C[C@@H](COc1ccn(-c2ccc(F)cc2)c(=O)c1)Oc1ccccc1	ACS Med Chem Lett	2017.0	CHEMBL4172540	>	>	IC50	nM	30000.0	IC50	uM	30.0
Reversible inhibition of recombinant human CYP3A4 by fluorescence-based assay	C[C@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)N=C(N)CO[C@H]1C(F)(F)F	J Med Chem	2018.0	CHEMBL4165225	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CN(C)CCNC(=O)[C@H]1c2ccccc2C[C@@H]1NC(=O)c1cc2ccccc2[nH]1	J Med Chem	2018.0	CHEMBL4164328	<	>	IC50	nM	19952.62	pIC50		4.7
Inhibition of CYP3A4 (unknown origin)	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	J Med Chem	2018.0	CHEMBL3301620	>=	>=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	COc1cnc(-n2cncn2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	J Med Chem	2018.0	CHEMBL4104608	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1ccc(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)cc1	ACS Med Chem Lett	2017.0	CHEMBL2361777	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1ccc(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)cc1F	ACS Med Chem Lett	2017.0	CHEMBL4165248	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1cc(F)c(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)c(F)c1	ACS Med Chem Lett	2017.0	CHEMBL4168668	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1ccc(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)c(F)c1F	ACS Med Chem Lett	2017.0	CHEMBL4160748	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC-MS/MS analysis	COc1cc(F)c(-c2c(C)nn3c(C(F)(F)F)cc(C)nc23)cc1F	ACS Med Chem Lett	2017.0	CHEMBL4172016	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)[C@@H](CO)NC(=O)c1nn(-c2c[n+]([O-])ccn2)c2c1C[C@@H]1C[C@H]21	ACS Med Chem Lett	2017.0	CHEMBL4175981	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midozolam as substrate by LC-MS/MS analysis	Cl.O=C(O)CNC(=O)c1c(O)cc(CCc2ccccc2)n2ncnc12	ACS Med Chem Lett	2017.0	CHEMBL4166742	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccccc2)[C@@H](C)C(F)(F)F)C1=O	ACS Med Chem Lett	2018.0	CHEMBL4174931	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NC/C=C\CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4096305	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NC/C=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4086147	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NCC1=C(CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CCCC1	ACS Med Chem Lett	2018.0	CHEMBL4167521	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(=C/CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)CN	ACS Med Chem Lett	2018.0	CHEMBL4159607	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(=C/CN)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4164075	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)=C(\F)CN	ACS Med Chem Lett	2018.0	CHEMBL4174727	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21)=C(/F)CN	ACS Med Chem Lett	2018.0	CHEMBL4169450	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(CN)=C(\F)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4161528	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	C/C(CN)=C(/F)CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4175500	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	FC1(F)CCC(NC/C=C\CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4164874	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NC(=O)NC/C=C\CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4160401	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NCC1CC1CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4163770	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NCC1CC1CN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL4163770	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	N[C@H]1CC[C@H](CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4171643	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	NC[C@H]1CC[C@H](CN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4167221	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	N[C@H]1CC[C@H](N(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4175088	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using BFC as substrate	N[C@H]1CC[C@@H](N(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4161850	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(O)C[C@]1(CC(F)(F)F)CCc2cc(-c3cnc(NC(=O)Nc4ccc(F)c(F)c4)cn3)ccc2C1=O	ACS Med Chem Lett	2018.0	CHEMBL4173715	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(NC(=O)c2cccc(S(=O)(=O)N[C@H]3CCOC3)c2)ccc1F	J Med Chem	2018.0	CHEMBL4159471	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 in presence of NADPH generating system by fluorescence assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2018.0	CHEMBL75	=	=	IC50	nM	65.0	IC50	uM	0.065
Inhibition of recombinant human CYP3A4 in presence of NADPH generating system by fluorescence assay	COc1cc(-c2nc(SCC(=O)NC(=O)Nc3ccccn3)nc(Nc3cccc(Cl)c3)c2C#N)cc(OC)c1OC	J Med Chem	2018.0	CHEMBL4161738	=	=	IC50	nM	17243.0	IC50	uM	17.243
Inhibition of recombinant human CYP3A4 in presence of NADPH generating system by fluorescence assay	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	J Med Chem	2018.0	CHEMBL6966	=	=	IC50	nM	8193.0	IC50	uM	8.193
Inhibition of CYP3A4 (unknown origin) after 2 hrs by firefly luciferase-luminescence based P450-glo assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2018.0	CHEMBL75	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin)	Nc1oncc1-c1ccccc1	ACS Med Chem Lett	2018.0	CHEMBL4166415	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Nc1oncc1-c1ccsc1	ACS Med Chem Lett	2018.0	CHEMBL4173485	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Nc1oncc1-n1cccn1	ACS Med Chem Lett	2018.0	CHEMBL4168975	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Nc1oncc1-n1cc(F)cn1	ACS Med Chem Lett	2018.0	CHEMBL4166624	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL3091687	>	>	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CC1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4159410	>	>	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCC1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4164702	>	>	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4166456	>	>	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4167058	>	>	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4159150	>	>	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CC[C@@H]1CCCNC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4163611	>	>	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CC[C@H]1CCCNC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4174290	>	>	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2018.0	CHEMBL518924	>	>	IC50	nM	6670.0	IC50	uM	6.67
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@H](CN(CCCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4170857	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1cnc2c(c1)CN[C@@H](CN(CCCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4175350	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1cnc2c(c1)CN[C@H](CN(CCCN1CCNCC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4167467	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1cnc(CN(CCCN2CCNCC2)[C@H]2CCCc3cccnc32)nc1	ACS Med Chem Lett	2018.0	CHEMBL4162125	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1cnc2c(c1)CCC[C@@H]2N(CCCN1CCNCC1)Cc1cc2ccccc2cn1	ACS Med Chem Lett	2018.0	CHEMBL4172802	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1cnc2c(c1)CCC[C@@H]2N(CCCN1CCNCC1)Cc1nc2ccccc2[nH]1	ACS Med Chem Lett	2018.0	CHEMBL4161613	=	=	IC50	nM	12700.0	IC50	uM	12.7
Inhibition of CYP3A4 (unknown origin)	c1cnc2c(c1)CCC[C@@H]2N(CCCN1CCNCC1)Cc1nc2ccccc2s1	ACS Med Chem Lett	2018.0	CHEMBL4172234	=	=	IC50	nM	9400.0	IC50	uM	9.4
Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4165032	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CCN1CCN(CCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4175653	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)N1CCN(CCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4159991	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	NC(=O)N1CCN(CCCN(C[C@H]2Cc3ccccc3CN2)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4160551	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	c1ccc2c(c1)CN[C@@H](CN(CCCN1CCN(C3CC3)CC1)[C@H]1CCCc3cccnc31)C2	ACS Med Chem Lett	2018.0	CHEMBL4167654	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCCN(C[C@H]2Cc3ccccc3CN2C)[C@H]2CCCc3cccnc32)CC1	ACS Med Chem Lett	2018.0	CHEMBL4170141	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using BFC/BZR as substrate	Cc1ccc(CN2CC[C@@H](N3CC[C@@H](c4ccc(O)cc4)[C@H](F)C3)C2=O)cc1	ACS Med Chem Lett	2018.0	CHEMBL3892956	>	>	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1-Hydroxymidazolam formation using midazolam as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis	COc1ncc(-c2cc(OC3CCOCC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F	J Med Chem	2018.0	CHEMBL4166144	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1-Hydroxymidazolam formation using midazolam as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis	COc1ncc(-c2cc(O[C@@H]3CCOC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F	J Med Chem	2018.0	CHEMBL4176771	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1-Hydroxymidazolam formation using midazolam as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis	CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(OC3CCOCC3)c2n1	J Med Chem	2018.0	CHEMBL4166594	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in 1-Hydroxymidazolam formation using midazolam as substrate after 10 to 20 mins in presence of NADPH by LC-MS/MS analysis	CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(O[C@@H]3CCOC3)c2n1	J Med Chem	2018.0	CHEMBL4174909	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCC#Cc1cccnc1	J Med Chem	2018.0	CHEMBL4171558	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cc1ccc(C#CCN)cn1.Cl.Cl	J Med Chem	2018.0	CHEMBL4164781	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cc1ccncc1C#CCN.Cl.Cl	J Med Chem	2018.0	CHEMBL4173088	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCc1ccncc1C#CCN.Cl.Cl	J Med Chem	2018.0	CHEMBL4175429	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	COc1ccncc1C#CCN.Cl.Cl	J Med Chem	2018.0	CHEMBL4167560	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCCc1ccncc1C#CCN.Cl.Cl	J Med Chem	2018.0	CHEMBL4171984	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCC#Cc1cnccc1-c1ccccc1	J Med Chem	2018.0	CHEMBL4164113	=	=	IC50	nM	39000.0	IC50	uM	39.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCC#Cc1cnccc1-c1ccco1	J Med Chem	2018.0	CHEMBL4163694	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCC#Cc1cnccc1-c1ccoc1	J Med Chem	2018.0	CHEMBL4174365	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCC#Cc1cnccc1-c1ccncc1	J Med Chem	2018.0	CHEMBL4160326	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCC#Cc1cnccc1-c1cccnc1	J Med Chem	2018.0	CHEMBL4170930	=	=	IC50	nM	92000.0	IC50	uM	92.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.Cl.NCC#Cc1cnccc1-c1cncnc1	J Med Chem	2018.0	CHEMBL4161777	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cc1ccncc1-c1ccc(CN)o1.Cl.Cl	J Med Chem	2018.0	CHEMBL4172417	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCc1ccncc1-c1ccc(CN)o1.Cl.Cl	J Med Chem	2018.0	CHEMBL4173133	=	=	IC50	nM	181000.0	IC50	uM	181.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	COc1ccncc1-c1ccc(CN)o1.Cl.Cl	J Med Chem	2018.0	CHEMBL4162449	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCCc1ccncc1-c1ccc(CN)o1.Cl.Cl	J Med Chem	2018.0	CHEMBL4169721	=	=	IC50	nM	4900.0	IC50	uM	4.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccccc2)o1	J Med Chem	2018.0	CHEMBL4159065	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccco2)o1	J Med Chem	2018.0	CHEMBL4161400	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccoc2)o1	J Med Chem	2018.0	CHEMBL4169324	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2ccncc2)o1	J Med Chem	2018.0	CHEMBL4176506	=	=	IC50	nM	39000.0	IC50	uM	39.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cccnc2)o1	J Med Chem	2018.0	CHEMBL4165895	=	=	IC50	nM	90000.0	IC50	uM	90.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cncnc2)o1	J Med Chem	2018.0	CHEMBL4168256	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cc1ccncc1-c1ccc(CN)s1.Cl.Cl	J Med Chem	2018.0	CHEMBL4176100	=	=	IC50	nM	37000.0	IC50	uM	37.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCc1ccncc1-c1ccc(CN)s1.Cl.Cl	J Med Chem	2018.0	CHEMBL4161819	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	COc1ccncc1-c1ccc(CN)s1.Cl.Cl	J Med Chem	2018.0	CHEMBL4172462	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	CCCc1ccncc1-c1ccc(CN)s1.Cl.Cl	J Med Chem	2018.0	CHEMBL4165249	=	=	IC50	nM	4300.0	IC50	uM	4.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccccc2)s1	J Med Chem	2018.0	CHEMBL4175869	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccco2)s1	J Med Chem	2018.0	CHEMBL4168669	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.NCc1ccc(-c2cnccc2-c2ccoc2)s1	J Med Chem	2018.0	CHEMBL4160749	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2ccncc2)s1	J Med Chem	2018.0	CHEMBL4172017	=	=	IC50	nM	214000.0	IC50	uM	214.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cccnc2)s1	J Med Chem	2018.0	CHEMBL4164142	=	=	IC50	nM	42000.0	IC50	uM	42.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis	Cl.Cl.Cl.Cl.NCc1ccc(-c2cnccc2-c2cncnc2)s1	J Med Chem	2018.0	CHEMBL4165094	=	=	IC50	nM	39000.0	IC50	uM	39.0
Inhibition of CYP3A4 in in human liver microsomes in presence of NADPH regeneration mixture using luciferin IPA-OH substrate by P450-Glo assay	Oc1ccc2c(c1)C(C1(c3ccc(Cl)cc3)CCC1)NCC2	J Med Chem	2018.0	CHEMBL4167229	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in in human liver microsomes in presence of NADPH regeneration mixture using luciferin IPA-OH substrate by P450-Glo assay	CCCS(=O)(=O)NCCOc1ccc2c(c1)C(C1(c3ccc(Cl)cc3)CCC1)NCC2	J Med Chem	2018.0	CHEMBL3643445	=	=	IC50	nM	620.0	IC50	uM	0.62
Inhibition of CYP3A4 in in human liver microsomes in presence of NADPH regeneration mixture using luciferin IPA-OH substrate by P450-Glo assay	CCCS(=O)(=O)NCCOc1ccc2c(c1)[C@@H](Cc1ccc(Cl)c(Cl)c1)[C@@H](N)CC2	J Med Chem	2018.0	CHEMBL4176494	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C	J Med Chem	2018.0	CHEMBL1276308	=	=	IC50	nM	9500.0	IC50	uM	9.5
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1	J Med Chem	2018.0	CHEMBL4163069	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)N(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@@H]23)cc1	J Med Chem	2018.0	CHEMBL4161754	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of human CYP3A4	CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1	J Med Chem	2018.0	CHEMBL3960662	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C1Nc2ccc(C(=O)N[C@H](CO)c3ccccc3)cc2/C1=C(\c1ccccc1)c1ncc[nH]1	Eur J Med Chem	2018.0	CHEMBL4160587	=	=	IC50	nM	3030.0	IC50	uM	3.03
Inhibition of human CYP3A4	NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL3091687	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4172669	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C[C@@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4162011	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4169280	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CCCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4177130	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	c1cnc2c(c1)CCC[C@@H]2N(CC1CC1)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1	J Med Chem	2018.0	CHEMBL4165854	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CC(C)N(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4173777	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	c1cnc2c(c1)CCC[C@@H]2N(CC1CCCCC1)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1	J Med Chem	2018.0	CHEMBL4176285	=	=	IC50	nM	1780.0	IC50	uM	1.78
Inhibition of human CYP3A4	FC1(F)CCC(CN(C[C@H]2Cc3c(cccc3N3CCNCC3)CN2)[C@H]2CCCc3cccnc32)CC1	J Med Chem	2018.0	CHEMBL4168418	=	=	IC50	nM	5620.0	IC50	uM	5.62
Inhibition of human CYP3A4	OCCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4172898	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	COCCN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4176403	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	Cc1cccnc1CN(C)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1	J Med Chem	2018.0	CHEMBL4169504	=	=	IC50	nM	1420.0	IC50	uM	1.42
Inhibition of human CYP3A4	Cc1cnc(CN(C)C[C@H]2Cc3c(cccc3N3CCNCC3)CN2)c(C)c1	J Med Chem	2018.0	CHEMBL4161589	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	Cc1ccc(CN(C)C[C@H]2Cc3c(cccc3N3CCNCC3)CN2)nc1	J Med Chem	2018.0	CHEMBL4166081	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	Cc1cnc2c(c1)CCC[C@@H]2N(C)C[C@H]1Cc2c(cccc2N2CCNCC2)CN1	J Med Chem	2018.0	CHEMBL4176701	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN1CCN(c2cccc3c2C[C@H](CN2CCC[C@H]4CCc5cccnc5[C@H]42)NC3)CC1	J Med Chem	2018.0	CHEMBL4171365	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2C[C@H]3C[C@@H]2CN3)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4163467	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2C[C@@H]3C[C@H]2CN3)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4175596	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCNC(C)(C)C2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4164970	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	C[C@H]1CN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)C[C@@H](C)N1	J Med Chem	2018.0	CHEMBL4160496	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	J Med Chem	2018.0	CHEMBL4168391	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CCN1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	J Med Chem	2018.0	CHEMBL4163874	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CC(C)N1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	J Med Chem	2018.0	CHEMBL4171755	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(C3CC3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4167324	=	=	IC50	nM	4230.0	IC50	uM	4.23
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(C3COC3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4175201	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(c3cccc(C(F)(F)F)c3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4161949	=	=	IC50	nM	2210.0	IC50	uM	2.21
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(c3ccccn3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4169875	=	=	IC50	nM	3160.0	IC50	uM	3.16
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(c3ncccn3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4167145	=	=	IC50	nM	3350.0	IC50	uM	3.35
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN(Cc3ccccn3)CC2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4159234	=	=	IC50	nM	6790.0	IC50	uM	6.79
Inhibition of human CYP3A4	C[C@H]1CN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)C[C@@H](C)N1C	J Med Chem	2018.0	CHEMBL4170542	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN3CCC[C@@H]3C2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4162609	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCN3CCC[C@H]3C2)CN1)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4173977	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN(C[C@H]1Cc2c(cccc2N2CCNCC2)CN1C)[C@H]1CCCc2cccnc21	J Med Chem	2018.0	CHEMBL4166059	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	CN1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)N(C)C3)CC1	J Med Chem	2018.0	CHEMBL4177338	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH by LC-MS/MS analysis	N#Cc1cc(F)cc(Oc2ccc3c(c2C(F)F)[C@@H](O)C(F)(F)S3(=O)=O)c1	J Med Chem	2018.0	CHEMBL4175320	=	=	IC50	nM	13300.0	IC50	uM	13.3
Inhibition of of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)C2	J Med Chem	2018.0	CHEMBL4173075	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCOC(=O)C1=C(CN2CCOCC2)NC(c2nccs2)=NC1c1ccc(F)cc1Br	Bioorg Med Chem	2017.0	CHEMBL3742114	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3CC[C@H](N)C3)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4214937	=	=	IC50	nM	34.0	IC50	nM	34.0
Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3C[C@H](O)[C@H](N)C3)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4210026	=	=	IC50	nM	250.0	IC50	nM	250.0
Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCN)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4202424	=	=	IC50	nM	240.0	IC50	nM	240.0
Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CC(O)CN)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4216413	=	=	IC50	nM	440.0	IC50	nM	440.0
Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCNC)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4207648	=	=	IC50	nM	560.0	IC50	nM	560.0
Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3CC[C@H](N)C3)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4204601	=	=	IC50	nM	90.0	IC50	nM	90.0
Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)[C@@H]3CC[C@H](NC)C3)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4207673	=	=	IC50	nM	49.0	IC50	nM	49.0
Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(Cl)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCNC)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4211388	=	=	IC50	nM	140.0	IC50	nM	140.0
Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CC(O)CNC)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4212859	=	=	IC50	nM	840.0	IC50	nM	840.0
Inhibition of human CYP3A4 expressed in Escherichia coli co-expressing CYP-reductase using diethoxyfluorescein as substrate measured after 10 mins by fluorescence assay	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CC(CNC)OC)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4210995	=	=	IC50	nM	480.0	IC50	nM	480.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated conversion of midazolam to 1-hydroxymidazolam measured after 5 mins by LC-MS analysis	CCc1cccc(-c2c(F)cccc2C(O)(CCCNC(=O)OC)[C@@H]2CCCN(C(=O)CCCNC)C2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4207648	=	=	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cc(S(=O)(=O)Nc2ncns2)ccc1Oc1ccc(-c2cccc(C(F)(F)F)c2)cc1-c1ccnc(CNCCC2CCNCC2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4217988	=	=	IC50	nM	1150.0	IC50	uM	1.15
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4076061	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4203948	=	=	IC50	nM	43400.0	IC50	uM	43.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4210866	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4206499	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4209130	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	Cl.N[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CSc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4204264	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1COc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4216985	=	=	IC50	nM	21600.0	IC50	uM	21.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	CCN[C@@H]1CCC=C(c2ccc(F)cc2)[C@H]1CNc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1Cl.Cl	Bioorg Med Chem Lett	2017.0	CHEMBL4212007	=	=	IC50	nM	16500.0	IC50	uM	16.5
Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL376488	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1cc(C)c(C)s1)[C@@](O)(CCN(C)C)c1cccc(F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4206467	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1cccnc1N(C)C)[C@@](O)(CCN(C)C)c1cccc(F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4205718	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccc(N(C)C)nc1)[C@@](O)(CCN(C)C)c1cccc(F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4204414	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) after 20 mins	CCSc1ccc([C@H](c2cc3cc(Br)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cccc(F)c2)cn1	Bioorg Med Chem Lett	2017.0	CHEMBL4212501	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1cncc(C)c1)[C@@](O)(CCN(C)C)c1cccc(F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4206931	=	=	IC50	nM	4600.0	IC50	uM	4.6
Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1cc([C@H](c2cc3cc(Br)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cccc(F)c2)cnc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4218132	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc(C)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4213428	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc(OC(F)F)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4216673	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc(C#N)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4210920	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins	N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1	J Med Chem	2017.0	CHEMBL4217292	=	=	IC50	nM	46000.0	IC50	uM	46.0
Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins	Cc1cc(CC(=O)Nc2ccn(Cc3ccc(C#N)cn3)n2)ccc1OCC(F)(F)F	J Med Chem	2017.0	CHEMBL4208907	=	=	IC50	nM	46000.0	IC50	uM	46.0
Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins	Cc1cc(CC(=O)Nc2ccn(Cc3ccc(C#N)cn3)n2)ccc1OCCC(F)(F)F	J Med Chem	2017.0	CHEMBL4204573	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of human CYP3A4 using testosterone as substrate preincubated for 30 mins	Cc1cc(CC(=O)Nc2ccn(Cc3ccc(C#N)cn3)n2)ccc1OC(F)(F)F	J Med Chem	2017.0	CHEMBL4212176	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of human CYP3A4	N#Cc1ccc(Cn2ccc(NC(=O)Cc3ccc(C4(C(F)(F)F)CC4)cc3)n2)nc1	J Med Chem	2017.0	CHEMBL4217292	=	=	IC50	nM	51000.0	IC50	uM	51.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OCC)c1OCC	Bioorg Med Chem Lett	2017.0	CHEMBL4211876	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL283196	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4202990	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4218749	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4202990	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1ccccc1/C=C/C(=O)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL4209004	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1cccc(/C=C/C(=O)c2ccncc2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4212722	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL2237704	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	O=C(/C=C/c1ccc2c(c1)OCO2)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL4210776	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	O=C(/C=C/c1cccc2ccccc12)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL1568243	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4214111	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)c(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL2237710	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	CCOc1c(OC)cc(/C=C/C(=O)c2ccncc2)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4213815	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OCC)c1OCC	Bioorg Med Chem Lett	2017.0	CHEMBL4211876	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4205073	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OCC	Bioorg Med Chem Lett	2017.0	CHEMBL4210137	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in yeast microsomal membranes using dibenzylfluorescein as substrate measured after 10 mins by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL283196	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1cccc(/C=C/C(=O)c2ccncc2)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4212722	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)cc1	Bioorg Med Chem Lett	2017.0	CHEMBL2237704	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	O=C(/C=C/c1ccc2c(c1)OCO2)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL4210776	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	O=C(/C=C/c1cccc2ccccc12)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL1568243	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1	Bioorg Med Chem Lett	2017.0	CHEMBL4214111	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1ccc(/C=C/C(=O)c2ccncc2)c(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL2237710	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	CCOc1c(OC)cc(/C=C/C(=O)c2ccncc2)cc1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4213815	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1ccccc1/C=C/C(=O)c1ccncc1	Bioorg Med Chem Lett	2017.0	CHEMBL4209004	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OCC	Bioorg Med Chem Lett	2017.0	CHEMBL4210137	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	COc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4218749	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in HEK293 cells using dibenzylfluorescein as substrate pretreated for 30 mins followed by substrate addition measured for 60 mins by fluorescence assay	CCOc1cc(/C=C/C(=O)c2ccncc2)cc(OC)c1OC	Bioorg Med Chem Lett	2017.0	CHEMBL4205073	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4-mediated midazolam metabolism in human liver microsomes	N[C@H]1CCN(c2cc3c(cc2F)n2ccnc2c(=O)n3C2CC2)C1	J Med Chem	2018.0	CHEMBL4210894	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4-mediated midazolam metabolism in human liver microsomes	N[C@H]1CCN(c2cc3c(cc2F)n2ncnc2c(=O)n3C2CC2)C1	J Med Chem	2018.0	CHEMBL4218256	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4-mediated midazolam metabolism in human liver microsomes	O=c1c2nccn2c2cc(F)c(-c3ccncc3)cc2n1C1CC1	J Med Chem	2018.0	CHEMBL4203118	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4-mediated testosterone metabolism in human liver microsomes	N[C@H]1CCN(c2cc3c(cc2F)n2ccnc2c(=O)n3C2CC2)C1	J Med Chem	2018.0	CHEMBL4210894	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4-mediated testosterone metabolism in human liver microsomes	N[C@H]1CCN(c2cc3c(cc2F)n2ncnc2c(=O)n3C2CC2)C1	J Med Chem	2018.0	CHEMBL4218256	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4-mediated testosterone metabolism in human liver microsomes	O=c1c2nccn2c2cc(F)c(-c3ccncc3)cc2n1C1CC1	J Med Chem	2018.0	CHEMBL4203118	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin)	CCN(CC)[C@@H](C)CNC(=O)c1cc(-c2cnn3ccc(-c4cccs4)nc23)nc(N2CC(OC)C2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4215300	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis	CC(C)(C)Cn1ncn(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)c1=O	Bioorg Med Chem Lett	2018.0	CHEMBL4210924	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis	OC(Cn1cnnn1)(c1ccc(F)cc1F)C(F)(F)c1ccc(-c2ccc(OCC(F)(F)F)cc2)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4211628	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis	O=c1n(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cnn1C1CCCC1	Bioorg Med Chem Lett	2018.0	CHEMBL4206432	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins with substrate followed by NADPH addition measured after 15 mins by LC/MS/MS analysis	O=c1n(-c2ccc(C(F)(F)C(O)(Cn3cnnn3)c3ccc(F)cc3F)nc2)cnn1C1CCCCC1	Bioorg Med Chem Lett	2018.0	CHEMBL4214518	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4 expressed in yeast microsomal membranes by fluorescence assay	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12	Bioorg Med Chem Lett	2017.0	CHEMBL50	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 expressed in yeast microsomal membranes by fluorescence assay	CC(C)=CCc1cc(C2CC(=O)c3ccc(O)c(CC=C(C)C)c3O2)ccc1O	Bioorg Med Chem Lett	2017.0	CHEMBL4078418	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 expressed in yeast microsomal membranes by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL283196	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in HEK293 cells by fluorescence assay	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12	Bioorg Med Chem Lett	2017.0	CHEMBL50	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in HEK293 cells by fluorescence assay	CC(C)=CCc1cc(C2CC(=O)c3ccc(O)c(CC=C(C)C)c3O2)ccc1O	Bioorg Med Chem Lett	2017.0	CHEMBL4078418	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in HEK293 cells by fluorescence assay	O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12	Bioorg Med Chem Lett	2017.0	CHEMBL283196	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCOc1c(Cl)cc(C(=O)Nc2ccc(C(=O)O)c(C)c2)cc1OC(C)C	Bioorg Med Chem	2018.0	CHEMBL4202767	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl	Bioorg Med Chem	2018.0	CHEMBL107430	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(OCc3ccccc3OC)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4208231	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(OCc3ccc(CO)cc3OC)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4213155	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(OCc3ccccn3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4218074	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(OCc3cccnc3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4206363	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(OCc3nccc(OC)c3OC)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4205861	=	=	IC50	nM	9900.0	IC50	uM	9.9
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)NC)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4210732	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)NC(C)C)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4209289	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)NCc3ccccc3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4213687	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)N(C)Cc3ccccc3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4218623	=	=	IC50	nM	8500.0	IC50	uM	8.5
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)N[C@H](C)c3ccccc3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4202404	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCCCNc1nc(N)nc2cccc(C(=O)N[C@@H](C)c3ccccc3)c12	Bioorg Med Chem Lett	2018.0	CHEMBL4207296	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CNc1ccc(C(N)=O)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4218848	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1ncc(C(=O)Nc2ccc(-c3cccc(OC4CC4)c3)cn2)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4079324	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ncc(C(=O)Nc2ccc(-c3ccsc3)cn2)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4217112	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1ncc(C(=O)Nc2ccc(-c3cccc(S(=O)(=O)C4CC4)c3)cn2)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4105066	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1ccc(OCCCCC[C@H]2CC[C@]3(CC2)COC(C)(C)C3)cc1	Bioorg Med Chem Lett	2018.0	CHEMBL4205617	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCOCC5)cc4)cn23)cc1	J Med Chem	2018.0	CHEMBL4211649	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	CN1CCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc(C#N)cc5)n4c3)cc2)CC1	J Med Chem	2018.0	CHEMBL4204438	=	=	IC50	nM	3900.0	IC50	uM	3.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCNCC5)cc4)nn23)cc1	J Med Chem	2018.0	CHEMBL4208772	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	N#Cc1ccc(-c2cnc3ccc(-c4ccc(C(=O)N5CCOCC5)cc4)nn23)cc1	J Med Chem	2018.0	CHEMBL4203889	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	CN1CCN(C(=O)c2ccc(-c3ccc4ncc(-c5ccc(C#N)cc5)n4n3)cc2)CC1	J Med Chem	2018.0	CHEMBL4213168	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	CN(C)C1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(C#N)cc5)cnc4cn3)cc2)CC1	J Med Chem	2018.0	CHEMBL4208246	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	N#Cc1ccc(-c2cnc3cnc(-c4ccc(C(=O)N5CCOCC5)cc4)cn23)cc1	J Med Chem	2018.0	CHEMBL4213819	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	CN1CCN(C(=O)c2ccc(-c3cn4c(-c5ccc(C#N)cc5)cnc4cn3)cc2)CC1	J Med Chem	2018.0	CHEMBL4216991	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 5 mins by LC-MS/MS analysis	NC(=O)c1ccc(-c2cn3c(-c4ccc(O)cc4)cnc3cn2)cc1	J Med Chem	2018.0	CHEMBL4212480	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	COc1cc2c(cc1-n1cnc3ccc(-c4ccnc5[nH]ccc45)cc31)CNC2	J Med Chem	2018.0	CHEMBL4213984	=	=	IC50	nM	3600.0	IC50	uM	3.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins in presence of NADPH-regeneration system by LC-MS/MS method	COCCCN1CCC(c2nnc(-c3cccc4cc(C(C)C)nn34)o2)CC1	J Med Chem	2018.0	CHEMBL4215911	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins in presence of NADPH-regeneration system by LC-MS/MS method	CC(C)c1cc2cccc(-c3nnc(C4CCN(CC5CCOCC5)CC4)o3)n2n1	J Med Chem	2018.0	CHEMBL4205936	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCN(CC)CC.NC(=O)c1ccc(-c2cc(C(=O)O)cc(-n3cc(-c4ccc(C(F)(F)F)cc4)nn3)c2)cc1	J Med Chem	2018.0	CHEMBL4211068	>=	>=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4 using midazolam as substrate	CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2N2CCC(C#N)(c3ccccc3)CC2)CC1	J Med Chem	2018.0	CHEMBL4206892	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 using midazolam as substrate	CS(=O)(=O)N1CCN(C(=O)c2cnc3ccc(F)cc3c2-c2ccc(C3(C#N)CC3)cc2)CC1	J Med Chem	2018.0	CHEMBL4206272	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of C-terminal His-tagged recombinant human CYP3A4 assessed as decrease in metabolism of luciferin isopropyl alcohol preincubated for 3 mins followed by NADPH addition measured after 30 mins	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	J Med Chem	2018.0	CHEMBL254328	=	=	IC50	nM	230.0	IC50	uM	0.23
Inhibition of C-terminal His-tagged recombinant human CYP3A4 assessed as decrease in metabolism of luciferin isopropyl alcohol preincubated for 3 mins followed by NADPH addition measured after 30 mins	C[C@]12CC[C@H]3[C@@H](C/C(=N/O)[C@H]4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1	J Med Chem	2018.0	CHEMBL4214976	=	=	IC50	nM	8570.0	IC50	uM	8.57
Inhibition of CYP3A4 (unknown origin)	O=C(NC[C@@H](Cc1ccccc1)N1CCC(O)(C(F)(F)F)CC1)C1(c2ccc(Cl)cc2)CCCC1	MedChemComm	2016.0	CHEMBL4208555	=	=	IC50	nM	2164.0	IC50	nM	2164.0
Inhibition of CYP3A4 (unknown origin)	COCCOc1ccc(N2CCN(CCn3c(=O)n(C)c4c3nc(N)n3nc(-c5nccs5)nc43)CC2)cc1F	ACS Med Chem Lett	2017.0	CHEMBL4215754	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(N2C(=O)CN(Cc3ccccc3)C2=S)cc1Cl	ACS Med Chem Lett	2017.0	CHEMBL2094291	=	=	IC50	nM	4015.0	IC50	nM	4015.0
Inhibition of CYP3A4 (unknown origin)	CN(C)c1ccc(N2C(=O)CN(Cc3ccc(F)cc3)C2=S)cc1Cl	ACS Med Chem Lett	2017.0	CHEMBL4204461	=	=	IC50	nM	1279.0	IC50	nM	1279.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(N2C(=O)CN(Cc3ccc(F)cc3Cl)C2=S)ccc1N(C)C	ACS Med Chem Lett	2017.0	CHEMBL4210886	=	=	IC50	nM	7760.0	IC50	nM	7760.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	ACS Med Chem Lett	2017.0	CHEMBL75	=	=	IC50	nM	29.6	IC50	nM	29.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC/MS/MS analysis	Cc1csc(NC(=O)c2cc(C(F)(F)c3cncnc3)cc3cccnc23)n1	Bioorg Med Chem Lett	2018.0	CHEMBL4205817	=	=	IC50	nM	5900.0	IC50	uM	5.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC/MS/MS analysis	Cc1cc(Oc2cncnc2)cc(C(=O)Nc2ccc(F)cn2)n1	Bioorg Med Chem Lett	2018.0	CHEMBL2386850	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH by LC/MS/MS analysis	O=C(Nc1ccc(F)cn1)c1cc(Oc2cncc(F)c2)cn2ncnc12	Bioorg Med Chem Lett	2018.0	CHEMBL4089114	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using terfenadine as substrate after 15 mins in presence of NADPH by LC/MS/MS analysis	C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=C(CF)OC(N)=N1	J Med Chem	2018.0	CHEMBL4213486	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4210484	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4211012	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cccc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2O[C@@H](C)C(F)(F)F)C3)c1	J Med Chem	2018.0	CHEMBL4206122	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3cncc(F)c3)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4206639	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2O[C@@H](C)C(F)(F)F)C3)ccn1	J Med Chem	2018.0	CHEMBL4218366	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(C3CCCC3)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4218894	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CC(C)Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1	J Med Chem	2018.0	CHEMBL4213968	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CC(C)(C)Oc1ccc(S(C)(=O)=O)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1	J Med Chem	2018.0	CHEMBL4216391	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(OCC2CC2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1	J Med Chem	2018.0	CHEMBL4211426	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(N2CCC(F)(F)CC2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1	J Med Chem	2018.0	CHEMBL4205471	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(N2CCC(F)(F)CC2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4210353	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2N2CCC(F)(F)CC2)C3)ccn1	J Med Chem	2018.0	CHEMBL4217712	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1	J Med Chem	2018.0	CHEMBL4205995	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CS(=O)(=O)c1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4214250	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(S(C)(=O)=O)ccc2-c2cccc(F)c2)C3)ccn1	J Med Chem	2018.0	CHEMBL4202565	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CCS(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4ccccc4F)nc3C2)c1	J Med Chem	2018.0	CHEMBL4209849	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CCS(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4214756	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CCS(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4ccnc(C)c4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4206403	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CC(C)S(=O)(=O)c1ccc(O[C@@H](C)C(F)(F)F)c(C(=O)N2Cc3cn(-c4ccccc4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4211293	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3ccccc3F)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4210589	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3cncc(F)c3)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4205726	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2O[C@@H](C)C(F)(F)F)C3)ccn1	J Med Chem	2018.0	CHEMBL4215015	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](Oc1ccc(C#N)cc1C(=O)N1Cc2cn(C3CCCC3)nc2C1)C(F)(F)F	J Med Chem	2018.0	CHEMBL4210095	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CC(C)Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3ccccc3)nc2C1	J Med Chem	2018.0	CHEMBL4202824	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	CC(C)Oc1ccc(C#N)cc1C(=O)N1Cc2cn(-c3cncc(F)c3)nc2C1	J Med Chem	2018.0	CHEMBL4214486	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2OC(C)C)C3)ccn1	J Med Chem	2018.0	CHEMBL4207171	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2OCC2CC2)C3)ccn1	J Med Chem	2018.0	CHEMBL4218903	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2N2CCC(F)(F)CC2)C3)ccn1	J Med Chem	2018.0	CHEMBL4211535	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	N#Cc1ccc(-c2cccc(F)c2)c(C(=O)N2Cc3cn(-c4cncc(F)c4)nc3C2)c1	J Med Chem	2018.0	CHEMBL4206650	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 7 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-n2cc3c(n2)CN(C(=O)c2cc(C#N)ccc2-c2cccc(F)c2)C3)ccn1	J Med Chem	2018.0	CHEMBL4212425	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4c3cnn4C)[C@@H](C)C2)c(C)c1	J Med Chem	2018.0	CHEMBL4211181	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	Cc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5cccnc5)nc34)CC2)cc1	J Med Chem	2018.0	CHEMBL4206816	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4scnc34)CC2)cc1	J Med Chem	2018.0	CHEMBL4217096	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4c3ncn4C)[C@@H](C)C2)c(C)c1	J Med Chem	2018.0	CHEMBL4209793	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5cccnc5)nc34)CC2)cc1	J Med Chem	2018.0	CHEMBL4205416	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sc(-c5ccccc5)nc34)CC2)cc1	J Med Chem	2018.0	CHEMBL4210308	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4scnc34)[C@@H](C)C2)c(C)c1	J Med Chem	2018.0	CHEMBL4215340	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4scnc34)[C@@H](C)C2)cc1	J Med Chem	2018.0	CHEMBL4203041	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4scnc34)[C@@H](C)C2)c(C)n1	J Med Chem	2018.0	CHEMBL4207928	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sccc34)[C@@H](C)C2)c(C)c1	J Med Chem	2018.0	CHEMBL4215244	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as decrease in midazolam 1-hydroxylation by LC-MS/MS analysis	COc1ccc(NC(=O)N2CCN(c3nc(N)nc4sncc34)[C@@H](C)C2)c(C)c1	J Med Chem	2018.0	CHEMBL4203566	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1	Eur J Med Chem	2018.0	CHEMBL55	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1	Eur J Med Chem	2018.0	CHEMBL110	=	=	IC50	nM	98200.0	IC50	uM	98.2
Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C	Eur J Med Chem	2018.0	CHEMBL125	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2	Eur J Med Chem	2018.0	CHEMBL267345	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH/substrate addition by LC-MS/MS analysis	CCN1CCC(N2CCc3nc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)ccc3C2)CC1	Eur J Med Chem	2018.0	CHEMBL4203179	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4	CC(CC(=O)O)c1cccc(-n2c(C(N)=O)cc3ccc(OC(F)(F)F)cc32)n1	ACS Med Chem Lett	2018.0	CHEMBL4215835	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate pretreated for 5 mins followed by NADPH addition and measured after 5 mins by LC-MS analysis	C[C@H]1COCCN1c1nc(-c2cnc(N)cc2F)cc(C2(S(C)(=O)=O)CC2)n1	ACS Med Chem Lett	2018.0	CHEMBL4211915	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate pretreated for 5 mins followed by NADPH addition and measured after 5 mins by LC-MS analysis	C[C@H]1COCCN1c1nc(-c2cnc(N)cc2F)cc(C2(S(C)(=O)=O)CC2)n1	ACS Med Chem Lett	2018.0	CHEMBL4211915	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate	O=C(Nc1ccc2[nH]nc(-c3ccncc3)c2c1)[C@@H]1CCN(CC(=O)N2CCN(c3ccc(-c4ncccn4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL3590107	=	=	IC50	nM	7800000.0	IC50	mM	7.8
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate	CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(F)cc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL3645235	>	>	IC50	nM	30000000.0	IC50	mM	30.0
Inhibition of CYP3A4 (unknown origin) co-incubated with substrate	CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(OC(C)C)nc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncn(C)n4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL4213970	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition	O=C(Nc1ccc2[nH]nc(-c3ccncc3)c2c1)[C@@H]1CCN(CC(=O)N2CCN(c3ccc(-c4ncccn4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL3590107	=	=	IC50	nM	5700000.0	IC50	mM	5.7
Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition	CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(F)cc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL3645235	=	=	IC50	nM	2000000.0	IC50	mM	2.0
Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition	CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc5c(c4)OCO5)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncccn4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL4218701	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of CYP3A4 (unknown origin) preincubated followed by substrate addition	CS[C@@]1(C(=O)Nc2ccc3[nH]nc(-c4ccc(OC(C)C)nc4)c3c2)CCN(CC(=O)N2CC=C(c3ccc(-c4ncn(C)n4)cc3)CC2)C1	ACS Med Chem Lett	2018.0	CHEMBL4213970	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 (unknown origin)	C[C@H](Nc1c(C(N)=O)nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc12)C1CCOCC1	ACS Med Chem Lett	2018.0	CHEMBL4217549	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc2c1N[C@@H](C)C1CCOCC1	ACS Med Chem Lett	2018.0	CHEMBL4218854	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1	J Med Chem	2018.0	CHEMBL4208229	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH	COCCNc1cc(O)c2c(=O)c3c(-c4nccs4)[nH]c(Cc4ccc5c(c4)OCO5)c3oc2c1	J Med Chem	2018.0	CHEMBL4218772	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cncc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)c1	J Med Chem	2018.0	CHEMBL4205724	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of CYP3A4 (unknown origin)	COc1cccc(NC(C(=O)c2c[nH]c3ccccc23)c2nc3ccccc3o2)c1	J Med Chem	2018.0	CHEMBL4203720	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OCCO)c1	J Med Chem	2018.0	CHEMBL4203293	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OC)c1	J Med Chem	2018.0	CHEMBL4212403	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OC)c1	J Med Chem	2018.0	CHEMBL4212403	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(NC(C(=O)c2c[nH]c3ccccc23)c2ccccc2)cc(OC)c1	J Med Chem	2018.0	CHEMBL4212403	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 using Luciferin-BE as substrate in presence of NADPH by P450-Glo luminescence assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2017.0	CHEMBL75	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Bioorg Med Chem	2018.0	CHEMBL376488	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2c1CCC2	Bioorg Med Chem	2018.0	CHEMBL4227597	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccoc12	Bioorg Med Chem	2018.0	CHEMBL4224771	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(C#N)cc2cc1[C@@H](c1cccc(F)c1)[C@@](O)(CCN(C)C)c1cccc2ccoc12	Bioorg Med Chem	2018.0	CHEMBL4229114	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1cccnc1OC)[C@@](O)(CCN(C)C)c1cccc2ccoc12	Bioorg Med Chem	2018.0	CHEMBL4229127	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc2ccoc12	Bioorg Med Chem	2018.0	CHEMBL4228130	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	CCOc1cc([C@H](c2cc3cc(Br)ccc3cc2OC)[C@@](O)(CCN(C)C)c2cccc3ccoc23)cc(OCC)n1	Bioorg Med Chem	2018.0	CHEMBL4227669	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1ccc2occc2c1	Bioorg Med Chem	2018.0	CHEMBL4226478	=	=	IC50	nM	9700.0	IC50	uM	9.7
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1ccc2occc2c1	Bioorg Med Chem	2018.0	CHEMBL4226743	=	=	IC50	nM	6900.0	IC50	uM	6.9
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(C#N)cc2cc1[C@@H](c1cccc(F)c1)[C@@](O)(CCN(C)C)c1cc2ccccc2o1	Bioorg Med Chem	2018.0	CHEMBL4227540	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cc2ccccc2o1	Bioorg Med Chem	2018.0	CHEMBL4226688	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(C#N)cc2cc1[C@@H](c1ccnc(OC)c1OC)[C@@](O)(CCN(C)C)c1cccc2c1OCC2	Bioorg Med Chem	2018.0	CHEMBL4225886	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1cccc(C)c1)[C@@](O)(CCN(C)C)c1cccc2c1OCO2	Bioorg Med Chem	2018.0	CHEMBL4225434	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(C#N)cc2cc1[C@@H](c1cccc(C)c1)[C@@](O)(CCN(C)C)c1cccc2c1OCO2	Bioorg Med Chem	2018.0	CHEMBL4228918	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins	COc1cc2ccc(Br)cc2cc1[C@@H](c1cccc(C)c1)[C@@](O)(CCN(C)C)c1cccc2c1OCCO2	Bioorg Med Chem	2018.0	CHEMBL4228396	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(Cc3ccccn3)ns2)n1	Bioorg Med Chem Lett	2018.0	CHEMBL4227082	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes	Cc1cn2c(-c3cn[nH]c3)cnc2c(Nc2cc(C(NC(C)(C)C)c3ccccn3)ns2)n1	Bioorg Med Chem Lett	2018.0	CHEMBL4225923	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2n1	Bioorg Med Chem	2018.0	CHEMBL3604734	=	=	IC50	nM	12589.25	pIC50		4.9
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1c2n[nH]cc2CN1C1=NC(NCc2c(F)cccc2C(F)(F)F)c2cccc(C(N)=O)c2N1	Bioorg Med Chem	2018.0	CHEMBL4227839	=	=	IC50	nM	158.49	pIC50		6.8
Inhibition of CYP3A4 (unknown origin)	Cc1n[nH]c2c1CN(C1=NC(NCc3c(F)cccc3C(F)(F)F)c3cccc(C(N)=O)c3N1)C2	Bioorg Med Chem	2018.0	CHEMBL4226243	=	=	IC50	nM	630.96	pIC50		6.2
Inhibition of human recombinant CYP3A4 using DEF substrate	CCOc1c2c(c(OCC)c3ccccc13)C(=O)N(c1ccc(CC(=O)O)cc1)C2=O	Bioorg Med Chem Lett	2018.0	CHEMBL4224936	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human recombinant CYP3A4 using 7BQ substrate	CCOc1c2c(c(OCC)c3ccccc13)C(=O)N(c1ccc(CC(=O)O)cc1)C2=O	Bioorg Med Chem Lett	2018.0	CHEMBL4224936	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1noc2c1CCc1ccccc1-2	Bioorg Med Chem	2018.0	CHEMBL4227117	=	=	IC50	nM	7270.0	IC50	uM	7.27
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1noc2c1ccc1ccccc12	Bioorg Med Chem	2018.0	CHEMBL4227911	=	=	IC50	nM	14600.0	IC50	uM	14.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem	2018.0	CHEMBL75	=	=	IC50	nM	34.5	IC50	uM	0.0345
Inhibition of CYP3A4 (unknown origin)	COC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OC(C)C)cc2)s1	Bioorg Med Chem Lett	2018.0	CHEMBL4226756	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OC(C)C)cc2)s1	Bioorg Med Chem Lett	2018.0	CHEMBL4225651	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CCOc1ccc(Oc2ncc(/C=C/[C@H](C)NC(C)=O)s2)cc1	Bioorg Med Chem Lett	2018.0	CHEMBL4226491	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2)s1	Bioorg Med Chem Lett	2018.0	CHEMBL4225397	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)s1	Bioorg Med Chem Lett	2018.0	CHEMBL4226229	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1nnc(Oc2ccc(OCC3CC3)cc2Cl)s1	Bioorg Med Chem Lett	2018.0	CHEMBL4225124	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)n1C	Bioorg Med Chem Lett	2018.0	CHEMBL4225976	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC3CC3)cc2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4224858	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4226182	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC3CC3)cc2Cl)nn1	Bioorg Med Chem Lett	2018.0	CHEMBL4227288	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1cnc(Oc2ccc(OCC3CC3)cc2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4226442	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CCOc1ccc(Oc2ccc(/C=C/[C@H](C)NC(C)=O)cn2)c(Cl)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4227033	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCCF)cc2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4226186	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc(OCC(F)F)cc2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4224836	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C)sc3c2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4225924	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2cc3sc(C)nc3cc2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4226500	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4225659	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)(C)O)sc3c2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4224749	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CCOc1nc2ccc(Oc3ccc(/C=C/[C@H](C)NC(C)=O)cn3)c(Cl)c2s1	Bioorg Med Chem Lett	2018.0	CHEMBL4225405	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3sc(C(C)C)nc3c2Cl)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4228805	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2C(F)(F)F)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4226825	=	=	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H](C)/C=C/c1ccc(Oc2ccc3nc(C(C)C)sc3c2F)nc1	Bioorg Med Chem Lett	2018.0	CHEMBL4229067	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human supersome CYP3A4 using testosterone as substrate assessed as testosterone 6beta-hydroxylation after 30 mins by HPLC-UV detection	O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1	Eur J Med Chem	2018.0	CHEMBL4239823	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human supersome CYP3A4 using testosterone as substrate assessed as testosterone 6beta-hydroxylation after 30 mins by HPLC-UV detection	O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2nsc3ccccc23)CC1	Eur J Med Chem	2018.0	CHEMBL4246655	=	=	IC50	nM	23000.0	IC50	uM	23.0
Inhibition of CYP3A4 (unknown origin)	COc1cccc(CC(=O)Nc2nc(-c3ccnc(N)c3)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL3581140	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 (unknown origin)	O=C(Cc1ccc2c(c1)OCO2)Nc1nc(-c2c[nH]c3ncccc23)cs1	Bioorg Med Chem Lett	2018.0	CHEMBL4248883	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4239032	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4237255	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of CYP3A4 (unknown origin)	CN(C)S(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4240458	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of CYP3A4 (unknown origin)	CCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4243123	=	=	IC50	nM	9300.0	IC50	uM	9.3
Inhibition of CYP3A4 (unknown origin)	CCCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4240605	=	=	IC50	nM	5700.0	IC50	uM	5.7
Inhibition of CYP3A4 (unknown origin)	CC(C)NS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4249070	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 (unknown origin)	COCCNS(=O)(=O)c1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4241959	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4249925	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of CYP3A4 (unknown origin)	CCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4250547	=	=	IC50	nM	5900.0	IC50	uM	5.9
Inhibition of CYP3A4 (unknown origin)	CCCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4241305	=	=	IC50	nM	3600.0	IC50	uM	3.6
Inhibition of CYP3A4 (unknown origin)	CC(C)S(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4244717	=	=	IC50	nM	4900.0	IC50	uM	4.9
Inhibition of CYP3A4 (unknown origin)	CCCCS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2018.0	CHEMBL4243658	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of CYP3A4 (unknown origin)	O=C(Cc1cccc(OCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1	Bioorg Med Chem Lett	2018.0	CHEMBL4238696	=	=	IC50	nM	14900.0	IC50	uM	14.9
Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1	Bioorg Med Chem Lett	2018.0	CHEMBL4245197	=	=	IC50	nM	17500.0	IC50	uM	17.5
Inhibition of CYP3A4 (unknown origin)	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1	Bioorg Med Chem Lett	2018.0	CHEMBL4245242	=	=	IC50	nM	20800.0	IC50	uM	20.8
Inhibition of CYP3A4 (unknown origin)	O=C(Cc1cccc(OCCCN2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1	Bioorg Med Chem Lett	2018.0	CHEMBL4242191	=	=	IC50	nM	12600.0	IC50	uM	12.6
Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1	Bioorg Med Chem Lett	2018.0	CHEMBL4248525	=	=	IC50	nM	19600.0	IC50	uM	19.6
Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	[2H]/C(c1nc[nH]c1C(C)(C)C)=c1/[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O	Bioorg Med Chem	2018.0	CHEMBL4063810	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	CC(C)(C)c1[nH]cnc1/C=c1\[nH]c(=O)/c(=C/c2ccccc2)[nH]c1=O	Bioorg Med Chem	2018.0	CHEMBL1096380	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1	Bioorg Med Chem Lett	2018.0	CHEMBL1873475	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1cccs1	J Med Chem	2018.0	CHEMBL4244935	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1ccc([C@H](CCN2[C@H]3CC[C@@H]2C[C@@H](n2c(C)nnc2C(C)C)C3)NC(=O)C2CCC(F)(F)CC2)s1	J Med Chem	2018.0	CHEMBL4248282	=	=	IC50	nM	10900.0	IC50	uM	10.9
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCCCC1)c1cccs1	J Med Chem	2018.0	CHEMBL4242114	=	=	IC50	nM	12300.0	IC50	uM	12.3
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCCC1)c1cccs1	J Med Chem	2018.0	CHEMBL4238063	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccsc1	J Med Chem	2018.0	CHEMBL4249798	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1cccs1	J Med Chem	2018.0	CHEMBL4244935	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1ccc([C@H](CCN2[C@H]3CC[C@@H]2C[C@@H](n2c(C)nnc2C(C)C)C3)NC(=O)C2CCC(F)(F)CC2)s1	J Med Chem	2018.0	CHEMBL4248282	=	=	IC50	nM	23400.0	IC50	uM	23.4
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCCCC1)c1cccs1	J Med Chem	2018.0	CHEMBL4242114	=	=	IC50	nM	21700.0	IC50	uM	21.7
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCCC1)c1cccs1	J Med Chem	2018.0	CHEMBL4238063	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccsc1	J Med Chem	2018.0	CHEMBL4249798	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2ccc3n(c2=O)CCN(C[C@@]24C[C@@H]2C(C)(C)Oc2ccc(C(F)(F)F)cc24)C3=O)cn1	MedChemComm	2017.0	CHEMBL4280986	=	=	IC50	nM	16300.0	IC50	uM	16.3
Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC-MS/MS method	CS(=O)(=O)Nc1nnc2cc(OCC34CC5CC(CC(C5)C3)C4)c(C3CC3)cn12	J Med Chem	2018.0	CHEMBL4279238	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC-MS/MS method	O=S(=O)(Nc1nnc2cc(OCC34CC5CC(CC(C5)C3)C4)c(C3CC3)cn12)C1CC1	J Med Chem	2018.0	CHEMBL4290579	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone/midazolam as substrate after 30 mins by LC-MS/MS method	CS(=O)(=O)Nc1nnc2cc(COc3cc(Cl)cc(Cl)c3)c(C3CC3)cn12	J Med Chem	2018.0	CHEMBL4285790	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1			CHEMBL4129721	=	=	IC50	nM	695.0	IC50	nM	695.0
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(C1CC1)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1			CHEMBL4126996	=	=	IC50	nM	636.0	IC50	nM	636.0
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(c1cccc(OC(F)(F)F)c1)N1CCN(c2ccc(/C=C/c3cc(Cl)cc(Cn4ccnc4)c3)cc2)CC1			CHEMBL4288256	=	=	IC50	nM	873.0	IC50	nM	873.0
Inhibition of CYP3A4 (unknown origin)	CCS(=O)(=O)N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1			CHEMBL4126284	=	=	IC50	nM	243.0	IC50	nM	243.0
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(N1CCN(c2ccc(/C=C/c3cc(F)cc(-c4ccncc4)c3)cc2)CC1)C(F)(F)F			CHEMBL4128368	=	=	IC50	nM	9360.0	IC50	nM	9360.0
Inhibition of CYP3A4 (unknown origin)	CCOC(=O)CNC(=O)N1CCN(c2ccc(/C=C/c3cc(Cl)cc(Cn4ccnc4)c3)cc2)CC1			CHEMBL4291002	=	=	IC50	nM	1670.0	IC50	nM	1670.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(CO[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)OC3)cc2)CC1			CHEMBL4289930	=	=	IC50	nM	109.0	IC50	nM	109.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1ccc2c(c1OC)C(OC)N(C)c1c-2ccc2cc3c(cc12)OCO3	MedChemComm	2018.0	CHEMBL4294195	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	Nc1nccc(-c2c[nH]c3ccc(Br)cc23)n1	MedChemComm	2018.0	CHEMBL44541	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c(-c2ccccc2)oc2c(ccc3ccoc32)c1=O	MedChemComm	2018.0	CHEMBL4282750	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c2occc2c(OC)c2c(=O)cc(C)oc12	MedChemComm	2018.0	CHEMBL44746	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1ccc(-c2cc(=O)c3c(O)c(OC)c(OC)cc3o2)cc1OC	MedChemComm	2018.0	CHEMBL226508	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c(C(=O)CC(=O)c2ccccc2)ccc2occc12	MedChemComm	2018.0	CHEMBL4285296	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c2ccoc2cc2oc(=O)ccc12	MedChemComm	2018.0	CHEMBL24171	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c2ccoc2c(OCC=C(C)C)c2oc(=O)ccc12	MedChemComm	2018.0	CHEMBL452751	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	COc1c2ccoc2c(OC)c2oc(=O)ccc12	MedChemComm	2018.0	CHEMBL140796	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	CC1=CC(=O)c2c(O)cccc2C1=O	MedChemComm	2018.0	CHEMBL295316	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control	O=C1C=CC(=O)c2c(O)ccc(O)c21	MedChemComm	2018.0	CHEMBL274056	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 by bioluminescence method	CCCCn1c(=O)c2c(nc3n2CCCN3CCc2ccc(OCC(=O)NCCCN(CC)CC)cc2)n(CCCC)c1=O	MedChemComm	2018.0	CHEMBL4291015	=	=	IC50	nM	230.0	IC50	uM	0.23
Inhibition of recombinant human CYP3A4 by bioluminescence method	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	MedChemComm	2018.0	CHEMBL75	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human liver microsome CYP3A4 expressed in baculosomes using fluorogenic-DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cnnn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	J Med Chem	2018.0	CHEMBL4284306	>	>	EC50	nM	20000.0	EC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Nc1nc(OCc2ccccc2)c2[nH]nnc2n1	MedChemComm	2017.0	CHEMBL333928	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 (unknown origin) using luciferin-IPA as substrate preincubated for 10 mins followed by NADPH regeneration system addition and measured after 10 to 30 mins by Promega P450-GloScreening assay	OCC1CCCC(c2ccc(O)cc2)CC1	Eur J Med Chem	2018.0	CHEMBL4293810	=	=	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin)	CC#C[C@@H](CC(=O)O)c1ccc(OC[C@H]2COc3ccc(Cl)cc3O2)cc1	Bioorg Med Chem	2018.0	CHEMBL4288001	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cn1cc(Cn2c(=O)c3cc(S(=O)(=O)NC4(C)CC4)ccc3n(CC3COC3)c2=O)cn1	J Med Chem	2018.0	CHEMBL4285867	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Cn2c(=O)c3cc(S(=O)(=O)NC4(C)CC4)ccc3n(CC3COC3)c2=O)on1	J Med Chem	2018.0	CHEMBL4283898	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH and Luciferin BE 50	CCOc1nc(Cl)ccc1C1(N2CCN(c3ccnc(C)c3)CC2)C(=O)N(S(=O)(=O)c2ccc(OC)cn2)c2ccc(C#N)cc21	Bioorg Med Chem Lett	2018.0	CHEMBL4281098	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH and Luciferin BE 50	CCOc1nc(Cl)ccc1C1(N2CCN(c3ccncc3)CC2)C(=O)N(S(=O)(=O)c2ccc(OC)cn2)c2ccc(C#N)cc21	Bioorg Med Chem Lett	2018.0	CHEMBL4280894	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH and Luciferin BE 50	CCOc1nc(Cl)ccc1C1(N2CCN(c3ccnc(C)c3)CC2)C(=O)N(S(=O)(=O)c2ccc(OC)cn2)c2ccc(C#N)cc21	Bioorg Med Chem Lett	2018.0	CHEMBL4281098	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin)	CCC[C@@H](CCO)Nc1nc(N)nc2c1CN(C(=O)c1csc(C)n1)CC2	Bioorg Med Chem Lett	2018.0	CHEMBL4276988	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC1CC(C)CC(C(=O)Nc2nc3ccc(C(F)(F)F)cc3s2)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4292052	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC1CC(C(=O)Nc2nc3ccc(Br)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4281073	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC1CC(C(=O)Nc2nc3ccc(Cl)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4295138	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC1CC(C(=O)Nc2nc3ccc(OC(F)(F)F)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4287884	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC1CC(C)CC(C(=O)Nc2nc3ccc(C(F)(F)F)cc3s2)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4292052	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC1CC(C(=O)Nc2nc3ccc(Br)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4281073	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC1CC(C(=O)Nc2nc3ccc(Cl)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4295138	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC1CC(C(=O)Nc2nc3ccc(OC(F)(F)F)cc3s2)CC(C)(C)C1	Bioorg Med Chem Lett	2018.0	CHEMBL4287884	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CCCCc1ccccc1NCc1ccc(C(=O)Nc2nc(CC(=O)O)cs2)s1	Eur J Med Chem	2018.0	CHEMBL4276719	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COCCCOc1cc2c(cc1OC)-c1cc(=O)c(C(=O)O)cn1[C@H](C(C)C)C2	J Med Chem	2018.0	CHEMBL4283853	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis	CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2([S@](C)(=N)=O)CC2)n1	J Med Chem	2018.0	CHEMBL3648329	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis	CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2(S(C)(=O)=O)CC2)n1	J Med Chem	2018.0	CHEMBL4291436	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis	C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cncc3[nH]ccc23)n1	J Med Chem	2018.0	CHEMBL4281240	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis	C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2cc[nH]c3nccc2-3)n1	J Med Chem	2018.0	CHEMBL4285417	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis	C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1	J Med Chem	2018.0	CHEMBL2325697	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 30 mins in presence of NADPH measured by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL2178718	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)nc(C)c1F	J Med Chem	2018.0	CHEMBL4293298	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	Cc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)nc(C)c1F	J Med Chem	2018.0	CHEMBL4288838	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)c(N4CCOCC4)n3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4278154	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)c(N4CCCC4)n3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4285940	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CCCOc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J Med Chem	2018.0	CHEMBL4278011	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CCOc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J Med Chem	2018.0	CHEMBL4294236	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	COc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J Med Chem	2018.0	CHEMBL3800286	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CCc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J Med Chem	2018.0	CHEMBL4279084	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	Cc1nc(N2C[C@H]3C(=O)N(C)C(=N)N[C@@]3(c3cc(-c4cccc(C#N)c4)cs3)C2)ncc1F	J Med Chem	2018.0	CHEMBL4289763	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncccn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL2178717	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cc3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL2178150	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ccc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL2178714	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(Br)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4282976	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(Cl)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4280271	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cc(F)cc(F)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4291347	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	COc1cc(C#N)cc(-c2csc([C@]34CN(c5ncc(F)cn5)C[C@H]3C(=O)N(C)C(=N)N4)c2)c1	J Med Chem	2018.0	CHEMBL4278329	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cc(F)cc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4288644	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4ccc(Cl)c(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4294969	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4ccc(F)c(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL4286732	=	=	IC50	nM	5700.0	IC50	uM	5.7
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis	CN1C(=N)N[C@@]2(c3cc(-c4cccc(C#N)c4)cs3)CN(c3ncc(F)cn3)C[C@H]2C1=O	J Med Chem	2018.0	CHEMBL2178718	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of human CYP3A4	CCOc1cc(CN2CCC3(CC2)CC(=O)N(c2ccc(C(=O)O)cc2)C3)cc(OCC)c1-c1ccc(F)cc1.O=C(O)C(F)(F)F	ACS Med Chem Lett	2018.0	CHEMBL4282052	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1cc(-c2[nH]c3cccnc3c2-c2cccc(C(F)F)n2)ccn1	ACS Med Chem Lett	2018.0	CHEMBL4284170	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	[2H]C([2H])([2H])Oc1ccc(-c2c(-c3ccnc(NC(C)=O)c3)[nH]c3cccnc23)nc1	ACS Med Chem Lett	2018.0	CHEMBL4280731	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate after 10 to 30 mins by LC/MS analysis	O=c1cc(NC2CCN(S(=O)(=O)C(F)(F)F)CC2)c2cc(C(c3ccc(Cl)cc3)c3nccs3)ccc2[nH]1	J Med Chem	2018.0	CHEMBL3921520	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate after 10 to 30 mins by LC/MS analysis	O=c1cc(/C=C/c2ccc(C(F)(F)F)cc2)c2cc(C(c3ccc(Cl)cc3)c3nccs3)ccc2[nH]1	J Med Chem	2018.0	CHEMBL3962890	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam/testosterone as substrate after 10 to 30 mins by LC/MS analysis	O=c1cc(NC2CCN(S(=O)(=O)C(F)(F)F)CC2)c2cc(C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)ccc2[nH]1	J Med Chem	2018.0	CHEMBL3945880	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis	COc1ccccc1N1C(=O)CSC1c1cccc(C(=O)NCCc2ccc(Br)cc2)c1	J Med Chem	2019.0	CHEMBL3261573	=	=	IC50	nM	19540.0	IC50	uM	19.54
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis	COc1ccc(-c2nc(C)nn2-c2cccc(C(=O)NCCCCc3ccccc3)c2)cc1	J Med Chem	2019.0	CHEMBL4528087	=	=	IC50	nM	36880.0	IC50	uM	36.88
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis	CCc1nc(-c2ncc(OC)cn2)n(-c2cccc(C(=O)NCCCCc3ccccc3)c2)n1	J Med Chem	2019.0	CHEMBL4582168	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH-generating system addition and measured after 20 mins by LC-MS/MS analysis	COc1ccc(-n2nc(C)nc2-c2cccc(C(=O)NCCCCc3ccccc3)c2)cc1	J Med Chem	2019.0	CHEMBL4587127	=	=	IC50	nM	37690.0	IC50	uM	37.69
Inhibition of recombinant human CYP3A4 expressed in insect cell microsomes in presence of NADPH-regenerating system after 15 to 45 mins by fluorescence probe substrate-based assay	N#Cc1ccc2nnc(C(=O)N3CCC(c4ccccc4C(F)(F)F)CC3)n2c1	J Med Chem	2019.0	CHEMBL4463039	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4 expressed in insect cell microsomes in presence of NADPH-regenerating system after 15 to 45 mins by fluorescence probe substrate-based assay	N#Cc1ccc2nnc(C(=O)N3CCC(c4cccc(F)c4C(F)(F)F)CC3)n2c1	J Med Chem	2019.0	CHEMBL3954871	=	=	IC50	nM	74000.0	IC50	uM	74.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins followed by substrate addition further incubated for 10 mins by LC-MS/MS analysis	Cc1cc(Cc2cc(-c3ccc(Br)cc3)on2)cc(C)c1OC(C)(C)C(=O)O	ACS Med Chem Lett	2019.0	CHEMBL4470753	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(F)CN1[C@@H]2CCC[C@@]1(c1c(F)cc(/C=C/C(=O)O)cc1F)c1[nH]c3ccccc3c1C2	ACS Med Chem Lett	2019.0	CHEMBL4452972	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Fc1cc(Cl)ccc1-c1ccc(Cn2nnc3ccccc32)cn1	J Med Chem	2018.0	CHEMBL4483344	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	FC(F)(F)c1cccc2c1nnn2CC1CC1	J Med Chem	2018.0	CHEMBL4460927	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4	O=C(OC(C(F)(F)F)C(F)(F)F)N1CCN(Cc2ccc(C(F)(F)F)cc2N2CCCC2)CC1	J Med Chem	2018.0	CHEMBL3945728	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 8 mins by LC-MS/MS analysis	O=C(NC1CC(F)(F)C1)c1nsc2cc(Nc3n[nH]c4cccnc34)ccc12	J Med Chem	2018.0	CHEMBL4588443	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn5c6cccc(F)c6cc5c4n3)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4590062	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)-c3cc5c(F)cccc5n3CN4)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4435877	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ccn5c6cccc(F)c6cc5c4n3)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL3901713	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)-c3cc5c(F)cccc5n3CC4)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL3947779	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1ccc2nc3cc(Cl)ccc3c(Nc3ccc(O)c(CN4CCN(C)CC4)c3)c2c1	J Med Chem	2019.0	CHEMBL463783	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1ccc2nc3cc(Cl)ccc3c(Nc3ccc(O)c(CN4CCN(CCN(C)C)CC4)c3)c2c1	J Med Chem	2019.0	CHEMBL4470176	>	>	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4 preincubated for 5 mins followed by NADPH addition and measured after 30 mins by luminescence based microplate reader analysis	Oc1ccc(-c2ccc(CNCCc3c[nH]c4ncc(F)cc34)o2)cc1	Eur J Med Chem	2020.0	CHEMBL4442855	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of human CYP3A4 preincubated for 5 mins followed by NADPH addition and measured after 30 mins by luminescence based microplate reader analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured for 15 mins by LC-MS/MS analysis	C[C@@H]1O[C@H](C)CN2c3c(cc4c(N5CC6(CC6)OC5=O)noc4c3F)CC3(C(=O)NC(=O)NC3=O)[C@@H]12	J Med Chem	2019.0	CHEMBL4533341	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition and measured for 15 mins by LC-MS/MS analysis	C[C@@H]1O[C@H](C)CN2c3c(cc4c(N5CC6(CC6)OC5=O)noc4c3F)CC3(C(=O)NC(=O)NC3=O)[C@@H]12	J Med Chem	2019.0	CHEMBL4533341	>	>	IC50	nM	25000.0	IC50	uM	25.0
Reversible inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)[C@H](F)CC1	J Med Chem	2019.0	CHEMBL3648680	=	=	IC50	nM	7500.0	IC50	uM	7.5
Reversible inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)CC(F)(F)C1	J Med Chem	2019.0	CHEMBL3623150	=	=	IC50	nM	3800.0	IC50	uM	3.8
Reversible inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)[C@H](F)CC1	J Med Chem	2019.0	CHEMBL3648680	=	=	IC50	nM	6300.0	IC50	uM	6.3
Reversible inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)CC(F)(F)C1	J Med Chem	2019.0	CHEMBL3623150	=	=	IC50	nM	4900.0	IC50	uM	4.9
Time dependent inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)[C@H](F)CC1	J Med Chem	2019.0	CHEMBL3648680	=	=	Ki	nM	1120.0	Ki	uM	1.12
Time dependent inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cn1ncc(NC(=O)c2nc(-c3c(F)cccc3F)sc2N)c1N1CC[C@@H](N)CC(F)(F)C1	J Med Chem	2019.0	CHEMBL3623150	=	=	Ki	nM	1160.0	Ki	uM	1.16
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(O[C@H]2CN(S(=O)(=O)c3ccc(Cl)cn3)C[C@@]2(O)CN)cc1F	J Med Chem	2019.0	CHEMBL4550510	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc(O[C@H]2CN(S(=O)(=O)c3ccc(Cl)cc3Cl)C[C@@]2(O)CN)cc1F	J Med Chem	2019.0	CHEMBL4517101	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 in human liver microsomes using terfenadine as substrate incubated for 15 mins in presence of NADPH by LC/MS/MS analysis	C[C@H]1SC(N)=N[C@](C)(c2cc(NC(=O)c3cnc(OCF)cn3)ccc2F)[C@H]1F	J Med Chem	2019.0	CHEMBL4557670	>=	>=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using terfenadine as substrate incubated for 15 mins in presence of NADPH by fluorescence method	C[C@H]1SC(N)=N[C@](C)(c2cc(NC(=O)c3cnc(OCF)cn3)ccc2F)[C@H]1F	J Med Chem	2019.0	CHEMBL4557670	>=	>=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@@H]1c1ccc(Cl)cc1	J Med Chem	2019.0	CHEMBL4537998	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1	J Med Chem	2019.0	CHEMBL4458424	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate treated prior to substrate addition by LC-MS/MS analysis	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@@H]1c1ccc(Cl)cc1	J Med Chem	2019.0	CHEMBL4537998	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate treated prior to substrate addition by LC-MS/MS analysis	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1	J Med Chem	2019.0	CHEMBL4458424	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1cnc(Nc2ccc(N3CCC(N(C)CCO)CC3)c(F)c2)nc1-c1cnn(C(C)C)c1	J Med Chem	2019.0	CHEMBL4447631	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cc1cnc(Nc2ccc(N3CCC(N(C)CCCO)CC3)c(F)c2)nc1-c1cnn(C(C)C)c1	J Med Chem	2019.0	CHEMBL4560698	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CCCCN(C)C1CCN(c2ccc(Nc3ncc(C)c(-c4cnn(C(C)C)c4)n3)cc2F)CC1	J Med Chem	2019.0	CHEMBL4436572	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	Cc1cnc(Nc2ccc(N3CCC(N(C)CCN4CCN(C)CC4)CC3)c(F)c2)nc1-c1cnn(C(C)C)c1	J Med Chem	2019.0	CHEMBL4461809	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in pooled human liver microsomes pre-incubated for 5 mins before NADPH addition and measured after 10 mins by UPLC-MS/MS analysis relative to control	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	17.0	IC50	uM	0.017
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1	J Med Chem	2019.0	CHEMBL4521594	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#CC3(N)CC3)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL4590564	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CN1CC(C#CC#Cc2cc3n(c2)C(=O)N(CC[C@](C)(C(=O)NO)S(C)(=O)=O)C3)C1	J Med Chem	2020.0	CHEMBL4520045	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#CC3CN(CCF)C3)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL4457739	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#CC3CN(CCO)C3)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL4437135	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#C[C@H]3C[C@@H]3CO)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL4438243	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#C[C@@H]3C[C@@]3(F)CO)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL3754389	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@@](CCN1Cc2cc(C#CC#C[C@H]3C[C@@H]3[C@@H](O)CO)cn2C1=O)(C(=O)NO)S(C)(=O)=O	J Med Chem	2020.0	CHEMBL4456704	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human recombinant CYP3A4 expressed in supersomes assessed as decrease in formation of D-luciferin using luciferin-IPA as substrate incubated for 10 mins in presence of NADPH by P450-Glo luminescence assay	CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C	J Med Chem	2020.0	CHEMBL1159650	=	=	IC50	nM	206.0	IC50	uM	0.206
Inhibition of CYP3A4 in CRISPR/Cas9-mediated CYP3A5 knock-out and doxycycline-induced CYP3A4 overexpressing human AsPC1 cells assessed as decrease in 1-hydroxymidazolam formation using midazolam as substrate pretreated with doxycycline for 24 hrs followed by incubation with compound for 24 hrs by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	117.0	IC50	uM	0.117
Binding affinity to His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli DH5alpha assessed as type 2 spectral shift by measuring dissociation constant by UV-vis spectrophotometric titration analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	Kd	nM	900.0	Kd	uM	0.9
Inhibition of recombinant human CYP3A4 using 7-benzyloxyquinoline fluorescent substrate in presence of NADPH-generating system after 15 mins	O=C(O)CNc1cccc(CN(Cc2ccc(-n3cccn3)cc2)S(=O)(=O)c2cccnc2)n1	J Med Chem	2018.0	CHEMBL3707245	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1	J Med Chem	2018.0	CHEMBL2006299	=	=	IC50	nM	850.0	IC50	uM	0.85
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	CCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1	J Med Chem	2018.0	CHEMBL4454552	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1	J Med Chem	2018.0	CHEMBL4476761	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	O=C(NCc1cccc2c1OCCO2)c1ccc(-c2ccncc2)cc1	J Med Chem	2018.0	CHEMBL4522042	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	CN(C)CCCOc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1	J Med Chem	2018.0	CHEMBL4436040	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3)cc2)c1	J Med Chem	2018.0	CHEMBL4448806	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(N)c3)cc2)c1	J Med Chem	2018.0	CHEMBL4474946	=	=	IC50	nM	11900.0	IC50	uM	11.9
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnc(F)c3)cc2)c1	J Med Chem	2018.0	CHEMBL4459800	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1	J Med Chem	2018.0	CHEMBL4472858	=	=	IC50	nM	6400.0	IC50	uM	6.4
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccncn3)cc2)c1	J Med Chem	2018.0	CHEMBL4460511	=	=	IC50	nM	19600.0	IC50	uM	19.6
Inhibition of C-terminal 4His-tagged CYP3A4 (unknown origin) expressed in Escherichia coli by spectrophotometric analysis	COc1cccc([C@@H](C)NC(=O)c2ccc(-c3ccnnc3)cc2)c1	J Med Chem	2018.0	CHEMBL4584824	=	=	IC50	nM	16700.0	IC50	uM	16.7
Inhibition of human CYP3A4	CC(C)(O)c1cccn2c(C3(c4ccc(Cl)cc4)CC3)nnc12	ACS Med Chem Lett	2018.0	CHEMBL4301600	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1nn(-c2ccccc2)nc1COc1cc(N)nc2[nH]nnc12	ACS Med Chem Lett	2018.0	CHEMBL4586955	=	=	IC50	nM	370.0	IC50	nM	370.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(COc2cc(N)nc3[nH]nnc23)cccc1-c1ccn(C)n1	ACS Med Chem Lett	2018.0	CHEMBL4466985	=	=	IC50	nM	1500.0	IC50	nM	1500.0
Inhibition of CYP3A4 (unknown origin)	Nc1cc(OCc2cc(-c3cccc(F)c3)ccc2Cl)c2nn[nH]c2n1	ACS Med Chem Lett	2018.0	CHEMBL4582838	=	=	IC50	nM	60.0	IC50	nM	60.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)CNC(=O)c1c(O)c2c(n(Cc3ccc(C(F)(F)F)cc3)c1=O)COC2	ACS Med Chem Lett	2018.0	CHEMBL4577928	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	Eur J Med Chem	2019.0	CHEMBL1397	=	=	IC50	nM	150.0	IC50	uM	0.15
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Eur J Med Chem	2019.0	CHEMBL64391	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC[C@@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](C)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	Eur J Med Chem	2019.0	CHEMBL4450683	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC1(c2ccc(Cl)cc2Cl)OCC(COc2ccc(N3CCN(c4ccc(-n5cnn(CCC(=O)O)c5=O)cc4)CC3)cc2)O1	Eur J Med Chem	2019.0	CHEMBL4587117	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	CC(=O)c1cccc(C(=O)Nc2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](C)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1	Eur J Med Chem	2019.0	CHEMBL4540110	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1	J Med Chem	2019.0	CHEMBL4445670	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with compound and measured by LC-MS/MS analysis	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1	J Med Chem	2019.0	CHEMBL4445670	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)C[C@]2(CC[C@H](Nc3cc(Nc4ccc(S(C)(=O)=O)cc4F)ncn3)CC2)CO1	Bioorg Med Chem Lett	2019.0	CHEMBL4591100	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCOc1ccc(-c2ccc(CCCc3nn(-c4ccc(C(F)(F)F)cc4)c(=O)n3-c3ccccc3F)cc2)cc1CC(=O)O	Bioorg Med Chem Lett	2019.0	CHEMBL4449687	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1cc(CNC(=O)c2cncc3c2cnn3-c2ccc(F)cc2)ccn1	Bioorg Med Chem Lett	2019.0	CHEMBL4441094	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1	Bioorg Med Chem Lett	2019.0	CHEMBL4456123	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4464625	=	=	IC50	nM	17000.0	IC50	uM	17.0
Competitive inhibition of CYP3A4 (unknown origin)	CC1=C(c2cccc(O)c2)[C@H](c2ccc(OCCN3CC(CF)C3)cc2)Oc2ccc(O)cc21	ACS Med Chem Lett	2019.0	CHEMBL4447340	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 (unknown origin) using BFC substrate	O=C(N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1(O)CCS(=O)(=O)CC1	J Med Chem	2019.0	CHEMBL4463581	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1ccc(-c2nn(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cnccc23)c(F)c1	ACS Med Chem Lett	2020.0	CHEMBL4456513	=	=	IC50	nM	4800.0	IC50	uM	4.8
Inhibition of human CYP3A4 using sorafenib as substrate by LC/MS/MS analysis	Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1cc(F)c(F)c(F)c1	ACS Med Chem Lett	2020.0	CHEMBL4463663	=	=	IC50	nM	27840.0	IC50	uM	27.84
Inhibition of recombinant CYP3A4 (unknown origin)	N#Cc1cnc2ccc(-c3c(-c4ccc(F)c(Cl)c4)ncn3CCO)nn12	ACS Med Chem Lett	2020.0	CHEMBL4514379	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	NS(=O)(=O)CC(=O)NCCSc1nonc1/C(=N/O)Nc1cccc(Cl)c1	ACS Med Chem Lett	2020.0	CHEMBL4585089	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	NS(=O)(=O)NCC(=O)NCCSc1nonc1/C(=N/O)Nc1ccc(F)c(C(F)F)c1	ACS Med Chem Lett	2020.0	CHEMBL4549976	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1cc(-c2cnc3ccn(CC(=O)N4CCC4)c3c2)ccc1F	ACS Med Chem Lett	2019.0	CHEMBL4443868	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1cc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)ccc1F	ACS Med Chem Lett	2019.0	CHEMBL4302264	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1nnc(Cn2ccc3ncc(-c4ccc(F)c(C)c4)cc32)o1	ACS Med Chem Lett	2019.0	CHEMBL4590530	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3cccc(C(F)(F)F)c3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4571666	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3cccc(C(F)(F)F)n3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4462073	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3cccc(Cl)c3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4451099	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1cccc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)c1	ACS Med Chem Lett	2019.0	CHEMBL4474982	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3ccc(F)c(Cl)c3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4593473	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3ccc(F)c(C(F)F)c3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4547576	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3ccc(F)c(F)c3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4591770	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3ccc(C(F)(F)F)s3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4531750	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1ccc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)s1	ACS Med Chem Lett	2019.0	CHEMBL4575739	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	Cc1csc(-c2cnc3ccn(CC(=O)N(C)C)c3c2)c1	ACS Med Chem Lett	2019.0	CHEMBL4529810	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes	CN(C)C(=O)Cn1ccc2ncc(-c3ccc(Cl)s3)cc21	ACS Med Chem Lett	2019.0	CHEMBL4211247	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)[C@H]1CC[C@H](C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC1	ACS Med Chem Lett	2019.0	CHEMBL3934548	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C#CCOc1cnc(C(=O)Nc2cc(F)c(F)c([C@@]3(C)N=C(N)S[C@@]4(COC)C[C@H]43)c2)cn1	J Med Chem	2020.0	CHEMBL4560579	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition and measured for 10 to 30 mins by LC-MS/MS analysis	C[C@H]1CN(c2cc(F)c3c(c2)N(C)C(=O)C32CCN(c3nc4c(c(=O)[nH]3)CCCN4C)CC2)C[C@@H](C)O1	J Med Chem	2020.0	CHEMBL4449082	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)N1CC[C@@H]([C@H]2c3ccccc3-c3cncn32)[C@H](O)C1	ACS Med Chem Lett	2020.0	CHEMBL4542307	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O[C@@H]1CCOC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4540245	=	=	IC50	nM	650.0	IC50	uM	0.65
Inhibition of CYP3A4 (unknown origin)	O[C@@H]1COCC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4548068	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2cnccc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4447185	=	=	IC50	nM	2400.0	IC50	uM	2.4
Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2ccccc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4577396	=	=	IC50	nM	840.0	IC50	uM	0.84
Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2ccncc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4437257	<	<	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2	ACS Med Chem Lett	2020.0	CHEMBL4520696	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc2c(c1)CC[C@@H]([C@H]1c3ccccc3-c3cncn31)[C@@H]2O	ACS Med Chem Lett	2020.0	CHEMBL4539108	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of CYP3A4 (unknown origin)	CP(C)(=O)c1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2	ACS Med Chem Lett	2020.0	CHEMBL4589215	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 (unknown origin)	N#Cc1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2	ACS Med Chem Lett	2020.0	CHEMBL4541824	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4 (unknown origin)	NC(=O)c1ccc2c(c1)[C@@H](O)[C@H]([C@H]1c3ccccc3-c3cncn31)CC2	ACS Med Chem Lett	2020.0	CHEMBL4544695	=	=	IC50	nM	3600.0	IC50	uM	3.6
Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2nncn2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4529817	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2nonc2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4590789	=	=	IC50	nM	8200.0	IC50	uM	8.2
Inhibition of CYP3A4 (unknown origin)	O[C@@H]1c2ccnn2CC[C@H]1[C@H]1c2ccccc2-c2cncn21	ACS Med Chem Lett	2020.0	CHEMBL4439294	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cn1ncc2c1CC[C@@H]([C@H]1c3ccccc3-c3cncn31)[C@@H]2O	ACS Med Chem Lett	2020.0	CHEMBL4440730	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method	CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)/C(=N\OC/C=C/c2ccc3c(c2)c(=O)c(C(N)=O)cn3CC)[C@H](C)[C@H]2OC(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL4459487	=	=	IC50	nM	5140.0	IC50	uM	5.14
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method	CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC/C=C/c2ccc3c(c2)c(=O)c(C(N)=O)cn3C2CC2)C[C@@H](C)/C(=N\OC)[C@H](C)[C@H]2OC(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL4466824	=	=	IC50	nM	14900.0	IC50	uM	14.9
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method	CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)/C(=N\OCC#Cc2ccc3c(c2)c(=O)c(C(N)=O)cn3CC)[C@H](C)[C@H]2OC(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL4537107	=	=	IC50	nM	7320.0	IC50	uM	7.32
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in metabolite formation using midazolam as substrate incubated for 10 mins in presence of NADPH by HPLC based mass spectrometric method	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL1136	=	=	IC50	nM	11800.0	IC50	uM	11.8
Inhibition of CYP3A4 (unknown origin)	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OCC=Cc2cnc3ccccc3c2)C[C@@H](C)C(=O)[C@H](C)[C@H]2NC(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL3989904	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins after substrate addition by HPLC analysis	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL1136	=	=	IC50	nM	11800.0	IC50	uM	11.8
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins after substrate addition by HPLC analysis	CC[C@H]1OC(=O)[C@H](C)[C@@H](OC(=O)NCCCc2cccnc2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)/C(=N\OC)[C@H](C)[C@H]2OC(=O)O[C@]12C	Eur J Med Chem	2019.0	CHEMBL4474918	=	=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins after substrate addition by HPLC analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4454027	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4570491	=	=	IC50	nM	38000.0	IC50	uM	38.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3ccccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4520100	=	=	IC50	nM	37000.0	IC50	uM	37.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(F)cccc3Cl)c3ccccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4475634	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	Cc1cccc(Cl)c1C(=O)c1cn(-c2ccc(C(=O)O)cc2)c2ccccc12	Bioorg Med Chem Lett	2019.0	CHEMBL4476185	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3c(F)cccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4446695	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cccc(F)c32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4567440	=	=	IC50	nM	16300.0	IC50	uM	16.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4455132	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4578385	=	=	IC50	nM	46000.0	IC50	uM	46.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4454027	=	=	IC50	nM	15500.0	IC50	uM	15.5
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(Cl)c(-c3ccccc3OC(F)(F)F)c(Cl)c2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL3609407	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3ccccc32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4570491	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3ccccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4520100	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3c(F)cccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4446695	=	=	IC50	nM	49000.0	IC50	uM	49.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	Cc1cccc(Cl)c1C(=O)c1cn(-c2ccc(C(=O)O)cc2F)c2ncccc12	Bioorg Med Chem Lett	2019.0	CHEMBL4592447	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cccc(F)c32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4567440	=	=	IC50	nM	13900.0	IC50	uM	13.9
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4455132	=	=	IC50	nM	30800.0	IC50	uM	30.8
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccnc32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4438970	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	Cc1cccc(Cl)c1C(=O)c1cn(-c2ccc(C(=O)O)cc2)c2c(F)cccc12	Bioorg Med Chem Lett	2019.0	CHEMBL4466120	=	=	IC50	nM	27200.0	IC50	uM	27.2
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3c(F)cccc32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4452714	=	=	IC50	nM	8340.0	IC50	uM	8.34
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3c(F)cccc32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4577020	=	=	IC50	nM	16400.0	IC50	uM	16.4
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3C(F)(F)F)c3cccnc32)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4556521	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis	O=C(O)c1ccc(-n2cc(C(=O)c3c(Cl)cccc3Cl)c3cccc(F)c32)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4578385	=	=	IC50	nM	44700.0	IC50	uM	44.7
Inhibition of CYP3A4 (unknown origin)	O=C(NCCCCN1CCN(c2cc(Cl)cc(Cl)c2)CC1)c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4583609	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cccc(N2CCN(CCCCNC(=O)c3ccc(-c4ccsc4)cc3)CC2)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4437341	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay	Cc1cc(-c2ccc3c([C@@H]4C[C@H]5C[C@H]5C[C@H]4C(=O)Nc4cn(C)nc4C(N)=O)noc3c2)n[nH]1	J Med Chem	2019.0	CHEMBL4562028	=	=	IC50	nM	3162.28	pIC50		5.5
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay	Cn1cc(NC(=O)[C@@H]2C[C@@H]3C[C@@H]3C[C@H]2C(=O)c2ccc(-c3cc[nH]n3)cc2)c(C(F)(F)F)n1	J Med Chem	2019.0	CHEMBL4470157	=	=	IC50	nM	3981.07	pIC50		5.4
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay	Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cn(C)nc3C(N)=O)c(F)c2)[nH]n1	J Med Chem	2019.0	CHEMBL4442899	=	=	IC50	nM	6309.57	pIC50		5.2
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay	Cn1cc(NC(=O)[C@@H]2CCCC[C@H]2C(=O)c2ccc(-c3cc[nH]n3)cc2)c(C(F)(F)F)n1	J Med Chem	2019.0	CHEMBL4463314	=	=	IC50	nM	19952.62	pIC50		4.7
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli assessed as maximum reduction in metabolite formation using coumarin based substrate by fluorescence assay	Cc1noc(C)c1NC(=O)[C@@H]1CCCC[C@H]1C(=O)c1ccc(-c2cc[nH]n2)cc1	J Med Chem	2019.0	CHEMBL4472275	=	=	IC50	nM	3981.07	pIC50		5.4
Inhibition of CYP3A4 (unknown origin)	CCn1cnc2c(-c3ccc(F)c(-c4ccc(S(=O)(=O)CC)cc4OC)c3)cnnc21	J Med Chem	2019.0	CHEMBL3647536	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCn1cnc2c(-c3ccc(F)c(-c4cc5c(cc4OC)C(=O)N(C)C5)c3)cnnc21	J Med Chem	2019.0	CHEMBL4545044	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1	J Med Chem	2019.0	CHEMBL3989870	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2019.0	CHEMBL157101	=	=	IC50	nM	182.6	IC50	uM	0.1826
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Eur J Med Chem	2019.0	CHEMBL104	=	=	IC50	nM	67.0	IC50	uM	0.067
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Eur J Med Chem	2019.0	CHEMBL106	=	=	IC50	nM	23969.8	IC50	uM	23.9698
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Eur J Med Chem	2019.0	CHEMBL638	>=	>=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O	Eur J Med Chem	2019.0	CHEMBL1397	=	=	IC50	nM	672.1	IC50	uM	0.6721
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3cncn3)c3ccc(F)cc3F)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4437301	=	=	IC50	nM	1022.3	IC50	uM	1.0223
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(F)cc3F)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4543140	=	=	IC50	nM	1312.3	IC50	uM	1.3123
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3cncn3)c3ccc(Cl)cc3Cl)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4441984	=	=	IC50	nM	351.2	IC50	uM	0.3512
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCN(CC)c1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(Cl)cc3Cl)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4470695	=	=	IC50	nM	127.2	IC50	uM	0.1272
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCC(CC)Oc1ccc2cc(C(=O)NCC(O)(Cn3cncn3)c3ccc(F)cc3F)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4471515	>=	>=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCC(CC)Oc1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(F)cc3F)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4518317	=	=	IC50	nM	332.0	IC50	uM	0.332
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCC(CC)Oc1ccc2cc(C(=O)NCC(O)(Cn3cncn3)c3ccc(Cl)cc3Cl)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4465284	>=	>=	IC50	nM	2500.0	IC50	uM	2.5
Inhibition of recombinant human CYP3A4 using Luciferin-PPXE as substrate preincubated for 10 mins followed by NADPH addition measured after 15 mins by luminometric method	CCC(CC)Oc1ccc2cc(C(=O)NCC(O)(Cn3ccnc3)c3ccc(Cl)cc3Cl)c(=O)oc2c1	Eur J Med Chem	2019.0	CHEMBL4582292	=	=	IC50	nM	251.5	IC50	uM	0.2515
Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL1213603	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](COC)[C@@H](O)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4570378	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](OC)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4577980	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2OC)S1	J Med Chem	2019.0	CHEMBL4519186	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCN(C)C1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4483089	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](C)[C@@H](O)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4110677	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@@H]2[C@@H](O)C[C@@H](CO)O[C@@H]2S1	J Med Chem	2019.0	CHEMBL4520749	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@@H]2C[C@H](O)[C@@H](CO)O[C@@H]2S1	J Med Chem	2019.0	CHEMBL4107048	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CF)[C@@H](O)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4543991	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CO)C(F)[C@@H]2O)S1	J Med Chem	2019.0	CHEMBL4554360	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2F)S1	J Med Chem	2019.0	CHEMBL4448352	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) using midazolam substrate	CC(C)(C)OC(=O)n1c2c(c3ccccc31)C[C@H]1C(=O)N3C[C@@H](CC(=O)O)C[C@H]3[C@@H]2N1C(=O)CC1CCC(F)(F)CC1	J Med Chem	2020.0	CHEMBL4588734	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC(C)(C)OC(=O)n1c2c(c3ccccc31)C[C@H]1C(=O)N3C[C@@H](CC(=O)O)C[C@H]3[C@@H]2N1C(=O)CC1CCC(F)(F)CC1	J Med Chem	2020.0	CHEMBL4588734	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	CCCNC1CN(c2ccnc(N)n2)C1.O.O=C(O)/C=C/C(=O)O	J Med Chem	2019.0	CHEMBL4441731	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	C=CC(=O)N(C)CCOc1c(N)ncnc1-c1cc(F)cc(NC(=O)c2ccc(C3CC3)cc2F)c1C	J Med Chem	2020.0	CHEMBL4483575	>=	>=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) in absence of cofactor	O=C(CCSc1nc2cc(Cl)ccc2o1)N1CCCC1	J Med Chem	2020.0	CHEMBL4566791	<	>	IC50	nM	39810.72	pIC50		4.4
Inhibition of CYP3A4 (unknown origin) in presence of cofactor	O=C(CCSc1nc2cc(Cl)ccc2o1)N1CCCC1	J Med Chem	2020.0	CHEMBL4566791	<	>	IC50	nM	39810.72	pIC50		4.4
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH	Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2sccc12	J Med Chem	2020.0	CHEMBL4526732	=	=	IC50	nM	7950.0	IC50	uM	7.95
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH	Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(S(N)(=O)=O)cc3)CC2)nc2ccsc12	J Med Chem	2020.0	CHEMBL4094163	=	=	IC50	nM	5920.0	IC50	uM	5.92
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH	Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1	J Med Chem	2020.0	CHEMBL175691	=	=	IC50	nM	2170.0	IC50	uM	2.17
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate incubated for 10 mins in presence of NADPH	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	36.6	IC50	uM	0.0366
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4459856	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)c(F)c2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4471614	=	=	IC50	nM	350.0	IC50	uM	0.35
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2F)cn1	ACS Med Chem Lett	2019.0	CHEMBL4445809	=	=	IC50	nM	4570.0	IC50	uM	4.57
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cc1cc(N2CCC(C3c4c(F)cccc4-c4cncn43)CC2)ccc1-c1cnn(C)c1	ACS Med Chem Lett	2019.0	CHEMBL4443301	=	=	IC50	nM	210.0	IC50	uM	0.21
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC([C@H]4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4522927	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4459856	=	=	IC50	nM	6080.0	IC50	uM	6.08
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)c(F)c2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4471614	=	=	IC50	nM	950.0	IC50	uM	0.95
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC(C4c5c(F)cccc5-c5cncn54)CC3)cc2F)cn1	ACS Med Chem Lett	2019.0	CHEMBL4445809	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cc1cc(N2CCC(C3c4c(F)cccc4-c4cncn43)CC2)ccc1-c1cnn(C)c1	ACS Med Chem Lett	2019.0	CHEMBL4443301	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 10 mins in presence of NADPH by UHPLC-MS/MS analysis	Cn1cc(-c2ccc(N3CCC([C@H]4c5c(F)cccc5-c5cncn54)CC3)cc2)cn1	ACS Med Chem Lett	2019.0	CHEMBL4522927	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1	ACS Med Chem Lett	2019.0	CHEMBL3989951	=	=	IC50	nM	2800.0	IC50	uM	2.8
Inhibition of CYP3A4 (unknown origin)	CON=C1CCC(CN2CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)CC1	Eur J Med Chem	2019.0	CHEMBL4475126	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCON=C1CCC(CN2CCN(c3nc(=O)c4cc(C(F)(F)F)cc([N+](=O)[O-])c4s3)CC2)CC1	Eur J Med Chem	2019.0	CHEMBL4571987	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=c1nc(N2CCN(CC3CCCCC3)CC2)sc2c([N+](=O)[O-])cc(C(F)(F)F)cc12	Eur J Med Chem	2019.0	CHEMBL3330226	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc32)c1C	ACS Med Chem Lett	2019.0	CHEMBL3109802	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1ncnc(Cn2cnc3c(C(=O)NCCF)cccc32)c1C	ACS Med Chem Lett	2019.0	CHEMBL4473847	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(C(=O)NCCF)c2ncn(Cc3ncnc(N(C)C)c3C)c2c1	ACS Med Chem Lett	2019.0	CHEMBL4515785	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(Cl)cc1NCC1C(c2ccc(S(N)(=O)=O)cc2)C1(C)C	ACS Med Chem Lett	2019.0	CHEMBL4541269	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1	Eur J Med Chem	2019.0	CHEMBL4436895	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate	COCc1nnc(N2C[C@@H]3C[C@]3(c3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1	ACS Med Chem Lett	2019.0	CHEMBL4591825	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human recombinant CYP3A4 using testosterone as substrate	COCc1nnc(N2C[C@@H]3C[C@]3(c3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1	ACS Med Chem Lett	2019.0	CHEMBL4591825	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CN(c2cnc3c(C#N)nn([C@H](C)c4ccc(Cl)cc4Cl)c3n2)CC[C@@H]1N1CCC[C@H]1CO	J Med Chem	2019.0	CHEMBL4558456	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1CC(c2cnc3c(C#N)nn([C@H](C)c4ccc(Cl)cc4Cl)c3n2)=CC[C@@H]1N1CCC[C@H]1CO	J Med Chem	2019.0	CHEMBL4459231	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2ccccc2-c2cncn21)C1CCCCC1	J Med Chem	2019.0	CHEMBL3629569	=	=	IC50	nM	170.0	IC50	uM	0.17
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(=O)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4566253	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(C1CCCCC1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4461262	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Cc1ccccc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4537319	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Cc1ccc(F)cc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4542242	=	=	IC50	nM	60.0	IC50	uM	0.06
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Cc1ccncc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4559452	=	=	IC50	nM	3800.0	IC50	uM	3.8
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Cc1cncnc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4473619	=	=	IC50	nM	8600.0	IC50	uM	8.6
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(Nc1ccccc1)N1CCC(C(O)CC2c3ccccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4577440	=	=	IC50	nM	510.0	IC50	uM	0.51
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2c(F)cccc2-c2cncn21)C1CCCCC1	J Med Chem	2019.0	CHEMBL3753837	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2c(Cl)cccc2-c2cncn21)C1CCCCC1	J Med Chem	2019.0	CHEMBL4552010	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2cc(Cl)ccc2-c2cncn21)C1CCCCC1	J Med Chem	2019.0	CHEMBL4546052	=	=	IC50	nM	10.0	IC50	uM	0.01
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2ccccc2-c2cncn21)C1CCC(F)(F)CC1	J Med Chem	2019.0	CHEMBL4570289	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC(CC1c2c(F)cccc2-c2cncn21)C1CCC(F)(F)CC1	J Med Chem	2019.0	CHEMBL4576829	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C1CCC(C(O)CC2c3c(F)cccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4543526	=	=	IC50	nM	10900.0	IC50	uM	10.9
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(N[C@H]1CC[C@H](C(O)CC2c3ccccc3-c3cncn32)CC1)c1ccccc1	J Med Chem	2019.0	CHEMBL4450473	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(N[C@H]1CC[C@@H](C(O)CC2c3ccccc3-c3cncn32)CC1)c1ccccc1	J Med Chem	2019.0	CHEMBL4550278	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	OC1CCC(C(O)CC2c3c(F)cccc3-c3cncn32)CC1	J Med Chem	2019.0	CHEMBL4517185	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@@H](O)CC1	J Med Chem	2019.0	CHEMBL4530496	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O[C@@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1	J Med Chem	2019.0	CHEMBL4446572	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1	J Med Chem	2019.0	CHEMBL3989951	=	=	IC50	nM	5700.0	IC50	uM	5.7
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	O[C@H](C[C@H]1c2c(F)cccc2-c2cncn21)[C@H]1CC[C@H](O)CC1	J Med Chem	2019.0	CHEMBL3989951	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)S(=O)(=O)c1cc2c(Nc3ccc4scnc4c3)ncnc2cc1OCCOP(=O)(O)O.[CaH2]	J Med Chem	2019.0	CHEMBL4516875	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using beetle D-luciferin as substrate by CYP450-Glo assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	MedChemComm	2018.0	CHEMBL75	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of CYP3A4 (unknown origin) using beetle D-luciferin as substrate by CYP450-Glo assay	Cn1cncc1-c1c[nH]c2ccc(C(N)=O)cc12	MedChemComm	2018.0	CHEMBL4474827	=	=	IC50	nM	3530.0	IC50	uM	3.53
Inhibition of CYP3A4 (unknown origin) using beetle D-luciferin as substrate by CYP450-Glo assay	CCn1cncc1-c1c[nH]c2ccc(C(N)=O)cc12	MedChemComm	2018.0	CHEMBL4469847	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 20 mins followed by substrate addition and measured after 5 mins by LC-MS/MS analysis	C[C@H]1CN(c2n[nH]c3nc(N[C@H]4CC[C@H](NS(=O)(=O)CCC(F)(F)F)CC4)ncc23)CCO1	J Med Chem	2019.0	CHEMBL4563818	<	>	IC50	nM	39810.72	pIC50		4.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 20 mins followed by substrate addition and measured after 5 mins by LC-MS/MS analysis	COc1ccccc1-c1n[nH]c2nc(N[C@H]3CC[C@H](NS(=O)(=O)CCC(F)(F)F)CC3)nc(OC)c12	J Med Chem	2019.0	CHEMBL4516798	=	=	IC50	nM	6309.57	pIC50		5.2
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 20 mins followed by substrate addition and measured after 5 mins by LC-MS/MS analysis	COc1nc(N[C@H]2CC[C@H](NS(=O)(=O)CCC(C)C)CC2)nc2[nH]nc(N3CCOC[C@H]3C)c12	J Med Chem	2019.0	CHEMBL4572962	<	>	IC50	nM	39810.72	pIC50		4.4
Inhibition of human CYP3A4 using midazolam as substrate	O[C@@H]1[C@H](O)[C@@H]2C[C@@H]2[C@H]1n1cnc2c(NC(C3CC3)C3CC3)nc(Cl)nc21	J Med Chem	2019.0	CHEMBL2012686	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH	Cc1cc(C#N)cc(C)c1Oc1nc(NC2CCN(Cc3ccc(C(N)=O)cc3)CC2)nc2c1COC2	J Med Chem	2019.0	CHEMBL4514678	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	36.6	IC50	uM	0.0366
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 2 mins by LC-MS/MS analysis	Cl.Cl.O=C(CN1CCOCC1)Nc1ccc(OC2CCN(C3CCC3)CC2)cc1	J Med Chem	2019.0	CHEMBL4593911	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes	C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2c(F)cc(/C=C/C(=O)O)cc2F)N1CC(C)(C)F	J Med Chem	2019.0	CHEMBL4448852	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes	C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2c(F)cc(/C=C/C(=O)O)cc2F)N1CC(C)(F)F	J Med Chem	2019.0	CHEMBL4436187	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 3 mins in presence of NADP by LC-MS/MS analysis	Cc1cc(/C=C/C#N)cc(C)c1Oc1ccnc(Nc2ccc(CN3CCN(S(C)(=O)=O)CC3)cc2)n1	J Med Chem	2019.0	CHEMBL4453186	=	=	IC50	nM	20500.0	IC50	uM	20.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 3 mins in presence of NADP by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	18.3	IC50	uM	0.0183
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by LC-MS/MS analysis	Cc1cc(/C=C/C#N)cc(C)c1Oc1ccnc(Nc2ccc(CN3CCN(S(C)(=O)=O)CC3)cc2)n1	J Med Chem	2019.0	CHEMBL4453186	=	=	IC50	nM	7820.0	IC50	uM	7.82
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 10 mins in presence of NADP by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	56.3	IC50	uM	0.0563
Inhibition of CYP3A4 (unknown origin)	OCc1cccc(-c2ccc3nc(-c4ccc(Cl)cc4)cn3c2)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4576867	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccccc1)c1cn2cc(-c3ccccn3)ccc2n1	Bioorg Med Chem Lett	2019.0	CHEMBL4472621	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4 preincubated for 10 mins followed by NADPH addition and measured after 10 to 30 mins by P450-Glo luminescence assay	OC[C@H]1CC[C@H](c2ccc(O)cc2)CC1	J Med Chem	2018.0	CHEMBL4526434	=	=	EC50	nM	89000.0	EC50	uM	89.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	O=C(NC1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1)c1cccnc1	Bioorg Med Chem Lett	2019.0	CHEMBL4593464	=	=	IC50	nM	0.4	IC50	nM	0.4
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Nc1ccc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	Bioorg Med Chem Lett	2019.0	CHEMBL4557596	>	>	IC50	nM	12.5	IC50	nM	12.5
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Cc1cc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cnc1N	Bioorg Med Chem Lett	2019.0	CHEMBL4474161	>	>	IC50	nM	12.5	IC50	nM	12.5
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Nc1ncc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	Bioorg Med Chem Lett	2019.0	CHEMBL4438972	>	>	IC50	nM	12.5	IC50	nM	12.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	O=C(NC1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1)c1cccnc1	Bioorg Med Chem Lett	2019.0	CHEMBL4593464	=	=	IC50	nM	2.4	IC50	nM	2.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Nc1ccc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	Bioorg Med Chem Lett	2019.0	CHEMBL4557596	>	>	IC50	nM	12.5	IC50	nM	12.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Cc1cc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cnc1N	Bioorg Med Chem Lett	2019.0	CHEMBL4474161	>	>	IC50	nM	12.5	IC50	nM	12.5
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH cofactor addition and measured after 10 mins by LC-MS/MS analysis	Nc1ncc(C(=O)NC2CCC(=Cc3cccc(Oc4ccc(C(F)(F)F)cn4)c3)CC2)cn1	Bioorg Med Chem Lett	2019.0	CHEMBL4438972	>	>	IC50	nM	12.5	IC50	nM	12.5
Inhibition of human CYP3A4 using atorvastatin as substrate	COCCN1CCN(c2ccc(OCc3ccccc3)c(C(=O)Nc3ccnnc3)c2)CC1	Bioorg Med Chem Lett	2019.0	CHEMBL4448579	=	=	IC50	nM	10000.0	pIC50		5.0
Inhibition of human CYP3A4 using atorvastatin as substrate	O=C(Nc1ccnnc1)c1cc(N2CCOCC2)ccc1OCc1ccccc1	Bioorg Med Chem Lett	2019.0	CHEMBL4457647	=	=	IC50	nM	6309.57	pIC50		5.2
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Nc1ncnc2c(C(=O)Nc3cccc4c3c(Br)nn4Cc3cccnc3)csc12	Bioorg Med Chem Lett	2019.0	CHEMBL4455896	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Cc1cccc(Cn2nc(C)c3c(NC(=O)c4csc5c(N)ncnc45)cccc32)n1	Bioorg Med Chem Lett	2019.0	CHEMBL4483816	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)COc1ncc(-c2cn(C)c3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl	J Med Chem	2019.0	CHEMBL4279180	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human liver microsomes	CC(C)COc1ccc(-c2cn(C)c3cc(C(=O)NS(C)(=O)=O)c(F)cc23)cn1	J Med Chem	2019.0	CHEMBL4550045	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of human CYP3A4	CCc1sc2ncnc(N[C@H](Cc3ccccc3)C(=O)O)c2c1-c1ccc(OCCN2CCN(C)CC2)c(Cl)c1C	J Med Chem	2019.0	CHEMBL4451346	=	=	IC50	nM	5200.0	IC50	uM	5.2
Inhibition of CYP3A4 (unknown origin)	[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC	J Med Chem	2019.0	CHEMBL4435170	>	>	IC50	nM	40000.0	IC50	uM	40.0
Induction of CYP3A4 (unknown origin) by PXR-transactivation assay	[2H]C([2H])([2H])NC(=O)c1nnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncn(C)n2)c1OC	J Med Chem	2019.0	CHEMBL4435170	>	>	EC50	nM	40000.0	EC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN	J Med Chem	2019.0	CHEMBL2058833	=	=	Ki	nM	156.0	Ki	nM	156.0
Inhibition of CYP3A4 (unknown origin)	Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1	J Med Chem	2019.0	CHEMBL303933	=	=	Ki	nM	90.0	Ki	nM	90.0
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using coumarin based substrate by fluorescence assay	COc1cc(N(CC2CC2)c2ccc(Cl)c3ccccc23)cnc1C(=O)[C@H]1C[C@@H]1C(=O)O	J Med Chem	2019.0	CHEMBL4454609	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using coumarin based substrate by fluorescence assay	COc1nc(N(CC(C)(C)F)c2cc(Cl)c(F)cc2F)cnc1C(=O)[C@H]1C[C@@H]1C(=O)O	J Med Chem	2019.0	CHEMBL3961833	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human CYP3A4	C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	J Med Chem	2020.0	CHEMBL1294	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(CC[C@@H](OC(=O)[C@@H]2CCCCN2C(=O)[C@@H]2CCC[C@@H]3CCCC[C@H]32)c2cccc(OCC(=O)O)c2)cc1OC	J Med Chem	2020.0	CHEMBL4454363	=	=	IC50	nM	8400.0	IC50	uM	8.4
Inhibition of CYP3A4 (unknown origin)	COc1ccc(CC[C@@H](OC(=O)[C@@H]2CCCCN2C(=O)[C@H](c2cc(OC)c(OC)c(OC)c2)C2CCCCC2)c2cccc(OCN3CCOCC3)c2)cc1OC	J Med Chem	2020.0	CHEMBL4560373	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1	J Med Chem	2020.0	CHEMBL4537673	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) measured under preincubated conditions	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1	J Med Chem	2020.0	CHEMBL4537673	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)Oc1cc(-c2cccnc2)ccc1C(N)=O	J Med Chem	2020.0	CHEMBL4450463	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(C)Oc1cc(-c2cncc(-c3cnn(C4COC4)c3)c2)ccc1C(N)=O	J Med Chem	2020.0	CHEMBL4587832	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1[nH]ncc1-c1cncc(-c2ccc(C(N)=O)c(OC(C)C)c2)c1	J Med Chem	2020.0	CHEMBL4569209	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2cncc(-c3ccc(C(N)=O)c(OC(C)C)c3)c2)cnn1C	J Med Chem	2020.0	CHEMBL4440223	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate in presence of NADPH incubated for 10 mins	Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)c(F)c2)nc2ccsc12	J Med Chem	2020.0	CHEMBL4442726	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate in presence of NADPH incubated for 10 mins	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	37.5	IC50	uM	0.0375
Inhibition of CYP3A4 in human liver microsomes	Cc1c(O)c(O)cc[n+]1[C@@H](CO)Cc1ccccc1.[Cl-]	J Med Chem	2020.0	CHEMBL4467408	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins by LC-MS/MS analysis	O=c1cc(N2CCN(CC3CCCCC3)CC2)sc2c([N+](=O)[O-])cc(C(F)(F)F)cc12	Eur J Med Chem	2018.0	CHEMBL4586075	>	>	IC50	nM	50000.0	IC50	uM	50.0
Reversible inhibition of CYP3A4 (unknown origin) in presence of NADPH by vivid red substrate-based assay	N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cc3)[C@](O)(CN)C2)c(Cl)c1	J Med Chem	2018.0	CHEMBL4456312	=	=	IC50	nM	100.0	IC50	uM	0.1
Reversible inhibition of CYP3A4 (unknown origin) in presence of NADPH by vivid red substrate-based assay	N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cn3)[C@](O)(CN)C2)c(Cl)c1	J Med Chem	2018.0	CHEMBL4547537	=	=	IC50	nM	300.0	IC50	uM	0.3
Reversible inhibition of CYP3A4 (unknown origin) in presence of NADPH by vivid red substrate-based assay	N#Cc1ccc(S(=O)(=O)N2C[C@H](S(=O)(=O)c3ccc(Cl)cn3)[C@@](O)(CN)C2)c(Cl)c1	J Med Chem	2018.0	CHEMBL4461475	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of CYP3A4 in human liver microsomes using [14C]-erythromycin as substrate preincubated for 2 mins in presence of NADPH followed by substrate addition and measured after 5 mins by liquid scintillation counting method	C[C@@H](Nc1nc2c(cnn2C2CCCC2)c(=O)[nH]1)C(=O)N1CC[C@H](F)C1	J Med Chem	2019.0	CHEMBL4580164	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COc1ccc2nc(N)sc2c1	J Med Chem	2019.0	CHEMBL97797	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(OC(F)(F)F)cc2s1	J Med Chem	2019.0	CHEMBL744	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(OCc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL2386433	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(OCc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4465714	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	N#Cc1ccc(COc2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4468228	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)c1ccc(COc2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4540341	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)C1CCN(C(=O)c2ccc(COc3ccc4nc(N)sc4c3)cc2)CC1	J Med Chem	2019.0	CHEMBL4566383	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	CSc1ccc2nc(N)sc2c1	J Med Chem	2019.0	CHEMBL4592124	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(SC(F)(F)F)cc2s1	J Med Chem	2019.0	CHEMBL95463	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(SCc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4475811	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(SCc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4439011	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	N#Cc1ccc(CSc2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4564287	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)c1ccc(CSc2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4577695	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)C1CCN(C(=O)c2ccc(CSc3ccc4nc(N)sc4c3)cc2)CC1	J Med Chem	2019.0	CHEMBL4441552	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(SCc3ccc(C(=O)NCc4ccccc4)cc3)cc2s1	J Med Chem	2019.0	CHEMBL4562350	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	CS(=O)(=O)c1ccc2nc(N)sc2c1	J Med Chem	2019.0	CHEMBL432942	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(S(=O)(=O)Cc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4440584	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(S(=O)(=O)Cc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4581441	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	N#Cc1ccc(CS(=O)(=O)c2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4464690	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)c1ccc(CS(=O)(=O)c2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4446494	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)C1CCN(C(=O)c2ccc(CS(=O)(=O)c3ccc4nc(N)sc4c3)cc2)CC1	J Med Chem	2019.0	CHEMBL4476655	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4469761	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4458858	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	N#Cc1ccc(CNC(=O)c2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4561783	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)c1ccc(CNC(=O)c2ccc3nc(N)sc3c2)cc1	J Med Chem	2019.0	CHEMBL4579215	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)C1CCN(C(=O)c2ccc(CNC(=O)c3ccc4nc(N)sc4c3)cc2)CC1	J Med Chem	2019.0	CHEMBL4452155	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCc3ccc(C(=O)NCc4ccccc4)cc3)cc2s1	J Med Chem	2019.0	CHEMBL4581650	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COc1cc(CNC(=O)c2ccc3nc(N)sc3c2)cc(OC)c1OC	J Med Chem	2019.0	CHEMBL4554726	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCc3ccccc3[N+](=O)[O-])cc2s1	J Med Chem	2019.0	CHEMBL4582026	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCc3ccccc3N)cc2s1	J Med Chem	2019.0	CHEMBL4460492	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NC(c3ccccc3)c3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4435791	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COC(=O)C1CCN(C(=O)c2ccc3nc(N)sc3c2)CC1	J Med Chem	2019.0	CHEMBL4545398	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCCc3cccs3)cc2s1	J Med Chem	2019.0	CHEMBL4554707	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)NCCc3c[nH]c4ccccc34)cc2s1	J Med Chem	2019.0	CHEMBL4528355	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)N(Cc3ccccc3)Cc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4444333	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2ccc(C(=O)N(CCO)Cc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4452773	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	COc1ccc(CN(Cc2ccc(Cl)c(Cl)c2)C(=O)c2ccc3nc(N)sc3c2)cc1OC	J Med Chem	2019.0	CHEMBL4462566	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2c(O)cc(C(=O)NCc3ccccc3)cc2s1	J Med Chem	2019.0	CHEMBL4552119	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2c(O)cc(C(=O)NCc3ccc(Cl)c(Cl)c3)cc2s1	J Med Chem	2019.0	CHEMBL4549839	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2c(C(=O)N(Cc3ccccc3)Cc3ccc(Cl)c(Cl)c3)cc(O)c(O)c2s1	J Med Chem	2019.0	CHEMBL4583705	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2c(C(=O)NCc3ccc(Cl)c(Cl)c3)cc(O)c(O)c2s1	J Med Chem	2019.0	CHEMBL4453795	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	Nc1nc2c(C(=O)NCc3ccccc3)cc(O)c(O)c2s1	J Med Chem	2019.0	CHEMBL4456198	<	<	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4 expressed in baculovirus infected insect cells using beetle D-luciferin as substrate preincubated for 30 mins followed by NADPH addition and measured after 30 mins by CYP450-Glo assay	N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1	J Med Chem	2019.0	CHEMBL55	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)CC1CCSS1	Bioorg Med Chem Lett	2019.0	CHEMBL4457447	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) using midazolam	COc1c(C#N)ccc2[nH]c(-c3cn4c(n3)[C@H](c3cccc(F)c3C)OCC4)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4451760	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1	Bioorg Med Chem	2019.0	CHEMBL4555459	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1	Bioorg Med Chem	2019.0	CHEMBL4564973	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	CC[C@]1(C(=O)N2CC[C@](c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3)(S(=O)(=O)c3ccc(F)cc3)C2)CC[C@H](C(=O)O)CC1	Bioorg Med Chem Lett	2019.0	CHEMBL3965066	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)C12CCC(C(=O)N3CC[C@](c4ccc(C(F)(C(F)(F)F)C(F)(F)F)cc4)(S(=O)(=O)c4ccc(F)cc4)C3)(CC1)CC2	Bioorg Med Chem Lett	2019.0	CHEMBL3964587	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H](O[C@H]1CC[C@]2(CCC(F)(F)CO2)CC1)c1nc(-c2cc(F)c(CS(C)(=O)=O)c(F)c2)no1	Bioorg Med Chem Lett	2019.0	CHEMBL4548931	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(Cc3ccc(B(O)O)c(F)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL3121193	=	=	IC50	nM	7100.0	IC50	uM	7.1
Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3ncnc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4451904	=	=	IC50	nM	8900.0	IC50	uM	8.9
Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3nccc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4439082	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4528447	=	=	IC50	nM	4200.0	IC50	uM	4.2
Inhibition of CYP3A4 in human liver microsomes using atorvastatin as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3cc(Cl)c4c(c3)COB4O)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4467259	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(Cc3ccc(B(O)O)c(F)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL3121193	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3ncnc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4451904	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3nccc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4439082	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4528447	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3cc(Cl)c4c(c3)COB4O)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4467259	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(Cc3ccc(B(O)O)c(F)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL3121193	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3ncnc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4451904	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(-n3nccc3-c3ccc(B(O)O)c(F)c3)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4439082	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3ccc(B(O)O)c(Cl)c3)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4528447	=	=	IC50	nM	8100.0	IC50	uM	8.1
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate preincubated for 7 mins followed by NADPH addition and measured by LC-MS/MS analysis	CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(c3cc(Cl)c4c(c3)COB4O)S(C)(=O)=O)c(C3CC3)cc12	J Med Chem	2019.0	CHEMBL4467259	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using BFC as substrate by fluorescence assay	Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cnn(C)c3C(=O)NOC(C)(C)C)cc2)[nH]n1	J Med Chem	2019.0	CHEMBL4563459	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using BFC as substrate by fluorescence assay	Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cnn(C)c3S(N)(=O)=O)cc2)n[nH]1	J Med Chem	2019.0	CHEMBL4474619	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using BFC as substrate by fluorescence assay	Cc1cc(-c2ccc(C(=O)[C@@H]3CCCC[C@H]3C(=O)Nc3cnn4c3C(=O)NCC4)cc2)n[nH]1	J Med Chem	2019.0	CHEMBL4542281	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 measured after 30 mins in presence of NADPH regeneration system by luminescent CYP3A4 P450-Glo assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	140.0	IC50	uM	0.14
Inhibition of human CYP3A4 measured after 30 mins in presence of NADPH regeneration system by luminescent CYP3A4 P450-Glo assay	CCn1cncc1-c1c[nH]c2ccc(I)c(F)c12	Eur J Med Chem	2019.0	CHEMBL4452569	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin) by fluorescence-based assay	CCc1cc(Cc2ccc(CC(N)=O)cc2)nc(-c2cccc(Cl)c2)n1	J Med Chem	2019.0	CHEMBL4573171	=	=	IC50	nM	5900.0	IC50	uM	5.9
Inhibition of CYP3A4 (unknown origin) by fluorescence-based assay	O=C(O)Cc1ccc(Cc2cc(-c3cccc(Cl)c3)nc(C(F)(F)F)c2)cc1	J Med Chem	2019.0	CHEMBL4541964	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin) by fluorescence-based assay	CCc1cc(Cc2ccc(CC(=O)NCCO)cc2)nc(-c2cccc(Cl)c2)n1	J Med Chem	2019.0	CHEMBL4593524	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 (unknown origin)	C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCCC2)ccc1C	J Med Chem	2019.0	CHEMBL4465111	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCCCC2)ccc1C	J Med Chem	2019.0	CHEMBL4540948	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C=CC(=O)Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3OC)ccc2N2CCOCC2)ccc1C	J Med Chem	2019.0	CHEMBL4464752	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	N#CC(C(=O)NCC(=O)NC1COC1)c1nc2ccc(-c3ccc(F)nc3)cc2s1	Bioorg Med Chem Lett	2019.0	CHEMBL4446981	>	>	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(C(=O)c2ccc(-c3ccc4nc(C(C#N)C(=O)NCC(=O)NC5CC5)sc4c3)cc2)CC1	Bioorg Med Chem Lett	2019.0	CHEMBL4438345	>	>	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1cccc(-c2ccc3nc(C(C#N)C(=O)NCC(=O)NC4CC4)sc3c2)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4557424	>	>	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin)	N#CC(C(=O)NCC(=O)NC1CC1)c1nc2ccc(-c3ccc(C(=O)N4CCOCC4)cc3)cc2s1	Bioorg Med Chem Lett	2019.0	CHEMBL4545633	>	>	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin)	N#CC(C(=O)NCC(=O)NC1CC1)c1nc2ccc(-c3ccccc3)cc2s1	Bioorg Med Chem Lett	2019.0	CHEMBL4587475	>	>	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1cc(C(F)(F)F)ccc1-c1cc2cnn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)c2cc1C	Bioorg Med Chem Lett	2019.0	CHEMBL4513792	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1cc(C(F)(F)F)ccc1-c1cc2cn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)nc2cc1C	Bioorg Med Chem Lett	2019.0	CHEMBL4589676	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1cc2c(cnn2[C@@H](CC(C)C)c2ccc(C(=O)NCCC(=O)O)cc2)cc1-c1ccc(C(F)(F)F)cc1Cl	Bioorg Med Chem Lett	2019.0	CHEMBL4468579	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	Cc1c(-c2ccc(C(F)(F)F)cc2Cl)ccc2nn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4582082	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(C(F)(F)F)ccc1-c1cc2cnn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)c2cc1C	Bioorg Med Chem Lett	2019.0	CHEMBL4513792	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(C(F)(F)F)ccc1-c1cc2cn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)nc2cc1C	Bioorg Med Chem Lett	2019.0	CHEMBL4589676	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc2c(cnn2[C@@H](CC(C)C)c2ccc(C(=O)NCCC(=O)O)cc2)cc1-c1ccc(C(F)(F)F)cc1Cl	Bioorg Med Chem Lett	2019.0	CHEMBL4468579	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1c(-c2ccc(C(F)(F)F)cc2Cl)ccc2nn([C@@H](CC(C)C)c3ccc(C(=O)NCCC(=O)O)cc3)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4582082	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccncc1)c1cn(Cc2ccc(Cl)c(Cl)c2)c(=O)c2cnn(C3CCNCC3)c12	Bioorg Med Chem Lett	2019.0	CHEMBL4452711	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS/MS analysis	Cc1ccc(C)c2oc(-c3nc(-c4ccc(C(=O)O)cc4)no3)cc12	Bioorg Med Chem Lett	2019.0	CHEMBL4459692	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1ccc(N(Cc2ccc(O)cc2)C(=O)c2ccc(O)cc2O)cc1	J Med Chem	2019.0	CHEMBL4540811	=	=	IC50	nM	6470.0	IC50	uM	6.47
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1ccc(N(Cc2ccc(Br)o2)C(=O)c2ccc(O)cc2O)cc1	J Med Chem	2019.0	CHEMBL4575355	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)c1ccc(N(Cc2cc(Br)cs2)C(=O)c2ccc(O)cc2O)cc1	J Med Chem	2019.0	CHEMBL4591977	<	<	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4	CC(C)(C)N1CCC(NC(=O)c2ccc(C(F)(F)F)cc2Cl)CC1	J Med Chem	2020.0	CHEMBL4435674	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of human CYP3A4	COc1c(OCCCCCCC(=O)O)cc2oc3cc4c(c(O)c3c(=O)c2c1CC=C(C)C)C=CC(C)(C)O4	J Med Chem	2020.0	CHEMBL4471352	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis	CCS(=O)(=O)Cc1cnc(Oc2ccc(F)cc2F)c(-c2cc(C)c3c(=O)[nH]ccn23)c1	J Med Chem	2020.0	CHEMBL4440098	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis	CCS(=O)(=O)Cc1cnc(Oc2ccc(F)cc2F)c(-c2cc(C)c3c(=O)[nH]ccn23)c1	J Med Chem	2020.0	CHEMBL4440098	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2cc(F)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)cc1	J Med Chem	2020.0	CHEMBL4438144	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)cc1	J Med Chem	2020.0	CHEMBL4467828	=	=	IC50	nM	19700.0	IC50	uM	19.7
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2ccc3nnn(-c4ccc5cn[nH]c5c4)c3c2)nc1	J Med Chem	2020.0	CHEMBL4581829	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	Nc1nn(-c2ccc3cn[nH]c3c2)c2cc(-c3ccnn3Cc3ccc(Cl)cc3Cl)cnc12	J Med Chem	2020.0	CHEMBL4527606	=	=	IC50	nM	4200.0	IC50	uM	4.2
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	Clc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5cn[nH]c5c4)c3c2)nc1	J Med Chem	2020.0	CHEMBL4454039	=	=	IC50	nM	35500.0	IC50	uM	35.5
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2cc(F)c3nnn(-c4ccc5[nH]c(=O)[nH]c5c4)c3c2)cc1	J Med Chem	2020.0	CHEMBL4516795	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2cc3c(cn2)nnn3-c2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1	J Med Chem	2020.0	CHEMBL4454426	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	O=c1[nH]c2ccc(-n3nnc4cnc(-c5ccnn5Cc5ccc(Cl)cc5Cl)cc43)cc2[nH]1	J Med Chem	2020.0	CHEMBL4527142	=	=	IC50	nM	4200.0	IC50	uM	4.2
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	O=c1[nH]c2ccc(-n3nnc4c(Cl)cc(-c5ccnn5Cc5ccc(Cl)cn5)cc43)cc2[nH]1	J Med Chem	2020.0	CHEMBL4522718	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 5 to 20 mins by LC-MS/MS analysis	N#Cc1ccc(Cn2nccc2-c2cc(Cl)c3nnn(-c4ccc5[nH]c(=O)[nH]c5c4)c3c2)nc1	J Med Chem	2020.0	CHEMBL4456158	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1cc(CCNc2nc(C#Cc3ccccc3)nc3c2ncn3[C@H]2[C@H](O)[C@H](O)[C@@H]3C[C@@H]32)ccc1O	J Med Chem	2020.0	CHEMBL4571380	=	=	IC50	nM	2230.0	IC50	uM	2.23
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 40 mins in presence of NADPH by LC-MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCN(C)CC4)cc3)c2C)cc(F)c1C(N)=O	J Med Chem	2020.0	CHEMBL4575655	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 40 mins in presence of NADPH by LC-MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCN(C(C)C)CC4)cc3)c2C)cc(F)c1C(N)=O	J Med Chem	2020.0	CHEMBL4548795	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 40 mins in presence of NADPH by LC-MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4C[C@H](C)N(C)[C@H](C)C4)cc3)c2C)cc(F)c1C(N)=O	J Med Chem	2020.0	CHEMBL4434717	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1	J Med Chem	2019.0	CHEMBL4163069	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C	J Med Chem	2019.0	CHEMBL4571052	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C	J Med Chem	2019.0	CHEMBL1276308	=	=	IC50	nM	9500.0	IC50	uM	9.5
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	CCC(=O)N[C@@H](C)c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4541056	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)[C@@H]1CCCN1C)c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4439536	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)C1CCOCC1)c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4540185	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1ncccn1)c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4552727	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1cccc(F)c1)c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4444464	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@@H](c1ccc(NC(=O)N2CC(c3cncc(N)c3)C2)cc1)N1Cc2ccccc2C1=O	ACS Med Chem Lett	2019.0	CHEMBL4469631	=	=	IC50	nM	4690.0	IC50	uM	4.69
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	CCC(=O)N[C@@H](C)c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4571655	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)[C@@H]1CCCN1C)c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4457730	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)C1CCOCC1)c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4441045	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1ncccn1)c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4575553	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1cccc(F)c1)c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4561577	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@@H](c1ccc(NC(=O)N2CC(c3ccc(N)nc3)C2)cc1)N1Cc2ccccc2C1=O	ACS Med Chem Lett	2019.0	CHEMBL4556614	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	CCC(=O)N[C@@H](C)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4451769	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)[C@@H]1CCCN1C)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4456070	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)C1CCOCC1)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4586676	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1ncccn1)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4532502	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](NC(=O)c1cccc(F)c1)c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4448916	=	=	IC50	nM	3110.0	IC50	uM	3.11
Inhibition of human recombinant CYP3A4 using midazolam as substrate incubated for 40 to 130 mins in presence of NADPH by LC-MS/MS analysis	C[C@@H](c1ccc(NC(=O)N2CC(c3cccnc3)C2)cc1)N1Cc2ccccc2C1=O	ACS Med Chem Lett	2019.0	CHEMBL4483695	=	=	IC50	nM	3040.0	IC50	uM	3.04
Inhibition of CYP3A4 in liver microsomes (unknown origin) using ketoconazole as substrate preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis	Cc1cc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccccc2)ccc1-c1cnc(NC2CC2)c2nccn12	Eur J Med Chem	2019.0	CHEMBL4586372	=	=	IC50	nM	3520.0	IC50	uM	3.52
Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	Clc1ccc(-c2cc(C(c3ccc(Cl)cc3)n3ccnc3)c[nH]2)cc1	J Med Chem	2019.0	CHEMBL4468270	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	Cn1cc(C(c2ccc(Cl)cc2)n2ccnc2)cc1-c1ccc(Cl)cc1	J Med Chem	2019.0	CHEMBL4569370	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	C=CCn1cc(C(c2ccc(Cl)cc2)n2ccnc2)cc1-c1ccc(Cl)cc1	J Med Chem	2019.0	CHEMBL4551139	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	Clc1ccc(-n2ccc(C(c3ccc(Cl)cc3Cl)n3ccnc3)c2)cc1	J Med Chem	2019.0	CHEMBL4438726	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	Clc1ccc(-c2c[nH]cc2C(c2ccc(Cl)cc2Cl)n2ccnc2)cc1	J Med Chem	2019.0	CHEMBL315874	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of human CYP3A4 in presence of NADPH by luciferase reporter gene assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	400.0	IC50	uM	0.4
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)N(C)C(C)c3ccccc3)CC2)n1	J Med Chem	2019.0	CHEMBL4548820	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCN(C(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1)C(C)C	J Med Chem	2019.0	CHEMBL4451661	=	=	IC50	nM	15400.0	IC50	uM	15.4
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#C/C=C2\CCN(C(=O)N(C)C(C)C)C2)n1	J Med Chem	2019.0	CHEMBL4464022	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCN(C(=O)N1CC/C(=C\C#Cc2cccc(C)n2)C1)C(C)C	J Med Chem	2019.0	CHEMBL4441964	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCCC(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4590911	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)c3ccccc3)CC2)n1	J Med Chem	2019.0	CHEMBL4483689	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	COc1ccccc1C(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4568857	=	=	IC50	nM	13800.0	IC50	uM	13.8
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	COc1cccc(C(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)c1	J Med Chem	2019.0	CHEMBL4567923	=	=	IC50	nM	4600.0	IC50	uM	4.6
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)c1	J Med Chem	2019.0	CHEMBL4460573	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)c3cccc(F)c3)CC2)n1	J Med Chem	2019.0	CHEMBL4456792	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)c3cccc(Cl)c3)CC2)n1	J Med Chem	2019.0	CHEMBL4535926	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	O=C(c1cccc(Cl)c1)N1CCC(=CC#Cc2cccc(Cl)n2)CC1	J Med Chem	2019.0	CHEMBL4455843	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#C/C=C2\CCN(C(=O)c3cccc(Cl)c3)C2)n1	J Med Chem	2019.0	CHEMBL4448788	=	=	IC50	nM	12900.0	IC50	uM	12.9
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#C/C=C2\CCN(C(=O)c3ccco3)C2)n1	J Med Chem	2019.0	CHEMBL4542890	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCS(=O)(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4453683	=	=	IC50	nM	17200.0	IC50	uM	17.2
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(S(=O)(=O)c3cccc(Br)c3)CC2)n1	J Med Chem	2019.0	CHEMBL4520868	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1ccc(S(=O)(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)cc1	J Med Chem	2019.0	CHEMBL4452522	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	COc1ccc(S(=O)(=O)N2CCC(=CC#Cc3cccc(C)n3)CC2)cc1	J Med Chem	2019.0	CHEMBL4592284	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(S(=O)(=O)c3ccc(C#N)cc3)CC2)n1	J Med Chem	2019.0	CHEMBL4513498	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCCCN(C)C(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4443478	=	=	IC50	nM	13400.0	IC50	uM	13.4
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2cccc(C#N)c2)CC1	J Med Chem	2019.0	CHEMBL4439229	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2cccc(Cl)c2)CC1	J Med Chem	2019.0	CHEMBL4472693	=	=	IC50	nM	12800.0	IC50	uM	12.8
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2cccc(F)c2)CC1	J Med Chem	2019.0	CHEMBL4475143	=	=	IC50	nM	4200.0	IC50	uM	4.2
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2cccc(C)c2)CC1	J Med Chem	2019.0	CHEMBL4446275	=	=	IC50	nM	5400.0	IC50	uM	5.4
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)OCCc3ccccc3)CC2)n1	J Med Chem	2019.0	CHEMBL4539036	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)OCc3ccccc3)CC2)n1	J Med Chem	2019.0	CHEMBL4548205	=	=	IC50	nM	7700.0	IC50	uM	7.7
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(C(=O)OC(C)(C)C)CC2)n1	J Med Chem	2019.0	CHEMBL4448804	>	>	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4441707	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CCC(=CC#Cc2ccccn2)CC1	J Med Chem	2019.0	CHEMBL4472416	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	COC(=O)N1CCC(=CC#Cc2cccc(C)n2)CC1	J Med Chem	2019.0	CHEMBL4544729	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CC/C(=C/C#Cc2cccc(C)n2)C1	J Med Chem	2019.0	CHEMBL4539998	=	=	IC50	nM	9700.0	IC50	uM	9.7
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CC/C(=C\C#Cc2cccc(C)n2)C1	J Med Chem	2019.0	CHEMBL4551786	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CC2(CC(=CC#Cc3cccc(C)n3)C2)C1	J Med Chem	2019.0	CHEMBL4551238	=	=	IC50	nM	17200.0	IC50	uM	17.2
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	CCOC(=O)N1CC(=CC#Cc2cccc(C)n2)C1	J Med Chem	2019.0	CHEMBL4464549	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#CC=C2CCN(c3ncccc3[N+](=O)[O-])CC2)n1	J Med Chem	2019.0	CHEMBL3597594	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1nc(C#Cc2cccnc2)cs1	J Med Chem	2019.0	CHEMBL292065	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human CYP3A4 using 7-benzyloxy-trifluoromethylcoumarin as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins	Cc1cccc(C#Cc2ccccc2)n1	J Med Chem	2019.0	CHEMBL66654	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1OCC2(CCN(c3nc(N)c(Sc4cccc(Cl)c4Cl)c(=O)n3C)CC2)[C@@H]1N	J Med Chem	2019.0	CHEMBL4546378	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1OCC2(CCN(c3nc4[nH]nc(-c5ccnc(NC6CC6)c5Cl)c4c(=O)n3C)CC2)[C@@H]1N	J Med Chem	2019.0	CHEMBL4439006	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes at 1 uM using midazolam as substrate by LC-MS/MS analysis	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1	J Med Chem	2019.0	CHEMBL3936761	=	=	IC50	nM	14300.0	IC50	uM	14.3
Inhibition of CYP3A4 in human liver microsomes at 1 uM using testosterone as substrate by LC-MS/MS analysis	C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1	J Med Chem	2019.0	CHEMBL3936761	=	=	IC50	nM	60600.0	IC50	uM	60.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	CC1(C)CCN1Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1	J Med Chem	2019.0	CHEMBL4460028	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	CN(Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1)C(C)(C)C	J Med Chem	2019.0	CHEMBL4471825	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	CC(C)N(C)Cc1cccc(F)c1CNc1cc(F)c(S(=O)(=O)Nc2cscn2)c(F)c1	J Med Chem	2019.0	CHEMBL4435054	=	=	IC50	nM	38000.0	IC50	uM	38.0
Inhibition of recombinant human CYP3A4 expressed in supersomes using 7-benzyloxyquinoline as substrate by fluorescence method	CNC(=O)C(=O)NCCCC/C=C\CCCCCCCOCC(=O)O	J Med Chem	2019.0	CHEMBL4473988	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4 expressed in supersomes using 7-benzyloxyquinoline as substrate by fluorescence method	CNC(=O)C(=O)NCCCC/C=C\CCCCCCCCCc1nnn[nH]1	J Med Chem	2019.0	CHEMBL4463477	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of recombinant human CYP3A4 expressed in supersomes using 7-benzyloxyquinoline as substrate by fluorescence method	CNC(=O)C(=O)NCCCC/C=C\CCCCCCCCCC(=O)O	J Med Chem	2019.0	CHEMBL1802692	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4 expressed in supersomes using 7-benzyloxyquinoline as substrate by fluorescence method	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	Cn1c(Sc2ccc(C(=O)NO)cc2)nnc1-c1cccs1	J Med Chem	2019.0	CHEMBL4537736	=	=	IC50	nM	26600.0	IC50	uM	26.6
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	O=C(NO)c1ccc(Cn2nnnc2-c2cccs2)cc1	J Med Chem	2019.0	CHEMBL4448410	=	=	IC50	nM	47400.0	IC50	uM	47.4
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	NCc1ccc(-c2cccnc2)s1			CHEMBL359657	=	=	IC50	nM	58700.0	IC50	uM	58.7
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	NCc1ccc(-c2cccnc2)o1			CHEMBL178090	=	=	IC50	nM	47100.0	IC50	uM	47.1
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	NCC#Cc1cccnc1			CHEMBL360541	=	=	IC50	nM	365000.0	IC50	uM	365.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1ccsc1-c1cccnc1			CHEMBL179669	=	=	IC50	nM	750.0	IC50	uM	0.75
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cn1cnc(-c2cccnc2)c1			CHEMBL360999	=	=	IC50	nM	261900.0	IC50	uM	261.9
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CNCc1ccc(-c2cccnc2)s1			CHEMBL369285	>	>	IC50	nM	400000.0	IC50	uM	400.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1ccsc1-c1ccc(F)nc1			CHEMBL179621	=	=	IC50	nM	39080.0	IC50	uM	39.08
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cncc(-c2ccsc2)c1			CHEMBL361153	=	=	IC50	nM	55900.0	IC50	uM	55.9
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1ccc(Cn2cnc(-c3cccnc3)c2)cc1			CHEMBL178780	=	=	IC50	nM	75100.0	IC50	uM	75.1
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1nccn1-c1cccnc1			CHEMBL368883	=	=	IC50	nM	152000.0	IC50	uM	152.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cncc(-c2c[nH]cn2)c1			CHEMBL178516	=	=	IC50	nM	140000.0	IC50	uM	140.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1cscc1-c1cccnc1			CHEMBL179704	<	<	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	O/N=C/c1ccc(-c2cccnc2)s1			CHEMBL178534	=	=	IC50	nM	12980.0	IC50	uM	12.98
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CCn1cnc(-c2cccnc2)c1			CHEMBL361364	=	=	IC50	nM	79200.0	IC50	uM	79.2
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Nc1ccc(-c2cccnc2)s1			CHEMBL3640762	=	=	IC50	nM	1590.0	IC50	uM	1.59
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cncc(-n2ccnc2)c1			CHEMBL179477	=	=	IC50	nM	77540.0	IC50	uM	77.54
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	O=Cc1ccc(-c2cccnc2)s1			CHEMBL179398	=	=	IC50	nM	23930.0	IC50	uM	23.93
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Fc1ccc(-c2ccsc2)cn1			CHEMBL179005	=	=	IC50	nM	114000.0	IC50	uM	114.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	NC[C@@H]1CC[C@@H](c2cccnc2)O1			CHEMBL4443442	=	=	IC50	nM	64710.0	IC50	uM	64.71
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cncc(-c2cccnc2)c1			CHEMBL179763	>	>	IC50	nM	400000.0	IC50	uM	400.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cncc(-c2ccc(CNCc3ccc(-c4cccnc4)s3)s2)c1			CHEMBL178711	>=	>=	IC50	nM	56990.0	IC50	uM	56.99
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CC(=O)c1ccc(-c2cccnc2)s1			CHEMBL362702	=	=	IC50	nM	26900.0	IC50	uM	26.9
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	O/N=C/c1ccc(-c2cccnc2)o1			CHEMBL178547	>	>	IC50	nM	400000.0	IC50	uM	400.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	c1cnc(-c2cccnc2)nc1			CHEMBL178878	>	>	IC50	nM	400000.0	IC50	uM	400.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1cscc1-c1ccc(F)nc1			CHEMBL425519	=	=	IC50	nM	114000.0	IC50	uM	114.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	Cc1ccc(-c2cccnc2)nc1			CHEMBL179589	=	=	IC50	nM	84230.0	IC50	uM	84.23
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CN1CCC[C@H]1c1cccnc1			CHEMBL3	=	=	IC50	nM	142400.0	IC50	uM	142.4
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CN(C)Cc1ccc(-c2cccnc2)o1			CHEMBL360998	=	=	IC50	nM	294000.0	IC50	uM	294.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	O/N=C\c1ccc(-c2cccnc2)o1			CHEMBL178330	>	>	IC50	nM	400000.0	IC50	uM	400.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CN(C)Cc1ccc(-c2cccnc2)s1			CHEMBL361969	=	=	IC50	nM	219000.0	IC50	uM	219.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	O=Cc1ccc(-c2cccnc2)o1			CHEMBL178708	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CC(=O)SCc1ccc(-c2cccnc2)o1			CHEMBL386124	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	SCc1ccc(-c2cccnc2)o1			CHEMBL214784	=	=	IC50	nM	6100.0	IC50	uM	6.1
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	CSCc1ccc(-c2cccnc2)o1			CHEMBL214990	=	=	IC50	nM	14800.0	IC50	uM	14.8
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in enzyme-mediated testosterone 6-hydroxylation in presence of NADPH-generating system, G6P and G6P dehydrogenase	ON=Cc1ccc(-c2cccnc2)o1			CHEMBL4466954	=	=	IC50	nM	51900.0	IC50	uM	51.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	Cc1csc2c1c(=O)n(CCc1ccccc1)c(=O)n2CC1CCCO1	Eur J Med Chem	2019.0	CHEMBL4451942	=	=	IC50	nM	16000.0	IC50	10'-6 mol/L	16.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition measured after 10 mins in presence of NADPH by LC-MS/MS analysis	CCn1c(=O)c2c(C)c(C(=O)N3CCC(O)CC3)sc2n(CCC(F)(F)F)c1=O	Eur J Med Chem	2019.0	CHEMBL4522981	>	>	IC50	nM	20000.0	IC50	10'-6 mol/L	20.0
Inhibition of CYP3A4 in human liver microsomes by HPLC-MS/MS analysis	O=c1[nH]c(CNC(CO)CO)c(I)c(=O)[nH]1	J Med Chem	2019.0	CHEMBL4455140	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis	CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1	J Med Chem	2019.0	CHEMBL4592045	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 15 mins by LC-MS/MS analysis relative to control	CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1	J Med Chem	2019.0	CHEMBL4592045	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1[C@@H]1C(C(=O)C(C)C)=C([O-])C(=O)N1c1ccc(-c2ccsc2)cc1.[Na+]	Bioorg Med Chem Lett	2019.0	CHEMBL4439812	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCC[S+](C)[O-]	Bioorg Med Chem Lett	2019.0	CHEMBL4437131	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCCO	Bioorg Med Chem Lett	2019.0	CHEMBL4537290	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1C(C(=O)C(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4454941	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C)C(=O)COc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4459015	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCC(=O)O	Bioorg Med Chem Lett	2019.0	CHEMBL4445659	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[S+]([O-])CCOc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4459391	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C)CCOc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4572081	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	COCCOc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4592312	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1C(C(=O)C(C)(C)C)=C(O)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL4457637	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3cccs3)cc2)C1c1ccccc1OCCO	Bioorg Med Chem Lett	2019.0	CHEMBL4465467	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccsc3)cc2)C1c1ccccc1OCCO	Bioorg Med Chem Lett	2019.0	CHEMBL4466252	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccoc3)cc2)C1c1ccccc1OCCO	Bioorg Med Chem Lett	2019.0	CHEMBL4562022	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1noc(-c2ccc(N3C(=O)C(O)=C(C(=O)C(C)(C)C)C3c3ccccc3OCCO)cc2)n1	Bioorg Med Chem Lett	2019.0	CHEMBL4526549	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(-c2ccc(N3C(=O)C(O)=C(C(=O)C(C)(C)C)C3c3ccccc3OCCO)cc2)no1	Bioorg Med Chem Lett	2019.0	CHEMBL4456152	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2ccc(N3C(=O)C(O)=C(C(=O)C(C)(C)C)C3c3ccccc3OCCO)cc2)on1	Bioorg Med Chem Lett	2019.0	CHEMBL4459785	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)C(=O)C1=C(O)C(=O)N(c2ccc(-c3ccon3)cc2)C1c1ccccc1OCCO	Bioorg Med Chem Lett	2019.0	CHEMBL4565775	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Nc2nccc(-c3ccn([C@H](CO)c4ccc(Cl)c(F)c4)c(=O)c3)n2)ccn1	J Med Chem	2016.0	CHEMBL4571067	=	=	IC50	nM	340.0	IC50	uM	0.34
Inhibition of CYP3A4 (unknown origin)	O=C(O)C[C@H]1CCCN(C[C@@H](O)c2ccc(-c3noc(-c4onc(-c5ccccc5)c4C(F)(F)F)n3)cc2)C1	J Med Chem	2016.0	CHEMBL4458575	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4 expressed in supersomes assessed as testosterone 6beta-hydroxylation after 15 mins by HPLC analysis	COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1ccc2cccnc2c1	ACS Med Chem Lett	2016.0	CHEMBL4447846	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in supersomes assessed as testosterone 6beta-hydroxylation after 15 mins by HPLC analysis	COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1cncc2ccccc12	ACS Med Chem Lett	2016.0	CHEMBL4469309	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2n[nH]c3cc(NC(=O)N[C@H](C)c4ccccc4)ncc23)ccn1	J Med Chem	2016.0	CHEMBL2408789	=	=	IC50	nM	3900.0	IC50	nM	3900.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H](NC(=O)Nc1cc2[nH]nc(-c3cnn(C)c3)c2cn1)c1ccccc1	J Med Chem	2016.0	CHEMBL3654680	=	=	IC50	nM	380.0	IC50	nM	380.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2n[nH]c3cc(NC(=O)N[C@H](C)c4ccccc4)ncc23)cc(C)n1	J Med Chem	2016.0	CHEMBL3654682	=	=	IC50	nM	780.0	IC50	nM	780.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H](NC(=O)Nc1cc2[nH]nc(-c3ccnc(F)c3)c2cn1)c1ccccc1	J Med Chem	2016.0	CHEMBL3663084	=	=	IC50	nM	29000.0	IC50	nM	29000.0
Inhibition of human CYP3A4	CC1=C(CC(=O)NCc2cc(Cl)ccc2CN)C(=O)N(NCc2ccccc2)CC1	J Med Chem	2016.0	CHEMBL4455063	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of human CYP3A4	CC1=C(CC(=O)NCc2cc(Cl)ccc2CN)C(=O)N(NCc2cccc(C(=O)O)c2)CC1	J Med Chem	2016.0	CHEMBL4443619	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(-c5ccc(F)cc5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4461070	>	>	IC50	nM	200000.0	IC50	uM	200.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4cccnn34)cc2s1	J Med Chem	2016.0	CHEMBL4436706	=	=	IC50	nM	34000.0	IC50	uM	34.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	CCOc1ccc2nnc(Sc3ccc4nc(NC(=O)NCCN5CCOCC5)sc4c3)n2n1	J Med Chem	2016.0	CHEMBL4462907	=	=	IC50	nM	4000.0	IC50	uM	4.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(-c5cccc(F)c5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4537541	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCCC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4551712	=	=	IC50	nM	2700.0	IC50	uM	2.7
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(NC5CCCCC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4466644	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(NC5CCOCC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4593634	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(NC5CC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4513820	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(Oc5ccccc5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4541666	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4460814	=	=	IC50	nM	31000.0	IC50	uM	31.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(OC5CCCCCC5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4451715	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	O=C(NCCN1CCOCC1)Nc1nc2ccc(Sc3nnc4ccc(Oc5cccc(F)c5)nn34)cc2s1	J Med Chem	2016.0	CHEMBL4472923	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of human recombinant CYP3A4 co-expressed with human P450 reductase and human b5 reductase assessed as reduction in 7-Hydroxyquinoline production using 7-benzyloxyquinoline as substrate and NADPH incubated for 15 mins by fluorimetry	CCCCOc1ccc2nnc(Sc3ccc4nc(NC(=O)NCCN5CCOCC5)sc4c3)n2n1	J Med Chem	2016.0	CHEMBL4472716	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of CYP3A4 (unknown origin)	Cc1nc2c(c(-c3ccn[nH]3)n1)C[C@@H](C)N(C(=O)c1cccc(C(F)(F)F)c1Cl)C2	Bioorg Med Chem Lett	2016.0	CHEMBL3674077	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4 (unknown origin)	Cc1nc2c(c(-c3ccn[nH]3)n1)C[C@@H](C)N(C(=O)c1ccc(Cl)cc1F)C2	Bioorg Med Chem Lett	2016.0	CHEMBL3674106	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH by LC/MS/MS analysis	O=C(c1cc(F)cc(Cl)c1)N1CCn2nc(-c3ccc(F)cn3)cc2C1	Bioorg Med Chem Lett	2016.0	CHEMBL4098822	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins in presence of NADPH by LC/MS/MS analysis	O=C(c1ccccc1)N1CCn2nc(-c3ccccn3)cc2C1	Bioorg Med Chem Lett	2016.0	CHEMBL4554361	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis	Cc1cc(-c2cnn3c(NCCN4CCOCC4)cc(Oc4cccc(F)c4)nc23)ccc1C(=O)NC1CC1	ACS Med Chem Lett	2016.0	CHEMBL4541788	=	=	IC50	nM	780.0	IC50	uM	0.78
Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis	Cc1cc(-c2cnn3c(NCC4CCOCC4)cc(N[C@@H](C4CC4)C(C)(C)O)nc23)ccc1C(=O)NC1CC1	ACS Med Chem Lett	2016.0	CHEMBL4542474	=	=	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis	Cc1cc(-c2cnn3c(NCC4CC4)cc(N[C@@H]4CCCC[C@H]4O)nc23)ccc1C(=O)NC1CC1	ACS Med Chem Lett	2016.0	CHEMBL4444859	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of BFC as substrate measured after 10 mins in presence of NADP by fluorescence analysis	Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1	ACS Med Chem Lett	2016.0	CHEMBL4469414	=	=	IC50	nM	510.0	IC50	uM	0.51
Inhibition of CYP3A4 (unknown origin) preincubated for 10 mins followed by addition of DBF as substrate measured after 10 mins in presence of NADP by fluorescence analysis	Cc1cc(-c2cnn3c(NC[C@H]4C[C@@](C)(O)C4)cc(Oc4cccnc4)nc23)ccc1C(=O)NC1CC1	ACS Med Chem Lett	2016.0	CHEMBL4469414	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(NC(=O)Cc3cnc(-c4ccnc(F)c4)c(C)c3)nc2)CC1	ACS Med Chem Lett	2016.0	CHEMBL4546441	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc2nc(NC(=O)Cc3ccc(-c4ccncc4)cc3)sc2c1	ACS Med Chem Lett	2016.0	CHEMBL4537314	=	=	IC50	nM	800.0	IC50	uM	0.8
Reversible inhibition of human CYP3A4	Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O	ACS Med Chem Lett	2016.0	CHEMBL3696475	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Fc1ccccc1-c1cc(Nc2ccncc2)c2cc[nH]c2n1	Bioorg Med Chem Lett	2016.0	CHEMBL4576833	=	=	IC50	nM	2511.89	pIC50		5.6
Inhibition of CYP3A4 (unknown origin)	CCn1c(=O)n(-c2cc(-c3cc(Cl)ccc3F)ncc2C)c2ccncc21	Bioorg Med Chem Lett	2016.0	CHEMBL4569690	>	<	IC50	nM	1584.89	pIC50		5.8
Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(CC(N)=O)c2cnccc21	Bioorg Med Chem Lett	2016.0	CHEMBL4564126	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of CYP3A4 (unknown origin)	Cc1cnc(-c2cc(Cl)ccc2F)cc1-n1c(=O)n(C)c2cnccc21	Bioorg Med Chem Lett	2016.0	CHEMBL4515962	=	=	IC50	nM	1584.89	pIC50		5.8
Inhibition of CYP3A4 (unknown origin)	Cn1c(=O)n(-c2cc(-c3cc(Cl)ccc3F)nc3[nH]ccc23)c2ccncc21	Bioorg Med Chem Lett	2016.0	CHEMBL4474551	=	=	IC50	nM	1000.0	pIC50		6.0
Inhibition of CYP3A4 (unknown origin)	Cn1c(=O)n(-c2cc(-c3ccc(F)cc3F)nc3[nH]ccc23)c2ccncc21	Bioorg Med Chem Lett	2016.0	CHEMBL4513488	=	=	IC50	nM	3981.07	pIC50		5.4
Inhibition of CYP3A4 (unknown origin)	O=c1[nH]c2cnccc2n1-c1cc(-c2cc(Cl)ccc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4470706	=	=	IC50	nM	3162.28	pIC50		5.5
Inhibition of CYP3A4 (unknown origin)	O=c1[nH]c2cnccc2n1-c1cc(-c2ccc(F)cc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4555703	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of CYP3A4 (unknown origin)	CC(C)(N)CNC(=O)c1cnccc1Nc1cc(-c2ccc(F)cc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4468495	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of CYP3A4 (unknown origin)	CNCCNC(=O)c1cnccc1Nc1cc(-c2ccc(F)cc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4470980	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of CYP3A4 (unknown origin)	C[C@H](O)CNC(=O)c1cnccc1Nc1cc(-c2cc(Cl)ccc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4467267	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of CYP3A4 (unknown origin)	C[C@H](O)CNC(=O)c1cnccc1Nc1cc(-c2ccc(F)cc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4443611	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of CYP3A4 (unknown origin)	O=C(NC1CC1)c1cnccc1Nc1cc(-c2cc(Cl)ccc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4483492	=	=	IC50	nM	15848.93	pIC50		4.8
Inhibition of CYP3A4 (unknown origin)	O=C(NC1CC1)c1cnccc1Nc1cc(-c2ccc(F)cc2F)nc2[nH]ccc12	Bioorg Med Chem Lett	2016.0	CHEMBL4452818	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of CYP3A4 (unknown origin)	Fc1cc(F)c(-c2cc(Nc3ccncc3)c3cc[nH]c3n2)cc1Cl	Bioorg Med Chem Lett	2016.0	CHEMBL4437930	<	>	IC50	nM	794.33	pIC50		6.1
Inhibition of CYP3A4 (unknown origin)	Cc1cccc(-c2cc(Nc3ccncc3)c3cc[nH]c3n2)n1	Bioorg Med Chem Lett	2016.0	CHEMBL4572312	=	=	IC50	nM	25118.86	pIC50		4.6
Inhibition of CYP3A4 (unknown origin)	Fc1ccc(-c2cc(Nc3ccncc3)c3cc[nH]c3n2)cc1F	Bioorg Med Chem Lett	2016.0	CHEMBL4526347	=	=	IC50	nM	1995.26	pIC50		5.7
Inhibition of CYP3A4 (unknown origin)	Fc1ccc(-c2cc(Nc3ccncc3)c3cc[nH]c3n2)c(F)c1	Bioorg Med Chem Lett	2016.0	CHEMBL4446613	=	=	IC50	nM	1258.93	pIC50		5.9
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1	J Med Chem	2016.0	CHEMBL4303596	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(-c2ccccn2)c1-c1ccccn1	J Med Chem	2016.0	CHEMBL3403678	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(N)=O)c1-c1ccccc1	J Med Chem	2016.0	CHEMBL4555334	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4516601	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N(C)C)c1-c1ccccc1	J Med Chem	2016.0	CHEMBL4570159	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CCNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4464055	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CC(C)NC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4461539	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCS(=O)(=O)CC2)c1-c1ccccc1	J Med Chem	2016.0	CHEMBL4449366	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCNCC2)c1-c1ccccc1	J Med Chem	2016.0	CHEMBL4449576	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	C[C@H](Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CC(O)C2)c1-c1ccccc1	J Med Chem	2016.0	CHEMBL4542785	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CNCCNC(=O)c1c(-c2ccccc2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4438514	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4470291	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CCNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4572863	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CCNCC2)c1-c1ccccn1	J Med Chem	2016.0	CHEMBL4442808	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CC(Nc1ncnc(N)c1C#N)c1nc2ccc(F)cc2c(C(=O)N2CC(O)C2)c1-c1ccccn1	J Med Chem	2016.0	CHEMBL4594095	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CNCCNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2ccc(F)cc12	J Med Chem	2016.0	CHEMBL4525494	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin) at 3 uM using midazolam substrate by LC-MS method	CNC(=O)c1c(-c2ccccn2)c([C@H](C)Nc2ncnc(N)c2C#N)nc2cccc(F)c12	J Med Chem	2016.0	CHEMBL4443843	>	>	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc(C(C)(C)C)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(F)c2)cs1	Bioorg Med Chem Lett	2016.0	CHEMBL4438330	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in human microsomes using midazolam as substrate coincubated with substrate for 30 mins measured after 5 mins in presence of NADPH by LC-MS/MS analysis	CC(C)COc1ncc(Oc2nccc3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl	J Med Chem	2016.0	CHEMBL4462738	=	=	IC50	nM	30700.0	IC50	uM	30.7
Inhibition of CYP3A4 in human microsomes using midazolam as substrate coincubated with substrate for 30 mins measured after 5 mins in presence of NADPH by LC-MS/MS analysis	CC(C)COc1ncc(-c2cc(F)c(C(=O)NS(C)(=O)=O)cc2F)cc1Cl	J Med Chem	2016.0	CHEMBL4470763	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human microsomes using midazolam as substrate coincubated with substrate for 30 mins measured after 5 mins in presence of NADPH by LC-MS/MS analysis	COc1cc(C(=O)NS(C)(=O)=O)c(F)cc1-c1cnc(Oc2cc(F)ccc2F)c(Cl)c1	J Med Chem	2016.0	CHEMBL4469805	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human microsomes using midazolam as substrate preincubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis	CC(C)COc1ncc(Oc2nccc3cc(C(=O)NS(C)(=O)=O)ccc23)cc1Cl	J Med Chem	2016.0	CHEMBL4462738	=	=	IC50	nM	18400.0	IC50	uM	18.4
Inhibition of CYP3A4 in human microsomes using midazolam as substrate preincubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis	CC(C)COc1ncc(-c2cc(F)c(C(=O)NS(C)(=O)=O)cc2F)cc1Cl	J Med Chem	2016.0	CHEMBL4470763	=	=	IC50	nM	48600.0	IC50	uM	48.6
Inhibition of CYP3A4 in human microsomes using midazolam as substrate preincubated with enzyme and NADPH prior to substrate addition by LC-MS/MS analysis	COc1cc(C(=O)NS(C)(=O)=O)c(F)cc1-c1cnc(Oc2cc(F)ccc2F)c(Cl)c1	J Med Chem	2016.0	CHEMBL4469805	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human liver microsomes CYP3A4 after 30 mins in presence of NADPH	Cc1c(-c2ccc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1cnc2ccccc2c1=O	J Med Chem	2016.0	CHEMBL3918580	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	CC(NC(=O)c1ccc(C(F)(F)F)cc1Cl)C1(N2CCN(S(=O)(=O)c3cn(C)nn3)CC2)CCC(F)(F)CC1.Cl	J Med Chem	2016.0	CHEMBL4448986	>	>	IC50	nM	7200.0	IC50	uM	7.2
Inhibition of recombinant human CYP3A4 preincubated for 10 mins followed by addition of BFC as substrate measured after 45 mins	C[C@@]1(c2ccc(F)cc2F)C[C@@H](c2cncnc2)SC(N)=N1	J Med Chem	2016.0	CHEMBL4444341	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1nc(C(=O)N[C@H]2CC[C@H](C)CC2)c(C)c(-c2ccc3c(c2C)N(C)CCO3)c1[C@H](OC(C)(C)C)C(=O)O	ACS Med Chem Lett	2016.0	CHEMBL4545710	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human recombinant CYP3A4	NC(=O)c1ccc(Cc2ccccc2)cc1-c1cccc(CCC(=O)O)c1	ACS Med Chem Lett	2016.0	CHEMBL4457557	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cells incubated for 30 mins by luciferase assay	O=c1c(O)c(-c2cccc(O)c2)oc2ccc(O)cc12	J Med Chem	2016.0	CHEMBL4464764	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using substrate preincubated for 10 mins followed by NADPH addition measured after 30 mins by LC-MS/MS analysis	COC(=O)C1=C(CN2CC(F)(F)C[C@H]2C(=O)O)NC(c2nccs2)=N[C@@]1(C)c1ccc(F)cc1	J Med Chem	2016.0	CHEMBL4541225	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human microsomal CYP3A4 expressed in baculovirus infected BTI-TN-5B1-4 cell microsomes using CYP/Luciferin as substrate pre-incubated for 30 mins followed by NADPH regeneration mixture addition and measured after 30 mins by Promega P450-Glo assay	COc1ccc2c(=O)c(O)c(-c3ccc4c(c3)OCO4)oc2c1	ACS Med Chem Lett	2019.0	CHEMBL4450031	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 (unknown origin)	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Bioorg Med Chem Lett	2019.0	CHEMBL106	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Bioorg Med Chem Lett	2019.0	CHEMBL104	=	=	IC50	nM	50.0	IC50	uM	0.05
Inhibition of CYP3A4 (unknown origin)	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Bioorg Med Chem Lett	2019.0	CHEMBL91	=	=	IC50	nM	850.0	IC50	uM	0.85
Inhibition of CYP3A4 (unknown origin)	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1	Bioorg Med Chem Lett	2019.0	CHEMBL808	=	=	IC50	nM	430.0	IC50	uM	0.43
Inhibition of CYP3A4 (unknown origin)	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Bioorg Med Chem Lett	2019.0	CHEMBL75	=	=	IC50	nM	200.0	IC50	uM	0.2
Inhibition of CYP3A4 in human liver microsomes using midazolam pre-incubated for 10 mins before NADPH addition and measured after 10 mins by LC/MS/MS analysis	CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2)c(F)c1	Bioorg Med Chem Lett	2019.0	CHEMBL4443920	=	=	IC50	nM	4050.0	IC50	uM	4.05
Inhibition of CYP3A4 in human liver microsomes using midazolam pre-incubated for 10 mins before NADPH addition and measured after 10 mins by LC/MS/MS analysis	CC(C)OC(=O)[C@H](Cn1ccnc1)NC(=O)c1ccc(-c2ccccc2)cc1F	Bioorg Med Chem Lett	2019.0	CHEMBL4514676	=	=	IC50	nM	42.9	IC50	uM	0.0429
Inhibition of CYP3A4 (unknown origin)	C[C@H]1NC(=O)c2cc(-c3cccc4c(=O)n(C)c(NC(C)(C)C)nc34)[nH]c21	J Med Chem	2016.0	CHEMBL3979678	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	Cl.NCc1ccc(-n2c(-c3cccnc3N)nc3ccc(-c4ccccc4)nc32)cc1	J Med Chem	2016.0	CHEMBL4513257	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(CN)cc4)c3n2)c1.Cl	J Med Chem	2016.0	CHEMBL4546484	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	Cl.Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1	J Med Chem	2016.0	CHEMBL4523032	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	CC(=O)Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1.Cl	J Med Chem	2016.0	CHEMBL4519558	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	Cl.Nc1cccc(-c2ccc3nc(-c4cccnc4N)n(-c4ccc(C5(N)CCC5)cc4)c3n2)c1	J Med Chem	2016.0	CHEMBL4574111	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate after 10 mins by LC/MS/MS analysis	Cl.Nc1ncccc1-c1nc2ccc(-c3cccnc3)nc2n1-c1ccc(C2(N)CCC2)cc1	J Med Chem	2016.0	CHEMBL4544109	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay	c1cncc(-c2cc(N3CCc4ccccc4C3)nc(-c3ccncc3)n2)c1	J Med Chem	2016.0	CHEMBL548646	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay	c1cncc(-c2cc(N3CCC(N4CCOCC4)CC3)nc(-c3ccncc3)n2)c1	J Med Chem	2016.0	CHEMBL4584780	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay	c1cncc(-c2cc(N3CCC(CN4CCOCC4)CC3)nc(-c3ccncc3)n2)c1	J Med Chem	2016.0	CHEMBL4569641	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of human CYP3A4 expressed in Escherichia coli pre-incubated for 5 mins before regenerating cofactor solution addition using Diethoxyfluorescein/7-Benzyloxyquinoline as substrate by fluorescence assay	Cc1cc(-c2nc(-c3cccnc3)cc(N3CCC(N4CCOCC4)CC3)n2)cc(C)n1	J Med Chem	2016.0	CHEMBL4570567	=	=	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human liver microsomes incubated for 15 mins using midazolam substrate in presence of NADPH by LC-MS/MS method	COc1ccc(-c2c(CO)n(Cc3ccccc3Cl)c3ccc(OC(F)(F)F)cc23)cn1	J Med Chem	2016.0	CHEMBL4557930	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 in human liver microsomes incubated for 15 mins using midazolam substrate in presence of NADPH by LC-MS/MS method	CSc1ncc(-c2c(CO)n(Cc3ccccc3Cl)c3ccc(OC(F)(F)F)cc23)cn1	J Med Chem	2016.0	CHEMBL4528799	=	=	IC50	nM	17600.0	IC50	uM	17.6
Inhibition of CYP3A4 in human liver microsomes incubated for 15 mins using midazolam substrate in presence of NADPH by LC-MS/MS method	COc1nn2cc(-c3c(CO)n(Cc4ccccc4Cl)c4ccc(OC(F)(F)F)cc34)nc2s1	J Med Chem	2016.0	CHEMBL4566669	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant CYP3A4 (unknown origin)	O=C(O)c1ccc(-c2c(/C=C/c3ccc4ccccc4n3)nc3c(N4CCOCC4)ccnn23)cc1	Bioorg Med Chem Lett	2016.0	CHEMBL3919436	>	>	IC50	nM	10000.0	IC50	uM	10.0
Time-dependent inhibition of human CYP3A4 using midazolam as substrate	CC(C)(C)Cc1cc(-c2onc([C@@H](CCC(=O)[O-])CC(=O)Nc3ccc(Cl)cc3Cl)c2C2CC2)no1.[Na+]	J Med Chem	2019.0	CHEMBL4537625	>	>	IC50	nM	50000.0	IC50	uM	50.0
Time-dependent inhibition of human CYP3A4 using testosterone as substrate	CC(C)(C)Cc1cc(-c2onc([C@@H](CCC(=O)[O-])CC(=O)Nc3ccc(Cl)cc3Cl)c2C2CC2)no1.[Na+]	J Med Chem	2019.0	CHEMBL4537625	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Bioorg Med Chem	2019.0	CHEMBL376488	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	COc1cccc(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2cccc3c2OCO3)n1	Bioorg Med Chem	2019.0	CHEMBL4563167	=	=	IC50	nM	7600.0	IC50	uM	7.6
Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1C(c1cccc(C)c1)C(O)(CCN(C)C)c1cccnc1C	Bioorg Med Chem	2019.0	CHEMBL4574868	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1C(c1cccc2c1OCO2)C(O)(CCN(C)C)c1cccnc1C	Bioorg Med Chem	2019.0	CHEMBL4515667	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cccc(C(c2cc3cc(Br)ccc3nc2OC)C(O)(CCN(C)C)c2ccc(C)nc2)c1F	Bioorg Med Chem	2019.0	CHEMBL4558224	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1C(c1cccc(C)c1)C(O)(CCN(C)C)c1cccnc1OC	Bioorg Med Chem	2019.0	CHEMBL4535649	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(C#N)cc2cc1C(c1cccc(C)c1)C(O)(CCN(C)C)c1cccnc1OC	Bioorg Med Chem	2019.0	CHEMBL4575859	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1C(c1cccc2c1OCO2)C(O)(CCN(C)C)c1cccnc1OC	Bioorg Med Chem	2019.0	CHEMBL4515863	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(C(O)(CCN(C)C)C(c2cc3cc(Br)ccc3nc2OC)c2ccnc(OC)c2OC)cnc1OC	Bioorg Med Chem	2019.0	CHEMBL4521403	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cccc(C(c2cc3cc(C#N)ccc3nc2OC)C(O)(CCN(C)C)c2cc(C)nc(C)c2)c1F	Bioorg Med Chem	2019.0	CHEMBL4522585	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Bioorg Med Chem	2019.0	CHEMBL376488	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2F)cc(OC)n1	Bioorg Med Chem	2019.0	CHEMBL4529465	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCOc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2F)cc(OCC)n1	Bioorg Med Chem	2019.0	CHEMBL4565089	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2OC)cc(OC)n1	Bioorg Med Chem	2019.0	CHEMBL4519972	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCOc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(Br)ccc3nc2OC)c2cccc(OC)c2OC)cc(OCC)n1	Bioorg Med Chem	2019.0	CHEMBL4532620	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2cccc3c2OCO3)cc(OC)n1	Bioorg Med Chem	2019.0	CHEMBL4543900	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc([C@](O)(CCN(C)C)[C@@H](c2cc3cc(C#N)ccc3nc2OC)c2cccc3c2OCCO3)cc(OC)n1	Bioorg Med Chem	2019.0	CHEMBL4519008	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1cc([C@](O)(CCN(C)C)[C@H](c2cccnc2OC)c2cc3cc(Br)ccc3nc2OC)cc(OC)n1	Bioorg Med Chem	2019.0	CHEMBL4574425	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCOc1cc([C@H](c2cc3cc(C#N)ccc3nc2OC)[C@@](O)(CCN(C)C)c2cc(OC)nc(OC)c2)cc(N(C)C)n1	Bioorg Med Chem	2019.0	CHEMBL4580150	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C	Bioorg Med Chem Lett	2020.0	CHEMBL4634634	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.c1cncc(OC[C@@H]2C[C@H]3C[C@H]3N2)c1	J Med Chem	2020.0	CHEMBL4643942	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ncccc1OC[C@@H]1C[C@H]2C[C@H]2N1	J Med Chem	2020.0	CHEMBL4645127	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1cncc(OC[C@@H]2C[C@H]3C[C@H]3N2)c1	J Med Chem	2020.0	CHEMBL4638732	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ccc(OC[C@@H]2C[C@H]3C[C@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4642118	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Fc1ccc(OC[C@@H]2C[C@H]3C[C@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4642865	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ccc(OC[C@H]2C[C@@H]3C[C@@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4641810	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.c1cncc(OC[C@@H]2C[C@@H]3C[C@@H]3N2)c1	J Med Chem	2020.0	CHEMBL4643543	=	=	IC50	nM	31900.0	IC50	uM	31.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ccc(OC[C@@H]2C[C@@H]3C[C@@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4645367	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ccc(OC[C@H]2C[C@H]3C[C@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4649507	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.c1cncc(OC[C@H]2NC[C@@H]3C[C@H]23)c1	J Med Chem	2020.0	CHEMBL4636163	=	=	IC50	nM	21100.0	IC50	uM	21.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1cncc(OC[C@H]2NC[C@@H]3C[C@H]23)c1	J Med Chem	2020.0	CHEMBL4647198	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.Clc1ccc(OC[C@@H]2CC[C@H]3C[C@H]3N2)cn1	J Med Chem	2020.0	CHEMBL4642287	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 2 min in presence of NADPH by LC-MS/MS analysis	Cl.c1cncc(OC[C@@H]2CC[C@H]3C[C@H]3N2)c1	J Med Chem	2020.0	CHEMBL4641432	>	>	IC50	nM	45000.0	IC50	uM	45.0
Inhibition of CYP3A4 I (unknown origin)	C[C@H]1CN(C(=O)Nc2cc(-c3cn([C@H]4CC[C@@](C)(O)CC4)c4cnccc34)ccn2)C[C@@H](C)O1	J Med Chem	2020.0	CHEMBL4640031	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 I (unknown origin)	CCN1CCN(C(=O)Nc2cc(-c3cn(C4CCOCC4)c4cnccc34)ccn2)CC1	J Med Chem	2020.0	CHEMBL4636064	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 II (unknown origin)	C[C@H]1CN(C(=O)Nc2cc(-c3cn([C@H]4CC[C@@](C)(O)CC4)c4cnccc34)ccn2)C[C@@H](C)O1	J Med Chem	2020.0	CHEMBL4640031	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 II (unknown origin)	CCN1CCN(C(=O)Nc2cc(-c3cn(C4CCOCC4)c4cnccc34)ccn2)CC1	J Med Chem	2020.0	CHEMBL4636064	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C)CC4)cn3)ncc2Cl)c1	J Med Chem	2020.0	CHEMBL4647703	=	=	IC50	nM	31400.0	IC50	uM	31.4
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1nn(C)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1	ACS Med Chem Lett	2020.0	CHEMBL4643577	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1nn(C)cc1C(=O)Nc1cccc(-c2cncn2C(C)C)n1	ACS Med Chem Lett	2020.0	CHEMBL4641666	=	=	IC50	nM	5900.0	IC50	uM	5.9
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1nn(-c2cnccn2)cc1C(=O)Nc1cccc(-c2nncn2C(C)C)n1	ACS Med Chem Lett	2020.0	CHEMBL4632672	=	=	IC50	nM	8800.0	IC50	uM	8.8
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3CCC4C=NNC4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL4640297	=	=	IC50	nM	5580.0	IC50	uM	5.58
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	COCCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5cccnn45)c3)cc2C2CC2)CC1	ACS Med Chem Lett	2020.0	CHEMBL4637502	=	=	IC50	nM	13500.0	IC50	uM	13.5
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3CCN(CCO)CC3)c(Cl)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL4642144	=	=	IC50	nM	13400.0	IC50	uM	13.4
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3CCN(CCO)CC3)c(C3CC3)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL4632471	=	=	IC50	nM	11700.0	IC50	uM	11.7
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3Cc4cn[nH]c4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL4638981	=	=	IC50	nM	7280.0	IC50	uM	7.28
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3Cc4ccc(O)cc4C3)c(Cl)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL4633367	=	=	IC50	nM	4610.0	IC50	uM	4.61
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1	ACS Med Chem Lett	2020.0	CHEMBL255863	=	=	IC50	nM	580.0	IC50	uM	0.58
Inhibition of human recombinant CYP3A4 expressed in insect cell microsomes in presence of NADPH by fluorescence assay	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12	ACS Med Chem Lett	2020.0	CHEMBL1171837	=	=	IC50	nM	11400.0	IC50	uM	11.4
Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates incubated for 15 to 30 mins by by LC-MS/MS analysis	CC(C)CCNC1=CC(=O)c2ccccc2C1=O	J Med Chem	2020.0	CHEMBL4642567	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 15 mins by LC-MS/MS analysis	O=C(CCCCCCC(=O)Nc1ccccc1)NOC(c1ccccc1)(c1ccccc1)c1ccccc1	J Med Chem	2020.0	CHEMBL4640366	=	=	IC50	nM	5560.0	IC50	uM	5.56
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins by LC-MS/MS analysis	Nc1ncnc2c1c(Oc1cc(C(F)(F)F)ccn1)nn2C1CC1	J Med Chem	2020.0	CHEMBL4634455	=	=	EC50	nM	50000.0	EC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins by LC-MS/MS analysis	Nc1ncnc2c1c(Oc1cc(C(F)(F)F)ccn1)nn2[C@@H]1CCCC[C@H]1O	J Med Chem	2020.0	CHEMBL4646408	=	=	EC50	nM	50000.0	EC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 10 mins by LC-MS/MS analysis	N#Cc1ccnc(Oc2nn([C@H]3C[C@H](F)C3)c3ncnc(N)c23)c1	J Med Chem	2020.0	CHEMBL4642579	=	=	EC50	nM	50000.0	EC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1	Bioorg Med Chem	2020.0	CHEMBL473417	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C)c(-c2ncc[nH]2)cc1NC(=O)c1ccc(OCc2ccccn2)cc1	Bioorg Med Chem	2020.0	CHEMBL4632769	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(C(F)(F)F)oc2ncnc(SCC(=O)N3CC(=O)N(C)C3)c12	Bioorg Med Chem Lett	2020.0	CHEMBL4633059	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CCOC(=O)Cc1nn(CNC(=O)CCCN2CCN(c3cccc(C)c3C)CC2)c(=O)c2c(F)cccc12	Bioorg Med Chem Lett	2020.0	CHEMBL4635232	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCOC(=O)Cc1nn(CNC(=O)CCCN2CCN(c3cccc(C)c3C)CC2)c(=O)c2cc(F)ccc12	Bioorg Med Chem Lett	2020.0	CHEMBL4646426	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1	Bioorg Med Chem Lett	2020.0	CHEMBL41	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCn1nnc2c(C)c([C@@H](CC(=O)O)c3ccc4c(c3)CN(C(=O)c3c(C)c(C)cc(C)c3C)CC4)ccc21	Bioorg Med Chem Lett	2020.0	CHEMBL4643134	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human CYP3A4	CCS(=O)(=O)Nc1cc(-c2cn(C)c3c(=O)[nH]ccc23)cc2c1ccn2C(C)(c1ccccn1)c1ccccn1	J Med Chem	2020.0	CHEMBL4648912	>=	>=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1	J Med Chem	2020.0	CHEMBL4647810	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1	J Med Chem	2020.0	CHEMBL4647810	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(C[C@@H](NC(=O)N2CCC3(CC2)OC(=O)Nc2ncccc23)C(=O)N[C@@H](CC2CCNCC2)C(=O)N2CCN(c3ccncc3)CC2)cc2cn[nH]c12	J Med Chem	2020.0	CHEMBL4635331	<	>	IC50	nM	50118.72	pIC50		4.3
Inhibition of CYP3A4 (unknown origin)	CC(C)[C@@H](NC(=O)c1cc(C(F)(F)F)ccc1F)C(=O)N1CCC2(CC1)C(=O)N(C)C(=O)N2c1ccc2[nH]ncc2c1	J Med Chem	2020.0	CHEMBL4636208	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 using testosterone as substrate	C[C@@H](Nc1nc2c(cnn2C(C)(C)C)c(=O)n1Cc1ccc(F)cc1)c1ccc(Cl)cc1	J Med Chem	2020.0	CHEMBL4644729	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4 using midazolam as substrate	C[C@@H](Nc1nc2c(cnn2C(C)(C)C)c(=O)n1Cc1ccc(F)cc1)c1ccc(Cl)cc1	J Med Chem	2020.0	CHEMBL4644729	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human microsomal CYP3A4 expressed in baculovirus infected insect cells using luciferin-IPA as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay	C[C@@H](NC(=O)c1nc(-c2cc(C(F)(F)F)ccn2)nc(O)c1O)C1CCCCC1	ACS Med Chem Lett	2020.0	CHEMBL4637717	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human microsomal CYP3A4 expressed in baculovirus infected insect cells using luciferin-IPA as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay	COc1ccnc(-c2nc(O)c(O)c(C(=O)N[C@H](C)C3CCCCC3)n2)c1	ACS Med Chem Lett	2020.0	CHEMBL4637524	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human microsomal CYP3A4 expressed in baculovirus infected insect cells using luciferin-IPA as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay	C[C@@H](NC(=O)c1nc(-c2cc(Cl)ccn2)nc(O)c1O)C1CCCCC1	ACS Med Chem Lett	2020.0	CHEMBL4633550	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human microsomal CYP3A4 expressed in baculovirus infected insect cells using luciferin-IPA as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay	C[C@@H](NC(=O)c1nc(-c2nccc3ccccc23)nc(O)c1O)C1CCCCC1	ACS Med Chem Lett	2020.0	CHEMBL4635907	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 using midazolam as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	=	=	IC50	nM	45800.0	IC50	uM	45.8
Inhibition of recombinant human CYP3A4 using testosterone as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human CYP3A4 using midazolam as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human CYP3A4 using testosterone as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human CYP3A4 using midazolam as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human CYP3A4 using testosterone as substrate	CS(=O)(=O)n1cc2c(n1)CN([C@@H]1C[C@H](N)[C@@H](c3cc(F)ccc3F)O[C@@H]1C(F)(F)F)C2	J Med Chem	2020.0	CHEMBL4646510	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)CN2CCNCc3cccc1c32	Bioorg Med Chem Lett	2020.0	CHEMBL4645774	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	c1cc2c3c(c1)C1(CCC1)CN3CCNC2	Bioorg Med Chem Lett	2020.0	CHEMBL4636196	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inactivation of CYP3A4 (unknown origin)	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C	J Med Chem	2020.0	CHEMBL1276308	=	=	Ki	nM	4700.0	Ki	uM	4.7
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4638454	=	=	IC50	nM	320.0	IC50	uM	0.32
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@@H](CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4644850	=	=	IC50	nM	85.0	IC50	uM	0.085
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)NC(CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1cccc2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4632678	=	=	IC50	nM	55.0	IC50	uM	0.055
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1c[nH]c2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4648061	=	=	IC50	nM	173.0	IC50	uM	0.173
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1c[nH]c2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4642007	=	=	IC50	nM	102.0	IC50	uM	0.102
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1cccc2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4644724	=	=	IC50	nM	356.0	IC50	uM	0.356
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1cccc2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4640859	=	=	IC50	nM	75.0	IC50	uM	0.075
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)NC(CSC(Cc1cccc2ccccc12)C(=O)NCc1cccnc1)Cc1cccc2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4639605	=	=	IC50	nM	244.0	IC50	uM	0.244
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 2 mins followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)NC(CSC(Cc1cccc2ccccc12)C(=O)NCCc1cccnc1)Cc1cccc2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4642617	=	=	IC50	nM	218.0	IC50	uM	0.218
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1	Bioorg Med Chem	2020.0	CHEMBL163	=	=	IC50	nM	130.0	IC50	uM	0.13
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CSCC(Nc1ccccc1)C(=O)NCc1cccnc1)Cc1c[nH]c2ccccc12	Bioorg Med Chem	2020.0	CHEMBL4638454	=	=	IC50	nM	430.0	IC50	uM	0.43
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1	Bioorg Med Chem	2020.0	CHEMBL4639033	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1	Bioorg Med Chem	2020.0	CHEMBL4635548	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@@H](CS[C@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1	Bioorg Med Chem	2020.0	CHEMBL4644634	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of human full length CYP3A4 assessed using 7-benzyloxy-4 (trifluoromethyl)coumarin as substrate preincubated for 20 mins in presence of NADPH followed by substrate addition and measured for 2 mins by fluorometric analysis	CC(C)(C)OC(=O)N[C@H](CS[C@@H](Cc1ccccc1)C(=O)NCCc1cccnc1)Cc1ccccc1	Bioorg Med Chem	2020.0	CHEMBL4645102	=	=	IC50	nM	310.0	IC50	uM	0.31
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	O=C(CCCCCc1ccccc1)N[C@H]1CC[C@H](O)CC1	J Med Chem	2020.0	CHEMBL4648137	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CCOc1ccc(-c2nnc([C@H]3C[C@H](NC(=O)c4ccccn4)C3)n2-c2ccccc2F)nc1	J Med Chem	2020.0	CHEMBL4633637	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	N#Cc1ccc2c(c1)[nH]c(=O)n2[C@H]1C[C@H](c2nnc(-c3ccncn3)n2-c2ccccc2Cl)C1	J Med Chem	2020.0	CHEMBL4095003	=	=	IC50	nM	1260.0	IC50	uM	1.26
Inhibition of CYP3A4 (unknown origin)	CC1Cc2cc(Cl)ccc2C(=O)N1c1cccnc1	J Med Chem	2020.0	CHEMBL4641568	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC1CN(c2cccnc2)C(=O)c2ccc(Cl)cc21	J Med Chem	2020.0	CHEMBL4644373	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)CN(c2cccnc2)C(=O)c2ccc(Cl)cc21	J Med Chem	2020.0	CHEMBL4638042	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cn4)CC3)cc2)c1=O	ACS Med Chem Lett	2020.0	CHEMBL4634077	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4 (unknown origin)	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6ccnc6)(c6ccc(Cl)cc6Cl)O5)cn4)CC3)cc2)c1=O	ACS Med Chem Lett	2020.0	CHEMBL4644787	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 (unknown origin)	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cnnn6)(c6ccc(Cl)cc6Cl)O5)cn4)CC3)cc2)c1=O	ACS Med Chem Lett	2020.0	CHEMBL4647183	>	>	IC50	nM	90000.0	IC50	uM	90.0
Inhibition of CYP3A4 (unknown origin)	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cnnn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)c(F)c2)c1=O	ACS Med Chem Lett	2020.0	CHEMBL4640665	>	>	IC50	nM	90000.0	IC50	uM	90.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@H]1C[C@H](C(=O)O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2020.0	CHEMBL4634542	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4	Cc1nc2c(-c3nnc[nH]3)cc(-c3ccncc3)cc2n1-c1ccnc2c(F)ccc(F)c12	ACS Med Chem Lett	2020.0	CHEMBL4634167	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of human CYP3A4	Cc1cc(-c2cc(-c3nnc[nH]3)c3nc(C)n(-c4ccnc5c(F)ccc(F)c45)c3c2)ccn1	ACS Med Chem Lett	2020.0	CHEMBL4637136	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of human CYP3A4	Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(C#N)c3)cc2n1-c1ccnc2c(F)ccc(F)c12	ACS Med Chem Lett	2020.0	CHEMBL4647791	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of human CYP3A4	Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3)cc2n1-c1ccnc2c(F)ccc(F)c12	ACS Med Chem Lett	2020.0	CHEMBL4639252	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human CYP3A4	Cc1nc2c(-c3nnc[nH]3)cc(-c3ccnc(N)c3F)cc2n1-c1ccnc2c(F)ccc(F)c12	ACS Med Chem Lett	2020.0	CHEMBL4470860	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](CN[C@@H](C(=O)Nc1ccc(-c2cnn(C)c2)cn1)c1ccccc1)c1ccc(C#N)cc1	ACS Med Chem Lett	2020.0	CHEMBL4641354	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CC1=C(C(=O)OC(C)C)C(c2ccoc2)n2c(nc3ccccc32)N1	J Med Chem	2020.0	CHEMBL3786336	=	=	IC50	nM	2680.0	IC50	uM	2.68
Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CC1=C(C(=O)OC(C)C)C(c2ccco2)n2c(nc3ccccc32)N1	J Med Chem	2020.0	CHEMBL3787197	=	=	IC50	nM	2900.0	IC50	uM	2.9
Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CCOC(=O)C1=C(C)Nc2nc3ccccc3n2C1c1cnoc1	J Med Chem	2020.0	CHEMBL4637204	=	=	IC50	nM	4920.0	IC50	uM	4.92
Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CCOC(=O)C1=C(C)Nc2nc3ccccc3n2C1c1ncc[nH]1	J Med Chem	2020.0	CHEMBL4632427	=	=	IC50	nM	4540.0	IC50	uM	4.54
Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CCOC(=O)C1=C(C)Nc2nc3ccccc3n2C1c1cocn1	J Med Chem	2020.0	CHEMBL4637285	=	=	IC50	nM	6410.0	IC50	uM	6.41
Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CC1=C(C(=O)OC(C)C)C(c2cocn2)n2c(nc3ccccc32)N1	J Med Chem	2020.0	CHEMBL4646279	=	=	IC50	nM	5920.0	IC50	uM	5.92
Inhibition of CYP3A4 (unknown origin) expressed in insect cell microsomes using dibenzylfluorescein substrate by fluorescence based assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	27.0	IC50	uM	0.027
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C	J Med Chem	2020.0	CHEMBL3040443	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@@H]1C(=O)N(Cc2c(C)ccc3ccccc23)c2ccc(C#N)cc2N(C(C)=O)[C@H]1C	J Med Chem	2020.0	CHEMBL3040443	=	=	Ki	nM	17000.0	Ki	uM	17.0
Inhibition of CYP3A4 (unknown origin)	NC(=O)c1cc(-c2ccc(F)cc2)c2ccc(CN3C(=O)CCC3=O)cc2n1	Bioorg Med Chem Lett	2020.0	CHEMBL3892073	>	>	IC50	nM	50000000.0	IC50	mM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1CCCCN1C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl	Bioorg Med Chem Lett	2020.0	CHEMBL4634571	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)(F)CC2)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4646118	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)CC2)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4643996	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1C[C@@H](F)CCN1C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl	Bioorg Med Chem Lett	2020.0	CHEMBL4634281	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)(F)C2)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4647147	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1CC(F)(F)CN1C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl	Bioorg Med Chem Lett	2020.0	CHEMBL4644553	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCN(CC)C(=O)c1nc(C(=O)NCC(C)(C)O)sc1-c1ccc(S(=O)(=O)N[C@@H](C)C(F)(F)F)c(Cl)c1Cl	Bioorg Med Chem Lett	2020.0	CHEMBL4643735	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCC(F)CC2)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4645439	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](NS(=O)(=O)c1ccc(-c2sc(NC(=O)CC(C)(C)O)nc2C(=O)N2CCC(F)CC2)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4648138	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N(CC)CC)c(Cl)c1Cl)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4639653	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC[C@H](NS(=O)(=O)c1ccc(-c2sc(C(=O)NCC(C)(C)O)nc2C(=O)N2CCCC[C@@H]2C)c(C(F)F)c1F)C(F)(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4646215	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(O)CNC(=O)c1nc(CC2CCCCC2)c(-c2ccc(S(=O)(=O)NC(C)(C)C)c3ccccc23)s1	Bioorg Med Chem Lett	2020.0	CHEMBL4129202	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using vivid DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay	O=C(Nc1ccc(SC(F)(F)F)c(Cl)c1)c1ccc(CN2CCCCC2)cc1	J Med Chem	2020.0	CHEMBL4634276	=	=	IC50	nM	15100.0	IC50	uM	15.1
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using vivid DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay	CC(C)(C)c1ccc(NC(=O)c2ccc(CN3CCCCC3)cc2)c(C(C)(C)C)c1	J Med Chem	2020.0	CHEMBL4640955	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using vivid DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay	O=C(Nc1ccc(C23CC4CC(CC(C4)C2)C3)cc1)c1ccc(CN2CCCCC2)cc1	J Med Chem	2020.0	CHEMBL4644544	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using vivid DBOMF as substrate preincubated for 10 mins followed by substrate addition and measured after 25 mins in presence of NAD+ by fluorescence assay	CC(c1ccc(C(=O)N2CCc3cc(C(C)(C)C)ccc32)cc1)N1CCCCC1	J Med Chem	2020.0	CHEMBL4640931	=	=	IC50	nM	24000.0	IC50	uM	24.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using fluorescent substrate in presence of NADPH by fluorescence assay	CC1CCN(c2ccc(NC(=O)c3ccc(CN4CCOCC4)cc3)cc2C(F)(F)F)CC1	J Med Chem	2020.0	CHEMBL4638872	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cell microsomes using fluorescent substrate in presence of NADPH by fluorescence assay	O=C(Nc1ccc(C23CC4CC(CC(C4)C2)C3)cc1)c1ccc(CN2CCOCC2)cc1	J Med Chem	2020.0	CHEMBL4647732	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CC(C)c1cc(COc2ccccc2CC(=O)O)cc(-c2ccc3c(c2)[C@H](N)CO3)c1	J Med Chem	2020.0	CHEMBL4643449	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins followed by NADPH addition and measured after 10 mins by LC-MS/MS analysis	CNC(=O)[C@H](C)Cn1cnc2ccc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4Cl)c3)cc2c1=O	ACS Med Chem Lett	2020.0	CHEMBL4632970	=	=	IC50	nM	23300.0	IC50	uM	23.3
Inhibition of CYP3A4 (unknown origin)	Cc1cc(-c2ccc(=O)n(C)c2C)cc2cn(C3CCNCC3)nc12	J Med Chem	2020.0	CHEMBL4641604	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	O=c1ccc(-c2cc(C(F)(F)F)c3nn([C@H]4CCNC[C@@H]4F)cc3c2)c2n1CCC2	J Med Chem	2020.0	CHEMBL4641633	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(-c2ccc(C34CCN(CC3)CC4)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1	J Med Chem	2020.0	CHEMBL4645216	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(-c2ccc(C34CCN(CC3)CC4)cc2)cc(-n2cc(-c3ccc(C(F)(F)F)cc3)nn2)c1	J Med Chem	2020.0	CHEMBL4646514	>	>	IC50	nM	3290.0	IC50	uM	3.29
Inhibition of CYP3A4 (unknown origin)	Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl	J Med Chem	2020.0	CHEMBL4633566	=	=	IC50	nM	8700.0	IC50	uM	8.7
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncnc(Nc3ccc(C(=N)N)cc3)c2O)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4636716	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncnc(Nc3ccc(C(=N)N)cc3Cl)c2O)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4643810	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncnc(Nc3ccc(CN)cc3)c2O)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4632936	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncnc(Nc3ccc4c(c3)CNC4=N)c2O)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4648414	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(-c2ncnc(Nc3ccc4c(c3Cl)CNC4=N)c2O)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4637996	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)Nc1cc(Nc2ccc3ncsc3c2)ncc1C(=O)NCCc1ccc(S(N)(=O)=O)cc1	ACS Med Chem Lett	2020.0	CHEMBL4636136	=	=	IC50	nM	0.9	IC50	nM	0.9
Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1cc(C(=O)NC2CC2)cn(Cc2ccccc2)c1=O	J Med Chem	2020.0	CHEMBL4635134	<	>	IC50	nM	39810.72	pIC50		4.4
Inhibition of CYP3A4 (unknown origin)	CNC(=O)c1cc(C(=O)NC2CC2)cn(Cc2cccc3[nH]ccc23)c1=O	J Med Chem	2020.0	CHEMBL4648431	<	>	IC50	nM	39810.72	pIC50		4.4
Inhibition of CYP3A4 (unknown origin) by Cyprotex-protocol assay	CNC(=O)c1cc(C(=O)NC2CC2)cn(Cc2ccccc2)c1=O	J Med Chem	2020.0	CHEMBL4635134	<	>	IC50	nM	199526.23	pIC50		3.7
Inhibition of CYP3A4 (unknown origin)	Cc1ccc2[nH]c(C(=O)N[C@H]3CN(S(=O)(=O)c4ccccc4)C[C@@H]3C(=O)N[C@H]3CCCNC3)cc2c1	J Med Chem	2020.0	CHEMBL4647963	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LC/MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1OC	J Med Chem	2020.0	CHEMBL4517408	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LC/MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1F	J Med Chem	2020.0	CHEMBL4636120	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 10 mins in presence of NADPH by LC/MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1OC	J Med Chem	2020.0	CHEMBL4517408	>	>	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 10 mins in presence of NADPH by LC/MS/MS analysis	COc1cc(-c2cncc(-c3ccc(N4CCNCC4)cc3)c2C)cc(OC)c1F	J Med Chem	2020.0	CHEMBL4636120	=	=	IC50	nM	14300.0	IC50	uM	14.3
Inhibition of CYP3A4 (unknown origin)	Cl.NC(=O)[C@@H]1CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1	ACS Med Chem Lett	2020.0	CHEMBL3544912	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes	O=C1c2cc(C(F)(F)F)ccc2NC12CCN(CC1CCOCC1)CC2	Bioorg Med Chem	2020.0	CHEMBL4634061	>	>	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin)	NC1=N[C@](CF)(c2cc(NC(=O)c3cnc(OCF)cn3)ccc2F)CCC1(F)F	Bioorg Med Chem Lett	2020.0	CHEMBL4643511	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C#N)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)(C)C#N)c1	J Med Chem	2020.0	CHEMBL4640712	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)n1	J Med Chem	2020.0	CHEMBL4635883	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam hydrochloride as substrate incubated for 20 mins in presence of NADPH by LC-MS/MS analysis	Cc1nn([C@H](C)c2ccc(Cl)cc2Cl)c2nc(N3CC([C@H]4CCCN(CCO)C4)C3)cnc12	J Med Chem	2020.0	CHEMBL4634054	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 in human liver microsomes using midazolam hydrochloride as substrate incubated for 20 mins in presence of NADPH by LC-MS/MS analysis	C[C@H](c1ccc(Cl)cc1Cl)n1nc(C#N)c2ncc(N3CC([C@H]4CCCN(CCO)C4)C3)nc21	J Med Chem	2020.0	CHEMBL4637143	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(/C=C2\CCCN3C2=NO[C@H](c2cc(F)cc(F)c2)[C@@H]3C)ccc1-n1cnc(C)c1	J Med Chem	2020.0	CHEMBL4643105	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(/C=C2\CCCN3C2=NO[C@H](c2cc(F)c(F)c(F)c2)[C@@H]3C)ccc1-n1cnc(C)c1	J Med Chem	2020.0	CHEMBL4634921	=	=	IC50	nM	29000.0	IC50	uM	29.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(C2=CC3=NO[C@H](c4cc(F)c(F)c(F)c4)CN3CCC2)ccc1-n1cnc(C)c1	J Med Chem	2020.0	CHEMBL4634696	=	=	IC50	nM	34000.0	IC50	uM	34.0
Inhibition of CYP3A4 (unknown origin)	COc1cc(C2=CC3=NOC[C@H](c4cc(F)c(F)c(F)c4)N3CCC2)ccc1-n1cnc(C)c1	J Med Chem	2020.0	CHEMBL4642697	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=c1[nH]ccc2cc(Nc3n[nH]c4cccnc34)ccc12	Bioorg Med Chem Lett	2019.0	CHEMBL4784617	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	c1cnc2c(Nc3ccc4cnccc4c3)n[nH]c2c1	Bioorg Med Chem Lett	2019.0	CHEMBL4783372	=	=	IC50	nM	440.0	IC50	uM	0.44
Inhibition of CYP3A4 (unknown origin)	c1cnc2c(Nc3ccc4c(-n5cccn5)nccc4c3)n[nH]c2c1	Bioorg Med Chem Lett	2019.0	CHEMBL4787268	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin)	FC(F)c1nccc2cc(Nc3n[nH]c4cccnc34)ccc12	Bioorg Med Chem Lett	2019.0	CHEMBL4779331	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COc1nnc2sc(C(=O)NC3CN(c4ncc(C(F)(F)F)cn4)C3)c(N)c2c1C	Bioorg Med Chem Lett	2019.0	CHEMBL4795177	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using midazolam as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay	CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(C(F)(F)F)cc2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4750688	=	=	IC50	nM	871.0	IC50	nM	871.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using midazolam as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay	CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(S(F)(F)(F)(F)F)cc2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4755729	=	=	IC50	nM	159.0	IC50	nM	159.0
Inhibition of recombinant human CYP3A4 expressed in baculovirus infected insect cells using midazolam as substrate incubated for 30 mins in presence of NADPH-regenerating system by fluorescence based assay	CN(C)c1ccc(CC(=O)N[C@@H]2CNC[C@H]2c2ccc(C(C)(F)F)cc2)cc1	ACS Med Chem Lett	2019.0	CHEMBL4759278	=	=	IC50	nM	2500.0	IC50	nM	2500.0
Inhibition of CYP3A4 (unknown origin) by fluorescence assay	Nc1ncc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c(C(F)F)n1	ACS Med Chem Lett	2019.0	CHEMBL4744705	>	>	IC50	nM	100000.0	IC50	uM	100.0
Metabolism-dependent inhibition of CYP3A4 (unknown origin)	CC(=O)Nc1c(F)cc(C(=O)N[C@H]2CC[C@H](O)CC2)cc1O[C@@H](C)c1ccccc1	J Med Chem	2020.0	CHEMBL4636881	<	>	IC50	nM	39810.72	pIC50		4.4
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Cl)cc(N2C=Nc3cc(C)c(-c4cc(F)cc(C(N)=O)c4)cc3C2C(=O)N(C)C[C@@H]2CCCN2)c1	Bioorg Med Chem Lett	2020.0	CHEMBL4761949	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate preincubated for 5 mins followed by addition of NADPH measured after 20 mins by LC-MS/MS analysis	O=C(O)CNC(=O)c1ncc(C#CCOc2ccc(Cl)cc2)cc1O	J Med Chem	2020.0	CHEMBL4162752	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate preincubated for 5 mins followed by addition of NADPH measured after 20 mins by LC-MS/MS analysis	O=C(O)CNC(=O)c1ncc(C#CCOc2ccc(Cl)cc2)cc1O	J Med Chem	2020.0	CHEMBL4162752	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(Cl)cc(-c2cnc3ncn(-c4cc(O)cc(F)c4)c(=O)c3c2CN(C)C[C@@H]2CCCN2)c1	Bioorg Med Chem Lett	2020.0	CHEMBL4778342	<	>	IC50	nM	10000.0	pIC50		5.0
inhibition of CYP3A4 in human liver microsomes	COc1cc(C(=O)N2CCC3(CC2)CC(=O)c2c(cnn2C(C)C)C3)cc(-c2ccc(C(=O)O)cc2)n1	J Med Chem	2020.0	CHEMBL4567446	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-c2ccn3nc(N)c(-c4cnn(C)c4)c3n2)cc2c1C(=O)N([C@@H](C)C1CC1)C2	J Med Chem	2020.0	CHEMBL4755842	=	=	IC50	nM	450.0	IC50	uM	0.45
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)Nc1cc2nc(-c3cc4c(c(C(F)(F)F)c3)C(=O)N([C@@H](C)C3CC3)C4)ccn2n1	J Med Chem	2020.0	CHEMBL4785086	=	=	IC50	nM	4600.0	IC50	uM	4.6
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 to 20 mins in presence of NADPH by LC-MS/MS analysis	C[C@@H](C1CC1)N1Cc2cc(-c3ccn4nc(N)c(-c5cnn(C)c5)c4n3)cc(C(F)(F)F)c2C1=O	J Med Chem	2020.0	CHEMBL4782083	=	=	IC50	nM	600.0	IC50	uM	0.6
Inhibition of CYP3A4 in human liver microsome using midazolam as substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis	CC(Sc1nc2ncccc2n1-c1ccc(C2CC2)c2ccccc12)C(=O)O	J Med Chem	2020.0	CHEMBL4759016	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsome using midazolam as substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis	CC(Sc1nc2cnccc2n1-c1ccc(C2CC2)c2ccccc12)C(=O)O	J Med Chem	2020.0	CHEMBL4750462	=	=	IC50	nM	36500.0	IC50	uM	36.5
Inhibition of CYP3A4 in human liver microsome using midazolam as substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis	O=C(CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12)NS(=O)(=O)c1ccc(Br)cc1	J Med Chem	2020.0	CHEMBL4756866	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsome using midazolam as substrate measured after 20 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	37.5	IC50	uM	0.0375
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCCc1ccccn1	J Med Chem	2020.0	CHEMBL4778430	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NC(C)Cc1ccccn1	J Med Chem	2020.0	CHEMBL4782206	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1ccccc1C(C)CNC(=O)c1c(C)c(-c2ccccc2)nc2ccc(Br)cc12	J Med Chem	2020.0	CHEMBL4761725	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1ccccc1C(C)CNC(=O)c1c(C)c(-c2ccccc2)nc2ccc(Br)cc12	J Med Chem	2020.0	CHEMBL4761725	=	=	IC50	nM	700.0	IC50	uM	0.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)Nc1ccc(C(=O)O)cc1	J Med Chem	2020.0	CHEMBL4764092	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4755942	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1CNc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4756085	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1COc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4790875	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Cl)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4751462	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(C(F)(F)F)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4782468	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(I)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4750703	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(C(C)(C)C)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4756068	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(C(=O)Nc2ccc(C(=O)O)cc2F)c2cc(Br)ccc2[n+]([O-])c1-c1ccccc1	J Med Chem	2020.0	CHEMBL4739939	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(C(=O)Nc2ccc(C(=O)O)cc2F)c2cc(Br)ccc2c(=O)n1-c1ccccc1	J Med Chem	2020.0	CHEMBL4759438	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)cc2ccc(Br)cc2c1C(=O)Nc1ccc(C(=O)O)cc1F	J Med Chem	2020.0	CHEMBL4789967	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NC12CCC(C(=O)O)(CC1)CC2	J Med Chem	2020.0	CHEMBL4789100	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(C(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4743035	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(C(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4743035	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4744552	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4744552	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1ccccc1C(CNC(=O)c1c(C)c(-c2ccccc2)nc2ccc(Br)cc12)CC(=O)O	J Med Chem	2020.0	CHEMBL4761670	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1ccccc1C(CNC(=O)c1c(C)c(-c2ccccc2)nc2ccc(Br)cc12)CC(=O)O	J Med Chem	2020.0	CHEMBL4761670	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1cccc(C(CNC(=O)c2c(C)c(-c3ccccc3)nc3ccc(Br)cc23)CC(=O)O)c1	J Med Chem	2020.0	CHEMBL4777724	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	COc1ccc(C(CNC(=O)c2c(C)c(-c3ccccc3)nc3ccc(Br)cc23)CC(=O)O)cc1	J Med Chem	2020.0	CHEMBL4762787	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4743411	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4743411	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl	J Med Chem	2020.0	CHEMBL4749767	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl	J Med Chem	2020.0	CHEMBL4749767	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4754421	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(-c2ccccc2)nc2ccc(Br)cc2c1C(=O)NCC(CCCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4754421	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CC(F)(F)C2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4741813	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCC2)nc2ccc(Br)cc2c1C(=O)NC[C@H](CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4643852	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCC2)nc2ccc(Br)cc2c1C(=O)NC[C@@H](CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4750758	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4779694	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4779694	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl	J Med Chem	2020.0	CHEMBL4749822	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1c(F)ccc(F)c1Cl	J Med Chem	2020.0	CHEMBL4749822	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1	J Med Chem	2020.0	CHEMBL4752237	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1	J Med Chem	2020.0	CHEMBL4752237	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1	J Med Chem	2020.0	CHEMBL4752237	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	CCC1CCCN(c2nc3ccc(Br)cc3c(C(=O)NCC(CCC(=O)O)c3ccccc3Cl)c2C)C1	J Med Chem	2020.0	CHEMBL4752237	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4784864	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH generating system by LC-MS/MS analysis	Cc1c(N2CCCCCC2)nc2ccc(Br)cc2c1C(=O)NCC(CCC(=O)O)c1ccccc1Cl	J Med Chem	2020.0	CHEMBL4784864	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 (unknown origin)	CC1(C)C(=O)Nc2nc(-n3nc(CCC(F)(F)F)c4cc(Cl)ccc43)nc(N)c21	Bioorg Med Chem Lett	2020.0	CHEMBL4758823	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes by LC-MS analysis	C[C@@H]1CCN(c2cc(-c3ccccc3)ccn2)C[C@H]1c1cc(C(F)F)nc2ncnn12	J Med Chem	2020.0	CHEMBL4741218	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2c(Cl)cc(C(N)=O)c3[nH]c4cc(C(C)(C)O)ccc4c23)cccc1-n1c(=O)cc2c(Cl)cccn2c1=O	ACS Med Chem Lett	2020.0	CHEMBL3928976	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin)	CCn1c(-c2cnc(C)nc2)nc2c(-c3cnc4c(c3)[C@](C)(NCC(C)(C)F)C(=O)N4)ncnc21	ACS Med Chem Lett	2020.0	CHEMBL4750385	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	Cc1ncc(-c2nc3c(-c4ccc5c(c4)[C@@]4(CCCN4C(=O)C4CC4)C(=O)N5C)ncnc3n2C)cn1	ACS Med Chem Lett	2020.0	CHEMBL4776201	>	>	IC50	nM	50000.0	IC50	nM	50000.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(O)CN1C(=O)[C@H](F)C[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2020.0	CHEMBL4782326	>	>	IC50	nM	20000.0	IC50	nM	20000.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	COc1cc(-c2ncc(COc3cccc([C@@H](CC(=O)O)C4CC4)c3)nc2CC(C)C)c(F)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4764485	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	COc1cc(-c2ncc(COc3cccc([C@@H](CC(=O)O)C4CC4)c3)nc2CC(C)C)c(F)cn1	Bioorg Med Chem Lett	2018.0	CHEMBL4764485	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of human CYP3A4 expressed in Sacchrosomes using dibenzylfluorescein as substrate by fluorescence based assay	COc1c(-c2ccc3c(c2)OCO3)oc2c(ccc3occc32)c1=O	Bioorg Med Chem	2018.0	CHEMBL577397	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in Sacchrosomes using dibenzylfluorescein as substrate by fluorescence based assay	O=c1cc(-c2ccccc2)oc2c1ccc1occc12	Bioorg Med Chem	2018.0	CHEMBL224157	>	>	IC50	nM	20000.0	IC50	uM	20.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate and in presence of co-factor by LC-MS/MS analysis	O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3716365	>	>	IC50	nM	50000.0	IC50	uM	50.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate and in presence of co-factor by LC-MS/MS analysis	O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3716365	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes using testosterone as substrate and in presence of co-factor preincubated for 20 mins followed by substrate addition by LC-MS/MS analysis	O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3716365	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 in human liver microsomes using testosterone as substrate and in presence of co-factor preincubated for 20 mins followed by substrate addition by LC-MS/MS analysis	O=c1nc(OC[C@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3717363	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate and in presence of co-factor preincubated for 20 mins followed by substrate addition by LC-MS/MS analysis	O=c1nc(OC[C@@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3716365	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate and in presence of co-factor preincubated for 20 mins followed by substrate addition by LC-MS/MS analysis	O=c1nc(OC[C@H]2COCCO2)cc2n1CCc1cc(C#CC3CC3)ccc1-2	J Med Chem	2020.0	CHEMBL3717363	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1CCN1c1nc(N2C[C@H]3[C@H](CC(=O)O)[C@H]3C2)cc(C(F)(F)F)n1	J Med Chem	2020.0	CHEMBL4549658	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes	C[C@@H]1Cc2c(ccc3[nH]ncc23)[C@@H](c2ccc(NC3CN(CCCF)C3)cn2)N1CC(F)(F)F	J Med Chem	2020.0	CHEMBL4650365	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of CYP3A4 in human liver microsomes	COc1cc(NC2CN(CCCF)C2)ccc1[C@@H]1c2ccc3[nH]ncc3c2C[C@@H](C)N1CC1(F)CC1	J Med Chem	2020.0	CHEMBL4742862	=	=	IC50	nM	11000.0	IC50	uM	11.0
Irreversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1	J Med Chem	2020.0	CHEMBL4537788	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using dextromethorphan as substrate by LC-MS/MS analysis	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1	J Med Chem	2020.0	CHEMBL4537788	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 5 mins in presence of NADPH by LC-MS/MS analysis	CNC(=O)c1cn(C[C@H](F)CCc2ccc(NC(=O)Cc3cc(OC4CC(F)(F)C4)cc(C)n3)nn2)nn1	J Med Chem	2020.0	CHEMBL4741924	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(n[nH]c2C(C)(C)C)C(=O)N1c1ccc(-c2ccsc2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL3684611	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nccs2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4799974	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nnc(C)o2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4762641	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2nc(C)no2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4745262	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2noc(C)n2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4745598	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(n[nH]c2C(C)(C)C)C(=O)N1c1ccc(-c2ncco2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL3684614	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2cc(C)no2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4750518	=	=	IC50	nM	2000.0	IC50	uM	2.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(C(=O)N(C)C)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4743161	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CCOC(=O)c1ccc(N2C(=O)c3n[nH]c(C(C)(C)C)c3C2c2ccccc2OC)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL3679906	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(F)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4745595	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)C)n[nH]c2C(=O)N1c1ccc(-c2ccon2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4765176	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1[nH]nc2c1C(c1ccccc1OCCO)N(c1ccc(-c3ccon3)cc1)C2=O	Bioorg Med Chem Lett	2020.0	CHEMBL3679944	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1n[nH]c2c1C(c1ccccc1OCCS(C)(=O)=O)N(c1ccc(-c3ccon3)cc1)C2=O	Bioorg Med Chem Lett	2020.0	CHEMBL4758458	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(C)c1[nH]nc2c1C(c1ccccc1OCC(=O)O)N(c1ccc(-c3ccon3)cc1)C2=O	Bioorg Med Chem Lett	2020.0	CHEMBL3679880	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(CCO)n[nH]c2C(=O)N1c1ccc(-c2ccon2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4741951	=	=	IC50	nM	16000.0	IC50	uM	16.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(C(C)(C)CO)n[nH]c2C(=O)N1c1ccc(-c2ccon2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4797432	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1C1c2c(n[nH]c2C(C)(CO)CO)C(=O)N1c1ccc(-c2ccon2)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL3684655	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1-c1nccc(COc2ccccc2C[C@@H](Oc2ncnc3sc(-c4ccc(F)cc4)c(-c4ccc(OCCN5CCN(C)CC5)c(Cl)c4C)c23)C(=O)O)n1	J Med Chem	2020.0	CHEMBL4788274	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates by LC/MS analysis	CC(=O)Nc1ncc(CN2CCC3(CCN(c4cc(C)nc5ccccc45)C3)C2)s1	J Med Chem	2020.0	CHEMBL4741417	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CN(C)CCn1cc2cc(NC(=O)c3cccc(C(F)(F)F)n3)c(C(C)(C)O)cc2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4791626	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CN(C)CCn1cc2cc(NC(=O)c3cccc(C(F)(F)F)n3)c(C(C)(C)O)cc2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4791626	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3nccc(F)c23)cs1	Bioorg Med Chem Lett	2021.0	CHEMBL4778806	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	O=C(Cc1cccc(OCCCC2CCNCC2)c1)Nc1nc(-c2c[nH]c3ncccc23)cs1	Bioorg Med Chem Lett	2021.0	CHEMBL4245242	=	=	IC50	nM	21000.0	IC50	uM	21.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncc(F)cc45)cs3)c2)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4742150	=	=	IC50	nM	27000.0	IC50	uM	27.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4245197	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(CCCOc2cccc(CC(=O)Nc3nc(-c4c[nH]c5ncccc45)cs3)c2)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4248525	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(Br)cc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4746642	=	=	IC50	nM	35000.0	IC50	uM	35.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(Cl)cc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4793675	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4nccc(Cl)c34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4778609	=	=	IC50	nM	8000.0	IC50	uM	8.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(O)cc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4751643	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncc(F)cc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4752045	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4nccc(F)c34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4757625	=	=	IC50	nM	36000.0	IC50	uM	36.0
Inhibition of CYP3A4 (unknown origin)	Cc1sc(NC(=O)Cc2cccc(NS(C)(=O)=O)c2)nc1-c1c[nH]c2ncccc12	Bioorg Med Chem Lett	2021.0	CHEMBL4763436	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3c[nH]c4ncccc34)ncn2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4781437	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nccc(-c3c[nH]c4ncccc34)n2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4752171	=	=	IC50	nM	48000.0	IC50	uM	48.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nnc(-c3c[nH]c4ncccc34)s2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4800244	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4794318	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2ccc(-c3c[nH]c4ncccc34)s2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4754058	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2cnc(-c3c[nH]c4ncccc34)s2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4754398	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	CS(=O)(=O)Nc1cccc(CC(=O)Nc2nc(-c3c[nH]c4ncccc34)cs2)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4249925	=	=	IC50	nM	8300.0	IC50	uM	8.3
Inhibition of CYP3A4 (unknown origin)	C[C@]12CCCN1CC1=NNC(=O)c3cc(F)cc4[nH]c2c1c34	J Med Chem	2020.0	CHEMBL4112930	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in in human liver microsomes at incubated for 10 mins in presence of CYP3A4 substrate/NADP+ by fluorescence based assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	11.0	IC50	uM	0.011000000000000001
Inhibition of CYP3A4 in in human liver microsomes at incubated for 10 mins in presence of CYP3A4 substrate/NADP+ by fluorescence based assay	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	J Med Chem	2020.0	CHEMBL6966	=	=	IC50	nM	21330.0	IC50	uM	21.33
Inhibition of CYP3A4 (unknown origin)	Cc1cccc(Cc2nc3cc(O[C@H]4CC[C@@H](C(=O)O)CC4)ccc3n2C)c1	Bioorg Med Chem Lett	2021.0	CHEMBL4778736	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH generating system addition and measured after 120 mins by LC-MS/MS	Cc1nc(-c2cccc(C#N)c2)n(OCc2ccc(C#N)cc2)c1C(=O)O	J Med Chem	2020.0	CHEMBL4786038	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 3 mins followed by NADPH addition by LC-MS/MS analysis	CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1cccc(Cn2ccnc2)c1	Bioorg Med Chem	2021.0	CHEMBL2086892	=	=	IC50	nM	120000.0	IC50	uM	120.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 3 mins followed by NADPH addition by LC-MS/MS analysis	COC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1cccc(C(=O)Cn2ccnc2C(C)(C)C)c1	Bioorg Med Chem	2021.0	CHEMBL4788892	=	=	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@]2(CC1)COc1cc(C(F)(F)F)ccc12	Bioorg Med Chem Lett	2021.0	CHEMBL4763375	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 (unknown origin)	C[C@@H](C(=O)Nc1ccc(Cl)cc1)[C@H]1CC[C@@H](c2ccnc3ccc(F)cc32)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4161733	=	=	IC50	nM	5100.0	IC50	uM	5.1
Inhibition of CYP3A4 (unknown origin)	O=C(Nc1ccc(Cl)cc1)C(=O)N1CC[C@H](c2ccnc3ccc(F)cc23)[C@@H](O)C1	Bioorg Med Chem Lett	2021.0	CHEMBL4753967	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CCS(=O)(=O)c1ccc(CNC(=O)N2CC(C)(C)c3nc(-c4c(OC)ncnc4C4CC4)ccc32)cc1	ACS Med Chem Lett	2021.0	CHEMBL4799596	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CNS(=O)(=O)c1ccc(CNC(=O)N2CC3(CCCC3)c3nc(-c4ccc(O)cc4C)ccc32)cc1	ACS Med Chem Lett	2021.0	CHEMBL4790808	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of human CYP3A4 in pooled human liver microsomes using midazolam as substrate incubated for 5 mins by LC-MS/MS	N#Cc1ccc(N2C3CCC2CN(C(=O)CCS(=O)(=O)c2cccc4ncsc24)C3)nc1	ACS Med Chem Lett	2021.0	CHEMBL4790083	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxy resorufin as substrate	O=C(O)C1CN(Cc2ccc3c(c2)CCc2c-3noc2-c2onc(-c3ccccc3)c2C(F)(F)F)C1	J Med Chem	2016.0	CHEMBL3959509	=	=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2)CCN1c1cccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1	J Med Chem	2016.0	CHEMBL4747534	=	=	IC50	nM	970.0	IC50	uM	0.97
Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	CNC(=O)c1ccc(N2CCN(c3cccc(C(=O)NC4C5CC6CC4CC(O)(C6)C5)n3)[C@H](C)C2)cn1	J Med Chem	2016.0	CHEMBL4779054	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	C[C@@H]1CN(c2ccc(C(C)(C)O)nc2)CCN1c1cccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1	J Med Chem	2016.0	CHEMBL4746745	=	=	IC50	nM	5400.0	IC50	uM	5.4
Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2)CCN1c1nccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1	J Med Chem	2016.0	CHEMBL4788862	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in pooled human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	C[C@@H]1CN(c2ccc(S(C)(=O)=O)cc2F)CCN1c1nccc(C(=O)NC2C3CC4CC2CC(O)(C4)C3)n1	J Med Chem	2016.0	CHEMBL4748750	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Nc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cn1	J Med Chem	2018.0	CHEMBL3754515	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(Oc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cc1)C(=O)O	J Med Chem	2018.0	CHEMBL4746566	>	>	IC50	nM	3000.0	IC50	uM	3.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins by LC-MS/MS analysis	C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc5nonc5c4)c(=O)c(O)c3C(=O)N12	Eur J Med Chem	2020.0	CHEMBL4784137	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 30 mins by LC-MS/MS analysis	C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)nc4F)c(=O)c(O)c3C(=O)N12	Eur J Med Chem	2020.0	CHEMBL4744587	>	>	IC50	nM	10000.0	IC50	uM	10.0
Competitive inhibition of human recombinant CYP3A4 expressed in baculovirus-infected insect cells using diltiazem as substrate incubated for 15 mins followed by NADPH-generating system addition by Michaelis-Menten plot analysis	C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O	J Med Chem	2020.0	CHEMBL190461	=	=	Ki	nM	1000.0	Ki	uM	1.0
Inhibition of recombinant CYP3A4 (unknown origin) in presence of BFC as substrate	Cc1nc2cc(F)c(-c3cnc(C(C)(C)O)nc3)nc2c(N[C@H](C)c2cc(C#N)ccc2F)c1Cl	J Med Chem	2020.0	CHEMBL4777447	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 15 mins by LC-MS/MS analysis	C[C@H]1CCCN1C[C@@H](C)NC(=O)c1ccc(-c2noc(C(F)(F)F)n2)cc1	ACS Med Chem Lett	2021.0	CHEMBL4798111	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 30 mins by LC-MS/MS analysis	C[C@H]1CCCN1C[C@@H](C)NC(=O)c1ccc(-c2noc(C(F)(F)F)n2)cc1	ACS Med Chem Lett	2021.0	CHEMBL4798111	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)c1cccc(Cl)c1	ACS Med Chem Lett	2021.0	CHEMBL4744727	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2C(=O)OC1CC1	ACS Med Chem Lett	2021.0	CHEMBL4749009	=	=	IC50	nM	60000.0	IC50	uM	60.0
Inhibition of CYP3A4 (unknown origin)	C[C@@H](NC(=O)c1ccc(F)cc1)c1ccc2c(n1)CCCN2c1ccnc(C(F)(F)F)n1	ACS Med Chem Lett	2021.0	CHEMBL4783395	=	=	IC50	nM	43000.0	IC50	uM	43.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2cc(F)c(N)cc2F)ccc2c3ocnc3c(=O)n(C3CC3)c12	RSC Med Chem	2020.0	CHEMBL4747990	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2cc(F)c(N)cc2F)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12	RSC Med Chem	2020.0	CHEMBL4764598	=	=	IC50	nM	12900.0	IC50	uM	12.9
Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2cnc3[nH]ncc3c2)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12	RSC Med Chem	2020.0	CHEMBL4787847	=	=	IC50	nM	22600.0	IC50	uM	22.6
Inhibition of CYP3A4 (unknown origin)	Cc1c(-c2ccc3[nH]ncc3c2)ccc2c3oc(CN)nc3c(=O)n(C3CC3)c12	RSC Med Chem	2020.0	CHEMBL4743440	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 (unknown origin)	Cc1nc2c(=O)n(C3CC3)c3c(Cl)c(N4CC[C@@H]([C@H](C)N)C4)c(F)cc3c2o1	RSC Med Chem	2020.0	CHEMBL4786331	=	=	IC50	nM	17500.0	IC50	uM	17.5
Inhibition of CYP3A4 in human liver microsomes measured after 30 mins	CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@H]2c1ccc(F)cc1	ACS Med Chem Lett	2019.0	CHEMBL4209316	=	=	IC50	nM	200.0	IC50	uM	0.2
Time dependent inhibition of CYP3A4 in human liver microsomes assessed as inhibition constant	CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@H]2c1ccc(F)cc1	ACS Med Chem Lett	2019.0	CHEMBL4209316	=	=	Ki	nM	83000.0	Ki	uM	83.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 15 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1	J Med Chem	2020.0	CHEMBL4744041	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 15 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1	J Med Chem	2020.0	CHEMBL4744041	>	>	IC50	nM	25000.0	IC50	uM	25.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using testosterone in presence of NADPH by LC-MS/MS analysis	Cc1cc(-c2ccnc(Nc3cnn(C)c3)n2)ccc1CNC(=O)N1CC(OC(C)C)C1	J Med Chem	2020.0	CHEMBL4744041	=	=	Ki	nM	50000.0	Ki	uM	50.0
Inhibition of recombinant CYP3A4 (unknown origin)	C[C@H]1C[C@H](C(=O)O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccccc3)c3cc(F)c(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	Bioorg Med Chem Lett	2020.0	CHEMBL4763134	>	>	IC50	nM	20000.0	IC50	uM	20.0
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as inhibition constant by Kitz-Wilson plot analysis	CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@H]2c1ccc(F)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4209316	=	=	Ki	nM	82500.0	Ki	uM	82.5
Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as inhibition constant by Kitz-Wilson plot analysis	CNc1nc(Nc2ccc(-n3cnc(C)n3)c(OC)c2)nc2c1CC[C@@H]2c1ccc(F)cc1	Bioorg Med Chem Lett	2020.0	CHEMBL4793756	=	=	Ki	nM	82500.0	Ki	uM	82.5
Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	CN(C)C(=O)c1ccc(Oc2nc(-c3ccc(N)nc3)nc(N3CCOCC3)n2)cc1	J Med Chem	2020.0	CHEMBL4793302	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	CN(C)C(=O)c1ccc(Oc2nc(-c3ccnc4[nH]ccc34)nc(N3CCOCC3)n2)cc1	J Med Chem	2020.0	CHEMBL4764922	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	CN(C)C(=O)c1ccc(Oc2nc(-c3cnc(N)s3)nc(N3CCOCC3)n2)cc1	J Med Chem	2020.0	CHEMBL4782133	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Nc1nc(OCc2ccccc2)c2[nH]nnc2n1	Bioorg Med Chem	2020.0	CHEMBL333928	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Nc1cc(Cc2ccccc2)c2nn[nH]c2n1	Bioorg Med Chem	2020.0	CHEMBL4753981	=	=	IC50	nM	6600.0	IC50	uM	6.6
Inhibition of CYP3A4 (unknown origin)	Nc1cc([C@H](Cc2ccccc2)c2ccccc2)c2nn[nH]c2n1	Bioorg Med Chem	2020.0	CHEMBL4761170	=	=	IC50	nM	3400.0	IC50	uM	3.4
Inhibition of CYP3A4 (unknown origin)	Nc1cc([C@H](CCCc2ccccc2)c2ccccc2)c2nn[nH]c2n1	Bioorg Med Chem	2020.0	CHEMBL4763067	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 (unknown origin)	Nc1cc([C@H](CCOCc2ccccc2)c2ccccc2)c2nn[nH]c2n1	Bioorg Med Chem	2020.0	CHEMBL4792720	=	=	IC50	nM	2600.0	IC50	uM	2.6
Inhibition of CYP3A4 (unknown origin)	Nc1cc([C@H](CCNCc2ccccc2)c2ccccc2)c2nn[nH]c2n1	Bioorg Med Chem	2020.0	CHEMBL4800005	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCCC2	Bioorg Med Chem	2020.0	CHEMBL4445443	=	=	IC50	nM	3700.0	IC50	uM	3.7
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3C(C)(C)C)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4754724	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3C3CCC3)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4795963	=	=	IC50	nM	590.0	IC50	uM	0.59
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CCF)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4750723	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CCO)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4741060	=	=	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CCCO)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4777113	=	=	IC50	nM	2200.0	IC50	uM	2.2
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CC(C)(C)O)CCCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4760389	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3C(C)C)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4794750	=	=	IC50	nM	2300.0	IC50	uM	2.3
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3CCF)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4786740	=	=	IC50	nM	40.0	IC50	uM	0.04
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3cc(C(C)(C)C)nn3CC(F)(F)F)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4751736	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc(C2(C)CC2)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(OC)n2)cs1	Bioorg Med Chem	2020.0	CHEMBL4749020	=	=	IC50	nM	4100.0	IC50	uM	4.1
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc(C(F)(F)F)cc1Nc1nc(-c2ccc(-n3cnc(C)c3)c(OC)n2)cs1	Bioorg Med Chem	2020.0	CHEMBL4763513	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3C)CCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4741605	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCC2	Bioorg Med Chem	2020.0	CHEMBL4758131	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CCF)CCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4759910	=	=	IC50	nM	10500.0	IC50	uM	10.5
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CC(F)(F)F)CCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4777391	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	COc1nc(-c2csc(Nc3c4c(nn3CCO)CCC4)n2)ccc1-n1cnc(C)c1	Bioorg Med Chem	2020.0	CHEMBL4761020	<	<	IC50	nM	50.0	IC50	uM	0.05
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCC2(C)C	Bioorg Med Chem	2020.0	CHEMBL4747572	=	=	IC50	nM	750.0	IC50	uM	0.75
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)C(C)CC2(C)C	Bioorg Med Chem	2020.0	CHEMBL4798079	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of recombinant CYP3A4 (unknown origin) by fluorescence-based assay	CCn1nc2c(c1Nc1nc(-c3ccc(-n4cnc(C)c4)c(OC)n3)cs1)CCCCC2	Bioorg Med Chem	2020.0	CHEMBL4745955	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin)	O=c1[nH]nc(-c2ccc(Cl)c(C(F)(F)F)c2)o1	J Med Chem	2020.0	CHEMBL4788846	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) incubated for 20 to 30 mins by P450-Glo assay	CC[C@@H](c1nc2cccc(F)c2c(=O)n1C1CC1)n1nc(-c2ccc(OC)c(F)c2)c2c(N)ncnc21	J Med Chem	2020.0	CHEMBL4781849	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CO[C@@H](C)c1c(NC(=O)Nc2cnc(-n3nccn3)c(Cl)c2)cnc2cc(Cl)nn12	J Med Chem	2020.0	CHEMBL4748253	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CO[C@@H](C)c1c(NC(=O)Nc2ccnc(C(F)(F)F)c2)cnc2cc(Cl)nn12	J Med Chem	2020.0	CHEMBL4746044	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes	CC(=O)N1CCN(CCOCc2ccn(-c3ccc(F)c(F)c3)n2)CC1.Cl	J Med Chem	2020.0	CHEMBL4743610	=	=	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate in presence of NADPH	C[C@@H](c1cc(OCC(F)F)ccn1)n1cnc2c(N)nc(Cl)nc21	J Med Chem	2020.0	CHEMBL4762103	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes in presence of NADPH by LC-MS/MS analysis	O=C1N2C[C@@H](CC[C@H]2F)N1OS(=O)(=O)[O-].[Na+]	J Med Chem	2020.0	CHEMBL4753698	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS analysis	O=C(N[C@H]1CCN(CC2CC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccc(F)cc2F)on1	J Med Chem	2020.0	CHEMBL4782111	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam substrate by LC-MS/MS analysis	O=C(N[C@H]1CCN(CC2CC2)C[C@@H]1C(=O)NC1(c2ncccn2)CC1)c1cc(-c2ccc(F)cc2F)on1	J Med Chem	2020.0	CHEMBL4782111	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis	Cc1cc(NC2CCc3cc(Cl)ccc3C2)n2nc(C(C)(F)F)nc2n1	J Med Chem	2016.0	CHEMBL4761666	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis	Cc1cc(N[C@H]2CCc3ccc(Cl)cc3C2)n2nc(C(C)(F)F)nc2n1	J Med Chem	2016.0	CHEMBL4751920	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis	Cc1cc(NC2CCc3cc(Br)ccc3C2)n2nc(C(C)(F)F)nc2n1	J Med Chem	2016.0	CHEMBL4747214	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis	Cc1cc(NC2CCc3ccc(Br)cc3C2)n2nc(C(C)(F)F)nc2n1	J Med Chem	2016.0	CHEMBL4753862	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using isoform-specific probe substrates in presence of NADPH-generating system by LC-MS analysis	Cc1cc(NC2Cc3cc(F)c(F)cc3C2)n2nc(C(C)(F)F)nc2n1	J Med Chem	2016.0	CHEMBL4794107	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(O)C#Cc1cnc(Nc2cnc(C#N)cn2)cc1NC[C@@H]1CNCCO1	J Med Chem	2016.0	CHEMBL4793954	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	C#Cc1cnc(Nc2cnc(C#N)cn2)cc1NC[C@@H]1CNCCO1	J Med Chem	2016.0	CHEMBL4740741	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cnc(Nc2cc(NC[C@@H]3CNCCO3)c(C3CC3)cn2)cn1	J Med Chem	2016.0	CHEMBL4792322	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cnc(Nc2cc(NC[C@H]3CNCCO3)c(Cl)cn2)cn1	J Med Chem	2016.0	CHEMBL4754960	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	N#Cc1cnc(Nc2cc(NC[C@H]3CNCCO3)c(C(F)(F)F)cn2)cn1	J Med Chem	2016.0	CHEMBL4169078	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes in presence of IPA as substrate	Nc1ccc(-c2nc(N3CCOCC3)c3ncn(CCCCCCC(=O)NO)c3n2)cn1	J Med Chem	2018.0	CHEMBL4785064	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes in presence of IPA as substrate	O=C(CCCCCCn1cnc2c(N3CCOCC3)nc(-c3cccc(CO)c3)nc21)NO	J Med Chem	2018.0	CHEMBL4749655	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes in presence of IPA as substrate	Nc1ncc(-c2nc(N3CCOCC3)c3ncn(CCCCCCC(=O)NO)c3n2)cn1	J Med Chem	2018.0	CHEMBL4787267	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes in presence of IPA as substrate	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1	J Med Chem	2018.0	CHEMBL1336	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of human recombinant CYP3A4	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2019.0	CHEMBL75	=	=	IC50	nM	240.0	IC50	uM	0.24
Inhibition of CYP3A4 (unknown origin) in baculosomes preincubated for 20 mins followed by addition of CYP enzyme-specific substrate and NADP+ and measured after 30 mins by fluorescence based analysis	CC(=O)Nc1ccc(O)cc1	Eur J Med Chem	2020.0	CHEMBL112	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4 (unknown origin) in baculosomes preincubated for 20 mins followed by addition of CYP enzyme-specific substrate and NADP+ and measured after 30 mins by fluorescence based analysis	CNC(=O)c1ccccc1S(=O)(=O)NCC(=O)Nc1ccc(O)cc1	Eur J Med Chem	2020.0	CHEMBL4800549	>	>	IC50	nM	10000.0	IC50	nM	10000.0
Inhibition of CYP3A4 (unknown origin) in baculosomes preincubated for 20 mins followed by addition of CYP enzyme-specific substrate and NADP+ and measured after 30 mins by fluorescence based analysis	O=C(CNS(=O)(=O)c1ccccc1C(=O)NCCc1ccc(O)c(O)c1)Nc1ccc(O)cc1	Eur J Med Chem	2020.0	CHEMBL4800229	=	=	IC50	nM	4820.0	IC50	nM	4820.0
Inhibition of CYP3A4 in human liver microsomes preincubated for 10 mins followed by NADPH addition by LC-MS/MS analysis	COc1ccc(C(Oc2ccc(N(CC(=O)O)S(=O)(=O)c3c(C)cc(C)cc3C)c3ccccc23)C(=O)O)cc1	Eur J Med Chem	2020.0	CHEMBL4740287	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsome using testosterone as substrate	O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(-c3ccc(C(F)(F)F)cc3Cl)cc1)C2	Eur J Med Chem	2020.0	CHEMBL583256	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsome using testosterone as substrate	CC1(COc2ccc(OC(F)(F)F)cc2)CCn2cc([N+](=O)[O-])nc2O1	Eur J Med Chem	2020.0	CHEMBL4066553	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes	Cn1cc(-c2nc3c(-c4ccnc(OC5CC5)c4)cnn3cc2OCCC(C)(C)O)cn1	ACS Med Chem Lett	2021.0	CHEMBL4751832	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	O=C(C1CCS(=O)(=O)CC1)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4750603	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4754719	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin)	N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3cnc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4748187	=	=	IC50	nM	12000.0	IC50	uM	12.0
Inhibition of CYP3A4 (unknown origin)	N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ncc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4793083	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	O=C(C1CCS(=O)(=O)CC1)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4435992	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 (unknown origin)	N#CCCN1C(=O)CC[C@H]1C(=O)N1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4763978	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4750756	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(O)CC(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4800380	=	=	IC50	nM	9100.0	IC50	uM	9.1
Inhibition of CYP3A4 (unknown origin)	O=C(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12)C1CCS(=O)(=O)CC1	ACS Med Chem Lett	2021.0	CHEMBL4744956	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[C@@](O)(CS(C)(=O)=O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)nc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4760466	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(O)CC(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4784900	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin)	O=C(N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12)C1CCS(=O)(=O)CC1	ACS Med Chem Lett	2021.0	CHEMBL4796103	=	=	IC50	nM	5800.0	IC50	uM	5.8
Inhibition of CYP3A4 (unknown origin)	C[C@](O)(CS(C)(=O)=O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4741364	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	C[C@@](O)(CS(C)(=O)=O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	ACS Med Chem Lett	2021.0	CHEMBL4779994	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H]1CC[C@H](N2CC[C@H](Nc3ncnc4ccc(C(F)(F)F)cc34)C2=O)[C@H](NC(C)=O)C1	ACS Med Chem Lett	2021.0	CHEMBL4760098	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3ccc(C(F)(F)F)cc23)C1=O	ACS Med Chem Lett	2021.0	CHEMBL4781426	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1CC[C@H](Nc2ncnc3ccc(OC(F)(F)F)cc23)C1=O	ACS Med Chem Lett	2021.0	CHEMBL4746510	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	Cc1cccc2c1c(=O)n(C[C@H]1CC[C@H](C(=O)O)CC1)c(=O)n2Cc1cccc(C(F)(F)F)c1C#N	ACS Med Chem Lett	2021.0	CHEMBL4761298	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CN[C@H](CNc1cc(F)c(S(=O)(=O)Nc2ncc(F)s2)cc1Cl)CC(C)(C)C.Cl	ACS Med Chem Lett	2021.0	CHEMBL4747709	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3c(C)[nH]nc3n2)c(OC(C)C)cc1C1CCN(C)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL3651854	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cn[nH]c3n2)c(OC(C)C)cc1C1CCN(C)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL4798141	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCN(C)CC1	Bioorg Med Chem Lett	2016.0	CHEMBL4762256	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	Cc1cc(Nc2nc(Nc3ccccc3S(=O)(=O)C(C)C)c3cc[nH]c3n2)c(OC(C)C)cc1C1CCNCC1	Bioorg Med Chem Lett	2016.0	CHEMBL4779222	=	=	IC50	nM	4600.0	IC50	uM	4.6
Inhibition of CYP3A4 (unknown origin)	CC[C@](CO)(c1ccc(Cl)cc1)n1ccc2c(NS(C)(=O)=O)cccc21	Bioorg Med Chem Lett	2016.0	CHEMBL4439903	>	>	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(Cl)c4F)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4746135	=	=	IC50	nM	8390.0	IC50	uM	8.39
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4ccccc4Cl)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4759692	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4ccccc4OC(F)(F)F)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4743615	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(OC(F)(F)F)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4751613	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Oc4cccc(Cl)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4761139	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Cc4cccc(Cl)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4744842	=	=	IC50	nM	1060.0	IC50	uM	1.06
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(OC(F)(F)F)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4798957	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	FC(F)(F)Oc1cccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)c1	Bioorg Med Chem Lett	2016.0	CHEMBL4755454	=	=	IC50	nM	1610.0	IC50	uM	1.61
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	CCc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(C(F)(F)F)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4752684	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(C(F)(F)F)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4788072	=	=	IC50	nM	48300.0	IC50	uM	48.3
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	FC(F)(F)c1cccc(Nc2nnc3n2CCOc2ccc(-c4ccncc4)cc2-3)c1	Bioorg Med Chem Lett	2016.0	CHEMBL4790150	=	=	IC50	nM	516.0	IC50	uM	0.516
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	Cc1cc(-c2ccc3c(c2)-c2nnc(Nc4cccc(Cl)c4)n2CCO3)ccn1	Bioorg Med Chem Lett	2016.0	CHEMBL4750179	=	=	IC50	nM	11800.0	IC50	uM	11.8
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	O=C(Nc1ccc(Cl)c(Cl)c1)N1CCOc2ccc(-c3ccncc3)cc2C1	Bioorg Med Chem Lett	2016.0	CHEMBL4755668	=	=	IC50	nM	192000.0	IC50	mM	0.192
Inhibition of human liver microsomes CYP3A4 using testosterone as substrate by MUX-MS/MS analysis	O=C(Nc1cccc(Cl)c1)N1CCOc2ccc(-c3ccncc3)cc2C1	Bioorg Med Chem Lett	2016.0	CHEMBL4787638	=	=	IC50	nM	325000.0	IC50	mM	0.325
Inhibition of CYP3A4 (unknown origin)	CCCCCCCCC1CCc2cc(CCC(N)(CO)CO)ccc2C1	J Med Chem	2016.0	CHEMBL4750944	=	=	IC50	nM	10400.0	IC50	uM	10.4
Inhibition of CYP3A4 (unknown origin)	CCCCCC[C@@H]1CCc2cc([C@H]3CC[C@](N)(CO)C3)ccc2C1	J Med Chem	2016.0	CHEMBL3806158	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of human liver microsome CYP3A4 using dextromethorphan as substrate incubated for 5 mins followed by NADPH addition and further incubated for 10 mins in shaking water bath by LC-MS/MS analysis	C=CC(=O)N1CCC(Cn2cc(-c3ccc4c(c3)OCO4)c3c(N)ncnc32)CC1	Eur J Med Chem	2018.0	CHEMBL4755698	=	=	IC50	nM	3190.0	IC50	uM	3.19
Inhibition of human CYP3A4 using midazolam as substrate	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F	Bioorg Med Chem	2018.0	CHEMBL4750196	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12	Bioorg Med Chem Lett	2018.0	CHEMBL4794578	=	=	IC50	nM	158489.32	pIC50		3.8
Inhibition of human liver microsome CYP3A4 using testosterone as substrate incubated for 20 mins by LC-MS/MS analysis	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	Eur J Med Chem	2018.0	CHEMBL3301620	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human liver microsome CYP3A4 using testosterone as substrate incubated for 20 mins by LC-MS/MS analysis	NC[C@H](NC(=O)c1ccc(-c2ccc(C(F)(F)F)c(F)c2)[nH]1)c1nc(CO)cs1	Eur J Med Chem	2018.0	CHEMBL4533529	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human liver microsome CYP3A4 using testosterone as substrate incubated for 20 mins by LC-MS/MS analysis	NC[C@H](NC(=O)c1ccc(-c2cc(F)c(Cl)c(F)c2)[nH]1)c1nc(CO)cs1	Eur J Med Chem	2018.0	CHEMBL4761836	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 20 mins by LC-MS/MS analysis	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12	Eur J Med Chem	2018.0	CHEMBL3301620	=	=	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 20 mins by LC-MS/MS analysis	NC[C@H](NC(=O)c1ccc(-c2ccc(C(F)(F)F)c(F)c2)[nH]1)c1nc(CO)cs1	Eur J Med Chem	2018.0	CHEMBL4533529	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of human liver microsome CYP3A4 using midazolam as substrate incubated for 20 mins by LC-MS/MS analysis	NC[C@H](NC(=O)c1ccc(-c2cc(F)c(Cl)c(F)c2)[nH]1)c1nc(CO)cs1	Eur J Med Chem	2018.0	CHEMBL4761836	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin)	O=C1c2nc3ccccc3n2CCN1CCCCOc1ccc(OC(F)(F)F)cc1	Eur J Med Chem	2020.0	CHEMBL4780781	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(OCC#CC#CCOc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4789776	=	=	IC50	nM	240.0	IC50	uM	0.24
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(OCC#CCOc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4739976	=	=	IC50	nM	860.0	IC50	uM	0.86
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NCCOCCOCCNc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4795924	=	=	IC50	nM	5650.0	IC50	uM	5.65
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NCCCCCCCCNc3ncnc4cc(OC)c(NC(=O)[C@@H]5CCCN5C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc34)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4760660	=	=	IC50	nM	430.0	IC50	uM	0.43
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(N[C@H]3CC[C@@H](Nc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4750995	=	=	IC50	nM	5530.0	IC50	uM	5.53
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(N[C@H]3CC[C@H](Nc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4753756	=	=	IC50	nM	3560.0	IC50	uM	3.56
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NC[C@H]3CC[C@H](CNc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C6CCCCC6)cc45)CC3)ncnc2cc1OC)C1CCCCC1	Bioorg Med Chem Lett	2021.0	CHEMBL4758649	=	=	IC50	nM	660.0	IC50	uM	0.66
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NC[C@H]3CC[C@@H](CNc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4781806	<	<	IC50	nM	620.0	IC50	uM	0.62
Inhibition of CYP3A4 (unknown origin)	CN[C@@H](C)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1cc2c(NC[C@H]3CC[C@H](CNc4ncnc5cc(OC)c(NC(=O)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)[C@H](C)NC)C(C)(C)C)cc45)CC3)ncnc2cc1OC)C(C)(C)C	Bioorg Med Chem Lett	2021.0	CHEMBL4788002	=	=	IC50	nM	460.0	IC50	uM	0.46
Inhibition of CYP3A4 (unknown origin)	C[C@H]1C[C@@H](c2ccncc2NC(=O)c2nc(-c3c(F)cccc3F)ncc2N)C[C@@H](O)[C@@]1(O)CF	J Med Chem	2020.0	CHEMBL4781892	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1C[C@@H](c2ccncc2NC(=O)c2nc(-c3c(F)cccc3F)ncc2N)C[C@@H](O)[C@]1(C)O	J Med Chem	2020.0	CHEMBL4758068	=	=	IC50	nM	26000.0	IC50	uM	26.0
Inhibition of human liver microsome CYP3A4 using sorafenib as substrate incubated for 20 mins by LC-MS/MS with HPLC analysis	Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1ccc(F)c(C(F)F)c1	ACS Med Chem Lett	2021.0	CHEMBL4754334	=	=	IC50	nM	20800.0	IC50	uM	20.8
Inhibition of human liver microsome CYP3A4 using sorafenib as substrate incubated for 20 mins by LC-MS/MS with HPLC analysis	Nc1cc(F)c(S(=O)(=O)N2CCC(O)CC2)cc1C(=O)Nc1ccc(F)c(F)c1	ACS Med Chem Lett	2021.0	CHEMBL4761323	=	=	IC50	nM	41000.0	IC50	uM	41.0
Inhibition of CYP3A4 (unknown origin)	Cc1cc(O[C@H]2CC[C@H](C(C)(C)C)CC2)c(CN2CCC(C(=O)O)CC2)c2ccccc12	ACS Med Chem Lett	2021.0	CHEMBL4748198	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4	CCC(c1nc2ncc(Cl)cc2[nH]1)[C@H]1CC[C@@H](c2ccnc3ccc(C(F)(F)F)cc32)CC1	ACS Med Chem Lett	2021.0	CHEMBL4756822	=	=	IC50	nM	1930.0	IC50	uM	1.93
Inhibition of recombinant human CYP3A4	COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(F)cc2)c(F)c1	J Med Chem	2020.0	CHEMBL4781596	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4	COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccccc2)c(F)c1	J Med Chem	2020.0	CHEMBL4784510	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4	COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(F)c(F)c2)c(F)c1	J Med Chem	2020.0	CHEMBL4762030	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4	COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(C)c(O)c2)c(F)c1	J Med Chem	2020.0	CHEMBL4790836	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of recombinant human CYP3A4	COc1cc(F)c([C@@H]2CNC(=O)[C@H]2NC(=O)Nc2ccc(Cl)s2)c(F)c1	J Med Chem	2020.0	CHEMBL4760897	=	=	IC50	nM	5600.0	IC50	uM	5.6
Inhibition of CYP3A4 (unknown origin)	C[C@]1(c2cc(/C=C(\F)c3ccc(C#N)cn3)ccc2F)N=C(N)S[C@@]2(C(=O)N3CCOCC3)C[C@H]21	Bioorg Med Chem Lett	2020.0	CHEMBL4760458	=	=	IC50	nM	5300.0	IC50	uM	5.3
Inhibition of CYP3A4 in human liver microsomes after 20 mins by LC-MS/MS analysis	CC(=O)NC[C@@H]1OC(=O)N2c3cc(F)c(N4CCSCC4)cc3OC[C@@H]12	J Med Chem	2020.0	CHEMBL4791225	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes after 20 mins by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	69.0	IC50	uM	0.069
Inhibition of CYP3A4 (unknown origin)	CNCCOc1ccccc1C(C)(C)Nc1nccn(-c2cc(C(=O)NC3CC3)ccc2C)c1=O	Bioorg Med Chem Lett	2020.0	CHEMBL4792347	=	=	IC50	nM	5011.87	pIC50		5.3
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate measured after 15 mins by LC-MS/MS analysis	Cn1c(=O)n(CC(=O)N2CCC2)c2cc(-c3ccc(C(F)(F)F)s3)cnc21	J Med Chem	2020.0	CHEMBL4779889	<	<	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 15 mins by LC-MS/MS analysis	Cn1c(=O)n(CC(=O)N2CCC2)c2cc(-c3ccc(C(F)(F)F)s3)cnc21	J Med Chem	2020.0	CHEMBL4779889	<	<	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using nifedipine as substrate measured after 15 mins by LC-MS/MS analysis	Cn1c(=O)n(CC(=O)N2CCC2)c2cc(-c3ccc(C(F)(F)F)s3)cnc21	J Med Chem	2020.0	CHEMBL4779889	<	<	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc2c3c([nH]c2c1)[C@@H]1N(CC3)C(=O)c2c(OC)cccc2N1C	J Med Chem	2020.0	CHEMBL4745832	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c([C@H]4C[C@H](O)C4)c(Cl)c32)c(F)cc1F	Bioorg Med Chem Lett	2020.0	CHEMBL4764602	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c([C@H]4C[C@@H](O)C4)c(Cl)c32)c(F)cc1F	Bioorg Med Chem Lett	2020.0	CHEMBL4800257	=	=	IC50	nM	24800.0	IC50	uM	24.8
Inhibition of CYP3A4 (unknown origin)	Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(N)C4)c(Cl)c32)c(F)cc1F	Bioorg Med Chem Lett	2020.0	CHEMBL4746307	=	=	IC50	nM	13600.0	IC50	uM	13.6
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	Bioorg Med Chem Lett	2020.0	CHEMBL8	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	Nc1nc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CC(O)C4)c(Cl)c32)c(F)cc1F	Bioorg Med Chem Lett	2020.0	CHEMBL2105637	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COC[C@](CO)(OC[C@H]1O[C@@H](n2ncc3c(NC4CCCC4)nc(Cl)nc32)[C@H](O)[C@@H]1O)P(=O)(O)O	J Med Chem	2020.0	CHEMBL4764985	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human liver microsome CYP3A4 using midazolam as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)n[nH]c(=O)c32)C1	ACS Med Chem Lett	2020.0	CHEMBL4754834	=	=	IC50	nM	37300.0	IC50	uM	37.3
Inhibition of human liver microsome CYP3A4 using midazolam as substrate preincubated for 10 mins followed by substrate and NADPH addition and measured after 10 mins by LC-MS/MS analysis	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1	ACS Med Chem Lett	2020.0	CHEMBL1873475	=	=	IC50	nM	40800.0	IC50	uM	40.8
Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate measured up to 20 mins by UHPLC-MS/MS analysis	CNC(=O)NC1CCN(C(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)CNC[C@H](C)c2ccccc2)CC1	ACS Med Chem Lett	2020.0	CHEMBL4743180	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human pooled liver microsomes using testosterone as substrate measured up to 20 mins by UHPLC-MS/MS analysis	CNC(=O)NC1CCN(C(=O)[C@@H](CCCCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)CNC[C@H](C)c2ccccc2)CC1	ACS Med Chem Lett	2020.0	CHEMBL4743180	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate measured after 5 to 20 mins in presence of NADPH by LC-MS/MS analysis	Cc1cc(-c2cnc3[nH]cc(-c4ccncc4)c3c2)cc2c1C(=O)N([C@@H](C)C1CC1)C2	ACS Med Chem Lett	2020.0	CHEMBL4779873	=	=	IC50	nM	300.0	IC50	uM	0.3
Inhibition of recombinant CYP3A4 (unknown origin) using BFC as substrate measured after 30 mins by fluorescence assay	Nc1n[nH]c2cc(-c3ccc(=O)n(Cc4ccccc4F)c3)ccc12	Eur J Med Chem	2021.0	CHEMBL4752141	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant CYP3A4 (unknown origin) using BFC as substrate measured after 30 mins by fluorescence assay	Nc1n[nH]c2cc(-c3ccc(=O)n(Cc4cccc(Cl)c4)c3)ccc12	Eur J Med Chem	2021.0	CHEMBL4764756	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 10 mins in presence of NADPH generating system followed by substrate addition and measured after 10 mins by LC-MS/MS analysis	CS(=O)(=O)O.[2H]C([2H])=CC(=O)Nc1cc(Nc2nccc(-c3cn(C([2H])([2H])[2H])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C	J Med Chem	2021.0	CHEMBL4784911	=	=	IC50	nM	27100.0	IC50	uM	27.1
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins in presence of NADPH generating system followed by substrate addition and measured after 10 mins by LC-MS/MS analysis	CS(=O)(=O)O.[2H]C([2H])=CC(=O)Nc1cc(Nc2nccc(-c3cn(C([2H])([2H])[2H])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C	J Med Chem	2021.0	CHEMBL4784911	=	=	IC50	nM	17300.0	IC50	uM	17.3
Inhibition of CYP3A4 (unknown origin)	CC(C)Oc1ccc(Nc2nc(=O)n(CC(C)(C)C(=O)O)c(=O)n2Cc2ccc(Cl)cc2)cc1F	Bioorg Med Chem Lett	2021.0	CHEMBL3985699	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	Cc1ccc(Cn2c(Nc3ccc(OC(C)C)c(Cl)c3)nc(=O)n(CCC(=O)O)c2=O)cc1	Bioorg Med Chem Lett	2021.0	CHEMBL4748113	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes using midazolam 1-hydroxylation as substrate by LC-MS/MS analysis	O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3o1)CC2	Eur J Med Chem	2021.0	CHEMBL4777349	=	=	IC50	nM	4590.0	IC50	uM	4.59
Inhibition of CYP3A4 in human liver microsomes using midazolam 1-hydroxylation as substrate by LC-MS/MS analysis	O=C1NCCC12CCN(c1c(Cl)cncc1-c1cc3ccccc3s1)CC2	Eur J Med Chem	2021.0	CHEMBL4791586	=	=	IC50	nM	2110.0	IC50	uM	2.11
Inhibition of CYP3A4 (unknown origin)	O=C1c2cc(-c3ccc(OC(F)(F)F)cc3)ccc2OCCN1Cc1ncccn1	J Med Chem	2016.0	CHEMBL3707392	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(C(NC(=O)c2cnc(-c3cccnn3)nc2O)c2ccc(OC)cc2)cc1	J Med Chem	2016.0	CHEMBL4783524	>	>	IC50	nM	60000.0	IC50	uM	60.0
Inhibition of CYP3A4 (unknown origin)	COc1ccccc1CC[C@@H]1CCc2cc([C@H]3CC[C@](N)(CO)C3)ccc2C1	J Med Chem	2019.0	CHEMBL4649457	=	=	IC50	nM	5500.0	IC50	uM	5.5
Inhibition of human liver microsome CYP3A4 in presence of NADPH incubated for 10 to 30 mins by LC-MS-MS analysis	COc1ccc2ncc(F)c(CC[C@@]3(O)CO[C@@H]4[C@@H](NCc5cc6c(cn5)OCCO6)CO[C@@H]43)c2n1	Eur J Med Chem	2020.0	CHEMBL4788651	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis	COc1ccc2cc(C(=O)NCCN(C)C)oc2c1.CS(=O)(=O)O	Eur J Med Chem	2020.0	CHEMBL4797998	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2020.0	CHEMBL75	=	=	IC50	nM	21.7	IC50	uM	0.0217
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition and measured after 5 mins by LC-MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2ccccc2NC(=O)Cn2cc(CN(C)C)nn2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	Eur J Med Chem	2020.0	CHEMBL4784058	=	=	IC50	nM	6148.0	IC50	uM	6.148
Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 0 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	CC[C@@H]1C[C@H](C)CC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)c(F)cc34)CN2C(=O)[C@H]1NC(=O)OC(C)(C)C(F)(F)F	J Med Chem	2020.0	CHEMBL4787795	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 0 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	[2H]C([2H])([2H])Oc1cc2ccnc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CC[C@@H](C)C[C@@H](CC)[C@H](NC(=O)OC(C)(C)C(F)(F)F)C(=O)N4C3)c2cc1F	J Med Chem	2020.0	CHEMBL4800520	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 0 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	CC[C@@H]1C[C@H](C)CC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)c(F)cc34)CN2C(=O)[C@H]1NC(=O)OC(C)(C)C(F)(F)F	J Med Chem	2020.0	CHEMBL4787795	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 0 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	[2H]C([2H])([2H])Oc1cc2ccnc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CC[C@@H](C)C[C@@H](CC)[C@H](NC(=O)OC(C)(C)C(F)(F)F)C(=O)N4C3)c2cc1F	J Med Chem	2020.0	CHEMBL4800520	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	CC[C@@H]1C[C@H](C)CC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)c(F)cc34)CN2C(=O)[C@H]1NC(=O)OC(C)(C)C(F)(F)F	J Med Chem	2020.0	CHEMBL4787795	=	=	IC50	nM	3020.0	IC50	uM	3.02
Inhibition of human CYP3A4 in human pooled liver microsomes in presence of testosterone as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	[2H]C([2H])([2H])Oc1cc2ccnc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CC[C@@H](C)C[C@@H](CC)[C@H](NC(=O)OC(C)(C)C(F)(F)F)C(=O)N4C3)c2cc1F	J Med Chem	2020.0	CHEMBL4800520	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	CC[C@@H]1C[C@H](C)CC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2(C)CC2)NC(=O)[C@@H]2C[C@@H](Oc3nccc4cc(OC)c(F)cc34)CN2C(=O)[C@H]1NC(=O)OC(C)(C)C(F)(F)F	J Med Chem	2020.0	CHEMBL4787795	=	=	IC50	nM	2850.0	IC50	uM	2.85
Inhibition of human CYP3A4 in human pooled liver microsomes in presence of midazolam as substrate preincubated for 30 mins in presence of NADPH followed by addition of substrate by LC-MS/MS analysis	[2H]C([2H])([2H])Oc1cc2ccnc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CC[C@@H](C)C[C@@H](CC)[C@H](NC(=O)OC(C)(C)C(F)(F)F)C(=O)N4C3)c2cc1F	J Med Chem	2020.0	CHEMBL4800520	=	=	IC50	nM	16400.0	IC50	uM	16.4
Inhibition of CYP3A4 (unknown origin)	C[C@H](Oc1cc2cc(F)cc(F)c2nc1N)c1cc(C(=O)O)ccc1-n1cccn1	J Med Chem	2021.0	CHEMBL4785484	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](Oc1cc2cc(F)ccc2nc1N)c1[nH]c(=O)ccc1-n1cccn1	J Med Chem	2021.0	CHEMBL4650304	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	[2H]C([2H])([2H])NC(=O)c1cnc(NC(=O)C2CC2)cc1Nc1cccc(-c2ncc(F)cn2)c1OC	J Med Chem	2021.0	CHEMBL4789639	>	>	IC50	nM	40000.0	IC50	uM	40.0
Inhibition of CYP3A4 (unknown origin)	C[C@H](O)CNC(=O)c1ncc(S(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1N	J Med Chem	2021.0	CHEMBL4785210	>	>	EC50	nM	100000.0	EC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in midazolam 1-hydroxylase activity by . high-pressure liquid chromatography-tandem mass spectrometry	CCCOc1nncc(-c2cnnc(OCCN(C)C)n2)n1	J Med Chem	2021.0	CHEMBL4853103	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation activity by high-pressure liquid chromatography-tandem mass spectrometry	CCCOc1nncc(-c2cnnc(OCCN(C)C)n2)n1	J Med Chem	2021.0	CHEMBL4853103	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	O=C(O)c1cc(-c2ccc(-c3cc(CO)on3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1	J Med Chem	2021.0	CHEMBL4864408	>	>	IC50	nM	30000.0	IC50	uM	30.0
Direct inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
Direct inhibition of CYP3A5 in human liver microsomes using midazolam as substrate	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
Direct inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
Time-dependent inhibition of CYP3A5 in human liver microsomes using midazolam as substrate preincubated for 30 mins	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
Time-dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
Time-dependent inhibition of CYP3A5 in human liver microsomes using testosterone as substrate preincubated for 30 mins	CCC(C)(C)C(=O)O	J Med Chem	2021.0	CHEMBL286013	>	>	IC50	nM	10000000.0	IC50	uM	10000.0
Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate	CNc1nc(NC2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N(C)CCN(C)C)n1	Bioorg Med Chem	2021.0	CHEMBL4852295	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate	CNc1nc(NC2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL4850549	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate	CNc1nc(Nc2ccc(C(=O)NCc3ccccc3C(F)(F)F)cc2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL4873163	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin) using diethoxyfluorescein as substrate	CNc1nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL2392711	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxyquinoline as substrate	CNc1nc(NC2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N(C)CCN(C)C)n1	Bioorg Med Chem	2021.0	CHEMBL4852295	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxyquinoline as substrate	CNc1nc(NC2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL4850549	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxyquinoline as substrate	CNc1nc(Nc2ccc(C(=O)NCc3ccccc3C(F)(F)F)cc2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL4873163	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 (unknown origin) using 7-benzyloxyquinoline as substrate	CNc1nc(N2CCC(C(=O)NCc3ccccc3C(F)(F)F)CC2)nc(N2CCN(C)CC2)n1	Bioorg Med Chem	2021.0	CHEMBL2392711	>	>	IC50	nM	33000.0	IC50	uM	33.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	COc1cc2c(cc1OCCCCCCC(=O)O)C[C@@H](C(C)C)n1cc(C(=O)O)c(=O)cc1-2	ACS Med Chem Lett	2021.0	CHEMBL4850531	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 5 mins followed by NADPH addition by LC-MS/MS analysis	COc1cc2c(cc1OCCCCCCC(=O)O)C[C@@H](C(C)C)n1cc(C(=O)O)c(=O)cc1-2	ACS Med Chem Lett	2021.0	CHEMBL4850531	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam or testosterone as substrate substrate in presence of NADPH by LC-MS/MS analysis	CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3c(c21)CC(=O)N3	J Med Chem	2021.0	CHEMBL4853979	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using midazolam or testosterone as substrate substrate in presence of NADPH by LC-MS/MS analysis	CCN1C(=O)N(c2c(F)c(OC)cc(OC)c2F)Cc2cnc3[nH]c(CN4CCOCC4)cc3c21	J Med Chem	2021.0	CHEMBL4297522	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes using terfenadine as substrate incubated for 15 mins in presence of NADPH by LC/MS/MS analysis	C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1	J Med Chem	2021.0	CHEMBL3916243	=	=	IC50	nM	33000.0	IC50	uM	33.0
Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins in presence of NADPH followed by substrate addition and measured after 2 mins by LC/MS/MS analysis	C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1	J Med Chem	2021.0	CHEMBL3916243	<	<	IC50	nM	10000.0	IC50	uM	10.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(-c3ccc(F)cc3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4869433	=	=	IC50	nM	110.0	IC50	nM	110.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(-c3ccccc3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4859908	=	=	IC50	nM	210.0	IC50	nM	210.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(-c3ccccn3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4855030	=	=	IC50	nM	210.0	IC50	nM	210.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(-c3cccc(-c4ccccc4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4855931	=	=	IC50	nM	7.1	IC50	nM	7.1
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3ccccc3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4846080	=	=	IC50	nM	310.0	IC50	nM	310.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3ccc4ccccc4c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4853722	=	=	IC50	nM	40.0	IC50	nM	40.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(-c4ccccc4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4863015	=	=	IC50	nM	17.0	IC50	nM	17.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3ccc4cnccc4c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4871587	=	=	IC50	nM	210.0	IC50	nM	210.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3ccc4c(c3)CCNC4)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4855956	=	=	IC50	nM	7000.0	IC50	nM	7000.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(Cc4ccccc4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4878518	=	=	IC50	nM	37.0	IC50	nM	37.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(Oc4ccccc4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4862053	=	=	IC50	nM	11.0	IC50	nM	11.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(Oc4cccc5c4CNC5)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4860429	=	=	IC50	nM	140.0	IC50	nM	140.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(O[C@H]4CCNC4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4877407	=	=	IC50	nM	13000.0	IC50	nM	13000.0
Time dependent inhibition of CYP3A4 (unknown origin) measured at 30 mins	Nc1cc(Cc2ccn(Cc3cccc(C4CCNCC4)c3)n2)c2nn[nH]c2n1	Bioorg Med Chem Lett	2021.0	CHEMBL4859470	=	=	IC50	nM	3300.0	IC50	nM	3300.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	Nc1ncc(-c2cc3ccccc3o2)c(N2CCC3(CCNC3=O)CC2)c1Cl	Eur J Med Chem	2021.0	CHEMBL4878007	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis	Cc1c(Cc2ccc(C(F)(F)F)nc2)c[nH]c1C(=O)NC(C)c1cn[nH]c1	J Med Chem	2021.0	CHEMBL4850116	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis	Cc1c(Cc2ccc(C(F)(F)F)nc2)c[nH]c1C(=O)NC(C)c1cnn(C)c1	J Med Chem	2021.0	CHEMBL4850393	=	=	IC50	nM	8500.0	IC50	uM	8.5
Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis	Cc1c(C2(c3ccc(C(F)(F)F)nc3)CC2)c[nH]c1C(=O)NC(C)c1nc[nH]n1	J Med Chem	2021.0	CHEMBL4848632	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis	Cc1c(C2(c3ccc(C(F)(F)F)nc3)CC2)c[nH]c1C(=O)NC(C)c1c[nH]cn1	J Med Chem	2021.0	CHEMBL4851471	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4 (unknown origin) by UPLC-MS analysis	Cc1c(C2(c3ccc(C(F)(F)F)c(C#N)c3)CC2)c[nH]c1C(=O)NC(C)c1nc[nH]n1	J Med Chem	2021.0	CHEMBL4876457	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of human CYP3A4 expressed in insect supersomes assessed as reduction in 10-hydroxymidazolam formation using midazolam as substrate measured after 30 mins in presence of NADPH by LC-MS/MS analysis	N=C(NO)c1ccc2nc(-c3cccc(-c4cn5ccccc5n4)c3)[nH]c2c1	Bioorg Med Chem	2021.0	CHEMBL4846752	=	=	IC50	nM	233.0	IC50	nM	233.0
Inhibition of CYP3A4 in human hepatocytes	COc1cc2c(cc1OC)C(=O)C(CC1(F)CCN(Cc3ccccc3F)CC1)C2	J Med Chem	2021.0	CHEMBL4859647	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 5 mins followed by NADPH addition and measured after 5 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSc2nc(N)n(C(=O)c3ccc(C)cc3)n2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	Bioorg Med Chem	2021.0	CHEMBL4856492	=	=	IC50	nM	3950.0	IC50	uM	3.95
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 5 mins followed by NADPH addition and measured after 5 mins by LC/MS/MS analysis	C=C[C@]1(C)C[C@@H](OC(=O)CSCCN(CC)CC)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	Bioorg Med Chem	2021.0	CHEMBL1234521	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate incubated for 10 mins by LC/MS/MS analysis	CC[C@]1(C)C[C@@H](OC(=O)CSc2nnc(N)[nH]2)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O	Bioorg Med Chem	2021.0	CHEMBL2103760	=	=	IC50	nM	240.0	IC50	uM	0.24
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	CCN(C(=O)c1cc(C(C)C)c(O)cc1O)c1cccnc1	Eur J Med Chem	2021.0	CHEMBL4871799	=	=	IC50	nM	3230.0	IC50	uM	3.23
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS/MS analysis	CCN(C(=O)c1cc(C(C)C)c(O)cc1O)c1cccnc1	Eur J Med Chem	2021.0	CHEMBL4871799	=	=	IC50	nM	1150.0	IC50	uM	1.15
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cc(c(F)cc1F)C(=O)NCc1cncc(c1)-c1ccnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4868571	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1ccnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4850101	=	=	IC50	nM	19600.0	IC50	uM	19.6
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCC1CCN(CC1)c1ccnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4866790	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cccc(c1)-c1ncnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4854600	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1ncnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4872630	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCCn1cc(cn1)-c1cnc3ccc-2nn13	Eur J Med Chem	2021.0	CHEMBL4873529	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1cnc3ccc-2cn13	Eur J Med Chem	2021.0	CHEMBL4864407	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCC1CCN(CC1)c1ncnc3ccc-2cc13	Eur J Med Chem	2021.0	CHEMBL4850446	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cc(c(F)cc1F)C(=O)NCc1cncc(c1)-c1ccnc3ccc-2nc13	Eur J Med Chem	2021.0	CHEMBL4875906	=	=	IC50	nM	6500.0	IC50	uM	6.5
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cccc(c1)Cc1cnc3sc-2nn13	Eur J Med Chem	2021.0	CHEMBL4853785	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using Luciferin-PPXE as substrate at 10 uM preincubated with enzyme and substrate for 5 mins followed by addition of NADPH regeneration system and measured after 60 mins by luminescence method	COc1ncc2cc1NS(=O)(=O)c1cccc(c1)C(=O)NCc1cncc(c1)-c1ncnc3sc-2cc13	Eur J Med Chem	2021.0	CHEMBL4852833	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(C)(O)C(=O)N[C@@H]1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	J Med Chem	2021.0	CHEMBL4761772	=	=	IC50	nM	11000.0	IC50	uM	11.0
Inhibition of CYP3A4 (unknown origin)	C[C@H]1C[C@H](C(=O)O)CC[C@H]1NN1CC[C@@]2(S(=O)(=O)c3ccc(F)cc3)c3ccc(C(F)(C(F)(F)F)C(F)(F)F)cc3CC[C@@H]12	J Med Chem	2021.0	CHEMBL4871326	=	=	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	NC(=O)c1ccc2c(c1)CCCN2Cc1ccc(C(=O)NO)cc1	J Med Chem	2021.0	CHEMBL4846435	>	>	IC50	nM	100.0	IC50	nM	100.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CCC(C)(NC(=O)c1cc(F)cc2cc(-c3ccc(Cl)cc3)oc12)C(=O)O	ACS Med Chem Lett	2021.0	CHEMBL4850551	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using midazolam as substrate	CC(C)(NC(=O)c1cc(F)cc2cc(-c3ccc(Cl)cc3)oc12)C(=O)O	ACS Med Chem Lett	2021.0	CHEMBL4854083	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CCC(C)(NC(=O)c1cc(F)cc2cc(-c3ccc(Cl)cc3)oc12)C(=O)O	ACS Med Chem Lett	2021.0	CHEMBL4850551	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin) using testosterone as substrate	CC(C)(NC(=O)c1cc(F)cc2cc(-c3ccc(Cl)cc3)oc12)C(=O)O	ACS Med Chem Lett	2021.0	CHEMBL4854083	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc(N)c2-c2ccc(F)cc2)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL3925871	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	NC(=O)c1c(N)ncnc1N1CCC(c2nc(-c3ccc(F)c(C(F)(F)F)c3)cn2CCN2CCC2)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL3949501	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6c(Cl)cccc6Cl)noc5C5CC5)C4)CC3)sc2c1	ACS Med Chem Lett	2021.0	CHEMBL4846941	=	=	IC50	nM	900.0	IC50	uM	0.9
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6ccccc6C(F)(F)F)noc5C5CC5)C4)CC3)sc2c1	ACS Med Chem Lett	2021.0	CHEMBL4874257	=	=	IC50	nM	10800.0	IC50	uM	10.8
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6ccccc6OC(F)(F)F)noc5C5CC5)C4)CC3)sc2c1	ACS Med Chem Lett	2021.0	CHEMBL4851875	=	=	IC50	nM	1000.0	IC50	uM	1.0
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1cc(F)c2nc(N3CCC4(C=C(c5c(-c6c(Cl)cncc6Cl)noc5C5CC5)C4)CC3)sc2c1	ACS Med Chem Lett	2021.0	CHEMBL4870156	=	=	IC50	nM	1800.0	IC50	uM	1.8
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1ccc(N2CCC3(C=C(c4c(-c5c(Cl)cccc5Cl)noc4C4CC4)C3)CC2)nc1	ACS Med Chem Lett	2021.0	CHEMBL4875500	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1ccc(N2CCC3(C=C(c4c(-c5c(Cl)cccc5Cl)noc4C4CC4)C3)CC2)cn1	ACS Med Chem Lett	2021.0	CHEMBL4868516	=	=	IC50	nM	6200.0	IC50	uM	6.2
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1ccc2cc(N3CCC4(C=C(c5c(-c6c(Cl)cccc6Cl)noc5C5CC5)C4)CC3)ccc2n1	ACS Med Chem Lett	2021.0	CHEMBL4872481	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1ccc2cc(N3CCC4(C=C(c5c(-c6c(Cl)cc(F)cc6Cl)noc5C5CC5)C4)CC3)ccc2n1	ACS Med Chem Lett	2021.0	CHEMBL4868096	=	=	IC50	nM	3100.0	IC50	uM	3.1
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1ccc2cc(N3CCC4(C=C(c5c(-c6c(Cl)cncc6Cl)noc5C5CC5)C4)CC3)ccc2n1	ACS Med Chem Lett	2021.0	CHEMBL4858615	=	=	IC50	nM	4700.0	IC50	uM	4.7
Inhibition of CYP3A4 (unknown origin) expressed in baculovirus infected insect supersomes preincubated for 15 mins followed by addition of NADPH regenerating system by fluorescence based analysis	O=C(O)c1cc(C(F)(F)F)c2cc(N3CCC4(C=C(c5c(-c6c(Cl)cncc6Cl)noc5C5CC5)C4)CC3)ccc2n1	ACS Med Chem Lett	2021.0	CHEMBL4862974	>	>	IC50	nM	40000.0	IC50	uM	40.0
Reversible inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO	J Med Chem	2021.0	CHEMBL4650316	=	=	IC50	nM	6500.0	IC50	uM	6.5
Reversible inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	C[C@@H]1Cc2c([nH]c3ccc(F)cc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO	J Med Chem	2021.0	CHEMBL4866043	=	=	IC50	nM	2700.0	IC50	uM	2.7
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO	J Med Chem	2021.0	CHEMBL4650316	=	=	IC50	nM	26000.0	IC50	uM	26.0
Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 10 mins followed by NADPH addition by LC/MS/MS analysis	C[C@@H]1Cc2c([nH]c3ccc(F)cc23)[C@@H](c2c(F)cc(NC3CN(CCCF)C3)cc2F)N1CC(F)(F)CO	J Med Chem	2021.0	CHEMBL4866043	=	=	IC50	nM	1600.0	IC50	uM	1.6
Inhibition of CYP3A4 in human liver microsomes incubated for 15 mins in presence of NADPH by LC-MS/MS analysis	C[C@@H](c1ccc2ccc(O[C@H]3CC[C@@H](C(F)(F)F)CC3)c(C(F)(F)F)c2c1)N1C2CCC1CC(C(=O)O)C2	ACS Med Chem Lett	2021.0	CHEMBL4871014	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	CC(C)N1Cc2cc(C(F)(F)F)ncc2C2=CN=C(NCc3c(F)ccc4c3CCO4)N3C=NC(C1=O)C23	J Med Chem	2021.0	CHEMBL4870920	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	O=C1C2N=CN3C(NCc4c(F)ccc5c4CCO5)=NC=C(c4cnc(C(F)(F)F)cc4CN1CC(F)F)C23	J Med Chem	2021.0	CHEMBL4854800	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	CC(F)(F)CN1Cc2cc(C(F)(F)F)ncc2C2=CN=C(NCc3c(F)ccc4c3CCO4)N3C=NC(C1=O)C23	J Med Chem	2021.0	CHEMBL4861394	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 (unknown origin)	COc1cc2c(cc1OC)[C@H]1C[C@@H](O)[C@H](CC(C)C)CN1CC2	Eur J Med Chem	2021.0	CHEMBL576222	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	COc1cc2c(cc1OCC(F)(F)F)CCN1CC(CC(C)C)C(O)CC21	Eur J Med Chem	2021.0	CHEMBL4854730	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of recombinant human CYP3A4	CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4cccc(C(F)(F)F)c4)n3)nc2)CC1	J Med Chem	2021.0	CHEMBL4859234	=	=	IC50	nM	7130.0	IC50	uM	7.13
Inhibition of CYP3A4 (unknown origin)	Cl.Cn1nccc1-c1ccc(C(=O)N[C@@H]2CNCC[C@H]2c2ccc(F)c(F)c2)c(F)c1	J Med Chem	2021.0	CHEMBL4556790	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver Microsome using midazolam as substrate preincubated for 10 mins followed by NADPH addition and further incubated for 10 mins as substrate by LC-MS/MS analysis	O=C(NC(Cn1ccnc1)C(=O)c1cccc(F)c1)c1ccc(-c2ccc(Cl)cc2)s1	Eur J Med Chem	2021.0	CHEMBL4863635	=	=	IC50	nM	1170.0	IC50	uM	1.17
Inhibition of CYP3A4 in human liver Microsome using midazolam as substrate preincubated for 10 mins followed by NADPH addition and further incubated for 10 mins as substrate by LC-MS/MS analysis	Cc1ccc(C(=O)C(Cn2ccnc2)NC(=O)c2ccc(-c3ccc(Cl)cc3)s2)cc1	Eur J Med Chem	2021.0	CHEMBL4878311	=	=	IC50	nM	1240.0	IC50	uM	1.24
Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate incubated for 20 mins by fluorescence based analysis	CS(=O)(=O)c1nccc(-c2c(-c3cccc(OCc4ccccc4)c3)nc3sccn23)n1	Eur J Med Chem	2021.0	CHEMBL4860202	=	=	IC50	nM	17800.0	IC50	nM	17800.0
Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate incubated for 20 mins by fluorescence based analysis	c1ccc(COc2cccc(-c3nc4sccn4c3-c3ccncn3)c2)cc1	Eur J Med Chem	2021.0	CHEMBL4866102	=	=	IC50	nM	20910.0	IC50	nM	20910.0
Inhibition of CYP3A4 (unknown origin) using BOMCC as a substrate incubated for 20 mins by fluorescence based analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2021.0	CHEMBL75	=	=	IC50	nM	2.38	IC50	nM	2.38
Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1	J Med Chem	2021.0	CHEMBL175691	=	=	IC50	nM	2170.0	IC50	uM	2.17
Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	Cc1cc(/C=C/C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc2c1CSCC2	J Med Chem	2021.0	CHEMBL4848008	=	=	IC50	nM	53900.0	IC50	uM	53.9
Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate in presence of NADPH incubated for 10 mins by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2021.0	CHEMBL295698	=	=	IC50	nM	26.9	IC50	uM	0.0269
Inhibition of CYP3A4 in human liver microsomes	CCS(=O)(=O)c1ccc([C@@H](NC(C)=O)C(=O)Nc2ccc(C(O)(C(F)(F)F)C(F)(F)F)cc2)cc1	J Med Chem	2021.0	CHEMBL4562895	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of CYP3A4 in human liver microsomes	CC(=O)N1Cc2cc(S(C)(=O)=O)ccc2[C@@H]1C(=O)Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1	J Med Chem	2021.0	CHEMBL4864604	>	>	IC50	nM	30000.0	IC50	uM	30.0
Inhibition of human hepatic CYP3A4	COc1c(OCc2ccc(F)cc2)cc2oc3cc4c(c(OC/C=C/C(=O)O)c3c(=O)c2c1CC=C(C)C)C=CC(C)(C)O4	J Med Chem	2021.0	CHEMBL4877549	>	>	IC50	nM	25000.0	IC50	uM	25.0
Inhibition of CYP3A4 in human liver microsomes assessed as midazolam 1'-hyrozylation reaction incubated for 30 mins in presence of NADP by LC-MS/MS analysis	CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cnn(C)c2)no1	J Med Chem	2021.0	CHEMBL4847050	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes assessed as testosterone 6-beta-hydroxylation reaction incubated for 30 mins in presence of NADP by LC-MS/MS analysis	CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cnn(C)c2)no1	J Med Chem	2021.0	CHEMBL4847050	>	>	IC50	nM	100000.0	IC50	uM	100.0
Induction of CYP3A4 in human hepatocytes assessed as mRNA expression incubated for 3 days by RT-RTPCR analysis	CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O	J Med Chem	2021.0	CHEMBL4297517	=	=	EC50	nM	2200.0	EC50	uM	2.2
Inhibition of CYP3A4 in human pooled liver microsomes using midazolam as substrate in presence of NADPH by LC-MS/MS analysis	CCN(C(=O)C1CC1)c1cc(-c2ccc(N3CCN(CC4CC4)CC3)nc2C)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C	J Med Chem	2021.0	CHEMBL4862681	=	=	IC50	nM	7580.0	IC50	uM	7.58
Inhibition of CYP3A4 in pooled human liver microsomes using midazolam or testosterone as substrate preincubated for 30 mins in presence of NADPH followed by substrate addition by LC-MS/MS analysis	Cc1c(C(=O)Nc2ccc3c(c2)B(O)OC3)nnn1-c1ccccn1	J Med Chem	2021.0	CHEMBL4874673	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of human CYP3A4 using testosterone as a substrate by LC/MS/MS analysis	Cc1cn(-c2ccnc(N[C@@H]3CCN(C(=O)c4nccs4)C3)n2)c(-c2ccccc2)n1	ACS Med Chem Lett	2021.0	CHEMBL4857273	=	=	IC50	nM	940.0	IC50	uM	0.94
Inhibition of human CYP3A4 using testosterone as a substrate by LC/MS/MS analysis	O=C(c1nccs1)N1CC[C@@H](Nc2nccc(-n3cc(C4CC4)nc3-c3ccccc3)n2)C1	ACS Med Chem Lett	2021.0	CHEMBL4876338	=	=	IC50	nM	290.0	IC50	uM	0.29
Inhibition of human CYP3A4 using testosterone as a substrate by LC/MS/MS analysis	O=C(c1nccs1)N1CC[C@@H](Nc2nccc(-n3cc(C4CC4)nc3-c3cccc(Cl)c3)n2)C1	ACS Med Chem Lett	2021.0	CHEMBL4875016	=	=	IC50	nM	190.0	IC50	uM	0.19
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	C[C@@H](C[C@@]1(C2CC2)NC(=O)NC1=O)C(=O)N1CCN(c2ccc(F)c(F)c2)[C@@H](C)C1	J Med Chem	2021.0	CHEMBL4874034	=	=	IC50	nM	7800.0	IC50	uM	7.8
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	C[C@H]1CN(C(=O)CC[C@@]2(C)NC(=O)NC2=O)CCN1c1ccc(Cl)c(Cl)c1	J Med Chem	2021.0	CHEMBL4859812	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate	C[C@H]1CN(C(=O)CC[C@@]2(C3CC3)NC(=O)NC2=O)CCN1c1cc(F)cc(F)c1	J Med Chem	2021.0	CHEMBL4650334	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	C[C@@H](C[C@@]1(C2CC2)NC(=O)NC1=O)C(=O)N1CCN(c2ccc(F)c(F)c2)[C@@H](C)C1	J Med Chem	2021.0	CHEMBL4874034	=	=	IC50	nM	1500.0	IC50	uM	1.5
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	C[C@H]1CN(C(=O)CC[C@@]2(C)NC(=O)NC2=O)CCN1c1ccc(Cl)c(Cl)c1	J Med Chem	2021.0	CHEMBL4859812	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate	C[C@H]1CN(C(=O)CC[C@@]2(C3CC3)NC(=O)NC2=O)CCN1c1cc(F)cc(F)c1	J Med Chem	2021.0	CHEMBL4650334	>	>	IC50	nM	100000.0	IC50	uM	100.0
Inhibition of CYP3A4 (unknown origin)	CCn1c(-c2cnc(C)nc2)nc2c(N[C@H]3CCN(C(=O)C4CC4)C3)ncnc21	J Med Chem	2021.0	CHEMBL4853960	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2c(Nc3ccccn3)[nH]c3c(C4=CCCCC4)c(-c4ccccc4)nn3c2=O)cc1	J Med Chem	2021.0	CHEMBL4573938	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2ccc(CO[C@H]3C[C@@H](N=C=S)C3)nc2)cc1F	J Med Chem	2021.0	CHEMBL4874855	=	=	IC50	nM	2600.0	IC50	uM	2.6
Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins	Cn1c(=O)[nH]c2c(Cl)cc3c(c21)CN(CC(F)(F)F)C(=O)[C@H](CC(=O)N1CCC(N2CCc4ccccc4NC2=O)CC1)C3	Bioorg Med Chem Lett	2021.0	CHEMBL4848032	=	=	IC50	nM	8100.0	IC50	uM	8.1
Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins	O=C(C[C@@H]1Cc2cc(Cl)c3[nH]c(=O)n(CC(F)(F)F)c3c2CN(CC(F)(F)F)C1=O)N1CCC(N2CCc3ccccc3NC2=O)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4857649	=	=	IC50	nM	8400.0	IC50	uM	8.4
Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins	O=C(C[C@@H]1Cc2cc(Cl)c3c(c2CN(CC(F)(F)F)C1=O)C(F)(F)C(=O)N3)N1CCC(n2c(=O)[nH]c3ncccc32)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4849710	>	>	IC50	nM	40000.0	IC50	uM	40.0
Time dependent inhibition of CYP3A4 (unknown origin) measured after 30 mins	O=C(C[C@@H]1Cc2cc(Cl)c3[nH]ncc3c2CN(CC(F)(F)F)C1=O)N1CCC(N2CCc3ccccc3NC2=O)CC1	Bioorg Med Chem Lett	2021.0	CHEMBL4746351	=	=	IC50	nM	100.0	IC50	uM	0.1
Inhibition of CYP3A4 (unknown origin) assessed as MDI shift	CNC(=O)c1cc(C(=O)N[C@H]2CC[C@H](O)CC2)n([C@@H](C)c2ccccc2)n1	J Med Chem	2021.0	CHEMBL4854042	<	>	IC50	nM	39810.72	pIC50		4.4
Inhibition of CYP3A4 (unknown origin) assessed as MDI shift	CNC(=O)c1cc(C(=O)N[C@H]2CC[C@H](O)CC2)c([C@@H](C)c2ccccc2)o1	J Med Chem	2021.0	CHEMBL4865767	<	>	IC50	nM	39810.72	pIC50		4.4
Direct inhibition of CYP3A4 in human hepatocytes	CCOC(=O)[C@@H](Cc1cn(C)c2ccccc12)NC(=O)[C@@H](N)CC(C)C.Cl	Eur J Med Chem	2020.0	CHEMBL4876008	=	=	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of human CYP3A4 assessed as dissociation constant	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@@]6(C)[C@@H](CC[C@H]6O)[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@H]2O	Eur J Med Chem	2021.0	CHEMBL4864434	=	=	Kd	nM	1600.0	Kd	uM	1.6
Inhibition of human CYP3A4 assessed as dissociation constant	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)[C@@H](O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O	Eur J Med Chem	2021.0	CHEMBL4862783	=	=	Kd	nM	5500.0	Kd	uM	5.5
Inhibition of human CYP3A4 assessed as dissociation constant	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)C(=O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O	Eur J Med Chem	2021.0	CHEMBL4871524	=	=	Kd	nM	1400.0	Kd	uM	1.4
Inhibition of human CYP3A4 assessed as dissociation constant	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](C/C=C\C[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]21)CC1=CC(=O)CC[C@@]13C	Eur J Med Chem	2021.0	CHEMBL4863362	=	=	Kd	nM	370.0	Kd	uM	0.37
Inhibition of human CYP3A4 assessed as dissociation constant	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](C/C=C/C[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]21)CC1=CC(=O)CC[C@@]13C	Eur J Med Chem	2021.0	CHEMBL4863066	=	=	Kd	nM	7100.0	Kd	uM	7.1
Inhibition of recombinant human CYP3A4 using BFC as substrate	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@@]6(C)[C@@H](CC[C@H]6O)[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@H]2O	Eur J Med Chem	2021.0	CHEMBL4864434	=	=	IC50	nM	22000.0	IC50	uM	22.0
Inhibition of recombinant human CYP3A4 using BFC as substrate	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)[C@@H](O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O	Eur J Med Chem	2021.0	CHEMBL4862783	=	=	IC50	nM	1200.0	IC50	uM	1.2
Inhibition of recombinant human CYP3A4 using BFC as substrate	C[C@]12CC[C@H]3[C@@H]([C@H](/C=C/C=C/C=C/[C@@H]4CC5=CC(=O)CC[C@]5(C)[C@H]5CC[C@]6(C)C(=O)CC[C@H]6[C@H]45)CC4=CC(=O)CC[C@@]43C)[C@@H]1CCC2=O	Eur J Med Chem	2021.0	CHEMBL4871524	=	=	IC50	nM	3600.0	IC50	uM	3.6
Inhibition of recombinant human CYP3A4 using BFC as substrate	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](C/C=C\C[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]21)CC1=CC(=O)CC[C@@]13C	Eur J Med Chem	2021.0	CHEMBL4863362	=	=	IC50	nM	800.0	IC50	uM	0.8
Inhibition of recombinant human CYP3A4 using BFC as substrate	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](C/C=C/C[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]21)CC1=CC(=O)CC[C@@]13C	Eur J Med Chem	2021.0	CHEMBL4863066	=	=	IC50	nM	6500.0	IC50	uM	6.5
Induction of CYP3A4 in human hepatocytes	Fc1cc(F)c(F)c(-c2ccc(N[C@H]3C[C@@H]4CN(CC5CCOCC5)C[C@@H]4C3)nn2)c1	ACS Med Chem Lett	2021.0	CHEMBL4850236	=	=	EC50	nM	1900.0	EC50	uM	1.9
Competitive inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis	FC(F)c1cncc(-c2ccc3ncc4nnc(C5=CCCOCC5)n4c3c2)c1	J Med Chem	2021.0	CHEMBL4851439	=	=	IC50	nM	15000.0	IC50	uM	15.0
Inhibition of CYP3A4 (unknown origin)	COc1nc(C2=NOC(C3CC3)C(c3ccc(Cl)cc3)N2)ccc1-n1cnc(C)c1	J Med Chem	2021.0	CHEMBL4848062	>=	>=	IC50	nM	14000.0	IC50	uM	14.0
Inhibition of CYP3A4 (unknown origin) by titration method	Cc1nc2c(cnn2-c2csc(C(=O)NC3COC3)c2)cc1Nc1c(F)cccc1Cl	ACS Med Chem Lett	2021.0	CHEMBL4845770	=	=	IC50	nM	1700.0	IC50	uM	1.7
Inhibition of CYP3A4T in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N	J Med Chem	2021.0	CHEMBL4864983	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4T in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2021.0	CHEMBL75	=	=	IC50	nM	22.0	IC50	uM	0.022000000000000002
Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	C=CC(=O)N1CCCC[C@H]1c1nc(-c2ccc(C(=O)Nc3cc(C(F)(F)F)ccn3)cc2)c(C(N)=O)n1N	J Med Chem	2021.0	CHEMBL4864983	>	>	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of CYP3A4M in human liver microsomes using midazolam as substrate incubated for 10 mins in presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2021.0	CHEMBL75	=	=	IC50	nM	7.0	IC50	uM	0.006999999999999999
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1	J Med Chem	2021.0	CHEMBL3545369	=	=	IC50	nM	28000.0	IC50	uM	28.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@@H](Oc3ccnc4ccccc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4852532	=	=	IC50	nM	1100.0	IC50	uM	1.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@H](Oc3ccnc4ccccc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4872522	=	=	IC50	nM	3300.0	IC50	uM	3.3
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@H](Oc3ccnc4ccc(F)cc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4846874	=	=	IC50	nM	1400.0	IC50	uM	1.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@@H](Oc3ccnc4ccc(F)cc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4875089	>	>	IC50	nM	5000.0	IC50	uM	5.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	O=C(NC[C@H]1[C@H]2C[C@H](Oc3ccnc4ccc(F)cc34)C[C@@H]12)c1ccc(Cl)cc1	J Med Chem	2021.0	CHEMBL4852881	=	=	IC50	nM	2100.0	IC50	uM	2.1
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	O=C(NC[C@@H]1[C@H]2C[C@@H](Oc3ccnc4ccc(F)cc34)C[C@H]21)c1ccc(Cl)cc1	J Med Chem	2021.0	CHEMBL4872803	=	=	IC50	nM	1900.0	IC50	uM	1.9
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	O=C(NC[C@H]1[C@H]2C[C@@H](Oc3ccnc4ccc(F)cc34)C[C@@H]12)c1ccc(Cl)cc1	J Med Chem	2021.0	CHEMBL4873928	=	=	IC50	nM	6700.0	IC50	uM	6.7
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@@H](Oc3ccnc4cc(F)ccc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4868112	=	=	IC50	nM	5400.0	IC50	uM	5.4
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@@H](Oc3ccnc4cccnc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4873892	=	=	IC50	nM	13000.0	IC50	uM	13.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@H]1[C@H]2C[C@@H](Oc3ccnc4ccncc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4870664	=	=	IC50	nM	18000.0	IC50	uM	18.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CC(NC(=O)c1ccc(C#N)cc1)[C@@H]1[C@H]2C[C@H](Oc3ncnc4cc(F)ccc34)C[C@H]21	J Med Chem	2021.0	CHEMBL4853036	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@H](NC(=O)c3cncc(F)c3)C[C@H]21	J Med Chem	2021.0	CHEMBL4854742	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@H](n3cnc4cccc(F)c4c3=O)C[C@H]21	J Med Chem	2021.0	CHEMBL4848111	>	>	IC50	nM	17000.0	IC50	uM	17.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@H](n3cc(C4CC4)nn3)C[C@H]21	J Med Chem	2021.0	CHEMBL4865079	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@H](n3cnc(C4CC4)n3)C[C@H]21	J Med Chem	2021.0	CHEMBL4848055	=	=	IC50	nM	31000.0	IC50	uM	31.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate incubated for 5 mins in presence of NADPH by LCMS/MS analysis	CCC(NC(=O)c1ccc(Cl)cc1)[C@@H]1[C@H]2C[C@H](n3cnc4cc(F)ccc43)C[C@H]21	J Med Chem	2021.0	CHEMBL4866113	=	=	IC50	nM	1300.0	IC50	uM	1.3
Inhibition of CYP3A4 in human liver microsome incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	Fc1ccc(C2(Cn3cncn3)COC(c3ccc(-c4ccccc4F)cc3)=N2)cc1	Eur J Med Chem	2021.0	CHEMBL4845963	=	=	IC50	nM	14800.0	IC50	uM	14.8
Inhibition of CYP3A4 in human liver microsome incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	Fc1ccc(C2(Cn3cncn3)COC(c3ccc(-c4cccc(F)c4)cc3)=N2)cc1	Eur J Med Chem	2021.0	CHEMBL4877100	=	=	IC50	nM	15200.0	IC50	uM	15.2
Inhibition of CYP3A4 in human liver microsome using Nifedipine as a substrate incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OCC5COC(Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O	Eur J Med Chem	2021.0	CHEMBL64391	=	=	IC50	nM	32.6	IC50	nM	32.6
Inhibition of CYP3A4 in human liver microsome using Nifedipine as a substrate incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	Eur J Med Chem	2021.0	CHEMBL75	=	=	IC50	nM	11.7	IC50	nM	11.7
Inhibition of CYP3A4 in human liver microsome using Nifedipine as a substrate incubated for 10 mins in the presence of NADPH by LC-MS/MS analysis	Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Eur J Med Chem	2021.0	CHEMBL91	=	=	IC50	nM	74.2	IC50	nM	74.2
Inhibition of CYP3A4 (unknown origin)	COc1ccc(-c2ccc(C(=O)O)cc2C)cc1-c1ncc(C(F)(F)F)cc1[C@@H]1CC[C@H]2[C@@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)OC(=O)N12	J Med Chem	2021.0	CHEMBL4865918	=	=	IC50	nM	9000.0	IC50	uM	9.0
Inhibition of CYP3A4 (unknown origin)	COc1ccc([C@H]2C[C@H](C(=O)O)C2)cc1-c1ccc(C(F)(F)F)cc1[C@@H]1CC[C@H]2[C@@H](c3cc(C(F)(F)F)cc(C(F)(F)F)c3)OC(=O)N12	J Med Chem	2021.0	CHEMBL3933320	=	=	IC50	nM	6000.0	IC50	uM	6.0
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12	J Med Chem	2021.0	CHEMBL2017291	=	=	IC50	nM	9700.0	IC50	uM	9.7
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay	COCCNc1nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c2n1Cc1ccccn1	J Med Chem	2021.0	CHEMBL4874790	=	=	IC50	nM	15800.0	IC50	uM	15.8
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay	COC[C@@H](C)n1c(C2CCOCC2)nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21	J Med Chem	2021.0	CHEMBL4878439	=	=	IC50	nM	25100.0	IC50	uM	25.1
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay	COc1cc2c(cc1-c1c(C)noc1C)ncc1nc(N(C)C)n(CC3CCOCC3)c12	J Med Chem	2021.0	CHEMBL4874356	=	=	IC50	nM	10000.0	IC50	uM	10.0
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VG as probe substrate incubated for 15 to 60 mins by fluorometric assay	COCCNc1nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c2n1[C@H](C)c1ccccn1	J Med Chem	2021.0	CHEMBL4874801	=	=	IC50	nM	7900.0	IC50	uM	7.9
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using DEF as probe substrate incubated for 15 to 60 mins by fluorometric assay	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc21	J Med Chem	2021.0	CHEMBL1232461	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using DEF as probe substrate incubated for 15 to 60 mins by fluorometric assay	COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12	J Med Chem	2021.0	CHEMBL2017291	=	=	IC50	nM	9700.0	IC50	uM	9.7
Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using VR as probe substrate incubated for 15 to 60 mins by fluorometric assay	COC[C@@H](C)n1c(C2CCOCC2)nc2cnc3cc(-c4c(C)noc4C)c(OC)cc3c21	J Med Chem	2021.0	CHEMBL4878439	>	>	IC50	nM	50000.0	IC50	uM	50.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition and measured after 5 mins by LC/MS analysis	C=CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1	Eur J Med Chem	2021.0	CHEMBL4863078	>	>	IC50	nM	10.0	IC50	nM	10.0
Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 5 mins followed by NADPH addition and measured after 5 mins by LC/MS analysis	CC#CC(=O)N1CCC(c2cnn3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)[nH]c23)CC1	Eur J Med Chem	2021.0	CHEMBL4878090	>	>	IC50	nM	10.0	IC50	nM	10.0
Inhibition of CYP3A4 (unknown origin)	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1	J Med Chem	2021.0	CHEMBL1976040	=	=	IC50	nM	19000.0	IC50	uM	19.0
Inhibition of CYP3A4 (unknown origin)	Cc1cn(-c2c(Cl)cccc2Cl)c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc12	J Med Chem	2021.0	CHEMBL4867107	=	=	IC50	nM	4500.0	IC50	uM	4.5
Inhibition of CYP3A4 (unknown origin)	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1ccc2c(n1)C(O)(CC)CC2	J Med Chem	2021.0	CHEMBL4871593	=	=	IC50	nM	7000.0	IC50	uM	7.0
Inhibition of CYP3A4 (unknown origin)	O=S(=O)(c1cccc(F)c1)n1ccc2c(N3CCNCC3)nc3ccccc3c21	J Med Chem	2021.0	CHEMBL4867565	=	=	IC50	nM	57000.0	IC50	uM	57.0
Inhibition of human recombinant CYP3A4 by fluorescence assay	COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC	J Med Chem	2021.0	CHEMBL6966	=	=	IC50	nM	5700.0	IC50	uM	5.7
Inhibition of human recombinant CYP3A4 by fluorescence assay	COc1cc2ncnc(-c3c(-c4ccccc4)n(Cc4ccccc4Br)c4ccccc34)c2cc1OCCCN1CCOCC1	J Med Chem	2021.0	CHEMBL4876875	=	=	IC50	nM	4100.0	IC50	uM	4.1
Inhibition of human recombinant CYP3A4 by fluorescence assay	CC(=O)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1	J Med Chem	2021.0	CHEMBL75	=	=	IC50	nM	80.0	IC50	uM	0.08
Inhibition of CYP3A4 in human liver microsomes using probe substrate in presence of NADPH regenerating system incubated for 60 mins by UFLC-MS/MS analysis	COc1ccc(N(C)c2nc(C)nc3ccccc23)cc1OC(C(=O)NO)C(C)C	J Med Chem	2021.0	CHEMBL4878408	=	=	IC50	nM	92790.0	IC50	uM	92.79
Inhibition of CYP3A4 (unknown origin)	CN(C[C@@H]1Cc2c(cccc2NC2CCNCC2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4849088	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N[C@H]2CC[C@H](N)CC2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4864332	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN1CCC(N(C)c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	ACS Med Chem Lett	2021.0	CHEMBL4857452	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C)C1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	ACS Med Chem Lett	2021.0	CHEMBL4876951	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN1CCN(Nc2cccc3c2C[C@@H](CN(C)[C@H]2CCCc4cccnc42)NC3)CC1	ACS Med Chem Lett	2021.0	CHEMBL4858136	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN1C[C@H]2CN(c3cccc4c3C[C@H](CN(C)[C@H]3CCCc5cccnc53)NC4)C[C@H]2C1	ACS Med Chem Lett	2021.0	CHEMBL4862509	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2NC2CCNCC2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4874526	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL518924	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL3091687	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N2CCC(N)CC2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4846946	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N2C[C@@H]3CNC[C@@H]3C2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4853570	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N2C[C@H]3CCN(C)[C@H]3C2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4862362	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N2C[C@@H]3CCN(C)[C@@H]3C2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4875030	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C[C@H]1Cc2c(cccc2N2CC[C@@H](N(C)C)C2)CN1)[C@H]1CCCc2cccnc21	ACS Med Chem Lett	2021.0	CHEMBL4877757	>	>	IC50	nM	20000.0	IC50	uM	20.0
Inhibition of CYP3A4 (unknown origin)	CN(C)[C@H]1CCN(c2cccc3c2C[C@H](CN(C)[C@H]2CCCc4cccnc42)NC3)C1	ACS Med Chem Lett	2021.0	CHEMBL4863276	>	>	IC50	nM	20000.0	IC50	uM	20.0
